<SEC-DOCUMENT>0001193125-20-019151.txt : 20200130
<SEC-HEADER>0001193125-20-019151.hdr.sgml : 20200130
<ACCEPTANCE-DATETIME>20200130092819
ACCESSION NUMBER:		0001193125-20-019151
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		27
FILED AS OF DATE:		20200130
DATE AS OF CHANGE:		20200130

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alector, Inc.
		CENTRAL INDEX KEY:			0001653087
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				462702363
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-236094
		FILM NUMBER:		20559921

	BUSINESS ADDRESS:	
		STREET 1:		151 OYSTER POINT BLVD., SUITE 300
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		415-231-5660

	MAIL ADDRESS:	
		STREET 1:		151 OYSTER POINT BLVD., SUITE 300
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Alector LLC
		DATE OF NAME CHANGE:	20150915
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>d838337d424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML><HEAD>
<TITLE>424B4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(4)<BR> Registration Nos. 333-236094 and 333-236159<BR>
</B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>8,350,000&nbsp;Shares </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g96o97.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>COMMON STOCK </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This is a public offering of
shares of common stock by Alector, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the NASDAQ Global Select Market under the symbol &#147;ALEC.&#148; On
January&nbsp;29, 2020, the last reported sale price of our common stock on the NASDAQ Global Select Market was $25.94 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging
growth company&#148; as defined under the federal securities laws and, as such, have elected to comply with certain reduced reporting requirements for this prospectus and may elect to do so in future filings. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our common stock involves risks. See the section titled &#147;<A HREF="#rom838337_4">Risk Factors</A>&#148; beginning on page 12 to read about
factors you should consider before buying shares of our common stock. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any other regulatory body
has approved or disapproved of these securities, or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">208,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and
commissions<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,525,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">196,225,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;margin-left:13%;border-bottom:1px solid #000000; width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See the section titled &#147;Underwriting&#148; for a description of the compensation payable to the
underwriters. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have granted the underwriters an option to purchase up to 1,252,500&nbsp;additional shares of our common stock at the
public offering price less underwriting discounts and commissions. The underwriters can exercise this option at any time within 30 days after the date of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David Wehner, a member of our board of directors, has agreed to purchase 20,000 shares of our common stock in this offering at the public offering price. The
underwriters will receive the same underwriting discounts and commissions on the shares purchased by Mr. Wehner as they will on the other shares sold to the public in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters expect to deliver the shares of common stock to purchasers on or about February 3, 2020. </P>
<P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="9%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:14pt">
<TD VALIGN="bottom"><B>Morgan&nbsp;Stanley</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Goldman&nbsp;Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BofA&nbsp;Securities&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cowen</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus dated January 29, 2020. </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_2">The Offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_3">Summary Consolidated Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_4">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_5">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_6">Market, Industry and Other Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_7">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_8">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc838337_22">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_9">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc838337_90a">Selected Consolidated Financial Data </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc838337_9b">Management&#146;s Discussion and Analysis of Financial Condition and Results
 of Operations </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc838337_23">A Letter from Arnon</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_10">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_11">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_12">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc838337_12a">Certain Relationships and Related Party Transactions </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_13">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_14">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_15">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_16">Material U.S. Federal Income and Estate Tax Considerations for <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders of our Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_17">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_18">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_19">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom838337_20">Where You Can Find Additional Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc838337_22a">Index to Financial Statements </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the underwriters have not authorized anyone to provide you any information other than that contained in this prospectus or in any free
writing prospectus prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We and the
underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of
the delivery of this prospectus or any sale of shares of our common stock. Our business, financial condition, results of operations, and prospects may have changed since that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For investors outside of the United States: we have not and the underwriters have not done anything that would permit this offering or
possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about,
and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained in greater detail elsewhere in this prospectus and is qualified in its entirety by
the more detailed information and financial statements included elsewhere in this prospectus. It does not contain all of the information that may be important to you and your investment decision. You should carefully read this entire prospectus,
including the sections titled &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; and our financial statements and related notes. In this prospectus, unless context
requires otherwise, references to &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;Alector,&#148; or &#147;the Company&#148; refer to Alector, Inc. </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ALECTOR, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our mission is to develop therapies that empower the immune system to cure neurodegeneration. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of
neurodegeneration. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. We are developing therapies designed to simultaneously counteract these pathologies by restoring
healthy immune function to the brain. Supporting our scientific approach, our Discovery Platform enables us to advance a broad portfolio of product candidates, validated by human genetics, which we believe will improve the probability of technical
success over shorter development timelines. As a result, in the last six years, we have identified over 120 immune system targets, progressed over ten programs into preclinical research, and advanced four product candidates, AL001, AL002, AL003, and
AL101 into clinical development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AL001, our first program in the clinic, modulates progranulin (PGRN), a regulator of immune activity in
the brain with genetic links to multiple neurodegenerative disorders, including frontotemporal dementia (FTD), Alzheimer&#146;s disease, and Parkinson&#146;s disease. AL001 is initially designed to treat FTD, a severe, rapidly progressing
neurodegenerative disorder that affects approximately 170,000 individuals in the United States and the European Union, with potentially higher prevalence in Asia and Latin America. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our AL001 program is initially aimed at treating FTD patients who have a known genetic mutation that causes a deficiency in PGRN, which is
called <FONT STYLE="white-space:nowrap">FTD-GRN.</FONT> The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for treatment of FTD to AL001, as well as Fast Track designation for the treatment of patients with FTD-GRN. Fast
Track designation is designed to facilitate the development and expedite the review of therapies which treat serious conditions and fill an unmet medical need. Programs with Fast Track designation may benefit from early and frequent communications
with the FDA, potential priority review, and additionally, a rolling submission of the marketing application. AL001 has successfully demonstrated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-mechanism</FONT></FONT> in
the Phase 1b portion of the study in <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> subjects by restoring PGRN levels in plasma and cerebrospinal fluid back to the normal range. In December 2019, we reported additional results from our AL001 Phase
1b study. Eight weeks after the first dose of AL001, a global proteomics profiling assay from the CSF of the eight symptomatic FTD-GRN patients showed a statistically significant normalization in a number of disease-associated proteins, including
inflammatory and lysosomal biomarkers (n=8; R=-0.36; P&lt;0.0005). At the end of the study, 12 weeks after the first dose, blood samples from five patients from this symptomatic FTD-GRN cohort were also available for plasma neurofilament light chain
(NfL) testing. In these five patients, no significant increases in plasma NfL levels were reported after 12 weeks. Moreover, an initial trend showing a 14% reduction in plasma NfL levels compared to baseline levels (n=5; mean=14%; range=-4% to 41%)
was also observed. The December 2019 issue of the medical journal, <I>The Lancet Neurology</I>, published analyses from the Genetic Frontotemporal Dementia Initiative (GENFI), which is a multicentre cohort study of families with genetic
frontotemporal dementia conducted across Europe and Canada, showing a significant increase in serum NfL levels over time in symptomatic GRN mutation carriers </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(p=0.019). Additionally, longitudinal analysis of the GENFI study, which have not been published to date, showed a mean increase of 24% in serum NfL levels of symptomatic <FONT
STYLE="white-space:nowrap">FTD-GRN</FONT> patients after 12 months. The Lancet publication also shows that increases in NfL levels in FTD patients were associated with cognitive decline and brain atrophy rates. NfL has been associated with disease
progression in FTD patients and identified as a marker of treatment effect in neurodegenerative diseases such as amyotrophic lateral sclerosis, spinal muscular atrophy, and multiple sclerosis in peer-reviewed journals. In the third quarter of 2019,
we advanced AL001 into a Phase&nbsp;2 study with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data in <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> patients expected in the first half of 2020.
The Phase&nbsp;2 study also includes an additional genetic subset of FTD patients <FONT STYLE="white-space:nowrap">(FTD-C9orf72).</FONT> In addition, in consultation with the FDA, we plan to advance AL001 into a Phase&nbsp;3 study in <FONT
STYLE="white-space:nowrap">FTD-GRN</FONT> patients in 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing AL101, our second product candidate in our PGRN program,
for patients suffering from more prevalent neurodegenerative diseases including Alzheimer&#146;s disease and Parkinson&#146;s disease, in addition to FTD. In line with our therapeutic hypothesis for FTD, mutations that moderately reduce the
expression levels of PGRN have been shown to increase the risk of developing Alzheimer&#146;s disease and Parkinson&#146;s disease, and increased PGRN levels have been demonstrated to be protective for these diseases in animal models. AL101 received
orphan drug designation from the FDA for treatment of FTD in July 2019, and we initiated the Phase 1 study of AL101 in the fourth quarter of 2019. We expect proof-of-mechanism data in 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own worldwide rights to both AL001 and AL101. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our next development programs, AL002 and AL003, focus on modulating check-point receptors on the brain&#146;s immune cells, with AL002
targeting Triggering Receptor Expressed on Myeloid cells&nbsp;2 (TREM2) and AL003 targeting sialic acid binding <FONT STYLE="white-space:nowrap">Ig-like</FONT> lectin&nbsp;3 (SIGLEC&nbsp;3), respectively. The AL002 and AL003 programs are aimed at
treating Alzheimer&#146;s disease patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the third quarter of 2019, we completed the Phase 1a portion of the study in healthy
volunteers with AL002. AL002 was generally safe and well-tolerated in the single ascending dose part of the Phase&nbsp;1 study. In addition, a dose dependent and statistically significant change in both soluble TREM2 (sTREM2) and a downstream
biomarker for microglia functionality in cerebrospinal fluid was observed upon treatment, indicating both target engagement and proof-of-mechanism in healthy volunteers. We believe that this is the first time that a drug product candidate that
targets TREM2 has successfully demonstrated safety, target engagement, and indicated proof-of-mechanism in healthy volunteers. In the second quarter of 2019, based on safety and tolerability observed in the Phase 1a study, we initiated the Phase 1b
portion of the study with AL002 in Alzheimer&#146;s disease patients. We expect proof-of-mechanism data from Alzheimer&#146;s disease patients in 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2019, we initiated a Phase 1a study in healthy volunteers with AL003 for the treatment of Alzheimer&#146;s disease
patients. Thirty-eight healthy volunteers were dosed over eight dose cohorts in the AL003 Phase 1a dose escalation trial. A dose dependent change in target engagement in a blood biomarker was observed upon a single dose treatment. One volunteer
treated with the second highest dose experienced aseptic hip monoarthritis and a second volunteer treated with the highest dose experienced an adverse drug reaction characterized by rash, fever, and thrombocytopenia, which were both deemed
treatment-related serious adverse events. The volunteers were treated with corticosteroids and recovered. In the fourth quarter of 2019, based on the safety and tolerability observed in the Phase 1a study, we initiated screening of Alzheimer&#146;s
disease patients in a Phase&nbsp;1b study (approximately 12 patients) with AL003 and expect dosing to commence in the first half of the first quarter of 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have partnered with AbbVie Biotechnology, Ltd. (AbbVie), a leader in neuroscience drug development, for the global development and
potential commercialization of AL002 and AL003. We are responsible for execution of the Phase&nbsp;1 and Phase&nbsp;2 studies. Following AbbVie&#146;s potential exercise of its option, Alector and AbbVie will share the development costs and will
split global profits after marketing approval. However, following AbbVie&#146;s option exercise for a program, we may opt out of sharing in development costs and profits or </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
losses from that program and instead receive a tiered royalty on sales of products from that program. As part of this partnership, we received $205.0&nbsp;million in upfront payments, of which
$5.0&nbsp;million and $200.0&nbsp;million were received by us in October 2017 and January 2018, respectively, $20.0&nbsp;million from the sale of shares of our preferred stock in October 2017 and are eligible for up to an additional
$985.6&nbsp;million in option exercise and milestone payments and a global profit share with AbbVie upon commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Discovery
Platform leverages large scale human genetic datasets, advanced tools in bioinformatics and imaging, and insights into neurodegeneration and immunology to identify immune system targets that play a critical role in the development of multiple
neurodegenerative diseases. Our Discovery Platform focuses on: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Target Selection</I></B><B>. </B>We identify mutations in genes that control the brain&#146;s immune
system, which we believe are the root cause of neurodegeneration, employ a suite of genetic tools to elucidate the immune dysfunction caused by these mutations, and then engineer immune modulating antibodies to counteract the harmful consequences of
these genetic mutations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Biomarker Selection</I></B><B>. </B>We are able to identify and employ molecular biomarkers, assays, and
precise imaging techniques to confirm target engagement and measure the effect of our product candidates, allowing us to potentially obtain clinical data earlier than would otherwise be expected using traditional clinical measures.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Patient Selection</I></B><B>. </B>We utilize genetic screening and other biomarkers to better align a
patient&#146;s specific diagnosis with the targeted intervention in our clinical studies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our immuno-neurology approach
and our Discovery Platform are designed to broadly address multiple neurodegenerative disorders. The breadth of our opportunity is reinforced by our ability to engineer therapeutics capable of modulating a broad array of immune targets, validated by
human genetics, across multiple mechanisms of action, including product candidates that activate, block, inhibit, or down-regulate a given target as therapeutically needed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table highlights our clinical programs. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g41p74.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table highlights ten of our identified preclinical and research programs. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g46l17.jpg" ALT="LOGO">
 </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above table reflects that we currently have ten preclinical and research programs in our
pipeline focused on targeting Alzheimer&#146;s disease, Parkinson&#146;s disease, amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis, and oncology. Currently, we estimate that these programs are one to three years or more away from
entering preclinical studies assuming that these programs meet our requirements for advancement into the preclinical stage. For each of our programs in our research and development pipeline we are working to identify biomarkers to be utilized in
preclinical studies for each program. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Immune System is Central to Neurodegeneration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The loss of healthy immune function in the brain, due to cellular aging or mutations of genes that regulate key immune cells, underlies the
onset and progression of multiple neurodegenerative disorders. Genomic analyses have shown that there is a strong correlation between genetic mutations that predispose individuals to neurodegeneration and dysfunction in the immune system. For
example, 22 of the top 25 risk genes identified by evaluating large-scale data on tens of thousands of Alzheimer&#146;s disease patients regulate immune function in the brain. As a result of these genetic mutations, the brain&#146;s immune function
deteriorates and subsequently would fail to carry out critical activities, which include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clearing or counteracting pathological neurodegenerative proteins such as amyloid-beta, TAU, alpha-synuclein, and
<FONT STYLE="white-space:nowrap">TDP-43;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">providing metabolic and functional support to nerve cells; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulating synaptic connections; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">protecting nerve cells by stimulating the regeneration of myelin sheaths around nerve fibers; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">controlling the neurotoxic activities of activated astrocytes and rogue microglia. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that restoring the immune system&#146;s ability to perform all of these vital functions in the brain is crucial to addressing
neurodegeneration given that past approaches focusing on single degenerative pathologies have proved inadequate to date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the early
20<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> century, the root cause of neurodegeneration has been thought to be misfolded and aggregated pathological proteins. Other observable pathologies, including destruction of synapses,
accelerated nerve cell death, and dysfunction of the brain support cells, were all thought to be consequences of these pathological misfolded proteins. As a result, attempts to develop therapies for neurodegeneration have been centered on blocking
the synthesis of, and removing or <FONT STYLE="white-space:nowrap">dis-aggregating</FONT> misfolded proteins. These attempts have been largely unsuccessful, as the disease continues to progress despite significant clearance of the misfolded protein.
We believe that the multiple pathologies found in degenerative brain disorders become independent of the misfolded proteins, and each other, at early disease stages and are driven primarily by dysfunction of the brain&#146;s immune system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, the brain&#146;s immune system undergoes gradual deterioration of functional characteristics as part of normal
biological&nbsp;aging or due to harmful genetic mutations that are linked to neurodegeneration and are associated with accelerated senescence of the brain immune cells. These cells are no longer capable of executing their beneficial and protective
roles and instead often become harmful and destructive to the brain. Based on our understanding of the role of genetic mutations in neurodegeneration, we have designed our product candidates to target the mutated genes linked to neurodegeneration,
with the goal of slowing or reversing the deterioration of the brain&#146;s immune cells to achieve therapeutic benefit. By restoring healthy immune function in the brain, we believe we can simultaneously counteract the multiple independent
pathologies responsible for neurodegeneration. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Team </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our team is led by seasoned executives with a proven track record of drug discovery and development in neuroscience, as well as substantial
operational and business expertise. Our <FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Chief Executive Officer, Arnon Rosenthal, Ph.D., has spent over 35&nbsp;years developing therapeutics in neuroscience and led teams responsible for the
development of the <FONT STYLE="white-space:nowrap">non-addictive</FONT> pain drug tanezumab and the migraine drug AJOVY, and multiple other programs in clinical development. He also held several leadership roles over a <FONT
STYLE="white-space:nowrap">16-year</FONT> career at Genentech, where he led the team that discovered the target for the cancer drug Erivedge. Our President and Chief Operating Officer, Shehnaaz Suliman, M.D., M.B.A., M.Phil., has more than 20 years
of experience in business development and drug development, and a demonstrated track record of building and leading teams across strategy, business development, commercial, and operational functions. She was previously Senior Vice President,
Corporate Development and Strategy of Theravance Biopharma, Inc. Our Chief Medical Officer, Robert Paul, M.D., Ph.D., served as the Therapeutic Area Lead for Neuroscience at Genentech, where among other projects, he oversaw the clinical development
of several product candidates, including the amyloid-beta antibody crenezumab in Alzheimer&#146;s disease, <FONT STYLE="white-space:nowrap">GDC-0134</FONT> in ALS, and <FONT STYLE="white-space:nowrap">GDC-0276</FONT> and <FONT
STYLE="white-space:nowrap">GDC-0310</FONT> in pain. Our Chief Development Officer, Robert King, Ph.D., previously served as the Senior Vice President of Development and Supply Chain at SciClone Pharmaceuticals. Our Chief Business Officer, Sabah
Oney, Ph.D., previously served as the Head of Global Sales and Business Development at Ariosa Diagnostics until and through its acquisition by Roche. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of our commitment to building a leading biotechnology company pioneering the discovery and development of next generation immune
therapies for neurodegeneration, we have appointed Richard Scheller, Ph.D., and Thomas S&uuml;dhof, M.D., both world-renowned neuroscientists, as Co-Chairs of our Strategic Portfolio Advice and Review Committee (SPARC). As key leaders of SPARC, Drs.
Scheller and S&uuml;dhof are tasked with supporting the advancement of our research and development pipeline and proprietary drug discovery platform. Dr. Scheller is a seasoned research and development executive with a strong track-record of
developing new medicines and leading multiple research and development organizations worldwide. He was previously Head of Therapeutics and Chief Scientific Officer at 23andMe, and spent 14 years at Genentech, where he was Executive Vice President of
Research and Early Development. Dr. S&uuml;dhof was awarded the Nobel Prize in Physiology or Medicine in 2013 for discoveries that advanced our understanding of how nerve cells communicate through processes underlying synaptic transmission and
synapse formation. Dr. S&uuml;dhof is currently studying mechanisms causing Alzheimer&#146;s, schizophrenia, and autism with the goal of expanding our understanding of neurological disorders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the strategic leadership provided by our executive team, coupled with the insights generated from our SPARC, will enable us to
continue building a leading research engine and discovery platform in immuno-neurology. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Strategy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to develop therapies that empower the immune system to cure neurodegeneration. The key tenets of our business strategy to achieve
this goal include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">building the leading, fully-integrated company focused on delivering innovative immuno-therapies, validated by
human genetics, for the treatment of neurodegeneration; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">applying our proprietary development capabilities to rapidly advance our product candidates through clinical <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> studies and beyond; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maximizing the therapeutic potential of our existing targets and product candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continuing to focus on discovering new targets and product candidates, validated by human genetics, to prosecute
the full power of our insights and platform. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to numerous risks and uncertainties that you should consider before investing in our company. These risks are described
more fully in the section titled &#147;Risk Factors&#148; in this prospectus. These risks include, but are not limited to, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are in the early stages of clinical drug development and have a limited operating history and no products
approved for commercial sale. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have incurred significant net losses in each period since our inception and anticipate that we will continue
to incur net losses for the foreseeable future. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our share price has been and may continue to be highly volatile, and you could lose all or part of your
investment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Drug development is a highly uncertain undertaking and involves a substantial degree of risk.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will need to obtain substantial additional financing to complete the development and any commercialization of
our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Due to the significant resources required for the development of our products, and depending on our ability to
access capital, we must prioritize development of certain product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Research and development of biopharmaceutical products is inherently risky. Our business is heavily dependent on
the successful development of our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may not be successful in our efforts to continue to create a pipeline of product candidates from our Discovery
Platform or to develop commercially successful products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may not be successful in our efforts to expand indications for approved product candidates.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have concentrated a substantial portion of our research and development efforts on the treatment of
neurodegenerative diseases, a field that has seen limited success in drug development. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may encounter substantial delays in our clinical trials, or may not be able to conduct or complete our
clinical trials on the timelines we expect, if at all. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product
candidates, which would prevent, delay, or limit the scope of regulatory approval and the commercialization of our product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Initial Public Offering (IPO) Transaction </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2019, we issued and sold 9,739,541 shares of common stock at a public offering price of $19.00 per share, including 489,541 shares
sold pursuant to the underwriters&#146; partial exercise of their option to purchase additional shares. We received aggregate net proceeds from the offering, net of underwriting discounts and commissions and offering expenses, of
$168.2&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were initially formed as a limited liability company in Delaware in May 2013 under the name Alector LLC and completed our restructuring to a
corporation in October 2017 under the name Alector, Inc. Our principal executive offices are located at 131&nbsp;Oyster Point Boulevard, Suite&nbsp;600, South San Francisco, California 94080. Our telephone number is <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">415-231-5660.</FONT></FONT> Our website address is www.alector.com. Information contained on, or that can be accessed through, our website is not incorporated by reference into this prospectus and should not be considered
to be part of this prospectus. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use Alector, the Alector logo, and other marks as trademarks in the United States and
other countries. This prospectus contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork, and other
visual displays, may appear without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> or TM&nbsp;symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law,
our rights, or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#146; trade names, trademarks, or service marks to imply a relationship with, or endorsement or
sponsorship of us by, any other entity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (JOBS Act). We will
remain an emerging growth company until the earliest to occur of: the last day of the fiscal year in which we have more than $1.07&nbsp;billion in annual revenue; the date we qualify as a &#147;large accelerated filer,&#148; with at least
$700&nbsp;million of equity securities held by <FONT STYLE="white-space:nowrap">non-affiliates;</FONT> the issuance, in any three-year period, by us of more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt
securities; and December&nbsp;31, 2024, which is the last day of the fiscal year ending after the fifth anniversary of our initial public offering. As a result of this status, we have taken advantage of reduced reporting requirements in this
prospectus and may elect to take advantage of other reduced reporting requirements in our future filings with the Securities and Exchange Commission. In particular, in this prospectus, we have not included all of the executive compensation related
information that would be required if we were not an emerging growth company. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting
standards, delaying the adoption of these accounting standards until they would apply to private companies. We have irrevocably elected not to avail ourselves of this exemption and we have adopted and will continue to adopt new or revised accounting
standards on the relevant dates on which adoption of such standards is required for other public companies that are not emerging growth companies. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_2"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common&nbsp;stock&nbsp;offered&nbsp;by&nbsp;us </P></TD>
<TD>8,350,000 shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding immediately after this offering </P></TD>
<TD>77,272,249 shares (or 78,524,749 shares if the underwriters exercise their option to purchase additional shares in full) </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Underwriters&#146; option to purchase additional shares of common stock from us </P></TD>
<TD>1,252,500 shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds to us from the sale of the shares of our common stock in this offering will be approximately $195.2&nbsp;million, or approximately $224.7 million if the underwriters exercise their option to purchase additional
shares in full, based upon an offering price of $25.00 per share, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We intend to use the net proceeds from this offering, together with our existing resources, as follows: (1)&nbsp;to fund Phase&nbsp;2 and Phase 3 clinical trials for AL001 in
<FONT STYLE="white-space:nowrap">FTD-GRN</FONT> and expand into <FONT STYLE="white-space:nowrap">FTD-C9orf72</FONT> and other potential indications; (2)&nbsp;to fund Phase 1 and Phase 2 clinical trials for AL002 and AL003; (3) to advance AL101
through Phase 1 clinical trials; (4) to continue to advance our preclinical development pipeline into Phase 1 clinical trials; (5)&nbsp;to further develop our Discovery Platform; and (6)&nbsp;to fund working capital and other general corporate
activities. See the section titled &#147;Use of Proceeds&#148; for more information. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>See the section of this prospectus titled &#147;Risk Factors&#148; beginning on page&nbsp;11 and other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in shares of our
common stock. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">NASDAQ trading symbol </P></TD>
<TD>&#147;ALEC&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on the
68,922,249 shares of our common stock outstanding as of September&nbsp;30, 2019, and excludes the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4,822,524 shares of common stock issuable upon exercise of options to purchase shares of our common stock
outstanding as of September&nbsp;30, 2019 under our 2017 Stock Option and Grant Plan (2017 Plan), at a weighted-average exercise price of $8.97 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,095,600 shares of common stock issuable upon exercise of options to purchase shares of our common stock
outstanding as of September&nbsp;30, 2019 under our 2019 Equity Incentive Plan (2019 Plan), at a weighted-average exercise price of $19.15 per share; </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,496,971 shares of common stock issuable upon exercise of options to purchase shares of our common stock that we
granted after September&nbsp;30, 2019 under our 2019 Plan, at a weighted-average exercise price of $17.15 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6,911,739 shares of common stock reserved for future issuance under our 2019 Plan as of September&nbsp;30, 2019,
as well as any automatic increases in the number of shares of common stock reserved for future issuance under this plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,478,492 shares of common stock reserved for issuance under our 2019 Employee Stock Purchase Plan as of
September&nbsp;30, 2019, as well as any automatic increases in the number of shares of common stock reserved for future issuance under this plan. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, this prospectus reflects and assumes the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of outstanding options after September&nbsp;30, 2019; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise by the underwriters of their option to purchase additional shares of common stock from us in this
offering. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">David Wehner, a member of our board of directors, has agreed to purchase 20,000 shares of our common stock in
this offering at the public offering price. The underwriters will receive the same underwriting discounts and commissions on the shares purchased by Mr. Wehner as they will on the other shares sold to the public in this offering. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_3"></A>SUMMARY CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize our consolidated financial data for the periods and as of the dates indicated. We derived the consolidated
statement of operations data for the years ended December&nbsp;31, 2018, 2017, and 2016 from our audited consolidated financial statements included elsewhere in this prospectus. We derived the consolidated statement of operations data for the nine
months ended September&nbsp;30, 2019 and 2018, and the consolidated balance sheet data as of September&nbsp;30, 2019, from our unaudited interim condensed consolidated financial statements included elsewhere in this prospectus. The unaudited interim
condensed consolidated financial statements have been prepared on the same basis as our annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal, recurring adjustments
that are necessary to present fairly the unaudited interim condensed consolidated financial statements. Our historical results are not necessarily indicative of the results that may be expected in the future, and our interim results are not
necessarily indicative of the results to be expected for the full year or any other period. You should read the following summary consolidated financial data in conjunction with our consolidated financial statements and the related notes appearing
elsewhere in this prospectus and the information in the section titled &#147;Selected Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(In thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,679</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(82,062</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,271</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(52,248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(74,858</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(34,875</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.62</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used in computing net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,302,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,142,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,173,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,663,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,154,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of September&nbsp;30, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 381,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">576,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">326,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">521,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">449,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">644,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(189,293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(189,293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">413,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The as adjusted consolidated balance sheet data reflects our receipt of net proceeds from the sale of 8,350,000
shares of common stock in this offering at the public offering price of $25.00 per share, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other
information contained in this prospectus, including our financial statements and the related notes and the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; included in this
prospectus, before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations, and growth prospects. In such an event, the
market price of our common stock could decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations and the market
price of our common stock. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business, Financial Condition, and Capital Requirements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are in the early stages of clinical drug development and have a limited operating history and no products approved for commercial sale, which may make
it difficult to evaluate our current business and predict our future success and viability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage
biopharmaceutical company with a limited operating history, focused initially on developing therapeutics for neurodegenerative diseases, including frontotemporal dementia (FTD), Alzheimer&#146;s disease, and Parkinson&#146;s disease. We commenced
operations in May&nbsp;2013. To date, we have only generated revenue from our collaboration arrangements and a government grant. We have no products approved for commercial sale and have not generated any revenue from product sales. Drug development
is a highly uncertain undertaking and involves a substantial degree of risk. We have begun a Phase 2 clinical trial for one product candidate, AL001, and we are currently in Phase&nbsp;1 clinical trials for three product candidates, AL002, AL003 and
AL101, but to date, we have not initiated or completed a pivotal clinical trial, obtained marketing approval for any product candidates, manufactured a commercial scale product or arranged for a third party to do so on our behalf, or conducted sales
and marketing activities necessary for successful product commercialization. Our short operating history as a company makes any assessment of our future success and viability subject to significant uncertainty. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will encounter risks and difficulties frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields, and we
have not yet demonstrated an ability to successfully overcome such risks and difficulties. If we do not address these risks and difficulties successfully, our business will suffer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred significant net losses in each period since our inception and anticipate that we will continue to incur net losses for the foreseeable
future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred net losses in each reporting period since our inception, including net losses of $52.2&nbsp;million,
$32.5&nbsp;million, and $15.1&nbsp;million for the years ended December&nbsp;31, 2018, 2017, and 2016, respectively, and $74.9&nbsp;million and $34.9&nbsp;million for the nine months ended September&nbsp;30, 2019 and 2018, respectively. As of
September&nbsp;30, 2019, we had an accumulated deficit of $189.3&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have invested significant financial resources in
research and development activities, including for our preclinical and clinical product candidates. We do not expect to generate revenue from product sales for several years, if at all. The revenue we currently generate from our collaboration
arrangement with AbbVie Biotechnology, Ltd. (AbbVie) is variable and limited in amount based on such arrangements. For our collaboration with AbbVie, we recognize collaboration revenue by measuring the progress towards complete satisfaction of the
performance of obligation measured as the program costs are incurred. The amount of our future net losses will depend, in part, on the level of our future expenditures and revenue. Moreover, our net losses may fluctuate significantly from quarter to
quarter and year to year, such that a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> comparison of our results of operations may not be a good indication of our future performance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to incur significant expenses and increasingly higher operating losses
for the foreseeable future. We anticipate that our expenses will increase substantially if and as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue our research and discovery activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance our Discovery Platform, including our target, patient, and biomarker selections; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">progress our current and any future product candidates through preclinical and clinical development;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate and conduct additional preclinical, clinical, or other studies for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">work with our contract development and manufacturing organizations (CDMOs) to scale up the manufacturing
processes for our product candidates or, in the future, establish and operate a manufacturing facility; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change or add additional contract manufacturers or suppliers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek regulatory approvals and marketing authorizations for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish sales, marketing, and distribution infrastructure to commercialize any products for which we obtain
approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make milestone, royalty, or other payments due under any license or collaboration agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">take steps to seek protection of our intellectual property and defend our intellectual property against
challenges from third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain, maintain, protect, and enforce our intellectual property portfolio, including intellectual property
obtained through license agreements, including as a result of the arbitration proceeding that we have initiated against our former consulting <FONT STYLE="white-space:nowrap">co-founder;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract, hire, and retain qualified personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide additional internal infrastructure to support our continued research and development operations and any
planned commercialization efforts in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience any delays or encounter other issues related to our operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">implement additional internal systems and infrastructure related to cybersecurity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">meet the requirements and demands of being a public company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">defend against any product liability claims or other lawsuits related to our products. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#146; equity and working
capital. In any particular quarter or quarters, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Drug development is a highly uncertain undertaking and involves a substantial degree of risk. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have no products approved for commercial sale. To obtain revenues from the sales of our product candidates that are significant or large
enough to achieve profitability, we must succeed, either alone or with third parties, in developing, obtaining regulatory approval for, manufacturing, and marketing therapies with significant commercial success. Our ability to generate revenue and
achieve profitability depends on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completing research and preclinical and clinical development of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining regulatory approvals and marketing authorizations for product candidates for which we successfully
complete clinical development and clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing a sustainable and scalable manufacturing process for our product candidates, as well as establishing
and maintaining commercially viable supply relationships with third parties that can provide adequate products and services to support clinical activities and commercial demand of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, assessing, acquiring, and/or developing new product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">launching and successfully commercializing product candidates for which we obtain regulatory and marketing
approval, either by collaborating with a partner or, if launched independently, by establishing a sales, marketing, and distribution infrastructure; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining and maintaining an adequate price for our product candidates, both in the United States and in foreign
countries where our products are commercialized; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining adequate reimbursement for our product candidates from payors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtaining market acceptance of our product candidates as viable treatment options; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">addressing any competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receiving milestones and other payments under our current and any future collaboration arrangements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintaining, protecting, expanding, and enforcing our portfolio of intellectual property rights, including
patents, trade secrets, and <FONT STYLE="white-space:nowrap">know-how;</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attracting, hiring, and retaining qualified personnel. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with drug development, we are unable to predict the timing or amount of our
expenses, or when we will be able to generate any meaningful revenue or achieve or maintain profitability, if ever. In addition, our expenses could increase beyond our current expectations if we are required by the U.S. Food and Drug Administration
(FDA) or foreign regulatory agencies, to perform studies in addition to those that we currently anticipate, or if there are any delays in any of our or our future collaborators&#146; clinical trials or the development of any of our product
candidates. Even if one or more of our product candidates is approved for commercial sale, we anticipate incurring significant costs associated with launching and commercializing any approved product candidate and ongoing compliance efforts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to obtain substantial additional financing to complete the development and any commercialization of our product candidates, and a failure
to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce, or terminate our commercialization efforts, product development, or other operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations have required substantial amounts of cash since inception, and we expect our expenses to increase significantly in the
foreseeable future. To date, we have financed our operations primarily through the sale of equity securities and through our government grant and upfront payments received in connection with our collaboration arrangement with AbbVie. Developing our
product candidates and conducting clinical trials for the treatment of neurodegenerative diseases, including FTD, Alzheimer&#146;s disease, and Parkinson&#146;s disease, will require substantial amounts of capital. We will also require a significant
amount of capital to commercialize any approved products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2019, we had cash, cash equivalents, and marketable
securities of $381.4&nbsp;million. In February 2019, we received $168.2&nbsp;million of net proceeds from the issuance of common stock upon the completion of our initial public offering (IPO), net of underwriting discounts and commissions and
offering expenses. Based on our current operating plan, we believe that our existing cash, cash equivalents, and marketable securities will be sufficient to fund our projected operations through at least the next 12&nbsp;months. Our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
estimate as to how long we expect our existing cash, cash equivalents, and marketable securities to be available to fund our operations is based on assumptions that may be proved inaccurate, and
we could use our available capital resources sooner than we currently expect. In addition, changing circumstances may cause us to increase our spending significantly faster than we currently anticipate, and we may need to spend more money than
currently expected because of circumstances beyond our control. We may need to raise additional funds sooner than we anticipate if we choose to expand more rapidly than we presently anticipate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will require additional capital for the further development and, if approved, commercialization of our product candidates. Additional
capital may not be available when we need it, on terms acceptable to us or at all. We have no committed source of additional capital. If adequate capital is not available to us on a timely basis, we may be required to significantly delay, scale
back, or discontinue our research and development programs or the commercialization of any product candidates, if approved, or be unable to continue or expand our operations, or otherwise capitalize on our business opportunities, as desired, which
could materially affect our business, financial condition, results of operations, and growth prospects and cause the price of our common stock to decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our
stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants
limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements
with pharmaceutical partners, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates, or grant licenses on terms that may not be favorable to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Due to the significant resources required for the development of our programs, and depending on our ability to access capital, we must prioritize
development of certain product candidates. Moreover, we may expend our limited resources on programs that do not yield a successful product candidate or fail to capitalize on product candidates or indications that may be more profitable or for which
there is a greater likelihood of success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have identified over 120 immune system targets. In the last six years, we
have progressed over ten programs into preclinical research. We currently have four product candidates in clinical trials. Together, the development of these programs and product candidates require significant capital investment. Due to the
significant resources required for the development of our programs and product candidates, we must focus our programs and product candidates on specific diseases and disease pathways and decide which product candidates to pursue and advance and the
amount of resources to allocate to each. Our drug development strategy is to clinically test and seek regulatory approval for our product candidates in indications in which we believe there is the most evidence that we will be able to quickly
generate <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data. We then intend to expand to clinical testing and seek regulatory approvals in other neurodegenerative indications based on genetic and
mechanistic overlap with the primary indication. However, even if our product candidates are able to gain regulatory approval in one indication, there is no guarantee that we will be able to expand to other indications, and we may expend significant
resources in seeking such approvals. In addition, we may focus resources on pursuing indications outside of neurodegeneration based on the same genetic and mechanistic rationale we utilize in determining on which of our discovery programs to focus.
Our decisions concerning the allocation of research, development, collaboration, management, and financial resources toward particular product candidates or therapeutic areas may not lead to the development of any viable commercial product and may
divert resources away from better opportunities. Similarly, our potential decisions to delay, terminate, or collaborate with third parties in respect of certain programs may subsequently also prove to be suboptimal and could cause us to miss
valuable opportunities. If we make incorrect determinations regarding the viability or market potential of any of our programs or product candidates or misread trends in the biopharmaceutical industry, in particular for neurodegenerative diseases,
our business, financial condition, and results of operations could be materially adversely affected. As a result, we may fail to capitalize on viable commercial products or profitable market </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases and disease pathways that may later prove to have greater commercial
potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing, or other royalty arrangements in cases in which it would have been advantageous for us to invest additional
resources to retain sole development and commercialization rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Discovery, Development, and Commercialization of Our Product
Candidates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and development of biopharmaceutical products is inherently risky. Our business is heavily dependent on the successful
development of our product candidates, which are in the early stages of preclinical and clinical development. We cannot give any assurance that any of our product candidates will receive regulatory, including marketing, approval, which is necessary
before they can be commercialized. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are at the early stages of development of the product candidates currently in our programs.
To date, we have invested substantially all of our efforts and financial resources to identify, procure intellectual property for, and develop our programs, including conducting preclinical studies and clinical trials in our programs for our product
candidates, AL001, AL002, AL003, AL101 and AL014, and providing general and administrative support for these operations. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for, and then successfully
commercialize our product candidates, and we may fail to do so for many reasons, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our product candidates may not successfully complete preclinical studies or clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a product candidate may on further study be shown to have harmful side effects or other characteristics that
indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors may develop therapeutics that render our product candidates obsolete or less attractive;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the product candidates that we develop may not be sufficiently covered by intellectual property for which we hold
exclusive rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the product candidates that we develop may be covered by third parties&#146; patents or other intellectual
property or exclusive rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the market for a product candidate may change so that the continued development of that product candidate is no
longer reasonable or commercially attractive; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at
all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if a product candidate obtains regulatory approval, we may be unable to establish sales and marketing
capabilities, or successfully market such approved product candidate, to gain market acceptance; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party
payors, if applicable. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of these events occur, we may be forced to abandon our development efforts for a program
or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be
successful in our efforts to further develop our current product candidates. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and
we may never receive such regulatory approval for any of our product candidates. Each of our product candidates is in the early stages of development and will require significant additional clinical development, management of preclinical, clinical,
and manufacturing activities, regulatory approval, adequate manufacturing supply, a commercial organization, and significant marketing efforts before we generate any revenue from product sales, if at all. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never completed a clinical development program. We currently have one product
candidate, AL001, in a Phase 2 clinical trial and three product candidates, AL002, AL003 and AL101, in Phase&nbsp;1 clinical trials. None of our product candidates have advanced into late-stage development or a pivotal clinical trial and it may be
years before any such trial is initiated, if at all. Further, we cannot be certain that any of our product candidates will be successful in clinical trials. We may in the future advance product candidates into clinical trials and terminate such
trials prior to their completion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our product candidates successfully complete clinical trials, we generally plan to seek
regulatory approval to market our product candidates in the United States, the European Union, and in additional foreign countries where we believe there is a viable commercial opportunity. We have never commenced, compiled or submitted an
application seeking regulatory approval to market any product candidate. We may never receive regulatory approval to market any product candidates even if such product candidates successfully complete clinical trials, which would adversely affect
our viability. To obtain regulatory approval in countries outside the United States, we must comply with numerous and varying regulatory requirements of such other countries regarding safety, efficacy, manufacturing and controls, clinical trials,
commercial sales, pricing, and distribution of our product candidates. We may also rely on our collaborators or partners to conduct the required activities to support an application for regulatory approval, and to seek approval, for one or more of
our product candidates. For example, for our AL002 and AL003 product candidates, our collaboration arrangement with AbbVie provides that we are responsible for the execution of the Phase&nbsp;1 and Phase&nbsp;2 studies. We cannot be sure that our
collaborators or partners will conduct these activities or do so within the timeframe we desire. Even if we (or our collaborators or partners) are successful in obtaining approval in one jurisdiction, we cannot ensure that we will obtain approval in
any other jurisdictions. If we are unable to obtain approval for our product candidates in multiple jurisdictions, our business, financial condition, results of operations, and our growth prospects could be negatively affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we receive regulatory approval to market any of our product candidates, whether for the treatment of neurodegenerative diseases or
other diseases, we cannot assure you that any such product candidate will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investment in biopharmaceutical product development involves significant risk that any product candidate will fail to demonstrate adequate
efficacy or an acceptable safety profile, gain regulatory approval, and become commercially viable. We cannot provide any assurance that we will be able to successfully advance any of our product candidates through the development process or, if
approved, successfully commercialize any of our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our efforts to continue to create a pipeline of
product candidates from our Discovery Platform or to develop commercially successful products. If we fail to successfully identify and develop additional product candidates from our Discover Platform, our commercial opportunity may be limited.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of our strategies is to identify and pursue clinical development of additional product candidates. Our Discovery Platform has
helped us identify over 120 immune system targets. In the last six years, we have progressed over ten programs into early preclinical development. We currently have four product candidates in clinical trials. Identifying, developing, obtaining
regulatory approval, and commercializing additional product candidates for the treatment of neurodegenerative diseases will require substantial additional funding beyond the net proceeds of this offering and is prone to the risks of failure inherent
in drug development. We cannot provide you any assurance that we will be able to successfully identify or acquire additional product candidates, advance any of these additional product candidates through the development process, successfully
commercialize any such additional product candidates, if approved, or assemble sufficient resources to identify, acquire, develop, or, if approved, commercialize additional product candidates. If we are unable to successfully identify, acquire,
develop, and commercialize additional product candidates, our commercial opportunity may be limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our efforts to expand indications for approved product candidates.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our drug development strategy is to clinically test and seek regulatory approval for our product candidates in indications in
which we believe there is the most evidence that we will be able to quickly generate <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data. We then intend to expand to clinical testing and seek
regulatory approvals in other neurodegenerative indications based on genetic and mechanistic overlap with the primary indication. Conducting clinical trials for additional indications for our product candidates requires substantial technical,
financial, and human resources and is prone to the risks of failure inherent in drug development. We cannot provide you any assurance that we will be successful in our effort to obtain regulatory approval for our product candidates for additional
indications even if we obtain approval for an initial indication. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, our product candidate AL001 is initially targeting <FONT
STYLE="white-space:nowrap">FTD-GRN</FONT> patients. In the third quarter of 2019, we advanced AL001 into a Phase&nbsp;2 study with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data in <FONT
STYLE="white-space:nowrap">FTD-GRN</FONT> patients expected in the first half of 2020. The Phase&nbsp;2 study also includes an additional genetic subset of FTD patients <FONT STYLE="white-space:nowrap">(FTD-C9orf72).</FONT> If we are unable to
successfully identify, develop, obtain regulatory approval for, and commercialize AL001 for other indications, our commercial opportunity for AL001 may be limited.&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have concentrated a substantial portion of our research and development efforts on the treatment of neurodegenerative diseases, a field that has seen
limited success in drug development. Further, our product candidates are based on new approaches and novel technology, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory
approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have focused a substantial portion of our research and development efforts on addressing neurodegenerative diseases.
Collectively, efforts by biopharmaceutical companies in the field of neurodegenerative diseases have seen limited success in drug development. There are few effective therapeutic options available for patients with FTD, Alzheimer&#146;s disease,
Parkinson&#146;s disease, and other neurodegenerative diseases. Our future success is highly dependent on the successful development of our product candidates for treating neurodegenerative diseases. Developing and, if approved, commercializing our
product candidates for treatment of neurodegenerative diseases subjects us to a number of challenges, including obtaining disease modifying activity and efficacious dose in target tissue and obtaining regulatory approval from the FDA and other
regulatory authorities who have only a limited set of precedents to rely on. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our approach to the treatment of neurodegenerative diseases
aims to identify and select targets enriched in microglia and other myeloid immune cells which are genetically associated with neurodegenerative diseases, identify and develop product candidates that cross the blood brain barrier in sufficient
quantity and potency to enable efficacious dosing in the brain and engage the intended target, identify and develop biomarkers that are signs of a disease or condition, to select the right patient population, and to demonstrate target engagement,
pathway engagement, and impact on disease progression of our product candidates. This strategy may not prove to be successful. We cannot be sure that our approach will yield satisfactory therapeutic products that are safe and effective, scalable, or
profitable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may encounter substantial delays in our clinical trials, or may not be able to conduct or complete our clinical trials on the
timelines we expect, if at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive, time consuming, and subject to uncertainty. We cannot guarantee
that any clinical trials will be conducted as planned or completed on schedule, if at all. We cannot be sure that submission of an investigational new drug application (IND) or a clinical trial application (CTA) will result in the FDA or European
Medicines Agency (EMA), as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues may arise that could suspend or terminate such clinical trials. A failure of one or more clinical
trials can occur at any stage of testing, and our future clinical trials may not be successful. Events that may prevent successful or timely initiation or completion of clinical trials include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the
initiation or continuation of clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in confirming target engagement, patient selection, or other relevant biomarkers to be utilized in
preclinical and clinical product candidate development; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching a consensus with regulatory agencies on study design; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in reaching agreement on acceptable terms with prospective contract research organizations (CROs) and
clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in identifying, recruiting, and training suitable clinical investigators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in obtaining required Institutional Review Board (IRB) approval at each clinical trial site;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">imposition of delays to clinical trials, including as a result of temporary or permanent clinical hold by
regulatory agencies for a number of reasons, including: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after review of an IND or amendment, CTA or amendment, or equivalent application or amendment;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as a result of a new safety finding that presents unreasonable risk to clinical trial participants;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">as a result of modifications to clinical trial protocols or related documentation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a negative finding from an inspection of our clinical trial operations or study sites; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the finding that the investigational protocol or plan is clearly deficient to meet its stated objectives;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in identifying, recruiting, and enrolling suitable patients to participate in our clinical trials, and
delays caused by patients withdrawing from clinical trials, or failing to return for post-treatment <FONT STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty collaborating with patient groups and investigators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure by our CROs, other third parties, or us to adhere to clinical trial requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to perform in accordance with the FDA&#146;s or any other regulatory authority&#146;s current good
clinical practices (cGCPs) requirements, or applicable EMA or other regulatory guidelines in other countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential
benefits; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the standard of care on which a clinical development plan was based, which may require new or
additional trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of clinical trials of our product candidates being greater than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical trials of our product candidates producing negative or inconclusive results, which may result in our
deciding, or regulators requiring us, to conduct additional clinical trials or abandon product development programs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of
our product candidates for use in clinical trials or the inability to do any of the foregoing. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any inability to
successfully initiate or complete clinical trials could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to or we
may elect to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical trial delays could also shorten any periods during which our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may
harm our business and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could also encounter delays if a clinical trial is suspended or terminated by us, by the
data safety monitoring board for such trial or by the FDA, EMA, or any other regulatory authority, or if the IRBs of the institutions in which such trials are being conducted suspend or terminate the participation of their clinical investigators and
sites subject to their review. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of
the clinical trial operations or trial site by the FDA, EMA, or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product
candidate, changes in governmental regulations or administrative actions, or lack of adequate funding to continue the clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Histopathological analysis of a <FONT STYLE="white-space:nowrap">26-week</FONT> toxicology study of AL002 in
<FONT STYLE="white-space:nowrap">non-human</FONT> primates identified minimal to marked granulomatous inflammation in the&nbsp;ciliary body&nbsp;and/or&nbsp;choroid&nbsp;of&nbsp;the eye. There were no other AL002- related gross or histopathological
findings in this toxicology study in the retina or any other tissues or organs. We have observed no drug-related, serious adverse events in the AL002 Phase 1 trial with over 50&nbsp;adults. In response to FDA feedback, we have implemented additional
ophthalmological assessments in our AL002 clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Thirty-eight healthy volunteers were dosed over eight dose cohorts in the AL003
Phase 1a dose escalation trial. One volunteer treated with the second highest dose experienced aseptic hip monoarthritis and a second volunteer treated with the highest dose experienced an adverse drug reaction characterized by rash, fever, and
thrombocytopenia, which were both deemed treatment-related serious adverse events. The volunteers were treated with corticosteroids and recovered. In the fourth quarter of 2019, based on the safety and tolerability observed in the Phase 1a study, we
initiated screening of Alzheimer&#146;s disease patients in a Phase&nbsp;1b study (approximately 12 patients) with AL003 and expect dosing to commence in the first half of the first quarter of 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may in the future advance product candidates into clinical trials and terminate such trials prior to their completion, which could
adversely affect our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delays in the completion of any clinical trial of our product candidates will increase our costs, slow
down our product candidate development and approval process and delay, or potentially jeopardize our ability to commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or
completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may encounter
difficulties enrolling patients in our clinical trials, and our clinical development activities could thereby be delayed or otherwise adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient
number of patients who remain in the trial until its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and nature of the patient population; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patient eligibility criteria defined in the protocol, including biomarker-driven identification and/or
certain highly-specific criteria related to stage of disease progression, which may limit the patient populations eligible for our clinical trials to a greater extent than competing clinical trials for the same indication that do not have
biomarker-driven patient eligibility criteria; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size of the study population required for analysis of the trial&#146;s primary endpoints;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proximity of patients to a trial site; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the design of the trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competing clinical trials for similar therapies or targeting patient populations meeting our patient eligibility
criteria; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinicians&#146; and patients&#146; perceptions as to the potential advantages and side effects of the product
candidate being studied in relation to other available therapies and product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain patient consents; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that patients enrolled in clinical trials will not complete such trials, for any reason.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our clinical trials may reveal significant adverse events, toxicities, or other side effects and may fail to demonstrate
substantial evidence of the safety and efficacy of our product candidates, which would prevent, delay, or limit the scope of regulatory approval and commercialization. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex,
and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for use in each target indication. For those product candidates that are subject to regulation as biological drug products, we will need to
demonstrate that they are safe, pure, and potent for use in their target indications. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time
during the clinical trial process. The results of preclinical studies of our product candidates may not be predictive of the results of early-stage or later-stage clinical trials, and results of early clinical trials of our product candidates may
not be predictive of the results of later-stage clinical trials. The results of clinical trials in one set of patients or disease indications may not be predictive of those obtained in another. In some instances, there can be significant variability
in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes
in and adherence to the dosing regimen, and other clinical trial protocols and the rate of dropout among clinical trial participants. Open-label extension studies may also extend the timing and cost of a clinical test substantially. Product
candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have
suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. This is particularly true in neurodegenerative diseases, where failure rates
historically have been higher than in many other disease areas. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing
approval. We cannot be certain that our current clinical trials or any other future clinical trials will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the
prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition, and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will
interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a
marketing application, we may be required to expend </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for any of
our product candidates, the terms of such approval may limit the scope and use of our product candidates, which may also limit its commercial potential. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may
achieve regulatory approval before us or develop therapies that are safer, more advanced, or more effective than ours, which may negatively impact our ability to successfully market or commercialize any product candidates we may develop and
ultimately harm our financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The development and commercialization of new drug products is highly competitive.
Moreover, the neurodegenerative field is characterized by strong and increasing competition, and a strong emphasis on intellectual property. We may face competition with respect to any of our product candidates that we seek to develop or
commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private
research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are a number of large pharmaceutical and biotechnology companies that are currently pursuing the development of products for the
treatment of neurodegenerative diseases, including FTD and Alzheimer&#146;s disease. Many of these current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in
research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may
result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established
companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies
complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more
convenient, or are less expensive than any products that we may develop. Furthermore, currently approved products could be discovered to have application for treatment of neurodegenerative disease indications, which could give such products
significant regulatory and market timing advantages over any of our product candidates. Our competitors also may obtain FDA, EMA, or other regulatory approval for their products more rapidly than we may obtain approval for ours and may obtain orphan
drug exclusivity from the FDA for indications our product candidates are targeting, which could result in our competitors establishing a strong market position before we are able to enter the market. Additionally, products or technologies developed
by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing any product candidates we may develop against competitors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we could face litigation or other proceedings with respect to the scope, ownership, validity, and/or enforceability of our
patents relating to our competitors&#146; products and our competitors may allege that our products infringe, misappropriate, or otherwise violate their intellectual property. The availability of our competitors&#146; products could limit the
demand, and the price we are able to charge, for any products that we may develop and commercialize. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The manufacture of our product candidates is complex, and we may encounter difficulties in production.
If we or any of our third-party manufacturers encounter such difficulties, or fail to meet rigorously enforced regulatory standards, our ability to provide supply of our product candidates for clinical trials or our products for patients, if
approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The processes
involved in manufacturing our drug and biological product candidates are complex, expensive, highly-regulated, and subject to multiple risks. Further, as product candidates are developed through preclinical studies to late-stage clinical trials
towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will
not achieve these intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to conduct clinical trials of our product candidates, or supply commercial products, if approved, we will need to manufacture them in
large quantities. Our CDMOs may be unable to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during <FONT
STYLE="white-space:nowrap">scale-up</FONT> activities. If our CDMOs are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development, testing, and clinical trials of that product
candidate may be delayed or become infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business. The same risk would apply to our internal manufacturing
facilities, should we in the future decide to build internal manufacturing capacity. In addition, building internal manufacturing capacity would carry significant risks in terms of being able to plan, design, and execute on a complex project to
build manufacturing facilities in a timely and cost-efficient manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the manufacturing process for any products that we may
develop is subject to FDA, EMA, and foreign regulatory authority approval processes, and continuous oversight, and we will need to contract with manufacturers who can meet all applicable FDA, EMA, and foreign regulatory authority requirements,
including complying with current good manufacturing practices (cGMPs) on an ongoing basis. If we or our third-party manufacturers are unable to reliably produce products to specifications acceptable to the FDA, EMA, or other regulatory authorities,
we may not obtain or maintain the approvals we need to commercialize such products. Even if we obtain regulatory approval for any of our product candidates, there is no assurance that either we or our CDMOs will be able to manufacture the approved
product to specifications acceptable to the FDA, EMA, or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Any of these
challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidate, impair commercialization efforts,
increase our cost of goods, and have an adverse effect on our business, financial condition, results of operations, and growth prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If, in
the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any product candidates we may develop, we may not be successful in commercializing those product candidates if and
when they are approved. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have a sales or marketing infrastructure and have no experience in the sale, marketing, or
distribution of pharmaceutical products. To achieve commercial success for any approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource these functions to third
parties. In the future, we may choose to build a focused sales, marketing, and commercial support infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are risks involved with both establishing our own commercial capabilities and entering into arrangements with third parties to
perform these services. For example, recruiting and training a sales force or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reimbursement specialists is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish
marketing and other commercialization capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot
retain or reposition our commercialization personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors that may inhibit our efforts to commercialize any approved product on our
own include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, customer
service, medical affairs, and other support personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to
prescribe any future approved products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement, and
other acceptance by payors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to price our products at a sufficient price point to ensure an adequate and attractive level of
profitability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restricted or closed distribution channels that make it difficult to distribute our products to segments of the
patient population; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive
disadvantage relative to companies with more extensive product lines; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unforeseen costs and expenses associated with creating an independent commercialization organization.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we enter into arrangements with third parties to perform sales, marketing, commercial support, and distribution
services, our product revenue or the profitability of product revenue may be lower than if we were to market and sell any products we may develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to
commercialize our product candidates or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our
products effectively. If we do not establish commercialization capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates if approved. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if any product candidates we develop receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients,
healthcare payors, and others in the medical community necessary for commercial success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The commercial success of any of our
product candidates will depend upon its degree of market acceptance by physicians, patients, third-party payors, and others in the medical community. Even if any product candidates we may develop receive marketing approval, they may nonetheless fail
to gain sufficient market acceptance by physicians, patients, healthcare payors, and others in the medical community. The degree of market acceptance of any product candidates we may develop, if approved for commercial sale, will depend on a number
of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efficacy and safety of such product candidates as demonstrated in clinical trials and published in
peer-reviewed journals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential and perceived advantages compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to offer our products for sale at competitive prices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sufficient third-party coverage or reimbursement; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to offer appropriate patient access programs, such as <FONT STYLE="white-space:nowrap">co-pay</FONT>
assistance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which physicians recommend our products to their patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">convenience and ease of dosing and administration compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the clinical indications for which the product candidate is approved by FDA, EMA, or other regulatory agencies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product labeling or product insert requirements of the FDA, EMA, or other comparable foreign regulatory
authorities, including any limitations, contraindications, or warnings contained in a product&#146;s approved labeling; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on how the product is distributed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of market introduction of competitive products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicity concerning our products or competing products and treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the strength of marketing and distribution support; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of any side effects. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any product candidates we develop do not achieve an adequate level of acceptance, we may not generate significant product revenue, and we
may not become profitable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Any products we commercialize may become subject to unfavorable pricing regulations, third-party reimbursement
practices, or healthcare reform initiatives, which would harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulations that govern marketing approvals,
pricing, and reimbursement for new drugs vary widely from country to country. In the United States, recently enacted or potential future legislation may significantly change the approval requirements in ways that could involve additional costs and
cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign
markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to
price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our
ability to recoup our investment in one or more product candidates, even if any product candidates we may develop obtain marketing approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to successfully commercialize any products that we may develop also will depend in part on the extent to which reimbursement for
these products and related treatments will be available from government health administration authorities, private health insurers, and other organizations. Government authorities and third-party payors, such as private health insurers and health
maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted
to control costs by limiting coverage and the amount of reimbursement for particular medications. Government authorities currently impose mandatory discounts for certain patient groups, such as Medicare, Medicaid, and Veterans Affairs hospitals, and
may seek to increase such discounts at any time. Future regulation may negatively impact the price of our products, if approved. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list
prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. Reimbursement
may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. In order to get reimbursement, physicians may need to show that patients have superior treatment outcomes with our products compared to
standard of care </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
drugs, including lower-priced generic versions of standard of care drugs. If reimbursement is not available or is available only to limited levels, we may not be able to successfully
commercialize any product candidate for which we obtain marketing approval. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors and coverage and reimbursement levels for products can
differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that may require us to provide scientific and clinical support for the use of our products to each payor
separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for
which the medicine is approved by the FDA, EMA, or other comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including
research, development, manufacture, sale, and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of
the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory
discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States.
Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors
for any approved products we may develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize product candidates, and our overall financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates for which we intend to seek approval may face competition sooner than anticipated. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we are successful in achieving regulatory approval to commercialize a product candidate ahead of our competitors, our product
candidates may face competition from biosimilar products. In the United States, our product candidates are regulated by the FDA as biologic products and we intend to seek approval for these product candidates pursuant to the Biologics License
Application (BLA) pathway. The Biologics Price Competition and Innovation Act of 2009 (BPCIA) created an abbreviated pathway for the approval of biosimilar and interchangeable biologic products. The abbreviated regulatory pathway establishes legal
authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#147;interchangeable&#148; based on its similarity to an existing brand product. Under the BPCIA, an application for a
biosimilar product cannot be approved by the FDA until 12&nbsp;years after the original branded product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact,
implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects
for our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that any of our product candidates approved as a biologic product under a BLA should qualify for
the <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be
reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar product, once approved, will be substituted for any one of our reference
products in a way that is similar to traditional generic substitution for <FONT STYLE="white-space:nowrap">non-biologic</FONT> products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. In
addition, a competitor could decide to forego the biosimilar approval path and submit a full BLA after completing its own preclinical studies and clinical trials. In such cases, any exclusivity to which we may be eligible under the BPCIA would not
prevent the competitor from marketing its product as soon as it is approved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In Europe, the European Commission has granted marketing authorizations for several
biosimilar products pursuant to a set of general and product class-specific guidelines for biosimilar approvals issued over the past few years. In Europe, a competitor may reference data supporting approval of an innovative biological product, but
will not be able to get it on the market until 10 years after the time of approval of the innovative product. This <FONT STYLE="white-space:nowrap">10-year</FONT> marketing exclusivity period will be extended to 11 years if, during the first eight
of those 10 years, the marketing authorization holder obtains an approval for one or more new therapeutic indications that bring significant clinical benefits compared with existing therapies. In addition, companies may be developing biosimilar
products in other countries that could compete with our products, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If competitors are able to obtain marketing approval for
biosimilars referencing our product candidates, if approved, such products may become subject to competition from such biosimilars, with the attendant competitive pressure and potential adverse consequences. Such competitive products may be able to
immediately compete with us in each indication for which our product candidates may have received approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If product liability lawsuits are
brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk
when and if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing, or sale. Any such
product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, or a breach of warranties. Claims could also be asserted under state
consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit testing and commercialization of our product candidates. Even successful defense
would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased or interrupted demand for our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants and inability to continue clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiation of investigations by regulators; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a diversion of management&#146;s time and our resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product recalls, withdrawals or labeling, marketing, or promotional restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exhaustion of any available insurance and our capital resources; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize any product candidate. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims
could prevent or inhibit the commercialization of products we develop, alone or with collaborators. Our insurance policies may have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to
pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements
with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Regulatory Approval and Other Legal Compliance Matters </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The regulatory approval processes of the FDA, EMA, and comparable foreign regulatory authorities are lengthy, time consuming, and inherently
unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The time required to obtain approval by the FDA, EMA, and comparable foreign regulatory authorities is unpredictable, typically takes many
years following the commencement of clinical trials, and depends upon numerous factors, including the type, complexity, and novelty of the product candidates involved. In addition, approval policies, regulations, or the type and amount of clinical
data necessary to gain approval may change during the course of a product candidate&#146;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory
authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical, or other studies. We have not submitted
for, or obtained regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, development of our product candidates and/or regulatory approval may be delayed for reasons beyond our control. For example, a U.S.
federal government shutdown or budget sequestration, such as ones that occurred during 2013, 2018, and 2019, may result in significant reductions to the FDA&#146;s budget, employees, and operations, which may lead to slower response times and longer
review periods, potentially affecting our ability to progress development of our product candidates or obtain regulatory approval for our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applications for our product candidates could fail to receive regulatory approval in an initial or subsequent indication for many reasons,
including but not limited to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA, EMA, or comparable foreign regulatory authorities may disagree with the design, implementation, or
results of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA, EMA, or comparable foreign regulatory authorities may determine that our product candidates are not safe
and effective, only moderately effective or have undesirable or unintended side effects, toxicities, or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the population studied in the clinical program may not be sufficiently broad or representative to assure efficacy
and safety in the full population for which we seek approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate to the FDA or comparable foreign regulatory authorities that a product
candidate&#146;s risk-benefit ratio when compared to the standard of care is acceptable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA, EMA, or comparable foreign regulatory authorities may disagree with our interpretation of data from
preclinical studies or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission
of a new drug application (NDA), BLA, or other submission or to obtain regulatory approval in the United States or elsewhere; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate to the FDA, EMA, or comparable foreign regulatory authorities that a product
candidate&#146;s risk-benefit ratio for a proposed indication is acceptable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA, EMA, or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test
procedures, and specifications, or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval policies or regulations of the FDA, EMA, or comparable foreign regulatory authorities may
significantly change in a manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This lengthy approval process, as well as the unpredictability of the results of clinical
trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory
approval, limit their commercial potential, or result in significant negative consequences. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adverse events or other undesirable
side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, EMA, or other
comparable foreign regulatory authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Drug-related side effects could affect patient recruitment, the ability of enrolled patients
to complete the study, and/or result in potential product liability claims. We are required to maintain product liability insurance pursuant to certain of our development and commercialization agreements. We may not be able to maintain insurance
coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. A successful product liability claim or series of claims brought against us could adversely affect our results of operations, business, and
reputation. In addition, regardless of merit or eventual outcome, product liability claims may result in impairment of our business reputation, withdrawal of clinical trial participants, costs due to related litigation, distraction of
management&#146;s attention from our primary business, initiation of investigations by regulators, substantial monetary awards to patients or other claimants, the inability to commercialize our product candidates, and decreased demand for our
product candidates, if approved for commercial sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if one or more of our product candidates receives marketing approval,
and we or others later identify undesirable side effects or adverse events caused by such products, a number of potentially significant negative consequences could result, including but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may withdraw approvals of such product and cause us to recall our products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require additional warnings on the label; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to change the way the product is administered or conduct additional clinical trials or
post-approval studies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to create a Risk Evaluation and Mitigation Strategy plan, which could include a medication
guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, and/or other elements, such as boxed warning on the packaging, to assure safe use; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we could be sued and held liable for harm caused to patients; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and
could significantly harm our business, financial condition, results of operations, and growth prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may in the future conduct clinical
trials for our product candidates outside the United States, and the FDA, EMA, and applicable foreign regulatory authorities may not accept data from such trials. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may in the future choose to conduct one or more of our clinical trials outside the United States, including in Europe or Australia. The
acceptance of study data from clinical trials conducted outside the United&nbsp;States or another jurisdiction by the FDA, EMA, or applicable foreign regulatory authority may be subject to certain conditions. In cases where data from foreign
clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
foreign data alone unless (i)&nbsp;the data are applicable to the United States population and United States medical practice; and (ii)&nbsp;the trials were performed by clinical investigators of
recognized competence and pursuant to cGCP regulations. Additionally, the FDA&#146;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies have similar
approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, EMA, or any applicable foreign regulatory
authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA, EMA, or any applicable foreign regulatory authority does not accept such data, it would result in the need for additional
trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining
regulatory approval of our product candidates in other jurisdictions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining and maintaining regulatory approval of our product
candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the
regulatory approval process in others. For example, even if the FDA or EMA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing, and promotion of
the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical
trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be
approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties,
and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any partner we work with fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing
approvals, our target market will be reduced, and our ability to realize the full market potential of our product candidates will be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even
if we obtain regulatory approval for a product candidate, our products will remain subject to extensive regulatory scrutiny. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
any of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission
of safety, efficacy, and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturers and manufacturers&#146; facilities are required to comply with extensive requirements imposed by the FDA, EMA, and comparable
foreign regulatory authorities, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance
with cGMP and adherence to commitments made in any NDA, BLA, or marketing authorization application (MAA). Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including
manufacturing, production, and quality control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any regulatory approvals that we receive for our product candidates will be subject to
limitations on the approved indicated uses for which the product may be marketed and promoted or to the conditions of approval (including the requirement to implement a Risk Evaluation and Mitigation Strategy), or contain requirements for
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
potentially costly post-marketing testing. We will be required to report certain adverse reactions and production problems, if any, to the FDA, EMA, and comparable foreign regulatory authorities.
Any new legislation addressing drug safety issues could result in delays in product development or commercialization, or increased costs to assure compliance. The FDA and other agencies, including the Department of Justice, closely regulate and
monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed, and distributed only for the approved indications and in accordance with the provisions of the approved labeling. We will have to comply
with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the
product&#146;s approved label. As such, we may not promote our products for indications or uses for which they do not have approval. The holder of an approved NDA, BLA, or MAA must submit new or supplemental applications and obtain approval for
certain changes to the approved product, product labeling, or manufacturing process. We could also be asked to conduct post-marketing clinical trials to verify the safety and efficacy of our products in general or in specific patient subsets. If
original marketing approval was obtained via the accelerated approval pathway, we could be required to conduct a successful post-marketing clinical trial to confirm clinical benefit for our products. An unsuccessful post-marketing study or failure
to complete such a study could result in the withdrawal of marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a regulatory agency discovers previously unknown
problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may
impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue warning letters that would result in adverse publicity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impose civil or criminal penalties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspend or withdraw regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspend any of our ongoing clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refuse to approve pending applications or supplements to approved applications submitted by us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impose restrictions on our operations, including closing our contract manufacturers&#146; facilities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seize or detain products; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require a product recall. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could
generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory
approval is withdrawn, the value of our company and our operating results will be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have received orphan drug designation from
the FDA for AL001 and AL101 for treatment of FTD and plan to seek orphan drug designation for some of our other product candidates, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug status,
including market exclusivity, which may cause our revenue, if any, to be reduced. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant
orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the
United States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. Orphan drug designation
must be requested before submitting an NDA or BLA. In the United States, orphan drug designation entitles a party to financial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and <FONT STYLE="white-space:nowrap">user-fee</FONT> waivers. After the FDA grants orphan drug
designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. While we
have obtained orphan drug designation from the FDA for AL001 and AL101 for treatment of FTD, we may be unable to reap the benefits associated with orphan drug status. In addition, we plan to seek orphan drug designations for some of our other
product candidates in the future but may be unable to obtain an orphan drug designation for any additional product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a
product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the
FDA may not approve any other NDA or BLA applications to market the same drug or biologic for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan exclusivity or if
FDA finds that the holder of the orphan exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan product to meet the needs of patients with the disease or condition for which the drug was designated. As a
result, even though the FDA has approved orphan drug status for AL001 and AL101 for treatment of FTD, the FDA can still approve other drugs that have a different active ingredient for use in treating the same indication or disease. Furthermore, the
FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have received Fast Track designation from the
FDA for AL001 for the treatment of patients with frontotemporal dementia carrying specific genetic mutation in the granulin gene, but we may be unable to obtain or maintain the benefits associated with the Fast Track designation. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fast Track designation is designed to facilitate the development and expedite the review of therapies which treat serious conditions and fill
an unmet medical need. Programs with Fast Track designation may benefit from early and frequent communications with the FDA, potential priority review, and the ability to submit a rolling application for regulatory review. Fast Track designation
applies to both the product and the specific indication for which it is being studied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, the FDA granted Fast Track
designation for AL001 for the treatment of patients with FTD carrying specific genetic mutations in the granulin gene. If our clinical development program does not continue to meet the criteria for Fast Track designation, or if our clinical trials
are delayed, suspended, or terminated, or put on clinical hold due to unexpected adverse events or issues with clinical supply, we will not receive the benefits associated with the Fast Track program. Furthermore, Fast Track designation does not
change the standards for approval. Fast Track designation alone does not guarantee qualification for the FDA&#146;s priority review procedures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods
of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell our products profitably. In
particular, in 2010, the Patient Protection and Affordable Care Act, or Affordable Care Act (ACA) was enacted, which, among other things, subjected biologic products to potential competition by lower-cost biosimilars, addressed a new methodology by
which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid
Drug Rebate Program, extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription
drugs, and provided incentives to programs that increase the federal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
government&#146;s comparative effectiveness research. The U.S. administration could repeal or change some or all of the ACA, and complying with any new legislation or reversing changes
implemented under the ACA could be time-intensive and expensive, resulting in a material adverse effect on our business. Until the ACA is fully implemented or there is more certainty concerning the future of the ACA, it will be difficult to predict
its full impact and influence on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been, and likely will continue to be, legislative and regulatory proposals at
the foreign, federal, and state levels directed at containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care
organizations, and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the demand for our product candidates, if we obtain regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to receive or set a price that we believe is fair for our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to generate revenue and achieve or maintain profitability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of taxes that we are required to pay; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of capital. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in
Medicare and other healthcare funding, more rigorous coverage criteria, lower reimbursement, and new payment methodologies. This could lower the price that we receive for any approved product. Any denial in coverage or reduction in reimbursement
from Medicare or other government-funded programs may result in a similar denial or reduction in payments from private payors, which may prevent us from being able to generate sufficient revenue, attain profitability, or commercialize our product
candidates, if approved. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or other
improper activities, including noncompliance with regulatory standards and requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of fraud,
misconduct, or other illegal activity by our employees, independent contractors, consultants, commercial partners, and vendors. Misconduct by these parties could include intentional, reckless, and negligent conduct that fails to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">comply with the laws of the FDA, EMA, and other comparable foreign regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide true, complete, and accurate information to the FDA, EMA, and other comparable foreign regulatory
authorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">comply with manufacturing standards we have established; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">comply with healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws;
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">report financial information or data accurately or to disclose unauthorized activities to us.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United
States, our potential exposure under such laws will increase significantly, and our costs associated with compliance with such laws are also likely to increase. In particular, research, sales, marketing, education, and other business arrangements in
the healthcare industry are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, educating, marketing and
promotion, sales and commission, certain customer incentive programs, and other business arrangements generally. Activities subject to these laws also involve the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
improper use of information obtained in the course of patient recruitment for clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted
a code of business conduct and ethics, but it is not always possible to identify and deter misconduct by employees and third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or
unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws. If any such actions are instituted against us, and we are not successful in
defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with healthcare laws, we could face substantial penalties and our business, operations, and financial conditions could be adversely
affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United
States, our operations will be subject to various federal and state fraud and abuse laws. The laws that may impact our operations include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal Anti-Kickback Statute, prohibits, among other things, persons from knowingly and willfully
soliciting, receiving, offering, or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the
purchase, lease, order, or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to
have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback
Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Federal civil and criminal false claims laws and civil monetary penalty laws, including the False Claims Act,
impose criminal and civil penalties, including through civil &#147;qui tam&#148; or &#147;whistleblower&#148; actions, against individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from
Medicare, Medicaid, or other third-party payors that are false or fraudulent or knowingly making a false statement to improperly avoid, decrease, or conceal an obligation to pay money to the federal government. Similar to the federal Anti-Kickback
Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) created new federal criminal
statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property
owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing, or covering up by any trick or device a material fact or making any
materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH) and
their respective implementing regulations, impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use,
or disclosure of, individually identifiable health information, relating to the privacy, security, and transmission of individually identifiable health information without appropriate authorization. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The federal Physician Payment Sunshine Act, created under the ACA, and its implementing regulations, require
manufacturers of drugs, devices, biologicals, and medical supplies for which </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
payment is available under Medicare, Medicaid, or the Children&#146;s Health Insurance Program to report annually to the U.S. Department of Health and Human Services under the Open Payments
Program, information related to payments or other transfers of value made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Federal consumer protection and unfair competition laws broadly regulate marketplace activities and activities
that potentially harm consumers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer
protection, and unfair competition laws may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales, and marketing arrangements, as well as submitting claims involving healthcare items or services
reimbursed by any third-party payer, including commercial insurers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">State laws require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary
compliance guidelines, and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">State laws also require drug manufacturers to file reports with states regarding pricing and marketing
information, such as the tracking and reporting of gifts, compensations and other remuneration, and items of value provided to healthcare professionals and entities. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">State and foreign laws also govern the privacy and security of health information in certain circumstances, many
of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of
our business activities could, despite our efforts to comply, be subject to challenge under one or more of such laws. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is
possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and
regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal, and
administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and
curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. In addition, the approval and commercialization of any of our product candidates outside the United States will
also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we or any contract manufacturers
and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and any contract manufacturers and suppliers we engage are subject to numerous federal, state, and local environmental, health, and safety
laws, regulations, and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment, and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous
materials into the ground, air, and water; and employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous
waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under certain environmental laws, we could be held responsible for costs
relating to any contamination at our current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may
impair our research, product development, and manufacturing efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workers&#146; compensation insurance
to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological or
hazardous waste insurance coverage, and our property, casualty, and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the
event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could have a material adverse effect on
our business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business is subject to complex and evolving U.S. and foreign laws and
regulations relating to security, privacy and data protection. These laws and regulations are subject to change and uncertain interpretation, and could result in claims, changes to our business practices, or monetary penalties, and otherwise may
harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A wide variety of state, national, and international laws and regulations apply to security and cybersecurity
requirements and the collection, use, retention, protection, disclosure, transfer, and other processing of personal data. These security and data protection and privacy-related laws and regulations are evolving and may result in ever-increasing
regulatory and public scrutiny and escalating levels of enforcement and sanctions. We are working to comply with the such laws, and we anticipate needing to devote significant additional resources to our compliance efforts. It is possible that the
new legislation may impose new obligations and requirements on similarly situated companies, and these laws may be interpreted and applied in a manner that is inconsistent from jurisdiction to jurisdiction or inconsistent with our current policies
and practices. Our actual or perceived failure to adequately comply with applicable laws and regulations relating to security, privacy and data protection, or to protect our systems, personal data and other data we process or maintain, could result
in regulatory fines, investigations and enforcement actions, penalties and other liabilities, claims for damages by affected individuals, and damage to our reputation, any of which could materially affect our business, financial condition, results
of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inadequate funding for the FDA and other government agencies could hinder our ability to hire and retain key
leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may
rely, which could negatively impact our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review and approve new products can be affected by a
variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in
recent years as a result. In addition, government funding of other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and
unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. In the past, the U.S. government has
experienced budgetary shutdowns and certain regulatory agencies, such as the FDA, have had to furlough critical FDA and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact
the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly
capitalize and continue our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business activities may be subject to the Foreign Corrupt Practices Act (FCPA) and similar anti-bribery
and anti-corruption laws. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business activities may be subject to the FCPA and similar anti-bribery or anti-corruption laws,
regulations or rules of other countries in which we operate, including the U.K. Bribery Act. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly
reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> governments. Additionally, in many other countries, the healthcare providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government
entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. Recently the Securities and Exchange Commission (SEC) and Department of Justice have increased their FCPA enforcement activities with
respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the
high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of our facilities, requirements to obtain export licenses,
cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more
countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Reliance on Third Parties </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
expect to depend on collaborations with third parties for the research, development, and commercialization of certain of the product candidates we may develop. If any such collaborations are not successful, we may not be able to realize the market
potential of those product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently use and expect to continue to use third-party collaborators for the research,
development, and commercialization of certain of the product candidates we may develop. For example, we have entered into the <FONT STYLE="white-space:nowrap">Co-Development</FONT> and Option Agreement with AbbVie (the AbbVie Agreement) for the
global development and potential commercialization of AL002 and AL003. We also collaborate with Adimab and others to further our development of product candidates and to enhance our research efforts directed to better understanding neurodegenerative
diseases. For additional information on our relationships with AbbVie and Adimab, LLC (Adimab), see the sections titled &#147;Business&#151;Strategic Alliance with AbbVie&#148; and &#147;Business&#151;Collaboration Agreements with Adimab.&#148; Our
likely collaborators for any other collaboration arrangements include large and <FONT STYLE="white-space:nowrap">mid-size</FONT> pharmaceutical companies, regional and national pharmaceutical companies, biotechnology companies, and academic
institutions. Such arrangements with any third parties, generally provide us with shared or limited control over the amount and timing of resources that our collaborators dedicate to the development or potential commercialization of any product
candidates we may seek to develop with them. Our ability to generate revenue from these arrangements with commercial entities will depend on our collaborators&#146; abilities to successfully perform the functions assigned to them in these
arrangements. We cannot predict the success of any collaboration that we enter into. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Collaborations involving our research programs, or any product candidates we may develop,
pose the following risks to us: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators generally have significant discretion in determining the efforts and resources that they will apply
to these collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not properly obtain, maintain, enforce, or defend intellectual property or proprietary rights
relating to our product candidates or research programs or may use our proprietary information in such a way as to expose us to potential litigation or other intellectual property related proceedings, including proceedings challenging the scope,
ownership, validity, and enforceability of our intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may own or <FONT STYLE="white-space:nowrap">co-own</FONT> intellectual property covering our
product candidates or research and development programs that results from our collaboration with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property or such product candidates or research
programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may need the cooperation of our collaborators to enforce or defend any intellectual property we contribute to
or that arises out of our collaborations, which may not be provided to us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may control certain interactions with regulatory authorities, which may impact our ability to
obtain and maintain regulatory approval of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes may arise between the collaborators and us that result in the delay or termination of the research,
development, or commercialization of our product candidates or research programs or that result in costly litigation or arbitration that diverts management attention and resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may decide to not pursue development and commercialization of any product candidates we develop or
may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#146;s strategic focus or available funding or external factors such as an acquisition that diverts resources
or creates competing priorities or collaborators may elect to fund or commercialize a competing product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a
clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators could independently develop, or develop with third parties, products that compete directly or
indirectly with our product candidates or research programs if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may restrict us from researching, developing, or commercializing certain products or technologies
without their involvement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators with marketing and distribution rights to one or more product candidates may not commit sufficient
resources to the marketing and distribution of such product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may lose certain valuable rights under circumstances identified in our collaborations, including if we undergo
a change of control; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may grant sublicenses to our technology or product candidates or undergo a change of control, and
the sublicensees or new owners may decide to take the collaboration in a direction which is not in our best interest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may become bankrupt, which may significantly delay our research or development programs, or may
cause us to lose access to valuable technology, <FONT STYLE="white-space:nowrap">know-how,</FONT> or intellectual property of the collaborator relating to our products, product candidates, or research programs; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">key personnel at our collaborators may leave, which could negatively impact our ability to productively work with
our collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborations may require us to incur short and long-term expenditures, issue securities that dilute our
stockholders, or disrupt our management and business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if our collaborators do not satisfy their obligations under our agreements with them, or if they terminate our
collaborations with them, we may not be able to develop or commercialize product candidates as planned; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborations may require us to share in development and commercialization costs pursuant to budgets that we do
not fully control, and our failure to share in such costs could have a detrimental impact on the collaboration or our ability to share in revenue generated under the collaboration; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborations may be terminated in their entirety or with respect to certain product candidates or technologies
and, if so terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates or technologies; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaboration agreements may not lead to development or commercialization of product candidates in the most
efficient manner or at all. If a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our development or commercialization program under such collaboration could be delayed,
diminished, or terminated. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may face significant competition in seeking appropriate collaborations. Recent business
combinations among biotechnology and pharmaceutical companies have resulted in a reduced number of potential collaborators. In addition, the negotiation process is time-consuming and complex, and we may not be able to negotiate collaborations on a
timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other
development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase
our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to
further develop product candidates or bring them to market and generate product revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not realize the benefit of collaborations
if we or our collaborator elects not to exercise the rights granted under the agreement or if we or our collaborator are unable to successfully integrate a product candidate into existing operations and company culture. In addition, if our agreement
with any of our collaborators terminates, our access to technology and intellectual property licensed to us by that collaborator may be restricted or terminate entirely, which may delay our continued development of our product candidates utilizing
the collaborator&#146;s technology or intellectual property or require us to stop development of those product candidates completely. We may also find it more difficult to find a suitable replacement collaborator or attract new collaborators, and
our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected. Many of the risks relating to product development, regulatory approval, and commercialization described in this
&#147;Risk Factors&#148; section also apply to the activities of our collaborators and any negative impact on our collaborators may adversely affect us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may
not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research, or testing. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
currently rely and expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions, and clinical investigators, to conduct some aspects of our research and preclinical testing and our clinical
trials. Any of these third parties may terminate their engagements with us or be unable to fulfill their contractual obligations. If we need to enter into alternative arrangements, it would delay our product development activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our reliance on these third parties for research and development activities reduces our
control over these activities but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the
trial. Moreover, the FDA requires us to comply with cGCPs for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible, reproducible, and accurate and that the rights, integrity, and
confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database within certain timeframes. Failure to do so can result
in fines, adverse publicity, and civil and criminal sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If these third parties do not successfully carry out their contractual
duties, meet expected deadlines, or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for any product candidates we may
develop and will not be able to, or may be delayed in our efforts to, successfully commercialize our medicines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also expect to rely on
other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors, including with the shipment of any drug supplies, could delay clinical development or marketing approval of
any product candidates we may develop or commercialization of our medicines, producing additional losses and depriving us of potential product revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We contract with third parties for the manufacture of materials for our research programs, preclinical studies, clinical trials, and for
commercialization of any product candidates that we may develop. This reliance on third parties carries and may increase the risk that we will not have sufficient quantities of such materials, product candidates, or any medicines that we may develop
and commercialize, or that such supply will not be available to us at an acceptable cost, which could delay, prevent, or impair our development or commercialization efforts. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have any manufacturing facilities. We currently rely on CDMOs for the manufacture of our materials for preclinical studies and
clinical trials and expect to continue to do so for preclinical studies, clinical trials, and for commercial supply of any product candidates that we may develop. We currently have established relationships with several CDMOs for the manufacturing
of our product candidates. We may be unable to establish any further agreements with CDMOs or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on CDMOs entails additional risks,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible breach of the manufacturing agreement by the third party; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or
inconvenient for us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reliance on the third party for regulatory compliance, quality assurance, safety, and pharmacovigilance and
related reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to produce required volume in a timely manner and to quality standards. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the United States. Our
failure, or the failure of our CDMOs, to comply with applicable regulations could result in clinical holds on our trials, sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals,
license revocations, seizures, or recalls of product candidates or medicines, operating restrictions, and criminal prosecutions, any of which could significantly and adversely affect supplies of our medicines and harm our business, financial
condition, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any medicines that we may develop may compete with other product candidates and products
for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any performance failure on the part of our existing or future third-party manufacturers
could delay clinical development or marketing approval. If any one of our current contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer and may incur added costs and delays in identifying and qualifying any
such replacement. Furthermore, securing and reserving production capacity with contract manufacturers may result in significant costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current and anticipated future dependence upon others for the manufacture of any product candidates we may develop or medicines may
adversely affect our future profit margins and our ability to commercialize any medicines that receive marketing approval on a timely and competitive basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend on third-party suppliers for key raw materials used in our manufacturing processes, and the loss of these third-party suppliers or their
inability to supply us with adequate raw materials could harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on third-party suppliers for the supply of the
raw materials required for the production of our product candidates, and we expect to continue to rely on third-party manufacturers for the commercial supply of any of our product candidates for which we obtain marketing approval. Our dependence on
these third-party suppliers and the challenges we may face in obtaining adequate supplies of raw materials involve several risks, including limited control over pricing, availability, quality, and delivery schedules. As a small company, our
negotiation leverage is limited, and we are likely to get lower priority than our competitors who are larger than we are. We do not have long-term supply agreements, and we purchase our required drug product on a development manufacturing services
agreement or purchase order basis. We cannot be certain that our suppliers will continue to provide us with the quantities of these raw materials that we require or satisfy our anticipated specifications and quality requirements. Any supply
interruption in limited or sole sourced raw materials could materially harm our ability to manufacture our product candidates until a new source of supply, if any, could be identified and qualified. We may be unable to find a sufficient alternative
supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on the part of our suppliers could delay the development and potential commercialization of our product candidates, including limiting supplies
necessary for clinical trials and regulatory approvals, which would have a material adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual
Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain and maintain patent protection for any product candidates we develop, our competitors could develop and
commercialize products similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop may be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect
to our proprietary product candidates and other technologies we may develop. We seek to protect our proprietary position by filing patent applications in the United States and abroad relating to our core programs and product candidates, as well as
other technologies that are important to our business. Given that the development of our product candidates is at an early stage, our intellectual property portfolio with respect to certain aspects of our product candidates is also at an early
stage. For example, we have filed or intend to file patent applications on aspects of our technology and core product candidates; however, there can be no assurance that any such patent applications will issue as granted patents. Furthermore, in
some cases, we have only filed provisional patent applications on certain aspects of our technology and product candidates and each of these provisional patent applications is not eligible to become an issued patent until, among other things, we
file a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application within 12 months of the filing date of the applicable provisional patent application. Any failure to file a <FONT STYLE="white-space:nowrap">non-provisional</FONT>
patent application within this timeline could cause us to lose the ability to obtain patent protection for the inventions disclosed in the associated provisional patent applications. Furthermore, in some cases, we may not be able to obtain issued
claims covering compositions relating to our core programs and product candidates, as well as other technologies that are important to our business, and instead may need to rely on filing patent applications with claims covering a method of use
and/or method of manufacture for protection of such core programs, product candidates, and other technologies. There can be no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assurance that any such patent applications will issue as granted patents, and even if they do issue, such patent claims may be insufficient to prevent third parties, such as our competitors,
from utilizing our technology. Any failure to obtain or maintain patent protection with respect to our core programs and product candidates could have a material adverse effect on our business, financial condition, results of operations, and
prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If any of our patent applications, or those of our collaborators, do not issue as patents in any jurisdiction, we may not be able to
compete effectively. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or their interpretation in the United States and other countries may
diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our patents or those of our collaborators
with respect to our product candidates. With respect to both our intellectual property and that of our collaborators related to our product candidates, we cannot predict whether the patent applications we and our collaborators are currently pursuing
will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors or other third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent prosecution process is expensive, time-consuming, and complex, and we or our collaborators may not be able to file, prosecute,
maintain, enforce, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain
patent protection. Although we enter into nondisclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, corporate collaborators, outside
scientific collaborators, CROs, CDMOs, consultants, advisors, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent
protection. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior art. Furthermore, publications
of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all.
Therefore, we cannot be certain that we or our collaborators were the first to make the inventions claimed in any of our or our collaborators&#146; patents or pending patent applications, or that we or our collaborators were the first to file for
patent protection of such inventions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent
protection, our ability to prevent our competitors from commercializing similar or identical technology and product candidates would be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions,
and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our or our collaborators&#146; pending and future patent
applications may not result in patents being issued which protect our product candidates or other technologies or which effectively prevent others from commercializing competitive technologies and product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be
reinterpreted after issuance. Even if patent applications we or our collaborators license or own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or
other third parties from competing with us, or otherwise provide us with any competitive advantage. Any patents to which we or our collaborators have rights may be challenged, narrowed, circumvented, or invalidated by third parties. Consequently, we
do not know whether product candidates or other technologies will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative
technologies or products in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner which could materially adversely affect our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance of a patent is not conclusive as to its inventorship, scope, validity, or
enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. We or our collaborators may be subject to a third-party preissuance submission of prior art to the United States Patent and Trademark
Office (USPTO) or become involved in opposition, derivation, revocation, reexamination, post-grant and <I>inter partes </I>review, or interference proceedings or other similar proceedings challenging our or our collaborators&#146; patent rights. An
adverse determination in any such submission, proceeding, or litigation could reduce the scope of, or invalidate or render unenforceable, such patent rights, allow third parties to commercialize our product candidates or other technologies and
compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we, or one of our collaborators, may have to participate in interference
proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our or our collaborators&#146; priority of invention or other features of
patentability with respect to our or our collaborators&#146; patents and patent applications. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which
could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our product candidates and other technologies. Such proceedings also may result in
substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. If we or our collaborators are unsuccessful in any such proceeding or other priority or inventorship dispute, we may
be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at
all, or may be <FONT STYLE="white-space:nowrap">non-exclusive.</FONT> If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the product candidates we may
develop. The loss of exclusivity or the narrowing of our owned and licensed patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, given the amount of time required for the development, testing, and regulatory review of new product candidates, patents
protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products
similar or identical to ours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of our patents and patent applications may in the future be
<FONT STYLE="white-space:nowrap">co-owned</FONT> with third parties. In addition, collaborators or future licensors may <FONT STYLE="white-space:nowrap">co-own</FONT> their patents and patent applications with other third parties with whom we do not
have a direct relationship. Our rights to certain of these patents and patent applications may be dependent, in part, on inter-institutional or other operating agreements between the joint owners of such patents and patent applications, who are not
parties to our license agreements. If our collaborators or future licensors do not have exclusive control of the grant of licenses under any such third-party <FONT STYLE="white-space:nowrap">co-owners&#146;</FONT> interest in such patents or patent
applications or we are otherwise unable to secure such exclusive rights, such <FONT STYLE="white-space:nowrap">co-owners</FONT> may be able to license their rights to other third parties, including our competitors, and our competitors could market
competing products and technology to the extent such products and technology are not also covered by our intellectual property. In addition, we may need the cooperation of any such <FONT STYLE="white-space:nowrap">co-owners</FONT> of our patents in
order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and
prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our rights to develop and commercialize our product candidates are subject, in part, to the terms and conditions of agreements with
others. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are heavily reliant upon option rights to certain patent rights and proprietary technology from third parties that are
important or necessary to the development of our product candidates and are subject to the terms and conditions of certain collaboration agreements with third parties. For example, in 2013 we entered into the Adimab Collaboration Agreement with
Adimab. Under the Adimab Collaboration Agreement, we are developing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
antibodies discovered by Adimab in our AL001 and AL101 product candidates, and we are developing antibodies optimized by Adimab in our AL002 and AL003 product candidates. Additionally, in
October&nbsp;2017, we entered into the AbbVie Agreement to <FONT STYLE="white-space:nowrap">co-develop</FONT> and commercialize medicines with AbbVie to treat Alzheimer&#146;s disease and other neurodegenerative diseases. In August 2019, we entered
into a new Adimab collaboration agreement for development of antibodies for use in future programs. For additional information on the Adimab Collaboration Agreement and the AbbVie Agreement, see the sections titled &#147;Business&#151;Adimab
Collaboration Agreements&#148; and &#147;Business&#151;Strategic Alliance with AbbVie.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our agreements with Adimab and AbbVie and
other agreements we enter into in the future may not provide exclusive rights to use certain intellectual property and technology retained by the collaborator in all relevant fields of use and in all territories in which we may wish to develop or
commercialize our technology and products in the future. As a result, we may not be able to prevent competitors or other third parties from developing and commercializing competitive products that utilizes technology retained by such collaborators
to the extent such products are not also covered by our intellectual property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, subject to the terms of any such agreements,
we do not have the right to control the preparation, filing, prosecution, and maintenance, and we may not have the right to control the enforcement and defense of certain patents and patent applications retained by the collaborator and provided to
us under a limited license. For example, under the Adimab Collaboration Agreements, patent rights relating to improvements to Adimab&#146;s background platform technology that are invented in the course of the research under the Adimab Collaboration
Agreements are assigned to Adimab. We also have an exclusive option under the Adimab Collaboration Agreements to obtain with respect to a specified number of antibodies directed against such target and discovered or optimized by Adimab, ownership of
certain patent rights relating to such antibodies, including certain patent rights. Until we exercise such option, we and Adimab each grant each other a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to the relevant intellectual
property. We cannot be certain that patents and patent applications that are controlled by our collaborators will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. If
our collaborators fail to prosecute, maintain, enforce, and defend such patents, or lose rights to those patents or patent applications, the limited rights we have licensed may be reduced or eliminated, our right to develop and commercialize any of
our product candidates that are subject of such licensed rights could be adversely affected, and we may have a reduced ability to prevent competitors from making, using, and selling competing products. In addition, even where we have the right to
control patent prosecution of patents and patent applications we have licensed to and from collaborators, we may still be adversely affected or prejudiced by actions or inactions of our collaborators that took place prior to the date upon which we
assumed control over patent prosecution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, our or our collaborators&#146; patents may be subject to a reservation of rights by
one or more third parties. For example, we received an award from the National Institute of Health in support of our research into the production and characterization of novel therapeutic antibodies against the neurotrophic factor PGRN degrading
receptor Sortilin (SORT1). As a result, the U.S. government may have certain rights to resulting intellectual property. When new technologies are developed with U.S. government funding, the U.S. government generally obtains certain rights in any
resulting patents, including a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license authorizing the U.S. government to use the invention or to have others use the invention on its behalf. The U.S. government&#146;s rights may also permit it
to disclose the funded inventions and technology to third parties and to exercise <FONT STYLE="white-space:nowrap">march-in</FONT> rights to use or allow third parties to use the technology developed using U.S. government funding. The U.S.
government may exercise its <FONT STYLE="white-space:nowrap">march-in</FONT> rights if it determines that action is necessary because we fail to achieve the practical application of the government funded technology, or because action is necessary to
alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such
inventions in facilities in the United States in certain circumstances and if this requirement is not waived. Any exercise by the U.S. government of such rights or by any third party of its reserved rights could have a material adverse effect on our
competitive position, business, financial condition, results of operations, and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our obligations in the agreements under which we option or license
intellectual property rights from our collaborators or future licensors or otherwise experience disruptions to our business relationships with our collaborators or future licensors, we could lose intellectual property rights that are important to
our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into agreements with our collaborators to option or license certain intellectual property and may
need to obtain additional intellectual property rights from others to advance our research or allow commercialization of product candidates we may develop. It is possible that we may be unable to obtain additional intellectual property rights at a
reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement
technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial condition, results of
operations, and prospects significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, manufacturing methods, product candidates, or future methods or products
resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, each of our agreements with collaborators do, and we expect our future agreements will, impose various economic, development,
diligence, commercialization, and other obligations on us. Certain of our collaboration agreements also require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products. In spite
of our efforts, our collaborators might conclude that we have materially breached our obligations under such agreements and might therefore terminate or seek damages under the agreements, thereby removing or limiting our ability to develop and
commercialize products and technology covered by these agreements. If termination of these agreements causes us to lose the rights to certain patents or other intellectual property, or if the underlying patents fail to provide the intended
exclusivity, competitors or other third parties may have the freedom to seek regulatory approval of, and to market, products similar to or identical to ours and we may be required to cease our development and commercialization of certain of our
product candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and growth prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, disputes may arise regarding intellectual property subject to a collaboration agreement, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of the option or license rights granted under the agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which our technology and processes infringe on intellectual property of the collaborator that is
not subject to the option or license rights granted under the agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sublicensing of patent and other rights under our collaborative development relationships;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations under the agreement and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from
the joint creation or use of intellectual property by our collaborators and us and our other partners; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the agreements under which we currently have rights to option or license intellectual property or technology from third parties
are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the
relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
material adverse effect on our business, financial condition, results of operations, and growth prospects. Moreover, if disputes over intellectual property that we have optioned or licensed
prevent or impair our ability to maintain our current arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our
business, financial conditions, results of operations, and growth prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our intellectual property and
proprietary rights throughout the world. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting, and defending patents on our product candidates and other
technologies in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from
selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products, and,
further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual
property rights may not be effective or sufficient to prevent them from competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems
in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual
property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary
rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at
risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other
remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual
property that we develop or license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant
licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the
value of such patent. If we, our collaborators or any of our future licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial
condition, results of operations, and prospects may be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance
with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these
requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications
will be due to be paid to the USPTO and various government patent agencies outside of the United&nbsp;States over the lifetime of our owned or licensed patents and applications. In certain circumstances, we rely on our collaborators or licensing
partners to pay these fees due to U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent agencies. The USPTO and various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> government agencies require compliance with several procedural,
documentary, fee payment, and other similar provisions during the patent application process. We also are dependent on our collaborators or licensors to take the necessary action to comply with these requirements with respect to our licensed
intellectual property. In some cases, an inadvertent lapse can be cured by payment of a late fee or by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other means in accordance with the applicable rules. There are situations, however, in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the
patent or patent application, resulting in a partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or technology, which
could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in U.S. patent law
could diminish the value of patents in general, thereby impairing our ability to protect our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the
patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements
for patentability are met, prior to March&nbsp;2013, in the United&nbsp;States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent.
After March&nbsp;2013, under the Leahy-Smith America Invents Act (the America Invents Act) enacted in September&nbsp;2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability
are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO
after March&nbsp;2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from
invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to either
(i)&nbsp;file any patent application related to our product candidates or other technologies or (ii)&nbsp;invent any of the inventions claimed in our patents or patent applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may
affect patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including
post-grant review, <I>inter partes</I><B><I> </I></B>review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a
patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court
action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America
Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our
business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the patent positions of companies in the development
and commercialization of pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations.
This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing
patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issued patents covering our product candidates and other technologies could be found invalid or unenforceable if challenged in court or before
administrative bodies in the United States or abroad. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we initiated legal proceedings against a third party to enforce a patent
covering our product candidates or other technologies, the defendant could counterclaim that such patent is invalid or unenforceable. In patent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of
several statutory requirements, including lack of novelty, obviousness, or <FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent
withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may raise claims challenging the validity or enforceability of our patents before administrative bodies in the United States or abroad,
even outside the context of litigation. Such mechanisms include <FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant review, <I>inter partes</I><B><I> </I></B>review, interference proceedings, derivation proceedings, and equivalent
proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation of, cancellation of, or amendment to our patents in such a way that they no longer cover our product candidates or other
technologies. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we or our licensing
partners and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product
candidates or other technologies. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations, and growth prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration, and specifics of any FDA marketing approval of any product candidates we may develop, one or
more of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent term extension of up to five years as compensation for patent term lost during the FDA regulatory review
process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a
method for manufacturing it may be extended. Similar extensions as compensation for patent term lost during regulatory review processes are also available in certain foreign countries and territories, such as in Europe under a Supplementary Patent
Certificate. However, we may not be granted an extension in the United States and/or foreign countries and territories because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply
within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we
request. If we are unable to obtain patent term extension or the term of any such extension is shorter than what we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial
condition, results of operations, and growth prospects could be materially harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims challenging the inventorship of our
patents and other intellectual property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to claims that former employees, collaborators or other third parties
have an interest in our patents, trade secrets, or other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> For example, we may have inventorship disputes arise from conflicting obligations of employees,
consultants, or others who are involved in developing our product candidates or other technologies. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership of our patents, trade secrets, or other
intellectual property. If the defense of any such claims fails, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to
our product candidates and other technologies. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a
material adverse effect on our business, financial condition, results of operations, and growth prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and competitive
position would be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to seeking patents for our product candidates and other technologies, we also rely on trade
secrets and confidentiality agreements to protect our unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology, and other proprietary information and to maintain our competitive position. We consider trade secrets and <FONT
STYLE="white-space:nowrap">know-how</FONT> to be one of our primary sources of intellectual property. Trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to protect. We expect our trade secrets and <FONT
STYLE="white-space:nowrap">know-how</FONT> to over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology, and the movement of personnel from academic to industry
scientific positions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We seek to protect these trade secrets and other proprietary technology, in part, by entering into <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CDMOs, consultants, advisors, and other
third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants, train our employees not to bring or use proprietary information or technology from former employers to us or in their
work, and remind former employees when they leave their employment of their confidentiality obligations. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or
proprietary technology and processes. Despite our efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches.
For example, on June&nbsp;18, 2019, we initiated a confidential arbitration proceeding against Dr.&nbsp;Asa Abeliovich, our former consulting <FONT STYLE="white-space:nowrap">co-founder,</FONT> related to alleged breaches of his consulting agreement
and the improper use of our confidential information learned during the course of rendering services to us as our consulting Chief Scientific Officer/Chief Innovation Officer. We are in the early stage of this arbitration proceeding and are unable
to assess or provide any assurances regarding its possible outcome. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, some
courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to
prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and
adversely harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in obtaining, through acquisitions or otherwise, necessary rights to our product candidates or other
technologies. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many pharmaceutical companies, biotechnology companies, and academic institutions are competing with us in the field
of neurodegeneration therapy may have patents and have filed and are likely filing patent applications potentially relevant to our business. In order to avoid infringing these third-party patents, we may find it necessary or prudent to obtain
licenses to such patents from such third-party intellectual property holders. We may also require licenses from third parties for certain technologies for use with future product candidates. In addition, with respect to any patents we <FONT
STYLE="white-space:nowrap">co-own</FONT> with third parties, we may wish to obtain licenses to such <FONT STYLE="white-space:nowrap">co-owners&#146;</FONT> interest to such patents. However, we may be unable to secure such licenses or otherwise
acquire any compositions, methods of use, processes, or other intellectual property rights from third parties that we identify as necessary for our future product candidates. The licensing or acquisition of third-party intellectual property rights
is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive
advantage over us due to their size, capital resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may
be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual
property rights or maintain the existing intellectual </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results
of operations, and growth prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that our employees, consultants, or advisors have wrongfully used or disclosed
alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our employees, consultants, and advisors are currently or were previously employed at universities or other biotechnology or
pharmaceutical companies, including our competitors and potential competitors. Although we try to ensure that our employees, consultants, and advisors do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of
others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#146;s current or former employer.
Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending
against such claims, litigation could result in substantial costs and be a distraction to management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, while it is our policy
to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each
party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims
against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property, such as with our arbitration claims against Dr.&nbsp;Asa Abeliovich, our former consulting Chief
Scientific Officer/Chief Innovation Officer. Such claims could have a material adverse effect on our business, financial condition, results of operations, and growth prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Third-party claims of intellectual property infringement, misappropriation, or other violation against us or our collaborators may prevent or delay the
development and commercialization of our product candidates and other technologies. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The field of discovering treatments for
neurodegenerative diseases is highly competitive and dynamic. Due to the focused research and development that is taking place by several companies, including us and our competitors, in this field, the intellectual property landscape is in flux, and
it may remain uncertain in the future. Additionally, the technology used in our product candidates is still in its infancy and no products utilizing similar technology have yet reached the market. As such, there may be significant intellectual
property related litigation and proceedings relating to our, and other third party, intellectual property and proprietary rights in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on our and our collaborators&#146; ability to develop, manufacture, market, and sell any product
candidates that we develop and to use our proprietary technologies without infringing, misappropriating, and otherwise violating the patents and other intellectual property rights of third parties. There is a substantial amount of complex litigation
involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation, and reexamination proceedings before the
USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may become party to, or threatened with, such actions in the future, regardless of their merit. As discussed above, recently, due to changes in U.S. law referred to
as patent reform, new procedures including <I>inter partes</I> review and post-grant review have been implemented. As stated above, this reform adds uncertainty to the possibility of challenge to our patents in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields in which we are developing
our product candidates. As the biotechnology and pharmaceutical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
industries expand and more patents are issued, the risk increases that our product candidates and other technologies may give rise to claims of infringement of the patent rights of others.
Although we believe that we do not infringe a valid claim of any third party&#146;s patents or other intellectual property, we cannot assure you that our product candidates and other technologies that we have developed, are developing or may develop
in the future will not infringe existing or future patents owned by third parties. We may not be aware of patents that have already been issued and that a third party, for example, a competitor in the fields in which we are developing product
candidates, and other technologies might assert are infringed by our current or future product candidates or other technologies, including claims to compositions, formulations, methods of manufacture or methods of use or treatment that cover our
product candidates or other technologies. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our product candidates or other technologies, could be found to be infringed by our
product candidates or other technologies. In addition, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates or other
technologies may infringe. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may have patents or obtain patents in the future and claim that the manufacture, use or sale of
our product candidates or other technologies infringes upon these patents. In the event that any third-party claims that we infringe their patents or that we are otherwise employing their proprietary technology without authorization and initiates
litigation against us, even if we believe such claims are without merit, a court of competent jurisdiction could hold that such patents are valid, enforceable and infringed by our product candidates or other technologies. In this case, the holders
of such patents may be able to block our ability to commercialize the applicable product candidate or technology unless we obtain a license under the applicable patents, or until such patents expire or are finally determined to be held invalid or
unenforceable. Such a license may not be available on commercially reasonable terms or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might
be nonexclusive, which could result in our competitors gaining access to the same intellectual property. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize our
product candidates or other technologies, or such commercialization efforts may be significantly delayed, which could in turn significantly harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Defense of infringement claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion
of management and other employee resources from our business, and may impact our reputation. In the event of a successful claim of infringement against us, we may be enjoined from further developing or commercializing our infringing product
candidates or other technologies. In addition, we may have to pay substantial damages, including treble damages and attorneys&#146; fees for willful infringement, obtain one or more licenses from third parties, pay royalties, and/or redesign our
infringing product candidates or technologies, which may be impossible or require substantial time and monetary expenditure. In that event, we would be unable to further develop and commercialize our product candidates or other technologies, which
could harm our business significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Engaging in litigation to defend against third parties alleging that we have infringed,
misappropriated, or otherwise violated their patents or other intellectual property rights is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of litigation or
administrative proceedings more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of
patent litigation or other proceedings against us could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition, results of operations, and
growth prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be
expensive, time consuming, and unsuccessful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe our patents or the patents of our licensing partners, or we
may be required to defend against claims of infringement. In addition, our patents or the patents of our licensing partners also may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
become involved in inventorship, priority, or validity disputes. To counter or defend against such claims can be expensive and time consuming. In an infringement proceeding, a court may decide
that a patent in which we have an interest is invalid or unenforceable, the other party&#146;s use of our patented technology falls under the safe harbor to patent infringement under 35&nbsp;U.S.C. &#167;271(e)(1), or may refuse to stop the other
party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted
narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of
litigation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to
incur significant expenses and could distract our personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities
analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources
available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to
sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and
continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our
trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented, or declared generic or determined to be
infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors or other third
parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by
owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names,
then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be
ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, financial condition, results of operations, and growth prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights do not necessarily address all potential threats. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations
and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make products that are similar to our product candidates or utilize similar technology but
that are not covered by the claims of the patents that we license or may own; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, or our current or future licensors or collaborators, might not have been the first to make the inventions
covered by the issued patent or pending patent application that we license or own now or in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, or our current or future licensors or collaborators, might not have been the first to file patent
applications covering certain of our or their inventions; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our owned or licensed intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our current or future pending owned or licensed patent applications will not lead to issued
patents; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal
challenges by our competitors or other third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors or other third parties might conduct research and development activities in countries where we do
not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of others may harm our business; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may choose not to file a patent in order to maintain certain trade secrets or
<FONT STYLE="white-space:nowrap">know-how,</FONT> and a third party may subsequently file a patent covering such intellectual property. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and
growth prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are highly dependent on our key personnel, and if we are not successful in attracting, motivating, and retaining highly qualified personnel, we may
not be able to successfully implement our business strategy. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to compete in the highly competitive biotechnology and
pharmaceutical industries depends upon our ability to attract, motivate, and retain highly qualified managerial, scientific, and medical personnel. We are highly dependent on our management, particularly our Chief Executive Officer, Dr.&nbsp;Arnon
Rosenthal, and our scientific and medical personnel. The loss of the services provided by any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements, could result in
delays in the development of our product candidates and harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conduct our operations at our facility in South San
Francisco, California, in a region that is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel is intense and the turnover rate can be high, which may limit our
ability to hire and retain highly qualified personnel on acceptable terms or at all. We expect that we may need to recruit talent from outside of our region and doing so may be costly and difficult. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided restricted stock and stock
option grants that vest over time. The value to employees of these equity grants that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more
lucrative offers from other companies. Although we have employment agreements with our key employees, these employment agreements provide for <FONT STYLE="white-space:nowrap">at-will</FONT> employment, which means that any of our employees could
leave our employment at any time, with or without notice. If we are unable to attract and incentivize quality personnel on acceptable terms, or at all, it may cause our business and operating results to suffer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, we had 121 full-time employees. As our development plans and strategies develop, and as we continue to implement
the requirements applicable to operating as a public company, we must </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
add a significant number of additional managerial, operational, financial, and other personnel. Future growth will impose significant added responsibilities on members of management, including:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, recruiting, integrating, retaining, and motivating additional employees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing our internal development efforts effectively, including the clinical and FDA review process for our
current and future product candidates, while complying with our contractual obligations to contractors and other third parties; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expanding our operational, financial and management controls, reporting systems, and procedures; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing increasing operational and managerial complexity. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future financial performance and our ability to continue to develop and, if approved, commercialize our product candidates will depend, in
part, on our ability to effectively manage any future growth. Our management may also have to divert a disproportionate amount of its attention away from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT>
activities in order to manage these growth activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently rely, and for the foreseeable future will continue to rely, in
substantial part on certain independent organizations, advisors, and consultants to provide certain services. There can be no assurance that the services of these independent organizations, advisors, and consultants will continue to be available to
us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any
reason, our clinical trials may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our
existing consultants or find other competent outside contractors and consultants on economically reasonable terms, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are
not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop our product candidates and,
accordingly, may not achieve our research, development, and commercialization goals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have engaged in strategic collaborations and may in the
future engage in acquisitions, collaborations, or strategic partnerships, which may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have engaged in strategic collaborations in the past, such as our strategic collaboration with AbbVie, and we may engage in various
acquisitions, collaborations, and strategic partnerships in the future, including licensing or acquiring complementary products, intellectual property rights, technologies, or businesses. Any acquisition, collaboration, or strategic partnership may
entail numerous risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased operating expenses and cash requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">volatility with respect to the financial reporting related to such arrangements, such as our expected variability
in the recognition of revenue each quarter from the AbbVie Agreement based on the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">percentage-of-completion</FONT></FONT> basis under the applicable accounting rules;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assumption of indebtedness or contingent liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issuance of our equity securities which would result in dilution to our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assimilation of operations, intellectual property, products, and product candidates of an acquired company,
including difficulties associated with integrating new personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of our management&#146;s attention from our existing product programs and initiatives in pursuing such
an acquisition or strategic partnership; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business
relationships; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that
party and their existing products or product candidates and regulatory approvals; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to generate revenue from acquired intellectual property, technology, and/or products sufficient to
meet our objectives or even to offset the associated transaction and maintenance costs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if we undertake
such a transaction, we may issue dilutive securities, assume or incur debt obligations, incur large <FONT STYLE="white-space:nowrap">one-time</FONT> expenses, and acquire intangible assets that could result in significant future amortization
expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our internal computer systems, or those used by our third-party research institution collaborators, CROs or other contractors or
consultants, may fail or suffer other breakdowns, cyberattacks, or information security breaches that could compromise the confidentiality, integrity, and availability of such systems and data, result in material disruptions of our development
programs and business operations, risk disclosure of confidential, financial, or proprietary information, and affect our reputation. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures, our internal computer systems and those of our future CROs and other contractors and
consultants may be vulnerable to damage from computer viruses and unauthorized access. As the cyber-threat landscape evolves, these attacks are growing in frequency, sophistication, and intensity, and are becoming increasingly difficult to detect.
Such attacks could include the use of key loggers or other harmful and virulent malware, including ransomware or other denials of service, and can be deployed through malicious websites, the use of social engineering, and/or other means. If a
breakdown, cyberattack, or other information security breach were to occur and cause interruptions in our operations, it could result in a misappropriation of confidential information, including our intellectual property or financial information,
and a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed, ongoing, or future clinical trials could result in delays in our regulatory approval efforts and
significantly increase our costs to recover or reproduce the data. Likewise, we rely on our third-party research institution collaborators for research and development of our product candidates and other third parties for the manufacture of our
product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or
damage to, our data or systems, or inappropriate disclosure of confidential, financial, or proprietary information, including data related to our personnel, we could incur liability or risk disclosure of confidential, financial, or proprietary
information, and the further development and commercialization of our product candidates could be delayed. There can be no assurance that we and our business counterparties will be successful in efforts to detect, prevent, or fully recover systems
or data from all breakdowns, service interruptions, attacks, or breaches of systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive data, which could result in financial, legal, business, or
reputational harm to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations, and those of our third-party research institution collaborators, CROs, CDMOs, suppliers, and other contractors and
consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics, and other natural or
<FONT STYLE="white-space:nowrap">man-made</FONT> disasters or business interruptions, for which we are partly uninsured. In addition, we rely on our third-party research institution collaborators for conducting research and development of our
product candidates, and they may be affected by government shutdowns or withdrawn funding. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely
on third-party manufacturers to produce and process our product candidates. Our ability to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a <FONT STYLE="white-space:nowrap">man-made</FONT> or natural disaster
or other business interruption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The majority of our operations including our corporate headquarters are located in a facility in South
San Francisco, California. Damage or extended periods of interruption to our corporate, development, or research facilities due to fire, natural disaster, power loss, communications failure, unauthorized entry, or other events could cause us to
cease or delay development of some or all of our product candidates. Although we maintain property damage and business interruption insurance coverage on these facilities, our insurance might not cover all losses under such circumstances and our
business may be seriously harmed by such delays and interruption. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business is subject to economic, political, regulatory, and other risks
associated with international operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to risks associated with conducting business internationally.
Some of our CDMOs are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">economic weakness, including inflation, or political instability in particular
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> economies and markets; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">differing and changing regulatory requirements in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> countries;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that
do not respect and protect intellectual property rights to the same extent as the United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties in compliance with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> laws and regulations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulations and customs, tariffs, and trade barriers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> currency exchange rates and currency controls;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in a specific country&#146;s or region&#146;s political or economic environment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shipping of biologics/drugs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trade protection measures, import or export licensing requirements, or other restrictive actions by U.S. or <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> governments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negative consequences from changes in tax laws; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with tax, employment, immigration, and labor laws for employees living or traveling abroad;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">workforce uncertainty in countries where labor unrest is more common than in the United States;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties associated with staffing and managing international operations, including differing labor relations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential liability under the FCPA, UK Bribery Act, or comparable foreign laws; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business interruptions resulting from <FONT STYLE="white-space:nowrap">geo-political</FONT> actions, including
war and terrorism, or natural disasters including earthquakes, typhoons, floods, and fires. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These and other risks
associated with our planned international operations may materially adversely affect our ability to attain profitable operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to
use our net operating loss carryforwards and certain other tax attributes may be limited. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, we had
federal and state net operating loss (NOL) carryforwards of approximately $17.5&nbsp;million and $17.1&nbsp;million, respectively, which will begin to expire in 2037, if not utilized. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
In addition, due to tax reform, we also have federal NOL carryforwards of $42.9&nbsp;million generated after December&nbsp;31, 2017, which do not expire. Under Sections&nbsp;382 and 383 of the
United States Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#147;ownership change&#148; (generally defined as a greater than <FONT STYLE="white-space:nowrap">50-percentage-point</FONT> cumulative change (by
value) in the equity ownership of certain stockholders over a rolling three-year period), the corporation&#146;s ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> net operating loss carryforwards and other <FONT
STYLE="white-space:nowrap">pre-change</FONT> tax attributes to offset its post-change taxable income or taxes may be limited. As a result of our initial public offering in February 2019, and other transactions that have occurred since our
incorporation, we may have experienced, and in connection with this offering may experience, such an ownership change. We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which are
outside our control. As a result, our ability to use our <FONT STYLE="white-space:nowrap">pre-change</FONT> net operating loss carryforwards and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes to offset post-change taxable
income or taxes may be subject to limitation. In addition, the enacted legislation commonly referred to as the Tax Cuts and Jobs Act of 2017 (the Tax Act) imposes certain limitations on the deduction of NOLs, including a limitation on the use of
NOLs generated in tax years beginning after December&nbsp;31, 2017 to 80% of current year taxable income. The Tax Act also eliminates the carryback and permits the indefinite carryforward of NOLs arising in tax years ending after December&nbsp;31,
2017, whereas NOLs arising in tax years ending prior to that date continue to have a <FONT STYLE="white-space:nowrap">two-year</FONT> carryback and twenty-year carryforward. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to This Offering and Ownership of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>An active trading market for our common stock may not be sustained. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to our initial public offering in February 2019, there was no public trading market for our common stock. Although our common stock is
listed on the NASDAQ Global Select Market, the market for our shares has demonstrated varying levels of trading activity. We cannot predict the prices at which our common stock will trade. It is possible that in one or more future periods our
results of operations and progression of our product pipeline may not meet the expectations of public market analysts and investors, and, as a result of these and other factors, the price of our common stock may fall. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price of our common stock may continue to be volatile, which could result in substantial losses for investors, including investors purchasing
shares in this offering. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading price of our common stock has been and may continue to be highly volatile and could be
subject to wide fluctuations in response to various factors, some of which are beyond our control. We priced our initial public offering at $19.00 per share on February&nbsp;6, 2019 and, our common stock reached a high of $27.00 per share during
April 2019 and a low of $13.64 per share during August 2019. On January&nbsp;29, 2020, the last reported sale price of our common stock was $25.94 per share. Some of the factors that may cause the market price of our common stock to fluctuate
include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of existing or new competitive products or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and results of clinical trials for our current product candidates and any future product candidates
that we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commencement or termination of collaborations for our product development and research programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to achieve development, regulatory, or commercialization milestones under our collaborations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure or discontinuation of any of our product development and research programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results of preclinical studies, clinical trials, or regulatory approvals of product candidates of our
competitors, or announcements about new research programs or product candidates of our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory or legal developments in the United States and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments or disputes concerning patent applications, issued patents, or other proprietary rights;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of expenses related to any of our research programs, clinical development programs, or product
candidates that we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of our efforts to develop additional product candidates or products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated changes in estimates as to financial results, development timelines, or recommendations by
securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcement or expectation of additional financing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of our common stock by us, our insiders, or other stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expiration of market standoff or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in our financial results or those of companies that are perceived to be similar to us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in estimates or recommendations by securities analysts, if any, that cover our stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market conditions in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic, industry, and market conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the other factors described in this &#147;Risk Factors&#148; section. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In recent years, the stock market in general, and the market for pharmaceutical and biotechnology companies in particular, has experienced
significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors
may seriously affect the market price of our common stock, regardless of our actual operating performance. These fluctuations may be even more pronounced in the trading market for our stock shortly following this offering. Following periods of such
volatility in the market price of a company&#146;s securities, securities class action litigation has often been brought against that company. Because of the potential volatility of our stock price, we may become the target of securities litigation
in the future. Securities litigation could result in substantial costs and divert management&#146;s attention and resources from our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If
securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock relies in part on the research and reports that industry or financial analysts publish about us or our
business. If one or more of the analysts covering our business cease to cover us or downgrade their evaluations of our stock or if we fail to meet their operating results estimates for us, the price of our stock could decline. If one or more of
these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales of substantial amounts of our common stock in the public markets, or the perception that such sales might occur, could cause the market price of
our common stock to decline significantly, even if our business is doing well. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of our
common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amount of our common stock in the public market, the market price of our common stock
could decline significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain holders of shares of our common stock have rights, subject to conditions, to require us to file
registration statements covering their shares or to include their shares in registration statements that we may file </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for ourselves or other stockholders. Registration of these shares under the Securities Act would result in the shares becoming freely tradeable in the public market, subject to the restrictions
of Rule 144 in the case of our affiliates. Any sales of securities by these stockholders could have a material adverse effect on the market price for our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You will incur immediate and substantial dilution as a result of this offering. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you purchase common stock in this offering, you will incur immediate and substantial dilution of $19.64 per share, representing the
difference between the offering price of $25.00 per share, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us, and the as adjusted net tangible book value per share of our common stock
as of September&nbsp;30, 2019, because the price that you pay will be substantially greater than our net tangible book value per share of the common stock that you acquire. As of September&nbsp;30, 2019, there were 5,918,124 shares subject to
outstanding options with a weighted-average exercise price of $10.84 per share. To the extent that these outstanding options are ultimately exercised or the underwriters exercise their option to purchase additional shares, you will incur further
dilution. See the section titled &#147;Dilution&#148; for a further description of the dilution you will experience immediately after this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our
technologies or product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to seek additional capital through a combination of public and private equity
offerings, debt financings, strategic partnerships and alliances, and licensing arrangements. We, and indirectly, our stockholders, will bear the cost of issuing and servicing such securities. Because our decision to issue debt or equity securities
in any future offering will depend on market conditions and other factors beyond our<B> </B>control, we cannot predict or estimate the amount, timing, or nature of any future offerings. To the extent that we raise additional capital through the sale
of equity or debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result in increased fixed
payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell, or license intellectual property rights and other operating restrictions that
could adversely impact our ability to conduct our business. Additionally, any future collaborations we enter into with third parties may provide capital in the near term but limit our potential cash flow and revenue in the future. If we raise
additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our principal stockholders and management own a significant percentage of our stock and will be able to exercise significant influence over matters
subject to stockholder approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our directors, executive officers, holders of more than 5% of our outstanding stock and their
respective affiliates beneficially owned 56.6% of our outstanding common stock as of December&nbsp;31, 2019. As a result, these stockholders, if they act together, may significantly influence all matters requiring stockholder approval, including the
election of directors and approval of significant corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change in control of our company that our other stockholders may believe is in their best
interests. This in turn could have a material adverse effect on our stock price and may prevent attempts by our stockholders to replace or remove the board of directors or management. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company,&#148; and the reduced disclosure requirements applicable to emerging growth companies may make our common stock
less attractive to investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act
of 2012 (JOBS Act). For so long as we remain an emerging growth company, we are permitted and plan to rely on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include not being required to comply with
the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002 (SOX), not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm
rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements, reduced disclosure obligations regarding executive compensation, and exemptions from the requirements of holding a
nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result, the information we provide stockholders will be different than the information that is available with
respect to other public companies. We cannot predict whether investors will find our common stock less attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading
market for our common stock, and our stock price may be more volatile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act provides that an emerging growth company
can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to
private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards, and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are
not emerging growth companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred and will continue to incur significant additional costs as a result of operating as a public
company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, and particularly after we are no longer an emerging growth company, we have incurred and will continue to incur
significant legal, accounting, and other expenses that we did not incur as a private company. The SOX, the Dodd-Frank Wall Street Reform, and Consumer Protection Act, the listing requirements of NASDAQ, and other applicable securities rules and
regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. We have hired, and expect that we will need to continue to hire,
additional accounting, finance, and other personnel in connection with our becoming, and our efforts to comply with the requirements of being, a public company, and our management and other personnel have devoted and will continue to devote a
substantial amount of time towards maintaining compliance with these requirements. These requirements have increased and will continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly.
For example, we expect that the rules and regulations applicable to us as a public company may make it more difficult and more expensive for us to maintain director and officer liability insurance, which could make it more difficult for us to
attract and retain qualified members of our board of directors. We are currently evaluating these rules and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and
regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could
result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to SOX Section&nbsp;404, we will be required to furnish a report by our management on our internal control over financial reporting
beginning with our second filing of an Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> with the SEC after we become a public company. However, while we remain an emerging growth company, we will not be required to include an
attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with SOX Section&nbsp;404 within the prescribed period, we will be engaged in a process to document
and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants, adopt a detailed work plan to assess
and document the adequacy of internal control over </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented, and implement a continuous reporting and
improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective
as required by SOX Section&nbsp;404. If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to maintain effective internal controls, our business, financial position, and results of operations could be adversely affected.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we are subject to reporting and other obligations under the Exchange Act, including the requirements of SOX
Section&nbsp;404, which require annual management assessments of the effectiveness of our internal control over financial reporting. However, our auditors will not be required to formally attest to the effectiveness of our internal control over
financial reporting pursuant to SOX Section&nbsp;404 until we are no longer an emerging growth company if we continue to take advantage of the exemptions available to us through the JOBS Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and
require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During the course of its testing, our management may identify material weaknesses or deficiencies which may not be remedied in time
to meet the deadline imposed by the Sarbanes-Oxley Act of 2002. These reporting and other obligations place significant demands on our management and administrative and operational resources, including accounting resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over
financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted
in the United States. Any failure to maintain effective internal controls could have an adverse effect on our business, financial position, and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will have broad discretion in the use of the net proceeds from this offering and may not use them effectively. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot specify with certainty the particular uses of the net proceeds we will receive from this offering. Our management will have broad
discretion in the application of the net proceeds, including for any of the purposes described in the section titled &#147;Use of Proceeds.&#148; Our management may spend a portion or all of the net proceeds from this offering in ways that our
stockholders may not desire or that may not yield a favorable return. The failure by our management to apply these funds effectively could harm our business, financial condition, results of operations and prospects. Pending their use, we may invest
the net proceeds from this offering in a manner that does not produce income or that loses value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not expect to pay any dividends for the
foreseeable future. Investors may never obtain a return on their investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should not rely on an investment in our common
stock to provide dividend income. We do not anticipate that we will pay any dividends to holders of our common stock in the foreseeable future. Instead, we plan to retain any earnings to maintain and expand our existing operations. In addition, any
future credit facility may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our common stock. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never
occur, as the only way to realize any return on their investment. As a result, investors seeking cash dividends should not purchase our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware law and provisions in our amended and restated certificate of incorporation and bylaws might
discourage, delay, or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions in our amended and restated certificate of incorporation and bylaws may discourage, delay, or prevent a merger, acquisition, or
other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares of our common stock. These provisions may also prevent or frustrate attempts by our stockholders
to replace or remove our management. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our charter documents: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish that our board of directors is divided into three classes, Class&nbsp;I, Class&nbsp;II, and
Class&nbsp;III, with each class serving staggered three-year terms; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that vacancies on our board of directors may be filled only by a majority of directors then in office,
even though less than a quorum; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that our directors may only be removed for cause; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">eliminate cumulative voting in the election of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize our board of directors to issue shares of preferred stock and determine the price and other terms of
those shares, including preferences and voting rights, without stockholder approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide our board of directors with the exclusive right to elect a director to fill a vacancy or newly created
directorship; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">permit stockholders to only take actions at a duly called annual or special meeting and not by written consent;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prohibit stockholders from calling a special meeting of stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require that stockholders give advance notice to nominate directors or submit proposals for consideration at
stockholder meetings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize our board of directors, by a majority vote, to amend the bylaws; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require the affirmative vote of at least 66 2/3% or more of the outstanding shares of common stock to amend many
of the provisions described above. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Section&nbsp;203 of the General Corporation Law of the State of
Delaware (DGCL), prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our
voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any provision of our amended and restated certificate of incorporation, amended and restated bylaws, or Delaware law that has the effect of
delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes
between us and our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws provide that, unless we consent to the selection of an alternative forum, the Court of Chancery of the State of
Delaware is the exclusive forum for (i)&nbsp;any derivative action or proceeding brought on behalf of us, (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
directors, officers, or other employees to us or our stockholders, (iii)&nbsp;any action arising pursuant to any provision of the DGCL or our certificate of incorporation or bylaws (as either may
be amended from time to time), or (iv)&nbsp;any action asserting a claim governed by the internal affairs doctrine, except, in each case, (A)&nbsp;any claim as to which such court determines that there is an indispensable party not subject to the
jurisdiction of such court (and the indispensable party does not consent to the personal jurisdiction of such court within 10 days following such determination), (B) which is vested in the exclusive jurisdiction of a court or forum other than such
court, or (C)&nbsp;for which such court does not have subject matter jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These exclusive-forum provisions may limit a
stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, employees, control persons, underwriters, or agents, which may discourage lawsuits against us and our directors,
employees, control persons, underwriters, or agents. Additionally, a court could determine that the exclusive forum provision is unenforceable, and our stockholders will not be deemed to have waived our compliance with the federal securities laws
and the rules and regulations thereunder. If a court were to find these provisions of our amended and restated bylaws inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur
additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business, financial condition, or results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements
other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials,
results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known
and unknown risks, uncertainties, and other important factors that are in some cases beyond our control and may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements
expressed or implied by the forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terms such as
&#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;would,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;could,&#148; &#147;intend,&#148; &#147;target,&#148; &#147;project,&#148; &#147;contemplate,&#148;
&#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;potential,&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions. Forward-looking statements contained in this prospectus include, but are not
limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other
positive results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and focus of our future clinical trials, and the reporting of data from those trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans relating to commercializing our product candidates, if approved, including the geographic areas of
focus and sales strategy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the expected potential benefits of strategic collaborations with third parties and our ability to attract
collaborators with development, regulatory, and commercialization expertise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates of the number of patients in the United States who suffer from the diseases we are targeting and
the number of patients that will enroll in our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size of the market opportunity for our product candidates in each of the diseases we are targeting;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to expand our product candidates into additional indications and patient populations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competing therapies that are or may become available; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the beneficial characteristics, safety, efficacy, and therapeutic effects of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing or likelihood of regulatory filings and approvals, including our expectation to seek special
designations, such as orphan drug designation, for our product candidates for various diseases; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain regulatory approval of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans relating to the further development and manufacturing of our product candidates, including additional
indications that we may pursue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">existing regulations and regulatory developments in the United States and other jurisdictions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for
the manufacture of our product candidates for preclinical studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent
terms where available and the outcome of our ongoing arbitration proceedings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the need to hire additional personnel and our ability to attract and retain such personnel;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional
financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital
expenditure requirements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS
Act; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our anticipated use of our existing resources and the proceeds from this offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which
we operate and financial trends that we believe may affect our business, financial condition, results of operations, and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking
statements speak only as of the date of this prospectus and are subject to a number of risks, uncertainties, and assumptions described in the section titled &#147;Risk Factors&#148; and elsewhere in this prospectus. Because forward-looking
statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our
forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any
forward-looking statements contained herein until after we distribute this prospectus, whether as a result of any new information, future events, or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject. These
statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not
be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_6"></A>MARKET, INDUSTRY, AND OTHER DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains estimates, projections, and other information concerning our industry, our business, and the markets for our product
candidates, including data regarding the estimated size of such markets and the incidence of certain medical conditions. We obtained the industry, market, and similar dataset forth in this prospectus from our internal estimates and research and from
academic and industry research, publications, surveys, and studies conducted by third parties, including governmental agencies. In some cases, we do not expressly refer to the sources from which this information is derived. In that regard, when we
refer to one or more sources of this type of information in any paragraph, you should assume that other information of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context
otherwise requires. Information that is based on estimates, forecasts, projections, market research, or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and
circumstances that are assumed in this information. While we believe that the data we use from third parties are reliable, we have not separately verified these data. Further, while we believe our internal research is reliable, such research has not
been verified by any third party. You are cautioned not to give undue weight to any such information, projections, and estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some
cases, we do not expressly refer to the sources from which data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is
derived from the same sources, unless otherwise expressly stated or the context otherwise requires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The sources of industry and market
data contained in this prospectus are listed below: ` </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Alzheimer&#146;s Association. &#147;2018 Alzheimer&#146;s Disease Facts and Figures.&#148;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Alzheimer&#146;s Association. &#147;Costs of Alzheimer&#146;s to Medicare and Medicaid.&#148;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Boeve, B., Baker, M., Dickson, D., Parisi, J., Giannini, C., et al. &#147;Frontotemporal dementia and
parkinsonism associated with the <FONT STYLE="white-space:nowrap">IVS1+1G-&gt;A</FONT> mutation in progranulin: a clinicopathologic study.&#148; <I>Brain: a Journal of Neurology</I>. Volume 129, Issue 11, November 2006. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Hansen, D., Hanson, J., Sheng, M. &#147;Microglia in Alzheimer&#146;s disease.&#148; <I>Journal of Cell
Biology</I>. Volume 217, Number 2, February 2018. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Kao, A., McKay, A., Singh, P., Brunet, A., Huang, E. &#147;Progranulin, lysosomal regulation and
neurodegenerative disease.&#148; <I>Nature Reviews Neuroscience.</I> Volume 18, Number 6, June 2017. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parkinson&#146;s Disease Foundation. &#147;Statistics.&#148; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sha, S., Miller, Z., Min, S., Zhou, Y., Brown, J., et al. &#147;An
<FONT STYLE="white-space:nowrap">8-week,</FONT> open-label, dose-finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations.&#148; <I>Alzheimer&#146;s</I><I></I><I>&nbsp;&amp; Dementia: Translational
Research</I><I></I><I>&nbsp;&amp; Clinical Interventions</I>. Volume 3, Issue 4, November 2017. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">World Health Organization. &#147;Neurological Disorders: Public Health Challenges.&#148; <I>World Health
Organization Press</I>. 2007. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Arthur, K., Calvo, A., Price, T. et al. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040.
Nat Commun 7, 12408 (2016). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Van der Ende, E., Meeter, L., Poos, J., Panman, J., Jiskoot, L., et al. &#147;Serum neurofilament light chain
in genetic frontotemporal dementia: a longitudinal, multicentre cohort study.&#148; <I>The Lancet Neurology</I>. Volume 18, Issue 12, December 2019. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net proceeds to us from the sale of the shares of our common stock in this offering will be approximately $195.2 million, or approximately
$224.7 million if the underwriters exercise their option to purchase additional shares in full, based on the offering price of $25.00 per share, and after deducting estimated underwriting discounts and commissions and estimated offering expenses
payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The principal purposes of this offering are to obtain additional capital to support our operations. We currently
anticipate that we will use the net proceeds from this offering, together with our existing resources, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $60.0 million to fund Phase&nbsp;2 and Phase 3 clinical trials for AL001 in <FONT
STYLE="white-space:nowrap">FTD-GRN</FONT> patients and expand into <FONT STYLE="white-space:nowrap">FTD-C9orf72</FONT> and other potential indications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $41.0 million to fund Phase 1 and Phase 2 clinical trials for AL002 and AL003;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $20.0 million to advance AL101 through Phase&nbsp;1 clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $41.0 million to continue to advance our preclinical development pipeline into Phase 1 clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $20.0 million to further develop our Discovery Platform; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the remainder to fund working capital and other general corporate activities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe opportunities may exist from time to time to expand our current business through license or acquisitions of, or investments in,
complementary businesses, products or technologies. While we currently have no agreements or commitments to complete any such transaction at this time, we may use a portion of the net proceeds for these purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operating expenses have increased and we expect them to continue to increase in 2020 and beyond as we advance our development pipeline and
accelerate our efforts to conduct clinical trials. Accordingly, we will need additional funds to complete our currently planned and future clinical trials and development programs. Based on our current operating plans and assumptions, we believe our
existing cash, cash equivalents, and marketable securities, together with the expected net proceeds from this offering, will enable us to meet our financial needs at least into the second half of 2022. The net proceeds from this offering, together
with our cash, cash equivalents, and marketable securities, will not be sufficient for us to fund any of our product candidates through regulatory approval, our preclinical development pipeline through Phase 1 clinical trials, or any product
candidates resulting from our Discovery Platform into preclinical studies and clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion
over the use of the net proceeds from this offering. The amounts and timing of our expenditures will depend upon numerous factors including the results of our research and development efforts, the timing and success of preclinical studies and any
ongoing clinical trials or clinical trials we may commence in the future, the timing of regulatory submissions, the amount of cash obtained through our existing collaborations and future collaborations, if any, and any unforeseen cash needs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending their uses, we plan to invest the net proceeds of this offering in short-term, interest-bearing, investment-grade instruments,
certificates of deposit or direct or guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_8"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not declared or paid any cash dividends on our capital stock since our inception. We intend to retain future earnings, if any, to
finance the operation and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. Payment of future cash dividends, if any, will be at the discretion of our board of directors after taking into account
various factors, including our financial condition, operating results, current and anticipated cash needs, the requirements and contractual restrictions of then-existing debt instruments, and other factors that our board of directors deems relevant.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc838337_22"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash, cash equivalents, and marketable securities and capitalization as of September&nbsp;30, 2019, as
follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an actual basis; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on an as adjusted basis to further reflect our issuance and sale of 8,350,000 shares of common stock in this
offering at the offering price of $25.00 per share, after deducting the estimated underwriting discounts and commissions and estimated expenses payable by us. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this table in conjunction with our consolidated financial statements and the related notes and the sections titled
&#147;Selected Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; that are included elsewhere in this prospectus. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of September 30, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(In&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and<BR>per&nbsp;share&nbsp;data)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">381,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">576,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, par value $0.0001 per share; 20,000,000 shares authorized and no shares issued
and outstanding, actual and as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, par value $0.0001 per share; 200,000,000&nbsp;shares authorized and
68,922,249&nbsp;shares issued and outstanding, actual; 200,000,000 shares authorized and 77,272,249 shares issued and outstanding, as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">407,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">602,871</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(189,293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(189,293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">413,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">218,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">413,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on the 68,922,249
shares of our common stock outstanding as of September&nbsp;30, 2019, and excludes the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4,822,524 shares of common stock issuable upon exercise of options to purchase shares of our common stock
outstanding as of September&nbsp;30, 2019 under our 2017 Stock Option and Grant Plan (2017 Plan), at a weighted-average exercise price of $8.97 per share; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,095,600 shares of common stock issuable upon exercise of options to purchase shares of our common stock
outstanding as of September&nbsp;30, 2019 under our 2019 Equity Incentive Plan (2019 Plan), at a weighted-average exercise price of $19.15 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,496,971 shares of common stock issuable upon exercise of options to purchase shares of our common stock that we
granted after September 30, 2019 under our 2019 Plan, at a weighted-average exercise price of $17.15 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6,911,739 shares of common stock reserved for future issuance under our 2019 Plan as of September&nbsp;30, 2019,
as well as any automatic increases in the number of shares of common stock reserved for future issuance under this plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,478,492 shares of common stock reserved for issuance under our 2019 Employee Stock Purchase Plan (ESPP) as of
September 30, 2019, as well as any automatic increases in the number of shares of common stock reserved for future issuance under this plan. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_9"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference
between the public offering price per share of our common stock and the as adjusted net tangible book value per share of our common stock immediately after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net tangible book value per share is determined by dividing our total tangible assets less our total liabilities by the number of shares of
our common stock outstanding. Our net tangible book value as of September&nbsp;30, 2019 was $218.6&nbsp;million, or $3.17 per share, based on the total number of shares of our common stock outstanding as of September&nbsp;30, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving further effect to our sale of 8,350,000 shares of common stock in this offering at the public offering price of $25.00 per share,
and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible book value as of September&nbsp;30, 2019 would have been approximately $413.8 million, or approximately
$5.36 per share. This represents an immediate increase in as adjusted net tangible book value per share of $2.19 to our existing stockholders and an immediate dilution in as adjusted net tangible book value per share of approximately $19.64&nbsp;to
new investors purchasing common stock in this offering. Dilution per share to new investors purchasing common stock in this offering is determined by subtracting as adjusted net tangible book value per share after this offering from the public
offering price per share paid by new investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table illustrates this dilution on a per share basis: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$<BR></TD>
<TD VALIGN="bottom" ALIGN="right">25.00<BR></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;<BR></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share as of September&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in as adjusted net tangible book value per share attributable to new investors purchasing
shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors purchasing shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters exercise their option to purchase 1,252,500 additional shares of common stock in this
offering in full at the public offering price of $25.00 per share, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, the as adjusted net tangible book value per share after this
offering would be $5.64 per share, and the dilution in as adjusted net tangible book value per share to new investors purchasing common stock in this offering would be $19.36 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes, on an as adjusted basis, as of September&nbsp;30, 2019, the number of shares of common stock purchased from us
on an as converted to common stock basis, the total consideration paid, or to be paid and the weighted-average price per share paid, or to be paid, by existing stockholders and by new investors in this offering at the public offering price of $25.00
per share, before deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Price Per<BR>Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders before this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,922,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">379,531,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">208,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,272,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">588,281,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The dilution information discussed above is illustrative only and will change based on the
actual offering price, the number of shares we sell and other terms of this offering that will be determined at pricing. The table above assumes no exercise of the underwriters&#146; option to purchase 1,252,500 additional shares in this offering.
If the underwriters&#146; option to purchase additional shares is exercised in full, the number of shares of our common stock held by existing stockholders would be reduced to 87.8% of the total number of shares of our common stock outstanding after
this offering, and the number of shares of common stock held by new investors participating in the offering would be increased to 12.2% of the total number of shares outstanding after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering is based on the 68,922,249 shares of our common stock
outstanding as of September&nbsp;30, 2019, and excludes the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">4,822,524 shares of common stock issuable upon exercise of options to purchase shares of our common stock
outstanding as of September&nbsp;30, 2019 under our 2017 Plan, at a weighted-average exercise price of $8.97 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,095,600 shares of common stock issuable upon exercise of options to purchase shares of our common stock
outstanding as of September&nbsp;30, 2019 under our 2019 Plan, at a weighted-average exercise price of $19.15 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,496,971 shares of common stock issuable upon exercise of options to purchase shares of our common stock that we
granted after September&nbsp;30, 2019 under our 2019 Plan, at a weighted-average exercise price of $17.15 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">6,911,739 shares of common stock reserved for future issuance under our 2019 Plan as of September&nbsp;30, 2019,
as well as any automatic increases in the number of shares of common stock reserved for future issuance under this plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,478,492 shares of common stock reserved for issuance under our ESPP as of September&nbsp;30, 2019, as well as
any automatic increases in the number of shares of common stock reserved for future issuance under this plan. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the
extent that any outstanding options are exercised or new options are issued under the equity benefit plans, or we issue additional shares of common stock or other securities convertible into or exercisable or exchangeable for shares of our capital
stock in the future, there will be further dilution to investors participating in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc838337_90a"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize our selected consolidated financial data for the periods and as of the dates indicated. We derived our
consolidated statement of operations data for the years ended December&nbsp;31, 2018, 2017, and 2016, and the consolidated balance sheet data as of December&nbsp;31, 2018 and 2017, from our audited consolidated financial statements included
elsewhere in this prospectus. We derived the consolidated statement of operations data for the nine months ended September&nbsp;30, 2019 and 2018, and the consolidated balance sheet data as of September&nbsp;30, 2019, from our unaudited interim
condensed consolidated financial statements and related notes included elsewhere in this prospectus. The unaudited interim condensed consolidated financial statements were prepared on the same basis as our audited consolidated financial statements
and reflect, in the opinion of management, all adjustments, which include only normal, recurring adjustments that are necessary to present fairly the unaudited interim condensed consolidated financial statements. Our historical results are not
necessarily indicative of the results that may be expected in the future, and our interim results are not necessarily indicative of the results to be expected for the full year or any other period. You should read the following selected consolidated
financial data in conjunction with our consolidated financial statements and the related notes appearing elsewhere in this prospectus and the information in the sections titled &#147;Summary Consolidated Financial Data&#148; and
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(In thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,679</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(82,062</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,271</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(52,248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(74,858</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(34,875</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.62</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used in computing net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,302,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,142,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,173,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,663,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,154,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 381,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 290,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 32,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">326,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">245,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">449,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">308,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(189,293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(114,435</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,187</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(97,398</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,033</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon the closing of our IPO in February 2019, all of the outstanding shares of our convertible preferred stock
converted into 45,374,836 shares of common stock. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc838337_9b"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results of operations together with the section
entitled &#147;Selected Consolidated Financial Data&#148; and our consolidated financial statements and related notes included elsewhere in this prospectus. This discussion contains forward-looking statements that involve risks and uncertainties,
including those described in the section titled &#147;Special Note Regarding Forward Looking Statements.&#148; Our actual results and the timing of selected events could differ materially from those discussed below. Factors that could cause or
contribute to such differences include, but are not limited to, those identified below and those set forth under the section titled &#147;Risk Factors&#148; included elsewhere in this prospectus. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage
biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain
disorders. We are developing therapies designed to simultaneously counteract these pathologies by restoring healthy immune function to the brain. Supporting our scientific approach, our Discovery Platform enables us to advance a broad portfolio of
product candidates, validated by human genetics, which we believe will improve the probability of technical success over shorter development timelines. As a result, in the last six years, we have identified over 120 immune system targets, progressed
over ten programs into preclinical research, and advanced four product candidates, AL001, AL002, AL003, and AL101 into clinical development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations have been financed primarily through the issuance and sale of convertible preferred stock, our collaboration with AbbVie, and
issuance of common stock upon the completion of our IPO. We completed our IPO in February 2019, and received $168.2&nbsp;million net proceeds, net of underwriting discounts and commissions and offering expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have not had any products approved for sale and have not generated any revenue from product sales nor been profitable. Further, we
do not expect to generate revenue from product sales until such time, if ever, that we are able to successfully complete the development and obtain marketing approval for one of our product candidates. We will continue to require additional capital
to develop our product candidates and fund operations for the foreseeable future. We have incurred net losses in each year since inception and expect to continue to incur net losses for the foreseeable future. Our ability to generate product revenue
will depend on the successful development and eventual commercialization of one or more of our product candidates. Our net losses were $52.2&nbsp;million, $32.5&nbsp;million, and $15.1&nbsp;million for the years ended December&nbsp;31, 2018, 2017,
and 2016, respectively, and $74.9&nbsp;million and $34.9&nbsp;million for the nine months ended September&nbsp;30, 2019 and 2018, respectively. As of September&nbsp;30, 2019, we had an accumulated deficit of $189.3&nbsp;million. Substantially all of
our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect our expenses will increase substantially in connection with
our ongoing activities, as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">advance product candidates through preclinical studies and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pursue regulatory approval of product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hire additional personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">operate as a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire, discover, validate, and develop additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require the manufacture of supplies for our preclinical studies and clinical trials; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain, maintain, expand, and protect our intellectual property portfolio. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not generated any
revenue from product sales and do not expect to do so in the near future. Our revenue to date has been primarily related to the AbbVie Agreement to <FONT STYLE="white-space:nowrap">co-develop</FONT> product candidates in two programs in clinical
development with AbbVie. We recognize revenue related to our research and development grant as the related research services are performed. We recognize revenue from the upfront payments under the AbbVie Agreement over time as the services are
provided. Revenues are recognized as the program costs are incurred by measuring actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. In addition to receiving the upfront payments, we may
also be entitled to development and regulatory milestone payments, <FONT STYLE="white-space:nowrap">opt-in</FONT> payments for continued development after
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> for AL002 and AL003, and other future payments from profit sharing or royalties after commercialization of product candidates from such programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that our revenue for the next several years will be derived primarily from the AbbVie Agreement. We recorded deferred revenue of
$159.4&nbsp;million as of September&nbsp;30, 2019. The deferred revenue is expected to be recognized over the research and development period of the programs through the completion of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> for AL002 and AL003. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development
Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses account for a significant portion of our operating expenses. We record research and
development expenses as incurred. Research and development expenses consist primarily of costs incurred for the discovery and development of our product candidates, which include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred under agreements with third-party contract organizations, preclinical testing organizations,
and consultants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to production of clinical materials, including fees paid to contract manufacturers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">laboratory and vendor expenses related to the execution of preclinical studies and clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">personnel-related expenses, including salaries, benefits, and stock-based compensation for personnel engaged in
research and development functions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs related to the preparation of regulatory submissions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party license fees; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">facilities and other expenses, which include expenses for rent and maintenance of facilities, depreciation and
amortization expense, and other supplies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expense all research and development costs in the periods in which they
are incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors, collaborators, and third-party service providers.
Nonrefundable advance payments for goods or services to be received in future periods for use in research and development activities are deferred and capitalized. The capitalized amounts are then expensed as the related goods are delivered and as
services are performed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specific program expenses include expenses associated with the development of our most advanced product
candidates, AL001, which is in a Phase 2 clinical trial, and AL002, AL003, and AL101, which are in Phase 1 clinical trials. We also have expenses related to the discovery and development of future product candidates and separately tracked expenses
related to programs that we expect to move out of preclinical studies and into Phase 1 clinical trials. We do not track personnel or other operating expenses incurred for our research and development programs on a program-specific basis. These
expenses primarily relate to salaries and benefits, stock-based compensation, facility expenses, including depreciation, and lab consumables. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At this time, we cannot reasonably estimate or know the nature, timing, and estimated costs
of the efforts that will be necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. We expect our research and development expenses to increase substantially for the foreseeable future as we
continue to invest in research and development activities related to developing our product candidates, as our product candidates advance into later stages of development, as we begin to conduct larger clinical trials, as we seek regulatory
approvals for any product candidates that successfully complete clinical trials, and incur expenses associated with hiring additional personnel to support our research and development efforts. The process of conducting the necessary clinical
research to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of personnel-related costs, including stock-based compensation, for our personnel in
executive, legal, finance and accounting, information technology, human resources, and other administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters, professional
fees paid for accounting, auditing, consulting, and tax services, insurance costs, and facility costs not otherwise included in research and development expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued
research activities and development of our programs. We also anticipate that we will incur increased expenses as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC and those
of the NASDAQ Stock Market on which our securities are traded, legal, auditing, additional insurance expenses, investor relations activities, and other administrative and professional services. We also commenced confidential arbitration in June 2019
with respect to certain intellectual property matters related to a former consulting <FONT STYLE="white-space:nowrap">co-founder</FONT> that are also expected to lead to increased legal expenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income, Net </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income,
net consists of interest earned on our cash equivalents and marketable securities and foreign currency transaction gains and losses incurred during the period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Nine
Months Ended September&nbsp;30, 2019 and 2018 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollar</B><br><B>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,145</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(169</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,314</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(82,062</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,271</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,791</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(74,858</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(34,875</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(39,983</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total revenue was $15.2&nbsp;million for the nine months ended September&nbsp;30, 2019, compared to $18.5&nbsp;million for the nine months
ended September&nbsp;30, 2018. We recognize revenue from the upfront payments under the AbbVie Agreement over time as the services are provided. Revenues are recognized as the program costs are incurred by measuring actual costs incurred to date
compared to the overall total expected costs to satisfy the performance obligation. Changes in estimates for revenue recognized over time are recognized on a cumulative basis. Revenue decreased by $3.1&nbsp;million as we had an increase in total
expected costs for the programs arising from changes to the Phase 2 protocol for AL002. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses were $74.8&nbsp;million for the nine months ended September&nbsp;30, 2019, compared to $48.9&nbsp;million for
the nine months ended September&nbsp;30, 2018. The increase of $25.8&nbsp;million was driven by a $9.2&nbsp;million increase in personnel-related expenses, including stock-based compensation, due to an increase in headcount and issuance of option
grants to employees. Expenses for AL101 increased by $5.7&nbsp;million as we did not incur any expenses for AL101 until the second quarter of 2018 and this year we are preparing to enter clinical trials in the fourth quarter of 2019. Further, there
was a $4.9&nbsp;million increase in facilities and other unallocated research and development related to the lease expense for the new headquarters and higher depreciation expense due to purchase of property and equipment. In addition, expenses
increased for AL001 by $3.0&nbsp;million and AL002 by $2.9&nbsp;million to support clinical trials that began in the second half of 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollar</B><br><B>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Direct research and development expenses</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AL001</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AL101</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AL002</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AL003</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,639</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other early stage programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Indirect research and development expenses</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related (including stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities and other unallocated research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses were $22.5&nbsp;million for the nine months ended September&nbsp;30, 2019, compared to $7.9&nbsp;million
for the nine months ended September&nbsp;30, 2018. The increase of $14.6&nbsp;million was primarily due to a $7.1&nbsp;million increase in personnel-related expenses, including stock-based compensation, as a result of an increase in headcount and
issuance of option grants to employees. Facilities and general overhead expenses increased by $5.1&nbsp;million due to additional lease expense related to the lease for the new headquarters, impairment loss on the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset related to the sublease, higher depreciation expense due to purchase of property and equipment, directors and officers insurance necessary to operate a public company, and other allocated
costs from the increased headcount. The increase is also due to a $1.5&nbsp;million increase in consulting expense to support the growth of the business related to information technology, accounting, human resources, and other administrative
functions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income, Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income, net was $7.2&nbsp;million for the nine months ended September&nbsp;30, 2019, compared to $3.4&nbsp;million for the nine months
ended September&nbsp;30, 2018. The increase of $3.8&nbsp;million was due to interest income earned after we invested the proceeds from the issuance of our common stock upon completion of the IPO into short-term marketable securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years Ended December&nbsp;31, 2018 and 2017 </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollar</B><br><B>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(694</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,679</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,609</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,841</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(52,248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,768</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Revenue</I></B><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total revenue was $27.7&nbsp;million for the year ended December 31, 2018, compared to $3.7&nbsp;million for the year ended December 31, 2017.
The increase of $23.9&nbsp;million was primarily due to collaboration revenue recognized from the upfront payments under the AbbVie Agreement, which was entered into in the fourth quarter of 2017, offset by a $0.7&nbsp;million reduction related to
grant revenue from the U.S. government. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Research and Development Expenses</I></B><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses were $73.0&nbsp;million for the year ended December&nbsp;31, 2018, compared to $29.9&nbsp;million for the
year ended December&nbsp;31, 2017. The increase of $43.1&nbsp;million was driven by an increase in expenses for four product candidates that we are preparing for or have entered into Phase 1 clinical trials and related increase in activities for the
manufacturing of clinical materials, including $10.6&nbsp;million for AL001, $3.2 million for AL101, $12.4&nbsp;million for AL002, and $9.2&nbsp;million for AL003. In addition, we had an increase in research and development expenses of
$3.3&nbsp;million related to other preclinical programs currently in development. Personnel-related expenses, including stock-based compensation, increased by $3.4&nbsp;million due to an increase in headcount, partially offset by a large number of
restricted stock awards held by non-employee founders that fully vested in the 2017, which had no related expense in 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Dollar</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Direct research and development expenses</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AL001</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AL101</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AL002</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AL003</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other early stage programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Indirect research and development expenses</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related (including stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facilities and other unallocated research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I></I><B><I>General and Administrative Expenses</I></B><I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses were $11.9&nbsp;million for the year ended December&nbsp;31, 2018, compared to $6.5&nbsp;million for the
year ended December 31, 2017. The increase of $5.4&nbsp;million was primarily due to a $3.9&nbsp;million increase in personnel-related expenses, including stock-based compensation, as a result of an increase in headcount and issuance of option
grants to employees in July and November 2018. The increase is also due to a $1.0&nbsp;million increase in consulting expense to support the growth of the business related to information technology, human resources, and other administrative
functions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Other Income, Net</I></B><I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income, net was $5.0&nbsp;million for the year ended December 31, 2018, compared to $0.2&nbsp;million for the year ended
December&nbsp;31, 2017. The increase of $4.8&nbsp;million was due to interest income earned after we invested the majority of the $205.0&nbsp;million upfront payments from the AbbVie Agreement and the proceeds from our issuance and sale in April,
July, and October 2018 of 9,373,633 shares of our Series E convertible preferred stock into short-term marketable securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital
Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception through September&nbsp;30, 2019, our operations have been financed primarily by net proceeds of
$210.5&nbsp;million from sales of our convertible preferred stock and through the $205.0&nbsp;million in upfront payments from the AbbVie Agreement. In addition, on February&nbsp;7, 2019, we completed our IPO through issuing and selling 9,739,541
shares of common stock at a public offering price of $19.00 per share, including 489,541 shares sold pursuant to the underwriters&#146; partial exercise of their option to purchase additional shares. We received aggregate net proceeds from the
offering, net of underwriting discounts and commissions and offering expenses, of $168.2&nbsp;million. As of September&nbsp;30, 2019, we had $381.4&nbsp;million of cash, cash equivalents, and marketable securities. As of September&nbsp;30, 2019, we
had an accumulated deficit of $189.3&nbsp;million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future Funding Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary uses of cash are to fund our operations, which consist primarily of research and development expenditures related to our programs,
and to a lesser extent, general and administrative expenditures. We expect our expenses to continue to increase in connection with our ongoing activities, in particular as we continue to advance our product candidates and our discovery programs. In
addition, we expect to incur additional costs associated with operating as a public company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our current operating plan, we believe that our existing cash, cash equivalents,
and marketable securities will enable us to fund our operating expenses and capital expenditure requirements through at least the next 12&nbsp;months. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our
available capital resources sooner than we currently expect. We may also choose to seek additional financing opportunistically. We expect to need to obtain substantial additional funding in the future for our research and development activities and
continuing operations. If we were unable to raise capital when needed or on favorable terms, we would be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future capital requirements will depend on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and progress of preclinical and clinical development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and scope of preclinical and clinical programs we decide to pursue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful enrollment in and completion of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish agreements with third-party manufacturers for clinical supply for our clinical trials
and, if our product candidates are approved, commercial manufacturing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain our current research and development programs and establish new research and development
programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">addition and retention of key research and development personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our efforts to enhance operational, financial, and information management systems, and hire additional personnel,
including personnel to support development of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter and
performing our obligations in such collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and amount of milestone and other payments we may receive under our collaboration arrangements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our eventual commercialization plans for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs involved in prosecuting, defending, and enforcing patent claims and other intellectual property claims,
including related to the ongoing arbitration proceeding that we commenced in June 2019; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of regulatory approvals. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could
significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements
associated with such operating plans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash flows for the periods indicated (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">127,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,993</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(70,481</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">145,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(224,119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(801</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(78,931</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(266,584</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash provided by (used in) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">131,146</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="top">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">(77</TD>
<TD NOWRAP VALIGN="top">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&nbsp;30, 2019, cash used in operating activities was $70.5&nbsp;million. This was mainly due to the net
loss of $74.9&nbsp;million and the decrease in deferred revenue of $15.2&nbsp;million as revenue was recognized related to the AbbVie Agreement. This was offset by a <FONT STYLE="white-space:nowrap">non-cash</FONT> charge of $11.0&nbsp;million for
stock-based compensation and an increase of $7.5&nbsp;million in accrued liabilities and accrued clinical supply costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine
months ended September&nbsp;30, 2018, cash provided by operating activities was $145.1&nbsp;million. The net cash inflow from operations primarily resulted from the receipt of a $200.0&nbsp;million upfront payment from AbbVie in January 2018, that
was reflected as a net increase in deferred revenue of $181.6&nbsp;million during the period. This was mainly offset by a net loss of $34.9&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2018, cash provided by operating activities was $127.5&nbsp;million. The net cash inflow from operations
primarily resulted from the receipt of a $200.0&nbsp;million upfront payment from AbbVie in January 2018, that was reflected as a net increase in deferred revenue of $172.5 million during the period. This was mainly offset by net loss of
$52.2&nbsp;million. In addition, the company had a non-cash charge of $6.9 million for stock-based compensation.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended
December&nbsp;31, 2017, cash used in operating activities was $17.8&nbsp;million. The net cash outflow from operations primarily resulted from our net loss of $32.5&nbsp;million offset by a non-cash charge of $6.0&nbsp;million and an increase in net
operating assets and liabilities of $8.7&nbsp;million. The non-cash charge consisted primarily of $5.4&nbsp;million for stock-based compensation. The increase in net operating assets and liabilities of $8.7&nbsp;million was primarily due to the
$6.7&nbsp;million increase in accrued liabilities and accrued clinical supply costs from growth of our business and commencement of manufacturing activities in 2017 and $2.1&nbsp;million increase in deferred revenue from receiving an upfront payment
of $5.0&nbsp;million in October 2017 from our collaboration with AbbVie offset by the revenue recognized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended
December&nbsp;31, 2016, cash used in operating activities was $13.0&nbsp;million. The net cash outflow from operations primarily resulted from our net loss of $15.1&nbsp;million offset by a non-cash charge of $2.0&nbsp;million for stock-based
compensation. Net operating assets and liabilities did not change significantly during the period due to offsetting small increases and decreases in the operating accounts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investing Activities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine
months ended September&nbsp;30, 2019, cash used in investing activities of $78.9&nbsp;million was primarily related to the purchase of short-term marketable securities of $411.2&nbsp;million offset by the proceeds from maturities of marketable
securities of $346.0&nbsp;million. In addition, we used cash for the purchase of $13.7&nbsp;million of property and equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the
nine months ended September&nbsp;30, 2018, cash used in investing activities of $266.6&nbsp;million was primarily related to the purchase of short-term marketable securities of $395.1&nbsp;million offset by the proceeds from maturities of short-term
marketable securities of $130.0&nbsp;million. In addition, we used cash for the purchase of $1.5&nbsp;million of property and equipment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2018, cash used in investing activities of $224.1&nbsp;million was primarily related to the purchase of
short-term marketable securities of $472.2&nbsp;million offset by the proceeds from maturities of marketable securities of $250.0&nbsp;million. In addition, we used cash for the purchase of $1.9&nbsp;million of property and equipment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2017 and 2016, cash used in investing activities of $0.8&nbsp;million and $2.3&nbsp;million,
respectively, was related to the purchase of property and equipment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&nbsp;30, 2019, cash provided by financing activities of $170.9&nbsp;million was primarily from net proceeds
of the issuance of 9,739,541 shares of our common stock upon the completion of our IPO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the nine months ended September&nbsp;30,
2018, cash provided by financing activities of $132.4&nbsp;million was mainly from the net proceeds of the issuance of 9,349,012 shares of our Series E convertible preferred stock in April 2018 and July 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2018, cash provided by financing activities of $131.1&nbsp;million was from net proceeds of the issuance
of 9,373,633 shares of our Series E convertible preferred stock in April&nbsp;2018, July, and October 2018, offset by payment of $1.9&nbsp;million of deferred offering costs for our IPO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2017, cash used in financing activities was less than $0.1&nbsp;million for payments of issuance costs
for our Series E convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2016, cash used in financing activities was
$0.1&nbsp;million for payments of issuance costs for our Series D convertible preferred units, which subsequently converted into convertible preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Other Commitments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our commitments and contractual obligations as of December&nbsp;31, 2018 (in&nbsp;thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments Due by Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Contractual Obligations:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;Than<BR>1 Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1 to 3<BR>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3 to 5<BR>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;Than<BR>5 Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2018, we signed a lease agreement to lease approximately 105,000 square feet in a new office in South
San Francisco at a cost of $73.9&nbsp;million over a <FONT STYLE="white-space:nowrap">ten-year</FONT> term. We moved into the space in May 2019 and it serves as our new headquarters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to our license agreement with Adimab, we have obligations to make future milestone and royalty payments. We will owe up to
$3.5&nbsp;million in milestone payments per program to Adimab for our product candidates. We will also owe <FONT STYLE="white-space:nowrap">low-</FONT> to <FONT STYLE="white-space:nowrap">mid-</FONT> single-digit royalty payments for commercial
sales of such product candidates. Due to the contingent nature of the milestone and royalty payments, they are not included in the table above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also entered into development and manufacturing services agreements with multiple contract manufacturers for the development and
manufacture of biologic products, the amount and timing of which may vary based on the timing of services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September 30, 2019,
there have been no material changes to our contractual obligations and other commitments as compared to those as of December 31, 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT
STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not entered into any
<FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements and do not have any holdings in variable interest entities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting
Polices and Estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management&#146;s discussion and analysis of our financial condition and results of operations is based on our
consolidated financial statements, which have been prepared in accordance with generally accepted accounting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
principles in the United States (GAAP). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and
the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on
various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual
results may differ from these estimates under different assumptions or conditions and any such differences may be material. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2014, the Financial Accounting Standards Board (FASB) issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2014-09,</FONT>
<I>Revenue from Contracts with Customers</I> (ASC 606). We have early adopted the new standard using the full retrospective method effective January&nbsp;1, 2017, which retrospectively applied the standard to all prior periods presented. Under
ASC&nbsp;606, an entity recognizes revenue when control of promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. In determining the
appropriate amount of revenue to be recognized as we fulfill our obligations under arrangements, we perform the following steps: (i)&nbsp;identify the contract(s) with a customer, (ii)&nbsp;identify the performance obligations in the contract,
(iii)&nbsp;determine the transaction price, (iv)&nbsp;allocate the transaction price to the performance obligations in the contract, and (v)&nbsp;recognize revenue when (or as) the entity satisfies the performance obligation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We signed
the AbbVie Agreement to <FONT STYLE="white-space:nowrap">co-develop</FONT> antibodies to two program targets in preclinical development. Under the terms of the AbbVie Agreement, AbbVie made $205.0&nbsp;million in upfront payments, of which
$5.0&nbsp;million and $200.0&nbsp;million was received by us in October 2017 and January 2018, respectively. We will perform research and development services for the antibodies in the two programs through the end of Phase&nbsp;2 clinical trials.
AbbVie will then have the exclusive right to exercise an option to enter into a license and collaboration agreement with us for one or both programs. If AbbVie exercises its option for a program, AbbVie will take over the development of the product
candidates for such program and costs will be split between the parties. We will also share in profits and losses upon commercialization of any products from such program. However, following AbbVie&#146;s exercise of its option for a program, we may
opt out of sharing in development costs and profits or losses for that program and instead receive a tiered royalty. Additionally, under the terms of the AbbVie Agreement, if AbbVie exercises both of its options, and both programs meet all
milestones, we are eligible to earn up to an additional $985.6&nbsp;million in milestone payments and option-exercise fees. We assessed the AbbVie Agreement in accordance with ASC&nbsp;606 and concluded that AbbVie is a customer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have determined that there are two research and development performance obligations as part of the agreement with AbbVie, one research and
development performance obligation for each of the two programs. The <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront cash payment of $5.0&nbsp;million and $200.0&nbsp;million received in October 2017 and January 2018, respectively,
was included in the transaction price. None of the remaining development and regulatory milestone and program <FONT STYLE="white-space:nowrap">opt-in</FONT> payment amounts have been included in the transaction price, as all these amounts were fully
constrained as of December&nbsp;31, 2018. As part of our evaluation of the constraint, we considered numerous factors, including that receipt of the milestone amounts is outside of our control and contingent upon success in future clinical trials.
Any consideration related to royalties on net product sales will be recognized when the related sales occur and therefore have also been excluded from the transaction price. We will <FONT STYLE="white-space:nowrap">re-evaluate</FONT> the transaction
price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize collaboration
revenue by measuring the progress toward complete satisfaction of the performance obligation using an input measure. In order to recognize revenue over the research and development </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
period, we measure actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Revenues are recognized as the program costs are incurred. We
will <FONT STYLE="white-space:nowrap">re-evaluate</FONT> the estimate of expected costs to satisfy the performance obligation each reporting period and make adjustments for any significant changes. Clinical trials are expensive and can take many
years to complete, and the outcome is inherently uncertain. Changes in our forecasted costs are likely to occur over time based upon changes in clinical trial procedures set forth in protocols, changes in estimates of manufacturing costs, or
feedback from regulators on the design or operation of our clinical trials. We have had changes to the overall expected costs to satisfy the performance obligations from period to period. For the three months ended September&nbsp;30, 2019, we had a
10%&nbsp;increase in the forecast of total expected costs due to changes to the clinical trial plans. For the three months ended September&nbsp;30, 2019, the increase in the overall expected costs to satisfy the performance obligation resulted in an
approximately $5&nbsp;million reduction in revenue compared to if the expected costs had remained the same, as a result of the cumulative catch up for the change in estimate. We recorded deferred revenue of $159.4&nbsp;million and
$174.6&nbsp;million as of September&nbsp;30, 2019 and December&nbsp;31, 2018, respectively. The deferred revenue is expected to be recognized over the research and development period of the programs through the completion of Phase&nbsp;2 clinical
trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We record accrued expenses for estimated preclinical study and clinical trial expenses. Estimates are based on the services performed pursuant
to contracts with research institutions, contract research organizations in connection with clinical studies, investigative sites in connection with clinical studies, vendors in connection with preclinical development activities, and contract
manufacturing organizations in connection with the production of materials for clinical trials. Further, we accrue expenses related to clinical trials based on the level of patient enrollment and activity according to the related agreement. We
monitor patient enrollment levels and related activity to the extent reasonably possible and make judgments and estimates in determining the accrued balance in each reporting period. If we underestimate or overestimate the level of services
performed or the costs of these services, our actual expenses could differ from our estimates. To date, we have not experienced significant changes in our estimates of preclinical studies and clinical trial accruals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation is measured at the date of grant, based on the estimated fair value of the award and recognized as an expense over the
employee&#146;s requisite service period (usually the vesting period) on a straight-line basis. We estimate the grant date fair value, and the resulting stock-based compensation, using the Black-Scholes option-pricing model. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the adoption of ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07,</FONT> beginning July&nbsp;1, 2018, we account for stock-based
compensation arrangements with <FONT STYLE="white-space:nowrap">non-employees</FONT> in a similar manner as employees and no longer need to remeasure the awards each period. We can choose to use the expected life or the contractual term on an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">award-by-award</FONT></FONT> basis. The fair value of these options is measured using the Black-Scholes option-pricing model reflecting the same assumptions as applied to employee options
in each of the reported periods. We adjust for actual forfeitures as they occur for both employees and nonemployees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recorded
stock-based compensation of $6.9&nbsp;million, $5.4&nbsp;million, and $2.0&nbsp;million for the years ended December&nbsp;31, 2018, 2017, and 2016, respectively. As of December&nbsp;31, 2018, we had $8.5&nbsp;million of unrecognized stock-based
compensation related to unvested restricted common stock, which we expect to recognize over a weighted-average period of 2.4&nbsp;years, and $28.9&nbsp;million of unrecognized stock-based compensation related to unvested stock options, which we
expect to recognize over a remaining <FONT STYLE="white-space:nowrap">weighted-average</FONT> period of 3.6&nbsp;years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Black-Scholes option-pricing model requires the use of highly subjective assumptions
which determine the fair value of stock-based awards. These assumptions include: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Expected Term</I>&#151;The expected term represents
the period that stock-based awards are expected to be outstanding. Our profit interest units did not have a contractual term. However, we estimated a constructive maturity of the profit interest units based on the expected exit or liquidity
scenarios for Alector. Our historical share option exercise is limited due to a lack of sufficient data points and did not provide a reasonable basis upon which to estimate an expected term. The expected term for stock options was derived by using
the simplified method which uses the midpoint between the average vesting term and the contractual expiration period of the stock-based award. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Expected Volatility</I>&#151;We have limited information on the volatility of our stock as shares of our common stock were not actively
traded on any public markets prior to February&nbsp;7, 2019. The expected volatility was derived from the historical stock volatilities of comparable peer public companies within our industry. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Risk-Free Interest Rate</I>&#151;The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the measurement date
with maturities approximately equal to the expected term. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Expected Dividend</I>&#151;The expected dividend rate is zero because we have
not historically paid and do not expect for the foreseeable future to pay a dividend on our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Conversion of
Alector LLC into Alector, Inc., Alector LLC had issued profit interest units to employees. The profit interest units had a &#147;strike price&#148; and are economically similar to a stock option with an exercise price. In the event of a distribution
by Alector LLC, the proceeds distributed to the holder would be reduced by the strike price. The strike price was established pursuant to the terms of the Alector LLC operating agreement. For accounting purposes, we measured the fair value of the
profit units based on valuations of our common stock prepared by an unrelated third-party valuation firm in accordance with the guidance provided by the American Institute of Certified Public Accountants Practice Guide, <I>Valuation of
Privately-Held-Company Equity Securities Issued as Compensation</I>, and the application of the Black-Scholes option-pricing model. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
vested profit interest units converted on a net issuance basis into shares of common stock and the unvested profit interest units converted on a net issuance basis into restricted common stock. All vesting provisions remained the same following the
Conversion. We continue to record stock-based compensation for the restricted stock over the vesting period based on the grant-date fair value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the conversion, the fair values of the shares of common stock underlying our stock-based awards were estimated on each grant date by our
board of directors. In order to determine the fair value of our common stock, our board of directors considered, among other things, contemporaneous valuations of our common stock prepared by an unrelated third-party valuation firm in accordance
with the guidance provided by the American Institute of Certified Public Accountants Practice Guide,<I></I><I>&nbsp;Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For our valuations performed prior to December&nbsp;31, 2017, we used the OPM backsolve method. In an option pricing method (OPM) framework,
the backsolve method for inferring the equity value implied by a recent financing transaction involves making assumptions for the expected time to liquidity, volatility, and <FONT STYLE="white-space:nowrap">risk-free</FONT> rate and then solving for
the value of equity such that value for the most recent financing equals the amount paid. This method was selected as management concluded that the contemporaneous financing transaction was an
<FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> transaction. We performed a valuation contemporaneously with the issuance of our Series D preferred units in December 2015. We also performed a valuation contemporaneously with our Conversion
in October 2017 based on term sheets for an anticipated Series E preferred stock financing. As of these valuation dates, we were at an early stage of development and future liquidity events were difficult to forecast. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For our valuations performed starting April 2018, equity value was allocated using the OPM and the Probability Weighted Expected Return Method
(PWERM) or the hybrid method. The hybrid method applied the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
PWERM utilizing the probability of going public and the OPM was utilized in the remaining private scenario. The hybrid method was used commencing April 2018, because of a near-term potential IPO
scenario that also factored in the inherent uncertainty associated with being able to complete an IPO. We performed valuations contemporaneously with the April 2018 and July 2018 issuances of our Series E preferred stock. We also performed a
valuation as of September&nbsp;30, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For valuations after the completion of the IPO, our board of directors determines the fair value
of each share of underlying common stock based on the closing price of our common stock as reported on the NASDAQ Global Select Market on the date of grant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest Rate Risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed
to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. The primary objective of our investment activities is to preserve capital to fund our operations. We also seek to maximize income from
our investments without assuming significant risk. To achieve our objectives, we maintain a portfolio of investments in a variety of securities of high credit quality and generally short-term duration, invested in compliance with our policy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We had cash, cash equivalents, and marketable securities of $381.4&nbsp;million and $290.4&nbsp;million as of September&nbsp;30, 2019 and
December&nbsp;31, 2018, respectively, which consisted primarily of bank deposits, money market funds, short-term government marketable securities, and corporate bonds. Such interest-earning instruments carry a degree of interest rate risk; however,
historical fluctuations in interest income have not been significant for us. Due to the generally short-term maturities of our cash equivalents and marketable securities, and the low risk profile of our marketable securities, an immediate 100 basis
point change in interest rates would not have a material effect on the fair market value of our cash equivalents and marketable securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign
Currency Risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our expenses are generally denominated in U.S. dollars. However, we have entered into a limited number of contracts
with vendors for research and development services with payments denominated in foreign currencies, including the Euro. We are subject to foreign currency transaction gains or losses on our contracts denominated in foreign currencies. To date,
foreign currency transaction gains and losses have not been material to our financial statements, and we have not had a formal hedging program with respect to foreign currency. A 10% increase or decrease in current exchange rates would not have a
material effect on our financial results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JOBS Act </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies may delay adopting new or revised
accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and,
therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earliest of (i)&nbsp;the last day of our first fiscal year in which we have total annual
gross revenues of $1.07&nbsp;billion or more, (ii)&nbsp;the date on which we are deemed to be a &#147;large accelerated filer&#148; under the rules of the SEC with at least $700.0&nbsp;million of outstanding equity securities held by <FONT
STYLE="white-space:nowrap">non-affiliates,</FONT> (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the previous three years, or (iv)&nbsp;the
last day of our fiscal year following the fifth anniversary of the date of the completion of our initial public offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc838337_23"></A>A LETTER FROM ARNON </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prospective Alector co-owner, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At Alector, we do
not view diseases of aging as immutable facts. We are on a mission to slow down their progression and prevent their occurrence. We envision a world where each individual retains his or her full brain function and cognitive faculties throughout
life&#151;a world where dementia and neurodegeneration are illnesses of the past just as smallpox, diphtheria, rubella, and polio have become. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the early 20<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> century, the root cause of neurodegeneration has been considered to
be misfolded proteins such as amyloid-beta plaques and TAU tangles in Alzheimer&#146;s disease, alpha-synuclein in Parkinson&#146;s disease, and TDP-43 in FTD and amyotrophic lateral sclerosis (ALS). Other pathologies that typify neurodegeneration,
including the dysfunction and destruction of neuronal connections, the accelerated death of nerve cells, and the dysfunction of the brain support cells, were thought to be consequences of these misfolded proteins. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our founding six years ago, we have challenged this widely held belief. We made the case that multiple pathologies that typify
neurodegeneration become autonomous of the misfolded proteins and of each other at early disease stages, and that for therapeutic purposes, these pathologies should be viewed as independent causes of the disorder. With this understanding, we
searched for an underlying biological process that these pathologies share. Discoveries on the genetic underpinning of neurodegeneration and on the functions of the brain immune system led us to conclude that these parallel pathologies are primarily
caused by a dysfunctional brain immune system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The specific scientific advances that enabled our conclusion were: (1)&nbsp;the
identification of harmful genetic mutations that increase the risk of developing Alzheimer&#146;s disease; (2)&nbsp;the revelation that the majority of these mutations are in proteins that regulate the brain immune system; and (3)&nbsp;the findings
that the immune cells in the brain are responsible for a myriad of functions, which include compacting and disposing of misfolded proteins, the regulation of neuronal connections, and the survival and function of the brain&#146;s support cells and
neurons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since most neurodegenerative diseases are diseases of aging, we postulated that the brain immune cells lose their competence
with time and are no longer able to support normal brain function or to repair avoidable brain pathologies. In futile attempts to act, the senescing immune cells may further exacerbate the disease by secreting toxic immune mediators and by
indiscriminate scavenging. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With this understanding, we devoted the last six years to the development of novel therapeutics that harness
the brain&#146;s immune system to treat neurodegeneration. We have advanced four of our product candidates into clinical trials and plan to test the impact of these product candidates initially in patients suffering from Alzheimer&#146;s disease and
FTD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I have invested much of my 35&nbsp;years in the biotech industry into building teams that develop innovative therapeutics in
neuroscience. During my 16&nbsp;years with Genentech, I built a team that discovered multiple neuronal survival factors and receptors in order to prevent degenerative nerve cell death. As the Founder, President, and Chief Science Officer of Rinat
Neuroscience, my team and I discovered clinical antibodies designed to target misfolded proteins. As a Co-Founder and the former Chief Executive Officer of Annexon Biosciences, my team and I developed clinical antibodies that prevent destruction of
neuronal connections. I am a named inventor on over 350 issued patents and patent applications and am an author on over 100 peer reviewed publications. My teams and I discovered the target for the approved cancer drug, Erivedge, and were responsible
for the development of the non-addictive antibody pain drug candidate, tanezumab, and the approved migraine antibody drug, AJOVY. Our work at Alector is based upon our understanding of the basic biology of degenerative brain disorders and how to
translate this understanding into effective therapeutics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The World Health Organization estimates that up to&nbsp;1&nbsp;billion people
are affected by neurological disorders. There are currently over 50&nbsp;million people with neurodegeneration worldwide, with over 10&nbsp;million new cases </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
each year. The Alzheimer&#146;s Association projected that the cumulative total cost of Medicare and Medicaid for individuals living with Alzheimer&#146;s disease will total $750&nbsp;billion by
2050 in the United States alone, an increase of over 300% from projected 2018 spending levels. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Degenerative brain disorders are among the
last medical frontiers that have yet to be conquered. If we are successful in our mission to treat neurodegeneration, Alector will have a profound social and economic impact on humanity. We invite you to join us and become a partner in this
meaningful venture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Best Regards, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arnon Rosenthal, Ph.D.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Co-Founder and Chief Executive Officer </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_10"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our mission is to develop therapies that
empower the immune system to cure neurodegeneration. </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage biopharmaceutical company pioneering immuno-neurology, a
novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. We are developing therapies designed to
simultaneously counteract these pathologies by restoring healthy immune function to the brain. Supporting our scientific approach, our Discovery Platform enables us to advance a broad portfolio of product candidates, validated by human genetics,
which we believe will improve the probability of technical success over shorter development timelines. As a result, in the last six years, we have identified over 120 immune system targets, progressed over ten programs into preclinical research, and
advanced four product candidates, AL001, AL002, AL003, and AL101 into clinical development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AL001, our first program in the clinic,
modulates PGRN, a regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, including FTD, Alzheimer&#146;s disease, and Parkinson&#146;s disease. AL001 is initially designed to treat FTD, a severe,
rapidly progressing neurodegenerative disorder that affects approximately 170,000 individuals in the United States and the European Union, with potentially higher prevalence in Asia and Latin America. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our AL001 program is initially aimed at treating a genetic subset of patients with FTD who have a known genetic mutation that causes a
deficiency in PGRN, which is called <FONT STYLE="white-space:nowrap">FTD-GRN.</FONT> The FDA has granted orphan drug designation for treatment of FTD to AL001, as well as Fast Track designation for the treatment of patients with FTD-GRN. Fast Track
designation is designed to facilitate the development and expedite the review of therapies which treat serious conditions and fill an unmet medical need. Programs with Fast Track designation may benefit from early and frequent communications with
the FDA, potential priority review, and additionally, a rolling submission of the marketing application. AL001 has successfully demonstrated <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-mechanism</FONT></FONT> in the
Phase 1b portion of the study in <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> subjects by restoring PGRN levels in plasma and cerebrospinal fluid back to the normal range. In December 2019, we reported additional results from our AL001 Phase 1b
study. Eight weeks after the first dose of AL001, a global proteomics profiling assay from the CSF of the eight symptomatic FTD-GRN patients showed a statistically significant normalization in a number of disease-associated proteins, including
inflammatory and lysosomal biomarkers (n=8; R=-0.36; P&lt;0.0005). At the end of the study, 12 weeks after the first dose, blood samples from five patients from this symptomatic FTD-GRN cohort were also available for NfL testing. In these five
patients, no significant increases in plasma NfL levels were reported after 12 weeks. Moreover, an initial trend showing a 14% reduction in plasma NfL levels compared to baseline levels (n=5; mean=14%; range=-4% to 41%) was also observed. The
December&nbsp;2019 issue of the medical journal, <I>The Lancet Neurology</I>, published analyses from the Genetic Frontotemporal Dementia Initiative (GENFI), which is a multicentre cohort study of families with genetic frontotemporal dementia
conducted across Europe and Canada, showing a significant increase in serum NfL levels over time in symptomatic GRN mutation carriers (p=0.019). Additionally, longitudinal analysis of the GENFI study, which have not been published to date, showed a
mean increase of 24% in serum NfL levels of symptomatic <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> patients after 12 months. The Lancet publication also shows that increases in NfL levels in FTD patients were associated with cognitive decline
and brain atrophy rates. NfL has been associated with disease progression in FTD patients and identified as a marker of treatment effect in neurodegenerative diseases such as amyotrophic lateral sclerosis, spinal muscular atrophy, and multiple
sclerosis in peer-reviewed journals. In the third quarter of 2019, we advanced AL001 into a Phase&nbsp;2 study with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data in <FONT
STYLE="white-space:nowrap">FTD-GRN</FONT> patients expected in the first half of 2020. The Phase 2 study also includes an additional genetic subset of FTD patients <FONT STYLE="white-space:nowrap">(FTD-C9orf72).</FONT> In addition, in consultation
with the FDA, we plan to advance AL001 into a Phase&nbsp;3 study in <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> patients in 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
are developing AL101, our second product candidate in our PGRN program, for patients suffering from more prevalent neurodegenerative diseases including Alzheimer&#146;s disease and Parkinson&#146;s disease, in addition to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
FTD. In line with our therapeutic hypothesis for FTD, mutations that moderately reduce the expression levels of PGRN have been shown to increase the risk of developing Alzheimer&#146;s disease
and Parkinson&#146;s disease, and increased PGRN levels have been demonstrated to be protective for these diseases in animal models. AL101 received orphan drug designation from the FDA for treatment of FTD in July 2019, and we initiated the Phase 1
study of AL101 in the fourth quarter of 2019. We expect proof-of-mechanism data in 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own worldwide rights to both AL001 and AL101.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our next development programs. AL002 and AL003, focus on modulating check-point receptors on the brain&#146;s immune cells, with AL002
targeting TREM2 and AL003 targeting SIGLEC&nbsp;3, respectively. The AL002 and AL003 programs are aimed at treating Alzheimer&#146;s disease patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the third quarter of 2019, we completed the Phase 1a portion of the study in healthy volunteers with AL002. AL002 was generally safe and
well-tolerated in the single ascending dose part of the Phase 1 study. In addition, a dose dependent and statistically significant change in both sTREM2 and a downstream biomarker for microglia functionality in cerebrospinal fluid was observed upon
treatment, indicating both target engagement and proof-of-mechanism in healthy volunteers. We believe that this is the first time that a drug product candidate that targets TREM2 has successfully demonstrated safety, target engagement, and indicated
proof-of-mechanism in healthy volunteers. In the second quarter of 2019, based on safety and tolerability observed in the Phase 1a study, we initiated the Phase 1b portion of the study with AL002 in Alzheimer&#146;s disease patients. We expect
proof-of-mechanism data from Alzheimer&#146;s disease patients in 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2019, we initiated a Phase 1a study in
healthy volunteers with AL003 for the treatment of Alzheimer&#146;s disease patients. Thirty-eight healthy volunteers were dosed over eight dose cohorts in the AL003 Phase 1a dose escalation trial. A dose dependent change in target engagement in a
blood biomarker was observed upon a single dose treatment. One volunteer treated with the second highest dose experienced aseptic hip monoarthritis and a second volunteer treated with the highest dose experienced an adverse drug reaction
characterized by rash, fever, and thrombocytopenia, which were both deemed treatment-related serious adverse events. The volunteers were treated with corticosteroids and recovered. In the fourth quarter of 2019, based on the safety and tolerability
observed in the Phase 1a study, we initiated screening of Alzheimer&#146;s disease patients in a Phase&nbsp;1b study (approximately 12 patients) with AL003 and expect dosing to commence in the first half of the first quarter of 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have partnered with AbbVie, a leader in neuroscience drug development, for the global development and potential commercialization of AL002
and AL003. We are responsible for execution of the Phase&nbsp;1 and Phase&nbsp;2 studies. Following AbbVie&#146;s potential exercise of its option, Alector and AbbVie will share the development costs and will split global profits after marketing
approval. However, following AbbVie&#146;s option exercise for a program, we may opt out of sharing in development costs and profits or losses from that program and instead receive a tiered royalty on sales of products from that program. As part of
this partnership, we received $205.0&nbsp;million in upfront payments, of which $5.0&nbsp;million and $200.0&nbsp;million were received by us in October 2017 and January 2018, respectively, $20.0&nbsp;million from the sale of shares of our preferred
stock in October 2017 and are eligible for up to an additional $985.6&nbsp;million in option exercise and milestone payments and a global profit share with AbbVie upon commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Discovery Platform leverages large scale human genetic datasets, advanced tools in bioinformatics and imaging, and insights into
neurodegeneration and immunology to identify immune system targets that play a critical role in the development of multiple neurodegenerative diseases. Our Discovery Platform focuses on: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Target Selection</I></B><B>. </B>We identify mutations in genes that control the brain&#146;s immune
system, which we believe are the root cause of neurodegeneration, employ a suite of genetic tools to elucidate the immune dysfunction caused by these mutations, and then engineer immune modulating antibodies to counteract the harmful consequences of
these genetic mutations. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Biomarker Selection</I></B><B>. </B>We are able to identify and employ molecular biomarkers, assays, and
precise imaging techniques to confirm target engagement and measure the effect of our product candidates, allowing us to potentially obtain clinical data earlier than would otherwise be expected using traditional clinical measures.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Patient Selection</I></B><B>. </B>We utilize genetic screening and other biomarkers to better align a
patient&#146;s specific diagnosis with the targeted intervention in our clinical studies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our immuno-neurology approach
and our Discovery Platform are designed to broadly address multiple neurodegenerative disorders. The breadth of our opportunity is reinforced by our ability to engineer therapeutics capable of modulating a broad array of immune targets, validated by
human genetics, across multiple mechanisms of action, including product candidates that activate, block, inhibit, or down-regulate a given target as therapeutically needed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 1. The following table highlights our clinical programs. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g41p74.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 2. The following table highlights ten of our identified preclinical and research programs. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g46l17.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The above table reflects that we currently have ten preclinical and research programs identified in our
research and development pipeline focused on targeting Alzheimer&#146;s disease, Parkinson&#146;s disease, ALS, progressive multiple sclerosis, and oncology. Currently, we estimate that these programs are one to three years or more away from
entering preclinical studies assuming that these programs meet our requirements for advancement into the preclinical stage. For each of our programs in our research and development pipeline we are working to identify biomarkers to be utilized in
preclinical studies for each program. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Immune System is Central to Neurodegeneration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The loss of healthy immune function in the brain, due to cellular aging or mutations of genes that regulate key immune cells, underlies the
onset and progression of multiple neurodegenerative disorders. Genomic analyses have shown that there is a strong correlation between genetic mutations that predispose individuals to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
neurodegeneration and dysfunction in the immune system. For example, 22 of the top 25 risk genes identified by evaluating large-scale data on tens of thousands of Alzheimer&#146;s disease
patients regulate immune function in the brain. As a result of these genetic mutations, the brain&#146;s immune function deteriorates and subsequently would fail to carry out critical activities, which include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clearing or counteracting pathological neurodegenerative proteins such as amyloid-beta, TAU, alpha-synuclein, and
<FONT STYLE="white-space:nowrap">TDP-43;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">providing metabolic and functional support to nerve cells; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulating synaptic connections; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">protecting nerve cells by stimulating the regeneration of myelin sheaths around nerve fibers; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">controlling the neurotoxic activities of activated astrocytes and rogue microglia. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that restoring the immune system&#146;s ability to perform all of these vital functions in the brain is crucial to addressing
neurodegeneration given that past approaches focusing on single degenerative pathologies have proved inadequate to date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the early
20<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> century, the root cause of neurodegeneration has been thought to be misfolded and aggregated pathological proteins. Other observable pathologies, including destruction of synapses,
accelerated nerve cell death, and dysfunction of the brain support cells, were all thought to be consequences of these pathological misfolded proteins. As a result, attempts to develop therapies for neurodegeneration have been centered on blocking
the synthesis of, and removing or <FONT STYLE="white-space:nowrap">dis-aggregating</FONT> misfolded proteins. These attempts have been largely unsuccessful, as the disease continues to progress despite significant clearance of the misfolded protein.
We believe that the multiple pathologies found in degenerative brain disorders become independent of the misfolded proteins, and each other, at early disease stages and are driven primarily by dysfunction of the brain&#146;s immune system. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, the brain&#146;s immune system undergoes gradual deterioration of functional characteristics as part of normal
biological&nbsp;aging or due to harmful genetic mutations that are linked to neurodegeneration and are associated with accelerated senescence of the brain immune cells. These cells are no longer capable of executing their beneficial and protective
roles and instead often become harmful and destructive to the brain. Based on our understanding of the role of genetic mutations in neurodegeneration, we have designed our product candidates to target the mutated genes linked to neurodegeneration,
with the goal of slowing or reversing the deterioration of the brain&#146;s immune cells to achieve therapeutic benefit. By restoring healthy immune function in the brain, we believe we can simultaneously counteract the multiple independent
pathologies responsible for neurodegeneration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Team </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our team is led by seasoned executives with a proven track record of drug discovery and development in neuroscience, as well as substantial
operational and business expertise. Our <FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Chief Executive Officer, Arnon Rosenthal, Ph.D., has spent over 35 years developing therapeutics in neuroscience and led teams responsible for the
development of the <FONT STYLE="white-space:nowrap">non-addictive</FONT> pain drug tanezumab and the migraine drug AJOVY, and multiple other programs in clinical development. He also held several leadership roles over a <FONT
STYLE="white-space:nowrap">16-year</FONT> career at Genentech, where he led the team that discovered the target for the cancer drug Erivedge. Our President and Chief Operating Officer, Shehnaaz Suliman, M.D., M.B.A., M.Phil., has more than 20 years
of experience in business development and drug development, and a demonstrated track record of building and leading teams across strategy, business development, commercial, and operational functions. She was previously Senior Vice President,
Corporate Development and Strategy of Theravance Biopharma, Inc. Our Chief Medical Officer, Robert Paul, M.D., Ph.D., served as the Therapeutic Area Lead for Neuroscience at Genentech, where among other projects, he oversaw the clinical development
of various product candidates, including the amyloid-beta antibody crenezumab in Alzheimer&#146;s disease, <FONT STYLE="white-space:nowrap">GDC-0134</FONT> in ALS, and <FONT STYLE="white-space:nowrap">GDC-0276</FONT> and <FONT
STYLE="white-space:nowrap">GDC-0310</FONT> in pain. Our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Chief Development Officer, Robert King, Ph.D., previously served as the Senior Vice President of Development and Supply Chain at SciClone Pharmaceuticals. Our Chief Business Officer, Sabah Oney,
Ph.D., previously served as the Head of Global Sales and Business Development at Ariosa, Inc. until and through its acquisition by Roche. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of our commitment to building a leading biotechnology company pioneering the discovery and development of next generation immune
therapies for neurodegeneration, we have appointed Richard Scheller, Ph.D., and Thomas S&uuml;dhof, M.D., both world-renowned neuroscientists, as Co-Chairs of our Strategic Portfolio Advice and Review Committee (SPARC). As key leaders of SPARC, Drs.
Scheller and S&uuml;dhof are tasked with supporting the advancement of our research and development pipeline and proprietary drug discovery platform. Dr. Scheller is a seasoned research and development executive with a strong track-record of
developing new medicines and leading multiple research and development organizations worldwide. He was previously Head of Therapeutics and Chief Scientific Officer at 23andMe, and spent 14 years at Genentech, where he was Executive Vice President of
Research and Early Development. Dr. S&uuml;dhof was awarded the Nobel Prize in Physiology or Medicine in 2013 for discoveries that advanced our understanding of how nerve cells communicate through processes underlying synaptic transmission and
synapse formation. Dr. S&uuml;dhof is currently studying mechanisms causing Alzheimer&#146;s, schizophrenia, and autism with the goal of expanding our understanding of neurological disorders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the strategic leadership provided by our executive team, coupled with the insights generated from our SPARC, will enable us to
continue building a leading research engine and discovery platform in immuno-neurology. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Strategy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to develop therapies that empower the immune system to cure neurodegeneration. The key tenets of our business strategy to achieve
this goal include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Building the leading, fully-integrated company focused on delivering innovative immuno-therapies, validated
by human genetics, for the treatment of neurodegeneration. </I></B>We believe that building a fully integrated company will allow us to more rapidly and efficiently develop therapies for patients as well as create value for our stakeholders. We are
focused on building an independent research, development, clinical, and ultimately commercial organization in order to prosecute the full potential of our immuno-neurology approach and Discovery Platform. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Applying our proprietary development capabilities to rapidly advance our product candidates through
clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> studies and beyond.</I></B><B> </B>We are focused on maximizing the probability of success of our product candidates by leveraging immunology,
neurobiology, and human genetics, as well as our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> bioinformatics, to enable better and earlier target selection.
In addition, we are also focused on a biomarker-driven approach, including proprietary tools and assays, to confirm target engagement, inform patient selection, and follow clinical outcomes. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Maximizing the therapeutic potential of our existing targets and product candidates. </I></B>Given the
central physiological roles played by the distinct targets of our product candidates, we believe that there is significant potential for us to address multiple indications with single targets. Our goal is to expand the therapeutic and commercial
potential of our existing targets and product candidates to additional indications. However, we will remain disciplined about advancing this strategy, leveraging our Discovery Platform capabilities to inform expansion areas of maximum value and
highest probability of success. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Continuing to focus on discovering new targets and product candidates, validated by human genetics, to
prosecute the full power of our insights and platform. </I></B>Our Discovery Platform is central to our efforts to rapidly identify new product candidates with compelling clinical promise. We will continue to invest in our Discovery Platform,
including evolving our proprietary analytical tools and assays, to further investigate several of our identified immune system targets as well as generate additional targets and product candidates. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Approach </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Role of the Innate Immune System and Microglia in Neurodegeneration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant evidence in the last decade has shown that neurodegenerative diseases, such as Alzheimer&#146;s disease, Parkinson&#146;s disease,
FTD, and ALS, are linked to a dysfunctional brain immune system. In contrast to the dual adaptive and innate components that characterize the broader human immune system, the brain&#146;s immune system consists primarily of innate immune cells,
known as microglia. These brain resident macrophages account for 10% to 15% of all cells found within the brain and are responsible for many aspects of brain health and maintenance. As the key innate immune cells in the brain, microglia respond to
infection and damage, clear cell debris and pathological proteins, nurture neurons and the brain support cells, and control the number and functionality of inter-neuronal connections. Microglia have been our initial focus and new scientific advances
have made it possible to understand how these key innate immune cells in the brain represent a crucial focal point for intervening, treating, or preventing neurodegenerative diseases (Figure&nbsp;3). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g21u52.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;3. Our antibody product candidates target microglia to harness their many potential beneficial roles in
treating neurodegenerative diseases. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Significant Scientific Data Support Our Hypothesis </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Understanding how the brain&#146;s immune cells affect its structure and function, in both normal and diseased states, is in our view, the key
to understanding many neurological diseases. Human genetic evidence, especially in the last five years, has supported the importance of the interactions between the brain and the innate immune system. For example, 22 of the top 25 risk genes for
Alzheimer&#146;s disease, identified using genetic linkage studies, candidate gene analysis, genome-wide association (GWAS) studies, and whole-genome or whole-exome sequencing, regulate immune function in the brain. Many of these risk genes have
been shown to express predominantly in microglia and to control the function of these cells (Figure&nbsp;4). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g14g22.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;4. Expression of genes linked to Alzheimer&#146;s disease is highly enriched in microglia.<SUP
STYLE="font-size:85%; vertical-align:top">1</SUP> * Red box added to highlight microglia. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Microglia have been shown to be key cells
in overall brain maintenance, health, and function and are the brain&#146;s first line of immune defense. These innate immune cells are tooled with &#147;microglial sensomes&#148; which enable them to constantly survey brain cells to identify and
respond to subtle signs of pathology or dysfunction. Microglia scavenge the brain for&nbsp;toxic misfolded proteins, cell debris, damaged or unnecessary nerve cells, dysfunctional or aged synapses, and infectious agents. In addition, microglia
support the generation of new neurons and synapses and remodel neuronal circuits. Microglia also control the survival and function of astrocytes and oligodendrocytes, the main brain support cells which control brain metabolism and blood supply and
replenish aged or damaged nerve fibers after injury. Further, microglia have been shown to modulate the permeability of the blood brain barrier allowing access to peripheral immune cells, to assist against infection or injury. Microglia can also
change their morphology, functionality, and number in response to changing brain environment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recent analysis of gene transcription at
the single-cell level in microglia from normal and diseased brains revealed that multiple microglia subtypes exist which may respond to specific disease pathologies in the brain. Our product candidates are designed to recruit microglia subtypes by
targeting microglia check-point proteins that control their survival, proliferation, migration, and function. This allows us to differentially modulate microglia activity as needed to counteract a given degenerative brain disorder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recent findings in the fields of human genetics, immunology, and neuroscience have indicated that as a result of normal aging or genetic
mutations, the beneficial functions of the microglia deteriorate leading to massive death of neurons and consequently to neurodegeneration. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Hansen, D., Hanson, J., Sheng, M. &#147;Microglia in Alzheimer&#146;s disease.&#148; <I>Journal of Cell
Biology</I>. Volume 217, Number 2, February 2018. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table outlines the key impact of functional and dysfunctional microglia: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; " ALIGN="center"><B>Functional Microglia</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:10pt; font-family:Times New Roman; " ALIGN="center"><B>Dysfunctional
Microglia</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt" BGCOLOR="#d8d8d8">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#d8d8d8" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Clear/counteract and form a barrier around pathological proteins such as
amyloid-beta</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Reduced ability to remove, or to limit the damage caused by pathological
proteins leading to dysfunction of neuronal connections and ultimately leading to neuronal cell death</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Provide metabolic and functional support to nerve cells</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Reduced ability to provide nourishing factors to neurons leading to neuronal
cell death</P></TD></TR>
<TR STYLE="font-size:1pt" BGCOLOR="#d8d8d8">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#d8d8d8" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Regulate healthy synaptic connections</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Indiscriminate destruction of synapses leading to reduced number of synapses
and dysfunctional neuronal connections</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Control the function of astrocytes, the brain&#146;s star shaped support cells
that help maintain the&nbsp;blood-brain barrier, provide nutrients to neurons, repair the nerve tissue following injury, and facilitate neurotransmission</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Inducement and conversion of beneficial astrocytes to toxic astrocytes leading
to neuronal cell death</P></TD></TR>
<TR STYLE="font-size:1pt" BGCOLOR="#d8d8d8">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#d8d8d8" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Control the survival and function of oligodendrocytes that provide protective
myelin sheaths around nerve fibers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Failure to support oligodendrocytes, leading to neuronal
dysfunction</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Discovery Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Discovery Platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and
immunology to: (1)&nbsp;identify immune system targets that play a critical role in the development of multiple neurodegenerative diseases, and&nbsp;rapidly develop antibody therapeutics to these targets, (2)&nbsp;interrogate and prioritize those
targets for activity using biomarkers and related proprietary assays and preclinical models, and (3)&nbsp;clinically test product candidates in genetically defined patient populations that are most likely to respond to treatment. We believe that
these platform capabilities provide us with the tools to solve the conceptual and technical challenges associated with development of drug candidates for neurodegeneration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on proprietary immuno-neurology bioinformatics algorithms and methodologies to analyze large genetic datasets from diseased and
healthy individuals, brain-based gene expression profiling, brain-based proteomics, and human pathology. These proprietary capabilities allow us to rapidly identify tractable targets, pharmacodynamic biomarkers, and patient populations associated
with aberrant immune function which lead to neurodegeneration. Specifically, the three priorities of our platform efforts are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Target Selection</I></B><B>. </B>Our target selection capabilities address a wide array of factors that we
believe inform efficient, optimized therapeutic outcomes, including genetic and mechanistic rationale. We leverage our
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> bioinformatics to identify genetic mutations in the brain immune system that we believe are the root cause of
neurodegeneration. We employ a suite of genetic tools to elucidate the immune dysfunction caused by these mutations. We then seek to engineer immune modulating antibody product candidates to functionally counteract the harmful consequence of these
genetic mutations. We leverage <I>in vitro </I>and <I>in vivo </I>functional tools to validate the activity of our product candidates and their ability to cross the blood brain barrier at sufficient quantities to be therapeutically effective.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Biomarker Selection</I></B><B>. </B>We are able to identify and employ molecular biomarkers, assays, and
imaging techniques that are tailored to our product candidates to confirm target engagement and quantify their therapeutic impact, allowing us to potentially obtain clinical data earlier than would be expected using traditional clinical measures.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Patient Selection</I></B><B>. </B>We utilize genetic screening and biomarkers to better align a
patient&#146;s specific diagnosis with the targeted intervention in our clinical studies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We employ gene expression
profiling, proteomics, brain imaging, and data on disease pathology as well as our own preclinical and clinical data to continually refine our proprietary immuno-neurology algorithms and methodologies. Using our Discovery Platform to identify
targets that are validated by human genetics, disease biomarkers, and responsive patient populations, we believe that we are positioned for greater probability of technical success on more efficient timelines relative to historical drug development
in neurodegeneration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the last six years, we have identified over 120 immune system targets through genetic analysis, progressed more
than ten programs to preclinical research, and advanced four product candidates into clinical development. Our AL001 program, initially aimed at treating a genetic subset of patients with FTD carrying a PGRN loss of function mutation <FONT
STYLE="white-space:nowrap">(FTD-GRN),</FONT> has successfully demonstrated safety, target engagement, and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-mechanism</FONT></FONT> with a well-tolerated safety profile in the
central nervous systems of healthy volunteers and FTD patients. Our AL002 program, aimed at treating patients with Alzheimer&#146;s disease, has also successfully demonstrated safety, target engagement, and proof-of-mechanism in the central nervous
systems of healthy volunteers in the single ascending dose part of our Phase 1 study. Our AL003 program, aimed at treating patients with Alzheimer&#146;s disease, has also successfully demonstrated safety and peripheral target engagement in healthy
volunteers in the single ascending dose part of our Phase 1 trial. Our AL101 program, aimed at treating patients with Alzheimer&#146;s disease and Parkinson&#146;s disease, has also successfully demonstrated target engagement, increases in the
disease associated pharmacodynamic marker PGRN in the brains of mice, rats and non-human primates, as well as reduction of social deficit symptoms of FTD in a social aversion test using FTD-GRN mice following intravenous injection. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline Programs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Progranulin Program
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our first development program is focused on modulating levels of PGRN, a key regulator of microglia function in the brain with
strong genetic links to FTD and other neurodegenerative disorders. Healthy individuals carry two copies of PGRN that function together to produce healthy levels of PGRN throughout the body. Mutations in both copies of the PGRN gene lead to a
neurodegenerative disease called neuronal ceroid lipofuscinosis, which is typified by childhood dementia, vision loss, and epilepsy. Mutations in a single copy of PGRN lead to a drop of between 50% and 70% in the level of PGRN and consequently lead
to development of FTD with greater than 90% probability. Moreover, large scale human genetic studies have shown that mutations in the gene for PGRN, which leads to a more modest decrease in the level of PGRN, increases the risk for Alzheimer&#146;s
disease and Parkinson&#146;s disease, making PGRN a significant risk gene for these disorders as well. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthy levels of PGRN are associated with many cellular processes that include, but are not
limited to, normal microglial activities, neuronal survival, and lysosome function. As shown in the figure below (Figure&nbsp;5), PGRN deficiency disrupts microglia-neuronal homeostasis in the brain and promotes neurodegeneration through the release
of cytotoxic cytokines and complement factors by dysfunctional microglia. Moreover, these microglia activate astrocytes, which in turn, damage neurons. Thus, lack of PGRN leads to disrupted health and function of both neurons and microglia and if
not corrected, rapid neurodegeneration. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g28j20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;5. PGRN deficiency disrupts homeostasis between microglia and neurons, and promotes neurodegeneration during
aging.<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>SORT1 Controls PGRN Levels in the Body </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Human and mouse genetic studies have identified the neurotrophic factor PGRN degrading receptor SORT1 as a major negative regulator of PGRN
levels in plasma and the brain. SORT1 is a sorting receptor on the cell surface and on the endoplasmic reticulum-Golgi apparatus within the cell. SORT1 binds to extracellular PGRN in the plasma and brain and transports it into the cells for
degradation by the lysosome resulting in decreasing levels of extracellular PGRN. SORT1 deficiency increases PGRN plasma and brain levels by two to three-fold in mouse models, while variants that modestly reduce expression of SORT1 increase the
level of PGRN in humans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, genetic loss of SORT1 in mice does not lead to the adverse effects associated with genetic loss of
PGRN, and PGRN continue to function as expected in the absence of SORT1. These studies and others have indicated to us that blocking SORT1 with a pharmacological agent would be a safe and effective approach in increasing the level of functional PGRN
in the brain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have developed two distinct product candidates that target SORT1, AL001 and AL101, designed to increase PGRN levels in
the brain of patients to counteract the damage sustained due to low PGRN levels in neurodegenerative disorders. Our first product candidate, AL001, is initially intended to target orphan disorders, including genetic forms of FTD such as in patients
that are missing a functional copy of the PGRN gene <FONT STYLE="white-space:nowrap">(FTD-GRN).</FONT> Our second PGRN product candidate, AL101, is intended to target widely prevalent neurodegenerative disorders such as Alzheimer&#146;s disease and
Parkinson&#146;s disease, in addition to FTD. We have worldwide development and commercial rights to our PGRN product candidates. </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Kao, A., McKay, A., Singh, P., Brunet, A., Huang, E. &#147;Progranulin, lysosomal regulation and
neurodegenerative disease.&#148; <I>Nature Reviews Neuroscience.</I> Volume&nbsp;18, Number&nbsp;6, June 2017. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>AL001 for the Treatment of FTD </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our first product candidate, AL001, is a humanized recombinant monoclonal antibody that is intended to be delivered by intravenous, peripheral
infusion to the blood stream to increase the levels of PGRN in the brains of <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> patients. AL001 functions by shutting down the SORT1 degradation mechanism for PGRN and increasing the circulating half-life
of the functional PGRN in the brain. AL001 received orphan drug designation from the FDA for the treatment of FTD in 2018 as well as Fast Track designation for the treatment of patients with FTD-GRN. Generally, if a product with an orphan drug
designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of market exclusivity. This exclusivity precludes the FDA from approving another marketing
application for the same indication for that time period, unless the later product is clinically superior. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of FTD </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FTD is a rapidly
progressing and severe degenerative brain disease with no approved treatment. FTD is a form of dementia found most frequently in individuals less than 65&nbsp;years old at time of diagnosis. Patients with FTD exhibit a range of symptoms including
personality changes including compulsive behavior, lack of restraint, apathy, and anxiety as well as language and behavioral problems. Average life expectancy in FTD patients is seven to 10&nbsp;years after the start of symptoms. FTD symptoms have
an insidious onset with clinical symptoms usually appearing between 45 to 65&nbsp;years of age at an average age of 58. Hence, FTD is considered an early-onset dementia as compared to late-onset Alzheimer&#146;s disease, and is more common than
Alzheimer&#146;s disease in early-onset dementia under the age of 60 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although FTD was poorly understood and thought to be rare,
over the past decade the scientific community has gained a knowledge about the biology of FTD as well as an awareness of disease prevalence. FTD affects 50,000 to 60,000 individuals in the United States and roughly 110,000 individuals in the
European Union. There are multiple heritable forms of FTD, such as <FONT STYLE="white-space:nowrap">FTD-GRN,</FONT> which represent 5% to 10% of all patients with FTD, and approximately 22% of heritable FTD cases. Healthy individuals carry two
copies of PGRN that function together to produce sufficient levels of PGRN throughout the body. Mutations in a single copy of PGRN lead to a 50% or greater decrease in the level of PGRN and lead to development of FTD with a greater than 90%
probability. Researchers have identified over 70 inherited loss of function mutations in PGRN that lead to FTD to date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rate of
disease progression in FTD is faster than in Alzheimer&#146;s disease, suggesting that clinical trials with disease-modifying agents have the potential to obtain clinical data more quickly and with fewer subjects in FTD than in Alzheimer&#146;s
disease. For example, the median survival from symptom onset in FTD is shorter than in Alzheimer&#146;s disease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that we can establish rapid clinical <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> patients given its genetically-defined patient population, fast rate of disease progression, and our ability to leverage fluid and imaging
biomarkers. In <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> patients, inhibition of SORT1 through AL001 represents a potential mechanism to compensate for the over 50% reduction of PGRN. AL001 is intended to reduce the ability of SORT1 to bind to
and degrade PGRN, leading to increases in the levels of PGRN through increasing its circulating half-life (Figure&nbsp;6). We have tested our PGRN program antibodies in various animal models, healthy volunteers, and
<FONT STYLE="white-space:nowrap">FTD-GRN</FONT> patients and have achieved significantly elevated, long-lasting levels of PGRN in the brain after intravenous administration. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g02g68.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;6. Mechanism of action for our PGRN programs. AL001 binds to SORT1 and prevents degradation of PGRN,
increasing its circulating half-life significantly. A similar mechanism of action is also applicable for AL101. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>AL101 for the Treatment of
Alzheimer&#146;s Disease and Parkinson&#146;s Disease </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing a second product candidate in our PGRN program, AL101,
that targets SORT1 for large patient populations such as Alzheimer&#146;s disease and Parkinson&#146;s disease. AL101 received orphan drug designation from the FDA for the treatment of FTD in July 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mutations that moderately reduce the amount of PGRN in the brain increase the risk for Alzheimer&#146;s disease and Parkinson&#146;s disease.
Moreover, some Parkinson&#146;s disease patients have been shown to have reduced levels of PGRN. In line with our therapeutic hypothesis, we plan to target PGRN as a potential disease modifying therapeutic for patients suffering from
Alzheimer&#146;s disease and/or Parkinson&#146;s disease following <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in FTD patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of Alzheimer&#146;s Disease </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Alzheimer&#146;s disease is a chronic neurodegenerative&nbsp;disease that usually starts slowly in people over 65&nbsp;years of age and worsens
over time.&nbsp;It is the most common cause of dementia, accounting for 60% to 70% of all cases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The most common early symptom of Alzheimer&#146;s disease is difficulty in remembering recent events. As the disease advances, symptoms can include problems with language, disorientation, mood
swings, loss of motivation, failure to manage self-care, and behavioral issues. As a person&#146;s condition declines, they often withdraw from family and society.&nbsp;Gradually, bodily functions are lost, leading to death. Although the speed of
progression can vary, the typical life expectancy following diagnosis is eight to ten years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While estimates of the prevalence of
Alzheimer&#146;s disease vary, the Alzheimer&#146;s Association estimates that, in 2018, there are 5.7&nbsp;million people in the United States suffering from Alzheimer&#146;s disease and that number is projected to rise to nearly 14&nbsp;million by
2050. Alzheimer&#146;s disease is the sixth leading cause of death in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to its debilitating effect on
patients&#146; cognition and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> functioning, Alzheimer&#146;s disease places a significant burden on the healthcare system. According to the Alzheimer&#146;s
Association, the aggregate cost of care in 2018 for patients with Alzheimer&#146;s disease and other types of dementia in the United States was estimated to be $232&nbsp;billion, over half of which is borne by the Medicare system. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Overview of Parkinson&#146;s Disease </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parkinson&#146;s disease is a long-term degenerative disorder of the central nervous system that mainly affects the motor system. Early in the
disease, the most obvious symptoms are shaking, rigidity, slowness of movement, and difficulty with walking. Cognitive and behavioral problems may also occur. Dementia becomes common in the advanced stages of the disease. Depression and anxiety are
also common, occurring in more than a third of people with Parkinson&#146;s disease. Other symptoms include sensory, sleep, and emotional problems. Parkinson&#146;s disease typically occurs in people over the age of 60. The average life expectancy
following diagnosis is between three to 10 years after the onset of symptoms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no disease modifying treatment for
Parkinson&#146;s disease, and the options for patients are limited to treatments that improve symptoms. Initial treatment is typically with the anti-Parkinson&#146;s drug medication levodopa, with dopamine agonists being used once levodopa becomes
less effective. As the disease progresses and neurons continue to be lost, these medications become less effective while at the same time they produce a complication marked by involuntary writhing movements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to the Parkinson&#146;s Foundation, more than 10&nbsp;million people worldwide are living with Parkinson&#146;s disease. An
estimated 930,000 people in the United States will be living with Parkinson&#146;s disease by the year 2020. This number is predicted to rise to 1.2&nbsp;million by 2030. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our PGRN Preclinical Data </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have conducted safety and efficacy studies of AL001 in <FONT STYLE="white-space:nowrap">non-human</FONT> primates, also referred to as NHPs,
and completed preclinical chronic good laboratory practice (GLP) toxicology testing through 26 weeks with no test article related adverse findings. In <FONT STYLE="white-space:nowrap">non-human</FONT> primates, AL001 recognizes and binds to SORT1
with potency similar to that seen in the binding between AL001 and human SORT1. In these <FONT STYLE="white-space:nowrap">non-human</FONT> primate experiments, AL001 delivered by intravenous injection to the blood stream blocked SORT1 and increased
levels of PGRN in both plasma and the CSF (Figure&nbsp;7). These experiments indicated that there were therapeutic levels of AL001 in the brain following delivery to the bloodstream systemically. These effects were observed after a single dose of
AL001 as well as during and after multiple dosing. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g69p62.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;7. AL001 blocks SORT1 and increases the level of PGRN in plasma and cerebrospinal fluid in NHP following
injection to the bloodstream, indicating that peripherally injected AL001 elicits the desired biological response in the brain (n=4) (** indicates p&lt;0.01 by T-test). </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AL101 is able to cross-react and bind to murine, rat, and
<FONT STYLE="white-space:nowrap">non-human</FONT> primate as well as human SORT1. AL101 binds SORT1 with similar potency in multiple animal models. Following injection, AL101 was shown to block SORT1 and increase the levels of PGRN in the plasma and
cerebrospinal fluid of mice (Figure&nbsp;8), rats, and <FONT STYLE="white-space:nowrap">non-human</FONT> primates, demonstrating again that administration of AL101 is effective in increasing PGRN levels in the brain in multiple animal models. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g72l82.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;8. AL101 blocks SORT1 and increases the levels of PGRN in the plasma and cerebrospinal fluid in normal mice
following intraperitoneal injection, indicating that peripherally injected AL101 elicits the desired biological response in the brain (* indicates p&lt;0.05 and *** indicates p&lt;0.001 by <FONT STYLE="white-space:nowrap">T-test).</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have conducted preclinical tests with AL101 in a mouse model created by introducing a mutation in one of the two copies for
the mouse version of PGRN <FONT STYLE="white-space:nowrap">(FTD-GRN</FONT> mice). AL101 blocked SORT1 and increased levels of PGRN in both the plasma and CSF of the <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> mice (Figure&nbsp;9). These changes
support the hypothesis that targeting SORT1 by administration of anti-SORT1 antibodies would lead to an increase of PGRN in the brains of <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> patients. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g74r49.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 9. AL101 blocks SORT1 and increases the levels of PGRN in the plasma and CSF in
<FONT STYLE="white-space:nowrap">FTD-GRN</FONT> mice following intraperitoneal injection, indicating that peripherally injected AL101 elicits the desired biological response in the brain (* indicates p&lt;0.05 and *** indicates p&lt;0.001 by <FONT
STYLE="white-space:nowrap">T-test).</FONT> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> mice also exhibit behavioral changes
such as an increase in submissiveness and social aversion. This can be assessed in a social aversion test in which mice are introduced at opposite ends of a tube. Normal mice will approach each other in the tube until one of them retreats on average
50% of the time. When an <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> mouse is placed into the tube together with a normal mouse, it is about three times more likely to retreat first. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We tested our hypothesis that increasing levels of PGRN, through inhibition of SORT1, would slow disease progression and lead to a beneficial
therapeutic effect in the <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> mouse model. In this experiment, administration of the <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> mice with AL101 for four weeks increased PGRN levels in the brains of <FONT
STYLE="white-space:nowrap">FTD-GRN</FONT> mice and significantly reduced the social deficit symptoms of FTD and restored healthy behavior in this social aversion test. Moreover, no adverse effects were observed in either <FONT
STYLE="white-space:nowrap">FTD-GRN</FONT> mouse model or normal mice after the treatment with AL101. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our PGRN Product Candidates Development Plan
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing two PGRN product candidates, AL001 and AL101. Our AL001 product candidate has demonstrated target engagement and
increases in the disease associated pharmacodynamic marker PGRN in the brains of primates, healthy volunteers, and <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> patients.&nbsp;Our second PGRN product candidate, AL101 has demonstrated target
engagement, increases in the disease associated pharmacodynamic marker PGRN in the brains of mice, rats and <FONT STYLE="white-space:nowrap">non-human</FONT> primates, as well as reduction of social deficit symptoms of FTD in a social aversion test
using <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> mice following intravenous injection.&nbsp;We initiated the Phase 1, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> study with AL101 in the fourth
quarter of 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AL001 successfully demonstrated
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-mechanism</FONT></FONT> in a dose-escalating Phase 1a study (n=50) in healthy volunteers and in the Phase 1b portion of the study (n=14) in
<FONT STYLE="white-space:nowrap">FTD-GRN</FONT> patients by showing a statistically significant increase in PGRN levels relative to baseline when compared to pooled placebo in plasma and in CSF at the
<FONT STYLE="white-space:nowrap">pre-specified</FONT> <FONT STYLE="white-space:nowrap">follow-up</FONT> time point. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AL001 was dosed in a
randomized, double-blind, placebo-controlled, dose-escalating Phase&nbsp;1a study in the United States with healthy volunteers being randomized and receiving a single dose of AL001 or placebo. Each of the dose levels consisted of a cohort of eight
healthy volunteers, with six receiving AL001 and two receiving placebo, representing a six to two randomization ratio of AL001 to placebo. The primary endpoints of the study are safety and tolerability. The secondary endpoints include
pharmacokinetic and pharmacodynamic measurements, including changes of PGRN in serum and the CSF. Pharmacodynamic characteristics include the biochemical and physiological effects of a product candidate, and pharmacokinetic characteristics describe
the time course, for example, product candidate absorption, distribution, metabolism, and excretion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The volunteers were dosed in five cohorts in escalating dose levels of AL001. Results showed
that AL001 was generally safe and well-tolerated, with no drug-related serious adverse events or dose-limiting adverse events reported in the study, achieving the primary objective of the study. Moreover, statistically significant increases in
plasma and CSF PGRN levels relative to baseline were also observed, and the magnitude and duration of the effect in plasma and CSF PGRN levels appeared to be dose dependent. Results in this dose-escalating Phase 1a study in healthy volunteers
successfully demonstrate <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-mechanism</FONT></FONT> for AL001 in both plasma and CSF. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g80e75.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 10. AL001 increases the level of PGRN in CSF in healthy volunteers in measured cohorts at the <FONT
STYLE="white-space:nowrap">pre-specified</FONT> <FONT STYLE="white-space:nowrap">follow-up</FONT> time point (the thirteenth day following injection) compared to pooled placebo in CSF (**** indicates p&lt;0.0001 by
<FONT STYLE="white-space:nowrap">T-test).</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the Phase 1b portion of the study (n=14), which was open-label, six asymptomatic <FONT
STYLE="white-space:nowrap">FTD-GRN</FONT> <FONT STYLE="white-space:nowrap">(aFTD-GRN)</FONT> patients and eight symptomatic <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> <FONT STYLE="white-space:nowrap">(FTD-GRN)</FONT> patients, were dosed with
AL001 over a <FONT STYLE="white-space:nowrap">one-month</FONT> period. </P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g84w86.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 11. AL001 elevates the level of PGRN in CSF compared to baseline in aFTD-GRN (purple bar) and FTD-GRN (blue bar)
mutation carriers after receiving one month of dosing with AL001 (* indicates p &lt; 0.05 by T-test and ** indicates p &lt; 0.01 by T-test). </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As shown in the figure below, after receiving their infusion of AL001, all 14 <FONT
STYLE="white-space:nowrap">FTD-GRN</FONT> mutation carriers&#146; <FONT STYLE="white-space:nowrap">CSF-PGRN</FONT> levels increased up to the normal range observed in healthy volunteers. In the <FONT STYLE="white-space:nowrap">FTD-GRN</FONT>
patients, their <FONT STYLE="white-space:nowrap">CSF-PGRN</FONT> levels remained elevated for one month following their final infusion of AL001 (Day 57). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g77u24.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 12. AL001 increases the level of PGRN in cerebral spinal fluid (CSF) from baseline level of <FONT
STYLE="white-space:nowrap">aFTD-GRN</FONT> and <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> mutation carriers, who initially have 50% or less (grey bars) compared to healthy volunteers (green bar), up to the normal range of PGRN (purple and blue
bars). </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, we reported additional results from our AL001 Phase 1b study. Eight weeks after the first dose of AL001, a
global proteomics profiling assay from the CSF of the eight symptomatic FTD-GRN patients showed a statistically significant normalization in a number of disease-associated proteins, including inflammatory and lysosomal biomarkers (n=8; R=-0.36;
P&lt;0.0005). At the end of the study, 12 weeks after the first dose, blood samples from five patients from this symptomatic FTD-GRN cohort were also available for NfL testing. In these five patients, no significant increases in plasma NfL levels
were reported after 12 weeks. Moreover, an initial trend showing a 14% reduction in plasma NfL levels compared to baseline levels (n=5; mean=14%; range=-4% to 41%) was also observed. The December 2019 issue of the medical journal, <I>The Lancet
Neurology</I>, published analyses from GENFI, which is a multicentre cohort study of families with genetic frontotemporal dementia conducted across Europe and Canada, showing a significant increase in serum NfL levels over time in symptomatic GRN
mutation carriers (p=0.019). Additionally, longitudinal analysis of the GENFI study, which have not been published to date, showed a mean increase of 24% in serum NfL levels of symptomatic <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> patients
after 12 months. The Lancet publication also shows that increases in NfL levels in FTD patients were associated with cognitive decline and brain atrophy rates. NfL has been associated with disease progression in FTD patients and identified as a
marker of treatment effect in neurodegenerative diseases such as amyotrophic lateral sclerosis, spinal muscular atrophy, and multiple sclerosis in peer-reviewed journals. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the third quarter of 2019, we advanced AL001 into a Phase&nbsp;2 study (approximately 32
patients). We plan to have Phase 2 trial <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data in <FONT STYLE="white-space:nowrap">FTD-GRN</FONT> patients in the first half of 2020 and expect to
include data from CSF biomarkers, brain imaging (Figure 13), and cognitive and behavioral tests. </P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g53l12.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;13. Decreasing clinical risk with volumetric brain imaging. The change in brain volume loss was driven by
symptomatic mutation carriers.<SUP STYLE="font-size:85%; vertical-align:top">2</SUP><SUP STYLE="font-size:85%; vertical-align:top">,</SUP><SUP STYLE="font-size:85%; vertical-align:top">3</SUP> </B></P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g58a33.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;14. Clinical plan for AL001 in <FONT STYLE="white-space:nowrap">FTD-GRN.</FONT> (Figure not to scale.)
</B></P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Boeve, B., Baker, M., Dickson, D., Parisi, J., Giannini, C., et al. &#147;Frontotemporal dementia and
parkinsonism associated with the <FONT STYLE="white-space:nowrap">IVS1+1G-&gt;A</FONT> mutation in progranulin: a clinicopathologic study.&#148; Brain: a Journal of Neurology. Volume 129, Issue 11, November 2006. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sha, S., Miller, Z., Min, S., Zhou, Y., Brown, J., et al. &#147;An
<FONT STYLE="white-space:nowrap">8-week,</FONT> open-label, dose-finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations.&#148; <I>Alzheimer&#146;s</I><I></I><I>&nbsp;&amp; Dementia: Translational
Research</I><I></I><I>&nbsp;&amp; Clinical Interventions</I>. Volume&nbsp;3, Issue 4, November 2017. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Potential Additional Applications for Our PGRN Program </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our initial PGRN program is currently targeted only at patients with <FONT STYLE="white-space:nowrap">FTD-GRN,</FONT> which is a subset of the
total FTD patient population. Beyond <FONT STYLE="white-space:nowrap">FTD-GRN,</FONT> we believe AL001 has the potential to treat other rare diseases that share pathological mechanisms with <FONT STYLE="white-space:nowrap">FTD-GRN.</FONT> In order
to treat any other rare diseases and the broader FTD patient population, we will be required to conduct additional clinical studies in order to obtain the applicable approvals for that specific patient population. We are enrolling an additional
genetic subset of FTD patients <FONT STYLE="white-space:nowrap">(FTD-C9orf72)</FONT> in our Phase 2 clinical trial of AL001. Following <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data in <FONT
STYLE="white-space:nowrap">FTD-GRN,</FONT> we intend to expand to additional FTD subpopulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, polymorphic mutations that
moderately reduce the expression levels of PGRN have also been shown to increase the risk of developing Alzheimer&#146;s disease and Parkinson&#146;s disease, and increased PGRN levels have been demonstrated to be protective for these diseases in
animal models. We are developing AL101 ultimately to target these large chronic neurodegenerative diseases (Figure&nbsp;15). In the fourth quarter of 2019, we initiated a Phase 1 study of AL101 in healthy volunteers. The study is a randomized,
double-blind, placebo-controlled Phase 1 trial expected to enroll up to 42 healthy volunteers at a single clinical study site in the United States. The study is designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and
bioavailability profile of intravenously and subcutaneously administered doses of AL101. For our other programs, we anticipate following a similar development approach to expand into additional patient populations as appropriate. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g52k24.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 15. Our PGRN programs have broad therapeutic potential, including FTD and other more prevalent neurodegenerative
diseases such as Limbic-predominant age-related TDP-43 encephalopathy (LATE), Parkinson&#146;s disease (PD), and Alzheimer&#146;s disease (AD). (Figure not to scale.) </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our TREM2 Program </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TREM2 is a
transmembrane receptor protein that is expressed on a subset of innate immune cells and selectively on microglia in the brain. TREM2 on microglia cells is thought to promote improved cell migration to the site of injury, improved cell survival,
increased phagocytosis, and increased cell proliferation. Rare individuals with homozygous TREM2 mutations, or mutations on both chromosomal copies, may develop neurodegeneration by the age of 40 with an average lifespan of 10&nbsp;years following
diagnosis. A gene variant in one of the two copies of TREM2 is found to increase the risk of Alzheimer&#146;s disease by threefold. Not only do mutations in a single copy of TREM2 increase the risk of Alzheimer&#146;s disease significantly, but
Alzheimer&#146;s disease patients with TREM2 mutations exhibit an earlier onset of symptoms by three years and an increased rate of brain volume loss compared to individuals without such mutation. Evidence also suggests that gain of function
mutation leading to increased extension of TREM2 confer a protective phenotype against Alzheimer&#146;s disease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discovery of strong genetic linkage of TREM2 to Alzheimer&#146;s disease in 2013 was one
of the first examples in which large scale genomic analyses were used to identify a rare gene variation and link it to an increase in the risk of late-onset Alzheimer&#146;s disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">TREM2 binds to membrane lipids and lipoproteins such as Apolipoprotein E (ApoE) which are normally found in the brain. Mutations in the gene
for ApoE are also known to significantly increase the risk of development of Alzheimer&#146;s disease and is the single highest risk factor for Alzheimer&#146;s disease. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>AL002 for the Treatment of Alzheimer&#146;s Disease </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidate, AL002, is a humanized, TREM2 activating, monoclonal antibody that is intended to be delivered by intravenous, peripheral
infusion into the blood stream (Figure&nbsp;16). AL002 is a microglia cell regulator that modulates the TREM2 receptor<B> </B>and is being developed for the treatment of Alzheimer&#146;s disease in collaboration with AbbVie. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g15f12.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;16. Mechanism of action of our TREM2 activating product candidate AL002. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are currently no cures or approved disease-modifying therapies for Alzheimer&#146;s disease, and there are only two classes of approved
therapies for symptomatic treatment: acetylcholinesterase inhibitors and glutamatergic modulators. These drugs are designed to help preserve neuronal communication, but only provide temporary benefit and do not slow or halt neuronal death. In
addition, antidepressants and antipsychotics are often prescribed <FONT STYLE="white-space:nowrap">off-label</FONT> to treat the symptoms of severe Alzheimer&#146;s disease in patients suffering from agitation, aggressive behaviors, psychosis, and
depression. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recent drug candidates under development for Alzheimer&#146;s disease include those focused on blocking synthesis, enhancing
clearance or disaggregating misfolded amyloid-beta or TAU proteins in the brain, reversing chronic inflammation, and repairing vascular dysfunction, metabolic dysregulation, as well as neurotoxicity. Almost all of these candidates were designed to
target just one of the multiple Alzheimer&#146;s disease pathologies, and most of these drug candidates have so far failed to demonstrate any significant benefit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although amyloid-beta plaques and TAU protein in the brain represent physical pathologies of
the disease and are believed to cause a loss of neuronal connectivity in the brain and neuronal death, recent scientific data paints a more complex picture. Therapeutic approaches that address only one of the multiple pathologies observed in
Alzheimer&#146;s disease, for example, pathology-directed therapies that clear amyloid-beta or TAU proteins, have had limited efficacy. More efficacious therapies will require addressing additional pathologies which we believe are associated with
microglial failure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our TREM2 Preclinical Data </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AL002 binds to TREM2 on the surface of microglia and is designed to optimize microglial activity through the phosphorylation of Spleen
Associated Tyrosine Kinase (Syk). With academic collaborators, we have demonstrated that AL002s, an antibody that is functionally similar to AL002 but cross-reacts to the mouse TREM2, can normalize gene expression signature associated with
Alzheimer&#146;s disease and reduce pathology in a mouse model of Alzheimer&#146;s disease. Furthermore, AL002s was shown to induce microglial proliferation, increase microglial survival, and decrease dystrophic neurites associated with damaged
neurons in an aggressive mouse model of Alzheimer&#146;s disease that expresses either the normal or genetic risk variant of the human TREM2. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g33c68.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;17. AL002s statistically significantly increases the number of microglia around amyloid-beta plaques (left)
and reduces the area occupied by amyloid-beta plaques (right) in a mouse model of Alzheimer&#146;s disease (**** indicates p&lt;0.001 by <FONT STYLE="white-space:nowrap">T-test).</FONT> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g77r31.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;18. AL002s statistically significantly improves cognitive deficit in a mouse model of Alzheimer&#146;s
disease (**** indicates p&lt;0.0001 by <FONT STYLE="white-space:nowrap">T-test).</FONT> </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>AL002 Development Strategy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe we are the first company to advance a TREM2 antibody for the treatment of Alzheimer&#146;s disease into clinical development. In the
third quarter of 2019, we completed a Phase 1a study (n=56) of AL002 in healthy volunteers (Figure 19). In the second quarter of 2019, based on safety and tolerability observed in the Phase 1a study, we initiated the Phase 1b portion of the study
(n=12) with AL002 in Alzheimer&#146;s disease patients. We expect proof-of-mechanism data from Alzheimer&#146;s disease patients in 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, we presented safety and biomarker data from the single ascending dose
(SAD) portion of the Phase 1a study with AL002 in healthy volunteers. The study achieved its primary safety endpoint and secondary PK, PD and biomarker endpoints. We believe this AL002 presentation is the first data in humans showing that a TREM2
activating antibody engages its target and elicits downstream activity in the CNS of healthy volunteers. In total, 56 healthy adults were enrolled into nine escalating dose cohorts in the SAD portion of the Phase 1 study. Results showed that AL002
was generally safe and well-tolerated. Target engagement as measured by reduced cerebrospinal fluid (CSF) soluble TREM2 (sTREM2) was observed in a dose-dependent manner. Additionally, AL002 elevated a biomarker for microglia activity in the CSF,
suggesting proof-of-mechanism in healthy volunteers (Figure 19). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g04g97.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 19. In healthy volunteers, a dose dependent decrease in sTREM2 and an increase in an immune activity biomarker
was observed in the AL002 Phase 1a clinical study. CSF samples were taken from the five highest dose cohorts. The data shown are derived from analysis of CSF samples from 34 healthy volunteers (* denotes p&lt;0.05 by T-test, *** denotes p&lt;0.001
by T-test). </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Histopathological analysis of a <FONT STYLE="white-space:nowrap">26-week&nbsp;toxicology</FONT> study of AL002 in <FONT
STYLE="white-space:nowrap">non-human</FONT> primates identified minimal to marked granulomatous inflammation in the&nbsp;ciliary body&nbsp;and/or&nbsp;choroid&nbsp;of&nbsp;the eye. There were no other AL002- related gross or histopathological
findings in this toxicology study in the retina or any other tissues or organs. We have observed no drug-related, serious adverse events in the AL002 Phase 1 trial with over 50 adults. In response to FDA feedback, we have implemented additional
ophthalmological assessments in our AL002 clinical trial. We expect proof of mechanism data from Alzheimer&#146;s disease patients in the first half of 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the completion of the Phase&nbsp;1 study, we are planning to initiate a
double-blind, placebo-controlled, Phase&nbsp;2 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial in Alzheimer&#146;s disease patients in early stages of the disease (Figure&nbsp;20) in 2020. In
addition to measuring molecular and genetic biomarkers, we intend to use novel imaging modalities focused on pathological proteins and neuronal health for an early <FONT STYLE="white-space:nowrap">read-out</FONT> on various molecular and genetic
biomarkers, imaging assessments, and clinical measures to establish <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> enabling pivotal Phase&nbsp;3 studies. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g29t30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;20. Clinical development plan for AL002 in Alzheimer&#146;s disease. (Figure not to scale.) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These clinical trials have been designed in close collaboration with AbbVie. Our desired outcome is to achieve informative endpoints to enable
efficient Phase&nbsp;3 clinical trial design and a rapid advancement towards marketing approval. For more information on our collaboration with AbbVie see the section titled &#147;Business&#151;Strategic Alliance with AbbVie.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our SIGLEC&nbsp;3 Program </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Large scale
genomic profiling of datasets from Alzheimer&#146;s disease patients has been used to identify the association between certain variants of SIGLEC&nbsp;3, also known as CD33, and increased risk to develop Alzheimer&#146;s disease. SIGLEC&nbsp;3 is an
inhibitory receptor expressed on microglia and acts as the brakes of the immune system in the brain, slowing down microglial activity. Excessive inhibition of the microglia by the disease risk variant of SIGLEC&nbsp;3, which increases expression of
the inhibitory SIGLEC&nbsp;3 receptor on microglia, leads to reduced functionality of the myeloid cells, and consequently, increased deposition of amyloid-beta plaques and accelerated loss of tissue in the brain of Alzheimer&#146;s disease patients
that carry this risk variant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our analysis further showed that the natural inhibitory ligands for SIGLEC&nbsp;3, which are required for
activation of SIGLEC&nbsp;3, are upregulated in the brain of Alzheimer&#146;s disease patients, further reducing the functionality of the microglia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consistent with the genetic findings in humans, Alzheimer&#146;s disease mouse models, in which the gene for SIGLEC&nbsp;3 was genetically
ablated, have microglia with improved phagocytosis of beta amyloid and displayed fewer amyloid-beta plaques compared to the same Alzheimer&#146;s disease model that expressed the mouse SIGLEC&nbsp;3 gene. In line with the findings that the presence
of SIGLEC&nbsp;3 increased the severity of Alzheimer&#146;s disease, a reduced number of certain disease associated microglia that are thought to counteract the progression of Alzheimer&#146;s disease was observed when the human SIGLEC&nbsp;3 in
Alzheimer&#146;s disease mouse models was over-expressed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Taken together, this data supports the hypothesis that blocking the function of
SIGLEC&nbsp;3 would increase the number of beneficial microglia and elicit a therapeutic benefit in Alzheimer&#146;s disease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>AL003 for Treatment
of Alzheimer&#146;s Disease </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidate, AL003, is a SIGLEC&nbsp;3 blocking, monoclonal antibody (Figure&nbsp;21) that
is intended to be delivered by intravenous, peripheral infusion into the blood stream. The function of SIGLEC&nbsp;3 on microglia is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
similar to the inhibitory function of <FONT STYLE="white-space:nowrap">PD-1</FONT> on <FONT STYLE="white-space:nowrap">T-cells.</FONT> AL003 acts similarly to
<FONT STYLE="white-space:nowrap">PD-1</FONT> inhibitors that have been employed successfully in immunotherapy of cancer. Both approaches aim to remove the &#147;brakes&#148; on the immune system to allow the system to work at its full capacity. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g59z81.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;21. Mechanism of action of our SIGLEC&nbsp;3 blocking product candidate AL003. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our SIGLEC&nbsp;3 Preclinical Data </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The activity of AL003 in mice was assessed in immunodeficient mice containing human immune cells to recapitulate the human immune system as
closely as possible. AL003 injected into the bloodstream of these mice blocks SIGLEC 3 on immune cells. In addition, a single intraperitoneal injection of AL003 into mice that express the human SIGLEC 3 in microglia leads to a long-lasting,
statistically significant blockade of SIGLEC 3 on the cell surface of microglia in the brain, indicating that AL003 is potentially able to cross the blood brain barrier and exert its desired activity (Figure&nbsp;22). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g94e00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;22. AL003 blocks SIGLEC 3 on microglia in mouse brain following injection to the blood stream (****
indicates p&lt;0.0001 by <FONT STYLE="white-space:nowrap">T-test).</FONT> </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>AL003 Development Strategy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our AL003 program is the most advanced SIGLEC 3 antibody program for the treatment of Alzheimer&#146;s disease as of today. Our
AL003 product candidate follows a similar clinical development plan to AL002 with some modifications. In the first quarter of 2019, we initiated a Phase 1a study (n=38) in healthy volunteers with AL003 for the treatment of Alzheimer&#146;s disease
patients. In the fourth quarter of 2019, we completed the Phase 1a portion of the study, and reported that the primary safety endpoint of the study had been achieved. Additionally, secondary PK and PD endpoints were also met. In the study, 38
healthy volunteers were dosed over eight dose cohorts in the SAD portion of the AL003 Phase 1a study. A dose dependent and long-lasting change in SIGLEC 3 indicating target engagement was observed upon a single dose treatment in these healthy
volunteers. One volunteer treated with the second highest dose experienced aseptic hip monoarthritis, and a second volunteer treated with the highest dose experienced an adverse drug reaction characterized by rash, fever, and thrombocytopenia, which
were both deemed treatment-related serious adverse events. The volunteers were treated with corticosteroids and recovered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the fourth
quarter of 2019, based on the safety and tolerability observed in the Phase 1a study, we initiated screening of Alzheimer&#146;s disease patients in a Phase 1b study (approximately 12 patients) with AL003 and expect dosing to commence in the first
half of the first quarter of 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the completion of the Phase 1 study, we intend to launch a double-blind,
placebo-controlled, Phase&nbsp;2 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial in Alzheimer&#146;s disease patients (Figure&nbsp;23). During this planned Phase&nbsp;2 trial, in addition to
measuring molecular and genetic biomarkers, we intend to employ imaging techniques focused on pathological proteins and neuronal health for an early read out on various molecular and genetic biomarkers, imaging assessments, and clinical measures to
establish <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> enabling pivotal Phase&nbsp;3 studies. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g77n88.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure&nbsp;23. Clinical development plan for AL003 in Alzheimer&#146;s disease. (Figure not to scale.) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These clinical trials have been designed in close collaboration with AbbVie. Our desired outcome is to achieve informative endpoints to enable
efficient Phase&nbsp;3 clinical trial design and a rapid advancement towards marketing approval. For more information on our collaboration with AbbVie see the section titled &#147;Business&#151;Strategic Alliance with AbbVie.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our MS4A4A Program </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MS4A4A is
among the most prominent genetic risk clusters known for late-onset Alzheimer&#146;s disease. Risk variants of MS4A4A are associated with an increase in the prevalence of Alzheimer&#146;s disease and a decrease in the age of onset. MS4A4A is a
transmembrane receptor protein that is expressed in a subset of innate immune cells, and selectively, in microglia in the brain. MS4A4A is thought to control microglia functionality and/or viability. Our product candidate AL014 was designed to
counteract the risk variants of MS4A4A and to functionally convert the risk variants of MS4A4A to the protective variant. AL014 was designed to mimic and exceed the beneficial activity of the protective MS4A4A variant, which we believe may
potentially decrease the progression of Alzheimer&#146;s disease. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g96a70.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 24. AL014 is designed to mimic and exceed the beneficial activity of the protective MS4A4A variant, which we
believe may stop or slow the progression of Alzheimer&#146;s disease. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>AL014 for the Treatment of Alzheimer&#146;s Disease </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidate, AL014, is a humanized, MS4A4A function modulating monoclonal antibody that is intended to be delivered by intravenous,
peripheral infusion into the bloodstream. AL014 was designed to mimic and exceed the beneficial activities of the protective MS4A4A gene variant in Alzheimer&#146;s disease, as determined by AL014&#146;s ability to partially phenocopy the gene
expression signature of the protective MS4A4A gene variant and to increase sTREM2 levels in the CSF of non-human primates in a dose-dependent manner. We anticipate initiating IND-enabling studies for AL014 in 2020. Based on this timeline, we expect
to initiate our first-in-human trial for AL014 within the next 12-15 months. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g838337g08e71.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure 25. AL014 increases sTREM2 and microglia biomarker in non-human primates. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Expansion of Our Discovery Platform to Other Indications </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Immuno-oncology </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Microglia display
similar gene expression signature and function to the innate cells of the peripheral immune system. These peripheral innate cells such as macrophages, NK cells and others, likely play a significant role in multiple chronic diseases including cancer,
inflammation, and autoimmune disorders. We are leveraging our expertise in the innate immune system to develop additional innate immune&nbsp;check-point&nbsp;focused programs, including programs targeting the Siglec protein family and the SIRP
protein family, for peripheral disorders, particularly cancer. We believe that products focused on innate&nbsp;immune biology will complement and expand the efficacy of current&nbsp;immuno-oncology drugs that target the&nbsp;adaptive&nbsp;immune
system. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Combination Therapies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our therapies are also likely to act in conjunction with each other or with other experimental drugs that are designed to remove pathological
proteins.&nbsp;Therapies such as antibodies against amyloid-beta, the TAU filaments or misfolded alpha-synuclein protein are designed to tag the pathological proteins and recruit microglia to dispose of the drug pathological protein complex. Aging
microglia are less likely to perform this function effectively, and our&nbsp;immuno-neurology therapies could ameliorate this deficiency. We are continuing to explore various combination strategies in preclinical models and will, in the future,
consider moving this strategy into the clinic based upon results from preclinical models. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Strategic Alliance with AbbVie </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2017, we
entered into the AbbVie Agreement. The primary goal of our global strategic collaboration with AbbVie is to <FONT STYLE="white-space:nowrap">co-develop</FONT> and commercialize therapeutics to treat Alzheimer&#146;s and other neurodegenerative
diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the AbbVie Agreement, we granted AbbVie an exclusive option to global development and commercialization for our TREM2 and
SIGLEC&nbsp;3 programs. The terms of the AbbVie Agreement included initial upfront payments of&nbsp;$205.0&nbsp;million and $20.0&nbsp;million from the sale of shares of our Series&nbsp;E preferred stock, and if AbbVie exercises its option for both
programs, we are eligible for up to an additional $985.6&nbsp;million in option exercise and milestone payments. Following AbbVie&#146;s exercise of its option, Alector and AbbVie will share the development costs and will split global profits after
marketing approval. However, following AbbVie&#146;s option exercise for a program, we may opt out of sharing in development costs and profits or losses from that program and instead receive a tiered royalty on sales of products from that program.
We are responsible for the design and execution of Phase&nbsp;1 and Phase&nbsp;2 studies, taking advantage of our significant <FONT STYLE="white-space:nowrap">in-house</FONT> expertise in running clinical trials in Alzheimer&#146;s disease.
Following its exercise of an option for a program, AbbVie will be responsible for certain development activities and global commercialization, taking advantage of its global clinical trial expertise and commercialization networks. Through this
partnership, we aim to leverage the strengths of both organizations efficiently to best achieve the desired outcome. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Exercise of
options.</I></B> AbbVie may exercise its option for a program at any time until the expiration of an option term for that program. For each program, the option term ends following a fixed period after AbbVie&#146;s receipt of the data package that
includes certain information relating to the applicable program&#146;s research and development activities. If AbbVie fails to exercise its option during the option term for a product candidate, we will retain all rights to that program. If AbbVie
exercises its option for a program, then AbbVie will lead development and commercialization activities worldwide. Once AbbVie opts in with respect to a given product candidate, AbbVie must use commercially reasonable efforts to develop and
commercialize the corresponding product globally. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Governance.</I></B> The collaboration is governed by a joint steering committee
(JSC). The JSC may establish additional subcommittees to oversee particular projects or activities. Subject to limitations specified in the AbbVie Agreement, if the applicable governance committee is unable to make a decision by consensus and the
parties are unable to resolve the issue through escalation to specified senior executive officers of the parties, then the issue is escalated to an alternative dispute resolution subject to final decision-making rights retained by each party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Exclusivity.</I></B> During the term of the AbbVie Agreement, each of Alector and AbbVie are subject to exclusivity requirements
prohibiting certain activities outside of the AbbVie Agreement directed to targets under the AbbVie Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual
Property.</I></B> Ownership of intellectual property created in connection with the AbbVie Agreement is generally determined on the basis of inventorship. Generally, each party has the first right to prosecute and maintain its own patents. We
generally have the first right to prosecute and maintain joint patents prior to AbbVie&#146;s exercise of its option for the program relating to such patent, and AbbVie has the right following its exercise of such option. AbbVie has the first right
to prosecute any infringement of jointly held patents developed under the AbbVie Agreement and our patents that are licensed under the AbbVie Agreement. Additionally, AbbVie has the sole right to prosecute its own patents. AbbVie has the first right
to defend against claims that a product developed under either of the programs that are the subject of the AbbVie Agreement infringe third-party intellectual property rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Term and Termination.</I></B> At any point during the term of the AbbVie Agreement, including during the research, development, and
clinical trial process, AbbVie can terminate the AbbVie Agreement in its entirety, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with respect to either program under the AbbVie Agreement, for convenience. In that event, all rights related to the applicable program revert to us. Additionally, AbbVie or we and can terminate
the AbbVie Agreement in connection with a material breach of the AbbVie Agreement by the other party that remains uncured for a specified period of time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Adimab Collaboration Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview &#151;
2014 Adimab Collaboration Agreement (2014 Adimab Agreement)</I></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2014, we entered into the 2014 Adimab Collaboration Agreement.
Under the 2014 Adimab Agreement, we are required to fund, and we and Adimab are required to use commercially reasonable efforts to conduct, certain research to discover and optimize antibodies directed against targets selected by us. We are
developing antibodies discovered by Adimab in our AL001 and AL101 product candidates, and we are developing antibodies optimized by Adimab in our AL002 and AL003 product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Governance.</I></B> Our collaboration with Adimab is governed by a research committee consisting of at least two representatives from
each party. The research committee prioritizes among research programs and prepares and finalizes new proposed research plans, among other activities. If the research committee is unable to make a decision by consensus and the parties are unable to
resolve the issue through escalation to specified senior executive officers of the parties, then either party may seek arbitration of the matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Exclusivity.</I></B> Pursuant to the 2014 Adimab Agreement, each party is subject to limitations on its ability to use information or
material provided by the other outside the scope of the collaboration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual Property.</I></B> Ownership of intellectual
property arising from the research is generally owned by the party that invents or creates the applicable intellectual property, although certain categories of intellectual property are specifically assigned to one party or the other. For example,
patent rights relating to improvements to Adimab&#146;s background platform technology that are invented in the course of the research are assigned to Adimab. Prior to our exercise of the option described below, we and Adimab each grant the other a <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> license to the relevant intellectual property we own to allow each party to carry out its rights and obligations in connection with the research; and except for Adimab&#146;s retained rights to
continue using and licensing its own libraries, each party agrees not to practice or license the patents arising out of the research that it owns for any purpose other than to carry out its rights and obligations in connection with the research.
Generally, each party has the obligation to prosecute, maintain, defend, and enforce its own patents, but we are subject to certain contractual restrictions on our ability to prosecute, practice, and license certain of our patents that arose out of
the research. These restrictions are lifted once we exercise the option described below as to such patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Exercise of
Options.</I></B> The 2014 Adimab Agreement granted us an exclusive option to obtain certain rights relating to a specified number of antibodies discovered or optimized by Adimab directed against the targets we selected. The option extended to
ownership of patent rights specifically covering the sequences of such antibodies, and the right to obtain worldwide, royalty-bearing, sublicensable licenses under certain technology owned or developed by Adimab to research, develop, make, have
made, use, sell, offer to sell, import and export such antibodies and products based on such antibodies for all human therapeutic, prophylactic and diagnostic uses. These licenses are exclusive, except as to Adimab background and platform technology
and Adimab&#146;s retained rights to continue using and licensing its own libraries, as to which the licenses are <FONT STYLE="white-space:nowrap">non-exclusive.</FONT> We have confirmed with Adimab in writing that key patents we have filed relating
to the programs partnered with AbbVie claim inventions owned solely by us, and do not include any such background or platform technology of Adimab. All of our options under the 2014 Adimab Agreement have either expired, are in the process of being
exercised, or, with respect to multiple targets and hundreds of antibodies (including the target programs partnered with AbbVie), have already been exercised. Upon our exercise of the option with respect to a target, we are subject to an obligation
to devote commercially reasonable efforts to commercialize products using the optioned rights to such target. The assigned and licensed patent rights we obtained from these option exercises are described in more detail above under the section titled
&#147;Business&#151;Intellectual Property.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Financial terms.</I></B> We fund Adimab&#146;s research in connection with our
collaboration, in accordance with the terms and limitations described in the 2014 Adimab Agreement. We also have potential milestone payments per program for use of antibodies and <FONT STYLE="white-space:nowrap">low-</FONT> to <FONT
STYLE="white-space:nowrap">mid-single</FONT> digit royalty payments for commercial sales of products incorporating such antibodies. However, if we enter into any transaction granting rights to the inventions or sell products created as a result of a
collaboration with a third party, we have a choice to pay a share of the resulting revenue instead of royalties from such sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Term and Termination.</I></B> We are able to terminate the 2014 Adimab Agreement, in its entirety or with respect to a products or
antibodies directed to particular targets, on three months prior written notice to Adimab. In addition, either party can terminate the 2014 Adimab Agreement in its entirety, or, subject to certain limitations, with respect to specific optioned
rights, for material breaches that remain uncured after 90 days&#146; notice to the breaching party. In the case of a termination before expiration of the 2014 Adimab Agreement, we would have certain continuing payment obligations to Adimab, or
would be required to adhere to certain restrictions as to the fruits of the collaboration. The 2014 Adimab Agreement expires on the twelfth anniversary of the first commercial sale of the products created under the collaboration, on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis. The licenses we and Adimab granted to each
other do not survive, subject to certain limitations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview&#151;2019 Adimab Collaboration Agreement (2019 Adimab Agreement) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2019, we entered into another Adimab collaboration agreement. Under the 2019 Adimab Agreement, we are required to fund, and we and Adimab
are required to use commercially reasonable efforts to conduct, certain research to discover and optimize antibodies directed against targets selected by us. We have not yet identified any research programs under the 2019 Adimab Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Governance.</I></B> Our collaboration with Adimab is governed by a research committee consisting of at least two representatives from
each party. The research committee facilitates communication regarding research under the 2019 Adimab Agreement and has the limited authority to amend a research plan in a manner not substantially affecting the resources required from a party. If
the research committee is unable to make a decision by consensus , no decision will be taken. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Exclusivity.</I></B> Pursuant to the
2019 Adimab Agreement, each party is subject to limitations on its ability to use information or material provided by the other outside the scope of the collaboration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual Property.</I></B> Ownership of intellectual property arising from the research is generally owned by the party that invents
or creates the applicable intellectual property, although certain categories of intellectual property are specifically assigned to one party or the other. Certain intellectual property relating to Adimab&#146;s background platform technology
including any improvements thereto that are invented in the course of the research are assigned to Adimab. Patents covering antibodies that are the subject of the collaboration are owned by us; however, prior to our exercise of the option described
below, we are prohibited from practicing such patents for any purpose other than to perform our research obligations under the 2019 Adimab Agreement. Upon the expiration of the option term described below, in the event we elect not to exercise our
option right with respect to an antibody, ownership of such patents is transferred to Adimab. Prior to our exercise of the option described below, we and Adimab each grant the other a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to
the relevant intellectual property we own to allow each party to carry out its rights and obligations in connection with the research. Generally, each party has the obligation to prosecute, maintain, defend, and enforce its own patents, but we are
subject to certain contractual restrictions on our ability to prosecute, practice, and license certain of our patents that arose out of the research. These restrictions are lifted once we exercise the option described below as to such patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Exercise of Options.</I></B> The 2019 Adimab Agreement granted us an exclusive option to obtain certain rights relating to a specified
number of antibodies discovered or optimized by Adimab directed against the targets we selected. The option extends to ownership of the applicable optioned antibody, and the right to obtain worldwide,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
royalty-bearing, sublicensable <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses under certain technology owned or developed by Adimab to research, develop, make, have made, use,
sell, offer to sell, import and export such antibodies and products based on such antibodies for all human therapeutic, prophylactic and diagnostic uses. Upon our exercise of the option with respect to a target, we are subject to an obligation to
devote commercially reasonable efforts to commercialize products using the optioned rights to such target. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Financial terms.</I></B>
We fund Adimab&#146;s research in connection with our collaboration, in accordance with the terms and limitations described in the 2019 Adimab Agreement. We are also responsible for certain development fees and, in the event we exercise the option
right, we are obligated to pay an option fee. We also have potential milestone payments per product for use of antibodies, subject to certain limitations on total payments owed on any given target, and
<FONT STYLE="white-space:nowrap">low-single</FONT> digit royalty payments for commercial sales of products incorporating such antibodies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Term and Termination.</I></B> We are able to terminate the 2019 Adimab Agreement, in its entirety or with respect to a products or
antibodies directed to particular targets, on 60 days&#146; prior written notice to Adimab. In addition, either party can terminate the 2019 Adimab Agreement in its entirety for material breaches that remain uncured after 90 days&#146; notice to the
breaching party. In the case of a termination before expiration of the 2019 Adimab Agreement, we would be prohibited from using the fruits of the collaboration. The 2019 Adimab Agreement expires, on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, on the later of the twelfth anniversary of the first commercial sale of such
product in such country and expiration of the last patent covering such product in such country, or, in the event no product is optioned under the 2019 Adimab Agreement, upon the last to expire option period. Upon expiration, the licenses Adimab
granted to us with respect to products for which we have exercised our option will continue on a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> royalty-free basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We must manufacture our
product candidates for clinical trial use in compliance with cGMP regulations. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and drug product containers
and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports, and returned or salvaged products. The manufacturing facilities for our product candidates must meet
cGMP requirements and FDA or comparable foreign regulatory authority&#146;s satisfaction before any product is approved for human clinical trial use. Our third-party manufacturers will also be subject to periodic inspections of their respective
facilities for general cGMP compliance by the FDA and other foreign authorities. These inspections may include review of procedures and operations used in the testing and manufacture of our products to assess compliance with applicable regulations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently have the infrastructure or internal capability to manufacture our product candidates for use in clinical trials and
commercialization. We rely, and expect to continue to rely, on third-party cGMP manufacturers for the production of our products for human clinical trials in compliance with FDA and other foreign authority regulations for such products. We rely on
CDMOs to manufacture and supply our preclinical and clinical materials to be used during the preclinical and clinical development of our product candidates. As part of our broad manufacturing strategy to expedite the manufacturing of our product
candidates and minimize manufacturing risk, we currently have established relationships with several CDMOs for the manufacturing of our drug substance or product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have long-term supply agreements and we purchase our required drug product on a development manufacturing services agreement or
purchase order basis. We expect to continue to rely on third-party manufacturers for the commercial supply of any of our product candidates for which we obtain marketing approval. We have personnel with significant technical, manufacturing,
analytical, quality, regulatory, including cGMP, and project management experience to oversee our third-party manufacturers and to manage manufacturing and quality data and information for regulatory compliance purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to comply with statutory and regulatory requirements subjects a manufacturer to
possible legal or regulatory action, including warning letters, the seizure or recall of products, injunctions, consent decrees placing significant restrictions on or suspending manufacturing operations and civil and criminal penalties. Contract
manufacturers often encounter difficulties involving production yields, quality control and quality assurance, as well as shortages of qualified personnel. Any of these actions or events could have a material impact on the availability of our
products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercialization Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
do not currently have any approved drugs and we do not expect to have any approved drugs in the near term. Therefore, we have no sales, marketing or commercial product distribution capabilities and have no experience as a company in marketing drugs.
When, and if any of our product candidates are approved for commercialization, we intend to develop a commercialization infrastructure for those products in the United States, Europe, Asia, and potentially in certain other key markets. We may also
rely on partnerships, such as our AbbVie collaboration, to provide commercialization infrastructure, including sales and marketing and commercial distribution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success
depends in part on our ability to obtain and maintain proprietary protection for our product candidates, technology and <FONT STYLE="white-space:nowrap">know-how,</FONT> to operate without infringing the proprietary rights of others and to prevent
others from infringing our proprietary rights. Our strategy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States
related to our proprietary technology, inventions, improvements and product candidates that are important to the development and implementation of our business. Our patent portfolio is intended to cover our product candidates and related components,
their methods of use and processes for their manufacture, our proprietary reagents and assays and any other inventions that are commercially important to our business. We also rely on trademarks as well as trade secret protection of our confidential
information and <FONT STYLE="white-space:nowrap">know-how</FONT> relating to our proprietary technology, platforms and product candidates. We believe that we have substantial <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets
relating to our technology and product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patent portfolio contains over 30 families, which include three issued patents and
over 190 pending patent applications, directed to over 15 different targets and/or technologies, that are solely owned or exclusively licensed by us. For our product candidates, we generally pursue multilayered patent protection covering the
composition of matter based on binding epitopes of the product candidates on the target protein, functional characteristics of the product candidates, degenerative sequence of the product candidates, and/or specific sequence of the product
candidates. In addition to composition of matter coverage, we also generally pursue claims directed to methods of making, nucleic acids, formulations, and methods of use of the product candidates. The method of use claims further include claims
directed to patient selection criteria, biomarkers, disease subgroups, pharmacodynamic and clinical <FONT STYLE="white-space:nowrap">end-points,</FONT> and dosage regimes. As further described below, we intend to strengthen the patent protection of
our product candidates and technologies through additional patent application filings. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>PGRN Programs </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own four patent families directed to our PGRN programs, AL001 and AL101, which include three issued U.S. patents, covering the compositions
and uses of our PGRN program product candidates. Two patent families are expected to expire in 2036, the third family is expected to expire in 2039, and the fourth patent family, assuming that the necessary
<FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications are timely filed and all other applicable requirements are satisfied for the U.S. provisional patent application, in 2040, in all cases excluding any patent term adjustments
and any patent term extensions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>TREM2 Program </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own three patent families directed to the TREM2 program covering the compositions and uses of our TREM2 program product candidates. The
patent families are expected to expire in 2035, 2036, and 2038, respectively, in all cases excluding any patent term adjustments and any patent term extensions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>SIGLEC&nbsp;3 Program </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own four patent
families directed to the SIGLEC&nbsp;3 program covering the compositions and uses of our SIGLEC&nbsp;3 program product candidates. Two patent families are expected to expire in 2036, the third patent family in 2038, and the fourth patent family in
2039, in all cases excluding any patent term adjustments and any patent term extensions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term of individual patents depends upon the
legal term for patents in the countries in which they are granted. In most countries, including the United States, the patent term is generally 20 years from the earliest claimed filing date of a
<FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application in the applicable country. In the United States, a patent&#146;s term may, in certain cases, be lengthened by patent term adjustment, which compensates a patentee for
administrative delays by the U.S. Patent and Trademark Office in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over a commonly owned patent or a patent naming a common inventor and having an earlier
expiration date. The Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Act) permits a patent term extension of up to five years beyond the expiration date of a U.S. patent as partial compensation for the length of time the
drug is under regulatory review while the patent is in force. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent applicable to each regulatory review
period may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it, may be extended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar provisions are available in the European Union and certain other foreign jurisdictions to extend the term of a patent that covers an
approved drug. In the future, if and when our product candidates receive approval by the FDA or foreign regulatory authorities, we expect to apply for patent term extensions on issued patents covering those products, depending upon the length of the
clinical trials for each drug and other factors. Expiration dates referred to above are without regard to potential patent term extension or other market exclusivity that may be available to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also rely, in some circumstances, on trade secrets to protect our technology. However, trade secrets can be difficult to protect. We seek
to protect our proprietary technology and processes, in part, by confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade
secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. For example, on June&nbsp;18, 2019, we initiated confidential arbitration proceedings against Dr.&nbsp;Asa
Abeliovich, our former consulting <FONT STYLE="white-space:nowrap">co-founder,</FONT> related to alleged breaches of his consulting agreement and the improper use of our confidential information learned during the course of rendering services to us
as our consulting Chief Scientific Officer/Chief Innovation Officer. We are in the early stage of this arbitration proceeding and are unable to assess or provide any assurances regarding its possible outcome. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and
pharmaceutical industries, including in the neurodegenerative disease field, are characterized by rapidly advancing technologies, strong competition and an emphasis on intellectual property. We face substantial competition from many different
sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions, governmental agencies and public and private research institutions. Some of the pharmaceutical and biotechnology companies that are
currently pursuing the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development of products for the treatment of the neurodegenerative disease indications for which we have research programs, including FTD, Alzheimer&#146;s disease and Parkinson&#146;s disease,
include large companies with significant financial resources, such as Biogen, Eli Lilly, GlaxoSmithKline, Merck and Roche Holding AG. We believe that the key competitive factors affecting the success of any of our product candidates will include
efficacy, safety profile, method of administration, cost, level of promotional activity and intellectual property protection.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product
candidates will compete with current therapies approved for the treatment of neurodegenerative diseases, which to date have been primarily targeted at treating the symptoms of such diseases rather than halting or slowing the progression of the
disease. However, in addition to such currently approved therapies, we believe that our product candidates, if approved, may also compete with other potential therapies intended to halt or slow the progression of neurodegenerative disease that are
being developed by a number of companies and institutions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Government authorities in the United States at the federal, state and local level and in other countries regulate, among other things, the
research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and
biological products. Generally, before a new drug or biologic can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review
and approved by the regulatory authority. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Drug Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs under the Food, Drug, and Cosmetic Act (FDCA) and biologics under the FDCA and the Public Health
Service Act (PHSA). Both drugs and biologics also are subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign
statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or post-market may subject an
applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#146;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls
or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement
action could have a material adverse effect on us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any future product candidates must be approved by the FDA through either a biologics
license application (BLA) or NDA process before they may be legally marketed in the United States. The process generally involves the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Completion of extensive preclinical studies in accordance with applicable regulations, including studies
conducted in accordance with GLP; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Submission to the FDA of an IND, which must become effective before human clinical trials may begin;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Approval by an independent IRB, or ethics committee at each clinical trial site before each trial may be
initiated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations,
good clinical practice (GCP), requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Submission to the FDA of a NDA or BLA; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A determination by the FDA within 60 days of its receipt of an NDA or BLA to accept the filing for review;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Satisfactory completion of a FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the
manufacturing facility or facilities where the drug or biologic will be produced to assess compliance with cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the drug or biologic&#146;s identity,
strength, quality and purity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Potential FDA audit of the preclinical study and/or clinical trial sites that generated the data in support of
the NDA or BLA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of the NDA or BLA, including consideration of the views of any FDA advisory committee,
prior to any commercial marketing or sale of the drug or biologic in the United States; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Compliance with any post-approval requirements, including the potential requirement to implement a Risk
Evaluation and Mitigation Strategy (REMS), and the potential requirement to conduct post-approval studies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The data
required to support an NDA or BLA are generated in two distinct developmental stages: preclinical and clinical. The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be
certain that any approvals for any future product candidates will be granted on a timely basis, or at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical Studies and IND </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preclinical developmental stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies
to evaluate toxicity in animals, which support subsequent clinical testing. The sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a
proposed clinical protocol, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational product to humans, and must become effective before human clinical trials may begin. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as<I> in vitro</I> and animal studies to
assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies.
An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND.
Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time
the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a
result, submission of an IND may not result in the FDA allowing clinical trials to commence. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical Trials </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the
supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#146;s control, in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for
their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used
to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals
participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative, and
must monitor the clinical trial until completed. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the
clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of an NDA or BLA. The FDA will accept a well-designed and well-conducted foreign
clinical trial not conducted under an IND if the trial was conducted in accordance with GCP requirements and the FDA is able to validate the data through an onsite inspection if deemed necessary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials in the United States generally are conducted in three sequential phases, known as Phase&nbsp;1, Phase&nbsp;2, and
Phase&nbsp;3, and may overlap. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase&nbsp;1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients
who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action, tolerability and safety of the drug. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase&nbsp;2 clinical trials involve studies in disease-affected patients to determine the dose required to
produce the desired benefits. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety risks are identified, and a preliminary evaluation of efficacy is conducted.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase&nbsp;3 clinical trials generally involve a large number of patients at multiple sites and are designed to
provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product approval. These trials
may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Post-approval trials, sometimes referred to as Phase&nbsp;4 clinical trials, may be conducted after initial marketing approval. These trials
are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase&nbsp;4 clinical trials as a condition of approval of an NDA or BLA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA and
written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the drug or biologic, findings from
animal or<I> in vitro</I> testing that suggest a significant risk for human volunteers and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Phase&nbsp;1, Phase&nbsp;2, and Phase&nbsp;3 clinical trials may not be completed successfully within any specified period, if at all. The FDA
or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval
of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the drug or biologic has been associated with unexpected serious harm to patients. Additionally, some clinical
trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
This group provides authorization for whether a trial may move forward at designated check-points based on access to certain data from the trial. Concurrent with clinical trials, companies
usually complete additional animal studies and also must develop additional information about the chemistry and physical characteristics of the drug or biologic as well as finalize a process for manufacturing the product in commercial quantities in
accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality and purity of
the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that our product candidates do not undergo unacceptable deterioration over their shelf life. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>NDA/BLA Review Process </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following
completion of the clinical trials, data is analyzed to assess whether the investigational product is safe and effective for the proposed indicated use or uses. The results of preclinical studies and clinical trials are then submitted to the FDA as
part of an NDA or BLA, along with proposed labeling, chemistry and manufacturing information to ensure product quality and other relevant data. In short, the NDA or BLA is a request for approval to market the drug or biologic for one or more
specified indications and must contain proof of safety and efficacy for a drug or safety, purity, and potency for a biologic. The application may include both negative and ambiguous results of preclinical studies and clinical trials, as well as
positive findings. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#146;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing
approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of FDA. FDA approval of an NDA or BLA must be obtained before a drug or biologic may be
marketed in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Prescription Drug User Fee Act (PDUFA), as amended, each NDA or BLA must be accompanied by a
user fee. FDA adjusts the PDUFA user fees on an annual basis. According to the FDA&#146;s FY 2020 fee schedule for prescription drug user fees, which became effective on October&nbsp;1, 2019, and will remain in effect through September&nbsp;30,
2020, the user fee for an application requiring clinical data, such as an NDA or BLA, is approximately $2.9&nbsp;million. PDUFA also imposes an annual program fee for each marketed human drug or biologic ($325,424 in 2020) and an annual
establishment fee on facilities used to manufacture prescription drugs and biologics. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business.
Additionally, no user fees are assessed on NDAs or BLAs for products designated as orphan drugs, unless the product also includes a <FONT STYLE="white-space:nowrap">non-orphan</FONT> indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA reviews all submitted NDAs and BLAs before it accepts them for filing, and may request additional information rather than accepting
the NDA or BLA for filing. The FDA must make a decision on accepting an NDA or BLA for filing within 60 days of receipt. Once the submission is accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> review of the NDA
or BLA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has 10 months, from the filing date, in which to complete its initial review of a new molecular-entity NDA or original BLA and respond to the applicant, and six months
from the filing date of a new molecular-entity NDA or original BLA designated for priority review. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs or BLAs, and the review process is often extended by FDA requests for
additional information or clarification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an NDA or BLA, the FDA will conduct a
<FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the
manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The FDA also may audit data from clinical trials to ensure compliance with
GCP requirements. Additionally, the FDA may refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts,
for review, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it
considers such recommendations when making decisions on approval. The FDA likely will reanalyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process. After the FDA evaluates
an NDA or BLA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that
the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the NDA or BLA identified by the FDA. The Complete
Response Letter may require additional clinical data, additional pivotal Phase&nbsp;3 clinical trial(s) and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a Complete Response
Letter is issued, the applicant may either resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA or BLA
does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Orphan Drugs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan
Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than
200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the
product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the
identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such
designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such approval, except in limited
circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care or in instances of drug supply issues. However,
competitors may receive approval of either a different product for the same indication or the same product for a different indication but that could be used <FONT STYLE="white-space:nowrap">off-label</FONT> in the orphan indication. Orphan drug
exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval before we do for the same product, as defined by the FDA, for the same indication we are seeking approval, or if a product candidate is
determined to be contained within the scope of the competitor&#146;s product for the same indication or disease. If one of our products designated as an orphan drug receives marketing approval for an indication broader than that which is designated,
it may not be entitled to orphan drug exclusivity. Orphan drug status in the European Union has similar, but not identical, requirements and benefits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expedited Development and Review Programs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has a fast track program that is intended to expedite or facilitate the process for reviewing new drugs and biologics that meet certain
criteria. Specifically, new drugs and biologics are eligible for fast track designation if they are intended to treat a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address unmet medical needs
for the condition. Fast track designation applies to both the product and the specific indication for which it is being studied. The sponsor can request the FDA to designate the product for fast track status any time before receiving NDA or BLA
approval, but ideally no later than the <FONT STYLE="white-space:nowrap">pre-NDA</FONT> or <FONT STYLE="white-space:nowrap">pre-BLA</FONT> meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product submitted to the FDA for marketing, including under a fast track program, may be
eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it treats a serious or life-threatening condition and, if
approved, would provide a significant improvement in safety and effectiveness compared to available therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A product may also be
eligible for accelerated approval, if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably
likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (IMM), which is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval,
the FDA may require that a sponsor of a drug or biologic receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. If the FDA concludes that a drug or biologic shown to be effective can be safely used only
if distribution or use is restricted, it may require such post-marketing restrictions as it deems necessary to assure safe use of the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, a drug or biologic may be eligible for designation as a breakthrough therapy if the product is intended, alone or in combination
with one or more other drugs or biologics, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more
clinically significant endpoints. The benefits of breakthrough therapy designation include the same benefits as fast track designation, plus intensive guidance from the FDA to ensure an efficient drug development program. Fast track designation,
priority review, accelerated approval and breakthrough therapy designation do not change the standards for approval, but may expedite the development or approval process. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Abbreviated Licensure Pathway of Biological Products as Biosimilar or Interchangeable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Patient Protection and Affordable Care Act, or ACA, signed into law in 2010, includes the BPCIA, which created an abbreviated approval
pathway for biological products shown to be highly similar to an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. The BPCIA attempts to minimize duplicative testing, and thereby lower development costs and increase
patient access to affordable treatments. An application for licensure of a biosimilar product must include information demonstrating biosimilarity based upon the following, unless the FDA determines otherwise: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analytical studies demonstrating that the proposed biosimilar product is highly similar to the approved product
notwithstanding minor differences in clinically inactive components; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">animal studies (including the assessment of toxicity); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a clinical trial or trials (including the assessment of immunogenicity and pharmacokinetic or pharmacodynamic)
sufficient to demonstrate safety, purity and potency in one or more conditions for which the reference product is licensed and intended to be used. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, an application must include information demonstrating that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proposed biosimilar product and reference product utilize the same mechanism of action for the condition(s)
of use prescribed, recommended or suggested in the proposed labeling, but only to the extent the mechanism(s) of action are known for the reference product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the condition or conditions of use prescribed, recommended or suggested in the labeling for the proposed
biosimilar product have been previously approved for the reference product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the route of administration, the dosage form and the strength of the proposed biosimilar product are the same as
those for the reference product; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the facility in which the biological product is manufactured, processed, packed or held meets standards designed
to assure that the biological product continues to be safe, pure, and potent. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biosimilarity means that the biological product is highly similar to the reference product
notwithstanding minor differences in clinically inactive components; and that there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity, and potency of the product. In
addition, the law provides for a designation of &#147;interchangeability&#148; between the reference and biosimilar products, whereby the biosimilar may be substituted for the reference product without the intervention of the healthcare provider who
prescribed the reference product. The higher standard of interchangeability must be demonstrated by information sufficient to show that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proposed product is biosimilar to the reference product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proposed product is expected to produce the same clinical result as the reference product in any given
patient; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">for a product that is administered more than once to an individual, the risk to the patient in terms of safety or
diminished efficacy of alternating or switching between the biosimilar and the reference product is no greater than the risk of using the reference product without such alternation or switch. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FDA approval is required before a biosimilar may be marketed in the United States. However, complexities associated with the large and
intricate structures of biological products and the process by which such products are manufactured pose significant hurdles to the FDA&#146;s implementation of the law that are still being worked out by the FDA. For example, the FDA has discretion
over the kind and amount of scientific evidence&#151;laboratory, preclinical and/or clinical&#151;required to demonstrate biosimilarity to a licensed biological product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA intends to consider the totality of the evidence provided by a sponsor to support a demonstration of biosimilarity, and recommends
that sponsors use a stepwise approach in the development of their biosimilar products. Biosimilar product applications thus may not be required to duplicate the entirety of preclinical and clinical testing used to establish the underlying safety and
effectiveness of the reference product. However, the FDA may refuse to approve a biosimilar application if there is insufficient information to show that the active ingredients are the same or to demonstrate that any impurities or differences in
active ingredients do not affect the safety, purity or potency of the biosimilar product. In addition, as with BLAs, biosimilar product applications will not be approved unless the product is manufactured in facilities designed to assure and
preserve the biological product&#146;s safety, purity and potency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The submission of a biosimilar application does not guarantee that the
FDA will accept the application for filing and review, as the FDA may refuse to accept applications that it finds are insufficiently complete. The FDA will treat a biosimilar application or supplement as incomplete if, among other reasons, any
applicable user fees assessed under the Biosimilar User Fee Act of 2012 have not been paid. In addition, the FDA may accept an application for filing but deny approval on the basis that the sponsor has not demonstrated biosimilarity, in which case
the sponsor may choose to conduct further analytical, preclinical or clinical studies and submit a BLA for licensure as a new biological product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The timing of final FDA approval of a biosimilar for commercial distribution depends on a variety of factors, including whether the
manufacturer of the branded product is entitled to one or more statutory exclusivity periods, during which time the FDA is prohibited from approving any products that are biosimilar to the branded product. The FDA cannot approve a biosimilar
application for 12&nbsp;years from the date of first licensure of the reference product. Additionally, a biosimilar product sponsor may not submit an application for four years from the date of first licensure of the reference product. A reference
product may also be entitled to exclusivity under other statutory provisions. For example, a reference product designated for a rare disease or condition (an orphan drug) may be entitled to seven years of exclusivity, in which case no product that
is biosimilar to the reference product may be approved until either the end of the twelve-year period provided under the biosimilarity statute or the end of the seven-year orphan drug exclusivity period, whichever occurs later. In certain
circumstances, a regulatory exclusivity period can extend beyond the life of a patent, and thus block biosimilarity applications from being approved on or after the patent expiration date. In addition, the FDA may
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under certain circumstances extend the exclusivity period for the reference product by an additional six months if the FDA requests, and the manufacturer undertakes, studies on the effect of its
product in children, a <FONT STYLE="white-space:nowrap">so-called</FONT> pediatric extension. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The first biological product determined to
be interchangeable with a branded product for any condition of use is also entitled to a period of exclusivity, during which time the FDA may not determine that another product is interchangeable with the reference product for any condition of use.
This exclusivity period extends until the earlier of: one year after the first commercial marketing of the first interchangeable product; 18&nbsp;months after resolution of a patent infringement against the applicant that submitted the application
for the first interchangeable product, based on a final court decision regarding all of the patents in the litigation or dismissal of the litigation with or without prejudice; 42&nbsp;months after approval of the first interchangeable product, if a
patent infringement suit against the applicant that submitted the application for the first interchangeable product is still ongoing; or 18 months after approval of the first interchangeable product if the applicant that submitted the application
for the first interchangeable product has not been sued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following approval of a new product, the manufacturer and the approved product are subject to continuing regulation by the FDA, including,
among other things, monitoring and record-keeping requirements, requirements to report adverse experiences and comply with promotion and advertising requirements, which include restrictions on promoting drugs for unapproved uses or patient
populations, known as <FONT STYLE="white-space:nowrap">&#147;off-label</FONT> use&#148;, and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available drugs for <FONT
STYLE="white-space:nowrap">off-label</FONT> uses, manufacturers may not market or promote such uses. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use. Further, if there are any modifications to
the drug or biologic, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA/BLA or NDA/BLA supplement, which may require the development of
additional data or preclinical studies and clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may also place other conditions on approvals including the
requirement for REMS, to assure the safe use of the product. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk
minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for
<FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards or if problems occur following initial marketing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events
of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical
studies to assess new safety risks or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the
market, or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters, or holds on post-approval clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve pending applications or supplements to approved applications;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">applications, or suspension or revocation of product license approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates marketing, labeling, advertising and promotion of products that
are placed on the market. Drugs and biologics may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the
promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant liability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other U.S. Regulatory Matters </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturing, sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory
authorities in the United States in addition to the FDA, including the Centers for Medicare&nbsp;&amp; Medicaid Services, other divisions of the Department of Health and Human Services, the Department of Justice, the Drug Enforcement Administration,
the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety&nbsp;&amp; Health Administration, the Environmental Protection Agency, and state and local governments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, in the United States, sales, marketing and scientific and educational programs also must comply with state and federal fraud and
abuse laws. These laws include the federal Anti-Kickback Statute, which makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any
remuneration that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid.
Violations of this law are punishable by up to five years in prison, criminal fines, administrative civil money penalties and exclusion from participation in federal healthcare programs. Moreover, the ACA provides that the government may assert that
a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pricing and rebate programs must comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more
recent requirements in the ACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Products must meet applicable child-resistant packaging
requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of biologic and pharmaceutical products is subject to additional requirements and regulations, including extensive
record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
failure to comply with any of these laws or regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines
or other penalties, injunctions, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals or refusal to allow a firm to enter into supply contracts, including government
contracts. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#146;s attention from the operation of our business. Prohibitions
or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes
in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: changes to our manufacturing arrangements; additions or modifications to product labeling; the recall or
discontinuation of our products; or additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Patent-Term Restoration and Marketing Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of FDA approval of any future product candidates, some of our U.S. patents may be eligible
for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits restoration of the patent term of up to five years as compensation for patent term lost during product development and FDA regulatory review process.
Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#146;s approval date. The <FONT STYLE="white-space:nowrap">patent-term</FONT> restoration period is generally <FONT
STYLE="white-space:nowrap">one-half</FONT> the time between the effective date of an IND and the submission date of an NDA or BLA plus the time between the submission date of an NDA or BLA and the approval of that application, except that the review
period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration
of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for our currently owned or licensed patents to add
patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA or BLA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a
five-year period of <FONT STYLE="white-space:nowrap">non-patent</FONT> marketing exclusivity within the United States to the first applicant to gain approval of a NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not
previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug
application (ANDA), or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted
after four years if it contains a certification of patent invalidity or <FONT STYLE="white-space:nowrap">non-infringement.</FONT> The FDCA also provides three years of marketing exclusivity for a NDA, 505(b)(2) NDA or supplement to an existing NDA
if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an
existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year
exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical
trials necessary to demonstrate safety and effectiveness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A reference biological product is granted 12 years of data exclusivity from the
time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product.
&#147;First licensure&#148; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for)
a biological product if the licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest or other related entity) for a
change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength or for a modification to the
structure of the biological product that does not result in a change in safety, purity or potency. Therefore, one must determine whether a new product includes a modification to the structure of a previously licensed product that results in a change
in safety, purity or potency to assess whether the licensure of the new product is a first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved, warrants exclusivity as the &#147;first licensure&#148;
of a biological product is determined on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis with data submitted by the sponsor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European Union Drug Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to the United States, the various phases of preclinical and clinical research in the European Union are subject to significant
regulatory controls. Although the EU Clinical Trials Directive 2001/20/EC has sought to harmonize the EU clinical trials regulatory framework, setting out common rules for the control and authorization of clinical trials in the EU, the EU Member
States have transposed and applied the provisions of the Directive differently. This has led to significant variations in the member state regimes. Under the current regime, before a clinical trial can be initiated it must be approved in each of the
EU countries where the trial is to be conducted by two distinct bodies: the National Competent Authority (NCA), and one or more Ethics Committees (ECs). Under the current regime all suspected unexpected serious adverse reactions to the investigated
drug that occur during the clinical trial have to be reported to the NCA and ECs of the Member State where they occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The EU clinical
trials legislation currently is undergoing a transition process mainly aimed at harmonizing and streamlining clinical-trial authorization, simplifying adverse-event reporting procedures, improving the supervision of clinical trials and increasing
their transparency. Recently enacted Clinical Trials Regulation EU No&nbsp;536/2014 ensures that the rules for conducting clinical trials in the EU will be identical. In the meantime, Clinical Trials Directive 2001/20/EC continues to govern all
clinical trials performed in the EU. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European Union Drug Review and Approval </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Economic Area (EEA), which is comprised of the 27 Member States of the European Union (including Norway and excluding Croatia),
Iceland and Liechtenstein, medicinal products can only be commercialized after obtaining a Marketing Authorization (MA). There are two types of marketing authorizations. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Community MA is issued by the European Commission through the Centralized Procedure, based on the opinion of
the Committee for Medicinal Products for Human Use (CHMP), of the EMA, and is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan
medicinal products, advanced-therapy medicines such as gene-therapy, somatic cell-therapy or tissue-engineered medicines and medicinal products containing a new active substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative
disorders, diabetes, auto-immune and other immune dysfunctions and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant
therapeutic, scientific or technical innovation or which are in the interest of public health in the EU. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their
respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in
another Member States through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized
Procedure. Under the Decentralized Procedure an identical dossier is submitted to the competent authorities of each of the Member States in which the MA is sought, one of which is selected by the applicant as the Reference Member State (RMS). The
competent authority of the RMS prepares a draft assessment report, a draft summary of the product characteristics (SPC), and a draft of the labeling and package leaflet, which are sent to the other Member States (referred to as the Member States
Concerned) for their approval. If the Member States Concerned raise no objections, based on a potential serious risk to public health, to the assessment, SPC, labeling or packaging proposed by the RMS, the product is subsequently granted a national
MA in all the Member States (i.e., in the RMS and the Member States Concerned). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the above described procedures, before granting the MA, the EMA or the competent
authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Coverage and Reimbursement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales
of our products will depend, in part, on the extent to which our products will be covered by third-party payors, such as government health programs, commercial insurance, and managed healthcare organizations. In the United States, no uniform policy
of coverage and reimbursement for drug or biological products exists. Accordingly, decisions regarding the extent of coverage and amount of reimbursement to be provided for any of our products will be made on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">payor-by-payor</FONT></FONT> basis. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products
to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The United States government,
state legislatures, and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price-controls, restrictions on reimbursement, and requirements
for substitution of generic products for branded prescription drugs. For example, the ACA contains provisions that may reduce the profitability of drug products through increased rebates for drugs reimbursed by Medicaid programs, extension of
Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part&nbsp;D beneficiaries and annual fees based on pharmaceutical companies&#146; share of sales to federal health care programs. Adoption of general controls
and measures, coupled with the tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceutical drugs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the
Secretary of the Department of Health and Human Services as a condition for states to receive federal matching funds for the manufacturer&#146;s outpatient drugs furnished to Medicaid patients. The ACA made several changes to the Medicaid Drug
Rebate Program, including increasing pharmaceutical manufacturers&#146; rebate liability by raising the minimum basic Medicaid rebate on most branded prescription drugs from 15.1% of average manufacturer price (AMP), to 23.1% of AMP and adding a new
rebate calculation for &#147;line extensions&#148; (i.e., new formulations, such as extended release formulations) of solid oral dosage forms of branded products, as well as potentially impacting their rebate liability by modifying the statutory
definition of AMP. The ACA also expanded the universe of Medicaid utilization subject to drug rebates by requiring pharmaceutical manufacturers to pay rebates on Medicaid managed care utilization and by enlarging the population potentially eligible
for Medicaid drug benefits. The Centers for Medicare&nbsp;&amp; Medicaid Services (CMS), have proposed to expand Medicaid rebate liability to the territories of the United States as well. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA), established the Medicare Part&nbsp;D program to provide a
voluntary prescription drug benefit to Medicare beneficiaries. Under Part&nbsp;D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. Unlike Medicare
Part&nbsp;A and B, Part&nbsp;D coverage is not standardized. While all Medicare drug plans must give at least a standard level of coverage set by Medicare, Part&nbsp;D prescription drug plan sponsors are not required to pay for all covered
Part&nbsp;D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part&nbsp;D prescription drug formularies must include drugs within each therapeutic category and
class of covered Part&nbsp;D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part&nbsp;D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment
for some of the costs of prescription drugs may increase demand for products for which we receive marketing approval. However, any negotiated prices for our products covered by a Part&nbsp;D prescription drug plan likely will be lower than the
prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in
payment that results from the MMA may result in a similar reduction in payments from <FONT STYLE="white-space:nowrap">non-governmental</FONT> payors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a drug product to receive federal reimbursement under the Medicaid or Medicare
Part&nbsp;B programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program. The required 340B discount on a given product is calculated based
on the AMP and Medicaid rebate amounts reported by the manufacturer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As noted above, the marketability of any products for which we
receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. An increasing emphasis on cost containment measures in the United States has increased and we
expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which
we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
in most foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the European Union provides
options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific
price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or
reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and
generally prices tend to be significantly lower. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Scientific Advisory Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have assembled a highly qualified scientific advisory board comprised of advisors who have, collectively, deep expertise in
neurodegenerative diseases, genomics, protein engineering, drug development, and drug discovery as well as translational medicine. Our scientists work in collaboration with these advisors to identify new disease targets, develop a biomarker
strategy, and accelerate discovery and development. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Affiliated Entity</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adam Boxer, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director of UCSF Neurosciences Clinical Research Unit</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marco Colonna, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Washington University School of Medicine in St. Louis</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Hauser, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chair of the Department of Neurology at UCSF</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Heneka, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director of the Department of Neurodegenerative Diseases and Gerontopsychiatry at the University of Bonn</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lewis Lanier, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chair of the Department of Microbiology and Immunology at UCSF</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liqun Luo, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Member of National Academy of Sciences, Stanford University</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Scheller, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Member of National Academy of Sciences</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas&nbsp;Christian&nbsp;S&uuml;dhof,&nbsp;M.D.,&nbsp;Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Nobel Laureate, Stanford University</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Vassar, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Northwestern University Feinberg School of Medicine</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Berislav Zlokovic, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chair of the Department of Physiology&nbsp;&amp; Neuroscience at USC Keck School of Medicine</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019 we had 121 full-time employees. More than 70% of our employees are engaged in research and development activities.
None of our employees are represented by a labor union or covered under a collective bargaining agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate headquarters are currently located in South San Francisco, California, where we lease approximately 105,000 square feet of
office, research and development, engineering, and laboratory space pursuant to a lease agreement that expires in April 2029, with an option to extend the term of the lease for an additional 10&nbsp;years. The new lease agreement also provides us a
right of first offer to expand into available office space in the building. We lease 8,763 square feet of additional office and laboratory space in Milpitas, California. We believe that these facilities will be adequate for our near-term needs. If
required, we believe that suitable additional or alternative space would be available in the future on commercially reasonable terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal
Proceedings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any
litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. We have initiated an arbitration against a third party as set forth below. Regardless of outcome, litigation can
have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
June&nbsp;18, 2019, we initiated a confidential arbitration proceeding against Dr.&nbsp;Asa Abeliovich, our former consulting <FONT STYLE="white-space:nowrap">co-founder,</FONT> related to alleged breaches of his consulting agreement and the
improper use of our confidential information that he learned during the course of rendering services to us as our consulting Chief Scientific Officer/Chief Innovation Officer. We are in the early stage of this arbitration proceeding and are unable
to assess or provide any assurances regarding its possible outcome. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_11"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table sets forth the names, ages, and positions of our executive officers and directors as of December 31, 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arnon Rosenthal, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Co-Founder,&nbsp;Chief&nbsp;Executive&nbsp;Officer,&nbsp;and&nbsp;Director</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shehnaaz Suliman, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Operating Officer</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Paul, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert King, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Development Officer</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sabah Oney, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Business Officer</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Calvin Yu</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Vice President, Finance</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tillman Gerngross, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Chairperson</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Louis J. Lavigne, Jr.*<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Terry McGuire<SUP STYLE="font-size:85%; vertical-align:top">(1)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Scheller, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Wehner<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP><SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kristine Yaffe, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Lead independent director </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the audit committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the compensation committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Member of the corporate governance and nominating committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr. Shehnaaz joined Alector in December 2019. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Arnon Rosenthal,
Ph.D., <FONT STYLE="white-space:nowrap">Co-Founder,</FONT> Chief Executive Officer, and Director. </I>Dr.&nbsp;Rosenthal <FONT STYLE="white-space:nowrap">co-founded</FONT> Alector in 2013 and has served as a member of our board of directors, as
Chief Executive Officer, and as our President since 2013. Dr.&nbsp;Rosenthal <FONT STYLE="white-space:nowrap">co-founded</FONT> Annexon Biosciences, Inc. and served as its acting Chief Executive Officer from August 2011 to December 2014 and served
as a member of the board of directors, including as Chairman from August 2011 February 2017. Dr.&nbsp;Rosenthal <FONT STYLE="white-space:nowrap">co-founded</FONT> Rinat Neuroscience Corporation (acquired by Pfizer Inc. in August 2006), and served as
President, Chief Scientific Officer and as a member of the board of directors from August 2001 to August 2006. From January 1985 to August 2001, Dr.&nbsp;Rosenthal served in various roles at Genentech, Inc., where he ultimately served as Staff
Scientist and was appointed as a permanent member of Genentech&#146;s Research Review Committee where his team discovered the target for the cancer drug Erivedge. Dr.&nbsp;Rosenthal conducted his post-doctoral fellowship at Genentech, Inc. He holds
a Ph.D. in biology from the Hebrew University of Jerusalem. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe Dr.&nbsp;Rosenthal is qualified to serve on our board of directors
because of the perspective and experience he provides as one of our founders and as our Chief Executive Officer, his experience as a founder and director of other life sciences companies, his educational background, as well as his broad experience
within the pharmaceutical industry, particularly in the area of neuroscience and drug discovery and development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Shehnaaz Suliman,
M.D., President and Chief Operating Officer</I>. Dr. Suliman has served as our President and Chief Operating Officer since December 2019. Dr. Suliman previously served as Senior Vice President, Corporate Development and Strategy of Theravance
Biopharma, Inc., a position she held from July 2017 to March 2019. Prior to her position at Theravance, Dr. Suliman worked for Genentech, Inc. as Group Leader and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Project Team Leader in the R&amp;D Portfolio Management and Operations Group from September 2010 to May 2015 and then as Vice President and Global Therapeutic Head, Roche Partnering from June
2015 to July 2017. Prior to Genentech, Dr. Suliman held various management roles of increasing responsibility at Gilead Sciences, Inc. between January 2005 and September 2010. Prior to Gilead, Dr. Suliman was an investment banker with Lehman
Brothers and Petkevich &amp; Partners, advising public and private companies on buy- and sell-side transactions. She is a member of the board of directors of Ultragenyx Pharmaceutical Inc., a pharmaceutical company, and 10x Genomics, Inc., a life
science technology company. Dr. Suliman received her M.D. at the University of Cape Town Medical School, South Africa, and holds an M.B.A., with distinction, and M.Phil. in Development Studies degrees from Oxford University, where she was a Rhodes
Scholar. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Robert Paul, M.D., Ph.D., Chief Medical Officer.</I> Dr.&nbsp;Paul has served as our Chief Medical Officer since October
2016. Dr.&nbsp;Paul joined Alector from Genentech, Inc., where he held various roles of increasing responsibility between 2009 and 2016, including as Assistant Group Medical Director and TA Head Neuroscience Early Clinical Development gRED from
October 2015 to October 2016, as Senior Medical Director from October 2013 to September 2015, as Medical Director from September 2011 to October 2013, and as Associate Medical Director from January 2009 to September 2011. From May 2002 to December
2008, Dr.&nbsp;Paul served as a Neurologist at the University of Munich. Dr.&nbsp;Paul is a board certified neurologist in Germany. He received a M.D. and a Ph.D. from Ludwig-Maximilians Universit&auml;t M&uuml;nchen. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Robert King, Ph.D., Chief Development Officer.</I> Dr.&nbsp;King has served as our Chief Development Officer since January 2017.
Dr.&nbsp;King joined Alector from SciClone Pharmaceuticals, Inc. (acquired by a consortium led by GL Capital Partners, LLC), a biotechnology company, where he served as Senior Vice President of Product Development and Supply Chain from June 2011 to
January 2017. Prior to SciClone Pharmaceuticals, Dr.&nbsp;King served as VP of Product Development and Manufacturing at Bayhill Therapeutics, Inc., a biotechnology company from 2006 to 2011. Dr.&nbsp;King served as VP Product Development and
Manufacturing at Rinat Neuroscience Corp. (acquired by Pfizer), a biotechnology company, from 2003 to 2006. Dr.&nbsp;King served in positions of increasing responsibility at COR Therapeutics, Inc. (acquired by Millennium Pharmaceuticals, Inc. in
2002) from 1993 to 2003. From 1991 to 1993, Dr.&nbsp;King served as a Scientist in the Purification and Pharmaceutical Sciences groups at California Biotechnology/Scios. From 1988 to 1991, Dr.&nbsp;King was a Scientist at Molecular Devices
Corporation. Dr.&nbsp;King received a Ph.D. in Chemical Engineering from the University of California, Berkeley, and a B.S. in Chemical Engineering from the University of Washington. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Sabah Oney, Ph.D., Chief Business Officer.</I> Dr.&nbsp;Oney joined Alector in October 2016. He has served as our Chief Business Officer
since January 2018 and previously as our Vice President of Business Development and Operations since October 2016. From January 2016 until October 2016, Dr.&nbsp;Oney served as a consultant to a number of biotechnology companies. Dr.&nbsp;Oney
previously served as Head of Global Sales and Business Development at Ariosa Diagnostics, Inc. (now a member of Roche Holding AG), a biotechnology company, from October 2015 to January 2016, and as Director of Business Development from September
2012 to October 2015. Dr.&nbsp;Oney received a Ph.D. in Genetics and Genomics from Duke University, an M.B.A. from Stanford University Graduate School of Business, and a B.S. in Genetics from the University of Kansas. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Calvin Yu, Vice President, Finance.</I> Mr.&nbsp;Yu has led our Finance team since June 2017. Mr.&nbsp;Yu joined Alector from Stemcentrx,
Inc. (acquired by AbbVie), a biotechnology company, where he served as Corporate Controller from February 2016 to June 2017. Prior to Stemcentrx, Mr.&nbsp;Yu held several senior level finance roles at publicly traded biotechnology companies,
including Senior Director of Finance and SEC Reporting at Adverum Biotechnologies, Inc. from September 2014 to February 2016, and Controller at Five Prime Therapeutics, Inc. from March 2010 to September 2014. Mr.&nbsp;Yu received his B.S. in
Accounting from San Francisco State University, College of Business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Tillman Gerngross, Ph.D., <FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Chairperson. </I>Dr.&nbsp;Gerngross <FONT
STYLE="white-space:nowrap">co-founded</FONT> Alector in 2013 and has served as a member of our board of directors and as Chairperson since 2013. Dr.&nbsp;Gerngross is a founder, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
director, and executive officer of numerous biotechnology companies. He is a founder and currently serving as Chief Executive Officer and as a director of Adimab, LLC. He is also a founder and
Chairman of the board of directors of Avitide, Inc. and a founder and the Chairman of the board of directors of Arsanis, Inc. Dr.&nbsp;Gerngross is currently a Venture Partner at SV Life Sciences Advisors, LLC, which he joined in 2006.
Dr.&nbsp;Gerngross <FONT STYLE="white-space:nowrap">co-founded</FONT> GlycoFi, Inc. and served as its Chief Scientific Officer from 2000 to 2006 until it was acquired by Merck&nbsp;&amp; Company, Inc. Dr.&nbsp;Gerngross currently teaches in the
departments of Biology and Chemistry, as well as at the School of Engineering at Dartmouth College, where he has taught since 1998. Dr.&nbsp;Gerngross attended the Technical University of Vienna, Austria, where he received a B.S. and M.S. in
Chemical Engineering and a Ph.D. in Molecular Biology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe Dr.&nbsp;Gerngross is qualified to serve on our board of directors
because of the perspective and experience he provides as one of our founders, his expertise and experience in antibody drug discovery and development, his experience as a founder and director of other life sciences companies, his educational
background, and his experience working in the venture capital industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Louis J. Lavigne, Jr.</I> Mr.&nbsp;Lavigne has served as a
member of our board of directors and as our Lead Independent Director since October 2018. Mr.&nbsp;Lavigne has been a Managing Director of Lavrite, LLC, a management consulting firm specializing in the areas of corporate finance, accounting, growth
strategy, and management, since 2005. Mr.&nbsp;Lavigne served in various executive capacities with Genentech, Inc. for over 20 years, including, Chief Financial Officer from 1988 to 2005, Executive Vice President from 1997 to 2005, Senior Vice
President from 1994 to 1997, Vice President from 1986 to 1994, and Controller from 1983 to 1986. He has served as a director, chair of the audit committee, and member of the compensation committee of DocuSign Inc., an eSignature transaction
management company, since July 2013; as a member of the board of directors of Zynga&nbsp;Inc., a social game company, since 2015, including as audit committee chairman and compensation committee member since 2015 and as Lead Director since 2017; and
as chairman of the board of directors and chairperson of the compensation committee of Accuray Incorporated, a radiation oncology company, since September 2009. Within the last five years, Mr.&nbsp;Lavigne also served on the board of directors, the
audit committee, and the science and technology committee of Allergan, Inc., a global health care company, from 2005 until its acquisition by Actavis plc in 2015; as a director and chair of the audit committee of NovoCure Limited, an oncology
company, from 2013 until October 2018; as a director, chair of the compensation committee and member of the audit committee of Assertio Therapeutics, Inc., a pharmaceutical company, since July 2013 until his resignation in May 2019; as a director
and chair of the audit committee of SafeNet, Inc., a private information security company, from 2010 until its acquisition by Gemalto NV in 2015; and as a director and chair of the audit committee of BMC Software, Inc., an enterprise systems
software vendor, from 2004 to 2007 and from 2008 to 2013, when it was acquired by a private investor group. Mr.&nbsp;Lavigne serves as a board member and is the former chairman of the UCSF Benioff Children&#146;s Hospitals and the UCSF Benioff
Children&#146;s Hospitals Foundation where he is also a member of the audit and finance committees. Mr.&nbsp;Lavigne holds a B.S. in Business Administration from Babson College and an M.B.A. from Temple University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe Mr.&nbsp;Lavigne is qualified to serve on our board of directors because of his extensive experience in business operations and
management, strategy, finance, accounting, and public company governance as a chief financial officer of a large, complex publicly-traded company and his extensive board leadership positions with a number of public company boards and audit
committees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Terry McGuire. </I>Mr.&nbsp;McGuire has served as a member of our board of directors since 2013. Additionally,
Mr.&nbsp;McGuire is a Founding Partner of Polaris Partners, a venture capital firm investing in technology and healthcare companies across all stages of development, where he has worked since 1996. Mr.&nbsp;McGuire serves on the board of directors
of Cyclerion, Inc., a publicly traded biotechnology company, since January 2019 and Pulmatrix, Inc., a publicly traded biopharmaceutical company, where he has served since May 2016. Mr.&nbsp;McGuire served on the board of directors of Trevena, Inc.,
a publicly traded biopharmaceutical company, from January 2008 to July 2014; on the board of Ironwood Pharmaceuticals, Inc., a publicly traded drug manufacturer, from 1998 to 2019 and on the board of directors of Arsanis, Inc., a publicly traded
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
biopharmaceutical company, from 2011 to 2019. Mr.&nbsp;McGuire is emeritus Chairman of the National Venture Capital Association, Chairman of the Global Ventures Capital Congress and chairs the
board of the Thayer School of Engineering at Dartmouth College. He also sits on the boards of Massachusetts Institute of Technology&#146;s The David H. Koch Institute for Integrative Cancer Research, The Arthur Rock Center for Entrepreneurship at
Harvard Business School and The Healthcare Initiative Advisory Board. Mr.&nbsp;McGuire holds an M.B.A. from Harvard Business School, and a M.S. in engineering from the Thayer School at Dartmouth College, and a B.S. in physics and economics from
Hobart College. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe Mr.&nbsp;McGuire is qualified to serve on our board of directors because of his expertise and experience in
the biotechnology industry through his role as a Founding Partner of Polaris Partners and his cumulative career in venture capital over a period spanning over 35 years, in which he has been involved in the evaluation, investment and oversight of
numerous biotechnology companies, as well as his experience as a director of several biotechnology companies, including other public companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Richard Scheller, Ph.D. </I>Dr.&nbsp;Scheller has served as a member of our board of directors since October 2018 and has served as
co-chair of SPARC since December 2019. Dr.&nbsp;Scheller has served as the Chairman of Research and Development at BridgeBio Pharma LLC since January 2019 and as a member of its board of directors since January 2018. Dr.&nbsp;Scheller previously
served as Chief Scientific Officer at 23andMe, a personal genetics company, from April 2015 to April 2019. Previously, Dr.&nbsp;Scheller was the Executive Vice President of Research and Early Development and a member of the Executive Committee at
Genentech, Inc. from February 2001 to December 2014. From January 2009 to December 2014, Dr.&nbsp;Scheller was also a member of the Enlarged Executive Committee at <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche&nbsp;Ltd. Since February
2015, Dr.&nbsp;Scheller has served as a member of the board of directors for ORIC Pharmaceuticals, Inc. Since March 2015, Dr.&nbsp;Scheller has served as a member of the board of directors for Xenon Pharmaceuticals Inc. Since January 2018,
Dr.&nbsp;Scheller has served as a member of the board of directors of BridgeBio Inc. Dr.&nbsp;Scheller&#146;s research on elucidating the molecular machinery and regulatory mechanism that underlie the release of neurotransmitters earned him the 2013
Albert Lasker Basic Medical Research Award. He is a member of the National Academy of Sciences and a member of the National Academy of Medicine. Dr.&nbsp;Scheller holds a Ph.D. in Chemistry from the California Institute of Technology and B.Sc. in
Biochemistry from the University of Wisconsin-Madison. He completed his post-doctorate in Molecular Neurobiology at Columbia University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe Dr.&nbsp;Scheller is qualified to serve on our board of directors because of his scientific background and his senior management
experience in the pharmaceutical industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>David Wehner</I>. Mr.&nbsp;Wehner has served as a member of our board of directors since
October 2018. He has served as Chief Financial Officer of Facebook, Inc. since June 2014. Mr.&nbsp;Wehner joined Facebook, Inc. in November 2012 as Vice President, Corporate Finance and Business Planning. From August 2010 until November 2012,
Mr.&nbsp;Wehner served as Chief Financial Officer at Zynga Inc., a provider of social game services. From February 2001 to July 2010, Mr.&nbsp;Wehner served in various positions at Allen&nbsp;&amp; Company, an investment bank, including as a
Managing Director from November 2006 to July 2010 and as a director from December 2005 to November 2006. Mr.&nbsp;Wehner holds an M.S. in applied physics from Stanford University and a B.S. in chemistry from Georgetown University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe Mr.&nbsp;Wehner is qualified to serve on our board of directors based on his substantial executive, strategy, finance, and
operational experience. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Kristine Yaffe, M.D.</I> Dr.&nbsp;Yaffe has served as a member of our board directors since August 2019.
Dr.&nbsp;Yaffe is currently a professor of psychiatry, neurology and epidemiology at the University of California, San Francisco (UCSF) and has served in that role since 2007. Dr.&nbsp;Yaffe has also served as the Roy and Marie Scola Endowed Chair
since 2009 and Vice Chair in Psychiatry at UCSF since 2016. Dr.&nbsp;Yaffe has received numerous awards for her groundbreaking contributions to the field including the American Academy of Neurology Potamkin Prize for Research in Pick&#146;s,
Alzheimer&#146;s, and Related Diseases. Dr.&nbsp;Yaffe holds a B.S. in biology-psychology from Yale </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
University, an M.D. from the University of Pennsylvania School of Medicine and has completed residencies in neurology and psychiatry at the University of California, San Francisco. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe Dr.&nbsp;Yaffe is qualified to serve on our board of directors based on her experience as an internationally recognized expert in
the field of cognitive aging, neurodegeneration and dementia. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors currently consists of seven members. The number of directors will be fixed by our board of directors, subject to the
terms of our amended and restated certificate of incorporation and amended and restated bylaws. Each of our current directors will continue to serve as a director until the election and qualification of his or her successor, or until his or her
earlier death, resignation or removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation provides that our board of directors is
divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of stockholders, with the other classes continuing for the remainder of their respective three-year terms. Our current
directors are divided among the three classes as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;I directors consist of Dr.&nbsp;Rosenthal and Mr.&nbsp;Wehner, and their terms will expire at the
annual meeting of stockholders to be held in 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;II directors consist of Mr.&nbsp;McGuire and Dr.&nbsp;Yaffe, and their terms will expire at the
annual meeting of stockholders to be held in 2020; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the Class&nbsp;III directors consist of Drs. Gerngross and Scheller and Mr.&nbsp;Lavigne, and their terms will
expire at the annual meeting of stockholders to be held in 2021. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At each annual meeting of stockholders, upon the
expiration of the term of a class of directors, the successor to each such director in the class will be elected to serve from the time of election and qualification until the third annual meeting following his or her election and until his or her
successor is duly elected and qualified, in accordance with our amended and restated certificate of incorporation. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so
that, as nearly as possible, each class will consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of our directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
classification of our board of directors may have the effect of delaying or preventing changes in control of our company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the NASDAQ Global Select Market (NASDAQ). Under the rules of NASDAQ, independent directors must comprise
a majority of a listed company&#146;s board of directors within one year of the completion of our initial public offering. In addition, the rules of NASDAQ require that, subject to specified exceptions, each member of a listed company&#146;s audit,
compensation and corporate governance, and nominating committees be independent. Audit committee members and compensation committee members must also satisfy the independence criteria set forth in
<FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3</FONT> and <FONT STYLE="white-space:nowrap">Rule&nbsp;10C-1,</FONT> respectively, under the Exchange Act. Under the rules of NASDAQ, a director will only qualify as an &#147;independent director&#148;
if, in the opinion of that company&#146;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To be considered to be independent for purposes of <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3</FONT> and under the rules of NASDAQ, a
member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors or any other board committee: (1)&nbsp;accept, directly or indirectly, any consulting, advisory or
other compensatory fee from the listed company or any of its subsidiaries or (2)&nbsp;be an affiliated person of the listed company or any of its subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To be considered independent for purposes of
<FONT STYLE="white-space:nowrap">Rule&nbsp;10C-1</FONT> and under the rules of NASDAQ, the board of directors must affirmatively determine that each member of the compensation committee is independent, including a consideration of all factors
specifically relevant to determining whether the director has a relationship to the company which is material to that director&#146;s ability to be independent from management in connection with the duties of a compensation committee member,
including, but not limited to: (1)&nbsp;the source of compensation of such director, including any consulting, advisory, or other compensatory fee paid by the company to such director and (2)&nbsp;whether such director is affiliated with the
company, a subsidiary of the company or an affiliate of a subsidiary of the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors undertook a review of its
composition, the composition of its committees, and the independence of our directors and considered whether any director has a material relationship with us that could compromise his or her ability to exercise independent judgment in carrying out
his or her responsibilities. Based upon information requested from and provided by each director concerning his background, employment, and affiliations, including family relationships, our board of directors has determined that Dr. Yaffe and
Messrs. Lavigne, McGuire, and Wehner do not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is &#147;independent&#148; as that
term is defined under the rules of NASDAQ. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In making these determinations, our board of directors considered the current and prior
relationships that each <FONT STYLE="white-space:nowrap">non-employee</FONT> director has with our company and all other facts and circumstances our board of directors deemed relevant in determining their independence, including the beneficial
ownership of our capital stock by each <FONT STYLE="white-space:nowrap">non-employee</FONT> director, and the transactions involving them described in the section titled &#147;Certain Relationships and Related Party Transactions.&#148; There are no
family relationships among any of our directors or executive officers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lead Independent Director </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has appointed Louis J. Lavigne, Jr. to serve as our Lead Independent Director. As a general matter, our board of
directors believes that appointing a Lead Independent Director, when either our Chief Executive Officer serves as Chairman or when our Chairman is not independent, creates an environment that encourages objective oversight of management&#146;s
performance and enhances the effectiveness of our board of directors as a whole. As Lead Independent Director, Mr.&nbsp;Lavigne will preside over periodic meetings of our independent directors, serve as a liaison between our Chairperson, Chief
Executive Officer, and our independent directors and perform such additional duties as our board of directors may otherwise determine and delegate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Role of the Board in Risk Oversight </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
board of directors has an active role, as a whole and also at the committee level, in overseeing the management of our risks. Our board of directors is responsible for general oversight of risks and regular review of information regarding our risks,
including credit risks, liquidity risks, and operational risks. The compensation committee is responsible for overseeing the management of risks relating to our executive compensation plans and arrangements. The audit committee is responsible for
overseeing the management of risks relating to accounting matters and financial reporting and potential conflicts of interest. The corporate governance and nominating committee is responsible for overseeing the management of risks associated with
the independence of our board of directors. Although each committee is responsible for evaluating certain risks and overseeing the management of such risks, our entire board of directors is regularly informed through discussions from committee
members about such risks. Our board of directors believes its administration of its risk oversight function has not negatively affected the board of directors&#146; leadership structure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors
has an audit committee, a compensation committee, and a corporate governance and nominating committee, each of which has the composition and the responsibilities described below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our audit committee are Messrs. Lavigne, McGuire and Wehner. Mr.&nbsp;Lavigne is the chairperson of our audit committee and both
Mr.&nbsp;Lavigne and Mr.&nbsp;Wehner have been designated as audit committee financial experts, as that term is defined under the SEC rules implementing Section&nbsp;407 of SOX, as each possesses financial sophistication, as defined under the rules
of NASDAQ. Our audit committee oversees our corporate accounting and financial reporting process and assists our board of directors in monitoring our financial systems. Our audit committee will also: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">select and hire the independent registered public accounting firm to audit our financial statements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">help to ensure the independence and performance of the independent registered public accounting firm;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approve audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> services and fees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review financial statements and discuss with management and the independent registered public accounting firm our
annual audited and quarterly financial statements, the results of the independent audit and the quarterly reviews and the reports and certifications regarding internal controls over financial reporting and disclosure controls; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prepare the audit committee report that the SEC requires to be included in our annual proxy statement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review reports and communications from the independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review the adequacy and effectiveness of our internal controls and disclosure controls and procedure;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review our policies on risk assessment and risk management; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review and monitor conflicts of interest situations, and approve or prohibit any involvement in matters that may
involve a conflict of interest or taking of a corporate opportunity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review related party transactions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish and oversee procedures for the receipt, retention, and treatment of accounting related complaints and
the confidential submission by our employees of concerns regarding questionable accounting or auditing matters. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
audit committee operates under a written charter, which satisfies the applicable rules of the SEC and the listing standards of NASDAQ. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation
Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our compensation committee are Messrs. Lavigne and Wehner. Mr. Wehner is the chairperson of our
compensation committee. Our compensation committee oversees our compensation policies, plans, and benefits programs. The compensation committee will also: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">oversee our overall compensation philosophy and compensation policies, plans, and benefit programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review and approve or recommend to the board of directors for approval compensation for our executive officers
and directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">prepare the compensation committee report that the SEC will require to be included in our annual proxy statement;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">administer our equity compensation plans. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation committee operates under a written charter, which satisfies the applicable rules of the SEC and the listing standards of
NASDAQ. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Corporate Governance and Nominating Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our corporate governance and nominating committee are Dr. Yaffe and Mr.&nbsp;McGuire. Mr.&nbsp;McGuire is the chairperson of our
corporate governance and nominating committee. Our corporate governance and nominating committee oversees and assists our board of directors in reviewing and recommending nominees for election as directors. Specifically, the corporate governance and
nominating committee will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identify, evaluate, and make recommendations to our board of directors regarding nominees for election to our
board of directors and its committees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consider and make recommendations to our board of directors regarding the composition of our board of directors
and its committees; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review developments in corporate governance practices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluate the adequacy of our corporate governance practices and reporting; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluate the performance of our board of directors and of individual directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate governance and nominating committee operates under a written charter, which satisfies the applicable rules of the SEC and the
listing standards of NASDAQ. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Scientific Advisory Board Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also reimburse each member of our scientific advisory board for all reasonable and necessary expenses in connection with the performance of
his or her services. In addition, we grant each new member an option to purchase shares of our common stock and in the future, we may make additional grants or may make cash compensation payments to our scientific advisory board members for
continued service on the scientific advisory board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Directors who are also our employees receive no additional compensation for their service as directors. Dr.&nbsp;Rosenthal was our only
employee director during 2019. See the section titled &#147;Executive Compensation&#148; for additional information about Dr.&nbsp;Rosenthal&#146;s compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the total compensation each of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors received during
the year ended December&nbsp;31, 2019. Other than as set forth in the table, we did not pay any compensation, make any equity awards or <FONT STYLE="white-space:nowrap">non-equity</FONT> awards to or pay any other compensation to any of our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors in 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned&nbsp;or</B><br><B>Paid&nbsp;in&nbsp;Cash&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Awards</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tillman Gerngross, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carl Gordon, Ph.D., C.F.A.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">284,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Louis J. Lavigne, Jr.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">331,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Terry McGuire</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">306,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Scheller, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Wehner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264,314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">302,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kristine Yaffe, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">506,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">522,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts disclosed represent the aggregate grant date fair value of the award as calculated in accordance
with ASC 718. The assumptions used in calculating the grant date fair value of the award disclosed in this column are set forth in the notes to our audited financial statements included elsewhere in this prospectus. These amounts do not correspond
to the actual value that may be recognized by the directors upon vesting of the applicable awards. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of December&nbsp;31, 2019, our non-employee directors held outstanding options to purchase the number of
shares of common stock as follows: Dr.&nbsp;Gerngross (20,000&nbsp;shares); Mr.&nbsp;Lavigne (90,000&nbsp;shares); Mr.&nbsp;McGuire (20,000&nbsp;shares); Dr.&nbsp;Scheller (101,834&nbsp;shares); Mr.&nbsp;Wehner (90,000&nbsp;shares); and
Dr.&nbsp;Yaffe (40,000&nbsp;shares). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Gordon resigned from our board of directors in June 2019. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have retained Radford, a national compensation consultant, to provide our board of directors with an analysis of market data compiled from
certain comparable public companies and assistance in determining compensation of directors. Our board of directors has adopted our Outside Director Compensation Policy. Our Outside Director Compensation Policy provides that all <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors will be entitled to receive the following cash compensation for their services: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$35,000 retainer per year for each <FONT STYLE="white-space:nowrap">non-employee</FONT> director;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$20,000 retainer per year for service as <FONT STYLE="white-space:nowrap">non-executive</FONT> chairman of the
board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$20,000 retainer per year for service as lead <FONT STYLE="white-space:nowrap">non-employee</FONT> director;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$15,000 retainer per year for the chairman of the audit committee or $7,500 retainer per year for each other
member of the audit committee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$10,000 retainer per year for the chairman of the compensation committee or $5,000 retainer per year for each
other member of the compensation committee; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">$8,000 retainer per year for the chairman of the nominating and corporate governance committee or $4,000 retainer
per year for each other member of the nominating and corporate governance committee. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each <FONT
STYLE="white-space:nowrap">non-employee</FONT> director who serves as the chair of a committee will receive only the additional annual fee as the chair of the committee and will not receive the additional annual fee as a member of the committee. All
cash payments to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors are paid quarterly in arrears on a prorated basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition to the cash compensation structure described above, our Outside Director Compensation Policy provides the following equity incentive compensation program for <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. Each <FONT
STYLE="white-space:nowrap">non-employee</FONT> director who first joins us (other than&nbsp;a director who becomes a <FONT STYLE="white-space:nowrap">non-employee&nbsp;director</FONT> as a&nbsp;result of terminating employment with us)
automatically&nbsp;will be&nbsp;granted on the first trading date on or after&nbsp;his or her&nbsp;start date as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director a <FONT STYLE="white-space:nowrap">one-time,</FONT> initial option
covering 40,000 shares&nbsp;of our common stock. Further, on the date of each of our annual stockholder meetings, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director who is continuing as a director following our annual stockholder
meeting automatically will be granted an annual option covering 20,000 shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each initial option&nbsp;will
vest&nbsp;as to 1/4th of the underlying shares on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the date the director&#146;s service as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director started and as to 1/48th of
the underlying shares each following month, subject to continued service through each relevant vesting date. Each annual option will vest as to 1/12th of the underlying shares each month after the award&#146;s grant date and will vest in full on the
earlier of the <FONT STYLE="white-space:nowrap">12-month</FONT> anniversary of the date of grant or on the date of our annual stockholder meetings following the date the annual option is granted, subject to continued service through each relevant
vesting date. In the event of&nbsp;a change in control of our company, all equity awards granted to a <FONT STYLE="white-space:nowrap">non-employee</FONT> director (including those granted pursuant to our Outside Director Compensation Policy) will
fully vest&nbsp;and become immediately exercisable,&nbsp;subject to&nbsp;continued service&nbsp;through such date. Each initial option and annual option will have a term of 10 years and will have an exercise price per share equal to 100% of the fair
market value of a share of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In any fiscal year, a <FONT STYLE="white-space:nowrap">non-employee</FONT> director may be
paid, issued, or granted cash compensation and equity awards with a total value of no greater than $750,000 (increased to $1,000,000 in the fiscal year of his or her initial service as an outside director) with the value of an equity award based on
its grant date fair value for purposes of this limit (annual director limit). Equity awards or cash compensation granted to a <FONT STYLE="white-space:nowrap">non-employee</FONT> director for his or her service as an employee or consultant (other
than a <FONT STYLE="white-space:nowrap">non-employee</FONT> director) will not count toward the annual director limit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Outside
Director Compensation Policy also provides for the reimbursement of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for reasonable, customary and documented travel expenses to attend meetings of our board of directors and
committees of our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compensation for our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors is&nbsp;not
limited to&nbsp;the equity awards and payments set forth in our Outside Director Compensation Policy. Our <FONT STYLE="white-space:nowrap">non-employee&nbsp;directors</FONT> will&nbsp;remain&nbsp;eligible to receive equity awards&nbsp;and cash or
other compensation outside of the Outside Director Compensation Policy, as may be provided from time to time at the discretion of our board of directors. For further information regarding the equity compensation of our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors, see the section of this prospectus titled &#147;<I>Executive Compensation&#151;Employee Benefit and Stock Plans&#151;2019 Equity Incentive Plan</I>.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee Interlocks and Inside Participation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the members of our compensation committee is or has been an officer or employee of our company. None of our executive officers
currently serves, or in the past fiscal year has served, as a member of the board of directors, or compensation committee (or other board committee performing equivalent functions or, in the absence of any such committee, the entire board of
directors) of any entity that has one or more executive officers serving on our board of directors or compensation committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct
and Ethics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a written code of business conduct and ethics that applies to our directors, officers, and employees,
including our principal executive officer, principal financial officer, principal accounting officer or controller or, persons performing similar functions. The code of business conduct and ethics is available on our website at www.alector.com. We
intend to disclose future amendments to such code, or any waivers of its requirements, applicable to any principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions, or
our directors on our website identified above. Information contained on the website is not incorporated by reference into this prospectus and should not be considered to be part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_12"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers for the year ended December&nbsp;31, 2019, which consist of our principal executive officer and the next two most
highly compensated executive officers, are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Arnon Rosenthal, Ph.D., our <FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Chief Executive Officer;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Robert Paul, M.D., Ph.D., our Chief Medical Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Robert King, Ph.D., our Chief Development Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following
table sets forth information regarding the compensation of our named executive officers for the year ended December&nbsp;31, 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards ($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arnon Rosenthal, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">525,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">262,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,984,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,775,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">396,764</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">237,540</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">4,816,115</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">3,564</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">5,453,983</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert King, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">362,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">145,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,726,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,236,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Development Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">352,297</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">147,800</TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">1,570,355</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">2,323</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">2,072,775</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Paul, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">392,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">156,840</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,726,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,276,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">326,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">180,670</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,707,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,216,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts disclosed represent the aggregate grant date fair value of the award as calculated in accordance
with ASC 718. The assumptions used in calculating the grant date fair value of the award disclosed in this column are set forth in the notes to our audited financial statements included elsewhere in this prospectus. These amounts do not correspond
to the actual value that may be recognized by the named executive officers upon vesting of the applicable awards. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported include life insurance premiums paid by us on behalf of our named executive officers.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported represent the estimated amounts of a bonus based on the achievement of company objectives
for the fiscal year ended December 31, 2019. As of the date of this prospectus, we are unable to definitively calculate the amount of these payments, and we anticipate that the actual amounts of these payments will be determined in March 2020.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts reported represent a bonus based upon the achievement of company objectives for the year ended
December 31, 2018, which was paid in March 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amount included in the &#147;Bonus&#148; column includes a portion of a signing bonus earned and paid in
2018 to Dr. Paul in the aggregate amount of $43,750. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information concerning outstanding equity awards held by each of our named executive officers as of
December&nbsp;31, 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of Shares<BR>of Stock<BR>That<BR>Have Not<BR>Vested<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market<BR>Value of<BR>Shares of<BR>Stock That<BR>Have Not<BR>Vested<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arnon Rosenthal, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/9/2017</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122,441</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,109,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/9/2017</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,031</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,310,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/2/2018</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177,083</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322,917</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/2/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/6/2018</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,479</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,521</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/6/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/6/2019</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,833</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">509,167</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/6/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert King, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/26/2017</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,524</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,507,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/2/2018</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,125</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,875</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/2/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/6/2018</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,083</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,917</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/6/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/6/2019</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,125</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,875</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/6/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Paul, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/4/2016</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,602</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,026,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/9/2017</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,857</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">342,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/2/2018</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,958</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">226,042</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/2/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/6/2018</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,083</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,917</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/6/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/6/2019</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,125</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,875</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/6/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column represents the fair market value of a share of our common stock on the date of grant, as determined
by our board of directors or its authorized committee. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This column represents the fair market value of the shares of our common stock as of December&nbsp;31, 2019,
based on the closing price of our common stock, as reported on the NASDAQ Global Select Market, of $17.23 per share on December 31, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This restricted stock grant of our common stock was granted pursuant to our 2017 Plan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares subject to the restricted stock grant vested, and continue to vest, 1/48th per month beginning on
the one month anniversary of August 1, 2017, subject to Dr. Rosenthal&#146;s continued status as a service provider on each such vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This restricted stock grant of our common stock was granted outside of the 2017 Plan, but is subject to the
terms of the 2017 Plan as if the grant was made under the 2017 Plan (except with respect to the forfeiture of unvested shares). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares subject to the restricted stock grant vested, and continue to vest, 1/48th per month beginning on
the one month anniversary of August&nbsp;1, 2017, subject to Dr. Rosenthal&#146;s continued status as a service provider on each such vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This option to purchase shares of our common stock was granted pursuant to our 2017 Plan.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares subject to this option vested, and continue to vest, 1/48th per month beginning on the one month
anniversary of July 2, 2018, subject to the executive&#146;s continued status as a service provider on each such vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">One-fourth of the total number of shares subject to the option grant vest on the one year anniversary of
November 1, 2018, and an additional 1/48th of the total number of shares subject to the option grant continue to vest, on the same day of each month thereafter, subject to the executive&#146;s continued status as a service provider through each such
vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This option to purchase shares of our common stock was granted pursuant to our 2019 Plan.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares subject to this option vested, and continue to vest, 1/48th per month beginning on the one month
anniversary of November&nbsp;6, 2019, subject to the executive&#146;s continued status as a service provider on each such vesting date. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">One-fourth of the total number of shares subject to the restricted stock grant vested on January&nbsp;26, 2018,
and an additional 1/48th of the total number of shares subject to the restricted stock grant vested, and continued to vest, on the same day of each month thereafter, subject to Dr.&nbsp;King&#146;s continued status as a service provider through each
such vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">One-fourth of the total number of shares subject to the restricted stock grant vested on October&nbsp;3, 2017,
and an additional 1/48th of the total number of shares subject to the restricted stock grant vested, and continued to vest, on the same day of each month thereafter, subject to Dr.&nbsp;Paul&#146;s continued status as a service provider through each
such vesting date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The shares subject to the restricted stock grant vested, and continue to vest, 1/48th per month beginning on
the one month anniversary of August&nbsp;1, 2017, subject to Dr. Paul&#146;s continued status as a service provider through each such vesting date. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Arrangements with Our Named Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dr.&nbsp;Arnon Rosenthal </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
entered into a confirmatory employment letter with Arnon Rosenthal, our <FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Chief Executive Officer. The confirmatory employment letter has no specific term and provides that Dr.&nbsp;Rosenthal is
an <FONT STYLE="white-space:nowrap">at-will</FONT> employee. Dr.&nbsp;Rosenthal&#146;s current annual base salary is $525,000 and he is eligible for an annual target cash incentive payment equal to 50% of his annual base salary. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dr.&nbsp;Robert King </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered
into a confirmatory employment letter with Robert King, our Chief Development Officer. The confirmatory employment letter has no specific term and provides that Dr.&nbsp;King is an <FONT STYLE="white-space:nowrap">at-will</FONT> employee.
Dr.&nbsp;King&#146;s current annual base salary is $362,500 and he is eligible for an annual target cash incentive payment equal to 40% of his annual base salary. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dr.&nbsp;Robert Paul </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered
into a confirmatory employment letter with Robert Paul, our Chief Medical Officer. The confirmatory employment letter has specific term and provides that Dr.&nbsp;Paul is an <FONT STYLE="white-space:nowrap">at-will</FONT> employee.
Dr.&nbsp;Paul&#146;s current annual base salary is $392,100 and he is eligible for an annual target cash incentive payment equal to 40% of his annual base salary. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Change in Control and Severance Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a change in control and severance agreement for each of our named executive officers, which agreement would provide for certain
severance and change in control benefits as described below. Each change in control and severance agreement will supersede any prior agreement or arrangement the named executive officer may have had with us that provides for severance and/or change
in control payments or benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a named executive officer&#146;s employment is terminated outside the period beginning on the date of
a change in control and ending 12 months following that change in control (the Change in Control Period) either (1)&nbsp;by the Company or any of its subsidiaries (the Company Group) without &#147;cause&#148; (excluding by reason of death or
disability) or (2)&nbsp;by the named executive officer for &#147;good reason&#148; (as such terms are defined in the named executive officer&#146;s change in control and severance agreement), the named executive officer will receive the following
benefits if he or she timely signs and does not revoke a release of claims in our favor: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">lump-sum</FONT> payment equal to 9 months (or 12 months in the case of
Dr.&nbsp;Rosenthal) of the named executive officer&#146;s annual base salary as in effect immediately prior to such termination (or if such termination is due to a resignation for good reason based on a material reduction in base salary, then as in
effect immediately prior to the reduction); and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payment of premiums for coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended
(COBRA), for the named executive officer and the named executive officer&#146;s eligible dependents, if any, for up to 9 months (or 12 months in the case of Dr.&nbsp;Rosenthal), or taxable monthly payments for the equivalent period in the event
payment of the COBRA premiums would violate or be subject to an excise tax under applicable law. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, within the Change
in Control Period, the named executive officer&#146;s employment is terminated either (1)&nbsp;by the Company (or any of its subsidiaries) without cause (excluding by reason of death or disability) or (2)&nbsp;by the named executive officer for good
reason, the named executive officer will receive the following benefits if the named executive officer timely signs and does not revoke a release of claims in our favor: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">lump-sum</FONT> payment equal to 12 months (or 18 months in the case of
Dr.&nbsp;Rosenthal) of the named executive officer&#146;s annual base salary as in effect immediately prior to such termination (or if such termination is due to a resignation for good reason based on a material reduction in base salary, then as in
effect immediately prior to the reduction) or if greater, at the level in effect immediately prior to the change in control); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">lump-sum</FONT> payment equal to 100% (or 150% in the case of
Dr.&nbsp;Rosenthal) of the named executive officer&#146;s target annual bonus as in effect for the fiscal year in which such termination occurs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">payment of premiums for coverage under COBRA for the named executive officer and the named executive
officer&#146;s eligible dependents, if any, for up to 12 months (or 18 months in the case of Dr.&nbsp;Rosenthal), or taxable monthly payments for the equivalent period in the event payment of the COBRA premiums would violate or be subject to an
excise tax under applicable law; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">100% accelerated vesting and exercisability of all outstanding equity awards and, in the case of an equity award
with performance-based vesting, unless otherwise specified all performance goals and other vesting criteria generally will be deemed achieved at 100% of target levels. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of the amounts provided for under these change in control and severance agreements or otherwise payable to our named executive officers
would constitute &#147;parachute payments&#148; within the meaning of Section&nbsp;280G of the Internal Revenue Code and could be subject to the related excise tax, the named executive officer would be entitled to receive either full payment of
benefits under his or her change in control or severance agreement or such lesser amount which would result in no portion of the benefits being subject to the excise tax, whichever results in the greater amount of
<FONT STYLE="white-space:nowrap">after-tax</FONT> benefits to the named executive officer. The change in control and severance agreements do not require us to provide any tax <FONT STYLE="white-space:nowrap">gross-up</FONT> payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under each named executive officer&#146;s change in control and severance agreement, the following definitions are used: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Cause&#148; means: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the named executive officer&#146;s dishonest statements or acts with respect to any Company Group member, or any
current or prospective customers, suppliers vendors or other third parties with which such entity does business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the named executive officer&#146;s commission of (1)&nbsp;a felony or (2)&nbsp;any misdemeanor involving moral
turpitude, deceit, dishonesty or fraud; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the named executive officer&#146;s failure to perform his assigned duties and responsibilities to the reasonable
satisfaction of the applicable Company Group member, which failure continues, in the reasonable judgment of the Company Group member, after written notice given to him by the Company Group member; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the named executive officer&#146;s gross negligence, willful misconduct or insubordination with respect to any
Company Group member; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the named executive officer&#146;s material violation of any provision of any agreement(s) between him and any
Company Group member relating to <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and/or assignment of inventions (such as the <FONT
STYLE="white-space:nowrap">at-will</FONT> employment, confidential information, invention assignment, and arbitration agreement with the named executive officer or any written Company Group policy or procedure to which the named executive officer is
subject). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Good Reason&#148; means that the named executive officer resigns from a Company Group member if one of the
following events occurs without his consent: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a material reduction of his duties, authorities, or responsibilities relative to his duties, authorities, or
responsibilities in effect immediately prior to the reduction, provided that (1)&nbsp;any change that results in Dr.&nbsp;Rosenthal not serving as the chief executive officer of, or reporting directly to the board of directors of, the parent
corporation in a group of controlled corporations including the Company or its assets (Parent) following a change in control (other than as the result of his voluntary resignation not at the request of the successor or the Parent) will be deemed to
constitute a material reduction in his duties, authorities, and responsibilities constituting &#147;Good Reason&#148; and (2)&nbsp;that continued employment of a named executive officer (other than Dr.&nbsp;Rosenthal) following a change in control
with substantially the same duties, authorities, or responsibilities with respect to the Company Group&#146;s business and operations will not constitute &#147;Good Reason&#148;; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a material diminution in his base salary except for <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">across-the-board</FONT></FONT> salary reductions similarly affecting all or substantially all similarly situated employees of the applicable Company Group member, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a change of more than 50 miles in the geographic location at which he provides services to the applicable Company
Group member. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For &#147;Good Reason&#148; to be established, the named executive officer must provide written notice to
our Chief Executive Officer (or our board of directors in the case of Dr.&nbsp;Rosenthal) and the applicable Company Group member within 90 days immediately following such alleged events, the applicable Company Group member must fail to materially
remedy such event within 30 days after receipt of such notice, and the named executive officer&#146;s resignation must be effective not later than 90 days from the occurrence of the alleged triggering event, and must not be effective until after the
expiration of the notice and cure periods described above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Incentive Compensation Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has adopted our Executive Incentive Compensation Plan (the Incentive Compensation Plan). The Incentive Compensation Plan
will be administered by a committee appointed by our board of directors. Unless and until our board of directors determines otherwise, our compensation committee will be the administrator of the Incentive Compensation Plan. The Incentive
Compensation Plan allows our compensation committee to provide cash incentive awards to selected employees, including our named executive officers, determined by our compensation committee, based upon performance goals established by our
compensation committee. Our compensation committee, in its sole discretion, will establish a target award for each participant under the Incentive Compensation Plan, which may be expressed as a percentage of the participant&#146;s average annual
base salary for the applicable performance period, a fixed dollar amount, or such other amount or based on such other formula as our compensation committee determines to be appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Incentive Compensation Plan, our compensation committee will determine the performance goals applicable to awards, which goals may
include, without limitation: attainment of research and development milestones, bookings, business divestitures and acquisitions, cash flow, cash position, contract awards or backlog, customer renewals, customer retention rates from an acquired
company, subsidiary, business unit or division, earnings (which may include earnings before interest and taxes, earnings before taxes, and net taxes), earnings per share, expenses, gross margin, growth in stockholder value relative to the moving
average of the S&amp;P 500 Index or another index, internal rate of return, market share, net income, net profit, net sales, new </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product development, new product invention or innovation, number of customers, operating cash flow, operating expenses, operating income, operating margin, overhead or other expense reduction,
product defect measures, product release timelines, productivity, profit, retained earnings, return on assets, return on capital, return on equity, return on investment, return on sales, revenue, revenue growth, sales results, sales growth, stock
price, time to market, total stockholder return, working capital, and individual objectives such as peer reviews or other subjective or objective criteria. As determined by our compensation committee, the performance goals may be based on GAAP or <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> results and any actual results may be adjusted by our compensation committee for <FONT STYLE="white-space:nowrap">one-time</FONT> items or unbudgeted or unexpected items and/or payments of actual awards
under the Incentive Compensation Plan when determining whether the performance goals have been met. The goals may be on the basis of any factors our compensation committee determines relevant, and may be on an individual, divisional, business unit,
segment or company-wide basis. Any criteria used may be measured on such basis as our compensation committee determines. The performance goals may differ from participant to participant and from award to award. Our compensation committee also may
determine that a target award or a portion thereof will not have a performance goal associated with it but instead will be granted (if at all) in the compensation committee&#146;s sole discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our compensation committee may, in its sole discretion and at any time, increase, reduce or eliminate a participant&#146;s actual award,
and/or increase, reduce or eliminate the amount allocated to the bonus pool. The actual award may be below, at or above a participant&#146;s target award, in our compensation committee&#146;s discretion. Our compensation committee may determine the
amount of any increase, reduction or elimination on the basis of such factors as it deems relevant, and it will not be required to establish any allocation or weighting with respect to the factors it considers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Actual awards will generally be paid in cash (or its equivalent) in a single lump sum only after they are earned and approved by our
compensation committee. Our compensation committee has the right, in its sole discretion, to settle an actual award with a grant of an equity award under our then-current equity compensation plan, which equity award may have such terms and
conditions, including vesting, as our compensation committee determines in its sole discretion. Unless otherwise determined by our compensation committee, to earn an actual award, a participant must be employed by us (or an affiliate of us, as
applicable) through the date the actual award is paid. Payment of bonuses occurs as soon as administratively practicable after the end of the applicable performance period, but no later than the dates set forth in the Incentive Compensation Plan.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has the authority to amend or terminate the Incentive Compensation Plan provided such action does not alter or
impair the existing rights of any participant with respect to any earned actual award without the participant&#146;s consent. The Incentive Compensation Plan will remain in effect until terminated in accordance with the terms of the Incentive
Compensation Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employee Benefit and Stock Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2019 Equity Incentive Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
2019 Plan provides for the grant of incentive stock options, within the meaning of Section&nbsp;422 of the Code, to our employees and any of our parent and subsidiary corporations&#146; employees, and for the grant of nonstatutory stock options,
restricted stock, restricted stock units, stock appreciation rights, performance units, and performance shares to our employees, directors, and consultants and our subsidiary corporations&#146; employees and consultants. As of September&nbsp;30,
2019, options to purchase 1,095,600 shares of our common stock remained outstanding under our 2019 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares</I>. As of
the date of this prospectus, a total of 11,140,799 shares of our common stock are reserved for issuance pursuant to our 2019 Plan. In addition, the shares reserved for issuance under our 2019 Plan will also include (1)&nbsp;those shares reserved but
unissued under our 2017 Plan as of the date of stockholder approval of the 2019 Plan and (2)&nbsp;shares of our common stock subject to or issued pursuant to awards granted under our 2017 Plan that, after the date our stockholders approved the 2019
Plan, expire or otherwise terminate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
without having been exercised in full or are forfeited to or repurchased by us (provided that the maximum number of shares that may be added to the 2019 Plan pursuant to (1)&nbsp;and (2) is
5,184,750 shares). The number of shares available for issuance under our 2019 Plan will also include an annual increase on the first day of each fiscal year beginning with our 2020 fiscal year, equal to the least of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">7,096,760 shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">5% of the outstanding shares of our common stock as of the last day of the immediately preceding fiscal year; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such other amount as our board of directors may determine. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an award expires or becomes unexercisable without having been exercised in full, is surrendered pursuant to an exchange program, or, with
respect to restricted stock, restricted stock units, performance units or performance shares, is forfeited to or repurchased by us due to failure to vest, the unpurchased shares (or for awards other than stock options or stock appreciation rights,
the forfeited or repurchased shares) will become available for future grant or sale under the 2019 Plan (unless the 2019 Plan has terminated). With respect to stock appreciation rights, only the net shares actually issued will cease to be available
under the 2019 Plan and all remaining shares under stock appreciation rights will remain available for future grant or sale under the 2019 Plan (unless the 2019 Plan has terminated). Shares that have actually been issued under the 2019 Plan will not
be returned to the 2019 Plan except if shares issued pursuant to awards of restricted stock, restricted stock units, performance shares, or performance units are repurchased by or forfeited to us, such shares will become available for future grant
under the 2019 Plan. Shares used to pay the exercise price of an award or satisfy the tax withholding obligations related to an award will become available for future grant or sale under the 2019 Plan. To the extent an award is paid out in cash
rather than shares, such cash payment will not result in a reduction in the number of shares available for issuance under the 2019 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Administration</I>. Our board of directors or one or more committees appointed by our board of directors will administer our 2019
Plan. The compensation committee of our board of directors will administer our 2019 Plan. In addition, if we determine it is desirable to qualify transactions under our 2019 Plan as exempt under
<FONT STYLE="white-space:nowrap">Rule&nbsp;16b-3</FONT> of the Exchange Act, such transactions will be structured to satisfy the requirements for exemption under <FONT STYLE="white-space:nowrap">Rule&nbsp;16b-3.</FONT> Subject to the provisions of
our 2019 Plan, the administrator has the power to administer our 2019 Plan and make all determinations deemed necessary or advisable for administering the 2019 Plan, including but not limited to, the power to determine the fair market value of our
common stock, select the service providers to whom awards may be granted, determine the number of shares covered by each award, approve forms of award agreements for use under the 2019 Plan, determine the terms and conditions of awards (including,
but not limited to, the exercise price, the time or times at which awards may be exercised, any vesting acceleration or waiver or forfeiture restrictions and any restriction or limitation regarding any award or the shares relating thereto), construe
and interpret the terms of our 2019 Plan and awards granted under it, prescribe, amend and rescind rules relating to our 2019 Plan, including creating <FONT STYLE="white-space:nowrap">sub-plans,</FONT> modify, or amend each award, including but not
limited to the discretionary authority to extend the post-termination exercisability period of awards (except no option or stock appreciation right will be extended past its original maximum term), and allow a participant to defer the receipt of
payment of cash or the delivery of shares that would otherwise be due to such participant under an award. The administrator also has the authority to allow participants the opportunity to transfer outstanding awards to a financial institution or
other person or entity selected by the administrator and to institute an exchange program by which outstanding awards may be surrendered or cancelled in exchange for awards of the same type, which may have a higher or lower exercise price and/or
different terms, awards of a different type, and/or cash or by which the exercise price of an outstanding award is increased or reduced. The administrator&#146;s decisions, interpretations, and other actions are final and binding on all
participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Options</I>. Stock options may be granted under our 2019 Plan. The exercise price of options granted under our
2019 Plan must at least be equal to the fair market value of our common stock on the date of grant. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
term of an option may not exceed ten years. With respect to any participant who owns more than 10% of the voting power of all classes of our (or any parent or subsidiary of ours) outstanding
stock, the term of an incentive stock option granted to such participant must not exceed five years and the exercise price must equal at least 110% of the fair market value on the grant date. The administrator will determine the methods of payment
of the exercise price of an option, which may include cash, shares or other property acceptable to the administrator, as well as other types of consideration permitted by applicable law. After the termination of service of an employee, director, or
consultant, he or she may exercise his or her option for the period of time stated in his or her option agreement. In the absence of a specified time in an award agreement, if termination is due to death or disability, the option will remain
exercisable for 12 months following the termination of service. In all other cases, in the absence of a specified time in an award agreement, the option will remain exercisable for three months following the termination of service. An option,
however, may not be exercised later than the expiration of its term. Subject to the provisions of our 2019 Plan, the administrator determines the other terms of options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Appreciation Rights</I>. Stock appreciation rights may be granted under our 2019 Plan. Stock appreciation rights allow the recipient
to receive the appreciation in the fair market value of our common stock between the exercise date and the date of grant. Stock appreciation rights may not have a term exceeding ten years. After the termination of service of an employee, director,
or consultant, he or she may exercise his or her stock appreciation right for the period of time stated in his or her stock appreciation rights agreement. In the absence of a specified time in an award agreement, if termination is due to death or
disability, the stock appreciation rights will remain exercisable for 12 months following the termination of service. In all other cases, in the absence of a specified time in an award agreement, the stock appreciation rights will remain exercisable
for three months following the termination of service. However, in no event may a stock appreciation right be exercised later than the expiration of its term. Subject to the provisions of our 2019 Plan, the administrator determines the other terms
of stock appreciation rights, including when such rights become exercisable and whether to pay any increased appreciation in cash or with shares of our common stock, or a combination thereof, except that the per share exercise price for the shares
to be issued pursuant to the exercise of a stock appreciation right will be no less than 100% of the fair market value per share on the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock</I>. Restricted stock may be granted under our 2019 Plan. Restricted stock awards are grants of shares of our common stock
that vest in accordance with terms and conditions established by the administrator. The administrator will determine the number of shares of restricted stock granted to any employee, director, or consultant and, subject to the provisions of our 2019
Plan, will determine the terms and conditions of such awards. The administrator may impose whatever vesting conditions it determines to be appropriate (for example, the administrator may set restrictions based on the achievement of specific
performance goals or continued service to us), except the administrator, in its sole discretion, may accelerate the time at which any restrictions will lapse or be removed. Recipients of restricted stock awards generally will have voting and
dividend rights with respect to such shares upon grant without regard to vesting, unless the administrator provides otherwise. Shares of restricted stock that do not vest are subject to our right of repurchase or forfeiture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Units. </I>Restricted stock units may be granted under our 2019 Plan. Restricted stock units are bookkeeping entries
representing an amount equal to the fair market value of one share of our common stock. Subject to the provisions of our 2019 Plan, the administrator determines the terms and conditions of RSUs, including the vesting criteria and the form and timing
of payment. The administrator may set vesting criteria based upon the achievement of company-wide, divisional, business unit or individual goals (including, but not limited to, continued employment or service), applicable federal or state securities
laws or any other basis determined by the administrator in its discretion. The administrator, in its sole discretion, may pay earned restricted stock units in the form of cash, in shares or in some combination thereof. In addition, the
administrator, in its sole discretion, may accelerate the time at which any restrictions will lapse or be removed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Performance Units
and Performance Shares</I>. Performance units and performance shares may be granted under our 2019 Plan. Performance units and performance shares are awards that will result in a payment to a participant only if performance objectives established by
the administrator are achieved or the awards otherwise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
vest. The administrator will establish performance objectives or other vesting criteria in its discretion, which, depending on the extent to which they are met, will determine the number or the
value of performance units and performance shares to be paid out to participants. The administrator may set performance objectives based on the achievement of company-wide, divisional, business unit, or individual goals (including, but not limited
to, continued employment or service), applicable federal or state securities laws or any other basis determined by the administrator in its discretion. After the grant of a performance unit or performance share, the administrator, in its sole
discretion, may reduce or waive any performance objectives or other vesting provisions for such performance units or performance shares. Performance units will have an initial value established by the administrator on or prior to the grant date.
Performance shares will have an initial value equal to the fair market value of our common stock on the grant date. The administrator, in its sole discretion, may pay out earned performance units or performance shares in cash, shares, or in some
combination thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Outside Directors</I>. All outside <FONT STYLE="white-space:nowrap">(non-employee)</FONT> directors will be
eligible to receive all types of awards (except for incentive stock options) under our 2019 Plan.&nbsp;To provide a maximum limit on the&nbsp;cash compensation and equity awards that can be made to our outside directors, our 2019 Plan provides that
in any given fiscal year, an outside director will not be granted&nbsp;cash compensation and equity awards with an aggregate value greater than $750,000 (increased to $1,000,000 in the fiscal year of his or her initial service as an outside
director), with the value of each equity award based on its grant date fair value as determined according to GAAP for purposes of this limit. Any cash compensation paid or awards granted to an individual&nbsp;for his or her&nbsp;services as&nbsp;an
employee&nbsp;or consultant&nbsp;(other than as an outside director) will not count toward this limit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Transferability</FONT> of Awards</I>. Unless the administrator provides otherwise, our 2019 Plan
generally does not allow for the transfer of awards and only the recipient of an award may exercise an award during his or her lifetime. If the administrator makes an award transferrable, such award will contain such additional terms and conditions
as the administrator deems appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Certain Adjustments</I>. In the event of certain changes in our capitalization, to prevent
diminution or enlargement of the benefits or potential benefits available under our 2019 Plan, the administrator will adjust the number and class of shares that may be delivered under our 2019 Plan and/or the number, class, and price of shares
covered by each outstanding award and the numerical share limits set forth in our 2019 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Dissolution or Liquidation</I>. In the
event of our proposed liquidation or dissolution, the administrator will notify participants as soon as practicable and, to the extent not exercised, all awards will terminate immediately prior to the consummation of such proposed transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Merger or Change in Control</I>. Our 2019 Plan provides that in the event of a merger or change in control, as defined under our 2019 Plan,
each outstanding award will be treated as the administrator determines, without a participant&#146;s consent. The administrator is not required to treat all awards, all awards held by a participant or all awards of the same type similarly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a successor corporation does not assume or substitute for any outstanding award, then&nbsp;the participant will fully vest&nbsp;in and have
the right to exercise all of his or her outstanding options and stock appreciation rights, all restrictions on&nbsp;restricted stock&nbsp;and&nbsp;restricted stock&nbsp;units will lapse, and for awards with performance-based vesting, unless
specifically provided for otherwise under the applicable award agreement or other agreement&nbsp;or policy applicable to the participant, all performance goals or other vesting criteria&nbsp;will be deemed achieved at 100% of target levels
and&nbsp;all other terms and conditions met. If an option or stock appreciation right is not assumed or substituted&nbsp;in the event of a change in control, the administrator will notify the participant in writing or electronically that such option
or stock appreciation right will be exercisable for a period of time determined by the administrator in its sole discretion and the option or stock appreciation right will terminate upon the expiration of such period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For awards granted to an outside director, in the event of a change in control,&nbsp;the outside director will fully vest in and have the
right to exercise all of&nbsp;his or her&nbsp;outstanding options and stock appreciation rights, all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
restrictions on restricted stock and restricted stock units will lapse and, for awards with performance-based vesting, unless specifically provided for otherwise under the applicable award
agreement or other agreement or policy&nbsp;applicable to&nbsp;the participant, all performance goals or other vesting&nbsp;criteria will be deemed achieved at 100% of target levels and all other terms and conditions met. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Clawback</I>. Awards will be subject to any clawback policy of ours, and the administrator also may specify in an award agreement that the
participant&#146;s rights, payments, and/or benefits with respect to an&nbsp;award will&nbsp;be subject to reduction, cancellation, forfeiture, and/or recoupment upon the occurrence of certain specified events. Our board of directors may require a
participant to forfeit, return, or reimburse us all or a portion of the award and/or shares issued under the award, any amounts paid under the award, and any payments or proceeds paid or provided upon disposition of the shares issued under the award
in order to comply with such clawback policy or applicable laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment; Termination</I>. The administrator has the authority to
amend, alter, suspend, or terminate our 2019 Plan, provided such action does not materially impair the rights of any participant. Our 2019 Plan automatically will terminate in 2029, unless we terminate it sooner. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2017 Stock Option and Grant Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our 2017 Plan was adopted by our board of directors and approved by our stockholders approved in 2017 and was most recently amended in November
2018. Our 2017 Plan permitted the grant of incentive stock options, within the meaning of Section&nbsp;422 of the Code, to our employees and our subsidiary corporations&#146; employees, and the grant of nonstatutory stock options, restricted stock
awards, unrestricted stock awards, and restricted stock units to officers, employees, directors, consultants, and key employees of ours and any of our subsidiary corporations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares</I>. Our 2017 Plan was terminated in connection with our initial public offering, and accordingly, no new awards will be
granted under the 2017 Plan. Our 2017 Plan continues to govern outstanding awards granted thereunder. As of September&nbsp;30, 2019, options to purchase 4,822,524 shares of our common stock and 1,191,750 shares of unvested restricted stock remained
outstanding under our 2017 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Administration</I>. Our board of directors or a committee appointed by our board of directors
administers our 2017 Plan. Subject to the provisions of our 2017 Plan, the administrator has the powers and discretion necessary or appropriate to administer the 2017 Plan and to control its operation. The administrator&#146;s powers include the
power to modify the terms and conditions of any award, not inconsistent with the terms of the 2017 Plan including the number of shares to be covered, price, exercise price, conversion ratio or other price relating thereto, any vesting acceleration
or waiver of forfeiture restrictions, and any restriction or limitation regarding any award. The administrator may at any time adopt, alter and repeal such rules, guidelines and practices for administration of the 2017 Plan and for its own acts and
proceedings as it deems advisable; interpret the terms and provisions of the 2017 Plan and any award (including award agreements); make all determinations it deems advisable for the administration of the 2017 Plan; and decide all disputes arising in
connection with the 2017 Plan. In addition, the administrator may modify the terms and procedures relating to the 2017 Plan and establish <FONT STYLE="white-space:nowrap">sub-plans</FONT> for the purpose of satisfying applicable foreign laws. The
administrator also has the authority to allow participants the opportunity to transfer outstanding awards to a financial institution or other person or entity selected by the administrator and to institute an exchange program by which outstanding
awards may be surrendered or cancelled in exchange for awards of the same type, which may have a higher or lower exercise price and/or different terms, awards of a different type and/or cash, or by which the exercise price of an outstanding award is
increased or reduced. The administrator&#146;s decisions and interpretations are final and binding on all persons, including us, all participants, and any other persons holding awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Options</I>. Stock options were granted under our 2017 Plan. The exercise price of options granted under our 2017 Plan must have been at
least equal to the fair market value of our common stock on the date of grant. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
term of an incentive stock option could not exceed 10 years, except that with respect to any employee who owned more than 10% of the voting power of all classes of our (or any subsidiary of ours)
outstanding stock, the term could not exceed five years, and the exercise price must have been equal to at least 110% of the fair market value on the grant date. Subject to the provisions of our 2017 Plan, the administrator will determine the
methods of payment of the exercise price of an option. After termination of the participant&#146;s service, a participant may exercise any portion of his or her vested or exercisable option for the period of time as determined by the administrator
and specified in the applicable option agreement. If termination is due to death or disability, the option generally will remain exercisable for at least twelve months. In all other cases, the option will generally remain exercisable for at least
three months. However, an option agreement may provide that the option will terminate immediately upon the termination of the participant&#146;s service for cause (as defined in the 2017 Plan), and in no event may an option be exercised later than
the expiration of its term. Subject to the provisions of our 2017 Plan, the administrator determines the other terms of options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Awards</I>. Restricted stock awards were granted under our 2017 Plan. Restricted stock awards are grants of shares of our
common stock that vest in accordance with terms and conditions established by the administrator. The administrator determined the number of shares of restricted stock granted to any employee, director, or consultant and, subject to the provisions of
our 2017 Plan, determined the terms and conditions of such awards. The administrator could impose whatever conditions for lapse of the restriction on the shares it determined to be appropriate (for example, the administrator could set restrictions
based on the achievement of <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals or continued service to us), except the administrator, in its sole discretion, may accelerate the time at which any restrictions will lapse or be
removed. Recipients of restricted stock awards generally have voting and dividend rights with respect to such shares upon grant without regard to the restriction, unless the administrator provided otherwise. Shares of restricted stock as to which
the restrictions have not lapsed are subject to our right of repurchase or forfeiture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Transferability</FONT> of Awards</I>. Unless the administrator provides otherwise, our 2017 Plan
generally does not allow for the transfer of awards other than by will or the laws of descent and distribution, and only the recipient of an award may exercise an award during his or her lifetime. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Certain Adjustments</I>. In the event of certain changes in our capitalization, the administrator will make an appropriate and proportional
adjustment to the number of shares that may be delivered under our 2017 Plan and the number, kind, and price of shares covered by each outstanding award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Sale Events</I>. Our 2017 Plan provides that in the event of a sale event, as defined under the 2017 Plan, (1)&nbsp;the 2017 Plan and all
outstanding options will terminate upon the effective time of the sale event, and (2)&nbsp;all unvested restricted stock and restricted stock unit awards will be forfeited prior to the effective time of the sale event, in each case unless such
awards are assumed or continued by the successor entity, or new stock awards of the successor entity or parent thereof are substituted therefore. In the event of termination of the 2017 Plan and all outstanding options pursuant to a sale event, each
optionholder will be permitted, within a period of time prior to the sale event as specified by the administrator, to exercise all such options which are then exercisable or will become exercisable as of the effective time provided that the exercise
of options not exercisable prior to the sale event shall be subject to the consummation of the sale event. In the event of forfeiture of restricted stock pursuant to a sale event, such restricted stock will be purchased from the holder at a price
per share equal to the original per share purchase price paid by the holder. In the event of a sale event, the company will have the right, but not the obligation, to make a cash payment to a holder of an award, without the consent of the holder, in
exchange for the cancellation of such award, in an amount equal to (1)&nbsp;the number of shares subject to the award multiplied by the value as determined by the administrator of the consideration payable per share of our common stock under the
sale event, minus (2)&nbsp;the aggregate exercise price for such shares (if any). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment; Termination</I>. Our board of directors
has the authority to amend or alter the 2017 Plan, provided such action will not impair the existing rights of any participant without the consent of the participant. As noted above, our 2017 Plan has been terminated and no further awards will be
granted thereunder. All outstanding awards will continue to be governed by their existing terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2019 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors has adopted, and our stockholders have approved, our 2019 ESPP. We believe that allowing our employees to participate in
our 2019 ESPP provides them with a further incentive towards promoting our success and accomplishing our corporate goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized
Shares</I>. As of the date of this prospectus, a total of 2,069,889 shares of our common stock are available for sale under our 2019 ESPP. The number of shares of our common stock that will be available for sale under our 2019 ESPP also includes an
annual increase on the first day of each fiscal year beginning with our 2020 fiscal year, equal to the least of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">591,397 shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the outstanding shares of our common stock as of the last day of the immediately preceding fiscal year; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such other amount as the administrator may determine. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>2019 ESPP Administration</I>. The compensation committee of our board of directors administers our 2019 ESPP and has exclusive
discretionary authority to construe, interpret, and apply the terms of the 2019 ESPP, delegate ministerial duties to any of our employees, designate separate offerings under the 2019 ESPP, designate our subsidiaries and affiliates as participating
in the 2019 ESPP, determine eligibility, adjudicate all disputed claims filed under the 2019 ESPP, and establish procedures that it deems necessary for the administration of the 2019 ESPP, including, but not limited to, adopting such procedures <FONT
STYLE="white-space:nowrap">and&nbsp;sub-plans&nbsp;as</FONT> are necessary or appropriate to permit participation in the 2019 ESPP by employees who are foreign nationals or employed outside the United States. The administrator&#146;s findings,
decisions and determinations are final and binding on all participants to the full extent permitted by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eligibility</I>.
Generally, all of our employees will be eligible to participate if they are customarily employed by us, or any participating subsidiary or affiliate, for at least 20 hours per week and more than five months in any calendar year. The administrator,
in its discretion, may, prior to an enrollment date, for all options to be granted on such enrollment date in an offering, determine that an employee who (i)&nbsp;has not completed at least two years of service (or a lesser period of time determined
by the administrator) since his or her last hire date, (ii) customarily works not more than 20 hours per week (or a lesser period of time determined by the administrator), (iii) customarily works not more than five months per calendar year (or a
lesser period of time determined by the administrator), (iv) is a highly compensated employee within the meaning of Section&nbsp;414(q) of the Code, or (v)&nbsp;is a highly compensated employee within the meaning of Section&nbsp;414(q) of the Code
with compensation above a certain level or is an officer or subject to disclosure requirements under Section&nbsp;16(a) of the Exchange Act, is or is not eligible to participate in such offering period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, an employee may not be granted rights to purchase shares of our common stock under our 2019 ESPP if such employee: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">immediately after the grant would own capital stock and/or hold outstanding options to purchase such stock
possessing 5% or more of the total combined voting power or value of all classes of capital stock of ours or of any parent or subsidiary of ours; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">holds rights to purchase shares of our common stock under all employee stock purchase plans of ours or any parent
or subsidiary of ours that accrue at a rate that exceeds $25,000 worth of shares of our common stock for each calendar year in which such rights are outstanding at any time. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Offering Periods</I>. Our 2019 ESPP includes a component that allows us to make offerings intended to qualify under Section&nbsp;423 of the
Code and a component that allows us to make offerings not intended to qualify under Section&nbsp;423 of the Code to designated companies, as described in our 2019 ESPP. Our 2019 ESPP provides for consecutive,
<FONT STYLE="white-space:nowrap">overlapping&nbsp;6-month&nbsp;offering</FONT> periods. The offering periods will be scheduled to start on the first </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
trading day on or after June&nbsp;1 and December&nbsp;1 of each year, except the first offering period commenced on February&nbsp;7, 2019 and will end on the first trading day on or before
December&nbsp;1, 2019, and the second offering period will commence on the last trading day on or after December&nbsp;1, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Contributions</I>. Our 2019 ESPP permits participants to purchase shares of our common stock through contributions (in the form of payroll
deductions or otherwise to the extent permitted by the administrator) of up to 15% of their eligible compensation, which includes a participant&#146;s base straight time gross earnings but excludes payments for incentive compensation, bonuses,
payments for overtime and shift premium, equity compensation income and other similar compensation. Unless otherwise determined by the administrator, a participant may make a <FONT STYLE="white-space:nowrap">one-time</FONT> decrease (but not
increase) to the rate of his or her contributions to 0% during an offering period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Exercise of Purchase Right</I>. Amounts contributed
and accumulated by the participant will be used to purchase shares of our common stock at the end of each offering. A participant may purchase a maximum of 2,000 shares of our common stock during an offering period. The purchase price of the shares
will be 85% of the lower of the fair market value of our common stock on the first trading day of the offering period or on the exercise date. Participants may end their participation at any time during an offering period and will be paid their
accrued contributions that have not yet been used to purchase shares of our common stock. Participation ends automatically upon termination of employment with us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Transferability</FONT></I>. A participant may not transfer contributions credited to his or her
account nor any rights granted under our 2019 ESPP other than by will, the laws of descent and distribution or as otherwise provided under our 2019 ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Merger or Change in Control</I>. Our 2019 ESPP provides that in the event of a merger or change in control, as defined under our 2019 ESPP,
a successor corporation (or a parent or subsidiary of the successor corporation) will assume or substitute each outstanding purchase right. If the successor corporation refuses to assume or substitute for the outstanding purchase right, the offering
period with respect to which the purchase right relates will be shortened, and a new exercise date will be set that will be before the date of the proposed merger or change in control. The administrator will notify each participant that the exercise
date has been changed and that the participant&#146;s option will be exercised automatically on the new exercise date unless prior to such date the participant has withdrawn from the offering period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment; Termination</I>. The administrator has the authority to amend, suspend or terminate our 2019 ESPP. Our 2019 ESPP automatically
will terminate in 2039, unless we terminate it sooner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>401(k) Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain a 401(k) retirement savings plan for the benefit of our employees, including our named executive officers, who satisfy certain
eligibility requirements. Under the 401(k) plan, eligible employees may elect to defer a portion of their compensation, within the limits prescribed by the Code, on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> or
<FONT STYLE="white-space:nowrap">after-tax</FONT> (Roth) basis, through contributions to the 401(k) plan. The 401(k) plan authorizes employer safe harbor contributions. The 401(k) plan is intended to qualify under Sections&nbsp;401(a) and 501(a) of
the Code. As a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plan, <FONT STYLE="white-space:nowrap">pre-tax</FONT> contributions to the 401(k) plan and earnings on those <FONT STYLE="white-space:nowrap">pre-tax</FONT>
contributions are not taxable to the employees until distributed from the 401(k) plan, and earnings on Roth contributions are not taxable when distributed from the 401(k) plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> Sales Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our directors and executive officers have adopted, and may adopt, written plans, known as Rule
<FONT STYLE="white-space:nowrap">10b5-1</FONT> plans, in which they have contracted or will contract with a broker to buy or sell shares of our common stock on a periodic basis. Under a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan, a
broker executes trades pursuant to parameters established by the director or executive officer when entering into the plan, without further direction from them. The director or executive officer may amend a Rule
<FONT STYLE="white-space:nowrap">10b5-1</FONT> plan in some circumstances and may terminate a plan at any time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Our directors and executive officers also may buy or sell additional shares outside of a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan when they are not in possession of material
nonpublic information subject to compliance with the terms of our insider trading policy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitation of Liability and Indemnification </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and
officers, and may indemnify our employees and other agents, to the fullest extent permitted by Delaware law. Delaware law prohibits our amended and restated certificate of incorporation from limiting the liability of our directors for the following:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any breach of the director&#146;s duty of loyalty to us or to our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payment of dividends or unlawful stock repurchases or redemptions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a director, then the
liability of our directors will be eliminated or limited to the fullest extent permitted by Delaware law, as so amended. Our amended and restated certificate of incorporation does not eliminate a director&#146;s duty of care and, in appropriate
circumstances, equitable remedies, such as injunctive or other forms of <FONT STYLE="white-space:nowrap">non-monetary</FONT> relief, remain available under Delaware law. This provision also does not affect a director&#146;s responsibilities under
any other laws, such as the federal securities laws or other state or federal laws. Under our amended and restated bylaws, we will also be empowered to purchase insurance on behalf of any person whom we are required or permitted to indemnify. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the indemnification required in our amended and restated certificate of incorporation and amended and restated bylaws, we
intend to enter into an indemnification agreement with each member of our board of directors and each of our officers prior to the completion of the offering. These agreements provide for the indemnification of our directors and officers for certain
expenses and liabilities incurred in connection with any action, suit, proceeding, or alternative dispute resolution mechanism or hearing, inquiry, or investigation that may lead to the foregoing, to which they are a party, or are threatened to be
made a party, by reason of the fact that they are or were a director, officer, employee, agent or fiduciary of our company, or any of our subsidiaries, by reason of any action or inaction by them while serving as an officer, director, agent or
fiduciary, or by reason of the fact that they were serving at our request as a director, officer, employee, agent, or fiduciary of another entity. In the case of an action or proceeding by or in the right of our company or any of our subsidiaries,
no indemnification will be provided for any claim where a court determines that the indemnified party is prohibited from receiving indemnification. We believe that these charter and bylaw provisions and indemnification agreements are necessary to
attract and retain qualified persons as directors and officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability and indemnification provisions in our amended
and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation
against directors and officers, even though an action, if successful, might benefit us and our stockholders. Moreover, a stockholder&#146;s investment may be harmed to the extent we pay the costs of settlement and damage awards against directors and
officers pursuant to these indemnification provisions. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons pursuant to the foregoing provisions, or
otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. There is no pending litigation or proceeding naming any of our
directors or officers as to which indemnification is being sought, nor are we aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc838337_12a"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a description of certain relationships and transactions since January 1, 2017 involving our directors, executive officers, or
beneficial holders of more than 5% of our capital stock. Compensation arrangements and indemnification arrangements with our directors and officers are described in &#147;Management&#151; Director Compensation,&#148; &#147;Executive
Compensation,&#148; and &#147;Management.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Private Placements</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Series E Preferred Stock Transaction </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2018, July 2018, and October 2018 we issued and sold an aggregate of 9,373,633 shares of our Series E preferred stock at a purchase
price of $14.2154 per share for an aggregate purchase price of approximately $133.2&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Purchasers of our Series E preferred
stock include one of our directors and venture capital funds that beneficially own more than 5% of our outstanding capital stock and/or are represented on our board of directors. The following table presents the number of shares and the total
purchase price paid by these entities and individual. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Investor</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Series&nbsp;E</B><br><B>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Purchase<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Polaris Venture
Partners<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">527,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,500,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with OrbiMed Private
Investments<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">351,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tillman Gerngross, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">750,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lavrite, LLC<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">150,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MRL Ventures Fund, LLC<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,500,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Wehner<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">349,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Entities affiliated with Polaris Venture Partners holding our securities whose shares are aggregated for
purposes of reporting share ownership information include Polaris Venture Partners Founders&#146; Fund VI, L.P. and Polaris Venture Partners VI, L.P. Terry McGuire, a member of our board of directors, is a partner at Polaris Venture Funds.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Entities affiliated with OrbiMed Private Investments holding our securities whose shares are aggregated for
purposes of reporting share ownership information include OrbiMed Private Investments IV AL, LP and OrbiMed Private Investments IV-AL (Feeder), LP. Carl Gordon, a member of our board of directors, is a partner at OrbiMed Private Investments.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr. Tillman Gerngross is one of our Founders and the chairperson of our board of directors.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Louis J. Lavigne, Jr., a member of our board of directors, is a managing director of Lavrite, LLC.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr. Christine Brennan, a former member of our board of directors, is a partner at MRL Ventures Fund, LLC.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">David Wehner is a member of our board of directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
party to a registration rights agreement, as amended, with certain holders of our capital stock, including Arnon Rosenthal, The Rosenthal Family Revocable Trust Dated November&nbsp;4, 1994, as restated on June&nbsp;9, 1999, Adi Rosenthal 2007 Trust
dated March&nbsp;27, 2007, Noam Rosenthal 2007 Trust dated March&nbsp;27, 2007, Shani Rosenthal 2007 Trust dated March&nbsp;27, 2007, Tillman Gerngross, Robert Paul, Robert King, Sabah&nbsp;Oney, Calvin Yu, MRL Ventures Fund LLC, Polaris Venture
Partners VI (AIV), L.P., Polaris Venture Partners VI, L.P., Polaris Venture Partners Founders&#146; Fund VI, L.P., PVP VI (AIV) Feeder Corp Holding Partnership, L.P., OrbiMed Private Investments IV&#151;AL, LP, OrbiMed Private Investments IV&#151;AL
(Feeder), LP., Lavrite, LLC, and David Wehner. Under our registration rights agreement, certain holders of our capital stock have the right to demand that we file a registration statement or request that their shares of our capital stock be covered
by a registration statement that we are otherwise filing. See the section titled &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information regarding these registration rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Relationship with Adimab, LLC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Tillman Gerngross, one of our Founders and the Chairperson of our board of directors since our founding in 2013, is the chief
executive officer of Adimab, a leader in yeast-based, fully human antibody discovery using its proprietary core technology platform. The Company has a collaboration agreement with Adimab, LLC (&#147;Adimab&#148;) under which the Company is
developing antibodies discovered by Adimab in its AL001 and AL101 product candidates, and the Company is developing antibodies optimized by Adimab in its AL002 and AL003 product candidates (&#147;2013 Adimab Agreement&#148;). In August 2019, the
Company signed a new collaboration agreement with Adimab for research and development of additional antibodies (&#147;2019 Adimab Agreement&#148;). For the years ended December&nbsp;31, 2018, 2017, and 2016, incurred expenses of $2.3&nbsp;million,
$0.4&nbsp;million, and $0.6 million, respectively, for services provided by Adimab under the 2013 Adimab Agreement. For the nine months ended September&nbsp;30, 2019, we incurred expenses of $2.8 million for milestones and services provided by
Adimab under the 2013 Adimab Agreement. Under the 2013 Adimab Agreement, the Company will owe up to $3.5&nbsp;million in milestone payments per program to Adimab for its product candidates. The Company will also owe low- to mid- single-digit royalty
payments for commercial sales of such product candidates. Under the 2019 Adimab Agreement, the Company will owe certain milestone payments per program for its product candidates and low single-digit royalty payments for commercial sales of such
product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Party Transaction Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our audit committee has the primary responsibility for reviewing and approving or disapproving &#147;related party transactions,&#148; which
are transactions between us and related persons in which the aggregate amount involved exceeds or may be expected to exceed $120,000 and in which a related person has or will have a direct or indirect material interest. The charter of our audit
committee provides that our audit committee shall review and approve in advance any related party transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a formal
written policy providing that we are not permitted to enter into any transaction that exceeds $120,000 and in which any related person has a direct or indirect material interest without the consent of our audit committee. In approving or rejecting
any such transaction, our audit committee is to consider the relevant facts and circumstances available and deemed relevant to our audit committee, including whether the transaction is on terms no less favorable than terms generally available to an
unaffiliated third party under the same or similar circumstances and the extent of the related person&#146;s interest in the transaction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consulting
Agreement with Dr. Richard Scheller </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2019, we entered into a consulting agreement with Dr. Richard Scheller, a member of
our board of directors and a member of our Scientific Advisory Board. Pursuant to this consulting agreement, Dr. Scheller will serve on SPARC and generally provide scientific advice regarding our products or services and research program. Pursuant
to this agreement, Dr.&nbsp;Scheller will receive an annualized payment of $200,000 and a stock option to purchase 100,000 shares of our common stock, vesting in equal monthly installments over a four year period for so long as Dr. Scheller serves
as a consultant under this agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participation in this Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">David Wehner, a member of our board of directors, has agreed to purchase 20,000 shares of our common stock in this offering at the public
offering price. The underwriters will receive the same underwriting discounts and commissions on the shares purchased by Mr. Wehner as they will on the other shares sold to the public in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_13"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the beneficial ownership of our common stock as of December 31, 2019 by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common
stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of the named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our current executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in accordance with the rules of the SEC, and thus it represents sole or shared voting or investment
power with respect to our securities. Unless otherwise indicated below, to our knowledge, the persons and entities named in the table have sole voting and sole investment power with respect to all shares that they beneficially owned, subject to
community property laws where applicable. The information does not necessarily indicate beneficial ownership for any other purpose, including for purposes of Sections&nbsp;13(d) and 13(g) of the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">David Wehner, a member of our board of directors, has agreed to purchase 20,000 shares of our common stock in this offering at the public
offering price. The underwriters will receive the same underwriting discounts and commissions on the shares purchased by Mr. Wehner as they will on the other shares sold to the public in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have based our calculation of the percentage of beneficial ownership prior to this offering on 69,052,873&nbsp;shares of our common stock
outstanding as of December 31, 2019. We have based our calculation of the percentage of beneficial ownership after this offering on 77,402,873 shares of our common stock outstanding immediately after the completion of this offering, assuming no
exercise by the underwriters of their option to purchase additional shares. We have deemed shares of our common stock subject to stock options that are currently exercisable or exercisable within 60&nbsp;days of December 31, 2019, to be outstanding
and to be beneficially owned by the person holding the stock option for the purpose of computing the percentage ownership of that person. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any
other person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, the address of each beneficial owner listed in the table below
is c/o Alector, Inc., 131&nbsp;Oyster Point Boulevard, Suite&nbsp;600, South San Francisco, California 94080. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Beneficially<BR>Owned&nbsp;Prior&nbsp;to&nbsp;this&nbsp;Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Beneficially<BR>Owned&nbsp;After&nbsp;this&nbsp;Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% Stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MRL Ventures Fund LLC<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,545,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,545,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with OrbiMed Private
Investments<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,532,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,532,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Polaris Venture
Partners<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,858,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,858,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Named Executive Officers and Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arnon Rosenthal, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,371,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,371,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert King, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">622,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">622,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Paul, M.D., Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">456,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">456,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tillman Gerngross, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,623,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,623,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Louis J. Lavigne, Jr.<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Terry McGuire<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Scheller, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Wehner<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kristine Yaffe<SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and directors as a group (11&nbsp;persons)<SUP
STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,150,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,150,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents beneficial ownership of less than one percent (1%) of the outstanding shares of our common stock.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information contained in a Schedule 13G filed on February&nbsp;14, 2019. Consists of 3,545,719 shares
held of record by MRL Ventures Fund LLC (MRL). All shares are held directly by MRL, which is a subsidiary of Merck Sharp&nbsp;&amp; Dohme Corp. The address for MRL is 320 Bent Street, Cambridge, Massachusetts 02141. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information contained in a Schedule 13D/A filed on December 19, 2019. Consists of (a)&nbsp;8,629,418
shares held of record by OrbiMed Private Investments <FONT STYLE="white-space:nowrap">IV-AL,</FONT> LP (OrbiMed <FONT STYLE="white-space:nowrap">IV-AL),</FONT> (b)&nbsp;2,762,811&nbsp;shares held of record by OrbiMed Private Investments <FONT
STYLE="white-space:nowrap">IV-AL</FONT> (Feeder), LP (OrbiMed <FONT STYLE="white-space:nowrap">IV-AL</FONT> (Feeder)), (c)&nbsp;97,700 shares held of record by OrbiMed Partners Master Fund Limited (OPM) and (d)&nbsp;42,400&nbsp;shares held of record
by The Biotech Growth Trust PLC (BIOG). OrbiMed Capital GP IV LLC (OrbiMed GP), is the general partner of OrbiMed <FONT STYLE="white-space:nowrap">IV-AL</FONT> and OrbiMed <FONT STYLE="white-space:nowrap">IV-AL</FONT> (Feeder). OrbiMed Advisors LLC,
or OrbiMed Advisors, is the managing member of OrbiMed GP. Dr.&nbsp;Carl Gordon is a managing partner at OrbiMed Advisors and is also a former member of our board of directors. OrbiMed Advisors exercises investment and voting power through a
management committee comprised of Dr.&nbsp;Gordon, Sven H. Borho, and Jonathan T. Silverstein. Each of OrbiMed GP, OrbiMed Advisors, Dr.&nbsp;Gordon, Sven H. Borho, and Jonathan T. Silverstein disclaims beneficial ownership of the shares held by
OrbiMed <FONT STYLE="white-space:nowrap">IV-AL</FONT> and OrbiMed <FONT STYLE="white-space:nowrap">IV-AL</FONT> (Feeder), except to the extent of its or his pecuniary interest therein, if any. OrbiMed Capital is the sole investment advisor of OPM
and BIOG. OrbiMed Capital exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. Each of Orbimed Capital, Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein
disclaims beneficial ownership of the shares held by OPM or BIOG, except to the extent of its or his pecuniary interest therein, if any. The address of the individuals and entities listed above is 601 Lexington Avenue, 54th Floor, New York NY 10022.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 9,350,877 shares held of record by Polaris Venture Partners VI (AIV), L.P. (PVP VI AIV), (b)
709,917 shares held of record by Polaris Venture Partners Founders&#146; Fund VI, L.P. (PVPFF VI), (c)&nbsp;498,468 shares held of record by Polaris Venture Partners VI, L.P. (PVP VI), and (d) 2,298,932 shares held of record by PVP VI (AIV) Feeder
Corp. Holding Partnership, L.P. (PVP VI Feeder, and together with </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
PVP VI AIV, PVPFF VI, and PVP VI, the Funds). Polaris Venture Management Co. VI, L.L.C. (PVM) is the general partner of the Funds and may be deemed to have sole power to vote and dispose of the
shares held by the Funds. Amir Nashat, Brian Chee, David Barrett, Bryce Youngren, Jon Flint, and Terry McGuire are the managing members of PVM who collectively make voting and investment decisions with respect to the shares held by the Funds. The
address of the individuals and entities listed above is One Marina Park Drive, 10th Floor, Boston, Massachusetts 02210. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 1,305,226 shares held of record by Dr.&nbsp;Rosenthal, of which 198,472&nbsp;shares are subject
to repurchase by us at the original purchase price as of December 31, 2019, (b)&nbsp;712,500 shares held of record by Adi Rosenthal 2007 Trust dated March&nbsp;27, 2007, for which Dr.&nbsp;Rosenthal serves as trustee, of which no shares are subject
to repurchase by us at the original purchase price as of December 31, 2019, (c)&nbsp;712,500&nbsp;shares held of record by Noam Rosenthal 2007 Trust dated March&nbsp;27,&nbsp;2007, for which Dr.&nbsp;Rosenthal serves as trustee, of which no shares
are subject to repurchase by us at the original purchase price as of December 31, 2019, (d)&nbsp;712,500 shares held of record by Shani Rosenthal 2007 Trust dated March&nbsp;27, 2007, for which Dr.&nbsp;Rosenthal serves as trustee, of which no
shares are subject to repurchase by us at the original purchase price as of December 31, 2019, (e)&nbsp;2,612,500 shares held of record by The Rosenthal Family Revocable Trust Dated November&nbsp;4, 1994, as restated on June&nbsp;9, 1999, for which
Dr.&nbsp;Rosenthal serves as trustee, of which no shares are subject to repurchase by us at the original purchase price as of December 31, 2019, and (f)&nbsp;1,295,000&nbsp;shares subject to options held by Dr.&nbsp;Rosenthal, of which
316,353&nbsp;shares are vested and exercisable within 60&nbsp;days of December 31, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 522,317&nbsp;shares held of record by Dr.&nbsp;King, of which 145,524&nbsp;shares are subject
to repurchase by us at the original purchase price as of December 31, 2019 and (b) 400,000&nbsp;shares subject to options held by Dr.&nbsp;King, of which 100,000&nbsp;shares are vested and exercisable within 60 days of December 31, 2019.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 283,719&nbsp;shares held of record by Dr.&nbsp;Paul, of which 79,459&nbsp;shares are subject to
repurchase by us at the original purchase price as of December 31, 2019 and (b) 594,000 shares subject to options held by Dr.&nbsp;Paul, of which 173,166&nbsp;shares are vested and exercisable within 60&nbsp;days of December 31, 2019.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 2,608,610 shares held of record by Dr.&nbsp;Gerngross, of which no shares are subject to repurchase
by us at the original purchase price as of December 31, 2019 and 20,000 shares subject to an option held by Dr.&nbsp;Gerngross, 15,000 of which shares are vested and exercisable within 60&nbsp;days of December 31, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 10,552 shares held of record by Lavrite, LLC, for which Mr.&nbsp;Lavigne serves as managing
director, and (b) 90,000 shares subject to options held by Mr.&nbsp;Lavigne, of which 38,333&nbsp;shares are vested and exercisable within 60 days of December 31, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 20,000 shares subject to an option held by Mr.&nbsp;McGuire, of which 15,000&nbsp;shares are vested
and exercisable within 60 days of December 31, 2019. Mr.&nbsp;McGuire, who is one of our directors, is a managing member of PVM. Mr.&nbsp;McGuire has no voting or investment power over the shares held by the Funds described in Footnote 3 above. The
address for Mr.&nbsp;McGuire is c/o PVM, One Marina Park Drive, 10th Floor, Boston, Massachusetts 02210. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 19,981 shares held of record by Dr.&nbsp;Scheller, of which no shares are subject to repurchase
by us at the original purchase price as of December&nbsp;31, 2018 and (b) 101,834 shares subject to options held by Dr.&nbsp;Scheller, of which 42,277 shares are vested and exercisable within 60&nbsp;days of December 31, 2019. </P></TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 24,621 shares held of record by Mr.&nbsp;Wehner and (b) 90,000 shares subject to options held
by Mr.&nbsp;Wehner, 38,333 of which shares are vested and exercisable within 60 days of December 31, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 40,000 shares subject to an option held by Dr.&nbsp;Yaffe, none of which shares are vested and
exercisable within 60 days of December 31, 2019. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (a) 11,150,200&nbsp;shares beneficially owned by our current executive officers and directors as of
December 31, 2019, of which 648,956&nbsp;shares may be repurchased by us at the original purchase price as of such date and (b) 855,962&nbsp;shares subject to options vested and exercisable within 60 days of December 31, 2019. </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_14"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following descriptions of our capital stock and certain provisions of our amended and restated certificate of incorporation and amended
and restated bylaws are summaries and are qualified by reference to the amended and restated certificate of incorporation and the amended and restated bylaws. Copies of these documents were filed with the SEC and referenced in the exhibits to our
registration statement, of which this prospectus forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 200,000,000 shares of common
stock, par value $0.0001 per share, and 20,000,000 shares of convertible preferred stock, par value $0.0001 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the
completion of this offering and the issuance of 8,350,000 shares of common stock in this offering, based on our shares outstanding as of September 30, 2019, there will be 77,272,249 shares of common stock outstanding. As of September&nbsp;30, 2019,
we had 50 stockholders of record. As of September&nbsp;30, 2019, there were 5,918,124 shares of common stock subject to outstanding options. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common
Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each
holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Our certificate of incorporation and bylaws do not provide for cumulative voting rights.
Because of this, the holders of a plurality of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose. With respect to matters other than the election
of directors, at any meeting of the stockholders at which a quorum is present or represented, the affirmative vote of a majority of the voting power of the shares present in person or represented by proxy at such meeting and entitled to vote on the
subject matter shall be the act of the stockholders, except as otherwise required by law. The holders of a majority of the stock issued and outstanding and entitled to vote, present in person or represented by proxy, shall constitute a quorum for
the transaction of business at all meetings of the stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to preferences that may be applicable to any then-outstanding convertible preferred stock, holders of our common stock are entitled to
receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of our liquidation, dissolution, or winding up, holders of our common stock will be entitled to share ratably in the net assets
legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of convertible preferred stock.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rights and Preferences </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our common stock have no preemptive, conversion, subscription, or other rights, and there are no redemption or sinking fund
provisions applicable to our common stock. The rights, preferences, and privileges of the holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our convertible preferred
stock that we may designate in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fully Paid and Nonassessable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our outstanding shares of common stock are, and the shares of common stock to be issued in this offering, upon payment and delivery in
accordance with the underwriting agreement, will be fully paid and nonassessable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors have the authority, without further action by the stockholders, to issue up to 20,000,000 shares of preferred stock in
one or more series and to fix the rights, preferences, privileges, and restrictions thereof. These rights, preferences, and privileges could include dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences,
sinking fund terms, and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock. The issuance of preferred stock could adversely affect the voting power of
holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing change in our control
or other corporate action. Upon closing of this offering, no shares of preferred stock will be outstanding, and we have no present plan to issue any shares of preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock Options </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
September&nbsp;30, 2019, we had outstanding options to purchase an aggregate of 5,918,124 shares of our common stock, with a weighted-average exercise price of $10.84 per share, under our 2017 Plan and 2019 Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the completion
of this offering, under our registration rights agreement, as amended, certain holders&nbsp;of&nbsp;shares of common stock or their transferees, have the right to require us to register the offer and sale of their shares, or to include their shares
in any registration statement we file, in each case as described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the completion of this offering, certain holders of shares of our common stock will be entitled to certain demand registration rights. At
any time beginning 180 days after the effective date of this offering, the holders of at least 25% of the shares (or a lesser percent for which the anticipated aggregate offering price would be at least $15 million) having registration rights then
outstanding can request that we file a registration statement to register the offer and sale of their shares. We are only obligated to effect up to two such registrations. Each such request for registration must cover securities the anticipated
aggregate public offering price of which, before deducting underwriting discounts and commissions, is at least $15&nbsp;million. These demand registration rights are subject to specified conditions and limitations, including the right of the
underwriters to limit the number of shares included in any such registration under certain circumstances. If we determine that it would be seriously detrimental to us and our stockholders to effect such a demand registration, we have the right to
defer such registration, not more than once in any twelve month period, for a period of up to 60 days. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Form
<FONT STYLE="white-space:nowrap">S-3</FONT> Registration Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the completion of this offering, certain holders of shares
of our common stock will be entitled to certain Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights. At any time when we are eligible to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> the holders
of the shares having these rights then outstanding can request that we register the offer and sale of their shares of our common stock on a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> so long as the request covers
securities the anticipated aggregate public offering price of which is at least $3&nbsp;million. These stockholders may make an unlimited number of requests for registration on a registration statement on Form
<FONT STYLE="white-space:nowrap">S-3.</FONT> However, we will not be required to effect a registration on Form <FONT STYLE="white-space:nowrap">S-3</FONT> if we have effected two such registrations within the twelve month period preceding the date
of the request. Additionally, if we determine that it would be seriously detrimental to us and our stockholders to effect such a demand registration, we have the right to defer such registration, not more than once in any twelve month period, for a
period of up to 60 days. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the completion of this offering, certain holders of shares of our common stock will be entitled to certain &#147;piggyback&#148;
registration rights. If we propose to register the offer and sale of shares of our common stock </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under the Securities Act, all holders of these shares then outstanding can request that we include their shares in such registration, subject to certain marketing and other limitations, including
the right of the underwriters to limit the number of shares included in any such registration statement under certain circumstances. As a result, whenever we propose to file a registration statement under the Securities Act, other than with respect
to (1)&nbsp;a registration related to any employee benefit plan or a corporate reorganization or other transaction covered by Rule&nbsp;145 promulgated under the Securities Act, (2)&nbsp;a registration in which the only stock being registered is
common stock issuable upon conversion of debt securities also being registered, or (3)&nbsp;a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering
the sale of our common stock, the holders of these shares are entitled to notice of the registration and have the right, subject to certain limitations, to include their shares in the registration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expenses of Registration </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will
pay all expenses relating to any demand registrations, Form <FONT STYLE="white-space:nowrap">S-3</FONT> registrations, and piggyback registrations, subject to specified exceptions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Termination </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The registration
rights terminate upon the earliest of (1)&nbsp;the date that is five years after the closing of our initial public offering and (2)&nbsp;a deemed liquidation event (as defined in our amended and restated certificate of incorporation, in effect prior
to the completion of our initial public offering). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Certain Provisions of Delaware Law, Our Amended and Restated Certificate
of Incorporation and Our Amended and Restated Bylaws </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain provisions of Delaware law and certain provisions that are included in
our amended and restated certificate of incorporation and amended and restated bylaws summarized below may be deemed to have an anti-takeover effect and may delay, deter, or prevent a tender offer or takeover attempt that a stockholder might
consider to be in its best interests, including attempts that might result in a premium being paid over the market price for the shares held by stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and
restated certificate of incorporation contains provisions that permit our board of directors to issue, without any further vote or action by the stockholders, shares of preferred stock in one or more series and, with respect to each such series, to
fix the number of shares constituting the series and the designation of the series, the voting rights (if any) of the shares of the series and the powers, preferences, or relative, participation, optional, and other special rights, if any, and any
qualifications, limitations, or restrictions, of the shares of such series. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Classified Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation provides that our board of directors is divided into three classes, designated
Class&nbsp;I, Class&nbsp;II and Class&nbsp;III. Each class will be an equal number of directors, as nearly as possible, consisting of <FONT STYLE="white-space:nowrap">one-third</FONT> of the total number of directors constituting the entire board of
directors. The term of initial Class&nbsp;I directors shall terminate on the date of the 2023 annual meeting, the term of the initial Class&nbsp;II directors shall terminate on the date of the 2020 annual meeting, and the term of the initial
Class&nbsp;III directors shall terminate on the date of the 2021 annual meeting. At each annual meeting of stockholders, successors to the class of directors whose term expires at that annual meeting will be elected for a three-year term. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Removal of Directors </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended
and restated certificate of incorporation provides that stockholders may only remove a director for cause by a vote of no less than a majority of the shares present in person or by proxy at the meeting and entitled to vote. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director Vacancies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation authorizes only our board of directors to fill vacant directorships. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Cumulative Voting </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended
and restated certificate of incorporation provides that stockholders do not have the right to cumulate votes in the election of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Special
Meetings of Stockholders </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and amended and restated bylaws provides that,
except as otherwise required by law, special meetings of the stockholders may be called only by the Chairperson of our board of directors, the Chief Executive Officer, the President, or our board of directors acting pursuant to a resolution adopted
by a majority of the board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Advance Notice Procedures for Director Nominations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our bylaws provide that stockholders seeking to nominate candidates for election as directors at an annual or special meeting of stockholders
must provide timely notice thereof in writing. To be timely, a stockholder&#146;s notice generally will have to be delivered to and received at our principal executive offices before notice of the meeting is issued by the secretary of the company,
with such notice being served not less than 90 nor more than 120 days before the meeting. Although the amended and restated bylaws will not give the board of directors the power to approve or disapprove stockholder nominations of candidates to be
elected at an annual meeting, the amended and restated bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a
solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of the company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Action by Written Consent
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and amended and restated bylaws provide that any action to be taken by the
stockholders must be effected at a duly called annual or special meeting of stockholders and may not be effected by written consent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amending our
Certificate of Incorporation and Bylaws </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation may be amended or altered in any
manner provided by the DGCL. Our amended and restated bylaws may be adopted, amended, altered, or repealed by stockholders only upon approval of at least majority of the voting power of all the then outstanding shares of the common stock, except for
any amendment of certain provisions set forth in the bylaws, which would require the approval of a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority of our then outstanding common stock. Additionally, our amended and restated certificate
of incorporation provides that our bylaws may be amended, altered, or repealed by the board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Authorized but Unissued Shares
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized but unissued shares of common stock and preferred stock will be available for future issuances without stockholder
approval, except as required by the listing standards of NASDAQ, and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized
but unissued and unreserved common stock and preferred stock could render more difficult or discourage an attempt to obtain control of the company by means of a proxy contest, tender offer, merger, or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Exclusive Jurisdiction </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws provide that, unless we consent to the selection of an alternative forum, the Court of Chancery of the State of
Delaware, or if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware, is the exclusive forum for (i)&nbsp;any derivative action or proceeding brought on behalf of us, (ii)&nbsp;any action
asserting a claim of breach of a fiduciary duty owed by any director, officer, or other employee to the us or our stockholders, (iii)&nbsp;any action arising pursuant to any provision of the DGCL or our certificate of incorporation or bylaws (as
either may be amended from time to time), or (iv)&nbsp;any action asserting a claim governed by the internal affairs doctrine, except, in each case, (A)&nbsp;any claim as to which such court determines that there is an indispensable party not
subject to the jurisdiction of such court (and the indispensable party does not consent to the personal jurisdiction of such court within 10 days following such determination), (B) which is vested in the exclusive jurisdiction of a court or forum
other than such court, or (C)&nbsp;for which such court does not have subject matter jurisdiction. Although our amended and restated bylaws will contain the exclusive of forum provisions described above, it is possible that a court could find that
such provision is inapplicable for a particular claim or action or that such provision is unenforceable, and our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business Combinations with Interested Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are governed by Section&nbsp;203 of the DGCL. Subject to certain exceptions, Section&nbsp;203 of the DGCL prohibits a public Delaware
corporation from engaging in a business combination (as defined in such section) with an &#147;interested stockholder&#148; (defined generally as any person who beneficially owns 15% or more of the outstanding voting stock of such corporation or any
person affiliated with such person) for a period of three years following the time that such stockholder became an interested stockholder, unless (i)&nbsp;prior to such time the board of directors of such corporation approved either the business
combination or the transaction that resulted in the stockholder becoming an interested stockholder; (ii)&nbsp;upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned
at least 85% of the voting stock of such corporation at the time the transaction commenced (excluding for purposes of determining the voting stock of such corporation outstanding (but not the outstanding voting stock owned by the interested
stockholder) those shares owned (A)&nbsp;by persons who are directors and also officers of such corporation and (B)&nbsp;by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held
subject to the plan will be tendered in a tender or exchange offer); or (iii)&nbsp;at or subsequent to such time the business combination is approved by the board of directors of such corporation and authorized at a meeting of stockholders (and not
by written consent) by the affirmative vote of at least 66 2/3% of the outstanding voting stock of such corporation not owned by the interested stockholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and our amended and restated bylaws provide that we must indemnify our directors and
officers to the fullest extent authorized by the DGCL. We are expressly authorized to, and do, carry directors&#146; and officers&#146; insurance providing coverage for our directors, officers and certain employees for some liabilities. We believe
that these indemnification provisions and insurance are useful to attract and retain qualified directors and executive directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
limitation on liability and indemnification provisions in our certificate of incorporation and bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions may also have the effect
of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. In addition, your investment may be adversely affected to the extent we
pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Listing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the NASDAQ Global Select Market&nbsp;under the symbol &#147;ALEC.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Transfer Agent and Registrar </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is American Stock Transfer&nbsp;&amp; Trust Company, LLC. The transfer agent and
registrar&#146;s address is 6201 15th Avenue, Brooklyn, New York 11219. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_15"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of substantial amounts of common stock in the public market, including shares issued upon exercise of outstanding options, or the
perception that such sales may occur, however, could adversely affect the market price of our common stock and also could adversely affect our future ability to raise capital through the sale of our common stock or other equity-related securities of
ours at times and prices we believe appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, based on our shares outstanding as of
September&nbsp;30, 2019, 77,272,249 shares of our common stock will be outstanding, or 78,524,749 shares of common stock if the underwriters exercise their option to purchase additional shares in full. All of the shares of common stock expected to
be sold in this offering will be freely tradable without restriction or further registration under the Securities Act unless held by our &#147;affiliates,&#148; as that term is defined in Rule&nbsp;144 under the Securities Act. The remaining
outstanding shares of our common stock will be deemed &#147;restricted securities&#148; as that term is defined under Rule&nbsp;144. Restricted securities may be sold in the public market only if their offer and sale is registered under the
Securities Act or if the offer and sale of those securities qualify for an exemption from registration, including exemptions provided by Rules 144 and 701 under the Securities Act, which are summarized below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, our executive officers, directors, certain of our other stockholders affiliated with certain of our
directors, and entities affiliated with OrbiMed Private Investments, have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters, subject to certain exceptions, not to dispose of or hedge any of their common
stock or securities convertible into or exchangeable for shares of common stock during the period from the date of this prospectus continuing through the date 90 days (or 30 days, in the case of entities affiliated with OrbiMed Private Investments)
after the date of this prospectus, except with the prior consent of Morgan Stanley&nbsp;&amp; Co. LLC and Goldman Sachs&nbsp;&amp; Co. LLC. See the section titled &#147;Underwriting&#148; for additional information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule&nbsp;144 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rule&nbsp;144, as
currently in effect, generally provides that, once we have been subject to the public company reporting requirements of Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act for at least 90 days, a stockholder who is not deemed to have been one
of our affiliates at any time during the preceding 90 days and who has beneficially owned the shares of our capital stock proposed to be sold for at least six months is entitled to sell such shares in reliance upon Rule&nbsp;144 without complying
with the volume limitation, manner of sale or notice conditions of Rule&nbsp;144. If such stockholder has beneficially owned the shares of our capital stock proposed to be sold for at least one year, then such person is entitled to sell such shares
in reliance upon Rule&nbsp;144 without complying with any of the conditions of Rule&nbsp;144. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rule&nbsp;144 also provides that a
stockholder who is deemed to have been one of our affiliates at any time during the preceding 90 days and who has beneficially owned the shares of our common stock proposed to be sold for at least six months is entitled to sell such shares in
reliance upon Rule&nbsp;144 within any three month period beginning 90 days after the date of this prospectus a number of shares that does not exceed the greater of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of shares of our capital stock then outstanding, which will equal 772,722 shares immediately
after the completion of this offering, assuming no exercise by the underwriters of their option to purchase additional shares; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume of our common stock during the four calendar weeks preceding the filing of a
notice on Form 144 with respect to such sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of our capital stock made in reliance upon Rule&nbsp;144 by a
stockholder who is deemed to have been one of our affiliates at any time during the preceding 90 days are also subject to the current public information, manner of sale and notice conditions of Rule&nbsp;144. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule&nbsp;701 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rule&nbsp;701 generally provides that, once we have been subject to the public company reporting requirements of Section&nbsp;13 or
Section&nbsp;15(d) of the Exchange Act for at least 90&nbsp;days, a stockholder who purchased shares of our common stock pursuant to a written compensatory benefit plan or contract and who is not deemed to have been one of our affiliates at any time
during the preceding 90&nbsp;days may sell such shares in reliance upon Rule&nbsp;144 without complying with the current public information or holding period conditions of Rule&nbsp;144. Rule&nbsp;701 also provides that a stockholder who purchased
shares of our common stock pursuant to a written compensatory benefit plan or contract and who is deemed to have been one of our affiliates during the preceding 90 days may sell such shares under Rule&nbsp;144 without complying with the holding
period condition of Rule&nbsp;144. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> Trading Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our executive officers and directors have adopted written plans, known as &#147;Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT>
trading plans,&#148; under which they will contract with a broker to buy or sell shares of our common stock on a periodic basis to diversify their assets and investments. Under these <FONT STYLE="white-space:nowrap">10b5-1</FONT> trading plans, a
broker may execute trades pursuant to parameters established by the executive officer or director when entering into the plan, without further direction from such officer or director. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the completion
of this offering, certain holders of shares of our common stock will be entitled to certain rights with respect to the registration of such shares under the Securities Act. The registration of these shares of our common stock under the Securities
Act would result in these shares becoming eligible for sale in the public market without restriction under the Securities Act immediately upon the effectiveness of such registration, subject to the Rule&nbsp;144 limitations applicable to affiliates.
See the section titled &#147;Description of Capital Stock&#151;Registration Rights&#148; for a description of these registration rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration
Statement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We filed a registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-8</FONT> under the Securities Act to
register all of the shares of our common stock subject to equity awards outstanding or reserved for issuance under our equity compensation plans. The shares of our common stock covered by such registration statement will be eligible for sale in the
public market without restriction under the Securities Act immediately upon the effectiveness of such registration statement, subject to vesting restrictions, the conditions of Rule&nbsp;144 applicable to affiliates, and any applicable market <FONT
STYLE="white-space:nowrap">stand-off</FONT> agreements and <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_16"></A>MATERIAL U.S. FEDERAL INCOME AND ESTATE TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material U.S. federal income tax consequences of
the ownership and disposition of our common stock acquired in this offering by a <FONT STYLE="white-space:nowrap">&#147;non-U.S.</FONT> holder&#148; (as defined below), but does not purport to be a complete analysis of all the potential tax
considerations relating thereto. This summary is based upon the provisions of the Code, Treasury Regulations promulgated thereunder, administrative rulings and judicial decisions, all as of the date hereof. These authorities may be changed, possibly
retroactively, so as to result in U.S. federal income tax consequences different from those set forth below. We have not sought, and do not intend to seek, any ruling from the Internal Revenue Service (IRS), with respect to the statements made and
the conclusions reached in the following summary, and there can be no assurance that the IRS or a court will agree with such statements and conclusions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary also does not address the tax considerations arising under the laws of any <FONT STYLE="white-space:nowrap">non-U.S.,</FONT>
state, or local jurisdiction or under U.S. federal gift and estate tax rules, except to the limited extent set forth below. In addition, this discussion does not address tax considerations applicable to an investor&#146;s particular circumstances or
to investors that may be subject to special tax rules, including, without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, insurance companies, regulated investment companies, real estate investment trusts, or other financial
institutions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons subject to the alternative minimum tax or the tax on net investment income; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pension plans and <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">controlled foreign corporations, passive foreign investment companies and corporations that accumulate earnings
to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers or dealers in securities or currencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">traders in securities that elect to use a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting for their securities holdings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that own, or are deemed to own, more than five percent of our capital stock (except to the extent
specifically set forth below); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who hold our common stock as a position in a hedging transaction, &#147;straddle,&#148; &#147;conversion
transaction,&#148; or other risk reduction transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who hold or receive our common stock pursuant to the exercise of any option or otherwise as compensation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who do not hold our common stock as a capital asset within the meaning of Section&nbsp;1221 of the Code
(generally, property held for investment); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons deemed to sell our common stock under the constructive sale provisions of the Code.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if a partnership (including an entity or arrangement classified as a partnership or flow-through entity
for U.S. federal income tax purposes) holds our common stock, the tax treatment of a partner in such partnership generally will depend on the status of the partner and upon the activities of the partnership. Partnerships holding our common stock and
partners in such partnerships should consult their own tax advisors regarding the tax consequences of the ownership and disposition of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>You are urged to consult your tax advisor with respect to the application of the U.S. federal income tax laws to your particular situation,
as well as any tax consequences of the purchase, ownership and disposition of our common stock arising under the U.S. federal gift or estate tax rules or under the laws of any state, local, <FONT STYLE="white-space:nowrap">non-U.S.</FONT> or other
taxing jurisdiction or under any applicable tax treaty. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder Defined </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, you are a <FONT STYLE="white-space:nowrap">&#147;non-U.S.</FONT> holder&#148; if you are a beneficial owner of
our common stock that, for U.S. federal income tax purposes, is not a partnership or: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation or other entity taxable as a corporation created or organized in the United States or under the
laws of the United States or any political subdivision thereof, or otherwise treated as such for U.S. federal income tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate whose income is includible in gross income for U.S. federal income tax purposes regardless of its
source; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust (x)&nbsp;whose administration is subject to the primary supervision of a U.S. court and that has one or
more U.S. persons who have the authority to control all substantial decisions of the trust or (y)&nbsp;that has made a valid election under applicable Treasury Regulations to be treated as a U.S. person. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described in the
section titled &#147;Dividend Policy,&#148; we have never declared or paid cash dividends on our common stock, and we do not anticipate paying any cash dividends on our common stock in the foreseeable future. However, if we do make distributions on
our common stock, those payments will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. To the extent those
distributions exceed our current or accumulated earnings and profits, the excess will constitute a return of capital and will first reduce your basis in our common stock, but not below zero, and then will be treated as gain from the sale or other
disposition of our common stock as described under &#147;&#151;Gain on Disposition of Our Common Stock.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussions
below on effectively connected income, backup withholding and Foreign Account Tax Compliance Act (FATCA), any dividend paid to you generally will be subject to U.S. federal withholding tax either at a rate of 30% of the gross amount of the dividend
or such lower rate as may be specified by an applicable income tax treaty between the United States and your country of residence. In order to receive a reduced treaty rate, you must provide us with an IRS Form
<FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or other appropriate version of IRS Form <FONT STYLE="white-space:nowrap">W-8</FONT> certifying qualification
for the reduced rate, and you will be required to update such forms and certifications from time to time as required by law. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of shares of our common stock eligible for a reduced rate of U.S.
federal withholding tax pursuant to an income tax treaty may obtain a refund of any excess amounts withheld by filing an appropriate claim for refund with the IRS. If the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds our common stock
through a financial institution or other agent acting on the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s behalf, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be required to provide appropriate documentation to
the agent, which then will be required to provide certification to us or our paying agent, either directly or through other intermediaries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends received by you that are treated as effectively connected with a U.S. trade or business conducted by you (and, if required by an
applicable income tax treaty, that are attributable to a permanent establishment or fixed base maintained by you in the United States) are generally exempt from the 30% U.S. federal withholding tax, subject to the discussion below on backup
withholding and FATCA withholding. In order to obtain this exemption, you must provide us with a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> or other applicable IRS Form <FONT STYLE="white-space:nowrap">W-8</FONT>
properly certifying such exemption. Such effectively connected dividends, although not subject to U.S. federal withholding tax, are taxed at the same graduated rates applicable to U.S. persons, net of certain deductions and credits. In addition, if
you are a corporate <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder, you may also be subject to a branch profits tax at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty between the United States and
your country of residence) on our earnings and profits for the taxable year that are effectively connected with a U.S. trade or business conducted by you, as adjusted for certain items. You should consult your tax advisor regarding the tax
consequences of the ownership and disposition of our common stock, including any applicable tax treaties that may provide for different rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on Disposition of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below regarding backup withholding and FATCA withholding, you generally will not be required to pay U.S. federal
income tax on any gain realized upon the sale or other disposition of our common stock unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with a U.S. trade or business conducted by you (and, if an applicable income
tax treaty so provides, the gain is attributable to a permanent establishment or fixed base maintained by you in the United States); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">you are an individual who is present in the United States for a period or periods aggregating 183 days or more
during the calendar year in which the sale or disposition occurs and certain other conditions are met; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our common stock constitutes a United States real property interest by reason of our status as a &#147;United
States real property holding corporation,&#148; or USRPHC, for U.S. federal income tax purposes at any time within the shorter of the five-year period preceding your disposition of, or your holding period for, our common stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that we are not currently and will not become a USRPHC for U.S. federal income tax purposes, and the
remainder of this discussion so assumes. However, because the determination of whether we are a USRPHC depends on the fair market value of our U.S. real property interests relative to the fair market value of our worldwide real property interests
plus our other assets used or held for use in a trade or business, there can be no assurance that we will not become a USRPHC in the future. Even if we become a USRPHC, however, as long as our common stock is regularly traded on an established
securities market, your common stock will be treated as U.S. real property interests only if you actually (directly or indirectly) or constructively hold more than five percent of such regularly traded common stock at any time during the shorter of
the five-year period preceding your disposition of, or your holding period for, our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you are a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder described in the first bullet above, you will be required to pay tax on the gain derived from the sale (net of certain deductions and credits) under regular graduated U.S. federal income tax rates
applicable to U.S. persons, and a corporate <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder described in the first bullet above also may be subject to the branch profits tax at a 30% rate, or such lower rate as may be specified by an
applicable income tax treaty. If you are an individual <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder described in the second bullet above, you will be subject to tax at 30% (or such lower rate specified by an applicable income tax treaty)
on the gain derived from the sale, which gain may be offset by U.S. source capital losses for the year, provided you have timely filed U.S. federal income tax returns with respect to such losses. You should consult your tax advisor regarding any
applicable income tax or other treaties that may provide for different rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Federal Estate Tax </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock beneficially owned by an individual who is not a citizen or resident of the United&nbsp;States (as defined for U.S. federal
estate tax purposes) at the time of their death will generally be includable in the decedent&#146;s gross estate for U.S. federal estate tax purposes. Such stock, therefore, may be subject to U.S. federal estate tax, unless an applicable estate tax
treaty provides otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Backup Withholding and Information Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, we must report annually to the IRS the amount of dividends paid to you, your name and address and the amount of tax withheld, if
any. A similar report will be sent to you. Pursuant to applicable income tax treaties or other agreements, the IRS may make these reports available to tax authorities in your country of residence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments of dividends on or of proceeds from the disposition of our common stock made to you may be subject to information reporting and
backup withholding at the statutory rate (currently, 24%) unless you </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
establish an exemption, for example, by properly certifying your <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status on a properly completed IRS Form
<FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or another appropriate version of IRS Form <FONT STYLE="white-space:nowrap">W-8.</FONT> Notwithstanding the
foregoing, backup withholding and information reporting may apply if either we or our paying agent has actual knowledge, or reason to know, that you are a U.S. person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax; rather, the U.S. federal income tax liability of persons subject to backup withholding will be
reduced by the amount of tax withheld. If withholding results in an overpayment of taxes, a refund or credit may generally be obtained from the IRS, provided that the required information is furnished to the IRS in a timely manner. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Account Tax Compliance Act </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions of the Code commonly referred to as FATCA, Treasury Regulations issued thereunder and official IRS guidance generally impose a U.S.
federal withholding tax of 30% on dividends on, and the gross proceeds from a sale or other disposition of our common stock, paid to a &#147;foreign financial institution&#148; (as specially defined under these rules), unless such institution enters
into an agreement with the U.S. government to, among other things, withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding the U.S. account holders of such institution (which includes
certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or otherwise establishes an exemption. FATCA also generally imposes a U.S. federal withholding tax of 30% on
dividends on and the gross proceeds from a sale or other disposition of our common stock paid to a <FONT STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (as specially defined under these rules) unless such entity provides
the withholding agent with a certification identifying the direct and indirect substantial U.S. owners of the entity and information with respect to such substantial U.S. owners, certifies that it does not have any such substantial U.S. owners, or
otherwise establishes an exemption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The withholding obligations under FATCA generally apply to dividends on our common stock and to the
payment of gross proceeds of a sale or other disposition of our common stock. The withholding tax will apply regardless of whether the payment otherwise would be exempt from U.S. nonresident and backup withholding tax, including under the other
exemptions described above. Under certain circumstances, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder might be eligible for refunds or credits of such taxes. An intergovernmental agreement between the United States and an applicable
foreign country may modify the requirements described in this section. The U.S. Treasury Department recently released proposed regulations under FATCA which, if finalized in their present form, would eliminate the federal withholding tax of 30%
applicable to gross proceeds of a sale or other disposition of our common stock, and has provided that such proposed regulations may be relied upon by taxpayers until final regulations are issued. Prospective investors should consult with their own
tax advisors regarding the application of FATCA withholding to their investment in, and ownership and disposition of, our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The preceding discussion of U.S. federal tax considerations is for general information only. It is not tax advice to investors in their
particular circumstances. Each prospective investor should consult its own tax advisor regarding the particular U.S. federal, state and local, and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of purchasing, holding, and
disposing of our common stock, including the consequences of any proposed change in applicable laws. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_17"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms and subject to the conditions in an underwriting agreement dated the date of this prospectus, the underwriters named below,
for whom Morgan Stanley&nbsp;&amp; Co. LLC, Goldman Sachs&nbsp;&amp; Co. LLC, BofA Securities, Inc. and Cowen and Company, LLC are acting as representatives, have severally agreed to purchase, and we have agreed to sell to them, severally, the
number of shares indicated below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,338,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,338,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,087,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,586,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and the representatives are collectively referred to as the &#147;underwriters&#148; and the
&#147;representatives,&#148; respectively. The underwriters are offering the shares of common stock subject to their acceptance of the shares from us and subject to prior sale. The underwriting agreement provides that the obligations of the several
underwriters to pay for and accept delivery of the shares of common stock offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other conditions. The underwriters are obligated to take and
pay for all of the shares of common stock offered by this prospectus if any such shares are taken. However, the underwriters are not required to take or pay for the shares covered by the underwriters&#146; option to purchase additional shares
described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters initially propose to offer part of the shares of common stock directly to the public at the offering
price listed on the cover page of this prospectus and part to certain dealers at a price that represents a concession not in excess of $0.90 per share under the public offering price. After the initial offering of the shares of common stock, the
offering price and other selling terms may from time to time be varied by the representatives. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters&#146; right to reject any order in
whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase up
to 1,252,500 additional shares of common stock at the public offering price listed on the cover page of this prospectus, less underwriting discounts and commissions. To the extent the option is exercised, each underwriter will become obligated,
subject to certain conditions, to purchase about the same percentage of the additional shares of common stock as the number listed next to the underwriter&#146;s name in the preceding table bears to the total number of shares of common stock listed
next to the names of all underwriters in the preceding table. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the per share and total public offering price,
underwriting discounts and commissions, and proceeds before expenses to us. These amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase up to an additional 1,252,500 shares of common stock. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">208,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">240,062,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions to be paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,525,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,403,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">196,225,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">225,658,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The estimated offering expenses payable by us, exclusive of the underwriting discounts and commissions, are
approximately $1 million. We have agreed to reimburse the underwriters for expenses of up to $40,000 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
relating to clearance of this offering with the Financial Industry Regulatory Authority, Inc. and compliance with state securities or &#147;blue sky&#148; laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on NASDAQ under the trading symbol&nbsp;&#147;ALEC.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our directors and executive officers, as well as certain of our other stockholders affiliated with certain of our directors and
entities affiliated with OrbiMed Private Investments, have agreed that, without the prior written consent of Morgan Stanley &amp; Co. LLC and Goldman Sachs &amp; Co. LLC on behalf of the underwriters, we and they will not, during the period ending
on and including the 90th day (or the 30th day, in the case of entities affiliated with OrbiMed Private Investments) after the date of this prospectus (the restricted period): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract
to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">file any registration statement with the SEC relating to the offering of any shares of common stock or any
securities convertible into or exercisable or exchangeable for common stock; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of the common stock </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">whether any such transaction described above is to be settled by delivery of common stock
or such other securities, in cash or otherwise. In addition, we and each such person agrees that, without the prior written consent of Morgan Stanley &amp; Co. LLC and Goldman Sachs &amp; Co. LLC on behalf of the underwriters, we or such other
person will not, during the restricted period, make any demand for, or exercise any right with respect to, the registration of any shares of common stock or any security convertible into or exercisable or exchangeable for common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The restrictions described in the immediately preceding paragraph do not apply to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the sale of shares to the underwriters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transactions by any person other than us relating to shares of common stock or other securities acquired in
this offering or in open market transactions after the completion of this offering; provided that no filing under Section&nbsp;16(a) of the Exchange Act is required or voluntarily made during the restricted period in connection with subsequent sales
of the common stock or other securities acquired in such open market transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the transfer of shares of common stock or any security convertible into common stock (i)&nbsp;to an immediate
family member of the <FONT STYLE="white-space:nowrap">lock-up</FONT> signatory, or to a trust or other entity formed for estate planning for the benefit of the <FONT STYLE="white-space:nowrap">lock-up</FONT> signatory or immediate family member,
(ii)&nbsp;by bona fide gift, will or intestacy, (iii)&nbsp;if the <FONT STYLE="white-space:nowrap">lock-up</FONT> signatory is a trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust, or (iv)&nbsp;by bona
fide gift to a charitable organization, provided that no filing under Section&nbsp;16(a) of the Exchange Act or other public filing, report, or announcement reporting a reduction in beneficial ownership of shares of common stock or any security
convertible into common stock shall be required or voluntarily made during the restricted period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the <FONT STYLE="white-space:nowrap">lock-up</FONT> signatory is a corporation, partnership, limited
liability company, trust, or other business entity, transfers of common stock or any security convertible into common stock (i)&nbsp;to another corporation, partnership, limited liability company, trust, or other business entity that controls, is
controlled by, manages, is managed by, or is under common control with the <FONT STYLE="white-space:nowrap">lock-up</FONT> signatory or its affiliates or (ii)&nbsp;as part of a disposition, transfer, or distribution by the <FONT
STYLE="white-space:nowrap">lock-up</FONT> signatory to its stockholders, partners, members, or other equity holders; provided that no filing under Section&nbsp;16(a) of the Exchange Act or other public filing, report, or announcement reporting a
reduction in beneficial ownership of shares of common stock or securities convertible into common stock shall be required or voluntarily made during the restricted period (other than any required Form 5 filing); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(i)&nbsp;the receipt by the <FONT STYLE="white-space:nowrap">lock-up</FONT> signatory from us of shares of our
common stock upon the exercise of options or the settlement of restricted stock units granted under a stock incentive plan or other equity award plan, as described in this prospectus, insofar as such option or restricted stock unit is outstanding as
of the date of this prospectus, or (ii)&nbsp;the transfer of shares of common stock or other securities convertible into common stock to us upon a vesting event of our securities, the settlement of restricted stock units, or the exercise of options
to purchase our securities on a &#147;cashless&#148; or &#147;net exercise&#148; basis to the extent permitted by the instruments representing such options or restricted stock units (and any transfer to us necessary to generate cash needed for the
payment of taxes due as a result of such vesting, settlement, or exercise) so long as such &#147;cashless exercise&#148; or &#147;net exercise&#148; is effected solely by the surrender of outstanding options or restricted stock units to us and our
cancellation of all or a portion thereof. In the case of either (i)&nbsp;or (ii), no filing under Section&nbsp;16(a) of the Exchange Act or other public announcement or filing shall be required or voluntarily made during the restricted period, and
the underlying shares issued to the <FONT STYLE="white-space:nowrap">lock-up</FONT> signatory shall continue to be subject to the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement. For the purpose of (ii), filings under
Section&nbsp;16(a) of the Exchange Act shall be permissible if such filings relate solely to &#147;net&#148; or &#147;cashless&#148; exercises or settlements of stock options, restricted stock units, or other equity awards that would otherwise
expire during the restricted period and any such filing includes a statement to the effect that such transfer is being made in connection with a &#147;net&#148; or &#147;cashless&#148; exercise or settlement of stock options, restricted stock units,
or other equity awards, and the <FONT STYLE="white-space:nowrap">lock-up</FONT> signatory provides written notice to Morgan Stanley &amp; Co. LLC and Goldman Sachs &amp; Co. LLC no later than two business days prior to making any such filings;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">f.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the establishment of a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the
Exchange Act for the transfer of shares of common stock, provided that (i)&nbsp;such plan does not provide for the transfer of common stock during the restricted period and (ii)&nbsp;to the extent a public announcement or filing under the Exchange
Act, if any, is required or voluntarily made regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer of common stock may be made under such plan during the restricted period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">g.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the transfer of shares of common stock or securities convertible into common stock to us pursuant to agreements
under which we or any of our equityholders have the option to repurchase such shares of common stock or other securities convertible into common stock upon termination of service of the <FONT STYLE="white-space:nowrap">lock-up</FONT> signatory;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">h.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the transfer of shares of common stock or other securities convertible into common stock pursuant to a bona
fide third party tender offer, merger, consolidation, or other similar transaction made to all holders of our capital stock involving a &#147;change of control&#148;, after the completion of this offering, that has been approved by our board of
directors, provided that in the event that such transaction is not completed, the <FONT STYLE="white-space:nowrap">lock-up</FONT> signatory&#146;s shares of common stock or securities convertible into common stock will remain subject to the terms of
the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the transfer of shares of common stock or securities convertible into common stock pursuant to a domestic order
or in connection with a divorce settlement; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">j.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the sale of shares of common stock under a trading plan pursuant to Rule
<FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act established prior to the execution of the relevant <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement and that has been disclosed to Morgan Stanley &amp; Co. LLC and
Goldman Sachs &amp; Co. LLC, provided that any filing required by Section&nbsp;16 of the Exchange Act that is made in connection with any such sales during the restricted period shall state that such sales have been executed pursuant to such trading
plan. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of any transfer pursuant to (c), (d) and (i)&nbsp;above, the donee, transferee, or distributee must
agree in writing to be bound by <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;restrictions.</FONT> In the case of (c)&nbsp;and (d) above, such transfer or distribution shall not involve a disposition for value. In the case of (g)&nbsp;and
(i) above, no filing under Section&nbsp;16(a) of the Exchange Act or other public filing, report, or announcement reporting a reduction in beneficial ownership of shares of common stock or securities convertible into common stock shall be
voluntarily made during the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
restricted period. In the case of (g)&nbsp;and (i) above, if <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;signatory</FONT> is required to file a report under Section&nbsp;16(a) of the
Exchange Act during the restricted period, <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;signatory</FONT> shall include a statement to the effect that such transfer is to us in connection with the repurchase of shares of common stock or
other securities convertible into common stock or pursuant to a qualified domestic order or in connection with a divorce settlement, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Morgan Stanley &amp; Co. LLC and Goldman Sachs &amp; Co. LLC, in their sole discretion, may release the common stock and other securities
subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above in whole or in part at any time with or without notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to facilitate the offering of the common stock, the underwriters may engage in transactions that stabilize, maintain or otherwise
affect the price of the common stock. Specifically, the underwriters may sell more shares than they are obligated to purchase under the underwriting agreement, creating a short position. A short sale is covered if the short position is no greater
than the number of shares available for purchase by the underwriters under the option to purchase additional shares described above. The underwriters can close out a covered short sale by exercising such option or purchasing shares in the open
market. In determining the source of shares to close out a covered short sale, the underwriters will consider, among other things, the open market price of shares compared to the price available under such option. The underwriters may also sell
shares in excess of such option, creating a naked short position. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned
that there may be downward pressure on the price of the common stock in the open market after pricing that could adversely affect investors who purchase in this offering. As an additional means of facilitating this offering, the underwriters may bid
for, and purchase, shares of common stock in the open market to stabilize the price of the common stock. These activities may raise or maintain the market price of the common stock above independent market levels or prevent or retard a decline in
the market price of the common stock. The underwriters are not required to engage in these activities and may end any of these activities at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the underwriters have agreed to indemnify each other against certain liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus in electronic format may be made available on websites maintained by one or more underwriters, or selling group members, if any,
participating in this offering. The representatives may agree to allocate a number of shares of common stock to underwriters for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to
underwriters that may make Internet distributions on the same basis as other allocations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include
securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Certain of the underwriters and their respective affiliates
have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for us, for which they received or will receive customary fees and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of their various business activities, the underwriters and their respective affiliates may make or hold a
broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers and may at any time hold long
and short positions in such securities and instruments. Such investment and securities activities may involve our securities and instruments. The underwriters and their respective affiliates may also make investment recommendations or publish or
express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short positions in such securities and instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Restrictions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Canada </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of our common
stock may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National <FONT STYLE="white-space:nowrap">Instrument&nbsp;45-106&nbsp;Prospectus</FONT> Exemptions or subsection
73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National <FONT STYLE="white-space:nowrap">Instrument&nbsp;31-103&nbsp;Registration</FONT> Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of
the shares of our common stock must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this
prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s
province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by the government of
<FONT STYLE="white-space:nowrap">a&nbsp;non-Canadian&nbsp;jurisdiction,</FONT> section 3A.4) of National <FONT STYLE="white-space:nowrap">Instrument&nbsp;33-105&nbsp;Underwriting</FONT> Conflicts
<FONT STYLE="white-space:nowrap">(NI&nbsp;33-105),&nbsp;the</FONT> underwriters are not required to comply with the disclosure requirements of <FONT STYLE="white-space:nowrap">NI&nbsp;33-105&nbsp;regarding</FONT> underwriter conflicts of interest in
connection with this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European Economic Area </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each member state of the European Economic Area (each, a Member State), no securities have been offered or will be offered
pursuant to the offering to the public in that Member State prior to the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Member State or, where appropriate, approved in another
Member State and notified to the competent authority in that Member State, all in accordance with the Prospectus Regulation, except that offers of securities may be made to the public in that Member State at any time under the following exemptions
under the Prospectus Regulation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to any legal entity which is a qualified investor as defined under the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus
Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such offer of securities shall require us or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or
supplement a prospectus pursuant to Article 23 of the Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the
representatives and us that it is a &#147;qualified investor&#148; within the meaning of Article 2(e) of the Prospectus Regulation. In the case of any shares being offered to a financial intermediary as that term is used in the Prospectus
Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a non-discretionary basis on behalf of, nor have they been acquired with a
view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public other than their offer or resale in a Member State to qualified investors as so defined or in circumstances in which the prior
consent of the representatives been obtained to each such proposed offer or resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an
&#147;offer to the public&#148; in relation to shares in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to
purchase or subscribe for any shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>United Kingdom </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each underwriter has represented and agreed that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it has only communicated or caused to be communicated and will only communicate or cause to be communicated an
invitation or inducement to engage in investment activity (within the meaning of Section&nbsp;21 of the Financial Services and Markets Act 2000 (FSMA) received by it in connection with the issue or sale of the shares of our common stock in
circumstances in which Section&nbsp;21(1) of the FSMA does not apply to us; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it
in relation to the shares of our common stock in, from or otherwise involving the United Kingdom. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hong Kong </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of common stock have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than
(a)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in the document being a
&#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation, or
document relating to the shares of common stock has been or may be issued or has been or may be in the possession of any person for the purposes of issuance, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are
likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong&nbsp;Kong) other than with respect to shares of common stock which are or are intended to be disposed of only to persons
outside Hong Kong or only to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance and any rules made under that Ordinance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Japan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No registration pursuant to
Article 4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as amended) (FIEL) has been made or will be made with respect to the solicitation of the application for the acquisition of the shares of common
stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, the shares of common stock have not been, directly or indirectly, offered or sold and will not be, directly or
indirectly, offered or sold in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">for&nbsp;re-offering&nbsp;or&nbsp;re-sale,&nbsp;directly</FONT></FONT> or indirectly, in Japan or to, or for the benefit of, any resident of Japan except pursuant to an exemption from the
registration requirements, and otherwise in compliance with, the FIEL and the other applicable laws and regulations of Japan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>For Qualified
Institutional Investors (QII) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please note that the solicitation for newly-issued or secondary securities (each as described in
Paragraph 2, Article 4 of the FIEL) in relation to the shares of common stock constitutes either a &#147;QII only private placement&#148; or a &#147;QII only secondary distribution&#148; (each as described in Paragraph 1, <FONT
STYLE="white-space:nowrap">Article&nbsp;23-13&nbsp;of</FONT> the FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph 1, Article 4 of the FIEL, has not been made in relation to the shares of common stock. The
shares of common stock may only be transferred to QIIs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">For&nbsp;Non-QII&nbsp;Investors</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please note that the solicitation for newly-issued or secondary securities (each as described in Paragraph 2, Article 4 of the FIEL) in
relation to the shares of common stock constitutes either a &#147;small number private </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
placement&#148; or a &#147;small number private secondary distribution&#148; (each as is described in Paragraph 4, <FONT STYLE="white-space:nowrap">Article&nbsp;23-13&nbsp;of</FONT> the FIEL).
Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph 1, Article 4 of the FIEL, has not been made in relation to the shares of common stock. The shares of common stock may only be transferred en bloc without subdivision
to a single investor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Singapore </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other
document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares of our common stock may not be circulated or distributed, nor may the shares of our common stock be offered or sold, or be made the
subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore (SFA),
(ii) to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275 of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with
the conditions of, any other applicable provision of the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where the shares of our common stock are subscribed or purchased under
Section&nbsp;275 of the SFA by a relevant person which is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole
business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a trust (where the trustee is not an accredited investor) the sole purpose of which is to hold investments and
each beneficiary of the trust is an individual who is an accredited investor, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">securities (as defined in Section&nbsp;239(1) of the SFA)
of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares of our common stock pursuant to an offer
made under Section&nbsp;275 of the SFA except: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any
person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)&nbsp;(B) of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as specified in Section&nbsp;276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures)
Regulations 2005 of Singapore. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Israel </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the State of Israel this prospectus shall not be regarded as an offer to the public to purchase shares of common stock under the Israeli
Securities Law, 5728 - 1968, which requires a prospectus to be published and authorized by the Israel Securities Authority, if it complies with certain provisions of Section 15 of the Israeli Securities Law, 5728 -1968, including, inter alia, if:
(i)&nbsp;the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions (the &#147;Addressed Investors&#148;); or (ii)&nbsp;the offer is made, distributed or directed to certain qualified investors defined in
the First Addendum of the Israeli Securities Law, 5728 - 1968, subject to certain conditions (the &#147;Qualified Investors&#148;). The Qualified Investors shall not be taken into account in the count of the Addressed Investors and may be offered to
purchase securities in addition to the 35 Addressed Investors. The company has not and will not take any action that would require it to publish a prospectus in accordance with and subject to the Israeli Securities Law, 5728 - 1968. We have not and
will not distribute this prospectus or make, distribute or direct an offer to subscribe for our common stock to any person within the State of Israel, other than to Qualified Investors and up to 35 Addressed Investors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Qualified Investors may have to submit written evidence that they meet the definitions set
out in of the First Addendum to the Israeli Securities Law, 5728 - 1968. In particular, we may request, as a condition to be offered common stock, that Qualified Investors will each represent, warrant and certify to us and/or to anyone acting on our
behalf: (i)&nbsp;that it is an investor falling within one of the categories listed in the First Addendum to the Israeli Securities Law, 5728 - 1968; (ii)&nbsp;which of the categories listed in the First Addendum to the Israeli Securities Law, 5728
- 1968 regarding Qualified Investors is applicable to it; (iii)&nbsp;that it will abide by all provisions set forth in the Israeli Securities Law, 5728 - 1968 and the regulations promulgated thereunder in connection with the offer to be issued
common stock; (iv)&nbsp;that the shares of common stock that it will be issued are, subject to exemptions available under the Israeli Securities Law, 5728 - 1968: (a)&nbsp;for its own account; (b)&nbsp;for investment purposes only; and (c)&nbsp;not
issued with a view to resale within the State of Israel, other than in accordance with the provisions of the Israeli Securities Law, 5728 - 1968; and (v) that it is willing to provide further evidence of its Qualified Investor status. Addressed
Investors may have to submit written evidence in respect of their identity and may have to sign and submit a declaration containing, inter alia, the Addressed Investor&#146;s name, address and passport number or Israeli identification number. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_18"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the issuance of our common stock offered in this prospectus will be passed upon for us by Wilson Sonsini Goodrich&nbsp;&amp;
Rosati, Professional Corporation, Palo Alto, California. Davis Polk&nbsp;&amp; Wardwell LLP, Menlo Park, California, is acting as counsel for the underwriters. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_19"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ernst &amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements at December 31, 2018
and 2017, and for each of the three years in the period ended December 31, 2018 as set forth in their report. We have included our consolidated financial statements in the prospectus and elsewhere in the registration statement in reliance on Ernst
&amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom838337_20"></A>WHERE YOU CAN
FIND ADDITIONAL INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1653087/000119312520015336/d838337ds1.htm">
<FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT></A> under the Securities Act with respect to the shares of our common stock offered by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain
all of the information set forth in the registration statement, as permitted by the rules and regulations of the SEC. For further information with respect to us and our common stock, we refer you to the registration statement, including the exhibits
filed as a part of the registration statement. Statements contained in this prospectus concerning the contents of any contract or any other document is not necessarily complete. If a contract or document has been filed as an exhibit to the
registration statement, please see the copy of the contract or document that has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. The SEC also
maintains an Internet website that contains the registration statement of which this prospectus forms a part, as well as the exhibits thereto. These documents, along with future reports, proxy statements, and other information about us, are
available at the SEC&#146;s website, www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the information and reporting requirements of the Securities Exchange
Act of 1934, as amended, and, in accordance with this law, will file periodic reports, proxy statements, and other information with the SEC. These periodic reports, proxy statements, and other information are available for inspection and copying at
the SEC&#146;s public reference facilities and the website of the SEC referred to above. We also maintain a website at www.alector.com where these materials are available. You may access these materials free of charge as soon as reasonably
practicable after they are electronically filed with, or furnished to, the SEC. Information contained on, or that can be accessible through, our website is not a part of this prospectus and the inclusion of our website address in this prospectus is
an inactive textual reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc838337_22a"></A>INDEX TO FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Audited Consolidated Financial Statements for the Years Ended December&nbsp;31, 2018, 2017, and
2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin838337_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin838337_2">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin838337_3">Consolidated Statements of Operations and Comprehensive
Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin838337_4">Consolidated Statement of Convertible Preferred Stock and Stockholders&#146;
 Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin838337_5">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin838337_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Unaudited Interim Condensed Consolidated Financial Statements for the Three and Nine Months
Ended September&nbsp;30, 2019 and 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin838337_7">Condensed Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-24</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin838337_8">Condensed Consolidated Statements of Operations and Comprehensive
Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-25</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin838337_9">Condensed Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-28</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin838337_10">Notes to Unaudited Interim Condensed Consolidated Financial
Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-29</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin838337_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Stockholders and the Board of Directors of Alector, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the
accompanying consolidated balance sheets of Alector, Inc. (the &#147;Company&#148;) as of December&nbsp;31, 2018 and 2017, the related consolidated statements of operations and comprehensive loss, stockholders&#146; deficit and cash flows for the
each of the three years in the period ended December&nbsp;31, 2018, and the related notes (collectively referred to as the &#147;consolidated financial statements&#148;). In our opinion, the consolidated financial statements present fairly, in all
material respects, the financial position of the Company at December&nbsp;31, 2018 and 2017, and the results of its operations and its cash flows for each of the three years in the period ended December&nbsp;31, 2018, in conformity with U.S.
generally accepted accounting principles. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#147;PCAOB&#148;) and are required to be independent with respect to the Company in accordance with the
U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in
accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The
Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the
purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and
performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used
and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the
Company&#146;s auditor since 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Jose, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;26, 2019 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin838337_2"></A>A<SMALL>LECTOR</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(In thousands, except share and per share data) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CURRENT ASSETS:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Receivable from collaboration partner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">232,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">252</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TOTAL ASSETS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">308,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">236,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS&#146; DEFICIT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CURRENT LIABILITIES:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,140</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued clinical supply costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, long-term portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent, long-term portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TOTAL LIABILITIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and Contingencies (Note 5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock; $0.0001 par value; 45,849,677 and 36,001,203 shares authorized as of
December&nbsp;31, 2018 and 2017, respectively; 45,374,836 and 36,001,203 shares issued and outstanding as of December&nbsp;31, 2018 and 2017, respectively; liquidation preference of $211,054 as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">STOCKHOLDERS&#146; DEFICIT:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value; 65,000,000 and 52,000,000 shares authorized as of
December&nbsp;31, 2018 and 2017, respectively; 13,764,829 and 13,776,153 shares issued and outstanding as of December&nbsp;31, 2018 and 2017, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(114,435</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,187</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TOTAL STOCKHOLDERS&#146; DEFICIT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(97,398</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,033</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS&#146; DEFICIT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">308,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">236,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin838337_3"></A>A<SMALL>LECTOR</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(In thousands, except share and per share data) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,679</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,132</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized loss on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(52,290</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.62</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used in computing net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,302,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,142,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,173,441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin838337_4"></A>A<SMALL>LECTOR</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statement of Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(In thousands, except member unit and share data) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred&nbsp;Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible</B><br><B>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-In</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive<BR>Loss</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance &#151; December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,001,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,707,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,597</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,760</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,136,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cancellation of common units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(326,082</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance &#151; December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,001,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,517,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,707</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,907</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,483,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cancellation of common units</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Conversion from LLC to corporation (Note 1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,001,203</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(77,485</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,001,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,992,752</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,825,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cancellation of restricted common stock post-conversion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance &#151; December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,001,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,776,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,187</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,033</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series E convertible preferred stock, net of issuance costs of $214</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,373,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Cancellation of restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance &#151; December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,374,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">210,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,764,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(114,435</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(97,398</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin838337_5"></A>A<SMALL>LECTOR</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(In thousands) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CASH FLOWS FROM OPERATING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(52,248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,480</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of discount on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,745</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from disposal of property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(218</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,483</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(184</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(809</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities and accrued clinical supply costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(354</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,771</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,993</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CASH FLOWS FROM INVESTING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,884</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(801</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(472,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maturities of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(224,119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(801</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CASH FLOWS FROM FINANCING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of deferred offering costs for initial public offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,904</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(77</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash, cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,587</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and restricted cash at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and restricted cash at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">NON-CASH</FONT> INVESTING AND FINANCING
ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment purchases included in accounts payable and accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance costs for convertible preferred stock included in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs for initial public offering included in accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tenant improvements paid by landlord</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B><A NAME="fin838337_6"></A>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>The Company and Liquidity </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Alector, Inc. (&#147;Alector&#148; or the &#147;Company&#148;) is a Delaware corporation headquartered in South San Francisco, California.
Alector is a biotechnology company focused on harnessing the immune system to cure neurodegenerative diseases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Conversion
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Alector was originally formed in May 2013 as a Delaware limited liability company under the name Alector LLC. In October 2017, the
Company completed a reorganization whereby the Company converted from a Delaware limited liability company named Alector LLC to a Delaware corporation named under the name Alector, Inc. (the &#147;Conversion&#148;). In conjunction with the
Conversion, (i)&nbsp;all of the Company&#146;s outstanding common units converted on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-1</FONT></FONT> basis into shares of common stock, par value $0.0001; (ii) all of the
Company&#146;s outstanding preferred units converted on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-1</FONT></FONT> basis into shares of convertible preferred stock, par value $0.0001; and (iii)&nbsp;the Company&#146;s
202,924 unvested restricted units converted on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-1</FONT></FONT> basis into shares of unvested restricted common stock. Prior to the Conversion, the Company had issued profit
interest units to employees. The Company&#146;s vested profit interest units converted on a net issuance basis into shares of common stock and the Company&#146;s unvested profit interest units converted on a net issuance basis into restricted common
stock. Fractional shares related to the conversion of profit interest grants were settled in cash. All vesting provisions remained the same following the Conversion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Initial Public Offering </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;7, 2019, the Company completed an initial public offering (&#147;IPO&#148;) through issuing and selling 9,739,541 shares of
common stock at a public offering price of $19.00 per share, including 489,541 shares sold pursuant to the underwriters&#146; partial exercise of their option to purchase additional shares. The aggregate net proceeds received by the Company from the
offering, net of underwriting discounts and commissions and estimated offering expenses, were $168.2&nbsp;million. Upon the closing of the IPO, all of the outstanding shares of convertible preferred stock automatically converted into shares of
common stock. Subsequent to the closing of the IPO, there were no shares of convertible preferred stock outstanding. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Summary of Significant Accounting Policies </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States
(&#147;GAAP&#148;) as defined by the Financial Accounting Standards Board (&#147;FASB&#148;). The consolidated financial statements include the accounts of Alector, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions
have been eliminated in consolidation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. The Company
evaluates its estimates, including those related to revenue recognition, manufacturing accruals, clinical accruals, fair value of assets and liabilities, income taxes uncertainties, stock-based compensation, and related assumptions on an ongoing
basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates<I>.</I> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash
equivalents, and short-term marketable securities. Cash and cash equivalents </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
are deposited in checking and sweep accounts at a financial institution. Such deposits may, at times, exceed federally insured limits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash, Cash Equivalents, and Restricted Cash </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash and
cash equivalents. Cash equivalents, which consist of amounts invested in money market funds, are stated at fair value. There are no unrealized gains or losses on the money market funds for the periods presented. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Restricted cash as of December&nbsp;31, 2018 relates to a letter of credit established for a lease entered into in June 2018. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheets
that sum to the total of the same amounts shown in the consolidated statements of cash flows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash, cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Marketable Securities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">All marketable securities have been classified as
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;available-for-sale&#148;</FONT></FONT> and are carried at fair value, based upon quoted market prices. The Company considers its <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">available-for-sale</FONT></FONT> portfolio as available for use in current operations. Accordingly, the Company may classify certain investments as short-term marketable securities, even though the stated maturity date may
be one year or more beyond the current balance sheet date. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive income and reported as a separate component of
stockholders&#146; deficit until realized. Interest income, realized gains and losses, and declines in value judged to be other than temporary, if any, on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities are included in other income, net. The cost of securities sold is based on the specific-identification method. The amortized cost of
securities is adjusted for amortization of premiums and accretion of discounts to maturity. In accordance with our investment policy, management only invests in money market funds and U.S. treasury securities. The Company has not experienced any
losses on its deposits of cash, cash equivalents, and marketable securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company periodically evaluates whether declines in the
fair value of our investments below their cost are other than temporary. This evaluation consists of qualitative and quantitative factors regarding the severity and duration of the unrealized loss, as well as our ability and intent to hold the
marketable securities until a forecasted recovery occurs. If it is determined that the decline in fair value of an investment is below its accounting basis and this decline is other than temporary, the Company would reduce the carrying value of the
security and record a loss for the amount of such decline. The Company has not recorded any realized losses or declines in value judged to be other than temporary on any investments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s financial instruments include cash and cash equivalents, receivables, accounts payable, and accrued liabilities. The
Company&#146;s financial instruments approximate fair value due to their relatively short maturities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company utilizes valuation techniques that maximize the use of observable inputs and
minimize the use of unobservable inputs to the extent possible. The Company determines the fair value of its financial instruments based on assumptions that market participants would use in pricing an asset or liability in the principal or most
advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Level</I><I></I><I>&nbsp;1</I> &#151; Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the
measurement date; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Level</I><I></I><I>&nbsp;2</I> &#151; Inputs are observable, unadjusted quoted prices in active markets for similar
assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of
the related assets or liabilities; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Level</I><I></I><I>&nbsp;3</I> &#151; Unobservable inputs that are significant to the
measurement of the fair value of the assets or liabilities that are supported by little or no market data. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization is
computed using the straight-line method over the estimated useful lives of the respective assets, generally three to five years. Leasehold improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When
assets are retired or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the consolidated balance sheet and the resulting gain or loss is reflected in the consolidated statements of operations in
the period realized. Maintenance and repairs are charged to the consolidated statements of operations as incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of
Long-Lived Assets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that
the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If the total of the undiscounted future cash
flows is less than the carrying amount of the assets, an impairment loss is recognized for the amount by which the carrying amount of the assets exceeds is fair value. The Company has not identified any such impairment losses to date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company early adopted the new revenue accounting standard (&#147;ASC 606&#148;) using the full retrospective method effective
January&nbsp;1, 2017, which retrospectively applied the standard to all prior periods presented. Under ASC 606, an entity recognizes revenue when control of promised goods or services are transferred to customers in an amount that reflects the
consideration that is expected to be received for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under arrangements, the Company performs the following steps:
(i)&nbsp;identify the contract(s) with a customer, (ii)&nbsp;identify the performance obligations in the contract, (iii)&nbsp;determine the transaction price, (iv)&nbsp;allocate the transaction price to the performance obligations in the contract,
and (v)&nbsp;recognize revenue when (or as) the entity satisfies the performance obligation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Collaboration Revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company signed an agreement in October 2017 with AbbVie to <FONT STYLE="white-space:nowrap">co-develop</FONT> antibodies to two program
targets in preclinical development. Under the terms of the agreement, AbbVie made $205.0&nbsp;million in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
upfront payments, of which $5.0&nbsp;million and $200.0&nbsp;million was received by the Company in October 2017 and January 2018, respectively. The Company will perform research and development
services for the antibodies to the two programs through the end of Phase 2 clinical trials which the Company expects to conduct through 2023. AbbVie will then have the exclusive right to exercise an option to enter into a license and collaboration
agreement with the Company for one or both of the programs for $250.0&nbsp;million each. If AbbVie exercises its option for the programs, AbbVie will take over the development of the product candidates for such program and costs will be split
between the parties. The Company will also share in profits and losses upon commercialization of any products from such program. However, following AbbVie&#146;s exercise of its option for a program, the Company may opt out of sharing in development
costs and profits or losses for that program and instead receive tiered royalties. Additionally, under the terms of the agreement, the Company will be eligible to earn up to an additional $242.8&nbsp;million in milestone payments per program related
to the initiation of certain clinical studies and regulatory approval for up to three indications per program. The Company assessed its collaboration agreement with AbbVie in the context of the delivery of the research and development services. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has determined that there are two research and development performance obligations as part of the agreement with AbbVie, one
research and development performance obligation for each of the two research and development programs. The <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront cash payments of $5.0&nbsp;million and $200.0&nbsp;million received in October
2017 and January 2018, respectively, were included in the transaction price. None of the remaining development and regulatory milestone and program <FONT STYLE="white-space:nowrap">opt-in</FONT> payment amounts have been included in the transaction
price, as all these amounts were fully constrained as of December&nbsp;31, 2018. As part of the Company&#146;s evaluation of the constraint, the Company considered numerous factors, including that receipt of the milestone amounts is outside the
control of the Company and contingent upon success in future clinical trials. Any consideration related to royalties on net product sales will be recognized when the related sales occur and therefore have also been excluded from the transaction
price. The Company will <FONT STYLE="white-space:nowrap">re-evaluate</FONT> the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes collaboration revenue by measuring the progress toward complete satisfaction of the performance obligation using an
input measure. In order to recognize revenue over the research and development period, the Company measures actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Revenues are recognized as
the program costs are incurred. The Company will <FONT STYLE="white-space:nowrap">re-evaluate</FONT> the estimate of expected costs to satisfy the performance obligation each reporting period and make adjustments for any significant changes.
Collaboration revenue under the Company&#146;s collaboration agreement with AbbVie during 2018 and 2017 was $27.5&nbsp;million and $2.9&nbsp;million, respectively. All revenue recognized during the year ended December&nbsp;31, 2018, was included in
deferred revenue at the beginning of the period. The Company recorded deferred revenue of $174.6&nbsp;million as of December&nbsp;31, 2018. The deferred revenue is expected to be recognized over the research and development period of the programs
through the completion of Phase 2 clinical trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Grant Revenue </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has grant revenue from the U.S. government. In March 2016, the National Institute on Aging, a division of the National Institute of
Health of the U.S. government, awarded the Company a Small Business Innovation Research grant. The Company recognized $0.2&nbsp;million, $0.9&nbsp;million, and $0.4&nbsp;million for the years ended December&nbsp;31, 2018, 2017, and 2016,
respectively, related to research performed under the grant. The Company recognizes grant revenue as the related research services are performed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Research and development costs are expensed as incurred and consist primarily of new product development. Research and development costs
include salaries and benefits, consultants&#146; fees, process development costs, stock-based compensation, and laboratory supplies, as well as fees paid to third parties </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
that conduct certain research and development activities on the Company&#146;s behalf. In addition, research and development costs include the reimbursable costs incurred for the grant
agreements, which includes payroll costs for time incurred on projects, laboratory supplies, and third-party research and development activities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A substantial portion of the Company&#146;s ongoing research and development activities are conducted by third-party service providers. The
Company records accrued expenses for estimated preclinical study and clinical trial expenses. Estimates are based on the services performed pursuant to contracts with research institutions, contract research organizations in connection with clinical
studies, investigative sites in connection with clinical studies, vendors in connection with preclinical development activities, and contract manufacturing organizations in connection with the production of materials for clinical trials. Further,
the Company accrues expenses related to clinical trials based on the level of patient enrollment and activity according to the related agreement. The Company monitors patient enrollment levels and related activity to the extent reasonably possible
and make judgments and estimates in determining the accrued balance in each reporting period. If the Company underestimates or overestimates the level of services performed or the costs of these services, actual expenses could differ from estimates.
To date, the Company has not experienced significant changes in its estimates of preclinical studies and clinical trial accruals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation for employee awards is measured on the grant date based on the fair value of the award and recognized on a
straight-line basis over the requisite service period. The fair value of options to purchase common stock are measured using the Black-Scholes option-pricing model. The Company accounts for forfeitures as they occur. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company adopted ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07,</FONT> Improvements to Nonemployee Share-Based Payment Accounting
(&#147;ASU <FONT STYLE="white-space:nowrap">2018-07&#148;)</FONT> in June 2018. The new standard simplifies the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees. The Company
early adopted ASU <FONT STYLE="white-space:nowrap">2018-07</FONT> effective July&nbsp;1, 2018. The early adoption of this new standard did not have a material impact on the Company&#146;s consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Loss </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Comprehensive loss includes net loss and certain changes in stockholders&#146; equity that are the result of transactions and economic events
other than those with stockholders. The Company&#146;s only element of other comprehensive loss was net unrealized losses on marketable securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The
Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have&nbsp;been included in the financial
statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the
differences are expected to recover or settle. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The deferred tax assets are recognized to the extent the Company believes that these assets are more likely than not to be realized. A
valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company&#146;s historical operating performance and the recorded cumulative net losses in prior fiscal
periods, the net deferred tax assets have been fully offset by a valuation allowance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company records uncertain tax positions using a <FONT
STYLE="white-space:nowrap">two-step</FONT> process. First, the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
of the position. Second, for those tax positions that meet the <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> recognition threshold, the Company recognizes the largest amount of tax
benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes
interest and penalties related to unrecognized tax benefits on the interest expense line and other expense line, respectively, in the accompanying statements of operations. Accrued interest and penalties are included on the related liability lines
in the balance sheet. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Employee 401(k) Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has a qualified contributory savings plan under Section&nbsp;401(k) of the Internal Revenue Code (the &#147;Code&#148;) covering
substantially all U.S. employees of Alector. The 401(k) plan is designed to provide <FONT STYLE="white-space:nowrap">tax-deferred</FONT> retirement benefits in accordance with the provisions of Section&nbsp;401(k) of the Code. Eligible employees may
defer up to 100% of their eligible compensation up to the annual maximum as determined by the Internal Revenue Service. The Company&#146;s contributions to the plan are discretionary. For the years ended December&nbsp;31, 2018 and 2017, the Company
did not make any contributions to the plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Segments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has one operating segment. The Company&#146;s chief decision maker, its Chief Executive Officer, manages the Company&#146;s
operations on a consolidated basis for purposes of allocating resources. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Offering Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Offering costs, consisting of legal, accounting, printer, and filing fees related to the IPO were deferred and offset against proceeds from the
IPO upon the effectiveness of the offering. As of December&nbsp;31, 2018, $2.7&nbsp;million of deferred offering costs were recorded as other assets in the accompanying consolidated balance sheets. There were no deferred offering costs for the IPO
as of December&nbsp;31, 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT> <I>Leases </I>(&#147;ASU <FONT
STYLE="white-space:nowrap">2016-02&#148;).</FONT> The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed
purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will
be accounted for similar to existing guidance for operating leases. The Company will make an accounting policy election to account for leases with a term of 12 months or less similar to existing guidance for operating leases. The Company will adopt
the new standard effective January&nbsp;1, 2019 on a modified retrospective basis and will not restate comparative periods. Management estimates that the adoption of this standard will result in recognition of approximately $27 &#150;
$32&nbsp;million as a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset for leased facilities and recognition of approximately $44 &#150; $50&nbsp;million as a corresponding liability for the lease
payments remaining on the lease less tenant improvement incentives on the consolidated balance sheets as of March&nbsp;31, 2019. Management does not expect a material change to the consolidated statement of operations and comprehensive loss or cash
flows. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Fair Value Measurements </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize the Company&#146;s financial assets measured at fair value on a recurring basis by level within the fair value
hierarchy: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair</B><br><B>Value</B><br><B>Hierarchy</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized</B><br><B>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair</B><br><B>Market</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(In&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Level&nbsp;1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Level&nbsp;1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash equivalents and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">290,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">290,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair</B><br><B>Value</B><br><B>Hierarchy</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized</B><br><B>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair</B><br><B>Market</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(In&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Level&nbsp;1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash equivalents and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, the remaining maturities of all investments were less than one year. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Balance Sheet Components </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment, Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Property and equipment, net consists of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Construction-in-progress</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, gross</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,901</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Accrued liabilities consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued employee compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued professional services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Commitments and Contingencies </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Operating Lease </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company leases its headquarters with its main offices and laboratory facilities in South San Francisco under a sublease agreement that ends
in April 2019. The Company also has laboratory facilities in Milpitas under an agreement that ends in January 2022. In June 2018, the Company signed a lease agreement to lease approximately 105,000 square feet in new office and laboratory space in
South San Francisco that will be the new headquarters when the current lease ends in April 2019. In connection with the lease, the Company entered into a letter of credit arrangement in the amount of $1.5&nbsp;million as collateral for the lease,
which is classified as restricted cash on the consolidated balance sheets. The lease is over a <FONT STYLE="white-space:nowrap">ten-year</FONT> term with an option to renew for a period of ten years. Rent increases, including the impact of a rent
holiday, were recognized as deferred rent, which is included in other liabilities in the accompanying consolidated balance sheets. Rent expense is recognized on a straight-line basis over the term of the original lease. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following are minimum future rental payments owed under the Company&#146;s operating leases as of December&nbsp;31, 2018: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(In&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023 and thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">74,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Rent expense for the years ended December&nbsp;31, 2018, 2017, and 2016, was $1.1&nbsp;million,
$1.1&nbsp;million, and $0.6&nbsp;million, respectively. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Convertible Preferred Stock </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company issued 9,373,633 shares of Series E convertible preferred stock in April 2018, July 2018, and October 2018 at an issuance price of
$14.2154 per share. The 24,621 shares issued in October 2018 were to a board member, a related party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following tables summarizes the authorized, issued, and outstanding convertible
preferred stock of the Company: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Issued&nbsp;and</B><br><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Issuance</B><br><B>Price&nbsp;per</B><br><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net</B><br><B>Proceeds</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Liquidation</B><br><B>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(In&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Convertible Preferred Stock:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,549,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,549,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,088,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,088,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,363,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,363,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series E</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,848,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,373,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,849,677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,374,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">210,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">211,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Issued&nbsp;and</B><br><B>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Issuance</B><br><B>Price&nbsp;per</B><br><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net</B><br><B>Proceeds</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Liquidation</B><br><B>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(In&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Convertible Preferred Stock:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">A-2</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,549,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,549,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,088,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,088,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,363,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,363,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,001,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,001,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company recorded its convertible preferred stock at the issuance price on the dates of issuance, net of
issuance costs. As of December&nbsp;31, 2018 and 2017, the Company classifies the convertible preferred stock as temporary equity because the shares are contingently redeemable outside the control of the Company. Upon the effectiveness of the IPO,
all shares of convertible preferred stock automatically converted on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-to-1</FONT></FONT> basis into shares of common stock. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Stock-based Compensation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company recognized stock-based compensation as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Determination of Fair Value </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The estimated grant-date fair value of all the Company&#146;s profit interest units and options to purchase common stock was calculated using
the Black-Scholes option pricing model, based on the following assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.1&nbsp;&#150; 6.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6.0&nbsp;&#150;&nbsp;10.0</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6.1&nbsp;&#150;&nbsp;10.0</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">73&nbsp;&#150;&nbsp;81%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">75%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">77%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.5&nbsp;&#150;&nbsp;3.1%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1.9&nbsp;&#150;&nbsp;2.4%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1.2&nbsp;&#150;&nbsp;2.5%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The fair value of each profit interest unit and stock option was determined by the Company using the methods
and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment and estimation by management. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Expected Term &#151;</I> The expected term represents the period that stock-based awards are expected to be outstanding. The Company&#146;s
profit interest units did not have a contractual term. However, there is a constructive maturity of the profit interest units based on the expected exit or liquidity scenarios for the Company. The Company&#146;s historical share option exercise is
limited due to a lack of sufficient data points and did not provide a reasonable basis upon which to estimate an expected term. The expected term was derived by using the simplified method which uses the midpoint between the average vesting term and
the contractual expiration period of the stock-based award. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Expected Volatility &#151;</I> The Company has limited information on the
volatility of profit interest units and stock options as the shares were not actively traded on any public markets prior to February&nbsp;7, 2019. The expected volatility was derived from the historical stock volatilities of comparable peer public
companies within its industry. These companies are considered to be comparable to the Company&#146;s business over a period equivalent to the expected term of the stock-based awards. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Risk-Free Interest Rate &#151;</I> The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for <FONT
STYLE="white-space:nowrap">zero-coupon</FONT> U.S. Treasury notes with maturities approximately equal to the profit interest units&#146; and stock options&#146; expected term. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Expected Dividend Rate &#151;</I> The expected dividend is zero as the Company has not paid nor does it anticipate paying any dividends on
its common stock underlying its stock options in the foreseeable future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Profit Interest Units </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The profit interest units have a &#147;strike price&#148; and are economically similar to a stock option with an exercise price. In the event
of a distribution by the Company, the proceeds distributed to the holder would be reduced by the strike price. Profit interest units generally vest 25% after <FONT STYLE="white-space:nowrap">one-year</FONT> with the remainder vesting quarterly over
the following three-year period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Activity for the profit interest units is shown below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B><br><B>of&nbsp;Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Grant</B><br><B>Date&nbsp;Fair</B><br><B>Value&nbsp;per</B><br><B>Unit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested as of December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,205,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,483,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(363,387</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled/forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,338</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange of unvested profit interest units for restricted common stock upon the
Conversion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,317,338</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As discussed in Note 1, on October&nbsp;12, 2017, the profit interest units were all converted to common stock
upon the Conversion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Units and Restricted Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The restricted units have no strike price and generally vest 25% upfront with the remainder vesting quarterly over a four-year period. The
restricted units converted into restricted common stock upon the Conversion in October 2017. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Activity for the restricted units is shown
below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B><br><B>of&nbsp;Units</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Grant</B><br><B>Date&nbsp;Fair</B><br><B>Value&nbsp;per</B><br><B>Unit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted units as of December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,480,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested prior to conversion from LLC to corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,277,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange of unvested restricted units for restricted common stock upon the Conversion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(202,924</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted units as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Activity for the restricted common stock is shown below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Grant</B><br><B>Date&nbsp;Fair</B><br><B>Value&nbsp;per</B><br><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted common stock as of December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange of unvested profit interest units for restricted common stock upon the
Conversion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,165,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange of unvested restricted units for restricted common stock upon the Conversion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202,924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(170,227</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled/forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(49,234</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted common stock as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,148,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,219,641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled/forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted common stock as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,917,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In the Conversion, the profit interest units and restricted units were cancelled and replaced with replacement
awards. The profit interest units were replaced on a net issuance basis and the restricted units were replaced on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-1</FONT></FONT> basis. Unvested units were replaced with
restricted common stock and vested units were replaced with common stock. The grant date fair value of the replacement awards was determined to be the fair value of the common stock on the date of the Conversion. The Company&#146;s outstanding
common stock, as presented, includes shares which are subject to repurchase. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The fair value of shares vested during the year ended
December&nbsp;31, 2018, 2017, and 2016, was $10.5&nbsp;million, $9.1&nbsp;million, and $4.1&nbsp;million, respectively. As of December&nbsp;31, 2018, total unrecognized stock-based compensation related to unvested restricted common stock issued to
employees was $8.5&nbsp;million, which the Company expects to recognize over a remaining weighted-average period of 2.4 years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2017
Stock Option and Grant Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;13, 2017, the Company adopted the 2017 Stock Option and Grant Plan (&#147;2017
Plan&#148;) under which the Board may issue stock options, restricted stock awards, unrestricted stock awards, and restricted stock units to employees, directors, and consultants. The board of directors has the authority to determine to whom options
or stock will be granted, the number of shares, the term, and the exercise price. If an individual owns stock representing 10% or more of the outstanding shares, the price of each share shall be at least 110% of the fair market value. Options
granted under the 2017 Plan have a term of up to ten years and generally vest over a four-year period with straight-line vesting and a 25% <FONT STYLE="white-space:nowrap">one-year</FONT> cliff. As of December&nbsp;31, 2018, the Company had reserved
8,899,858 shares of common stock for issuance under the 2017 Plan, of which 121,062 shares were available for issuance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Activity for the options to purchase common stock shown below (in thousands, except share
and per share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Exercise</B><br><B>Price&nbsp;Per</B><br><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Remaining</B><br><B>Contractual</B><br><B>Term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Intrinsic</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(In&nbsp;years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,063,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled/forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,396</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,063,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,063,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying
stock options and the fair value of the Company&#146;s common stock for stock options that were <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money.</FONT></FONT> As of December&nbsp;31, 2018, Alector was still not a
public company and the latest board-approved stock price of $10.14 was used to estimate the intrinsic value. The fair value of shares vested during the year ended December&nbsp;31, 2018, was $2.5&nbsp;million. As of December&nbsp;31, 2018, total
unrecognized stock-based compensation related to unvested stock options was $28.9&nbsp;million, which the Company expects to recognize over a remaining weighted-average period of 3.6 years. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Income Taxes </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company was classified as a partnership for U.S. income tax purposes through the Conversion on October&nbsp;12, 2017. The Company incurred
net losses for the years ended December&nbsp;31, 2018 and 2017. The Company has not reflected any benefit of such net operating loss carryforwards in the accompanying financial statements and has established a full valuation allowance against its
deferred tax assets due to the uncertainty surrounding realization of such assets. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">A reconciliation of the federal statutory rate to the
Company&#146;s effective tax rate is as follows for the years ended December&nbsp;31, 2018 and 2017: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax benefit at federal statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,038</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Pre-conversion</FONT> passthrough loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,387</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(351</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal uncertain tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impact of federal rate change</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nondeductible expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change of valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The tax effects of temporary differences that give rise to significant components of the
Company&#146;s deferred tax assets consist of (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued bonus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,286</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,026</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">214</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,124</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(214</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,124</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(214</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In assessing the realization of deferred tax assets, management considers whether it is more likely than not
that some portion or all of the deferred assets will be realized.&nbsp;The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become
deductible. Evaluating the need for a valuation allowance for deferred tax assets often requires judgment and analysis of all the positive and negative evidence available, including cumulative losses in recent years and projected future taxable
income, to determine whether all or some portion of the deferred tax assets will not be realized. As of December&nbsp;31, 2018, the Company has utilized a full valuation allowance to offset the net deferred tax assets as the Company believes it is
not more likely than not that the net deferred tax assets will be fully realizable. The valuation allowance increased on a net basis by $12.3&nbsp;million during the year ended December&nbsp;31, 2018. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, the Company had federal and state net operating loss (&#147;NOL&#148;) carryforwards of approximately
$17.5&nbsp;million and $17.1&nbsp;million, respectively. Federal and state NOL carryforwards will begin to expire in 2037, if not utilized. Due to tax reform, the Company also has federal NOL carryforwards of $42.9&nbsp;million generated after
December&nbsp;31, 2017, which do not expire. As of December&nbsp;31, 2018, the Company also had federal and California tax credit carryforward of approximately $3.3&nbsp;million and $1.1&nbsp;million, respectively. The federal tax credits will begin
to expire in 2036 while the California tax credits have no expiration date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Generally, utilization of the NOL carryforwards and credits
may be subject to an annual limitation due to the ownership change limitations provided by Section&nbsp;382, which provides for limitations on NOL carryforwards and certain <FONT STYLE="white-space:nowrap">built-in</FONT> losses following ownership
changes, and Section&nbsp;383, which provides for special limitations on certain excess credits, etc., of the Code, and similar state provisions. Accordingly, the Company&#146;s ability to utilize NOL carryforwards may be limited as the result of
such an &#147;ownership change.&#148; The carryforwards could be subject to an annual limitation, resulting in a reduction in the gross deferred tax assets before considering the valuation allowance. Further, a portion of the carryforwards may
expire before being applied to reduce future earnings. The Company is not aware of any changes in ownership that would result in material limitations under Section&nbsp;382 at this time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the
&#147;Tax Act&#148;). The Tax Act reduces the federal corporate income tax rate from 35% to 21% effective January&nbsp;1, 2018, which the Company expects will positively impact the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Company&#146;s future effective tax rate and <FONT STYLE="white-space:nowrap">after-tax</FONT> earnings in the United States. The Company has recorded a decrease related to deferred tax assets
and deferred tax liabilities, with an offset by the valuation allowance. As a result, the tax provision impact related to the federal tax rate change is zero. On December&nbsp;22, 2017, Staff Account Bulletin No.&nbsp;118 was issued to allow
companies to record provisional amounts for those impacts, with the requirement that the accounting be completed in a period not to exceed one year from the date of enactment. As a result, as of December&nbsp;31, 2017, the Company performed a
provisional estimate of the effect of the Tax Act in the financial statements. The primary impact of the Tax Act resulted from the <FONT STYLE="white-space:nowrap">re-measurement</FONT> of deferred tax assets and liabilities due to the change in the
corporate tax rate, reducing our deferred tax assets by $2.3&nbsp;million with a corresponding reduction in the valuation allowance. This had no effect on the Company&#146;s effective tax rate. In the fourth quarter of 2018, we completed our
analysis as of December&nbsp;31, 2018, with no material changes from our provisional estimate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the activity
related to the Company&#146;s unrecognized tax benefits for the years ended December&nbsp;31, 2018 and 2017 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance&nbsp;as&nbsp;of&nbsp;December&nbsp;31,&nbsp;2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases related to tax positions taken during the prior year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases related to tax positions taken during the current year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases related to tax positions taken during the current year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">877</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If the unrecognized tax benefits for uncertain tax positions as of December&nbsp;31, 2018, is recognized, there
will be no impact to the effective tax rate as the tax benefit would increase the deferred tax assets, which is currently offset with a full valuation allowance. The Company&#146;s policy is to include interest and penalties related to unrecognized
tax benefits, if any, within the provision for taxes in the consolidated statements of operations. The Company did not accrue any interest or penalties and does not have any tax positions for interest or penalties for the year ended
December&nbsp;31, 2018. The Company does not have any tax positions for which it is reasonably possible that the total amount of gross unrecognized tax benefits will significantly change within 12 months of December&nbsp;31, 2018. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s income tax returns generally remain subject to examination by federal and most state tax authorities. The Company is
currently not subject to any income tax audits by federal or state taxing authorities. The statute of limitations for tax liabilities for all years remains open. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Related Party Transactions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In 2014, the Company entered into a collaboration agreement with Adimab, LLC (&#147;Adimab&#148;), which (as amended, and together with certain
applicable option exercise letters the Company sent to Adimab, the &#147;Adimab Collaboration Agreement&#148;). The Company works with Adimab to discover and optimize antibodies directed against certain targets selected by the Company. Under the
Adimab Collaboration Agreement, the Company is required to fund, and the Company and Adimab are required to use commercially reasonable efforts to conduct certain research to discover and optimize antibodies directed against targets selected by the
Company. The Company is developing antibodies discovered by Adimab in its AL001 and AL101 product candidates, and the Company is developing antibodies optimized by Adimab in its AL002 and AL003 product candidates. The Chief Executive Officer of
Adimab is a <FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Chairperson of the board of directors of Alector. For the years ended December&nbsp;31, 2018, 2017, and 2016, Alector incurred expenses of $2.3&nbsp;million, $0.4&nbsp;million, and
$0.6&nbsp;million for services provided by Adimab, respectively. The year ended December&nbsp;31, 2018, included expenses of $2.3&nbsp;million related to milestones. The Company will owe up to $3.5&nbsp;million in milestone payments per program to
Adimab for its product candidates. The Company will also owe <FONT STYLE="white-space:nowrap">low-</FONT> to <FONT STYLE="white-space:nowrap">mid-</FONT> single-digit royalty payments for commercial sales of such product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Net Loss Per Share </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods
presented due to their anti-dilutive effect: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,374,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,001,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,001,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock subject to future vesting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,917,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,148,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,480,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,063,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Profit interest units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,893,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,356,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,172,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,374,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Selected Quarterly Financial Data (Unaudited) </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following table provides the selected quarterly financial data for 2018 and 2017. The Company believes that the following information
reflects all normal recurring adjustments necessary for a fair statement of the information for the periods presented. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months&nbsp;ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;per&nbsp;share&nbsp;data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19,017</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,815</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,231</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,225</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,373</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,317</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,121</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,437</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.00</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months&nbsp;ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B><br><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;per&nbsp;share&nbsp;data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,807</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,286</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,495</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,778</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,033</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,226</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,443</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Subsequent Events </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;7, 2019, the Company completed an IPO through issuing and selling 9,739,541 shares of common stock at a public offering price
of $19.00 per share, including 489,541 shares sold pursuant to the underwriters&#146; partial exercise of their option to purchase additional shares. The aggregate net proceeds received by the Company from the offering, net of underwriting discounts
and commissions and estimated offering expenses, were $168.2&nbsp;million. Upon the closing of our IPO, all of the outstanding shares of convertible preferred stock automatically converted into shares of common stock. Subsequent to the closing of
our IPO, there were no shares of convertible preferred stock outstanding. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s board of directors adopted, and the
Company&#146;s stockholders approved, the 2019 Equity Incentive Plan (the &#147;2019 Plan&#148;), effective February&nbsp;6, 2019. The 2019 Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock,
restricted stock units, stock appreciation rights, performance units, and performance shares to the Company&#146;s employees, directors, and consultants. The Company has reserved for issuance 7,688,156 shares of common stock pursuant to the 2019
Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s board of directors adopted, and the Company&#146;s stockholders approved,
the 2019 Employee Stock Option Plan (&#147;2019 ESPP&#148;), effective on February&nbsp;6, 2019. The 2019 ESPP will enable eligible employees of the Company to purchase shares of common stock at a discount. The Company has reserved for issuance
1,478,492 shares of common stock pursuant to the 2019 ESPP. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin838337_7"></A>A<SMALL>LECTOR</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(In thousands, except share and per share data) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CURRENT ASSETS:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">86,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">294,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">385,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TOTAL ASSETS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">449,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">308,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS&#146; EQUITY (DEFICIT)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CURRENT LIABILITIES:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued clinical supply costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, long-term portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent, long-term portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,478</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities, long-term portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TOTAL LIABILITIES</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock; $0.0001 par value; zero and 45,849,677 shares authorized as of
September&nbsp;30, 2019 and December&nbsp;31, 2018, respectively; zero and 45,374,836 shares issued and outstanding as of September&nbsp;30, 2019 and December&nbsp;31, 2018, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">STOCKHOLDERS&#146; EQUITY (DEFICIT):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value; 200,000,000 and 65,000,000 shares authorized as of
September&nbsp;30, 2019 and December&nbsp;31, 2018, respectively; 68,922,249 and 13,764,829 shares issued and outstanding as of September&nbsp;30, 2019 and December&nbsp;31, 2018, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">407,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(189,293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(114,435</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TOTAL STOCKHOLDERS&#146; EQUITY (DEFICIT)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(97,398</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS&#146; EQUITY (DEFICIT)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">449,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">308,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these condensed consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin838337_8"></A>A<SMALL>LECTOR</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Consolidated Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(Unaudited) </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(In thousands, except share and per share data) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended<BR>September&nbsp;30, </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>September&nbsp;30, </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,149</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,815</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(82,062</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,271</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,738</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,317</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(74,858</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,875</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gain (loss) on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(215</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(140</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(31,953</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,365</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(74,590</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(35,015</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.47</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.25</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3.13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used in computing net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,572,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,441,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,663,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,154,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these condensed consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>LECTOR</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders&#146; Equity (Deficit) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(Unaudited) </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(In thousands, except share data) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible</B><br><B>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-In</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Other</B><br><B>Comprehensive</B><br><B>Income&nbsp;(Loss)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Equity<BR>(Deficit)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance &#151; December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,374,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">210,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,764,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(114,435</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(97,398</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Conversion of convertible preferred stock into common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45,374,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(210,520</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,374,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common stock upon initial public offering, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,739,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168,223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Forfeiture of restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,039</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Unrealized gain on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance &#151; March&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,871,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">399,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(132,995</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">266,186</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Forfeiture of restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,934</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Unrealized gain on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance &#151; June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,831,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">402,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">245,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Unrealized loss on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(215</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(215</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,738</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,738</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance &#151; September&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,922,249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">407,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(189,293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">218,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these condensed consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>LECTOR</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Consolidated Statement of Convertible Preferred Stock and Stockholders&#146; Equity (Deficit) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(Unaudited) </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(In thousands, except share data) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Convertible</B><br><B>Preferred&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-In</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Other</B><br><B>Comprehensive</B><br><B>Loss</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance &#151; December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,001,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,776,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(62,187</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(52,033</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Forfeiture of restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,324</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Unrealized loss on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,437</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,437</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance &#151; March&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,001,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,764,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70,624</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(59,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series E convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,941,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Unrealized gain on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,121</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,121</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance &#151; June&nbsp;30, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,943,028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,764,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(92</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(81,745</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69,398</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series E convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,407,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Unrealized loss on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,317</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,317</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance &#151; September&nbsp;30, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,350,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">210,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,764,829</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(140</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(97,062</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(82,783</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these condensed consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin838337_9"></A>A<SMALL>LECTOR</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(Unaudited) </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(In thousands) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CASH FLOWS FROM OPERATING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(74,858</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(34,875</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of discount on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,027</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,778</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impairment loss on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from disposal of property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,269</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,638</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(604</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued liabilities and accrued clinical supply costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,218</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">181,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities and other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,771</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70,481</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CASH FLOWS FROM INVESTING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,692</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,467</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(411,239</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(395,117</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maturities of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(78,931</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(266,584</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CASH FLOWS FROM FINANCING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of common stock upon initial public offering, net of issuance
costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(278</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the exercise of options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash, cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and restricted cash at beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents, and restricted cash at end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">88,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">NON-CASH</FONT> INVESTING AND FINANCING
ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment purchases included in accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs for initial public offering included in accounts payable and accrued
liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tenant improvements paid by landlord</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these condensed consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin838337_10"></A>A<SMALL>LECTOR</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Unaudited Interim Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>(Unaudited) </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>The Company and Liquidity </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Alector, Inc. (&#147;Alector&#148; or the &#147;Company&#148;) is a Delaware corporation headquartered in South San Francisco, California.
Alector is a biotechnology company focused on harnessing the immune system to cure neurodegenerative diseases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Initial Public
Offering </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;7, 2019, the Company completed an initial public offering (&#147;IPO&#148;) through issuing and selling
9,739,541 shares of common stock at a public offering price of $19.00 per share, including 489,541 shares sold pursuant to the underwriters&#146; partial exercise of their option to purchase additional shares. The aggregate net proceeds received by
the Company from the offering, net of underwriting discounts and commissions and offering expenses, were $168.2&nbsp;million. Upon the closing of the IPO, all of the outstanding shares of convertible preferred stock automatically converted into
45,374,836 shares of common stock. Subsequent to the closing of the IPO, there were no shares of convertible preferred stock outstanding. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Summary of Significant Accounting Policies </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United
States (&#147;GAAP&#148;) as defined by the Financial Accounting Standards Board (&#147;FASB&#148;). In the opinion of management, these unaudited condensed consolidated financial statements include all normal, recurring adjustments that are
necessary to present fairly the results of the interim periods presented. The condensed consolidated financial statements include the accounts of Alector, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been
eliminated in consolidation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The results of operations for the interim periods are not necessarily indicative of the results of operations
to be expected for the full year. These interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December&nbsp;31, 2018, and the notes thereto, which are included elsewhere in this
prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expense during the reporting
period. The Company evaluates its estimates, including those related to revenue recognition, manufacturing accruals, clinical accruals, fair value of assets and liabilities, income taxes uncertainties, stock-based compensation, and related
assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates<I>.</I> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash
equivalents, and short-term marketable securities. Cash and cash equivalents </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
are deposited in checking and sweep accounts at a financial institution. Such deposits may, at times, exceed federally insured limits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Cash, Cash Equivalents, and Restricted Cash </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash and
cash equivalents. Cash equivalents, which consist of amounts invested in money market funds, are stated at fair value. There are no unrealized gains or losses on the money market funds for the periods presented. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Restricted cash as of September&nbsp;30, 2019 relates to a letter of credit established for a lease entered into in June 2018. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance
sheets that sum to the total of the same amounts shown in the condensed consolidated statements of cash flows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">86,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,472</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash, cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">88,446</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company adopted Accounting Standards Update <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT> <I>Leases </I>on January&nbsp;1,
2019. Upon adoption, the Company recorded a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and a lease liability for all leases with a term of greater than 12 months. The Company adopted the
guidance on a modified retrospective basis and did not restate comparative periods. The Company elected to adopt the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allows
the historical lease classification of existing leases be carried forward. As a result of the adoption, the Company recorded operating <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets of
$31.4&nbsp;million and lease liabilities of $38.9&nbsp;million on January&nbsp;1, 2019. The prior deferred rent balances of $7.5&nbsp;million under legacy guidance, primarily related to a tenant improvement allowance, was derecognized. The lease
liabilities balance increase through September&nbsp;30, 2019 due to additional tenant improvement allowance paid by a landlord. There was no effect on accumulated deficit as a result of the adoption. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company determines whether the arrangement is or contains a lease at the inception of the lease. Leases are recognized on the balance sheet
as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities. Lease liabilities and their corresponding
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets are recorded based on the present value of lease payments over the expected lease term. The Company utilizes the appropriate incremental borrowing
rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset may be required for items such as initial direct costs paid or incentives received and any prepaid or accrued rent. Rent expense for the operating lease is recognized on a straight-line
basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company elected to exclude from its balance sheets recognition of leases having a term of 12 months or less (&#147;short-term leases&#148;)
and elected to not separate lease components and <FONT STYLE="white-space:nowrap">non-lease</FONT> components for its long-term leases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s financial instruments include cash and cash equivalents, accounts payable, and accrued liabilities. The Company&#146;s
financial instruments approximate fair value due to their relatively short maturities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company utilizes valuation techniques that
maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines the fair value of its financial instruments based on assumptions that market participants would use in pricing an asset
or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized
in one of the following levels: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Level</I><I></I><I>&nbsp;1</I> &#151; Inputs are unadjusted, quoted prices in active markets for
identical assets or liabilities at the measurement date; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Level</I><I></I><I>&nbsp;2</I> &#151; Inputs are observable, unadjusted quoted
prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data
for substantially the full term of the related assets or liabilities; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Level</I><I></I><I>&nbsp;3</I> &#151; Unobservable inputs
that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company signed an agreement in October 2017 with AbbVie Biotechnology, Ltd. (&#147;AbbVie&#148;) to
<FONT STYLE="white-space:nowrap">co-develop</FONT> antibodies to two program targets in preclinical development (&#147;AbbVie Agreement&#148;). Under the terms of the AbbVie Agreement, AbbVie made $205.0&nbsp;million in upfront payments, of which
$5.0&nbsp;million and $200.0&nbsp;million was received by the Company in October 2017 and January 2018, respectively. The Company will perform research and development services for the antibodies to the two programs through the end of Phase 2
clinical trials which the Company expects to conduct through 2023. AbbVie will then have the exclusive right to exercise an option to enter into a license and collaboration agreement with the Company for one or both of the programs for
$250.0&nbsp;million each. If AbbVie exercises its option for the programs, AbbVie will take over the development of the product candidates for such program and costs will be split between the parties. The Company will also share in profits and
losses upon commercialization of any products from such program. However, following AbbVie&#146;s exercise of its option for a program, the Company may opt out of sharing in development costs and profits or losses for that program and instead
receive tiered royalties. Additionally, under the terms of the AbbVie Agreement, the Company will be eligible to earn up to an additional $242.8&nbsp;million in milestone payments per program related to the initiation of certain clinical studies and
regulatory approval for up to three indications per program. The Company assessed its collaboration agreement with AbbVie in the context of the delivery of the research and development services. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes collaboration revenue by measuring the progress toward complete satisfaction of the performance obligation using an
input measure. In order to recognize revenue over the research and development period, the Company measures actual costs incurred to date compared to the overall total expected costs to satisfy the performance obligation. Revenues are recognized as
the program costs are incurred. We <FONT STYLE="white-space:nowrap">re-evaluate</FONT> the estimate of expected costs to satisfy the performance obligation each reporting period and make adjustments for any significant changes. Clinical trials are
expensive and can take many years to complete, and the outcome is inherently uncertain. Changes in our forecasted costs are likely to occur over time based upon changes in clinical trial procedures set forth in protocols, changes in estimates of
manufacturing costs, or feedback from regulators on the design or operation of our clinical trials. Collaboration revenue under the Company&#146;s collaboration agreement with AbbVie during the three and nine months ended September&nbsp;30, 2019 was
$2.7&nbsp;million and $15.2&nbsp;million, respectively, the entire amount of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
which was included in deferred revenue at the beginning of the respective periods. The Company recorded deferred revenue of $159.4&nbsp;million as of September&nbsp;30, 2019. The deferred revenue
is expected to be recognized over the research and development period of the programs through the completion of Phase 2 clinical trials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Loss </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Comprehensive loss includes net loss and certain changes in stockholders&#146; equity that are the result of transactions and economic events
other than those with stockholders. The Company&#146;s only element of other comprehensive loss was net unrealized gain (loss) on marketable securities. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Fair Value Measurements </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize the Company&#146;s financial assets measured at fair value on a recurring basis by level within the fair value
hierarchy: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value</B><br><B>Hierarchy</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized</B><br><B>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Market</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(In&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Level&nbsp;1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Level&nbsp;1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">299,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">299,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate bonds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Level&nbsp;2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash equivalents and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">380,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">242</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">381,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value</B><br><B>Hierarchy</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized</B><br><B>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Gains</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Unrealized</B><br><B>Losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Market</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Level&nbsp;1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government treasury securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">Level&nbsp;1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total cash equivalents and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">290,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">290,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Level&nbsp;2 securities are valued using third-party pricing sources. The pricing services
utilize industry standard valuation models for which all significant inputs are observable. There were no transfers between levels of the fair value hierarchy during the three and nine months ended September&nbsp;30, 2019. The Company classifies
marketable securities available to fund current operations as current assets. As of September&nbsp;30, 2019, the remaining contractual maturities of $349.3&nbsp;million investments were less than one year and $31.8&nbsp;million investments were
after one year through two years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Balance Sheet Components </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment, Net </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment, net consists of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,457</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Construction-in-progress</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, gross</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,035</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,901</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Liabilities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued liabilities consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued employee compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued professional services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Leases </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In June 2018, the Company signed a lease agreement to lease approximately 105,000 square feet in new office and laboratory space in South San
Francisco which serves as the new headquarters (the &#147;Headquarters&#148;). The lease is over a <FONT STYLE="white-space:nowrap">ten-year</FONT> term with an option to renew for a period of ten years. The Company occupied the premises and began
to make rent payments on May&nbsp;1, 2019. The lease commencement date was in January 2019, as that is when the Company was given control of the space. The landlord paid for $15.7&nbsp;million of tenant improvements. In connection with the lease,
the Company entered into a letter of credit arrangement in the amount of $1.5&nbsp;million as collateral for the lease, which is classified as restricted cash on the consolidated balance sheets. The Company previously leased approximately 16,000
square feet as its headquarters with its main offices and laboratory facilities in South San Francisco under a sublease agreement that ended in April 2019. The Company also leases approximately 9,000 square feet of laboratory facilities in Milpitas
under an agreement that ends in January 2022 with an option to extend for four years. None of the leases included the options to extend in the calculation of the lease liabilities as such extensions are not reasonably certain to occur. Variable
lease costs for all of the Company&#146;s leases consist of operating expenses for the spaces. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In May 2019, the Company entered into an
agreement to sublease approximately 25,000 square feet of the Headquarters (the &#147;Sublease&#148;). The term of the Sublease commenced in June 2019 and lasts for 30 months. The sublessor has the option to extend the Sublease for one additional
year subject to the consent of the Company. The sublessee is required to pay its proportionate share of operating expenses for the space. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In June 2019, in connection with the Sublease, the Company evaluated the related <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset for impairment. The lease costs plus amortization expense of the leasehold improvements in the subleased space exceeded the sublease income over the
remaining sublease term. As such, the Company recorded an impairment charge of $1.2&nbsp;million in general and administrative expenses to write-down the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
asset such that no ongoing loss is expected to be recognized over the sublease period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The components of lease expense were as follows (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months<BR>Ended<BR>September&nbsp;30,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months<BR>Ended<BR>September&nbsp;30,</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,346</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Variable lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sublease income and reimbursement of variable lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(540</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(723</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Rent expense under legacy leasing guidance for the three and nine months ended September&nbsp;30, 2018 was
$0.2&nbsp;million and $0.8&nbsp;million, respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2019, the weighted-average remaining lease term for
operating leases was 9.5 years and the weighted-average discount rate was 8.8%. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following are the undiscounted cash flows owed under
the Company&#146;s operating leases as of September&nbsp;30, 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(In&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019 (remaining three months)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,376</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total undiscounted lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Present value adjustment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,692</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Stock-based Compensation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company recognized stock-based compensation as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,104</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Activity for the restricted common stock is shown below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average&nbsp;Grant</B><br><B>Date&nbsp;Fair</B><br><B>Value&nbsp;per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted common stock as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,917,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(669,125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56,973</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted common stock as of September&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,191,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2019, total unrecognized stock-based compensation related to unvested restricted
common stock was $5.4&nbsp;million, which the Company expects to recognize over a remaining weighted-average period of 1.7 years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2019 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;6, 2019, the Company adopted the 2019 Equity Incentive Plan (&#147;2019 Plan&#148;) under which the Board may issue incentive
stock options, nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units, and performance shares to the Company&#146;s employees, directors, and consultants. The Company initially reserved for
issuance 7,688,156 shares of common stock pursuant to the 2019 Plan. The Company&#146;s 2017 Stock Option and Grant Plan (&#147;2017 Plan&#148;) was terminated; however, shares subject to awards granted under it will continue to be governed by the
2017 Plan. Shares reserved for issuance but not issued pursuant to, or not subject to, awards granted under the 2017 Plan were added to the available shares in the 2019 Plan. Shares subject to awards granted under the 2017 Plan that are repurchased
by, or forfeited to, the Company will also be reserved for issuance under the 2019 Plan. The board of directors, or a committee appointed by the board of directors, has the authority to determine to whom options or shares will be granted, the number
of shares, the term, and the exercise price. If an individual owns stock representing 10% or more of the outstanding shares, the exercise price of each share shall be at least 110% of the fair market value and the term of the award shall not exceed
than five years. All other options granted under the 2019 Plan must have an exercise price at least equal to the fair market value on the date of grant and have a term not to exceed ten years. The shares generally vest over a four-year period with
straight-line vesting and a 25% <FONT STYLE="white-space:nowrap">one-year</FONT> cliff. As of September&nbsp;30, 2019, the Company had reserved 12,829,863 shares of common stock for issuance under the 2019 Plan, of which 6,911,739 shares were
available for issuance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Activity for the options to purchase common stock shown below (in thousands, except share and per share amounts):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Exercise</B><br><B>Price&nbsp;Per</B><br><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted</B><br><B>Average</B><br><B>Remaining</B><br><B>Contractual</B><br><B>Term</B><br><B>(In&nbsp;years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Intrinsic</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,063,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,133,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100,016</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(178,648</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of September&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,918,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable as of September&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">891,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest as of September&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,918,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">26,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value is calculated as the difference between the exercise price of
the underlying stock options and the fair value of the Company&#146;s common stock for stock options that were <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">in-the-money.</FONT></FONT> As of September&nbsp;30, 2019, total
unrecognized stock-based compensation related to unvested stock options was $34.6&nbsp;million, which the Company expects to recognize over a remaining weighted-average period of 2.8 years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>2019 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">On February&nbsp;6, 2019, the Company adopted the 2019 Employee Stock Option Plan (&#147;2019 ESPP&#148;). The 2019 ESPP will enable eligible
employees of the Company to purchase shares of common stock at a discount. The Company has reserved for issuance 1,478,492 shares of common stock pursuant to the 2019 ESPP. The initial offering period began upon completion of the IPO on
February&nbsp;7, 2019 and will end on the last trading day on or before December&nbsp;1, 2019. Each subsequent offering period will be approximately six months long. ESPP participants will purchase shares of common stock at a price per share equal
to 85% of the lesser of (1)&nbsp;the fair market value per share of the common stock on the first trading day of the offering period or (2)&nbsp;the fair market value of the common stock on the purchase date. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Related Party Transactions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has a collaboration agreement with Adimab, LLC (&#147;Adimab&#148;) under which the Company is developing antibodies discovered by
Adimab in its AL001 and AL101 product candidates, and the Company is developing antibodies optimized by Adimab in its AL002 and AL003 product candidates (&#147;2013 Adimab Agreement&#148;). In August 2019, the Company signed a new collaboration
agreement with Adimab for research and development of additional antibodies (&#147;2019 Adimab Agreement&#148;). The Chief Executive Officer of Adimab is a <FONT STYLE="white-space:nowrap">Co-Founder</FONT> and Chairperson of the board of directors
of Alector. For the three and nine months ended September&nbsp;30, 2019, the Company incurred expenses under the 2013 Adimab Agreement of $2.0&nbsp;million and $2.8&nbsp;million, respectively, the majority of which is related to milestone payments.
For the three and nine months ended September&nbsp;30, 2018, the Company incurred expenses under the 2013 Adimab Agreement of $1.8&nbsp;million, the majority of which is related to milestone payments. The Company had $2.0&nbsp;million and zero in
accrued liabilities due to Adimab as of September&nbsp;30, 2019 and December&nbsp;31, 2018. Under the 2013 Adimab Agreement, the Company will owe up to $3.5&nbsp;million in milestone payments per program to Adimab for its product candidates. The
Company will also owe <FONT STYLE="white-space:nowrap">low-</FONT> to <FONT STYLE="white-space:nowrap">mid-</FONT> single-digit royalty payments for commercial sales of such product candidates. Under the 2019 Adimab Agreement, the Company will owe
certain milestone payments per program for its product candidates and low single-digit royalty payments for commercial sales of such product candidates. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Net Loss Per Share </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods
presented due to their anti-dilutive effect: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;and&nbsp;Nine</B><br><B>Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,350,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted stock subject to future vesting</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,191,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,161,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,918,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,048,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares committed under ESPP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,161,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,559,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g838337g02g68.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g02g68.jpg
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MFW;FWL;Q5/SG=]GY/[7\%V'[W[?_ ,H:=^E+5^9XX@]WZF3A/WOK=/>_;_\
ME#3OTI:OS/'$'N_4R<)^]];I[W[?_P H:=^E+5^9XX@]WZF3A/WOK=/>_;_^
M4-._2EJ_,\<0>[]3)PG[WUNGO?M__*&G?I2U?F>.(/=^IDX3][ZW3WOV_P#Y
M0T[]*6K\SQQ![OU,G"?O?6Z>]^W_ /*&G?I2U?F>.(/=^IDX3][ZW3WOV_\
MY0T[]*6K\SQQ![OU,G"?O?6Z>]^W_P#*&G?I2U?F>.(/=^IDX3][ZW3WOV__
M )0T[]*6K\SQQ![OU,G"?O?6Z>]^W_\ *&G?I2U?F>.(/=^IDX3][ZW3WOV_
M_E#3OTI:OS/'$'N_4R<)^]];I[W[?_RAIWZ4M7YGCB#W?J9.$_>^MT][]O\
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M$PBA;RIG+DSM.HZ_4K;-U4]I?2<4X6B9-_'I**NI&N,FJ[Q-BN@+@K07JIB
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MQ&9QC-T[';%$R1WZ,N@<R^L8%T(%4CXZMKI7 Z)"KRME:D?N:TQS7IW0%*B
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M(F$3")A$PBP[8.PJ1JBDV?9&R;3"TJB4N'=SUIM5A>I1\/"Q+(G?7=O'2P@
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M1YCF+N^5X\ZFL:I.+^D;&[BT31;LWF&W-DPZB\?-7M^H@?R$C6X1UYY"Z_1
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M]75HTV%OF8IX9Y=F^>1_GW6+5CMZ^U9K#U-T'*5S/MRG RT;9]6:9F&3HH"
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MTZ]71>D?NI--VQ.K*1\<[*BF5N9)6H>G<<<,\+M.S3Y8LWU@R[2PY I!D>6
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M8"JU>G&SR$P^46C9NOLFS<S+^:#/OU<0OP1L[[;DY&6IFI=4935%TK5^5QA
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M\>F?TK:=+@+O75E/)@Z18ST>B]]KY%-,ZA6TM%+**Q<NS$XG8RC-VS5Z*('
M-8+M2:A;LTK#<,U6:2&1O4Y1DX\0[\Q+;B!_YPNSMV.MSL=?KY2A4R-4N*O=
MKQ6(G?;=AE%BX#9G?8P=W"0=_-,2%^UE4I[(.XV/N0?9QW^<@(]20M7'FR0>
M^(QNW2$[I> K;64K^P"=\H"8K..HMFGK2[3])%1K+?J7RB:1BW7H+(M0U# !
MEPQ9",Z)._)I)'&2#L]I3QA$S^KK']3NK)Z3\264TI:DB#BGQ<L>2!F;SGCB
M8X[3;^Z-:669V]?5-ZV9><=FPBU23")A$PB81,(F$3"+TU>Q0XV/N,/9QZ"J
ML_'GC;GL*+?[KNC55(R#E"5V@X+.0;)\V. *MI*(H@5"#DVR_P#ED)"+<IJ%
M2,7R*>M^LLB.3U#>EC+BA@(:<+^IQK-P&XOZQ.?KC%_6),ZV\Z/L2>'TIC()
M1<+%D#R%@7;9V.X761B3<V(*W41FS]K$#\N36;7.X5O7M/M=^N,JV@JC2*W.
M6^TS;PPE:0]<K<8ZF9N4=& !$K>/C63EVL( (@FD;H CZ,MN&*2Q-%!"+G+-
M($40-S.20F !;YR(F9OG=7=8GBJP369S&*"O%)/-(78,<40/)(9?,("Y/\S+
MRQNT!YEW;G?RDV-R MRSUM$R\@I!ZUJKI;RB5%U?"N7*=0J[=,ASMTW2;192
M6L*S4"(2=JE9V7*FF+\2%V<P.'AP>,KT(F%R >.S*S;//9-FZZ5_7L[LP1L_
M:,01AN_"M-=3Y^QJ3,V\G.Y,!EU52%W[*].-W:"%FW=F+9WDE=NPYCD/9N+9
M0MSV%;Z81,(F$3")A%9KV3//&<X"<O*1L-U)NR:>O#MAK_>\$0ZJC-[09=\D
MF-F!D7O%6F]?/E4[7#JI$*]619RL DY096&1!6V]4X,,[B9Z["/E<+%/1-^8
MS@V_5\7J"<6>(VY,[B>SE&.UWZ)U+)IG.5[1&[4+)#5R4?:XE6,F;KN%M]Y*
MI.TP.S<3L)Q,[#*6_IZ-739ZV;O&;A!VS=H).FKILJ1=LY;+IE50<-UTC&26
M062.51)5,QB*)F*<AA*(#FMCL[.[.SL[.[.SML[.W8[.S]K.S\V6X#.Q,Q"[
M$),SB3.SL[.V[.SMV.SMVL[=CLN$M_P3M'AV;^S7.&YMWM]J/R?N?[%&OAAZ
MHWWC29^S8/)'S^'BZB'+X^#+'>/?KZY$^(I/[US."Y#W>#(/,N_Q=38R"FF$
M3")A$PB81,(F$49>3NZU-,0%(?-3_P"<3E\@T'Z92@952K1+A.3LQ40'J/E'
M#9-M&]2AU DB80$!  '7SY0W2V?1/A=(7*Q?YQF-:8>&[&+,\IZ;QDX9'4+0
M[[^?/!'6QSNS;L&0)V=G9F?(W1QH\=77LS!(WHZ>#NG 3OL(Y.U&5;&N?^S'
M(4ECM?;>NS>OLD@0[.39$4(+=]'R#4IR#T(NU>,W:0&*/00,FLW<(* /00,1
M1,_I 2CF?J]B&S#!:K2A-!8BCL5YXB8HY890&2*6,Q[" P(3 F?9Q=G98[EC
M.,Y(90<#C(XY8S;8A,7<3 Q?DXNSB3/R=G9UYO?;4]F?.<".1DG:*1!.C<8=
MTS,G/ZHF&J!SQM,EG9U9&<U#)KE*)63RM'.NO4BNCB::I?F2R#I_*0UE+'[&
MZ.U&&=QXQ3&/Y2I@,=H'?8I@'80MBWK&3L:7;\R;B9V$3CXM3.D#2,FF<J<U
M>-_R/D)#EI&+.X5S?<Y*)OMYI1;N\&_\97X78B..;AI=R\%8"81,(F$3")A%
ML"]@IV9,MR^W_%<AMGUY4.-.@K(QF5S234WM?M#:429O*5NB,2KE\A(PL$Y%
MC9+X/=<M18)Q=9=H"%I,NRL/7.I Q- L?6D_[XWXR!N%_.K5CW&2<MNT3-N*
M.#D_%Q2,_H]GR?T:Z0/.Y,,I<B?\D8R49'XQ\R[<C=CBK#OV%'$_#+9_.%Q8
M(29^N=QWY-NWQ/66M;C>3%1.M 0RZ\>BX$00<2[DQ&,,V6[HE.*3B5=,T50(
M('\F<_=$!Z"&H_2AK,.C[0&JM8$T1RX7$S348I]^IGRE@@IXJO*PN)/'/DK%
M6*1@=CZLBX79^U;@Z5PA:CU#B<,SF(7KD83G'MQQU(V>:W(&[.W%'6CE,>)N
M'B9M^Q9=79QG9J_!V..-WH^?AXV:8F$0$1:2C-%\W$1#T"/D5R=>G\>N7/@L
MO5U!A,/GJ+N5+-XO'Y>F[ON[U<E4BN0.[MZ^JF#?YUY5^G+CKUW'SMM/1MV*
M<S-RZVM,<,FWS<8/LN9SU5U$PB81,(F$3")A$PBA/S#_ 'K3GBQ]]9!94C]?
MP\53D]7Q\%-C*:J)A$PBA+RA]:/'?Q4?[Q5#)CR+N\'4"YCW^+*;604U"/M(
M][O>-'!'E+NB(>GC;#4]26!C4I),XIJ1UVN?F]%I$@F8!*(G8VVS0SHA"F*9
M0R0)E.4Q@,'M:=HMDLYC*9CQ1RVHRE'WH(=YYQ_XH8S;?U;[JWM69(L1IO,Y
M "X98*,HP%OMPV)]JU<O^&>:-V;U[;>M>56(B(B(CU$?2(CZ1$1_:(CFSRTP
M3"+LRF:6W'L>*>SVO-3;,OD'&NU(^1F:90[3:(I@_1;(/%F3V1@XI\S:NTFC
MELZ4;+K)K$;.$%S$!)5,QNM-<IUR8+%JM 9,Q"$T\41$+N[,3"9"[L[L[,[-
MMNSMS9=ROC[]L"EJT;EF,"<3DKUII@$F9B<2.,"$2878G9W9V9V?D[+Y*;J7
M:NQG<Y'Z]UGL&]OZRW.[LC*FTRQVAW7VJ9U4CN9QM"1KY:);D4073.L_(W3*
M=%4@F R9P#F:W5KL!6+-> 9'VC*::.)I'['V!S(6)^UOS=^;>U1KT;MLI JT
M[5DX6=Y1KUY9BB9MV=Y!C G!F=G9W)F;L?V+[JAI'<^PHE_/4'46S[Q!Q;YQ
M%R<S4*#:[+$QTFT;-WCN.?R,+$O6;1\U:/&CIPT<+)N$6SINNHF5)=,QN);M
M.N0A/;K0F0L0A+/%&1"[NS$(F8NXN[.S.S;.[.S=K*4&.R%H"EK4;EB,"<#D
M@JSS !BS$0$<8$(D(D).+NSLSL[ML[+$5:E:T8!Q:UJS84JLTG_<FZLJL+))
MP#:T^9J2/N:<3!VP1R,_[7HK/O:91R61\S24<^;>1(8X56EB>1HFEC>5X^M:
M-C'K'BWX>L8-^)X^+S>-FX=^S?=4'@G:)YWAE:$9>H*9XS:(9^%RZEY-N!I>
M%G+JW?CX6=]ME^=CJ]EITLM 6ZNSM5G6R#%TXA;'$OX.60;2;)O)QKA:.DV[
M5XDA(1SMK(,53HE3=LG+=V@91!9-0W,<L<P-)%($H.Y,QQF)@[B3B3,0N[.X
MDSB3;]A,[/VLZXFAFKR/%/%)!*S"[QS1E'(S&+&#N!L),Q 0D+NVQ"[$V[.S
MK@LFJ:WY?8P^]WVQ.$%\TQ+O3NGO'W;LFS@D3*";S&B;,9%N,4U IA$Q>MT)
ML1<HAT3\FLFF0H"F<1P7TDT1KYJ"X [-?J"YOM^=/6+J2?\ _P"/D[>WL6R_
M0_DBM:=LT)"<BQEXQC9W_-K6Q:<!_P#U#6G]FSLS<EL>2L5&SL7)0DRP:2L/
M,,'D5*QC]NFZ82,;(-U&CY@]:K%.BY:/&JRK=RW5(9-9%0Z:A3%,(#CT2("$
MP)Q,"8A(7V(2%]Q)G;M9V=F=G;DZRN8!(!QR")QR"0&!,Q"8$SB0D+]CB3.[
M.S]CL^SKS'.UC[/:S=GKRDL5';L)!QI&_N9.Y:$MBY5EV\A35W@&<5%[('[Y
M5K3KUR[1@)U-10'CQG[2691LU:61BD&R.EL_'G\9',Y"UV!AAO1-LSC,S=DK
M#ZHK#,\@;-LS\<;.[QDM0=;:7FTOF9:[ 3XZT1SXR=]W8H'+=X"+US57)HI&
M=^(AZN;9AE%E6#ERJSTPB81,(F$3"*Y3L5>SDE^>?**&E[?!+J<;])2<1<-P
M2CIN;VKLSILOY[6=4ME#%[CMY<WC3_\ 4"*1B&CZ6UFW)W#60=0B;ZT-9:A#
M!XPPB-ORC=$X:@,_G1L[<,EI]GW%H6?T;_SIG!MG%C<;]Z/M*2:ES$<D\;OB
M<<<<]\R;S)B9^*&D/J(K!#Z5F_,KM(^[&4;%Z31"$3(5-,I2$(4I"$(4"D(0
MH 4I2E*  4I0  *4       Z9KLMLU1;[(GWP^TOV:]VKL.\48S._;]2]*I.
M&Z@D=)PL@,I>;:4H /46DI6:+)UJ0$Q13%K/F1$2J+I#E[=']%KFHH9#;B"C
M!-<=GY<8\,$7Q&2<9!^<-_4L<=*>2+'Z2L11EPR9.S7Q[.S]K1EQV9MMGY'%
M6.(M]VX9';ULO.CS8):K)A$PB81,(F$3")A%Z;W8I[W?<@^S3XS6B;>G?66F
MU>0U!8EEE!7<&<:HFG]+@UG:YA%1P\D*=%UJ5=KK"*RKA^H=4ZB@F5/K=K&B
M-#4>2B!N&.64;<;-V-M: 9C9F]3#*4@LWL%EM[T?9(LII'$32%Q300E1E??=
M]Z4A5XW)W[7(ZX0R$[]KN;]ZLPM_P3M'AV;^S7.6RW-N]OM5Y/R?N?[%&OAA
MZHWWC29^S8/)'S^'BZB'+X^#+'>/?KZY$^(I/[US."Y#W>#(/,N_Q=38R"FF
M$3")A$PB81,(F$52_:+RZBUUUU "<?(QU7DY<J?7T I-2WF1S]/V=3%@4R]?
M]A<^9GR[<I)+J[0F%<GZJAIS(901W[&DR^3\DD+;VN.$C;?YF6T70%4$,/G[
MVWG6,E6J.7M&G5ZYFW^9[Q/\5)KA-MQ*_P"KD*C).@/9]=D;PZJ:A^JSRMB!
MBU]\0!'J<K5!,\,MW>\*8Q[=580%XGWMA/DC=)T>M>CJ'2]^PQ:AT*$&*D R
M]+:P#L382X#/VD-:&,L3*P\3QO2@DE=GMQL^.NF+2Q8/4AY6O%MC<^1VQ(6\
MR+(;L]Z%]N3RF36QWVXNOD$-^I+;N?D%Q\U'RCU+;=([OI["[:\N;+S63BG@
M&2<LW20^4CIR#DD1*\A+##.@(]AYF/51>,7293IG%,RJ:FW="_;QEN*[2E*&
MQ"6XDW)V_G 8\CC-O-,"W8F?9UA+)XNCF:4^/R, V*M@>$P+L<7;M&2,V\Z.
M6,O.CD!V(2;=GYKS_NTH[#/DIPAE;!?]9Q<[OWC,FJY?L[[6XLSZY4&*ZG5*
MRVM5HM$SAB6.1 R:]XA6BU/>)HIO9 U5>/T8%#.^G=:X[-#'!9(*.2V87@D)
MFAG+WJLI;,7%S: W:4=W$>M8>L?635O1SEM.G+:IA)D\1NY#9A!RL5@]0W80
M9W'A;L>Q&SP$S,1]21-$U&^7JL=)A$PB_P! !$0  $1$0   .HB(^@   ](B
M(_L#"+8,[,SL#=_\N):O;/Y&Q5DX_P#&T%6LD/MRQ-$;6V@P[Q%RLJ56Y1N+
MFN0DBW[HC>K,Q3:G:N6[JL1%G(===A86I-=4,4,E;'E'?R/:/F%QU:Q<MYI
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MWB#TR<<LD,@2PR'%*#\021F4<@$W(@,78A=O:SLZIS0PV(C@L11SPRBX20S
M,L4@OS$XS8@,7];$SL_L5 _)WV-IP1W:_D;'J)Y>>,-G?G57,SHCM"U:V,[7
M$3JN#T*UG6>,$P.(>0C:K;JO#-4^\DWC4R"GY*^\;TB9RD(QVF@R48[-Q3L\
M=C9O5U\6S%\Y2Q2F_K)8RS'1-IO(D4M$K&'F+=^&L[35')^;O6G=R'Y@AGAC
M;U JG;?[%,W\R>*DH/+#3]DCP.((.;?2;I27AR=?U1590KC8""1Q#]I22"P
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M+"6W"S;,I7[([3/G/MRSZHN&P.0,].3NDKTQV=K51&LT"#C838T<J@LRO<A
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M+O"L'9P@Q-YO$39U+DRLJC?VK ("2+8U ?N5*J,&1^1!FP?IN8UBR9H56Q=
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M+N\'4"YCW^+*;604U\,G&1\U&R$/+,V\C%2S%W&2<>\2(NT?Q[]!1J]9ND%
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MC[ZR"RI'Z_AXJG)ZOCX*;&4U43")A%"7E#ZT>._BH_WBJ&3'D7=X.H%S'O\
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MN*6E,[O"3OMQ'&[>=!*[=G6!V%V=8$C"S-:&J-%8?546]N-Z]X X8,C786L
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MDE%]EG32?1EB\ <5[(&.5R@.QQD0;4JIMVL]> MWDE!^T;$W:SL)Q10FV[[
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M7]MC*2PN&QVZ[---F)1=.6]SZHZ+Z/2'K[7$DF=?'9#'5<%'3IQQ1RNY38:
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M ##_ /%Y^AKRF?\ 6/\ N'[E\XNHB]QOK^]/T64#^6VO_F'_ .+QY3/^L?\
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M$6$5&M2*.Y!^X;M&R9UE2%'U<-ALEJ#)T\/B:QV[]Z5HH(0]O:YR2$_FQ0Q
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M8T_E[M;9WW[0J7CR.-CVW[&"D+=C;L[=BOK'=,&NJ'"QY*#(QCRCR-*"3?\
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M 1 BDNG;*LM!.+0A9(%>M-&RSQS8$)=@O"H-&Z?E5W*LHDX.R(@DE_E%%3+
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M4BN?I5H9W:G56XQY#)LK578:PM4C& QT$9B/;OR-U!  ZJH OY%7T!T4(8!
M!#IA%D^$4)^8?[UISQ8^^L@LJ1^OX>*IR>KX^"FQE-5$PB810EY0^M'COXJ/
M]XJADQY%W>#J!<Q[_%E-K(*:81,(F$42-S3$NQNBB#*5DF:'M8P/Y%J^=-TN
M\8%>\;R:2I"=XW0.H].H] ZCGJ5  H6<A%WXB[7%G?ZV70L$32=CNWFMR=V]
MJZH]TEB^/YKZ4??X^=GJX_U8?1'[E0XS]XOI/]Z>Z2Q?'\U]*/O\?'5Q_JP^
MB/W)QG[Q?2?[T]TEB^/YKZ4??X^.KC_5A]$?N3C/WB^D_P!Z>Z2Q?'\U]*/O
M\?'5Q_JP^B/W)QG[Q?2?[T]TEB^/YKZ4??X^.KC_ %8?1'[DXS]XOI/]Z>Z2
MQ?'\U]*/O\?'5Q_JP^B/W)QG[Q?2?[T]TEB^/YKZ4??X^.KC_5A]$?N3C/WB
M^D_WI[I+%\?S7TH^_P ?'5Q_JP^B/W)QG[Q?2?[U@.TYZ<<:ZN2#B9EET58%
M\15%:1>*I*$%/TE43.L8ARC_ !*8! ?XAF'OE @#="G2:[ +.VD,ML["S/\
MQ/<KTZ.B+^'6E?.+_75/UO\ K%67GPC7T"3")A$PBG)QCEI5A1YE%C)R#)(U
MK=J&2:/7+9,R@Q$*45#$14(43B4A"B80[PE*4.O0H=/K'\@X!+HEU*Y"+O\
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M?'/_ "0]+/\ YK^D3_U*U+_\L6Z/\,M(?^56F_\ TYC/_BD_0ANG_HAVA_Z
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M953YNJ?@,>C_ !Q)Z3\<*>:\V?C*J?-U3\!CT?XXD])^.%/->;/QE5/FZI^
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-).SOV>Q2!G9NWVK_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g838337g04g97.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g04g97.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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MWG4XL98&.R*3NS7#V] @-&-RP2X$G2KS:2VII)X\573+#%[,9L^(Y?/25/\
M6G'""L9FW,U1IZ=[9OJP8.!8X-BJT'CFZLXO*&V,2I>E;UAHXKH$F2B;VMO4
MM^EKDH<U#T:8! R>Q#%4U7OJDMR\?$]C(U/?BX]AL-?&35WI;E!B6PO@V,^)
M)/F%[MVQD.Y31<\6NX(?5%7N"F&I?9[E+;HH]?7,]+4;Q"FZ52&%0YK)>3%Q
MSX='(3JINE<XM5;:/#%\3QIR<3*T.\4;L"=W"CA%,TISRFB$RZ_E/&T%76U+
M+/99@W31#R?&^JFJ83=EC4?=6].Q-; XN4>>6)K7#=W9[TD2IU4>2I3W-9(U
M4EBW50J)T2VQ4HG7C3KD5!U'V];EK>"%&NTZM.?*3MBV&_DIR)*@$I:D+Q&E
M5C]04W7LV98O,)4UGM#:4],[W(69 \R!L.3-B!U >Y@-]KG&B"&%..CQ7IN+
M).F3XMY$JD?$'ZCH5?U;4\JD[]8EDM5X<@5]0===&3=BZ6F33J_H#9LDD6TL
M]XRK8HFSG9Y!54F=X[5BE-%E<.:H^X/\BG"!F<0Z$)<*BHTDL'5JJ6%/QG@L
M<\:O958U\1XX5W*X5S+9JBAZUC%<3NN&^;7Q-7!SLV;1J!N6NG)MSJZM3H=5
M<:F4MI.-*R(09+HC9-G01_@\C>9 EKTIV*7Q]\?M1Y_[X88>/#C(U%CC5K)9
M5HJ^:3KRU5:;N'Q@.F)O ^U$4.IP-901EJ3Q&F"F;=9#):BL*N+%X\C$S3-<
MLE"Z3,J>"2-1*'6+KEH6"##7.%:N:F,-\F/> .1JLJ2=5**%-U;<+>YJ)XT?
M)3';5[L;M03O[IU-<BZD*S:XK84_MGK2/45'G6^YO) P>%)6_P -RONG7-]:
M44*C&GAO;#GPAW4K8L$3D8\NR]Q-*?V+3N6<SB-543_]NMAM]/JTS\?B;Q=N
M6KQT;^EZ:I'.$<J1YW3DTC2]P7TT%NDZ<%2P5I77-Z<=&JJ9*B82XK&6U@%7
MKR_M3_:*L">3/#DVP!*0F=$Q[RJ$N!)9UJVE1;4JXK'?LJ3-\2?MZ><:VTV2
MF)MZZ3HXCP?V+?0H,XR<YJ@4ED=3S+G=O8RY*S(F@]Q6+BB)HZ$MCRC>T FA
M,J<R-H' 3B U$,88:^&*&'_JUN/B_BL:R=XWZ<NBX[/ZLI.^X/6<4G_-THJ,
ML#C4LBD\@B+Y&+JJQKL^/)##9>SLKOM_BY2Q2QO;D!&D;7LXHIP;VMI*&)+@
MAI84KBJX[,6O#EQ&N5PYVKV>6OXNF%K7=?CW&.EJ:ZQ.E8I[=?/UGQZPI57U
M'3NP(0.NZV@L)1W#02QD<8F8]*)=,W%Y;-$MNF!Q1B^N)(<2\^G#P&;4-(L%
M5-/:LWC6K\&"I155";]?^+U>#'3$(FB.OJ]E=>4/S]X:[]T$.T+,?S>C[<?N
MV817S@%VI\EJBR&+O[A%-2],<XK9"C2:L25H),S-2:-'(M&8(U>/%MTPPPWX
MUQ\-..N'L2SQ:NU2G=[%"Z/Y?.C*X/B5F0=3)YS:I#X4B\-JP -,P72I"UQP
MY -39<;5H6N-,[0X +9W\2J2NKX8VE%10X-1;W_P5HEAKJJV[/'Q%>I_&*L=
MZZ+H6'1NIJ^=*6MB8\YU9)UZ-7:*R802QN@^;2.@B&USG:R&L=2&.T13.34B
M.@$?62V0NL<-U)W1VAZE7I@0AJX8YT;6*V.F6>:>+IQ)T9$"T/&(Z\@L"\/'
MKN=5O#FB*]*5%U;-T%.U=(YL_5XFCB"-\P((#:'2DG70\QZB<7J^12NQYQ*U
MD0;'PA@@JQ TE*WF1GGJ@"=3&*&M6FME&\\%GBUX\\,27@_%ROXOI"<UNAH*
M'2NH:VM=\YWDT[8QSM"XK+$CW/Y5O*+/:'A>E45Z*MW60'I6AJKTF2.ED&01
M:18I2]8@ :WZ&*A6&.+55AA]]3.JW-^+,DFP>(%=$7\*MU\1FZZCK@+^Z4S$
M[SKZJZQF<D6,YL.L2+P=5!R9W+9/'$9[ O\ =N3*W:;'M;4\-41B0 :3KI M
M;%JQ6&KZ?55<Z9;GC3''Q5(+W]W+V].)?%>6T<AIJKK/A_=_%=2VE:G/<LES
MM")Y6_2T#FMF,,8C+K)&!2_Q1S;Q0)R;;&)W[:<%K(NB;BRJ4+?)5Z #S\_/
MG)26+Q?I6U5;5X:-<>.ZF!LJX,!@# & , 8 P!@# & , _D8-& & 7I:",(@
M"V 8RQZT+6];]$PL01@%Y;_>C ((P[\A!%K>M;P"Q*?ESG%)-*SL<BCZO!/Z
M:B22!U5--PUC,E$ AS<@<&MMCT7>S$8W%K;6QM>'I"V$IU =MR5^?R40B /K
MOI8)JZ4JZ/-5P?G1<Q3]W<9<F]*2>(S3H#G.G+CED$  F*2&Q(#'I2ZM"(M;
MMR U 6.J%0:K9 N(AN&F)?M4SZ6F&J_:/LYQI@P4363:Y'0K1?SQ1+H[NS^X
MU#7BUZ?K$@%N/3HIBC.:N=+0JIN9FBM)^N4"2[,42R"-<=86^*O9@A+V1&SM
MR= <26D)" *O>\*I8Y)YKP[=Y:*/^'WP[%"9$GC/)U!,)$N;CV:3DM58Q9$6
M^LA\O9)_[AN8"&X 53&GFL:C\G0,IFMM;8\LS<M;DB4U*5L(5>]\[*%ZT\/:
MHNHXFNCY9,1KMP?K9:+FF[@;1U&6ZSV5-F6'%P%O=K!BEQP"9M;RZM\52M;8
MU2%M,9)(A2L[>UB=U,>$X,B\%$UM>5,VJ*M=C6W8\,<C^:J\,CC.MZSYXKM\
MI6"7 OYD8266M+%MN&Q"4SY&=]<RJ<JW(YT PH4).SYRO62](T(&Y&P,;Z:6
MM8FMN.3)QEB7$\<:5SIS=&9+:;4]5=D.K2^S^O8A,GEBC,\AC,Z2-A;W9<UQ
M*T6YM:+'CB%2L(--3,TX:V9I;Y0WE""F>4C<C(7%G%IRPA&-7O+46)Q3R);:
M:L$=H<TTG8"2EFQN8ZH32ZN8N_$0)@:2V\INCL=*<6X\M#'$@&EJV7'@A$S;
M,;4!HT(C4:<98E1-5HVJYXE>%\]465(02PJHZ^+DQ=I'W<!^!%FD+J"X%,)#
M6JBS K=)M'AFIU?@!##)#H>G(<;"%HV?M%K16!5[WE3/96M.2N--YY;QS!SI
M(:0*YI?*2K%VY\(1M;>33#A#F556Q:%C?4LG9T@(B<D$S!3MDB1(WI"5I)Z"
M9S3$+"M!.+"/0)M.J;3WIX\Y;)!X>W"S571U1M/(G.[16BF9--B*H4T5-#&M
MB53MB2JF]GEZI(@:4^E,B;FQ<O9TKL>(Q86RN#@S:-]RURM(<%76M77?5UYS
MZ+O#]X><PUZ6OY,Y_5$U.!017"8VK8EM)#T*F6+9Z8TLR339I,0QAF[DX2].
MQ#*,9TDE6JGM*A)<CS%(@J\<7CGB\>4]HWB#CP^76G/CN8Z/-FEW,,EB]MR4
M=;Q<3O84?FI99<U:I0KVW>FY))H$D@4Q";^^E1B=.<_B<#B"A@"KPQ>#JL7@
MUDUQE=-?-U LDL;YXT4W7#;-&J7JI^VRE%$F=.^H)NMKE/4*N6)7(I*%42_J
M:M2IJ_.="S-*S(B04Q"-VW@"1H*O>\J>"M:<E<>7$MVKX2XP7N-6.RWEJB%3
ME2*<A)4JP^LXH:= $:1_42Q AC@AMN](D+9*U:J4M*+6AI6F2J3WYM*2NQHU
M8@J\<7CB\7B][WETK'H*DK@4J%EIU3 K"5JX)*ZO5*)?&6I].45S.E3*NF<(
M.,<$QXC(Q*%D;8%3XS"WM$Y'LS::J),&D)V *M9-K%/PK)\JV%41ZMX!$Y-,
M)G&(='&"66"&,@G,C:6E&A>9:&&,_P!;\3#('!.4!2Z:CC'OW)9M*S#=-[?_
M .BIO8ROWN""R<*XFY!KBV);>L#YHI.(W!.RWDJ6V(PUU&6Z4/0)*(0I/M0X
MIV\ RC)2,8S)0:ET0;)#1F&O8UY@QBV)JZ4JZ;JNG,4K#/#MX2KIOLEI@W(W
M/T6:[?8%42LMN9JPBR1%+XBM6@<U</<TH&[V'404N)1*\Z+)0)V Q:G3*A-V
MSTY RPUGAB\,5CD]_+QDOQ-Z : 34-&E,;!H]MXV\P@HQ$- (GVL)&8F&$1)
MB42?>R!D# (H16]EB#L&]ZP01TK+C/DZEV:PH[4W.E.UVQ6PTF1ZR&F(P*/,
MB"91L:5S0AC#XG1(2BU<73I'MY3HHUO06)O*=W,*%O3Z7J_91+;>;;\/CY<,
M7M+CH*3J%K752YMU:PI"XT5&72%TTM2QYM)4U?$GIE98X[QR#' 3Z'&V9R8(
MXPLZUO:]ITRAN9VY(86(E(2 (@L1-?#SX6LAFBT=G_)'/TR88.IF"R&LTDJZ
M*.[9%E-@R11,9R<P(EK::G:1RV6*U<DD'M(LG3H]JE#DKT:K.,-$)UHEE$U6
ME<7C3+FV%6MW%_)+20P)FWFZET2>*J:F61HA/7L:+*8E=#JGY=2ZEJ+TW^BB
M.JU7*9(H@IA&@"C9KZZB;-I_;RCV0*O>]NU[<^?;O*"E?AN<!3I1'5<SXXYR
ME*F(MBAEBQ[[4\/<S8\T*I5(IPI;6<:MK-V@1'S&72B3G)DVRRC'R0.[D(.U
M2]0:8"BB6435<Z-HFO@@8 P!@# & ?X(00!$,8M!"'6Q"$+>@A"$.O/8A;WY
M:UK6M;WO>]ZUK6O/> ?[\/P8 P!@# & , _P0=#"( O/T1!V'?EO>M^0M>6_
M+>MZWK?EOX=;UO7PZWK> 6:)YRY^3RVMY\32%3!G=.14,&J::[KV*#EM:0P"
M(UM!%H+)!M0GF+,!;<H5(2VIE6HT8$BQ<G 2$I:K <)J\JNCQ:KF]YY-O<J\
MR= OD3D]Z\]TM<<C@AGLD-?;.K*'3AWC/FI"L$2RN$D9W%4@2B6@+6C1D&A2
M#6E$JQDB4$E&@!-JM&U7.C:KRE4KZ,I-U=79]<Z>JUQ>WZ;P:S'QX7U_$U;J
M\V16"1I05K8#JX*&DQ6XS:O4+"QHH/*E9QS[$TC,U)V%>@);D8"1%7OXO \U
MX:LM:Q<-\5QC<A%'>1>9644M"J+E VRB:P1CD1*V4,,W4IGL9,7 -T2&S.*Q
M>5[2+=G)@R*-Q]Y 4%P9FU0F$U;S;?A?)T8% =3<$5#TY%C(_OW(JY:X6DAN
M*5.T<IOG>P$=BSQOB@(2C?[,A]Y5#:4,FSXW1I,V(624.;'J7,6F%B);'\AM
M;]MIX*)KFIF\JUPHU3^+/T5AX=7'M:UISS6RVD*^M;?+S,G:J@GUS0>$6#9,
M;6 =39"ND2*5.4:*,:7QUE"A1)U8XXD9&U.^F%K&IM;=(T):4-9XXM5SHZ+D
M)12RKJSGKDUO,YKN"S-X8V.81AD=97$F"1.3/&[#;T;3/H^UKG=O6*F]DG#4
MW-[9+VI(:4@DK>A1HWDA:F3$E@$&+B4=*>#';-145=4U2<V3ZIX7=[/RKSV_
M2GG=8_$P&Y$:!,:QU; (V[5>>_00A"VL[8H0FH61FAR%*@8U);B266T&8,]6
M.K2K5JKQS7'CTD]X#%.:+!5NT]AE60 QWCM[3N0+Y*Y4X5$I$1T#&T"JFYK8
MB)5*8BQO;C-%,<:SX(7:C7[;'*X220A99.\1,Y+LT8U>_93/9G3^&\J=UY[Y
M^>*@+Y\>Z0IYTH0EO;&XJD76MH6MJ(IJ8'='(&="76RMF-AI;>ROR%O>VU,%
MFTF;G9&C<DH"5B<@X )M.J;3WIX\Y;LKA[BA-72FHTG)',2"J'.4-DU5ULWT
M75S= G"9-)0R6F5*(FBC!#"JD:%*8<E2/)J$QQ+1'*$8%'M4\XH8:T5:ZSK2
ME:NM-U=Q8)Z@?A>BM&/54Y<]<\.=F\]3RN83%8^W<L(GPVG9A>PI3;D"*8W!
MEK%<R0QLE;DW2B>K)&B7H8NRRHPUXDSLT29T2&*Q/IL75XIUQI5+!\N="3(^
M1>3E,OLV?F\TT"JG-R,#Q#[AEI]1U^ID=G1F1)P)Y'&K"=S6 Q=+6:1)=$DR
M%JD!RY&^)RDQ;J0K+((T 15X8O#%8O![UN+8-4GX);^MBN<65AHMOZ]88N'I
M=-%VZKV=%.&ML,C:2DM62CF">*%-J:7;@.T5>B FD@9T&L])FP2'4'T7Y!C2
MN-/O<_#2FZN.ZO&?MM6@^!*PC,/MNW*)Y@B<7YMVC-@$TD=1UTG0TM[K2DA4
M@^LQ7];@Q0L*J:/B=T2EL04(=25Q \%A"Y&^V\!.)U2;QSQ>--^\N0Y17FWH
MYZG[;+JN@EHO%=:DE$S0=FTZ!Q"0SS)HA<SET";G.P(D!)*X'*D(X4X2,N+J
MWN$/;FTHD#FH5/4:4(VP,5MW/![5D\-JYT>4IM3EZJ[/GB-6.(5Q9DIEE"PN
M=2)1 7"(J+$FMH%N$*H*-*+!,C+>T69(%1#(IBL?;F^0R)9$$Q:!F<2V$AP:
MTZH*/I\%,^3,_BNN)>,J@>'*0U-R/S)5[^\LSG'7=\KRAJLA;PZ1]Z)VG>6)
MQ<XW%6U:M9G8@6R'-L4GF(EY.]EJB#0;]' ;;S;?*VSU%7(7**V3U=-%?,]!
M*)=1[&Q1BFI*;4, $^53&XL )<6C]=.6V#VW#66+@ '4::X^:WHH_P"6]LY"
M(6][V%7BJNCS57CR[RH]\X\];"6'=$4WL)0+5+*#NL83L)1=ZJBUMW%EAVR>
M0 7&L**5VF .M!L%266?+=.YH CT%7O>S;NRYMFXI(KC7D0B<-EF$\M\[EV*
MQD1!,QSD%,5UJ6,A-?-J1F@@&5_U'/=1I^LYG;VYHC(F]2F&R-3:V-S<).B;
MD1!"BW"KWOG*L][ASSM@BD4W0]-;B\#A4MK:#QO=80G;!#:ZGS:A9IU 8JS[
M8_<Z/0N:,[8VM4LBS0G1L<B;6]$A>$*Q*E(*+"KSJZYUKMWE,M_'G);1-VZR
MVKF+GYLL-GA::N&F;-].U\BE+7 $4<!#D4+;WQ-'RG%%&$</ "))61,H+;D\
M6#J.DIP,^O:6!K1;WG7-Y[^7C+MHJZKYM@"6IV^"PU!5B&)$P%%6J.,,B: (
MX*F:0L">%I8<2A!'4\3(8@ 928X4W 9RFD 6X",*,.B="*NM:XYUVUWEL(+R
M=RY6$98X77'.-%P6(QB>I+4CD9B=3P5A8V&SV\@U(W6,SMC:Q)TC;.VY&<:B
M;Y:D*)?T*(>T:1P)3>16A+;>+;;RJV\MQ('! P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!%KN4.Q
M\3]A #_QA<M=!!#Z_+UBJ:7:UZ_M>O?PX)6#7*B0<0%H<3BX];\]"CK(+6_N
MZ$VIMZWZ_7Z];\_7@@J+ & , 8 P!@# & , 8 P!@# -.Z*^"]V\T0&.5\LC
ML%U$V133=_ 8B9ZQ"&#J1KZMY^9IRN]/9OM0*%FXZI)<M(="1;T]/LI#'B#?
M;Z920:/U4:3KRK+--.G_ /3QRPIGDI#S[PR>H7"4N3S/.;*_ZVKMVLGQ(G*)
M4G+;]%5[/6$WZ9Z@16A1_30)*TCVZ(W)JK4APC;BJ@Z@FVJ[$XZ4PPK3L,TQ
M,(426]?>XI)Y0TB6+VO+8]O%<*PO"IMUV0=,V.?5T3LJ?SGORMK2<J[>;;=B
M4/2/$</@%*%RCG]TDDC7NC8SII7:,3=IDN;9ZG*U-ET*CZ>P'(]N6)#4X:_W
MM,*0M9+"*K=53;C1/"CQ,?'6/-4OY>KJL5/2$ K!;7DA2^(ROH#CF3V_,$$/
MY+>+>7P)_HI96EBL$*?(1*;"J9M:9 @CT%BRQMEC8XSXU+1:-]TV+E"!A\Q*
M=:TK7TM6DJM*J>;Q3;3J]R;2HB9W/OA]=>;9.;+%3PYL9O:3KX-]CKF^6R<M
MA>FYNY<XIG%:W"BE+-L8']N=(_/94RMA[*(G3PO![>4(B1F(3/(0VL5[+QNJ
M+Y>$7P?T_P JWW8%D7#6C!5D;L;FR$Q29,T5EU?.[,]WY&K0E[_(9,4DB(ED
MLDJ!Q8).$,=L2Y)=9-PO3>!61-9:@'[F1MN$1Q)I).J3;5:UHTMN6:=4J+Y*
M*;_#S\0)-V<V>(8>_P!1#FZKNI[F[I2FF,.K%;^2'N-D\U:C0[U_=-'!W1(U
MT$S,=D):U+K9.;NQPB4ZF 7,O2,(:T-*4?WM*UPK76K1);<$ZY;'D1^#X1_0
MT@Y7Z%J*5\F5"IO]UJU4SO\ TD[7^LD#GV5;B;IYEMINGCO"3];BK0K.@K:\
MITD_MQ FLB(.+_\ N>Q@]% %C\I.$ZV*=72N5*:N%,'X<ERNKQ=_;2\.SL4+
M)>-P\XQ"%5;T&FZX>+&YMBZV;LB..QZB;GX8J_DZR(DN5L6SF5J! 7MLW,FI
ME3!+*7K:C81L?H>ZC8;L0HE@GE2CPKBHG$GS8/B;P>!X]R>$5/D+^]MD"IF!
MW%4=93+PAEE5P^9R"(I7&=P;C(^SV7H-J/!* J&IF>YA$I<E2.!C^:F23(#R
M]DJ%*SS.)411<WR!1*F+Q>NZ[JZM.AY<1=;PYJ,=?[(%UX>F=$\BYIXALF]J
M[Y:/1B<1,K18/8DNC%X=(1!"%2G)3!<J(D+*96 ?:BA:0C02YP;PC I+5A"\
MZX;?/_<1/TL.]TK_ /54AV[5Q*O&;!628# & , 8 P!@# & , 8 P!@# & 6
M$Z/O1#0%;*I64Q*)K.'Q<7$:GK5N5%(W>R[*=42]6Q15$J- <!M;BDC:YR29
M20U.>AA4!C\JFSL7MHCJ_>A*5>+>]WGTD"V?O'H6TH%3*^C*BJI]L)XX#J3O
M&XF:<S"51Y@3MUN,RXZ&5%7*EF8W]<%_F#U#[-3)I?)M'-<411=J&M8Y(:_F
M[: I1XY5I6F[/;XO&3J@'4U%SVN:NL@-DPF+(+9K6!6G&F27S",L,B!&;&C+
M9*XZ-:UK74H\LX]L=4WGL 1DC-T/1)A@=:%L&FFT\TZ/E1(7! P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P",';@?2XPZ[#O?
MEZ7,%^A\_N>=4RS7G_WX)6+2WM%]8*/V2$0X>M>7IQ6/#\OA\O2:$8O+S_%Y
MX(*JP!@# & , I:;S:*5M#I18$[?4$8AD+8723RB0NANR6]F8F5&:O<G!4,(
M1CV6F2D&&>QE%F'G"T$H@HTX8"Q!F8NH9XA-QV3$6IMC]&,<)N^T^U)IRO4L
M#LQ^=D2**QB'TTY= N-A7-IC1KG%%(6:JXV_J7R QT>A%3I2RP8N0E%>WI.6
M,J=%7EOIAX:>"KXB55 ]8LDZK^0+[N75Y3UCUW;MFT78#.?.49<06S>KWD"-
M4\05ZE!<><G2-RF-.,9FK6E7MR=W94,E3LSL$Y8@-6*A#XLME?/P$L&5[99(
MUHWN.N[6_,K@7LY [LJ](Z-:XH)@RA&HW!":>D4EA-+,+V,DX8=& &#>_2"+
M6A!ZF , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# (
MW7_RG4?22B).UAEV BE%>MTV;X'*:ZNB[*:>H\"P6]J;I1HU;3%C5XL?DCFG
M8VHI0WORIP2Z3ISTR8"8IQ<=*A*=/#Q)])!J)^&I9%'UY5L3YNZ/11:3LO',
M5XPMJ9VQ")Y<0Y;%(D8[.D=LJNT+U=J%UKJ4PR0S.RUD&@SA)IE6,=89DAA[
M:P(H_#F5*:)<5:U5:Q.+=GGLVX5I0D9?]'UI5O EO5U'(PU'LM3<:3NNX>M=
MVUM<'M)'J^I)VC<:":Z&(PGC5(VYJ2?\.5[#K1P-F% *\]!T(6,2>]KI)U8(
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 1G[
M3#H?'/60-Z]+0N9[W#L/P^>A5;*M;UY?C\_+!,.:Y5TEZ*]WL4 @XM_"*'QG
M>_X=LJ+>_P#OP05A@# & , 8!:FZ:4KGH.OW"K[5:WIXAKD[Q5_4)(]-IQ7C
MR2]PB4-$TBCHW2ZN)'$Y@T+6.4L+.](SVE^1#TK;R/9=F%:$6($Z&/5B\,,%
M6F.TSI6[):BMUIZV6]55A(KGD-U7Q%6(3I4\FI1]K67L=AWB[OLC22>OI_/6
M^0V Q2B(S%X=%D)=7T;X56\>:QC+6WK9JNE%@FFJ47$M^W:ZDN^=^:451P%]
M9[$<X[;-A3^T;%NFRI@9#$S&PN5@68^#='0J)11S=)6IC46CS.G8H=&FY9(G
MYVU'XVV&O3VZNIJQ:<(;KX%1<B/V\E)DZ.I'I(D()2I$O077:9,F3% (3IDY
M'65V%$D$$E!"62226$)91180@+ $( !T'6M:$$F, 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@&*CQ+NR;$Y3W7!$7G=54W&9##[/FSK
M9=NL9CPTRF45R^U6E8*!B"Q9*HE&(Y.+$CTUFLP3.S\J?7 R/5G($\7B#NIT
MZ/$9>?1TX\A*5=C;V)?[/BYR4W&MY/O0-4OTU=WF&S1M:K7M"$0RU:Y0JV^O
MKB@T0E*MKC=C1!.J>9&48W+TH1L3@Y-,A>HV]R&/O3Y%UNHZY-B5,#SVKB>:
M\2Y>0EC@@8!&_LCXH?5/S;[Q^C&48)AS7*NDDA@@8 P!@# & , 8 P!@# &
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M<U24>4F*+0G%GFG)Q!=W & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M_*/-<GRL&*', , SO>%!]B.R_P HQ7]&6?/U@R?+\B!E2S,# & , 8 P!@#
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M\.*MP<5ZA0<(>P;;=7Y_,EL62+<\I?8LD/SB.P/ZVUW8())8 P!@# & , 8
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M5JM\N=(;GWE8[+,ZY+ALLN*)=:GS*4CAI%JO&E'N8_N&6?\ AE])?YK\@?\
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M6E/1)V,Q<:J)4IS2 & .+$("W79'Q0^J?FWWC]&,HP3#FN5=))#! P!@# &
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MT#GJ?5./RE"/YNE6?[<GN5AI?V6A[TD^_FGOGJ;.UU,]T-Y_ 6 UXLZL7^,
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M%\-6Q4,)J*:[J*50MS-LWH<KE&KX594IAU>R*;0*)2*23YI8I,L?!N(6626
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M)Q8A%FE&EB",LP A & 01!%L.];P?F?7 & 1MY2^Q9(?G$=@?UMKNP"26 ,
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M;ZFA^4U:_P A=L_S8[G9]$>RZ[VG_P"0H;JCNUO-]N[JZ;0=$++1/  P!@#
M& 4590=CKF?@UY>8H5*@Z\_@\Q,2_6O/\7GO +1<:"T+D#E,0=^81<VT8+6_
M7KSUNL(OO6_+?KUZM_;]>"8LWROI))8(& , MS<+U&XW4=I2*8D.*J(,-<S=
MZE29G)+4NRB-M<9<USX0UIS?(I0XFMA"HM$29O19JD10!_O1;P%FO/H,#?$D
MGL:&7_1$&^L:^H'5C589]&:)M#Q#)A?\70K';BU=TK7<1;ZK+KI T.XU5?O;
M*>Q.JV3CAL96PZ4M*!T/?6F')'YYLS=&ME:)X)K;3.NSSXM@J5RJ.P:-/LQE
MSND8(Q&6M8]/STO&(M$UM3>2-0L6J1@",824Y(!&#]  A;UKR"$6]ZUL8$.F
M;Q!*.EG/U==$0%ILFP(_<]L2^E:3@\:BZ FR[9GL.G%D0Q<@BS#)'Z/M#6A5
MI*FG,]+=)S(8@C9J^953]+S(TI2KFQ(,M5U:=%1)M[$G3.E=ZRVD@Z+N^'=!
M0$N?0U+(6<M+(Y9"91$YDU!8II!9Y I$XQ.:0F7LQ:I>G0OT=?VM8C/&@<'-
MF=$NDCU'W9X8'-L=5@AJG3RI^?R/$H_E+[%DA^<1V!_6VN[!!)+ +43ZYXA6
MSFC:9$SVPXJER +B2; :&O*UFP"<2@]-HM8]5=74Q9F]?[(G,$)K<%Z9S"G$
M0K$DTE5)CCA-*[O"TNDH&$]9U#8AS(7$$%XN2>0N^F-L=U/+'4++&_=#3L8Q
MG^Z,I?:=;8VR(4#H2>E=79Z=6]I:/:RH]T6I$R8\XL&FMW.OG)*X(& , C=*
M/C?4;\V[JOZ3^-L$['RKHB)(X(& , ^*C_DY_P#>3?Y@L CUQ]\4GEOYNE)?
M1I&< D7@# & 1O1?&\DGS;X3])U@8!)# & :4_U65]D3BC^1=W?[<K;*_P!-
M?PMW]SM'OI1[(ZECL?IGWY<OP%XFH?G1SU@, W</J3O[#G8GY3*M_HM*,L+0
MKU/;N[2?>1GC#JI>S.B7M9>7QJSFRAU[\4WJ#YN]U_1K)L[9;O45L[UM'P,9
MYUT4]=.C7M_<_E&S'(_RD3:R, E!Q#\='D/YT% _2O$\^R[NR%A[\LOP\!UG
M37UFZ6^YF_O)5K.M1EV&JT8!@U\0OJ[EQZZ!J[FV1=,>')6CNU0GH,NQYKU0
MTPJ['FM79YCT!@ZBECX1^[G3:VLA756EBSI5(7>8/X6R1L$/!&"F5:L=$9Z<
M9PPQ--I1-895QSQR=:,GAX?+!5<:YICS53EL\\7="BY+,E)-C<PL9+%6+X[+
MGY2L>O,L%NWDJ<Y2F<#C29,\N=CO+DO7Z])22@T M(6(BK7%-.B^^SW+8MA-
MK!B, C?V1\4/JGYM]X_1C*,$PYKE7220P0, 8 P!@# & , 8 P!@&,^]PQ\^
M3OE>SOJ'M$&F";T--RVB%T;3S]&&U\=K>;9#6A+')VWD-]&[M\$E419'^:%*
M9"\&QV)$I%LU5*4:]7[.,ER+;MXL=NU9;W@L23_.ZT^1-TFDI5TWI:#:EDDB
M@XVRZ:^KBO5#.\PU\6-+DYLK?$:/J!Z<6QZ]B*6-#TM->F)Y8SV]Q9_8_9S3
M-B'R)<E?G9)'! P"/O2%<L\[@"E<+GJINCYI&1EGPB$6VCBH6?2AU<&Q&^&I
M)!*8U*$\?,"TEC7GC3M^AN>VQ,@&,(ADC+$I\;7(1G8^8X29.TK6Y>'!QPR0
M578\T;7.8I&6J5SHFKYGBR!1#YSJ.$U0F.7/<TE(U30..[7%'Q]L;RU;DL%[
M.5L(FK_&>7'G7+FQ\1D:P8C .:!X_'RMW6W^$TI_5SJ'*ETG[.6[^S?$[.;'
M. GM4Z*>QOK_ !#>YAVS@2W!@'35\"#Y)SD'^(+.^G&SLMS1OL)8?8SOC,XU
MO<.';3TL[O=GD2["PGU29\E[-?RN4_\ TB.SYM+.P\SN\CWS.<ZG;MF6+VJO
M?XLCG2Y5AL%& ; WU-#\IJU_D+MG^;'<[/HCV77>T_\ R%#=4=VMYOMW=73:
M#HA9:)X & , 8 P"D+!#H<"FX-^>M#B$E#O>OAUH3,MUOR_'Z\ LKQ6/V3C?
MDLSR\O3YFH<?EY^?EZ56147EY^KS\O/R\_+6"8LWROI),X(& , C]T_T!67-
M5,R^RK0FM70Q 2TO37%"K=L&)UI$IM.S(X]NL;K[ZYYHXMC(4X2H;0J2E)S#
MS#-HREROV Q.C4; )2;=$FWQ)OH,+OA]N'*UFWKSA:<3Z\\*V<V;^YDH1Q*@
M^<Z+;ZUN2,-8ZWE"@V*0E IZ^G3I'55;,[S(4#@O74H;)D]=I)/%?_RNQNJW
MVB,HDU6JCY6W2M<7][MSSSVNAL1X,##G'N8.@:LI_E:7M==:GEE<O]U=A= N
MU0,<NA:!YGM4]&3KLV-I 0Z12=_88$1.6^"=&1:P6UNE<LC+::)G=XDYO3.Y
MK?9"'GRF;:;>-$X88<MJ4/RPDA.;>7GU37]@/U[(I[7,UN+HNY>@5,!KF][$
M@ZN!M]ANC<V1:(2>3T;/8PT2Y_;X5%HVMD^D[G(8PVS%QD2>,.CJWZ ^NHQ;
MW8X)8I;%R<VVE*EY..6I*Q4JL8T)KD>B9KVZR:DA[R\O$C>#DK?U9=*1.:ZR
M&0KG1_?7(PHD USR^.3B[N:K9JUR7*UAYR@P02DP!@$;^2OL#Q?^45H?2O-\
M$O/P0]")(8(& , C=*/C?4;\V[JOZ3^-L$['RKHB)(X(& , ^*C_ ).?_>3?
MY@L CUQ]\4GEOYNE)?1I&< D7@# .;2X?5!WBRD+UQ!73#6$HE8I*+#^X;0
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MU-]GP-]@,P@#0SM,;K9NE3,M7,+"K;H0M>?\,_G,G3'+BI7#Q+9GO,OF#$8
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MRXTM,M%&W!$DEI%=%6Z/#U8=87WY'(?X5/-_Z<:Q_:C+I-6U'N?,S4)^J>;
M@=XSSD%72DVB-P)8[$;A3R!35LD9K 3L2AR>:_,;B'DZ)K7<ML.7EHU9B(I:
M(@:H"52,@)@2#=AZ-I?9;5:9MA=GLT^>H)<]1N3)F35"W%*HHM2&+5K1TK2M
M'3(]8]39?]Q7)8=+8+ZOJZ;HBM%KNB*SPWI>5CL$4^&7)MZF125:YTIS5+<<
M"C<"B4+BA45-95U8#X=+DQ)RE3%I&G3IRC#U"@]C<RB2"2@;,-..-,2A+***
M $0S#!B"   [$+>M:WO.G?:R\OS=;OV2T?1GIOT>:#_IEHI_>*Z/KA]?K'FG
MWH2C_(#M_P"$Q]K+R_-UN_9+1]&/1YH/^F>BG]XKH^N&X7]3&6I6%'U/U<WW
M58\"J!>_V'6ZQB0VC,(]7ZQZ2(HU(R%BII32QQ:3G),D..))4GHP'%$&FEEF
MB ,P.M]ZT0LUHLTBVJT2)TAQ393A4Z5'*<24$2;A4<,+:3P;5:'DCJDKZN:^
M[VT7F7->UV7O+D7=>$$^9=EOLMO@DQQVF1%!!-BLDV;#+BBA3<,,;A<23:32
M9L&]3]9<KOW,/1S&Q]+\_/+V\T-;[2SL[3<M<N+H[.CC7TA1M[:VMZ.2'*US
M@N5G$I4:-*2:H5*#2R""QFC"'?9[9#%%8[7#"G%%%9I\,,,*;BBB<J-))+%M
MO!)8MX(H71F9!(TDT?GSXX),F3?=U39TZ;$I<J5*EV^SQS)DR9&U!!+@@3BC
MCB:AAA3BB:2;.7/]8\T^]"4?Y =O_"93WVLO+\W6[]DM'T9LQ]'F@_Z9Z*?W
MBNCZX?(,.EPS3" 161B/) 48<2%C<Q&E .V9HD9A>DNQE@-V4;HH0@ZT9LLS
MT-[] 7D^UEY?F^W?LEH^C'H[T'_3+13^\5T?7.-$D^.F%\CG7/+$AD+,[,+
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M")<H4KQ:U]WR(TWAUO[?EOTM:^#?I?; H5PMZ?N'I!]V]HBQ?^[;TB1+Z/\
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ME,F?W)P>7U_?7-<XKURLP9A^BPE%%C!NI<K & , 8 P!@# & , 8 P!@# &
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M.GCGYZ/DB\D._P#H(-E-NM:^YYH"DX]Z_NABWO[>]X!$R2]6TVT]'0[E>26
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M.$22+N[5#[ =HN@9K+D"J)P!5/):W115&:L'+I2A71MD1V:ZQ)<J?42MKVF
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MFK[Y'#\Q3?K< >]Z:OOD</S%-^MP![WIJ^^1P_,4WZW 'O>FK[Y'#\Q3?K<
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$6 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g838337g08e71.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g08e71.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( .D"20,!$0 "$0$#$0'_Q  >  $
M P " P$!            !P@)!08#! H" ?_$ $T0  $$ @(!  8&!P0$"@L
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M[%BNZDM%R2:O1 I^C!FXB4Q>0A5(\WA\J>,+ UX4:D'!&2Q>,>[N@R;%PL[
MS8BGBKG53W/Y$Y;3-QQ6,4KY JP)18]3,ACLRE+B"VD^A9"(+W4A."4T6(2
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M<^HIOKZ-N1D_> , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M;35];;KR3Y.^MK66S-BL&1@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P#TR)$>(8.RA9^S%C![=5V_(D72#)@R:(:<J+NG
M;MSNDW;-T4]=MU5EE-$T]..=M]N...>< ]A%9%RBDX;JIKMUTTUD%T5-545D
M5=>-TE4E=.=M%$U--M=TU--N==]>>-M>>>.>.< \F , 8 P!@# & , 8 P!@
M# & , 8!DSY,[;N"I;2\92-9VE*X7'+A\A-.TQ:D1"HQO01.H,=!S22O1Q<D
MXC[B6MM-WD79-%V@>2C!)(:Y>M# TCQNCN@-12:E=;1;7G=+\RF'9F\>TE,>
M10?85]Q#O-775 C8<8KSKF;I:]*9D'6*R)>WBC?6(Q>_J9 P(Q;4-2M6SM"X
MY"2$;"8)E$2L2CSJ.LF[$NHH*DG'3*VE=WS76O+6SLM]/B=;\6?>/L1:5\=8
MH_:,RE%C">SGC#E_;RPQKE1R51#7)&NU<HB2!.#"EE%6\/CI&%GV\*2A<<X&
MQW;8!$546&A1,@])"RBDI6Y3R_)_H7G4\PE8B)'6X&>]._(I43&T+3KNGH_-
M+?ZIEJ]@32:6A*!\1B;0U*#DG29L$79<DAKOZFKEWRCHMLV:.5$^$MAQFN6
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M["V.G&^VR@8/LYYCL2AX< %WMZ^OU]:LI]YAOV-]3/Q+^@'\P<9P0UKP!@#
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MN-%4>5$]P.I_4MVD_?2+_P" 51?Y7 'U+=I/WTB_^ 51?Y7 'U+=I/WTB_\
M@%47^5P!]2W:3]](O_@%47^5P!]2W:3]](O_ (!5%_E< ?4MVD_?2+_X!5%_
ME< ?4MVD_?2+_P" 51?Y7 'U+=I/WTB_^ 51?Y7 'U+=I/WTB_\ @%47^5P!
M]2W:3]](O_@%47^5P#D^J$VL661^W EG2MI.)!5U]6!5[26MXX.BBYP''FL?
M(#'1(,'4V%($$]3:S151@FW161;M]]T?;\K*J@6HP!@# & , 8 P!@# & ,
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MZKN^O[X- ?)7)/S<X ^J[OK^^#0'R5R3\W. /JN[Z_O@T!\EDD_-S_R_[_\
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M 8 P#(OQ,?K#RB?BX=L/X2I7 -=, 8 P!@# & , 8 P!@# & , 8 P!@# &
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M]8>43\7#MA_"5*X!KI@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M[(X*&%PV%4EAL/0PZFTYJA2ITL[5[.62,<S5W9N]KNQ)^>8<XP!@# & , 8
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M:B>VNZ>^FT2I7G7;3?7TZ[:[<?V\;:\\\<\?V\<\_P!^"&O& , 8 P!@# &
M, 8 P!@# & , 8 P!@'5G$YA326,($ZF$6;3HH-6,C(6XD E&6$0[;975P58
M1Q1WJ8=C4-D5M5GS=FHU2V25XW5UY3W]':C@L9+"SQT<)BI8&E4C1J8R-"J\
M+3K2MEI3Q"AW,*DKK+"4U)W5EJCC=6DJBI.I3564<T:3G%5)16\E"^9Q75*Q
MVG.J<@P!@# & , 8 P!@# (^FM2U59+V/$;%K.OI\0B)%(O%'\UAD<E+V,%D
M-]54"D>='1K]<*115UU42>C=VSE/?77?17C;CCG /;WK2N%)PE9N\ A.]DH#
MN Z%A;Q4%M.$1/"2Z' M*6<L.3R8[A!TY1X9:/\ AMPDX73]EZBRG&P7Y<A%
MJTKF#$I&9A, A,.+S!YR1EI6+14%'R4I(<OB9/E_(WPE@T=&WG)(T9(<NB:K
MI?E\6)N^=_;OW2BH&97F&_8WU,_$OZ ?S!QG -:\ 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@&<GDCB'<VU:C<TEU2K*
MCY['+?A5EPVZ25R6K.*NWCX8FRCHR/L(NZ@(<N9*[29J3ES>0H[?#DDA8W1I
MJ2;*E-/6&HVO=MJVJLD^?BT5=\:G2>Z.MMY2N:S'I_TQZE0PI4I2)+-^HUEV
M=)]["DBTMAI0$O8$?F(6/A%/HJ*$R36.GTF;\ZU4D9IEP^;,B;M%X+*2?.3?
M^LDNNUF]S;W!@R=.](NU]E]EKFG5O=D*@,=;+NB$QJ&3U'&*)?,;18T,7A4I
MCL?JT#<1Z=G4 C+F32#6?3LD+A;-S-#_ "\;+:L@[:,CHX-75E:.JUO?\K?F
M560\%XLQ#&*$WMT:1LNK:"Z==>J$EPJ*O6XH(!Z86/S9D:ELR#N3&ZSLM:Y)
M :"F@(2]U9Q<(T<J@C!@@]T79"Y];^,I>LE9KFM.MCO2WAM2'2#ZZ8M8X%EV
M#.WUY ;NF+XF$*.8$ZU\@U<.:SE42&Z-GC<_NWJ,2(K4C&2SKV6TR=0V1-78
MV&:S_A[$ S\N222_NNZ?/>[\K^%G9AEX@^AQNC^MU)W314/OMMUCJ,%44%E=
M@LGOQG<6/;--S9-1$63:M6KF4'$'$@(MD>%$$'CQ1%KMJW3TUP9;NV^K;(/\
M*%<PBH8EY%JOK6-CH=7\"\J/9Z+0Z*B-%-!<?CPB$TDT&"F&BRBRNK5FV3T1
M1U454WXTUXXVWVY_MP0VIP!@# & , 8 P!@# & , 8 P!@# & , R8L#Q;M)
MUY%(OWPYNP\,:A"40D3VLT@/*CI4W"(RPC(P>*EVIY'4=%"Z YN[/B5(^[6<
M<K&F2;KV!SVHS]6P'VG3P/V>XKL-^Q:%65>GC,/#B3Q%HJCC<3/$U:E7"=P^
M\Q5)U)0H55B(*.6A-QS4+5/G:W9]5N-T^,>USCD=.;P_=WO*E25**C5[Q9:<
MDKSCW<FVYK-[_NZSY^4GT0P!@# & , 8 P#![RI=5H_J<&7\&8]_+GM.WIW%
MJMCU+]<^Z2_66NP>HBN9$:4.$'IXP%@T5';C8 1W=D'BCHE(9@=&"FVFZY%M
MHD-Q?)Y4NLHI_E?\2=_$)"I7!*=N4/,ZGORG#*UW*/N8OV+[3QOMY.G;16L:
MX10-,;-C"[QD-C;GENHT8Q!=\[=C'[$H3VV11-(-TA)ZM6:>G*.5;OE9?$UJ
MP9& , R4\PW[&^IGXE_0#^8.,X!K7@# & , 8 P!@# & , 8 P!@# & , 8!
M"'99Y;(_K[<SZB&VKNY&E;RUQ6S?V#=TLI+4@[K83[BT>:[LW935?CC<0T>Z
M*,G135H@\34;**Z;>UV<APJIQ_@\..2R<'GQ'"1XC+-**6$=:*JYY0:G"EET
MJS@U.-+/*#4DCJXYXE8+%/!J^*6'JO#JR=ZJ@W!)/W7+-;*I>ZY64M+F(?A2
MF'D+D5CW.U[/*W<1J1O'M7+9]?#.5H%F5G*'&6J ^'.9FT2*<L-PG)U20"AJ
MOP48LD(WY:M73M+WC]J^V;!]@,/P[@T^S*X+3XK+$.,H<"GA94I\,5">:IC(
MX.;I=XJZH*A5J1[^HI5EFE&#R_*]EJO&YUL4N(^V/#J"RO&1J1DJ^=>[2=6*
MFXY,V>,7DBU"R3>OT5Y_/9]H, 8 P!@# & , 8 P!@# & , 8!FYY!Z\[D.F
ML&O+IG;E(UQ,Z=BEKM)6P[&O[);52YBDO915^_F3A"(S>.0?:0PIO#'/+(C;
M$9E\?#"C1@B*<Q=VB\7+C4;;-.SMM:_I=?Q(!\:G<'LGVIM6>)6)VJ\9W8*M
M8/"2C9\$Z/*VOI.0,^?26+IQLQ,&UHR,ZHO"70%G-6@LM'TT!STMZFNSLA[)
M'W0622MI)-Z^];;T2-H<&!@# & , R+\2_ZP\HGXN';#^$J5P#73 & , 8 P
M!@# & , 8 P!@# & , 8!TF>0 )8HEL&/$IL,:-2"9)->!V/8-8%MW"3=RVU
M2<G:XDT5-.Q_*;I3=04Z(+#%G&C9TJTW<LVBR/=P./K</JRK4*>"J3E3=-QQ
MW#N'\2I*+E&5XT.(X;%485+Q256%.-11<HJ:C.:>*E.-199.:2=_YNK4I/\
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MBB2W0"/7S]%\P&FTU9*W76_AZ&E^#(P!@# & 9%^)?\ 6'E$_%P[8?PE2O\
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M,G.-!U)NC&;WG&EFR*3N[R4;N^YG+',YY8YVK.5EF:Z.6]O"]CF,X30P!@#
M& , 8 P!@# & , 8 P!@# ( [5KZM>M=Z/%)^RJQNQJZ9/WEA$R\DCPN*,&(
M1V[(%"TDACEG,XR)T9(KHE)-#7K&7QU@JX-1=ZS/,1[E(5;KGX?7[_)F*70"
M]9964MID]>MY]/H#U?DT6M_KSU6A/7KL79';1[>4]>6J.LTA*II<1T:ZW=@^
MOT2$G8B*.2MUP4!H3R6$Y^<&*E&R2HW)<K2<MW=9;7Y**ZZ:^&BL?19@XQ@#
M & , R*\2_\ [_Y1/Q<>V/\ "5*_^7]V :ZX P!@# & , 8 P!@# & , 8 P
M!@$8W!<==4+ BMFVK(.8O"0C@6U)F>!1DURV7,DFP@;I\/ #RA1;W@@\;(>L
M@R5U2]I[5;9-'3=37TN$<(XCQW'4N&\+P_M6-K1JRI4>]HT<T:-.56H^\Q%2
ME266G"3]Z:;M97;2.#$XFAA*4J^(GW=*+BI3RRE9R:C'2$92U;2T7F4V^UBZ
M#?\ 7IO_ (9VW_L)GV'^"OMY_H+_ *EPC_[SSOV_PG_._P#D8G_TD'&?)WTB
M<=DZXFB-S[[QL/1UU1@B1^KRTM>6YN23V@BH9G[IM"N'JO#QA%3J_O"+=1JA
M[C[)RLBJY::+^U1^S3MK'LYQ'!RX-;$UN-\%Q-.G^T.%^]1PV X_2K3SK&Y%
MDGBJ$<LI*4L]XQ:C)QZLN.<+]MH5/:O<CA<5!ON<1]Z=7"2BK=S=W4).Z5E;
M5JZO./VL70;_ *]-_P##.V_]A,\7_!7V\_T%_P!2X1_]YVOV_P )_P [_P"1
MB?\ TEKZ+["5%V3B)"=4Q*^9A%A<A=Q5\3Y!R(![$\Q'"BSIC[G)A(=^I[)@
M;&+^\I-=VF_O/LDU]E45TT_E>-\ XMV<Q<,#QG"^QXJIAX8J%+O\/B+T*E2K
M2A//AJU:FKU*-6.5R4UENXI2BWW\+B\/C:;JX:IWE-3=-RR3A::49-6J1A+:
M47>UM=]&31GCG9& , 8 P!@&6WEFKSL+9E%59'NN\([$V67UOH(]L&!]9^S$
M:ZDSH]72-96MHON3N>3\Z-!<9%352$DW8)!3V\B)MA _E/V6V[AL-0M=W:6F
MC:S:Z<M?F>MXFZMN"J*=MD-=%/\ 8VF)&5N9<R,CO9OMA'.X\Y* ]JYKX<B=
M#VM&$M1["*JD!Y$<TAJKEZ[$E1Q@FHLDB;0:MPD[M:IZ<HY>;Y61JE@R, 8!
MDIYAOV-]3/Q+^@'\P<9P#6O & , 8 P!@# & , 8 P!@# & , 8 P"(K]M\3
M0-*VA=1T60-BJQA1Z8NPPOE/5^5U#,E'*0]LJM_H6^SQ?5)OL[6XY19IJ;NE
M==DT=M>?6X#PBMQ[C/#.#4*E.C5XGC:&#A6JW=.DZTU%U))>])0C>62/O3:4
M4TVCKXO$QP>%Q&*G&4XX>C4JN$?O2R1<LJY*]K7>BW>B9EQXQ_+ 5[XV+856
MS*IAU>R.,QA2=Q\C&3)(X%?1U R-"/A9C8BQ;J,S3)P9&*M7J2O#4RBH^YT'
MC-V&NCO]-^TK[*Z78;A_#^)X/BM3B&'Q.)6!Q%/$T:="M3Q,J-2O"K1[NI)3
MH3C1J*4&L]&2A>I552\/G^ =HI<8K5Z%7#1H3I0[Z$J<Y3C*GF4'&6:,;3BY
M1M).TTW[L,NNTF?CA]0, 8 P!@# & , 8 P!@# & , 8!6ON,A"''5B_4[(E
MRD"A&M7RI<_,4H>TL;>/MFHY5R@_^K<@)/,+)TT>I-M%*X? S3*?IJ;Q!T)(
MH&5&:PJW7/7;ZV\^1\UW3&KXUW%NN "JW[/S]:PJ8B/9&=SQZ;\86G5VER2-
M[C*PZQ6&TC0L=)H$V!33FJHXJ)B+592;/.+%CAV=2A1['8\XK$D.27NK9:VM
M[V9JVO+1ZO=\M/$^N7!Q# & , 8!D7XF/UAY1/Q<.V'\)4KC]WU^H-=, 8 P
M!@# & , 8 P!@# & , 8 P#^<\<<\>CGCCGC_DYX]/'_ (X!^?9I_P#-Z?\
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MM(X]P3Y, R;)J)9K<SS\PW[&^IGXE_0#^8.,X!K7@# & , 8 P!@# & , 8
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MR22<VCIX/AN!X?WGL>&IT'5:=1PNW*U[*\G)J,;O+!-15W9(L=GSIWA@# &
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M@GHDB@BEIPFDBBDGQKHDDEIKKHFGIKKIIIKQKKQQQQQQ@&2'B7_6'E$_XO\
MUN';#^$J5_\ /^_ -=, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M# & , 8 P!@# & , 8 P!@# & , 8 P!@# ,E/,-^QOJ9^)?T _F#C. :UX
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MR\G=M]+)?Q\E8U^P9& , 8 P#(OQ+_K#RB?BX=L/X2I7_?\ U?W8!KI@# &
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M0K-01J3(*A2Q_55>.!'4A?.A23=^KJU',B+-OS';E?U*K\S;3(!@# & , 8
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
A8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g838337g14g22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g14g22.jpg
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M_*F2GBTYQ;CQXY<=></'Z4-H6H_8#KJXQF+2%+=IZUIM$%;CB'T(2DD25*4
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M )_&'Q#:L:^.O*?>'J/MQJ38S?:?@#]N+'[6ZN0OMA[="E37[S0C2-2.1)4
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M)2=]U*'TJ^G@//TG[\SUMS$"\B)/GZ8Y1Z?,?MQ_0$CR5*_A7M] \ H5OO\
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MEK5WB+E +8,%)L8F-P+3:2J:[)4NJ8J_PL$:PEXH33K%G2'0 >^W2%1.Q-X
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MVE]H:@M+CA2I1EP@BT:8WG TZF=S&27&>9/9NXY1M.39C;JT-O3BAM0AQT^
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M+359D=92.+0Y4*6&WJ-UE92' @!6E9*2>8'A(WU+R:G;RVAN<:E+>AQ+F$]
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M(TV%-9D19"7K J9?;.[;@#LI;9*5;'9:5 _<=(*O-ZYZF?:75*6AQM25)*4
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M^.:_RTXYNC\4Y?\ HU_81M^KZXRD[=LFO6-(]"DLV;S8:TZTR#0"&?H",;I
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M)W 2 !ZP,8^ZW6]M#U]UK:B6$R,V<KQ1:FV7UMI4X=(=-$J64A0^HI0D?&Y
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M54[2&$-)<*U/+<(;2V$E:ED)"23MTMH67A64:BTXE'M-.HK*%A(3WJ"5:H
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MMY8,Q2KV57(!:#<&/?2/K,3ZX +MDCS&-4X2WF9#;?X'; K<2M"02J( G=8
MW^2!OO\ ;;J:\>*2KAZIA2?YPS%P?Z!\3:=KR?*)QC@X1F[*8\1R_,+@;0\W
M: )GT&-4<-6%6$G8_P#D8^X\GU$;G8?UVWZIMK\Z_/[,3K.TZ:=G_'JZ[:+"
M_H?KB':_.!N@HR5!/_9ASR5A'Q!?W\DC?^G4HX;3-14;_D4["=W$],0C,S#;
M?]LVF/S3UQ1F(6];!$_\0M(,,.&*6_<S8[(7P]P2$EYQ/,@\20G< ;$D;CJ1
MU;+KG=]VVM8&L&$*,%6G?2"!86GSPUH4B#JT@F /$-K_ &>1V.'ZTY9"&7:
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M.)6E>Q0I).R@L CB0KR-NO+%7J5F58I*TJ"*RI6DA06' NLT-A"D$I,I=2H
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M>9V?\$9E8_S1_P 1&PT&;GEOZ##?3#4^T--RH1MZ@ SS^N-JX[+J'FE*04I
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MD -$=(M3Z/5C!;:YP;(ZZMK[M,B9/E5[S4:.S[=])=><*4I0D$@;J)\J V^
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MER5H4%J#$5M;SI2VD%2R&T'9(.ZOX?&_B(H>0\MMELDK<6A" 4Z05*(2)5,
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MIUMO9I(<5R4&ED;I&PV2=]_RW(L)^J;905J"BE)'NZ29-A GD3][8CP22GI
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MH),?DXU#5!Y2-[XJJH[2LB:IW*-QBN#K#"Z=9"&2@K0R[3:I#TE)64JVG3N
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MUS):(<B2[)4R&'4$,MN08[:U%2QL%.H\;GE^;Q69Y25U.]2,H?#E0D-MEQ*
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MU&JQ)Z#\9MTL$VCI)Z8B*<L4DA7?)D$&.[ V(,3)Z;\M\-3!2'$[<M_J._\
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M'I(=<D)<<"0V/J4 22? \=,?%7:G69;Q#FU"C)Z-Q-/5=WWBJAT%<-H,D!!
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MUW3?N)=<6ZK7O @IPDJXZ"2 /)W\?[KY/\OG?;[[DGIO]ESW_=BA_P"AE_\
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1Z F,M0<,)3KJ4.*)68,?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g838337g15f12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g15f12.jpg
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M:.J/'VFIMR-2IBE,4IBE,4IBE,4IBE,4IBE82;5_SS.J/T57O_3BS9BU??\
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M2Z&664$14=2,BY$ 4?2LDY,H\D7Z_59V[645.(=0*7+*QV.V8<M<2S6B,F+
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M5*3U4Y9J) '.NG$V@V2<ZVW%C7IY+L@1DOHM,E48.%P-$J?2"VE"%GY:B<D
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MJN1,&IT2"F+5>=,83]Z(=0-WX=GL_D[(]?Z,SH\@AHNW':< 0,H6%.?G?O\
M5@?*%=#47"I()S?N_+S-VZKX$VOKA.)?0">NFJ<%)K.'$E"DC((L3(+NSE5=
M+/HXJ(,W:SE4A5'"BZ*AUCE*=0QC  ALF+4@K#A?45IR"5E:]:0.0"N8R[,C
MPK%[>1M"FNCHW:R2MO=MZ%%1S45(RTJ)/$D@YGB:_5QM[7[M6%6=T!)TM6S
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M,>&UNF%.J"UEL*41FL)0%99Y9Z0<@-69S)X"H4:2MJBBB1RLHY X)KOE2&4
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ME32TZLBK>#0D K40E)(Z\J[,6*+(O$F;]C8]M9<EOS@ZMDQFF4E2W XV0X%
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MXI]^O-GV34R0.L&2KZ]>2)AE8)6OD24%#Q9Y!PJSZ7+(K. %LVC2LQ?.G/\
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MO2T_.V-R1[8)F4FWB2!&J3J6?NI!PFV(HJJ1N19VJJH5$JJRRA4BF @'54,
-=HYA'G++E7&>?.O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g838337g21u52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g21u52.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!@P)# P$1  (1 0,1 ?_$ .H  0 " P$! 0$! 0
M       ("08'"@4$ P(+ 0$!  $% 0$!              0#!08'" (!"1
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M2F*5JG9.B-'[E9K1VX--:IVM'N$#-7#'9.O*C>6:[8Y2D.W6;6B'E$%4#D*
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M>U;E-DR84<,ARX59G2WI*$^$2#W>_I:]Q4&7>MJ@Q(L^7(C&%.R+&][JS/\
M! ([_P  L2;6-;9RWU<Z8I3%*8I3%*8I3%*I'_$3^^X_N/9>O[;^2_A58O\
M+_SW\>IN>/W\!%]_3<\F/]1_E;D+/_3K^QA_<I4_;O\ #M^WG_?25-S(53J8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I51/FEY/,=
M <.;-2&1VRUXY%)RFJ8!DL":@MZL]8 .QY\S=3H*J+&NNRL"&*/<B]E6RGQ
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M^0^C'_W5V=(HHMT4F[=)-!N@F1%!!$A4D444B@1)))(@%(FFF0H 4H    =
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MS)G.D+0RG2_,\-U8>9B"#Y*Y'W7(GZ9ZCW7&QQK,DT0UMRI/9E/G52"/**I
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MY_I+:N\=$RASF1J&QY-&/1+Z@(-)6(E5F8*MR' 02 T0Z514$.T3&3(!A$2
M =BC*AEQVDA'U7*CAG3R!U#IKY$E8'RUQ$^)/!DK#.;Y6)+-!)Y2C&-]/+)$
MI\U69>*]UL;F;Y']*7G9CYS:5='T!*RSLLZ %EU8W5U29TFAR+M0Y1*,@G/N
M( BZP]RCA5,RQA]50Q\P'KW-@VOHT;;B(L4.L:*.UI97ED;SL"VG   "P%JV
M+[.\')W?KC[TS'::;25V;B%AA2&)?,I5->)))-R;U=UY>_--J7QI59'7]28L
M-O<O+Q&$6U_J%LX,XC*JV?*$0873:YXURG*14$N8QACHUOTDIQ<GII>@W]9Z
MAHC:=FEW)O$?T,13JW?Y%\O>> ]ZNA=YWN':T\-+/F,-%[O*WD[AQ/OU5KX^
M/"'NWF'M-+R'>:.;LFQ]B6MRUGJ5QJMPE;I-HQNX,]KY-LPK5-O&5BHQYEU%
M&% C4&K-%,Y0DN@'=1AKGG[U#B1?=^S +&-"X]_E/:>]C[G8:M.W;%/FR_>6
M]DM(=0A][F'8.Y!IW]HKKYC(R-A8V/AH:/8Q,1$L6D9%148T081L9&L$$VK&
M/CV+5-)JR8LFJ14TDDRE333*!2@   9B9))N=2:S( * JBRBONSY7VF*4Q2F
M*4Q2F*4Q2F*4Q2F*4Q2F*4Q2H*[VYI0=!U-L3:^KVK#8:>@-OL:'O^E.4WT=
M;J[ -[.K4K&\B62RS-1%Z5PY;R,8]52<1S^.(J8H@'>JAE6U=,RY>X0[?G$P
MG+QC)CN+%&;EYU!.NFA5E!#*UO,<,WKJV'!VR?<]N"SC!RA'DQFX=5#\CE1I
MK<AD8@JRW\I6;,1*L)V)C)R*<D>1<S',I6-=I?%-TPD6R3MFY3$?CV+MUBF#
M_<.8Q)&\4C12"TBD@CN(-B*R^*5)HEFB-XW4,#W@BX/X*^EJ[:O40<,W+=VW
M$ZR0+M5DW"(J-UE&[A,%4C'()T'"1DSAUZE.42CT$!#/+*RFS @^7\->E97'
M,A!7O&O#0_@.E?1GRO5,4K3^_M-UOD%IO8>G;4FE]%7JMOHA)ZJW(Z/"S'8#
MFOV-JBH(%.^KDZW;O4.H@ JH% ?@(AEQVC<IMHW*'<L?])$X-N',.#*?(RW4
M^0U:M[VG'WS:9]JR;>'-&5O:_*W%7'E5@&'E%<YWC2YQ/.)%^LW$/DB]- T5
MI=YV!BIJ0/W-=5[#:S"\78(J6<G,7VE*FY9N<RJP!Z3!\)G!P*BX<K)[EZVZ
M67J'$3J+91SY1B5BHXRQD74@=KJ. XLNG$*#H;V?=8OTOFR=+;^>3#$S*K'A
M#*&LP8]D;,-3P5O2.C,1U')*IK)IK(J$515(15)5(Y5$U4U"@8BB9RB)3D.4
M0$! 1 0'-%$$&QXUT:""+C4&O[SY7VN<_P R7.IL9N]XA:JFBKK'4;+[QGXQ
M<>QN"!TG<=K-L[1/VJ+F5*1S- 3X)@5%F8PF%Z@3<OLVZ5:XZBSUL-? 4_@,
MI'O)[K?)-:&]J_6:\IZ6VU[FX.0P/"VHB!]^3NT3Y8'H^!;5!$H3>N\'C816
M?2<%JNONQ+V@DC&MD[9;D2B(?; <JR<*/PZ=HH?9Z_#Q[6-P)EQ-K4Z!6E8>
M<\B?@L_X:]^Q7; (<W>'&K,L*GS#G?\ #>/\%=#^:=K>U,4IBE1&YR7S1.O.
M-FPIOD+ 05PI"\:M&QU)F2)F<7"W.FCH:[!0!P 7C"=6=)BHF^;"5>.234=@
M<A43&#(>EL3=<S>X8MG=X\H-<NOQ$!',S=A6WQ3HQ(76]8OUCF[+@=/SS;ZB
M2X96PC;B[D'E5>T-?4,-5 +7%JI]\7^A[9QDVUIVQ7J$*E?^36MMGSTA'2BK
MALYU7HJH,J].-)>80[B)EM6QKR\A!*1<>D7&LU4UB@Z="1OL;KK=L??-OR8<
M5OJF#/$H(U$L[EE('S(T#\/A,01Z*ZZK]G6RY/3VYXD^:GU[<<>9B#<&''0*
MP9OGRR&/C\!%(/I-9;)]-WG;/)OD[,;FJ%U=PG#W4C:SZWI$7&JK!&\@;V('
MB[9>1],2-96GU672.UC'@F71.NR[FH *KLP85N6+M^Q[&NVY$0;J/(*R.3QQ
MX^*)WAW&K#0V;TN"UL#:<S<^HNHGW;%F*=*XH>*,#ADR<'D[BB-HC:BZ^CQ:
MK%,PVL\IBE,4IBE,4IBE4C_B)_?<?W'LO7]M_)?PJL7^7_GOX]3<\?OX"+[^
MFYY,?ZC_ "MR%G_IU_8P_N4J?MW^';]O/^^DJ;F0JG4Q2F*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2F*5#_GCQ_=<E^+&T]7Q)G(6A6)3M%+2;*BG[ZWU%8L["0ZY3'(
M@HVGUV@L#BIW%2]R"H!WIE$-A>RSJQ.B^N<'>\CE]1$GA3$CX,4HY'<=MXP>
M<6U/+R\":UQ[6>D).N.@<_8L?F]?,?BP@&W--"?$1#V6D(\,WT'-S<5%19\/
MO)%?<W&DNL;.[<*;"X].F=%E$GP'*_7I;@KLU"=K$4[3$&.91[B'$@@!R!%%
M,?YRG4<Y_P!PO1J].=9_?>$H&T;NIG4K\$3"WC@?UF99;\#XI T%8#_MPZV?
MJ;HC[BSV)WG9F$#!OA&$W]7)O\E5:&W$>$"=35LV:$KH6F*4Q2F*4Q2F*56]
MY5.5O_*AQ$O$_!RAX[9>QRGUAK$[93L?LIZQLW02MF;&*(J-S5.MHNWJ*W:8
MA7Y6R9O^]#,(]H'4/^GNFY9HFY<Z?\U%;B&8&[#NY%NP/RN4=M=;?[*?8E_^
M[O;MMNV;E")>D-I(W'< PNCPP.OAX[=C>LY!CB9+@F$S,/@&J!]-\9G\M4N)
M/CRC6S]A<^3<Y!\P.9K]$RC-Y6=*09'!]7:\?.$#>HW5"L$<28M7 )K-)^49
M]0Z'+VZ@VS8GDQ]NZ,0$96>ZYF:>!6!;^%&3V>C=K'42.O?7Z>]?^V#%PM\Z
MY_W4Y;Q2]/\ 1V--TOTHALZ9&[3%1N.<BG1AZP4Q_$0LLN%CY%M5-^O=6HU9
M>J'HCBNPKBE*0'U45J;B-:.*ZK61C_HD8!:(62.Q5AS1G_#BW,04A1^8)>WX
M9T@<;'./ZH40XO)R<A *\MK<MN'+;2W"VE?A"F^[U%O8ZEBR\A.H1E>LC)61
MEG&1S^+XXE!#B7Q/3YP>8-Z5[U05>O'/L'16RG^G];Z\=\A?'CR<M\>TOVFG
M,ZV;V_C/<)1;VK?:^O)R:7%:,"GIF]="03,H=TQ2&/DB*&*V>*:@R^BLS:<X
M[;@PG-Z,SY )(2P#XKG3Q8V;AR<0PO=1R2 ^BQ_3SIO_ '8=+>TKI"+KSJ[=
M8^E?]U71V [86ZK"S8O4&+&.9MMSH8A:3UH^@\#!1',PRL-D!E@257C9X2<E
MN$5LW%K^W[@KU_XQ/51?:?@4EI12R,)MU* X<S3N*>1:;&H^YB1,G(,V;YTU
M=/C%7(!1 YCY!T1TMOG2N1DX>3DI-L)UA77F#$ZL019+CX2JQ!;4=M]*?[N?
M]Q7LA_W%['L'5&P[#E;7[8XUY-TF(C&.\*Q\JQ+(DA?*Y9;&"66&.2.$&)B1
MRJM4O^1;JA-A>M);D9MO3+.Q$G39IR! _P"(?LQ%]%$%3X#U0CV2O0/C_J^Q
MG7GLQS3-LLF&Q]*"8V_JN P_\N:OR4]J^"(-]BS5'HSP"_\ 60E?_IY:CQX+
M.&#/?._)#?MYC2/-=<>W45(PS)VAZC.Q;5?>LYJZ)BJ$%-=K3D6AI98"F Z;
MPK # 9-4X94]HN_-MVVC;<<VRLD$$CBL8^%[K7Y1Y.;M%4_9ITZNZ;H=TR1?
M$Q"" >#2GX/N);F/EY>PUVG9H2NB:\F>G(FL0DM8IY\A&0L''/):5D')^Q!G
M'L$#N73A4W_P4D4Q'H'41^0/CE?%Q9\W)CP\52^3*X55'$LQL /.34?+R\?!
MQ9,W+<1XL2%W8\%51<D^8"O\WSFALR.W+RGWALF&2!..M^Q+%+M$R#W]HOI%
M=PNF4Q3J%5*F[54(0Q3&*8A0$!'KU'K[U=<+'@V]6#KBXT,'-W^#$L9/F)4G
MS5Q8^0V?DY&Y%2C9>5//R]J^-*\@'G 8 ^6NJ'P7\+[#IOC?==U7%"2IFQ^1
M;1NC4'OL(XUAJ6M(YHY&N3[)K.,)%BD]LDS(*29$';5PU<-6<>JHFH0XDS07
MM%WZ/<-S3;\<AL;%OS:Z&0_"&GR0+=X)85T5[,>GI-MVE]RR5*967;EN-5C'
MP3K\HGFL18@*:PWQP^!:&XQ<E=K<Q>86U&?,#D7+;&L<YJ>X6!C(.F5?CWK]
M1PTVE9V%B(L9UNF624#H4AG,?7.T08KN%12<H8ON.^G)QDP\1?!QPH# =OS1
M;XOOGM[JRS;.GUQ<I\W-?QLDL2I/9\XW^-[P[+\1T59C]9+3%*8I3%*8I3%*
M8I3%*8I3%*8I3%*8I3%*8I7,[Y6*],Z[Y.R<WI26<5^U\@]-OJ;M6D2S+Z+K
MVTHQXT6JY9*MOYE)*I6FP-&8M$C,DW!)EA)M&;MJBJ=8QR[NZ!FBS-C6+<U#
MX^'DAXG!NT1!YK,!Z:J3<\UN1E+*Q %JY[]I<$V!U$TVT,4R<[$,<T;"RS C
MDNA;T'8#E'*#XBNJ,H)-QEVB>8_+&X:8UOQMU$M5]:\K]"(,H27U9N6!3@W^
M\=;UN'1:U^.K+BXBQ^BKG#,&*:,K'+J,73UN/O6SQ(I%TTX^Z]-]/XVYS;UN
M(DGZ?RR6$L+<P@D8W8L$O="3=6',%/HLIN"96R]5]396TX^P;68\?J;" 5H9
MUY3D1(ME"&2UI%  =259AZ:N+$#8/&OFM&:PY5_>\N3"5U75^1,\\"\Z3N7N
M6<GQWY0NUV1II>%(]1(HMJK=+V02?M'1.C89!^94?0*DMZL/>^F'SM@]<QBN
M1/AH.29+$9&*+\O-;^UA *D<>5;:W%IW3_5T>W=2^HY:MC8V>Y\3'DN#BYAM
MS<M_['()#*1IS-?T;&]^>:EK=E,4IBE<=WF2U8WUWS1GI]@W*WCMMTRK;$*1
M%,I&Z<KV/*?.%+VE*'N7<C4S/5^HB85'@F'_ % &='>S;/.9TRD+F[X\K1^6
MVCK[@#\H\U<J^U?;5P.K7G06CRHDE\E]4;W24YCY6KY>&?E7W3Q;CHZ@VMB&
MX-/L !".K4Q)GCK/4FYC_%.IVDS60.$8B!A,6->(N&X=H$;G: )S#]ZEZ!VS
M?G;+QSZMN)XL!=7_ *ZW&OS@0>TAJ\])^TK=^G(UPLD>M;4O!&-G0?,>QT^8
MP([%*ZU.;D;YR(.Q:Q>UWC=0[Q5=AV!FK'/+CL!O7$&M,0=(&2<R%6:05@GC
M3<XEWB#19V5HBW4 %3HK=/2'%MF]ELL.<)MZEBDPT-PD?-=[< Q95Y5[P+D\
M+CC68[_[8X9]N,&P0S19[BQ>4):.XU*!6;F;Y);E .I!X5SK/W[Z5?/924>N
MY*3DG;E_(R+]RL\?/WSQ8[AV]>NW!U'#IVZ<*&4444,8YSF$QA$1$<W(B)&@
MCC 5%   %@ .  [ .P5HAW>5S)(2TC$DDFY).I))U))U)-=H7B=HJ-'X+:>-
MZ14W]R-;+U*'(8I@76G+5+(Q:HB0QP P5M@Q(8.O4!((" #\ YH]H&4<KJK)
M^1%R(/\ M07_ /(M76GLRPQA]&8FGIR\\A_[G:W_ (!:L<S#*SZF*55[S0\I
M.E>+:<I3:FLRVWNE#U6@U"$D4QK]3>E,=(QKW86OKIL7+10@]T8W]20,8 *J
M#8ARK!G73/0FY[\5R<@''VPZ\[#TG'ZM3Q!^4;+W<UK5KGJWVC[1TX&Q,4C*
MW<:<BGT4/ZQA>Q'R!=N_E!O7,)L#E+OWD;O2F[,OR_WT[9#VZ$D*7K1:&?RE
M'*JUFF4@SI</0XMP55>'F5VB39T@B<7\@F/15=14?4S>>'L.T;-M4N#B#P,=
MHV#R7 ?52"YD/:+D@GT5[ !I7.N=U)O>_;S%N&:?6<E)5,<7*3'HP(C6,'X+
M$ $#TF'%B=:MYD>&?E(Y5-;CN;:.S:CJJR7?6DAKMCK>0<+P<HIKZ1G(JSN:
M,LQK4+*-J5$S[^';'<&6>K2S@I1;2 %2.L0==IU+T)L#1[;@029$$4XD,@](
M>(%*A[LP+E03:RA!\)-0#6TI.D_:/U*LN[;ED18V1-CF(1$\I\(L',=D4B-6
M*B]V+GX+Z$BLWX:\>.2&O]K4=CK6-Y%Z :ZW=Q;C>6I-T2;Z<XN;!CG$BSB[
M6XTS?(!X]1D;1(L'KJ39-5(9XB@[#[9*D*3M5B]2;QLN9@2OFMAY;3 ^!+"
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MJLCS$:S.F*5S<_Y%UKCT=3:.IQT.^3=W5],H*].@),_HI\@NIW"00$Y%61"
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MMB+A[,]DP]VWEY\U0\>,@<(=06)LI/>%U-NTVOI<'M[*4I2@4H 4I0 I2E
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M#'C8C*_JT'([#7TRQ8K?@>46OW,2#J"!32\>-V#59XZ4!)NW()U#]!'H'4
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MV(>(>-VEMV>+'3=/,X=H,"_2>P?7CI=P1XX4339JQU02DW2:PB4$E4"F$Q
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MI[B&O[ECP-2*RUU=JX]_\A;:+*Q[[U=K5@Z*LI2*A(24HFF<ID^Z9>))1P&
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M L6NQ-RUK@&U2.X2<I;AP+Y)53<;.,&>A#L7=9OE;;.")#::#-KLE)N-9NU
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MBQHH4+@IHIJHD5-[9HF=O3]0I"E%P-PL\S,Q:I^T $QB5]PS2ZB(B()A]CH
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M^F)61(!'LB\<D* =$U5U#)_#X=13[@()O]_3KD?*WG=LY/"S,F:2+Y)<\O\
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M1S-'&S6[RJDV]VU9:_>^X4!-/[6S;AZ+-N4>B:2)/FE$"_\ PS@'4P_*(_\
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MFYX#I\Y"&!]Q>?\ #6I/;%@+D=-Q9P'YW'R5U^;("K#W6Y/P6[:Y./D^(_
M^4<Z!KF6H5[1VI4J/.ND8TRUD!1<ZBY88R1VD:L8PBNU</CF] RA%!'H5+U
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M^H= RG>)?1%01$0 H"/40$1#X9-7.G&+ZF"!#?W==;>:]6H['@-NWWPX)R[
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ML?*[5DT_ QL#Y+V)[!5T:2J2Z2:R*A%D5B$5252.51)5)0H'3434((E.0Y1
M0$!$! <LU7RO[Q2F*4Q2F*4Q2F*4Q2M8[DU@QW'KBR:^>SUBJ:DRBS<1-MJ,
MFYA[-5+%#2#2:KEDA)!HL@JF^A)N/0<%()O36!,4U $AS ,[;<Y]MS4S%1)
MI-T< JZD%65@>QE)'DXC6K=NVW)NV!)@N\D1< JZ$JZ,I#(ZD=JL >XVL=#5
M.\1Y5+AQ=V5-\;N<%$7EK505V46IN+5@M72-LB74>V>P%LE:8_68)IFG(IP@
M[<*LG1#$45.G[!)1,R>;'DZ"QM]PEWKI>4+CS GP9;CD()#('%_@D$ ,.R_.
M0;UJJ+VE973FX/T_UA"6R8"!X\-CSJ0"KM&;?"4AB5/:1R BU:5\LWDTXBWO
MA^K0]:;-;7FV;"M%6<$K<?!V!A-Q$-6Y).P/I"59SL=$#' +Z/0:I@IU]4RQ
MC$[B$,<OGI+8=RZ=W[U[>8S%%%&]O25BY8<H"\I-Q8DDFP%K$W(!^];]3;1U
M/TU]W;%*)III4OZ+J(U0\Y+<RBQN  !<F]P+ D<<^P-M6BWE78-3G@X)0#)C
M'LE3>X>)#U 0D'H FHL4X#\4R@1+I\!*80ZCF6Y;WEYUXT_-XY[ =3_6/;YA
M8>>M>[5L.%@6E?\ .Y0^,> /S1V><W/E'"M".&77K\/E_P!W_M^&8^R5DJM:
MMP<;VA6NST#I$*GZD)+IJ=A0+WD[45.TW0 ZE[TP'I_M#+]TN"-U'[-JQWJP
M\VSF_9(O]-6FZHU9;]V['INJ:%')2EON\TVAH5LX4!!HFL8JCAS(/G(D4%K'
M1+%!5TY5 IA2;HG,!3"'0=D9N]0;1M<N5.2D,:W9AQMW+\YC8#RFU:RV[9,G
M>MVAP<50^1,W*JGA<ZDM\U1<GCH+UU_\/?&)H/BVPBK#,1,?M;<:)47+K8%I
MC47#.#D"@0PDHE>="Z95U-JH4?3>""LF?J817(0P(DYIZCZYW??G:&-CC[<=
M!&IU8?K&%BU^T:+Y+ZUUCTK[.]DZ;19Y57)W4:F5Q<*?U:FX6W8VK_. T%D^
M856P*B3S(XBZ_P"8&II2C6AHS86Z/;NG^N;U[<!DZ?9?2 4#@NF07#BORATR
M(R3,>XBZ'SR@5=)!5/(>F^HLOIS<%RH"3CD@2)V.OY0XJ>P^0D'&.J^E\'JK
M;&P\D!<I03%);5'\_$J>#KVC7X0!'#O>J39-;72UZ_N,<>)M5+L$M6;!'',5
M3VLM"O5F#U--8@BDY;BL@(I*D$4U4Q*<@B4P"/4>)E09N-'F8S<V/*@93WAA
M<>;RCL.E<=YN'D;?ERX.6O+DPNR,.YE-CYQW'@1J*Q3)%1:GIX^=6<>MP;GC
MZ9R-VLZIM6DI>LL*YKAHG9VQ]Q6Z4D%VD17W5BB(UU"UN*9.2ID<*NW#-VX,
M\219J%.959#$^K\_>-NVPY.S8XEG56+2'E/@H!<L%)#,2.  (%B6' '->AMM
MV+==V7$W_),6,S($B'./'<DA5+*"J &URQ5CS (;W([3J;2ZEKNL0U+HM=B*
MG5*\S(PA8""8H1\9'M4Q$W8@V0*4O>JH8QU%#=5%5#&.<QCF,8>9LG)R,R=L
MG*=I,AS=F8W)/G_%W#05UQB8F+@8Z8F'&L6-&+*JBP \P]\\2=3K63Y0J13%
M*8I3%*8I3%*I'_$3^^X_N/9>O[;^2_A58O\ +_SW\>IN>/W\!%]_3<\F/]1_
ME;D+/_3K^QA_<I4_;O\ #M^WG_?25-S(53J8I3%*8I3%*8I3%*8I3%*8I3%*
M8I3%*UUL[46KMU5U"H[<U]4=DUAM*M9UO 72!CK#%(3+%%TV:2B+*20<()OF
M[9^ND50  P)K')U[3F 96)FYF!+X^%*\4Q%KJ2IL;7%QV:#\%1,W PMQB$&?
M%'-"&#<KJ&%Q>QL>W4_A-9)!0%4H=<9P-9A*]3*C7F:B<?"P4;&UVN0<>D*C
ME4C..CT6<9&,TQ,=0P$(0@=1,/V1RE))-D2F25FDF8ZDDLQ/E)N2:K1108L(
MBA5(X$&@4!54>0"P KD@\X?/+5G(>4H''_2LXPNU9UC89.VW2^1*B;NO2EP6
MCE(.*@ZM)IAZ<JS@XYV\.[>(&4:.%G29$3F] YAW3[/^G,S;$DW+/4QRS*%1
M#HP6]R6'820+ Z@ WXUHCVD]3X6[/%M6W,)(87+.XU4O;E"J>T $W(T)(MPJ
M@1N]=-2+)H+J))N2E*NF0YBD6*3N[2JE*( H4HF'H ]0ZYM&')FQ[B)B W'N
M-N_OK4.1A8N6R/D(K/&25) )6_&Q[+V'"O5+&HF(522DA06.4#%;IMS.E$RF
M#J05NBB2:0B'0>P!$P!\O0<S?#Z2&5CKD[SF&"9UNL:QF5@"+@OZ2JE]#R D
MVX\IK!\[K'U3);%V7"$\*-9I&D$2L0?2">B[/;4<Y 6_#F''SGK,&HE,DNFZ
M;J=WIK$ Q!ZEZ=Q%4C_/24#J ]/B A\@CF.[WL<FSRJ5D6?$DOR2*"+VXAE.
MJL+@VU!!NK'6V2;%OT6]1->-X,R.W/&Q!M?@58:.IL1?0@BS*-+YNUL46]00
MCD:NT*Z,4$P](K84CB!?MBASJ( H0! !$>HF'_>.9%TUNF#)D)@';H\B>30*
M>3E.FI)=38 7))O[IK#>H.GMUQEDW1MVFBQ$U)_.<PU%@ C6)O8  +K;0#A9
MWX9^3>O>-G,21#:,DPJ%/VS2I367UA?J^E$5BRN+'7INO.)F0'HDQA7;F$48
MJN#@5!!1TFJJ=)!-0Y=-^U':,C=,>=<* 1SX^4S>"IYK!>9653\8K>XMQL0H
MU K?OLEWG&VC+@;.R#)!DXBIXSCEN6Y'1V'Q0UK&_"X+'0FNX%)5)=)-=!1-
M9%9,BJ*R1RJ)*I*% Z:B:A!$ATSD$! 0$0$!ZAG-Q!!L>-=1 @BXU!K7&V-R
M:KT54'E]W!?:SKRHLC DI,V:218(N'1RF.E'QK<1,]EY1<I#"DT:)+.5>@]A
M#=,E86#F;C.,;!C>68]BB_NGL \IL*B9VX8.V8YRL^5(H!VL;:]P[2?(+GR5
MEM5L\!=JQ7+G59-":J]N@8>SUN9:@J#66@)^/;RL/)M@6326!!_'.TU2=Y2F
M[3AU !^&4)H9,>9X)@5F1BK#N(-B/<(JO!-%DPID0,&AD4,I' JPN#[H-Z][
M*=5:_P ]CR;0C:O\\N2\>T*!$37\LD8I4DT?^(FX"%FW8B1(I2"<SJ0.)C=.
MXYNIC?$1SI[IB4R[#C.>/A_B)']%<G]5Q"'J++C7AXI/X0#_ $U U1(BGP.4
M#!_O^4/^@0Z"&7S4<*QQA7Y%023'N*0 '[ B(B(?]'<(],]J;CRU3(M5X?BE
M\4;3F2UD-U[KD)R T5 38PD+"PABL)O9\TQ+ZDPW;S"G>I#5>&4.DBY<HI'6
M=+'400414144)K[K+K([$PP-O"MN++<DZB,'AIVL=2 = +$@@@'9/0W0B]0*
M=RW(LNV*UE4:&0CCKV*- 2!<FX!!!(OJW7X5.#.R=9.*91-:):<MK!@J2J;"
MJ4O87LNQD03#VYK(VGIB3;VZ-66(4'!'?<Y],3>@N@<>_->;9U_O^'F"?,E.
M1C,?21@HT^80!RD=G9W@UL[=?9QTYFX)@P8AC9:CT)%+'7YX)/,#VW]+N(KB
MOY :,O7&W;MTTUL1F5K9J7++QZKAN"GL)9F!S"PFHI90I!7CI)OT43-\I1ZD
M-T,4P!O_  \N#/Q8\S&/-!*@93Y".WN(X$=ATKG3-P\C;\N3!RARY$3E6'E!
MMIW@\0>T6-73\*O/3M+34-!:WY/5B1W;2HA%I&1VP8A^W:;8AXMN)4B%F"R9
MB0^PC-&A0(F=RO'/SB'<N[7,/7->;_[-\//D;+VAQCY#7)0B\9/DMJFO<&'<
MHK9/3OM0SMNC7#WI#DXRV D!M*!Y;Z2:=Y5N]C73KQEYH<;>7D"K-:*V7$6A
MXQ;I+SM0=@K"7JM J/8 SE2E"MY=NU]<!3(\2(LP7.40174 .N:BW?8=UV.3
MP]QA9%)T8:HWF8:>YH1V@5N?9NHMGW^+Q-LF5V ])#HZ_P!93K;RBZGL)J4N
M6>KW3%*8I3%*8I5=/E?OO)*@<"]]K\1]77C;&_K?7$M;T>&U]$KS=CK?U_=I
M5F>O[2-9@H^77I==?NGK444E^Q^1N94GH J<BO26+#FX5QI7OB!LK13C;7B9
MWUS C([A5Q5X\Z_\EN\85+3=3<WN2FF:U4BMF:UT_<6H%DTIJRWF^)1D*ZDI
M,2?\:@ (*$*X27^5(Y@?3 ](FU7I>/[_ "+*WR8OLO7^1^L=::.I+W2NUN0D
M#?-?;D:[6/KVC:?7?+6VM[XJ#.%9VBF6@*]'*2,>L1OUEB*H(MV7J+!T52:*
MPTU-ZO[X_<G^/'*NEI;"XX[EU[N6I&38F=R5$LD?,N(->1;B[:1EIATE2S=1
MG#MRB8T?*-F;Y+M$#I%$! /M4R"NAKP^2_#[C'S%IAJ#R9TI0]OU\B3I.,4M
M$.F:PUE1Z0J;E[3;@P,RMM+DUB$ IG44]9N#%^:)Q*(@,C&R\G#?Q,9V1O)P
M/G' ^Z*B96%BYJ>'E1JZ^4:CS'B/<-4O+^,CR%>/D5[#XG^7C[8>IHTB3@G!
M?F<]5NE#]LU.5=6$U?LI):+=4Q-W\4F[1/Z!* ?.=RJP_$MY^\MOS_1W6'EE
M/]K'H?.P[??\@JR?=>X[=Z6T3<T(_LI=1YE;L\VGE-;2U#YU=6UN^,]!^2/2
MNQ?&_P @3G09-R;>;N)S0UT7 2-EI:E;OB(\M=+ *.B*G%\^*E"-R "995PH
M!LI3;)*R>/MSKD8_S=&'G7C?R#7R"JT._P 2R>K[G&V-D?.U0^4,-+>4Z>4U
M>7 S\%:8:,L=8FHFQUZ:9HR,//0,BSEX:6CW) 4;OHR4CUG#%^S7(/4BJ1SD
M,'Q 1RR,K*2K AAV&KZK*ZAD(*G@1J*];/E>J8I3%*8I3%*@YN/CG:]B725O
M>V>6VTJ)J.';O$8'6>F9AWH^';1[M(J"_P!\"Y,+#,SM_?.@* @ !')$4'L0
M1(4RA5<EPM^P]MPA#B8&,^:;%I9P)C<?_C0JJQC_ -Q/:2;6Q+<.FL_=]P,^
M9N65'@"X2#&)@%CQ\1PS-*3_ -@'8 +WY6O+!7>/.I)F'>:"O6S)^^VJ7<FM
M*FS[,A<)&2ABLUQ)9XX[V.0L[ J+I)!HFK+K+G>$,/IIIBW4.?8G2_6&][A"
M^.\,$>(BV5XTY+&_P0M^3A<Z 6[>(MJSK7H?I_:9H\J/(R),^5[M'))SDK8^
MF6L'&ME](GF[#Z)O4)I;1]NY%;(:U*+=+)BN563LUH>I+R",%#H"4'$@Z#U4
MS.EU5#D1;HBHGZRQRE[B$[CE^[UN:;=C-FY)+R$V OJS'LN?PD]@'N5'Z>V:
M7>,Q-OQ $B NS :(H[;"W;H!VD\>)JX:G\!./E):H@]JKB[RB8)F6E;@_</2
MJJ$ /4[8=H9C!D;F4ZB!#MU# 'P$YOE'6&5U+NN2QY7$2=R"WOF[>_6Z<'HS
M8\-1SQF:4?&D)/\ XBRV]P^>MCR6@-0+PKVO#JZA(0K] [=TP952%CTSD.)C
M <AV#-LL@X3.<3D53,55-3YY3 ;XY;!N.>)!+XTID!T)8G\9][A5Y.T;683!
MZO"(B-0$4?B L>T$:WUJG69T"YT)R+D($A5G-7E*[*3=+DEP$RBL6N[9HJ,7
M"O0"GD8A4QFZOV3D$BH@7U0*&[.@-P3<YQ,;"=8V##N-QJ/(1P]T=E<[>TO:
M7V:(XZW.,\BLA[U]+0^53H?</;5N?B7>M67/[1 NBM^UR&RV2*ZYSD%LZ<ZC
MOA&YD!*<A3.'*G1N4# 8!!8>@=W:(9)[059ND<OEOIX1\X$T?XN/N5B_LQ=4
MZWPN:VOBC7L)@DM;RGA[M=IN<SUUO3%*8I7%GY1/JM;>8F[KYJY%[/4IK+5"
MNV^WQ3-5W3F^R6U2CX^9B&LZU3/' [,K#J H0Z@**O4'0D Q"]V=,="^/C].
M8N)GD)E%79$)L_AER5)4ZVU]Q2M]:Y(]HWJV5U5F9NV@OB!D5W47C$H0!E##
M2_HZZW+!K:5OZN^-6L./OO:(DIY9_P A7FGZ1R(XR6YFY<1]:V;4'$6X"XT5
M2 >* FG+H3Z8M$SB?W0$,F\$J;=-9(]HFZVG'J^ZH@&SC)?'R4(NT3W]!^8=
MG+KW<5U)!%[@]GV,WK6RR.6WTXL>5B."0DR$'Q(^4_&#>B/C<'L%!!_7A-QQ
MU#R0X:[YK=/BB,.:NK[:.Q:9+^\,SN)48!E'NZG'5[Y[91&&EI%F_C'*9@,1
MM*+MW*YBF]IV.I]ZW'9>I<2?):_3,\?AN+73TB0Y;CZ0!5@>U05'QK_>D-@V
MO?\ I/-Q\5>7J[&E\6-KVD]$ H%X>BQ#(1V.58V]&TN=/>1GG!RPG*WK74U.
MT+I:Q2<?-1[>[[?3V$O$7BY4AA%.[E7Z:XC81W$M[(R92Z4@O$*-7B[5H;N%
M7M#J..[ET9TOT_$^;N$F7DPJ5/)#X=T1R0C/=@>4D%0]P">RLIVKKWK'J::/
M;]LBPL2=E8"2?Q2LDD84R+&0I4. P8H0Q"]M7AZ=9;;CM=5UEO.;IECV@@F]
M+9IF@1TC%U5Z89%V:./'LY7M>$43BC($7,)$B*+E.8B9"B!0U=N3;>^8[;4L
MJ8)MRK(06&@O<C3C>W'2UR:W#M2;I'@1IO+Q2;B+\[1 A#J;6#:_!M?A<WL
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MAQ1J@MLQE78[8BM;A3WAC47KZ1J[6UFCT!GDJ\\DFS.07ARR7J>W%9,% 2Z
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M<DCHN4N]9F(:(5?E*_2*FO/2#AL].LY,;U%>QK938Z7-7BU;SZVRMNX^<O\
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MUNG'"T1&H_+SQ/OW"RX2<J:#A>05,C)/9W$B]/ +ZB;F*N$&O8)>M*.DU4S
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MCZ=M$S&M9.0H]J.U(FC9*I*%$5&JJZ)4E/F',BJ=%!42B=%$Y% 2-!5%^L_
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M]@\;O$_+?7E+HQ4$DA2 23K4A<Q&LRIBE,4IBE,4IBE,4IBE,4IBE,4JD?\
M$3^^X_N/9>O[;^2_A58O\O\ SW\>IN>/W\!%]_3<\F/]1_E;D+/_ $Z_L8?W
M*5/V[_#M^WG_ 'TE3<R%4ZF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2HW<
MJ^-=?Y9ZG4TO<;9:ZM2)BT5B:N2-0<-&<E:X*M2)9CZI.7KQN[*RC9*4;-EE
M52)F5*9L7MZ#\0NNS[K)LN;Z_ B/D*C!>:Y"EA;FL+7(%Q[M6C?-GBWW!^[L
MB1TQF=2_)8%E4WY;F]@38D^2H,[DX OMG<VN&D]"UJ'J/%;B)K5C,1+!@X:D
M2<WB MBCNHT.*ACO7#T6R!X6*?O72K845FC91%1<ZZR?9D.#U(N)L&?'([/O
M&;*02?D%;,Y-K=K  &X)! L*QG<.EFS>H]OEC18]CP(00!;X:M=4 O?L5B2+
M$ @DDBK=\PFL]IBE4O\ E"\59>9+V)W-IJ:@Z1R!KL:A%/QFC.8ZN[%A(SU%
MHA"4DXQH[>1-MA##Z3&1%)4BC?L;.!(FD@JWSSI'K'[B5L'.5I-M8W%M60GC
M8$@%3Q*]^HU)!UYUIT1_J%EW#;V6/=4%C?19 .%R 2&'!6L=-#H 1S4C0>3_
M  CY&1-FW]K6 AM@E?>WJ6S.1<1;]BZSBY\!+]'7F%FZJM/0UPF(5)MW-#+$
MF$& B*IVA7"22B&U?6=HW_:VAVV5FQK>E' 520CM0AK%0>VW*3P#6)!T]ZKO
M73F[K-ND*KE7]&3(#R1ANQPR\P<BVE^<+Q*W (ZM/'S2N:CL%=X<CN8M$W_K
M_95,2>TZF:VK$2>HMW,D_82,;:XZWHU2D.V@L(Y-TR/'(1_H*F<]RJ@G;)AF
MG.I<C85_^/VO!DQLF*2S,['FT!!4KS.#<V/,6OIH-36\.E<;J)O_ )+=]PBR
ML6:.Z)&HY;D@A@_*A%A<<H6QOJ=!5H68C6:5B<_>Z=59JH5VQV2)A9N_2CR$
MID;(NR-G-CEX^-<2[N.BRJ="N':4<U.KV=0$P!T+U,( ,B'$R<B*2:%&:*%0
MSD"X4$V!/DN;5%GS<3&FB@R)%2:=BL8)L78 L0.\V%ZRS(]2J8I3%*_!TV2>
M-G#1<O>@Z06;+$^3N273,DH7K_\ &(80STCM&XD3X2D$><:UXD19$:-]48$'
MS'0UR_\ [(O9#JT\[M O*X9+6M^3K^].,>TA*V6KT5?(&:L0,Z6MZ2ZSR(D7
M$3<7<4^3.D!UF#4K@H" I"&Y!UQ@\F!GA_SH)BGCUY@I ]/AJ 5!!'RB.-:/
M/0&X>)N.VE+P,!-CR:<I92?0XZ%E8@@_)!X5M_PI\S+8W=V#Q\<A/I*'VAJ0
MTRUU82PF.256@:R9<++K)V+@WJJ/J2F@=W%@45"GAP63)V(LD?4M/7^P1#EZ
MDVZQQ9K>)R\.9O@R"W8_!OG6.I8U>/9QU',>;I;=+KF07\+FX\J_"C-^U.*_
M-N- HKHHS5];;J,/+_B+I[G!HZP<?=Y(VU2BS\C"S8N*3;YFEV&+GZV^+)UZ
M:8R,2N5L\7AI-,CE%M(-WT>+A--51N<Z29B2<3+FPIQD06YP"-0"+'B/^EC4
M7-PX<^ X\_-X9(.A(-QP/N>6X\E4R!HWS3>-(J2W&_:\9Y4N+L(DX[=%<@)!
MM2N4--@VP**H,*7MI59V6[&8L&R:)!=N'0  %080!>[N"\>/LVY?XA#BY)^,
MFJ$^5>S_ (NU63P-\VO_  SC+Q!\1]) /(W;_P 66I:\4O-OPSY%VD-/;'D;
M3P[Y,,#H1]@X]\JXDVJ[2VGU#>D>)K]@GO95JQKKN.GM&PK,Y=TD<I_8)B)B
MEBY6RYF.OC1VFQNQT](6\H&H_%Y:F8F^X62_@RDPY7:DGHF_D)T/DX'R5<)E
MHJ\TQ2J2O/QSD#A7X_;ZWK$XVA]Q<D%5^/\ JM87YF+V$&Y1CM&^WU%5N8'S
M)*DT?W9T7R?P9R[IAW" G*!E5(UYF\@JB'2GD*G_ !5WKD9KS4?*ZX^0SBOH
M'B!I*%C272]1^P:4[YZ;.M$(VJ6I>/NQ*S$O')* M5'$]*&A4EU%&D9!R2!S
M*O8I,#_*J%>< D68GWJZ0>.?E5UA>:O8QYCT*<\;.RZ9/UNI3%,YAVFHZRJ]
MOL5CKYK FGI39EKD*S7]N,6+=(WN@8I)/F9%&ZCALD1TW%3[5(H?BZCR5:2S
M>-)%HUD(]TV?,'S9!XR>LUTG+1XT<I%7;.FKE QT7#9PB<IR'(82G*(" B X
MKQ4)N6?CMXK<R(+:"6U-;0[;8.TM)S&A)'=%<CXYAM*'H<E/PUN8-(R><-';
M=T>N6^O,Y%@5Z@Z304352 OMW3I)97I6*\.%<J/D_P#&)L'06O85[LKG!<>9
M_*?:U5UWQ?T/JUCK.E:DVJEPQUA/L)S<%'X_4F'LL\VV?MIM'NHENL= S)W(
MQDC)(+MGJLD(!\JLC@GA9>/NU#:'W12879W)CEOXZ=,RO'&O[$3U5XO^!^AE
M(MI79?:_(N^04'$;9VGMG6H2U@IUBG];420<IKA,D?,33=E@W#WU7WN#BKU8
MV"N;]IJ]?QW>24^L*/K71/'SQS[9V%PJU]N!OQDL?-#CXE"O:[;^0<N^3D-I
M[7@.+]=K!;=%:5G;Y-NY<)-B\591,6Y2:D;(*I)1I54V3M)]+N_]:Z!=+<JN
M,_(YU9X_0>_=0[CDJ4Z,RM\7KC8%8MLK6%P7.U+].Q<-).Y"+06<I'32563(
MDJ<ABD,82F /M4B".(K/=:[8U?N:NJV_4>Q*3LZJMYJ9K;BQ4*SPULA6]AKS
MP\?.P;B2@WCYHA+P[U,4G+<QP51/T Q0ZAU4((XUL#%?*8I3%*UON-232U+L
MQ6$_^>4J%;5(CKZO_P YD@7YF'_<""__ +V!/] ]_P#L^.6C?C(-ERC#^E]7
M?E\_*;<->-6/J9LE>G,]L/\ Q8PYBG'X?AMR\-?A6X:]U<9=2_TI?_@_^@,_
M-CJ'X35^=71GP5JU7@[R';ZOGHG3UQ4 ->;$LX-:S)J&^%,OUA5*1NS4$P]$
MZQ<I$ (;IT*SE504Z>FZ6.ENS_;W[6'BS?\ 0&^->!M<:0\5-P#&WD)(Y;<-
M2=+FND/9_P!51]#9T.TYAMTONF;R*>S%S9SZ/F@RG%F[(\E@_P &9RER$U4?
M]?VK_;]C_P!6=HUU*#6J)BKG)W?:_DZ_8SX:]AJUI*5[H)OM8_9^QGRO5_+6
MO).O#\[YG3_J_P#OXK[?SU(#B3$'9W>U.0( )A62H&-\ Z'5E62A Z?*/4$#
M?]'3/HJG*=!4F]\::KN^]7V76=D$J#::035CI+T"N58:99F]:-E$4A.D)Q05
MZD4*4Z9SH*'(!R";N#)ND^I<WI+?8-\PM7B-F6]@Z'1E)UXC47! 8 D&UJPG
MKSHS;>ONE\GIG<](I@"CVN8Y%-T<#3@=#8@E2P!!-QPA<FM,1O%_F:>JSEOC
MIFF628/#V:S4ALM)(-%_?(Q]D;LD9H*V@_EH9Z#=PX 5$VXKJ&*"O0!,':.S
M=13'<L;J?%QGQXMR@N(YR$%W  9BGB<J%^22]BW*WP=:X"W#IW%&Q9O1>3F)
MF96QY/*9<<&0\J$GE02>$'=4\6$"ZH72P;2NV_A)8-(SG&K7#7CZ]?.==5B/
M6K2+:9(DA98R>:+&?V!I:FJ!C-VUA<R4D9XN"0BW4!T55 1043,/(_M-P^I\
M3K3-;JY57>)G$A*7,;(1RQF(G4QA5"+?TARE6LP(KN3V2;GTCN?0. >B7=MC
M@C,0$@ E213S2+,HT$I9N=N7T3SAD)1E-2OS JV33%*8I3%*8I3%*8I3%*8I
M3%*8I5(_XB?WW']Q[+U_;?R7\*K%_E_Y[^/4W/'[^ B^_IN>3'^H_P K<A9_
MZ=?V,/[E*G[=_AV_;S_OI*FYD*IU,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4
MIBE,4IBE,4IBE>3-3\%6V19&Q343 QYG;)@5_-2+.+9&?23I)C',BNGRR" N
MW[U<B*"?=WJJG*0H"80#*D4,LS<D*L[V)LH)-@+DV'8!J3V"J4T\..GB3NJ1
MW NQ %R; 7-M2= .TZ"HY<F-QZCUZ?3NMMNTM&_1?(O:U?T]%5Z1@(BQU[Z2
MGE2HMI&R1LX1:/<1+:17:I')Z:JG5<#@02D.(7C9=LS\Y<G,P)/";#QVF+!B
MK67B%(UN1<]@TMVBK%O^\;;MS8F#N,7BKGY*P*I4,MVX%@VG*"0.TZW[#6P-
M-['U%=&-NI^H5X=O&:0N,IIR>K$'$I0,;3IVFD09K5Z.B6[=JR;Q+!+M2;BV
M(#8 3,F3H*9BEB;C@[AB-%/N ;FR8A,K$\Q=7U#$ZFYXF^O;VU-VO<=LS5FQ
MMM*\N),T#JHY0C)H5 T%AP%M-+#@:C!Y$MU[/T7J!K9JO67LOJN?^L=$W?:*
MFZDF6T-8UZYPBD!7MB:\>M9!BP92E=F7IE?5==2"[]JD51MZIG*5^Z.VS!W7
M<3!.X7/3ED@5P#%*R-S-'(""2& M8=G,;-;E..==[ON.S;4,C&C+;:_/'D.A
M(FA61>598B" "K&]S\;E%UOS"C#_ )^K1M:5X?ZYV0^3L.U-#<K-9R\9N./6
M5&$V)K%TZ1CU9"P-Q6:/T)U\S5:>Y,=$B[IJH;URMW15RJ[3_P!)08$>XYN$
M.3 R]OE!A/PHY0+V7B.4&]M; C2ZVMIO_6V3N<NU8&X-XFY86YQ,)Q\&6$FU
MV&A#$<M]+D'TN5N:_6CG/M=.4Q2F*4Q2F*5'JQ\4>/%KW54>1<SJV -NVCJG
M6K^QHQ>7@)_O4C7,/TG!@)*,9VQ-*+=J-TR2R3TB21NT@%  Z72/>MTBP'VM
M)F^[Y!8H;,.-].8$KKKZ)%6B78=HFW%-W>!/O*,W$@NK<+>ERD!M#;T@:D+E
MKJ[TQ2F*5$OE=P5XE\WJJ%3Y.Z/I6T$6K-PR@['(L#1M\J:;D3G4&H7^%4CK
MA6BF7,"ITFCU-!<Y0]9-0 Z9+Q<[+PFY\9V7O'8?..!J'EX&'GIR94:OW'M'
MF(U'X:I\-P!\HWCF(>4\:/*D_*C0T,@@+?A/S7DRS,E%1;,Q>L%I_<+=Q7VT
M%]I.<C)@96M1;;KZCD7ZO3K=O7]LW#3<HO"G/]I'^-EUOY3J>ZU6;[NW7;==
MKF\;'']E+K;R*VEO(/1'?>MX:(\Z_'F5OR6@><>O=@>.3DLB9HW<43D<U58:
MXG5G!O0"1IFY_H^-J[VMKN"']O(RJ4.R=$[1;+. 'KE&?8\@1^/A,N1C=Z<1
MYUXW\@N:KX^_XQD]7SU;&RNY_@GS-PMY38=UZGMNG@UQ8Y6;ET-R2V[46NUI
MS2=9O<9K6*FY4EJU#+5_;,"$7.NYG7LF$K2;-[^,5(H@[] #J"1 QSJE0; E
M9""#8Z$5?U<\OHG0UH2Y^'SA=.WKB[9*1KN%TO2>,>ZI#?K?2^IJG2*GJ[:V
MRA@FL95[3L^+95LLM/3U%?Q3->*<"\ B+8'+4Z1TW(F35ZYVU\M4P^6_6FR8
MOR([(WINS@EN?GEJ63X1/-)\$ZEK[4Q=T:BIG(JX.7#.5>[GKC50[VLR[:8D
MW;QI* @HZ,U4;F9%4>,T%6/RJB6Y; V-]:KGJ-%Y/:@V9QQUD_Y(3E(UGX/.
M,6G.2O, E\D+);-85+>-[V5>MKHZ7J]:H3JJ2EOOYM3[6&J1[8\S]&RWT">)
M.X1:)]RBO5P03;5CI713P:\\NA>7TW<J]=]4W'C4Z@-"VOE)6IZ^W77L_0K9
MH.FSR]=L%J=7>+F(^)I,_"R+94'\9+@W39 @MZCO[4;/M4FC*^76I-T^EZ-\
MPO#6CV3F9PV2@JS:9>>EX'6NP;2PLDQ#EBY*2KT;L#7>U=9R4)*(0MRB4C.(
MV8B';+Z2C%R+(G69K(++*^7*-Z)K=FL_'5PAT]#: @M=<;-<5]GQ;FK59-#.
MCL7\U/:^L5X:D9V^?:VB?D)6RS<U8TD$#.W4H[?+JK,VJHF]5HV.DKX68WN>
M-5%//'YY)_''PYY.:P\=_*9GM:@P5)L<AQ-T%8](Z_:[=UU8[EN.HW&\O&6W
M'DLG'W^>B]?.K:$6C)1H@\DWC4J3<ATD2#\KWS(S L-:YND+]R7T?M+E%RO&
M+W!4]F4.A0G!#2K_ &5QNUGQ%WCL[E+S1CIF1?$VS%:C=_5N[2^J:O$VNPQ\
M](O73IV[85U9R9'UBE(JK8$!=+<>_05W;>.WA]7."'#;1G&2!(S5D*%4&J]]
MF60BHE9]H6(QI[8MB(X421<+LW]KD')60*AWH1R;=#_2D4 ^U'9N9B:FMBO-
M,4IBE?@Z;INVR[58H&2<)*(J%,4# )5"B4>I3=2F#X_(/P'*<L:S1-$WP6!'
MX:\LH=2C:J1:N3?DUQPGN->Y96K.H]5&GV23D976\J":GT?(P*BPN2QB3HXF
M3%]7B+D;."F,!_@F<0 %B /Y[>U7I+<.E=VGCGC8;>27B>QY60G0 ]I6]B!J
M.) %<)[_ -%3]!]6MM3+;;LJ5VQ&^*T?PN2_#FB!"-<CXI^.H.KE8:?NLY0]
M54P%E-@WJ[5F,KJ#=+W#B/72EFSD9QTCT$$H^*%#UE5%.B94DSG,/80XA@GL
MJV+<=YZU@R]O4F)"5#VN.=QRJ!_5!+MV*J^E:XJV=?2SY^WX70^U$GJG<\_'
M2%!JR!)5<S,.Q$*@DM86YCP1B.PQU'-'I3=.P3!U 1*)3  ]/D'IUZ#GZCAE
M;X)!K] ;]U:^F:F!@,()]0'K\0#J'V<5Z!K2LA$13UPY;,7T>\=-N[W#=J\;
M.%T.T_IF]9%)0ZB?:I\T>X Z&^&0X-PP,J5H,:>&2=/A*KJS+K;4 DC737MT
MKXDT;DJC*6'8""16NI:LF*)^J8_9^QDNU5PU;2X\1OL;!93=O;ZD4U+_ -/1
MX(X%>). J66>JI5PR>2?5$E'R>RX20344L6M[Q.OB.!*<%'C%!^X3>NBB;Y_
MMG\0L5Z41^)@(0?LYW]'X'4/0V+NN&!IC1RJ!V#EM(O_ &ZW\JVK\J-L;*Z,
M]JV=T]N1-GRYL=R>#-XC&&37CSGEY3\F2]66> 7D.>9?[#T]*O1/]:ZO'[!B
MDE5NTB=HI[AO6+>FBF8PB=[.QLDQ="'^KT(_K\@#FKO;SMPWOI+:.M8Q?)A8
MXLY'$\P+(3W!71[?MAWUT9_MOSSTYUEOG0$AMAS 9F.#P'*0KA>\F.2,&W_X
M3W5TWYRE79=,4IBE,4IBE,4IBE,4IBE,4IBE4C_B)_?<?W'LO7]M_)?PJL7^
M7_GOX]3<\?OX"+[^FYY,?ZC_ "MR%G_IU_8P_N4J?MW^';]O/^^DJ;F0JG4Q
M2F*4Q2F*4Q2F*4Q2F*5%[FCN&V:!XP[9V_14XA:UTF(B'T,G/,UY"(,L^M$%
M#K ]9MW;!9<@-)%02@58G0_0>H@'0;YTUMV/NV^8^W97-ZO*Q!Y38Z*QT-CV
MCNK&^KMURMCZ<RMUPN0Y4*J5YA==75=0".PGMJ##3RC19_'DXY.+IUW[]#9X
M.JQIP$7+$J[G43$[1<L<+X'IJZ>O#]83H X*86B:C8JWJE[LRENAG_U>-D'/
M]VD>+S]O@]NMK<W-^;O;C9K6K#5]I$9Z$/41\/[W!\'P]>7UCL-KWY>7\[:_
MP05O>LJT?S*VGL9#@<\L]TTU6W/(F'VJ_O=0=U;9);/:5:=(S+2-'6KV&A[#
M3J^G&H,"*/\ Z>E&GJE$?0$YOFA'W/IS PSNJP19+KAM$$<-'RKS@$^("5=K
MW]'D4V[;5)V;JW<L]=E?)FQ(VSTF,B%)>=_#+ >$55HUL!=O$=;_ !;U("#\
MCO"ZRWUYK:"WA#R=H:%D!(5I7KFM"R*L2V?/))M"V4E<&O32[=HP,H3VKE4K
MKN*5L98_<4MIEZ-ZEAQ!FRXK+ ;<63F%[ $KS<PU/:!;ML*OD/7_ $CD9IV^
M',1LD7X+)RGE!)"OR<K6 N+$\WQ;FORU]Y).%6T+*:J4[>,4YE"U^<LYE)JL
MWBH1:<16H^0F+ NO+V^LP4<U/$P\6L[5(JH0PMR"<G< &Z?<OHSJ7!@]8R<5
MA'SJOHLCF[$!=$9B;D@"W;H:^8/M Z0W+(]5Q,Q3)X;/Z22(.5 6;TG10.50
M6-SPU%ZR+3?/CB3ORU2-*U?N*)F;-&L)"6-&RL):JB+V)B6_NY.1BG-O@H)G
M)H1[4BBJQ45#K)((J+&(")14RCN72G4&TP+DYV,RP,0+AE>Q.@!",Q%SH+Z$
MD"]]*K[3UOTOO>2V'MN6KY"J6LRNEU47)4NJ@@"Y-C< $D6UK$JSY,>$=QO4
M+K:M;M;RUOLMOAJ+7&#2B[+49SECGY%I#Q#9A.%IHP0LWDJ\(@5VHY3:@/VP
M5 2$JAI$_174V-BMFS8I7'2,NQ+QW55!))7GYK@"]K7[+7TJ-C^T/H_+S4V_
M'S V5)*L: 1RV9V(50&\/EL6-N8D+VWMK43*=SRW/9^(KC=DW<=(Z[MR/*=U
MIY.6N-0V8^ISNK-V22Z,8WBM?QEZL1;8^.H(I.54TV %3-ZITQ[>Z_Y/2NVP
M=0#;(H\F;'. )K(\8<-?C>0HO(.T ENZ]8OB=:[OD]+'>)I</'RAN1@YI$F,
M90"]@L0D;G/82 NFI&E3'MGD7X:4;:+[3MJW9$P]XB9H]:F4%Z_<58&%L*;Q
M%BK$2]M;UY:KQR[9RJ8KA55V5LS%)0'"J1B],QS'Z.ZDRL$;C!C,V*R\P]).
M9EM>X3FYC<< !<W%@:RS*Z]Z2PMR;:<G,5,Q7Y&'+)RJU[<K.%Y!8\26LMCS
M$6J;68S685';EAH5AR9X^;,TN\<)L75M@@-7I-85"HQ5MA7;:=JD@Z%$IUQ8
M(3\:W!T4@=ZC0RI _P!67GI_=GV/>(-S476-_2'>C JX'EY2;=QL:L/4VRIU
M#L>1M+GE:5/1/<ZD,A/DY@.;O6XKFKY*\MYZQ<:>--<NLH>*Y9\0M^FKEQJU
MC067E7RM$9./J[<WPJ* ,F0B\ T92)_6.HN_*JJ<2E62,?=>R=/10[WFS8R\
MW3^XXG,C+P'B'TD'=\(LNE@MAV&W/W4'5$T_3^WX^6W+U/M6;R2(X](^&#RR
M'O\ @JKZW+7)XB]H/A:B;3-:AWGO2WF,,KO'>$Y.F. +IMY \8V!S+3#1 ZR
MJ*2#JS6%^W^ >H)F@@<Q@*3I@OM,D@BW'%VK'_1XN*J^:YL ?,JJ?=T[:V-[
M)(LF;:\S><K])F9C-VV-A=F \KLP[_1U[*N$L-?A+9 3=6LL8TFJ[9(F1@IV
M'?I LQE(>6:*L)*/=I#T!1L\9KG3.'V2F'-<PS2X\RSP,5F1@RD<00;@CR@U
MM2>"'*@?&R%#P2*593P*L+$'R$&U<3''S0KZ?\@U1TM3"J3D;2>1;M!Q(K(@
MLG]1]67AS(3<T_!0J:/:-<KJA@*IV%67.1(/G*%*/3N\;LL/2$FYY/H/+A#3
MY\J *H_[F]P7/97(6Q[*\_7,6T8GIQPYY!/ZN&0EF/\ VJ>/$D#B:[?\Y>KL
M*OQ]PAZXM?71]R"(.!;^H3UP0,<R95Q1[O4!$RA1*!NG01 0Z]<^V-N:QY;\
M:^<R\W+<<UKV[;5"SC#SCUKR,J^Q9Z30:ZCD=9[0=ZSGX*ZV:*24(X=/U6=.
M?C(.4HELDZMID%$4V70RJ3]NNW(=<"$65R;?>ELW9IX8D)R$G@$JLBGL%W%A
M<V30\W J03:Y Q'IWK';]^QIYI ,63'R3$RR..)-HS<\HN]B O$,"H+6!,V<
MQBLOIBE,4IBE,4IBE,4IBE:3WWQNT+RCHCO6?(;4M&V_2'9CJA!W:":2Q8]V
M8GIA)P+\Y22M<FDB#T3?1Z[9XE_V%"Y6@R9\5_$QW9'[P?Q]_F-4,C&Q\N/P
MLE%>/N(_%W'RC6J0I#Q'\NN#4B]N?A[Y@S%(IP2JDV]X0\J'LILSCK+@JHHN
M^C*C9UB/K91O=_ .\I?I5XH(>O-I$*'2]#=<3-')N\(9[6\1/1?W1P/XOFU8
MCL^9@'GV:8JE[^%)Z2>X>(_'\ZLNUOYR&FHKE$Z2\K'&C97C[VS(2"L/$[&E
MX]]?.+=]=H=I1>U/;$ C((M6RRBA?4$OTI%L"CW.91/H8"^9-D,J&;:Y%R(N
M[@X\ZG_T)[!7N+?A"X@W>)L:8Z<QUC/F8?\ J!VFKT*/>Z1LVJPMZUQ<*O?J
M39&9)"O6^F3T79ZS.,5!$"/(F=A73V,D&QC%$.])4Y>H"'7J Y8W1XV*2 JX
MX@BQ'N5?HY(Y4$D3!D/ @W!]T56ES8\07%7F%5^53Q""^]'O3EAJ^HZWOF\*
MN$E(/'A-<WJ@;(H4I.TAS,M*K.+QMFUC#(O5DTV4F^BD#M/>I )%$_-5E<K;
MN%4,\E/$+O\ UUJ2%HJNKM!QVS.3^RT-5<N.9_$ZBSFN*1K;@1KY&C;+NTOL
M35KB10@8?:M_M=$^EGSZO0H-98&*L8Z6_P",0*K\JH'!-^P< >^HF4K;G,6C
MTW4O//C;OC9NE[1SFYMZZXX<"> <<FQF]+6SB=IEDRTY .+U3K"1VTB6D)!P
M<?#+RK!)HX()_I %!-))NF2O5E)Y3V#4^6NB#C5YS=:\C^5<YQYC>,V^("A?
M?MNG'NE\A&C6+NE-?[,I(',XC-E5NM M8].Q]E(D8\.ZD <I.TQ[U1;D1>&:
M?:I&,A;W'"KT<53K3&]^.^CN3M'2UMR!U?4-M49O886V-*Y<HM.39,;-75E%
MH>=CS"*;F/DV95U4O5143.HV<+('$R"RJ9U?02#<<:W/BOE,4IBE<K7D/V7N
M-GR_VI5938-M1KT$[K@U.#CIN5BX&.@Y&I0LJT]E%M'I&8N1/(* X<=HJ++@
M<3"  !"\@^UK<=V3JC*QI)Y1 G)R*&8*%**18 VOJ;GB3?S5^>?MAZ@ZKB]J
MNY;;DYV4,&%XO!C61TC6-X(W7E16Y;^D>9N+->_</$TUS)Y):R7;GA-I6288
M 8OJP5R>K7"&6)U 12*WG5';A@!Q#XF:*MU/_C9JC#]J'7/2TW/MNX3-"#K'
M,?&C([N63FY;]Z%6\M9?T9U]U=MP41YLTT6GH3,95/D],DK_ -I4^6OAW_R7
MO/)*T,]B;$08L8NF01H:O0$ B]0BDC&5*M*/6361>O5@E+&_23]0QE!'TD4$
MS#VH@.6[V@]?=1>T++Q,/<3 F9X80)%S"*/FU=R&9SPL7-S<* . KYU!U?E]
M49TG6&]IR[;@PE(8T!UL?2**Q/YR>0 :GX(0,;)>M4Z_Y*$U)K"VHT2NR4)R
M#V7;'2<YMMU&0I5J5K<6 )IT_6\R1=>Q1\E++MBF>.C B0J( 1(GJID<!M+8
M=WV[ICI+[FZ?/_R]@K3V7F6*P!$9'I!I'])VT&M@+@-6D-J]HN7L6WYV;B8<
MN/U_N^<YDSF2/ZMB<GHXV')<S*S<HYW/* @ 4<RB2O[T7R,VIJ;9<!L>-NEJ
M?+M9N,>VB/>STH];W"%3=)?3$-.(.G:B4F60C?433,MW&06$BJ8D4(0Y<<V/
MJ_<^FNI(-V6>7P?%7Q@68B2,FS!Q?TM-1?4$ C45D'1_674NR;G'O6)E9,F2
MDJ/(K2.PG12"\<@9B&\1.906^"Q#J0RAA=%S9YQU]:ML]>Z0MC.96LC))Y.6
MB#<&41;13I,13CT'!0(*:S@@]5$QZ''KT.!2 8BN>^V_VQ03;>.G.C\D/'*M
MYIXR=5/"-6%M#Q>WPM%^#S!^RNM/:'A#%3!Z>G666=0QD0W"H1W]C'Y)U'Q@
M.#5.0-KM=9>DME9F7L?:HHQI2,DBN%Q.:0:"#M!-[T5(9ZP<KI 1R@<PIN$3
M&3. E,(9QUL'4>X]+]4X>_;?*\>3#D(203Z2%K.K=ZLMP0="*U:T^Y+@S9>W
M2LF[)&TD3W-Q*@YT+:CF4N!SJ39U)5M":Z3X1%G=Z95+I'HB6/MU8@K0Q*(&
M$2LY^*:RK8HB8A#"((.R_* #_NS]=L3(7,Q(LM/@2QJX\S*&'XZZEV7<XMZV
M?$WB#2#+QHIE\BRHKCWFK,M:0A8N1FU1)VF4;M" /3IT#U5S&#_9\1 /_)D@
M5<V-Q6X<^UXKG#\PVHU(/9\1LA*-$]<V?6$XV7<^D)FREHKJ 13UJY,0.Q,S
MNM"Q%,#=#*^FJ)>O8;IV;_MXWV'<NFY^G<A@T^)*;*>V&:[<.T"0R VX76_$
M5^=7^['I;(V7KK%ZPPU9<7<($NX'#)Q[*=1P)B\$K?5BKD7Y3:H;P^,;I >0
MW7=#K(/5%8&SV29?JI@())TDM4F6%E=/^X!1(V?P3UN! ,/Q743 G5029(ZU
MGPMHZ%ZBZ:W=AR!4: -Q:3Q8^3E[2Q'AO8<%#$^B&K(?9W%F[_UYTQU?LRGG
M?G3(Y>"Q^#+X@8\.53XJ7/%B@'I$5W:YQ57>E1&YV[ON?''BIM/<VODH5:WT
MWZD?1"5B8N)*'-]8=CU"JO\ WC)J]CEUND9.+"GVK$[50*8>H )1R#I;;,;>
M=^@VW+YACR<]^4V/HQNPL2#VJ.SA6+=:;QE[!TUD[O@A#E1>'R\P)7TI40W
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MKC);GGKF;H/95G C/6"AJR"1"J$9$=2LJ<ZH"I&LD^H%^ML^/F R;1,)#_\
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ME48\:D=K/,4++Y8EE)[ ;&T\(CQ3[*DXZ-^N&TZ!'NQ(<7\?"U^P3S9@H'H
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M:WG[+(LF#V9]/PY8MD+LN$"+6(MCQV4@\&46#>4&M\,X])FLNHF  "Q2 /\
MM^:)A#_\;+Y6>5Z.*5JO=D/1)C5UR#8]/A[U58J#D9UY6YN/;2+5ZM$,UW;8
M$4W*9P;/?4)VI+D[5$C&[@,'RY?^E\C=<??L8;+DR8F?)*L8D1BI4.0#>W%;
M<5-P;6M6*=<8^Q3]*YLG4>'#G;5!CO,T,B!PQC4LM@0;-?16%BI-P17"GOFZ
MV/1G)JC\@=2KFU*Y?NWL&L% </H-O"-%@.T4:(+@Z4>K(+0D@9,?77545!H
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MC[DF/F6\)9E#]W+S"Y\Q77S5O@3M/@O/B7,QA<H.WGY38><-IYZ_9HB!C%$
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M/]D^QY&0W/*,3DOQTBD>)1[BH![E36S6E;6IBE,4IBE,4IBE,4IBE,4JD?\
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MHT,H8!342$OI>_:K[")MW!W_ *0USHH0'@8ZS<OQE<D!9.73E(Y6L+%2+%[
MO]S\^%*>F>OHR=LEF9X\M!88W/\ V;Q*I9HBVH93SH2Q*N#=>F&%FH>QQ3"=
M@)-A-0THW([CI2,=(O6#ULIU[%FSIN=1%9,1 0ZE$>@@(#\0SC?)Q<G"R'Q<
MN-XLF-K,K JRGN(.HK]#</-Q-QQ8\[ ECFPY5#(Z,&5@>T,+@BO3RA4FF*4Q
M2F*4Q2F*4Q2F*52/^(G]]Q_<>R]?VW\E_"JQ?Y?^>_CU-SQ^_@(OOZ;GDQ_J
M/\K<A9_Z=?V,/[E*G[=_AV_;S_OI*FYD*IU,4IBE,4IBE,4IBE8NZDV]ACK
MPJTW'JS+ BK,5$'7JDCY3TA4;)/3-#BJB0RA>TXEZB  8.@F*)<LTV9%NF)E
M8NS9$39\0*7#7"26NH?E-P+Z&VO$<015!G$J.L##Q!IQX'RVKYJ_<6TP\/"O
MV#Z LS9J#MU"220@8Z!5 15=Q;X@"REX\JX]OJHF$0ZAWE((],I;7OT.?.=O
MRHI,7=T3F:&0<1>Q:-QZ$J7TYE.EQS!2;5\BR!(WAL"LP%R#^,'@1YJS'+]4
MBL5N3Y]#P+ZP,%3">O-EYARQ$$O0DX]DD9>09JF.45$E#,B',B<ABB18"B('
M+W$-9=_R<G VR3=,4GFQ4:5DTY9$07=3?4'D!*$$6< GF%U-#(9HXC*OQ!>W
M>!Q'X.'E_!6#['BS7Q[6J&E)JL8>9:2-DFG#4B1EW,;#J19&+9N*X"0ON'\D
M13KVF[?2 >@].F8YU9AGJ;(P^FDF:+ R$?(E90"S1Q&,(JW^4\@;@;<M['A4
M?+3UEDQ@;1L"QMW"UO?-;$JS:*95V&90:ZCF(91[=E'N%A,91=JT)[=-4QS)
MH^IZ@)]0.4H$. ]2_-$,RK9HL+'VK'Q]N8O@QQ*B,>)51R@WL+WM>X !XC2U
M2H0BQ*L9O&!8>Y7O9<ZJTQ2F*4Q2L?M=LJM$K<U<;Q9:_3:C6X]Q+6*U6N9C
MJ]6X&*:%[W4G-3DNY9QD7'MB?%19=5-,@?$1#%*Y7N:W^5+H&J7<.-OC!T]=
M/(WRAGGB\!6AU]!V=QIY">*!R=(E> C7=[W HR.3U#(U]FA%.6X"=.9( ".*
M5$.J>$CR\^8>R0NW?-[RWL&C-(C(-Y^N\*M%OH0C^-;"8%FK9Q"1"LQJ77<@
MDT6+Z,I)#=[2! .W>^V5#J52NJ3A1XZ.&'CQHIJ%Q'T-3=5MWS5JWL]M;-EI
MS95Z.UZ'(O>=D3ZTE<;,4KH3K(M5W@L&1U3@T003'L!2ILXI3%*8I3%*8I3%
M*8I7Y+H(.D%FSE%)PV<)*(.&ZZ9%D%T%B"FJBLDH!DU4E4S"4Q3 (& >@_#'
M#4<:<=#PKE \A_@*O="VA_SV>'BV.N/?(JJ/G5I?Z-JTJUJ-7LKPQ#JR)]2O
MG!T:_5W4V7O0?526*-4EVZYT0%DB4S5WE.W[ZDD7J.[CQ,<Z<QU(_K=IM\H>
MD/+Q&([ET])'+Z_LI\/)&O*- ?ZO8+]JGT3Y.!V?XT/\A>H;9M3;B;Y&:\3B
MER[KLB6EN9^V1;RD:YOEH9B#;Z,L#.?!!QI_8+X0#O82(DB'KG_W1P@HX;1P
M4]RV!XE]:VX^+B'6PU('DM\(>4:]_::J[7U&DS^I[D/!S ;7.BD^6_P3Y#H>
MPZ@5TYE,4Y2G(8IR'*!B'*(&*8I@ZE,4P=0,4P#U 0^7,:K*:_K%*8I3%*8I
M3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I7ESD)$6:%F*Y/Q[67@;!%R$)-
MQ+Y(J[*3B)5HLPDH]XB;YJS5ZS7.FH4?@8AA#*<T,61"\$ZAH74JRG@5(L0?
M(0;&HV;AXNXX<NWYT:RX,\31R(PNKHZE71AVJRD@CM!JC;:/B(GH9\]DM&7V
M/FH0RBJ[6H7[U8Z<CD>XYTV+&U1[=U'SG: E(G[MLP,4I>JBZIQ$V<P=:_[?
M\G*+YG262G,23X$UU\MDD4$7[@R@=["N7\K_ &]YFSY!;IO,3(VV_HQ9%UFC
M'8HE4%)K: %UB8 79Y&-ZA!8^.NX]<2GT1<M<6B)=@KZ:2A8Q61CW8]PE S&
M5B_>QCY,3%'H9)8X9R+U9TCUCT[E'#W?;LN*4FP/AED;^HZ<R./*K&H\?2&]
M;9*(<W%E1[\;<RGS,MU(\QJZS@+QN>ZKJ3S8=UB5(^[W%$J$;&OVYD9"NU<I
MB*E2<HJE(JTD9MP0JJR9@[TD4DBCVF,J7.OO]M_LMR>E-IDZMZA@:+J'/7EC
MC=2'@Q[WLP-BLDS ,RD75%0:$NM;XZ)Z?;:L,Y>4O+F2\ >*KW'N)XGN%O+5
MB&=/UG-,4IBE:9Y"R4W&:7V*>K;%@]46YW6)1A4+[86Z;R-@+*Z:*EBG2C$[
M5^=XIZX="D3;.E2_ZR(JB7TS9)TACX^3U)AKF8<N?@+.K2P1DAI(P1SCFNO*
M+<264=A9;W&)]<Y[[=TIG3P9\.V9I@98LB472.4@\AY;,6-^ 57;M",18\Y,
MQRGYF5VF*ZZW'NR%O5+>/G;5W+TJ-??6RZQA3)FD(!&PR]'K\JA&J%6)WG4;
M^J1-8$U^J(@D/9F)T![.LK<AO/3^V/B[FJ@A)F'A0M\60QI.Z%M#8!K$K=?2
M'-7Y^;U[6_:.FS-L&];H<S9Y'97>%")<A-.>)97@20(01?F0$!N5_0/*<2Y2
M[6W+=]=U)O<-):ITS6%8]DTU^4E=(VV_-5J/3,FU?!*2<A*W D"IV]WNUB,6
MC]3O,D=<2+"2Z=!]/]-;;O.0^W;IN&YYX=CD?G+X:2,=5Y45(>?LY 7:,6#!
M;K?$_:=U=UKN/3F(FY;+M6R[5X:KB 0@9\D*#T6YY&DG$1X^(PC25N;D9R'M
M'BU<-K=KE2HH7&84B[%<M4N=L)P#E1+W,'#F?.$&S:726.FHE*OF[0YB(_%0
MHK$ _8/>!<RVWVB[;O1R&VQ/$P\;<!B<XORN_*"2EAJBD@$\-"1?2^N>I/9G
MOO3^/BIOOAQ;CE[5]X>'P=(N<JJ2W)L[A;A1J"5# >D!&ZJ4>OKVVO*V:87"
M-<V2+CWLB].BUCXM-\[3;M'[X?17(FQ1<G(*G<!D^P!^:;KTS,=RS<B+;YGQ
M4YIUB9E4:EK"Y51<'F(O;4&_:*PWI[*FW#=(-K3PL7$9P&?Y(/QF9N8 ?*)!
M-KFKMZ\7R \%8178]8JL/MC1[PHRDU#,)Z-L4"+-TD51.PE1K<P\=01U4>A@
MDV*9V9P*7W0&+Z1<YBSC[(?:KE#9LW(DV_JE?11VC:-[@ZQWE0!['^S<AQKR
M6/,:[*V1/;W[$</[^Q,2+=.B7].5$ECFCY6%Q,!#(QCN-?&C!C-AXEQRBI(:
MJ\L-KVA5Y6T07$^U69E5UB(7(E&O!+',UD3',<7$K5T:=]*Q\=[8HBD[5,#5
M<Z9P]0@E.4F#;[[ ]OV/.CP<K?\ '@EG%X?'@\-)/(LIFY&:_%1Z2@@V(()V
MUT[_ +E=WW[!DW#%Z8R<C&@MXQQLCQ7C!/%X1!SHMN#L>1B".86-O<@_-%QD
M4< SNE-V[25RF[7#M6!@9^);&*!2JE45BK'],B9-3J'0K 1$ Z_ 1[0AY?\
MMNZV1?$V[)V_)7L =XV/=8-'R</G_P#.KQMW^Z7H+(;P]RQ=RQ'OJ3''(@[[
ME)>?_P#A_P#*K0]9;,HVXZ)7-F:UL#6TTBV,U7T#.LTG3=)XBW>.8YV0[5\W
M:OF;IC(LUFZZ*R2:J*Z1R'*!BB&:.WK9=TZ=W2;9=YA:#<\=@KH2"02 PU4E
M2&4AE()!4@@D&N@=BWS:NI=I@WS9)ER-KR%+1R $ @$J=& 8%64JRL 58$$
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MV^&2#8+<#G5=*)9\HG)R(W.(#H+V ':Q'$]__,5M@FD=5OZC<ZFK H2M5V3
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M<BR(H-S;^H;[V[O?E\LW(JC#K'0?,)[=[GK:R,A29S6NYZM24J2)LD*_,AT
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MNF6,7&('PB*_-3IS;7W#.#L+HI_":M9X7?2;9Y(-RF5".$BJ"A1[A3, (>Y
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M7.[=9T;:]$EBF]]5;_68BTPIUA150(]09R[5TFRDVR:YO0=H>FY;G'N24(8
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M[":R<5$B9?M!>H%  'J;K_K/W3DWC=(_@SR>Z>;\=ZM\FR;3+\+'C'F'+_\
M3:HA6K_&?\1%A'K$:(O-%#N1'I5=Z[>>  )%.4Y?_IO;;B/:X$P&/\>H"4.P
M2AU 9:]2;LO&16\ZK_0!4-^E]F;A&R^9V_I)J/T[_B=>,V7[?H^]\N:OVKJJ
MC]!;1UJX[TU.O:U-]9M*V+H@CU^:(=%1Z?..;)"]4[D.*Q'SJ?Z&%1FZ1VL\
M&F'F9?Z5-:SDO\1/@LJ]64B.1G+)C'&]/V[62E]/2KU+HDF"OK/VNIH9!?O7
M QB]K9/M((%'N$!,:H.K,VVL<5_^[\HU2/1V!?26:WG7\D5\/_\ R(<*/_\
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M;F@ 46 L*_1\^8QC1=_)/&L>Q:D%5R]?.$6C1NF @ J+N5SIHHD 1#XF, 8
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M<)+)&([]YVS;7 EA(4=)$!NZDE6(#'EX@K>_F'#NI8&][MD/S&+GC>-RMD8
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MD2146%)%(A/C;UEM,LRK$KJK#T4 ^%QOVG\->EV+"6%H&:5T9E/I.3\'A;L
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MF_EL_G78^M?-^ST^I_K/M58#^;=]YO\ %E]&_7[_ /VN_5[ZO?\ /E_];/\
MFY^MG_\ %'UH_P#W<SW]8\;X]^7]1>_A?@\.W_;R_.JG]5\#XMN;_P#N+6\7
+\/B7_P"[F^;7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g838337g28j20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g28j20.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
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M-;=OD/I30O9YGZT^@GIW]'.6_AL?]>-;=OD/I30O9YGZT^@GIW]'.6_AL?\
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M?#Y"N@G17V/=<_JK6?RN5O[Q\/D*L3W1X_,U+'(U*G%*<4IQ2HUDZ=ZLF&V
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MHJJW9V"[[ HJ^EL;@C7Y//:&IN [RMBN+J_KP8$*JS"&L#G^[H.SKJJU-L*
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M;B!OK$S->6RB-[50\\8LXIGE247$J($N@VHF*3&N/#1A= '$XOP^>^6%8IM
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M#_QV[CNY_:5/F*M-EUCUKU XH7.=>XRGTU'FII;/9&YS']B::PC AHMPW1B
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M+Q#8V,BLJJP&.IK6%C(;2N,BC8QMD<CQ-K1M)Y'K!'6&!V(/8?G6G?6%KQ&
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M830Z7'Z<$A<P2^RRCI$1TU%-1:,YRC@,NXJF>!+A"K94D8#K@2)D@G2Q!QG
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MHO,;;$D9][/E@<Q5+'.^=OV=OC]_E6A7O7T$(:N6%$_!^I?)/\O]WE_3Z_\
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M1SO@+"S*<U& JK2V*/0': E]?//%+51:G2TV>E)?42#'K;[,K 8TPQ+N=LZ
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MC(&3I4&V<.@W*'J/6=!ZB3D'(Z@3JPSO'-ZI<-J?!:"8@*)XQU$C"].G)U4
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M M_W-/2^Z@AN8>'PM#<11SQ,;^R4M'*@="5,X(RK X(R.NO+]\?U,OXKXO\
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M'"^2&IS>?CL<['+-.V%6L?\ /]=;%S2+[=-$R-9%PJQ2$*%D1C^J.E']'V6
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M!763[3.]+98V)YC!P07Z/:EBRL8H32V6D4(H0IH\BE-1OW.:&KF2&&P!5Z%
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ML*/>V*-KIIG,9[DTKV0P1(JR3S21PPL?*]C% $G &2>0&YK#,%!9B%4#)).
M!VDU#=UXD^I*6EM+E]^63'6!E%.'2AOJ]9W#1/D]KXZYK:VI!BD<Q(WV5M8
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M9.SHJ.ZC=%<TU5;1/8L3X[.N$/C?&OGYQN85#*US%\U\V*BM7S7S3Z^4UOD
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M2VG3'@:0SX]HL,A2?T0O(D#WBV=S@ $9.@G27FJ7I9(K;4R0K$P5I@I*F=I
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M9CQ_NWJGWB70?M2MDJ[X9TN@%AM15B,:)-6202QRB1O2[)2-"IP6<OD$Y&C
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M14U;B%@L,S5YELL5D587("^2V/X=>H4AE;)+6DDPVH4T*K[3;D>ZN-B>UCV
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M_+ZT^_@Q'YFZK]]4?W?&@]WG]*:QW^7UI]_!B/S-U7[ZH_N^-![O/Z4UCO\
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*%& !5;'))K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g838337g29t30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g29t30.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ O0)4 P$1  (1 0,1 ?_$ !\
M 0 " P # 0$!           ("04&!P,$"@$""__$ $H0  $#! $! PD' @0%
M @(+  4#! 8  0('" D95M41$A,4%1A8F-86(3>1DY:V<G,7(E?4(R0Q090E
M)@IQ,C8X0D5187=XE[?_Q  = 0$  @(# 0$              P4$!@$"!P@)
M_\0 4A$  00! P$!"@P% @,$"00# @ ! P0%!A$2$R$'%!8B55:5H='3%1<8
M(S$R46&!DK'4"$&1D]4D,T)7<5)BEO E)C0V4W)U=K4W8W."ML'Q_]H # ,!
M  (1 Q$ /P#["= : U7.=3QF42>/."!LDH<Q>.\#I]GBK9E("C!M:S=D2;MD
M_,:MD4[^C2Q\^^-\\_.SRRRO(1.SNS/^GV*,19V9^W_RZ[+[J6C.Z+K]SRGQ
MFNO,OM]3>Q<\&^_U>Q/=2T9W1=?N>4^,TYE]OJ;V)P;[_5[$]U+1G=%U^YY3
MXS3F7V^IO8G!OO\ 5[$]U+1G=%U^YY3XS3F7V^IO8G!OO]7L3W4M&=T77[GE
M/C-.9?;ZF]B<&^_U>Q/=2T9W1=?N>4^,TYE]OJ;V)P;[_5[$]U+1G=%U^YY3
MXS3F7V^IO8G!OO\ 5[$]U+1G=%U^YY3XS3F7V^IO8G!OO]7L3W4M&=T77[GE
M/C-.9?;ZF]B<&^_U>Q/=2T9W1=?N>4^,TYE]OJ;V)P;[_5[$]U+1G=%U^YY3
MXS3F7V^IO8G!OO\ 5[$]U+1G=%U^YY3XS3F7V^IO8G!OO]7L3W4M&=T77[GE
M/C-.9?;ZF]B<&^_U>Q/=2T9W1=?N>4^,TYE]OJ;V)P;[_5[$]U+1G=%U^YY3
MXS3F7V^IO8G!OO\ 5[$]U+1G=%U^YY3XS3F7V^IO8G!OO]7L3W4M&=T77[GE
M/C-.9?;ZF]B<&^_U>Q/=2T9W1=?N>4^,TYE]OJ;V)P;[_5[$]U+1G=%U^YY3
MXS3F7V^IO8G!OO\ 5[$]U+1G=%U^YY3XS3F7V^IO8G!OO]7L3W4M&=T77[GE
M/C-.9?;ZF]B<&^_U>Q/=2T9W1=?N>4^,TYE]OJ;V)P;[_5[$]U+1G=%U^YY3
MXS3F7V^IO8G!OO\ 5[$]U+1G=%U^YY3XS3F7V^IO8G!OO]7L3W4M&=T77[GE
M/C-.9?;ZF]B<&^_U>Q/=2T9W1=?N>4^,TYE]OJ;V)P;[_5[$]U+1G=%U^YY3
MXS3F7V^IO8G!OO\ 5[$]U+1G=%U^YY3XS3F7V^IO8G!OO]7L3W4M&=T77[GE
M/C-.9?;ZF]B<&^_U>Q/=2T9W1=?N>4^,TYE]OJ;V)P;[_5[$]U+1G=%U^YY3
MXS3F7V^IO8G!OO\ 5[$]U+1G=%U^YY3XS3F7V^IO8G!OO]7L3W4M&=T77[GE
M/C-.9?;ZF]B<&^_U>Q/=2T9W1=?N>4^,TYE]OJ;V)P;[_5[$]U+1G=%U^YY3
MXS3F7V^IO8G!OO\ 5[$]U+1G=%U^YY3XS3F7V^IO8G!OO]7L3W4M&=T77[GE
M/C-.9?;ZF]B<&^_U>Q/=2T9W1=?N>4^,TYE]OJ;V)P;[_5[$]U+1G=%U^YY3
MXS3F7V^IO8G!OO\ 5[$]U+1G=%U^YY3XS3F7V^IO8G!OO]7L3W4M&=T77[GE
M/C-.9?;ZF]B<&^_U>Q/=2T9W1=?N>4^,TYE]OJ;V)P;[_5[$]U+1G=%U^YY3
MXS3F7V^IO8G!OO\ 5[$]U+1G=%U^YY3XS3F7V^IO8G!OO]7L3W4M&=T77[GE
M/C-.9?;ZF]B<&^_U>Q/=2T9W1=?N>4^,TYE]OJ;V)P;[_5[$]U+1G=%U^YY3
MXS3F7V^IO8G!OO\ 5[$]U+1G=%U^YY3XS3F7V^IO8G!OO]7L3W4M&=T77[GE
M/C-.9?;ZF]B<&^_U>Q/=2T9W1=?N>4^,TYE]OJ;V)P;[_5[$]U+1G=%U^YY3
MXS3F7V^IO8G!OO\ 5[$]U+1G=%U^YY3XS3F7V^IO8G!OO]7L3W4M&=T77[GE
M/C-.9?;ZF]B<&^_U>Q/=2T9W1=?N>4^,TYE]OJ;V)P;[_5[$]U+1G=%U^YY3
MXS3F7V^IO8G!OO\ 5[$]U+1G=%U^YY3XS3F7V^IO8G!OO]7L3W4M&=T77[GE
M/C-.9?;ZF]B<&^_U>Q/=2T9W1=?N>4^,TYE]OJ;V)P;[_5[$]U+1G=%U^YY3
MXS3F7V^IO8G!OO\ 5[$]U+1G=%U^YY3XS3F7V^IO8G!OO]7L3W4M&=T77[GE
M/C-.9?;ZF]B<&^_U>Q/=2T9W1=?N>4^,TYE]OJ;V)P;[_5[$]U+1G=%U^YY3
MXS3F7V^IO8G!OO\ 5[%Q[8<.X:ZL(M0LS1?M3S[,.FRC@-3:<SDSU60(RIT$
M0:1N%X2 XY7*LH+-R+%!$?FLY%PV5DT\,A\=,.6;F7V^IO8N>FS_ &_U9OU_
MZK=XGH;C=-A]R8&)R+U;'%CEG@<_Q/BCY/VB-:%FJ:PN5W"DT5KL'S91=!5G
M@NS5SR:/$T':*R";F7V^IO8N.#?:_J]BVKW4]&=T77[GE/C-.9?;ZF]B<&^_
MU>Q/=3T9?_I$75_^MO\ ZSRG_M]U_P#\9_[7^Z].9?;ZF]B<&^_U>Q?GNIZ+
M^[_VDY^__I_[HE/W_P#R_P#6:<R^WU-[$X-]_J]BTT=I?BB78P,F+L*(#MH(
MI.-<O6<YD#AM-VR\<>R]!W&5DSF6!AFO%ASR0(NV5U6RHE&[U-7)#-//-S+[
M?4WL3IM]_P#Y_!;E[JFB_)Y?LDY\GD\OE^U$I\GD_P#S\OMGR>2G,OM]3>Q.
M#??ZO8GNIZ+MY?+$G/W6\M__ '1*?NM]_P!]_P#UG[K?=?[_ /\ 2].9?;ZF
M]B<&^_U>Q8!IQ]XU/I.<AK0-=Q)XV(CIXZ'3D\MNX&"9:ZD3..NW.7M6R&/M
M5Q%)!@@CBKDXPQ'9++HI(N&BCAS+[?4WL3@WVOZO8OZCO'GC=+&+LE' F15D
MQ/2:,.W#>32VV+<]#I"3BDE&*8JE4U,7 F0!B0U>_F>C44:Y*MU%FRB*RCF7
MV^IO8G!OM?U>Q5\;ZBX6$;8ED7C391@$%Y!;,FF;MV\R1L\CH@@X\KEXLX<J
M>>Z=+J6]*KGYEL[88>;ACCC:07W9G?\ \]JC)MG=E9-Q2_ B%_W9-_+#E1G]
M9_P_1E*'U6_']74B:ZKLE$2B)1$HB41*(E$2B)1$HB^<[M3.10[D5.X<G/.,
MLO;QWJ$G.(P;B@RB,K;\DI%JU";#X\AMB/G1L^?L_*'8/W2SUX:@K>-+9QPS
M=5\@LH@V1V;X)K/5C/IVPY8UKA7','JC+TR/HD+QB_C.S,S#(Y^,/8_:ZUGX
M6LM:D#JU#8<D5)J; ;6RAZC"TP$TCMXK.[NY1L'BEV[[*7W#GJ99[?)B=8;B
MUML4-LV6S+E.,UQ+P<#9L=2;19\>IW)6SZ)P0HI,RIU_-PT$9B')OVH&#@7Y
MM(JU&E?6D<V"6%=Q?19Y8)8BB".F4H%([S1/9B!V.1N#"P%(Y<>)$3#Q=QV?
M=\RCE>NXQ3Q2C+(=MHC&-F@F:M(;.$;\W)Y!C9G+D(BY<F8MVV;:;=6[CNQA
M&XY=+-?;W@9;2CS4S*0Z[ED9@"<V-9;N-OX[KM8 J#V:<A""!(N*(M"EY;-(
MJK&E&BF$C2%J9HX*]/@>R\D !)7-IVF<)1.3IMWN+'*Q<HAD=Q%V=F #Y,_B
M[KO\,UFCG,XK$95WA8XC&)I"[X)PB<=IGC9G(79^<@.&WCL*R6V.JQH32T#U
M1-I[KG? Y_MF+3Z>,=?I1:"YSF)P#6CU!E*YM+D5]DMHM["3NZ:N0EHI*I65
ME+-RDXC(PMC?*V/$.(L3R3!')7=H3CC>3G)TSDE;<(P^:<^3[.S\P!@=O'<5
MS-F*T$<,DL5@7F"61HN$?4".%V8Y#WE8./;N/ S<V[08E,C8L^EA/CY(=G<?
M%(9().6UOC-M7/9UD;:P=^F3$(&@Q>08"$L#^0BPIQB348LL&Q!WCA@QQ59J
MKW71P8XQ:R,5CF(M+TY6#CU&V+B0CR\7ENW'=]V;Z>W;99\DAE6*6MP(RBYQ
M/)R:-^3,0D7'QN.S[[-VO]"YSP/W=,N2'#_0&]-A)!4)KLR LY+(THXQ<#0:
M9%=Z^;YXC6+IZ1<-FUDVZ?FI*OG.=LO.O=6_E\EI<A %6[9KQ<NG%(X#R?<M
MF9OI=F9G?\&46/G.U2K6)>/4EC8RXML.[N_T,[N[-^+J6U8:S$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(J^R7$LKL_>4TF&Q2<D#0D-R()[:B5XA.Y
MK 9=(5L^).HM'Q%\'F6M)9&Y5&H_&%"F^@Y,!D59^UR9AR3R8YCS3E1\7._Z
M;?1]^_\ T]2B[LOA)L\ER!;)H1!MM*&;!V)IN:']C[!]F2@=J",ZOVNS?G&$
M1/2G9ZVT%=B[%T+JW46J=F2-6)EW4L<"XJY3D1%HK-W<7+EG;;[^W;;[V?M^
MC;L=^QFVV[?QV\/TW9U(@$?$[:V;#'KN'Z)CFJX>^C<7*D_8D]USJ[8T!UQN
MQXA)"&#0[-!LIWINO:CBZ[1A<?)BL'18.W!.'I2MT3?9^S_SVL^S;?1]&W_G
M9NNZUX-/8AQTGNCWYF)#VVT]F:\D4P#1<:Z;1/'74<)ZN%3J$)8-&T=1(%M@
MZ\@I\$2E#:-QI3-64,DB[$TZ!.I%("X=]WW_ /._K_\ /V?0W)GW3:D:69UC
M&I+J8,R?R S+84>SU^NJ<TBM??>Z=Z,H%J<2@LV!@X/-G.RHM"=IK,<PSZ20
M**R"*DA\@9RD&X@9<\OTVV_D_9MV_P __P#O\OY])V7P.O+8?QEB47;:N !.
M/.F#&N6L5? W;L(X>DY%Q[(E@HE^T'M'S&'S^#:HV/IG8#E-DU*$83N R0S'
MD7#=<*^+C?Z?M=]_Y_?]^_TONLM,>&,F-<6LM"!WVL62Y7:\DV@3 I1]T+UQ
M&4S<RD\_CD5U\%R9'P#89KN6D8D3P:S77TSA>QD8S(F$AUZ!M/<74/)OV[ON
M_L^C].SZ?O7)U.GA.D8^3 IF=#EGCHFW;&YP0UAAC/-HP%66QR3L==2E_(&T
MZCT4A&M6L)U]%X-&$HU/<74?@8M-H7@Q B[(-BY=]_M^[[&]N_\ -^SM[>U<
MT:]*F;MP&OA)O;L=DC:.QD?%I*USC#Q)DS10U5QVAKJ5Z^&9*.G(24@SVK=P
MOM8^QRT4-ZY9[Q5M%)N*3CI<1-B<OI[/I]KO_P#[;^C?A:%QWA$CA<!(K3%M
MB.EL_P!A;+VL?"8.6SS&,*[(FYN5"(>H[9*KCWI"'QM^$C!LD-77&&#PDH8'
M*Y,WZ'D+J_L_15R\IOQXGG]<;_B "I@^JWX_JZA/ZS_A^C*P;BE^!$+_ +LF
M_EARHS^L_P"'Z,I ^JWX_JZD375=DHB41*(E$2B)1$HB41*(E$48>//%6!\=
MBV\3X!RO(CN\N0&S>0!@T<&!L2P$KL_(/F4B88BR9HO+QH=F(QS8INEE7.63
MMSDX44OE:]95FW)9: 2;B,%>*NPBY;$T7+8R9WVY/OV[=G8VRQ*U2.L5@A?D
M5BS+9(B8>0O+QW 79M^+<>S?M[>U1N:=,35:(+5T;<[$V*J-UB]YGN6JK)8,
M**%4>;#&6#ITED2;#LE1CF(MI<]RA[]AABNDY:M'!&SN^.>.64^5E<I2:*/>
M5J+/OR=F[PX=/LW[6/@W-G^U]MEBMB86&$7EEVA>\[.W$7=K[&TG:S=CAS?@
M[?S9G?=<RU1TC(;J"#[GB,9WG)L7FY8/I[7Y$IGI3C5<(.C^E2AA['FK[7*^
MIG6O)C>0M2MF<Y?R^.%3LG626).323MW>Z,LN9DFD@,H!^8DGE9NO9Y.5@18
MOG.LT@<>/S; 0B+>+QV910X4(([$86#WGC@C=^]ZG$1@<G#>+HO$?+E\XY@Y
M&[;\F=^SU,.CCJ<3 -.1F(;>FT;E^HK[=;(3AUKS1DO'' N\).A+YN"1U9,-
M:FM70\>..-47$ 3AD8"VA.&3G!GB\R<YYVY^&IGDG,X0()^@[QM).#B5<'CC
M+JA(TINXO\YS(NIV;[;+K\!PM%  3R"</6;J/%7,2&P?4D%H9(BAC9B;>/I@
M/3_EON^]KMXDPM"+P1)7-$9:*_9)-=NS%L,TF%A'L?!5!@)8#0C+--OY,TV8
MP6P%M[VQ19L&K3!-NG4<WZG4_GSY]KN_;RY=KN[D_;_-W=W_ )N[]JN>#=/I
M_P N'#L9F[-N/8S,PM_T9F9OH9F9<TXRZ'!<8=":NT#&39:1@=61=O%A9PZF
MS2+DVK=PY<8N7Z8]%!E@OEDYRQO9NBFGYN./DQ\OEO>6W8*W9FLF(B4QN;B.
M_%G?^3;]O]5%4KC4K0U@(B&$&!B+;D[-_-]NS^B[K6.LA*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(J<.4WX\3S^N-_P 0
M 5,'U6_']74)_6?\/T96#<4OP(A?]V3?RPY49_6?\/T92!]5OQ_5U(FNJ[)1
M$HB41*(M3,SV#1UT68R"9Q,$] Q-[/3C,S(@XQT&@PQ19$E,RS=Z\05'1,>J
MW<)/9$\P1#M%$%L%WB>26=L>XQR$S.,9DQ&T8N(D[%(_T1L[-VF_\A;QG_DR
MZ%)&+NQ2 +B#R$Q$+.,;?3([._8#?S)_%;^;K96KIL];-WC-P@[9NT$G31VU
M537;.FRZ>*J#ANNEEFDL@LEGBHDJGEDFHGECGAE?&]KWZ.SL[L[;.W8[/V.S
MM]+.R[L^_:W:S]K.W\UCEI" ;G6<77.!T),1$DCP^.K$V29U\##NAK$N99B,
MU\2#H2*>F@[,D10;YLV+HL-;NEDEG[7!7MQ)Q<^)<&=A<MGXL1,[B+E]#.["
M3LSON[,[M]#KKR%B8.0\W9R8=VY.(NS$3#]+LSD+.[-LSNS/]++]92  2*&@
M8XV((&HWF/3D0=D29.B@',LSL0%8&AZ"RCL7F3896?#\7R*%WC.]G+:RB-[9
MT<29A)Q)A+?B3L[,6S[/Q?Z'V?L?;Z'['1B%W(6(7(=N0L[.X\FW'DS=K;MV
MMO\ 2W:RR]=5V2B)1$HB41*(E$2B)1$HBY28WOH^/1 /L$_N75(. R$BL' 3
M<QL.(C(@<+-\R*3@6'DKTP@%)D4%!!9-9DR>KN4LQ9'#-+')DYLE,->P1E$,
M$Q2"W(HQB-S%NSM(&'DS>,/:[;=K?:RA*Q7$!E*>$8R=Q&0I08")M]V$W+B[
MMQ+=F??L?['72!A,::',# 8@Q+"2C-L0&%!CM!^.(L'B.#AH^8/FJBK9XS=(
M*)KMG+=51%='/!1+/+#*V5XG9Q=V)G9V?9V=MG9V^EG9^UG4K.Q,Q"[$+LSL
M[.SL[/\ 0[.W8[/_ "=E[U<+E*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB41*(E$2B*G#E-^/$\_KC?\0 5,'U6_']74)_6?\/T96#<4OP(A?\
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MM>&P 121<2A.K,$@MWP<3\AG/D3'MRZFX;LQ;6^<#M/S70W%#4^K=B#QH27
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MI"QD=I[C1.+2<7E*7@)6'9YG@BB@Y]*-@74_>@T!_JE&?U7G^TK*^4;W$/\
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MC,DU7$PXZ]-1P_PRT<D=S.U\I+9.L4+6*V*Q^2>D,H69I2A<N'/([T\8O/\
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M,LSB\IA##&1O'%&(X>)[H?<GP76^"":AWPT;3/!B<@Q2#"Q-$!$4!%PCYFX
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MW&/1\2NEF&J9\-')0.2F[E]IME")+$+%CCVSAXAAKR1Q8>K$"AC)NW;XXNV
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MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%@92
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M8&ZD;/*TEMZ;$_\ */YQF?8O^%V=]GW9O6C/59$'(G(CQK0TB@IAO$8G+8.
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M%>8H"E>8:S[1N4$9OV/'$3N(N+"+LV[,S.J_NAUJ=4M*QT'"2N^E,8X60A&
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M^#!B>)F:8>'#K$7/<"[-^#"3?]Y54^J)9\7G,8].,1S>9^&#F:4G*N?4ZG0
M.&T@[]G-R%]O^%3/,];:\\F?*-[M7BJ&ENLN5NJ-$ZUG$ CNZIAKJ1#%^/\
M@4^RI<5LZ-QRYRPHRL7=9R>+^S$D2;?!(=8JB/7*MRE,&BNA#C&JY4XK.+MW
MK4,\E*&Q$37W'J@5623AS!@9HI>3N+[EQ<F!QOY.Z'WS8S)7<+'/4S=+&U+%
M:+(3U90?&<^B87(HNIPD<W>:'@S&S,'-@<V/6#O6>+E)6I)Q/&:$Q%O;IR2[
MIR#8I'I[([Q>/P"0%A)$)+@:1H07.INXJV&7$M@18\8N29Y-5'1Y-TV77?21
MZ- 8ND>3FF?PBAU&4LE>)I9+$8F,D)\#"/C*Y<G,(PXEOM&[.S-#)K^0I^M'
MB*\#-I6?2H0169>C%6E.,XYXV.,Y&*%@X-&<DG,=N4C$SD4<>-W4YW)Q4XT"
M- :@&6CY@-R]C?+)'8S>2E&RA-Q'H> BF>KY%$VC9!D>A1O[/-'QM)Z6ND^Q
MR]34'W]$DYQLLCIFGE<D=^V74 \1+B7K/&+\6EF.7OJ.9W<HY@ZCB#B&X_3R
M[795.)U??PN(#&40Z4@9R+-M;:8V<GB@BA[SE@%F&2O)TA*1BDV)O%X]C$I$
M=KO!CDCY, -@\*XC*^-/*+8P/>,OT$&W1-M?OXAO<<-:#CFR=>;6B8!H< ?;
M?)D@0E@%R")H.WOIT63Y@)>/A;JN\$9PCQLE?,S19+&5SI0WSIPV!FHD9$%>
MQ5FD<).CR<8I&,79MG(2)A)K7PYKR2Y>*UI^"?$9BW'D9\9'D+%4H,D(",MN
MK=@B&6+OGBQ3Q/&;.6["0@1@7+S_ %0V:H;ES#=>\6=7:DU[R<T=!=#AHC"3
MA=.^NH]!C)HVA)C)Q^.=%-I3DXY..,#TD/J"'+Y)LQQRQMZO;SLF/2[L>(FL
M92U;L8R]/?.:<!?OF2<8P>( $F&K #1MPCCYLSN7VK#EUB+AG(*N&IT:N8QM
M?&1P5Y)&[UBKR22--)(0D=VS(\CM)-)TW)F'?ZJA?P_Y*R#A[R5U'R4B\<"R
M\SJF1K&D8S(,UD19MF0#DX\6'J.V^"JX]TL(,/K#"B2#G(43LS)6:._5?5E;
MK+XV/+XVWC99#A"U&P/+'LY@XF,@$S/V$S& \A=VYCN.[;[MK^"R\N"R]'+0
MPQSR4I7D:&7=@D$XSB,7=MW$G"0N!LSN!\3XEQV>QB:=7.(OM?2;6.KN( ;6
M4:DG*K6O+E\1(;WGVS)F7V1!I.(/ED)7*9D%65-"C[,0@#&-Q+*,H1EKBF\]
M6-O\R"Q'78=)2C8BLVLN=F6+%6<0(C0KUH0K3Q'&#Q10FS <;FYDYE*\K[MO
M&/%AVNQKBN566G3P4=.&7-5,X1EDK-NP=NM,$IM/-8C=Y(Y!!H@$!A:%O&VD
M)S<^7O.J;)7>VNHAM:^G@6#KJ":EE6J3H:TN?Y(:S:R@<V'JF1+SV'922+L\
M6]E4V;Q 2FKEEYN2^%K>6^2VEHVJ:>J=^'MI^W%; ^B.]EXC<F QZGS;/OLY
M,Y_]%AEK.8KVJ;O>$?+4]&:C)'URVIC,# \@%T]YG%FWXDP,_P!K*2VO.M^&
MC,PX^[XG7![5VSN7NA->#=1M.2!':,[ NI'KX4#,1U#TVN!S!>),9ZZ$&7S-
M_.WESB_JY(PV%"!+1V/;B*VQH@Y8;]"#-VJV(O6"N/CFJP2-'8(PD?:R1-,4
M#$ N,#<&W$',S=B<[:KW1(X9\7DK.G:=S.XRJ%$<L=VS$4M4(I(FWJ +P#9(
M)"8K)=1]CD$(P8AZ=5FB^2Y'2'+:"\KF<392$I!]O?XM(PQT57'L"#KVVY,^
MQ53"3)TX;M_/<W0]=P8*J>;A93U?RW\VVU7L:-W$SXIY2C&>GWH\S Q$+<&#
MFP.3,[]F^W)F^]:9C<N6.S=;-# ,IUKW?S5W-Q$WZCR=-Y&%W9NW;EQ=_P">
MRDMLOJ3R'9&C]B:4<:I#"F>P>H9*^H"XD",I?.G(P[*1[U@IK1%AF&12<B6>
M+RZN$DS<I/%KIVQR$IVR\MJRMIN.M>KWFMF3U]/Q8!HWB%F((B$FLN3'NQ/Q
M[8]MF_[:N+>KI;>/M8]Z48#:U3-J=Y6F(G"282%Z;#TV9P'EOUMV)]O]METJ
M=]6Z4SC<74)VZMI2/CG?/[1XC29T(G,R+AOK5F)@L>A&)\2]R )*2-RN@ P(
M78/&XI)-5SDA9SE@E93/'@TG%!4T_4:[(38"Z=P#>$6>RYSR3/&8]3YMF>3C
MR9S?9M]NU95G6\UF_JB\^/B M38Z/'R1M8-VJ#'6BK]4"Z3/*[M$Q<28&9RV
MW[-U(17KG"W<W;;@(\+HB\W:8XWO.,L_G]]X["L*>P=W'T0RRVL=>+!W,-U4
MZ=N6C(@3\UA+EWF+7U)!XQQ>E7!"O\!S:%Z@YJ9J09%LG!!WC7Y-.TCGM:L,
M;36F9G<0\:)AWY.)<08;1^Z,!66OGI^ LC)B2Q%JS\(VN!5RB:-WIU7!Z])R
M=A(_%G=^/$2'E(YV(<&^0^FS&N^G]MO?NT>FK*R_%N'#XPEMW9NXI9KSD[HC
M6T50]%AK3'0+W)JWVS-1K!-Q'-=S-BF_$,UK)R@,*<EEW)$QKV<Q]T+&?J4*
MNI(1RDSRO4K4XK.,OV)7W[Y^$!9WJ0F3M)8A=Q-VWB,F'80VG3N5H25=,7LG
M<TE-)AJXP]_7+\U7,8VI VS5/@PN+7K BQ0U9Q8P9]IXP<W(Y*=9MU2O5,)3
M H7K-B?A#'JP'NI)$I85//Q!<VFB=>J =?$@7L=? 6T)#/573PS9VL^9+K*-
M_9:GH_.OM\&EN71L362CG?2D>G)8AC$P!WC9I+ GS;DXENS!LS.S;\^U:)8U
MGMUJU>F,M<=;2ZL@F.4HY)&:4GCJG'TWX"8;.4F[D+OMTWV6B..I_)'$WZC<
MUOJ()BMU#XB8B9YA:6/[I:P2+O7;W-Z(7]B6SDRB%W=T\47J8C'.V%LKYXWR
M\ELAM,1M#IR'OL]M/2A*!=$?]5Q$1V-NI\UOQ^EG/;=8KZPE>QJN?O&/?5,)
MPRCUR_T?,B+E&_3^>VY;;$P?1]*^BCC/RZX_A9AQRYH<A]K=-R72767&]2.3
MKD7']MR\=R[)BF$"D <1K-EQ6)YHN4MN+$7XYK)YLDQ)7)@%94"C;44**LFZ
M/G>2Q.0.'(X7'U-1PQVLEU8,=)4A+$"3SQF=DLJ&^]1@$GCAY#QDZ1R.9"[O
MZIB,[C(Y\5G\K=TG/-3Q/2L96*]..=, K2QA3'"GL[7B,A&:PPGSB>:.$0"0
M6;Y*.+/)9]Q>Y4:TY/"HFTE[_6LX>31I$2!580T+*.FQ-K9@X+-F3Y9IAAB2
MOG==)DO>^25L?1VMG>^/K&4Q@Y3%6<64KPC9@&%YA!C<.+@_)@<A9_J_1R;Z
M5XCALN>&S53,A ,YU+!6&@,W 3Y"8\7-A)Q[#^EA?M;Z%V;5O/DYK!?GPNVU
ML)+WYVP6?P@WBO(GC2VND9[*"LF7("KIBE_M"J-4*9M$F[OV7@XP1Q5S52RS
MOA;#M8 +7P#O9(/@*>O.&T;/WR\$81L)>.W3Y<-]VY[;[;.L^GJ:2H^IG:H!
M^$E>U7DWE(>]>^9SG<P\1^KP<^+"7#DS;[LI8DNL)%Y3#HC)MB<'M-[(YB0/
M03?CM%^4DREI\V%1B(Y@[%AY*8X_$@KV!'MA"FKUTZ:RA\5\N!9PLJBQ1"^B
M (U0Z0EBFECKYNY7P\U]\C+BX8HP-YB)C.,,@)C8"N3LS/$(_4;M)S^<5V>N
MX9H()K>G*%O/5L8.+AS-B>22-H %PCFDQ9QE6EM Q.33$?8;N["T>T3<)8=3
M*1,))TX9'CJ8*HIT[1:(P UO*WV.&T,49(QD7I2ZM@M\HSEDHRLU\QE@7M;!
M2ZOEOEC;"^>6FHWCU''WV>VH2<I'Z0_Z7>(H]@;G\[];?MX?1LJT=72C+I27
MO&-_!8&"(>L7^LVF&;>1^G\SVCQ\5C['W45#?)Z:J\OCO,F(,V,0V"]Y%&>2
M$>%^D4,BX]*B&QW6R6 E517!DH8%#R3C >O99)K<FQ34Q621LXSPQM QD+8B
M/#S$4U<<<&.D+L Y(AK-6(VVY,!$+<FVWXD_9OLJ63,6/AV3/5Q&"T65DRL0
M;O($4QVBMB#N["\@";\7W8>8L^[-OLIT<H>I[JO>L-W(UUMP0U!H_;G)>6QF
M9<A=UY30_M.128O'RUY"\RUB)EH)HTTM:4G%'3F5*QAX^<'&K]\W(K.G2J)%
MO1XS3%JC-3>SG;EZIC898<?2Z(58XAD#IMWR<4CO=Z0,S1-*(M&XBX["W%]C
MS.L*62KWQJ:;HXZ]EYX9\ID.^);LLIQ&\A/3CGC$<?UI')YGA(GD$C8W=W8F
MR.Y^K[*]QRKJ#RAWI"/ E.?FN=*Z\.,V\U)/L-:M]- F@-H4$K*1]ME(UCV#
M6SARV>8"L&.>=TTEG-L?.OTI:0BIQ:?B:])(V!LW; .\ B]E[DCFXDW4?IM'
MOLSMSY?<N^0UU/?FU1,6.BC?4U7'U9!:P9=Z-CXVC$P=XFZSR[;NQ,##]#._
MTKR ^L!*PG.31_-K#1\><&-)\>1'']GK_*:DDQL@8"8-)H3C)7)^T?R=,':Z
M,E4(9#DACE'!1I@WLZRQ5R5PY/2,1X.]A>_I&"[D"R#V.B/*,BGBGZ31]38F
M9XN/)R9^W?;LV=%KJ>/46.U!\'1/)C\5'BQK=\&P2C'6FK]9Y.ER$G:5RX,!
M,SCMR[=UI6HNK#M/1T-Z?T<U]KZ-M"_ B7[YD88\3,D'[;: KD&>+/YC&9"%
M29LO8;1,"=*QYL]'DWKGSET2Z6+9VU22M+;TI5NRY^2Q8D(,[#1C,! 1>J>/
M 6AEC-R+F_4 9'$A%NQP?<7=04=;7<=7TS#5JPC)IJQDYHY3D,FN!E)9"GAE
MC9AZ8M'*<3$)D_:TC;$+,NC.^K-KF S33TFXI<"=*\=V&O>0=N1\V;OY>=V[
M+-CS!0<Y$.HXSV!) (<YKS7N3!\Z7'PV,HJ"@YI 06'II>HNVA/';2=F>&Y%
ME<]=R)6,?\'0.T(5(JT7)C:5Z\<AA8L<A9BFD=C.-S G?DSCE%K:K6L4)L+I
MK'XH:N4^%K#%-)>GMSN+@4(VIHHY*E5Q(G&"%G".1HS#;@0GY=J]6^(3#66\
M]5ZYX@A]7A][;UUWR*E$B?;WGVS9NZV/"IR-FA'(R?EX2Z)*.%,!;<*# "!D
M80BK95X[],;=.E+UQ5TE-%9HVK.7.R=&A9QT48T(*L#5IX"@'A'%)N,@<W,Y
M#*1Y781VC9F7-W6]>>GD:53!!3CR61JY6>4LE9N6"MU[(6#>26>/8HC8&CBB
MC"%H1W+>4G=5^<U>3Q+F9R?VOR8+Q%C R.U"0(DYB0XLN<9!\@<1C\3P20*N
M60Y=YBX2 8/<LE&2%TU'.:-L<L4[*9[!A<8.&QE3&A,4XU1D%I2!HW/G-)+N
MX,1,VW4X_6??;?\ GLM8U!F#S^8NY<X!K'=.(W@ WD&/IP10;,;B#ENT7+M%
MMG?;^6ZL;6ZS62FUM=[S1XL15CM>-<0I9Q$GDB:[3EF0S8D:+QZ. 8K)$XZ]
M"O&$/=PRPP^[3'C<WZA_*3Y(%B]TPPZ]M=;1VU6Q1?*2E4ER\66@C>K%RKR!
M)))+%U!-BF:9R!N1<6CZ>XAN9+:WU^_?M3)-AH!NPX*;!V96N3N%J(XHHX)F
MB("& J_"4N <GEZVQR?-BZB'QYZ@$LXZ<:YAQ[C6O(Z=5DO(S2W(YE,3I)VJ
MD+/Z4/ )"'CSN+),[(&0YEY'VZ1//,PQ5LU7623PROY,ZM\A@(LCDHLA)8DC
M:/'7<:4,8MN4=T)(SD&5RW P:1W'Q";=F=U1XO4\^*Q$^*AJPR/-E<?E1L2F
M3L$N/DBECB*%AVDCD*(6/<Q?B[LWVJ9.Y^LI%MF@^8S&+\. <"D?-^!#XSN.
M=/=]; G\DPD 6^:@$E%T)&"3CT;A8M=P]7PU^'",;K9/,DLY1BV9"D!]-3T=
M+6DPY2Y@YX\).4M.!J%>"/IGV2#*\<CR23$S"W?!F6S#V1;D;E?7]>P6X\\,
M.!CK2ZBJC#?LED[5F9I8]WC.%I8^E%7 G)VJA&._+;K<1!@KZYP\ORO-C;L=
MVR8@X^ .H_J;76JL HTVY/-W+;7HI46@9S>.AXU1)<GBKZ99G9OFFVRQ\S!=
M:U_.ML&$Q X6I)4"<K#26[-OF0-&[/8-B<.+$6[#MLQ;]OV,M8U'GI-0WHKT
ME<*I14:M+IA(\C.U4'%I.1"+LY[[N.SL/T;NK'-;=;()%C/&O;^P^$.K]L\L
M^,^OPVH8KR-*[0G<><%-: AQ4(R:D-;BV*\55G-@IHHUM.B2QG-HY*$GPP&P
MR6:(L-<LZ*.4,E3KYNU4Q.2L'<EQP58)&"R9 ;N-DB:7H<P!^@+ SL(B1EVN
M6U5.Z%'">(O6].T[V;Q%:.C#ECN68G.I$)Q@)5 %X7LM'(8]\F\CLYF01ANS
M#S""]5Z&O];!]3<I>'<6Y,PW6^V]G[;T5C;<^P-0F=<.]MS)]/)9#3Y*(#R"
M.R8,ZD3W)UF!-#QN+E/#%L[66:H#T&&3/I28;)VL7F)<;+8J5:E[_1U[866J
M0M!#-&,Q"]:=HVVY@1[?2+,^[OB5M;0'4CHYG PY>O4O7+V._P#2%JC)4*]8
M*S-!*< DUNN\I._3D =V\5W<6%A]/4'5)U?#R<_*[&X*:L+$Y!MK_%;7\KXY
M[&EO#_9NL$DQ+,*TUHTVCJX03F<HU:R9,$'*$4,D<+*FW) ^^>/"N8MR([6]
M+VIAKA7SMH1CJ=ZV(LC7BR]:T_(C>R]6T8PQ6B(G9Y0'ZC#&S,')CZT=94X#
MM26]-TC.6]W[5FQ5J?!7*;, QC3&[3 [$U(1%G:"0FWD(I2(CX/'X-P]7[:&
M[1?.YE(-;1B-F.<,VXWRA>2QDT1;*:A:\9S,;=PMJ$'JL55)4_=#8L*;%"[\
M@)5S(8N"39J@DH@-;*FD*U(L$\=F20,)#D8NE* NUQ\D$C3.9,7S0L4I.(B)
MMQV%W=V<GZW]=7,C'J0):<,)ZBLXF=Y89"9Z+8@X2KC&+C\^1!  G(9@_+<V
M9F=@&_%/EOQSBCS=O+_:^Q.FQ))_/>'DF@\@WGH3;TM*\D]^3,A!Q,?B$(:\
M8COH7VI7:[@:R0F)8B/7(X("HTP(/A,>0?)"-$^"<C*-+$5:^I(X(,Q'/'1O
MU(AQM"$9BDFG?)@W&V+"1/" DP[G(0B<CBY^F-G,5 >1SMZUI*6U9P4U:7(X
MN].>6R5@J\<4%=L1+L5)W<1:>0A<V:.$"((F)H_G%;]2N1-W_39?VU0%RRZ<
MJUE8^G>5/K6VE>TT S'S3&7L:]XQ_P 4%@P\K*QC_AN,U_\ Z2=D\O17TU&X
MZD'OL_\ UB_W'Z0_Z7YF2'Q/'^=_W'+QN'T;?>O*!U;*)Z3/O*-WTK_M-UB_
MUG^HCG^<^;^9^IQ\7J?3O_+9=I$=7"/2T9NB!<G^),>Y!Z<V/R@V9RO@D*8[
MJV!IR4ZEGNTCA<S(0([8T('K$)-"5;%W22X,B%8Y/'3EZ15=8JYCDA6$>DI(
M2ISXS+28^Y6QE;%3S%2KW(K<%6, C,ZTY,,<S<&=C WV9F%FVY<K"/7$4X9"
MMF,)%E*%O,7,W6KCD+5":C9NR')+$%NN+G+7?F^\91CR)R-WWX,'H1/JR151
MGR0UAN'A-IK8O%3?\HB<X'\;(7*Y5I41JR8P4</#Q^01&=Q!J^DJCXB.%#<I
MJY62;OI*^:WR9O0 AV_".^TNE)&?'6:>:N5\K0BFA+)31173M13N121S02N,
M?$2,N@S.[1"^SL9L)MUAUM"XY:G?T]0M87)S06 Q->>;'A2GK"(12P68!*9R
M, #O@G9BF)O%**,BC*,//;G,[YRR72!U74$1TL.T?HF*:(C\2@Y8H3C=@$1)
M&GPM46@70Q>AF+5L7P%,!"KTNHT8L&_I2KQ;)12]G@<&.#CO UN:X5Z]+>DE
MG 1DZDH@),3@_$R=P<R-A!G(GV 65/J749:CEQTCT8,>&.QL.-B@K&9P]* Y
M"!P8VY1B+&P!&Y2.(BVYD^[KM\/ZK$L@>G>#<0C.F8NSW-P%G,J/Z@W>K,9/
MFW*0J?&B):?ZZEFM$,&H8BQF39<8#+'L#:19H(%J)@K!W)4@Y4PIM*Q6+><E
MEN2O3ST$4=NDT,6X35P$*]B*R^YB4+L4@1N#@YDW4YL LK&#6D]:AIV"''PC
MD-,V)I:&1>>9V.O9D([56>FW&,QL"X1')U&D$ ?I=,C)UL.]NJ7 );I;D!J3
MC)PP@W% ARXD 8]R<G8?:TSV<6GN <V[DU@,1%R(2%&ZSC;X^0(N'@,+9^.L
M/)D1;5NV27360CHZ7GBNX^WD\S/E1Q$9AC(#JPUA@Y@T74F.,S*S(,8@PF?$
MN0"3N^SL\N2UE5GQ^4HX?3]?"'G)8Y,Q9"]8N'9Z<A3=. )8XPJ1%*9N4<?(
M.!D#,S.SM$3C1S!+<;M1\N=3#X..E37EEJ1AJ@H:>&W(MQ"VK$D\)8F6#- >
M\3,KJ9/+I79N%V">-L+9V7O>]\;6^2Q Y&WB;93E$^*ME;$&!C:9R!AX$3D/
M!NS?DS%_T5%B,Z>)HYRD%<)AS=$:1R%(X/783(^H(L)-([\MN+N+?SW4G-!]
M3&$0_COJWC7R>XD1GE9"- 2J52S0A!7<,^TP=A"LV,?:.3QN2N(:S*M=A0HH
M?_\ 4%8V8:,DU,+V8N73EFV'I,JR_IJ>;(6LEC,M+BI\A%%%?'O.O=CG: .G
M%)$TS@]><8_%:4'+;ZS,Q.3E<8S5U>OBJ>)S&#AS5?&333XPGOV<?)7>Q)U9
MHI7KB;6JYR^,\4C"VWBN[BPL/O\ $OJX3KB?R(Y#;RCVB=3E8WR 8!/6='"$
MG$.UA"9#!)$,D&J)#'![5H76S<ZY48NTQMG7_/OWI5V;7*HF/([RZ9724&5Q
M^.HR7K0RX\CVO'M-:GCGC*.W'(3N'98Y,Y;>*+"P,#AV+OA-<6<)E<KD8L;2
M.+*#'OC@9Z].O+6E"6E+$(B;N]3B3!R\8R-Y'-I/&?0N,O4@<:KU]N_27(S2
MH[E=H_?>R$-TS"*DMDR[4$V&[C2R_P"9GT9V;"4'I46\-I8H(2)DJ)>)DT&;
M9NFLR:+EFQ3(R>G&M6*5W'72Q5ZA6[RAE&M#<@*G_*O)6G<0)@?=XR8A<7)W
MV=V!QQ</JMZ57(X[*X\<UCLG;;(3PE<GH6 OM]-F*Y78I *3L:87 F-A9MQ%
MY&/N\8ZNL'#8\E]?NN#^MAO&SD5 M40-?3.K]I3;5,DCS?3A@^>C)@QN<*,)
M3">%SA&1OOMX\+LF+J5,6[ 9FY8,+EFY? ETC.?P;8;-V2R6/L6IVN6JL%N*
M1[@ $H!2,AA@&,8Q[W8"(8B<BXD7!PLHM<5@^%ZI:=J!B<K6I5GH4[EBE+$-
M"266&23(1@<]F20Y2[Y*01>86$'<1YL?LGNLX7*S529BN,\)B6'9RR?IS,(G
M'I[(OLJ!@9DJR(AI>"1,""QQ%S&4&R@MK'RITSZ\QNSNZ/V=-5W#Y'HT A:$
MLE/+_P"L46HBED@CZLD\8D)PR.! #M*[\GD",.);[1[.S-S)KXSL=\!B*\#>
M"DVE!@BLR]&*M(8G'/$QQG(Q0L/ 8CDDY#QWDW9W*O\ X2\OYOPAWN+W7#(_
M'YHU5CLC@D\U[+,5[QK8>NYBSQ8R:)&%&W_,MDG>*+-^Q>)8+X-"PT>X=L2;
M%-T,>7^;Q$&;HE2FDDA=I(YX+$.W4KV(7Y1R@S]C[;D),^VX$3,0EL0ZSI[.
MV-.Y(,A7BBL"\4M:S5GWZ-JK./&:"1V[68MA,29G83 '(3%B I@[&ZJ @7 -
M2ZAX9\5H9Q"U3K3D=$^5I>,VV7--V&-@[C@KP8[B;J22V7-01/"(BLA+#'&+
M(I*8Y7'C,D23?U+S5Z>MI8RL6[F8RLV7MV<;+B@E[VAI!7ISB32M'%"1B\Q\
MR^==V^L6XOOV7MK6<85:-' 86O@Z53+09J2'ONQD3M7ZQ 4+S33M$?0#IA\P
MV_U V-N/;T[<?6.AVP8=S" :^X.ZWU!)^<468C][[#&[9GLMD1R8,7^;U.4,
M61]AB!"B;7<DE?LB!&"$G)(FY*E#)-SBA9+&IZ.FKS8@[&;LVXL),YT:Y5((
MHPA=MND1 74,^P&ZID6P@P@ L[K,R&O(+5?.Q5=.U*$VHH1')6@NV9Y9)Q+D
MTPC(#11Q]IOT(P!G,RD.0WVVQ$?ZS4BB\XX;;4#\<81;97%WCT.XH38T_G,I
M?Q[?G'X7'%@#2%'8<JSQ%PY^DY>D9/:1#%C#I:1.&UGK9Y'F*,?OWDT;'+!F
M*IY&?O;)Y LK" P1#)0R!2-(\P3,_.8=A&+IDP,T;/Q<9">11QZ^FALX"['B
MJ[7,-BPPMB0K,Q19/&!$\0UY:[BP0$Q$<S2@YN\KMR8HA:)::]ZJH364]XWR
M?A1Q U/Q.CO'78DCV>B$RDQ[<<PV1()@()QB2A9SM>3#@,T<P5W$#T@CC"*,
MEVR8IL96<MW^;D>#S%3#I8[,&1BS67MY:3(UXZSGTXZ<-:.$QEB."K$4D+3M
M-''(4Q,[FX,SBS%)S@+6D=2SB9M/X*EA(L5:EN-'UI+\]N6<)(98[%V8(K#U
MG@EEB& 79@:1R8MQCX?WNCJC:^-Z5VMI/BQPP@_$H-R+V!$=A<D#8?:TRV@8
MV2ZA4ARE@2. /M&("M==0]&1JN'V,="(O1[1L[>C1R;)D0(INU/2]@+M6[E,
MS/ECQU>:OC0.K#5"LT\?2.0^F9O8F>-F'J&XD[L)$Y.(NR_K&K)C[N/PV KX
M2/*VH+66D"[8N26WKR]>.*/JA&U6!I7<NE&Q"PD0"PB9\O+L'JZRJ?;VY\[Q
M7TE'QKSG=QO1X[&X\E-"+EMKI@C (I [2@40SCZ2LA=Y(19,E<6[:BT;*O,V
M_KGF(XJJ<5])104,#1:[(0X+(OD0D>$6>R7?$MCI$/4=HQWE<>3.;[,S[;NE
MK7$UG)ZFR3X^(#U)B?@J2)K!N-0.]8*W6 GB9Y2V@8^!,#;D[;[,SKS:WZQ6
MR]7X\060'4$+(Q_C-Q_V5QHFD:D)PJ_$;WU7M=_'WTK%'\6C(<[B3FRT:%NQ
MC@6Z*8MR+-HN\1?L<'0M[Q8T?6M?"[R6YADR>0K9*&2, $Z-JJ,@Q''NY-*V
MTA,3$P[B3LSB3L8]JFO+=/X"&.C7.+$8NUA[$,LAE'DJ5PHBF"7B(E 6\(.#
M@YLQB).Q"S@6 .=2+0HF6Z6<Z:Z<G'N)ZVUE-3,UFD!W/(3O*$OMY4X +1I6
M/22>[1#XD1D5"L#;LI%0S40[1"2UB!DBF9!819JZ[AIN^<5QKFH\A+9LPA##
M/2C#%A4:.0)&DC@JFXE*9 PRFY,\D1''XK%NT4FK,8$^/>AI3%PU*=@[%BKD
M)9<Q)>>2(X7BEM78^80QC(1P1L!-'.,<KN?#B_\ '+GJ@#=_\8@_$;46@"6C
MM/M=K([>+-IIR%V3R3D5SS$([!BX]##>QF(V^OH(Q1>KNK18*U72R?6LY2=M
M\WIVYKG$:8+'Y,\O;OC>ME5>H+PX^MC8^!2#(4DP5B+OBP3BP]61V?CV.S\8
M^#.:P#)X>/!T<8>.H#=:\;6,I;RTO4&,HPB@DMB'>M86)RZ,;.W+QF=G*7J:
M5Q9ZAD;T]Q[/\3>0O&\/RCX^/=G);GBL:MM><Z0FD&V3[$PCCXD$V%!4")%0
M 5#IW0(1I<=9!1=P^=)O$E'BGDFRFGI+F0CRV/R1XO(-5>E+)WI!>AGK<^H(
MG7G<1:03[1D8M]F%MO%6/AM4PT,7+A,IB8\SBRN-D(8N_;..L5[?3:$CCM5F
M(WB.-MBB<=MW(F+<G7<A/5QAB\2Y+ZCFO"+5[K06_#T!D034>JMDSC2#>#/=
M<LTV89H<ET19NY)L@68]7;OY8V)+@7)<JL1<LGHALX8L1>">DIFEQMN#-VFO
MT([$9V[=:&\\S67=S>.*4ACK$&[C"XL; +"Q";L1%8QZX@>#+T;&GJ98S)R5
MI0HTK=C'-7>J+" R3P"4UH).+%.Q/&1FYN) Q"(?NUNLG)-HE^0YJ_'J'Q5?
MD/POBG#LP,!30O<#$1L5=G%VTRB[!V"5=XI9-S&#)O%2)-Y9HDQ3RRD+K)7*
MV'-71T=4<>'PA-*V.S,V7 CA#G,4S SPRDTC#NSAN\HB.^_^VVR7=>2W9,I)
M\%P0OE<!!@I CL&\< 0%(XV(1*)RVV-A:$S+9A_W7W[(BBN41_8_$C2?3Z;!
M8E#603E1EM\;N>2S14 -'%YJ(4@R:$GR7'8CXQ&(_P"UK'"DKR)+9#V;-=PJ
MTQ32RSM;'C K9:[J!SEF<\5WH5**!I#((#:?>+8N4LLG#@,7%N3DS<E1QYB2
MW@\?I=HX*XAFN_@R$UAX@"2Q&]9FFW#C##%SZAS\WXB+NX[,K#>NMS0#[^D7
M&G1T6V)K3:2^G=3@)1O[8VF#3.1:TV%R?F$4BT?G10%)1R23.7#XZ#A81B%/
M?>LV0,D0BR;5P.<-4]>T-ACH1Y*]+7LU6N6I(J%>X!1V:^,AEED@"2(NV$I#
MF,CC^AW 3;=B9WVGNCY^/)RXC'06ZEUZ%&*;)V\?(,M.UF+$$,=DXI@\6<(H
MZ\8QR_2+2'&["XN+4"UOR\R2B+_1J_\ AZN.LGT%TWX:\F@QP)-[WGTKWXB(
M((9)/6,=E(F*Q.'KK)J8^7!,_$H,$E3.UKWO[//-+J6P6NJEA\[=T#(QW]1S
M- ?(*,$5!R%_%>2(Y99F;;_X<LYQ/_W@?^2^J^Y=BIL9I. K .$F2M39-@-O
M&&*8(8('=G^AI8*T<X_]V5M]GW933Y]].OCWU$M8-(#N@8^&2*,J/7VN-HQ>
M[5M-H 5?)I8//9[AT@X:E(^7]6:82&+E$5AI5-JU<I7'FAXDR-I<#J'(:>M/
M8I$)1R,PV*LN[P6 9]VY,SLXR!N_3E!V(=W;Q@(P+8-3:5Q>JJ8UL@!!+"Y%
M4N0[-8JF3,Q<'=G$XI-AZL)LX'Q$FXR $@?YRO._B%CPIWQ)]*8;!RV5A'G[
MMGC),HI:'Y.L6ZMT\<\A%I)*+(Y96M:][6)*6M?_ *5]%8/+_#-&*[WOWMU1
M8NGU>MQW9NSGTXM_I_[++Y4U+@O![)S8[OKOOHDX];H=#EM_^WU9MOSNH65<
MK7THB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(OZPQ\_/##R^3S\L<?+Y/+Y/.O:WE
M\GW>7R>7_IY;4?L9W^Q%]>/1OZ&_'_<D9AW+'D!,RFU0C,M@Y!Z.O&6T>AJY
M<99L\17G16YTV^F@/%19)3[,MV4:8/56]D#JAL,Y>!W'DFL-;Y"G)+BJ$(53
M(-CN]5Y)F NQV@'@ PGMV=1WD(6?<.!L)M[EH+N=8R_#!F\I8.[&)L4>.Z+1
M0/(&SL]D^K(5B/=V?HL,(D[;2O)&Y1O]G"**+9%)NW22;MVZ2:*""*>"2***
M6%L$DDDL+8X)I)X8XX)IX8XX888VQQM:UK6KQMW=W=W=W=WW=W[7=W^EW?\
8F[KWUF9F9F9F9FV9F[&9F^AF;^3,O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g838337g33c68.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g33c68.jpg
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M"ADA.%AUE[36,;<:(I4C)%%9)4%"0U-QDIC1U]G_Q  > 0$  @(" P$
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M6)@+J;S)I)I>/&TM75,TT &LK4\N6Y*62>A\$::T*B@% * 4 H!0"@% * 4
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M$)M7.6HB3<X $M!K>+%@0BY<OL?I*    '@$" "%N5 080((0=L< P@\,<<
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M0"@% * 4 H!0"@% * 4 H!0"@% 1O,7--)?T%=/X*<J5>M:XD.YZGP,/ZSF
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M@C<?2W)>IFY&J\/MJ4W0A0RY8NS<@L<2TMJ4AI3\;T7OIW0_=Q,U):#F74/
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M)C/V* 4!4W67X\[G^=D;_+KKI0EW+5^++94(% * 4 H!0"@% * 4 H!0"@%
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MH)GS^!LH!@CA$F*\G"J@&12Y@P=P-&202?B$1&"$-8&12H0XC;/M_%(FR@%
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MVPQ*7$&Z@&(E[0['M:%3BLNT84KVZE64EFO=$6AMZPHFDK8LESS*T:JWT_\
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M:]&G3J6*][^37F_3=9UGW%4-8_+!SJH>IZIWBNG.A7L$]5B@% * [P?T5O\
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M^FM8VQ9"57HK*"4J*2^&:P,H I^XNUD<U*4DOE3[5ES7M8JG+)F.INAC% *
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MMT:4ZX?"'S!;G4]I]RISLV!7/+!+ZS6#]ZU4X9*^7Y^@H4 H!0'[;:^,;?\
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MA:)IP\JYO(\CDY222FI*3SK4CH/H4/0)7DQIPM%TD3$_3HJ<QHI8;NDAY'P
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M -YYA>0EM]/I+K2?X1_/FR_JK4?O:VSZN_ 5_NFPB_Q#M7_3F"AD36OYNF*
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ME''"U%!'!$E%!'"U%#$DTTT1K^JLX?/\,#%^ON[_ ".N$_9?!GZ.V%_*+/\
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MPE@%3/,5?4@FY( +:(.00W#>T,&O-M* ^>:8,II:<O--^-%2]V([?Z:;9SK
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M,R@B.-GQ]>-6AB7,LZQD6RY5HA4L^6:RK7E<\TWGOT1U)U CDB=CB=$&/W)
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MYQ#Q(K]P'525<M2X'FT)% * 4!7/7'N?+?ER?WV4>K1>CZJ*P^EZS+&54L*
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M5^3*UENREAM:Y-VIW/;;,:#M&@5WZWM=0$O)^U3/#8\D,;>5J)1P0FC,U@1
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M!JKA.*+W.]LJ1$QBJ@"I+;';[:#3T<LVDU'20;OD\FCHS+9Q-"*$"@% * 4
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+!0"@% * 4 H#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g838337g41p74.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g41p74.jpg
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M-5%8ER(C)"=65];70I66U-49.#EQ>+&V,W5W>9BRM[C8)3=3<W:3M=+3_\0
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M;*OKJR6P3"+O!9C*16Z<4C0-@SPM5+R2MB=@H5QJ<HI[!!*B/6>RY-D:1$)
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M&Z'8BP8JP:Y73UBQ.255S;JP248)KNA??;+FUA89HY 2022H*E2JMKZIIXU
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M@$!;D%F4 G&W24RU+R*\P@6.,2%V"%1JFAA[1>2(*H,NICJ+64A49B!B6,>
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M9FW6Y&$4D3E3(^+^#>A'6\'L6GL$=PP==PQS3),7,\43)=].E67*BJ8JRZJ
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M![:?W7&R+PM?L_7-'A1R,MVV]KW_ (VFJT>X\;UU/#B4*Z['+&F[)LVE2*Z
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M1<\2GS8YIO[4:9X"9('!S';.U\7&PLR"#&2Q;>>.L$S;@R!]9KT1V,VN+6;
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M2T$U*&?*6!JL6D*/*1"GW%:L*RZTY"QJN1:H19<<(RDHHW.8QJ.^_'CP]/\
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M'L2Q<EG@XD>4\QEE.GG1F-H73*\P5Z<WA80TMXR:=*0Z3X;SIXXXB#<%47F
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M==34VR:\UHL!,<>S"TBC7"T56NKC^K@ITE"9[-2<TZ8:VW[1WO?_ /L;GUG
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MJ_6:CTQP_HZT?7EPM--KGD[>V@#Q. SV9DYHK"Y[SO\ QO\ W[X"^&W%<*V
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M 9=4ZXL>H=;K 3'#M'6E:PMUGHM>\GZNK9PD-9[,R<T5A<[[G>]]^\W/K.^
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M_FNO?E.(W8FTY#49']<V1_:Z@,Y6KXV<Y1>VVZ@*UZA' ?[[KF59#]D6N6:
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MG(+S&]G\B;M[A5VQD:GG'R?SM$4$;F!UG,C)SC'2'PG0@ #)9  + "N4  <
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M/ZR -FR&&&EOU3SY'D;'U'8]QVP@[^T23Q&9C=U:D(X&UJB!LH.QZ=+Q+K?
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MRPD8'MI%6M,ERS0!6/I^SME"+8[TV,V2CK#"%J_6@U(2#M=T6 @[V!1Z0JD
MBI 6J-$6:LL)&![:1?C3)<LT ^A]/V=HH1;'>FPFR4=88Q'-<I?#KUU9[+23
M6R>.U1M>K"=7#66NNP:Z-)TPN!(3*[21TB(T*PS'S1,\Z2&5*.PB.PU*$VPN
M.#4F:N3&;&W V-[<;&W'U6W[K;X]K7);P\@RQ\8.R^-<=@/K2L[EB3 JTY\6
M,U77ZT?L=+V!&*"8;PV'5PU5SLY.JE6I3<>"+?,YA\FFI,O%QA8]QXVX'CW?
M7PQU2.3WASU"*4ERMM\6*S"H<72<XI)?*:_#1:O#OE*LMZT)+R>SPCM#XY77
M35QN-">9RPP@TMFSV"!E#!LEI>+"S=QWOR.]N/UVYX@_Q0-_5;@1Q F\AM<:
M/U)<B(&Y:GKP4*1!CA(9N%ZHH.K<Z#,!0<7V,JM!*%,:QZ3+%H8P6(-P%89F
MR$=[W1O)X\\S1*"69X$>&:0R1JK,#$NH"S;6//'ENF&>S=',EDS."".HD2H@
MB$4K.B$3,58DIVK@;@<#SQ\T47[0?MT9#"3H7A^Z$'CW0\"Q5R9%$6>)#< 4
M.6=KPPX$D-"6V,P],GYV8' )P<UA5V7F=&1WX;V1!A?H7DWRS4R^-ZC4KK&R
MZ*?4KLH=48:KAV1E=5-B58, 00<?*O*SG(56\1TP5XVE1NLJM+1*[(\BFUFC
M61'1G!*AU920RD"FL_:*-BAX8B='X)<<A8_S"\0,QF,=@P_/2FYD(+B(D8#F
MF/-4FC9"(+2%GW MEYC$3TF,]_!V0^#3+R2HS6J++;4HB@)6][7%[B]C:_&Q
MMB!^%W-0JL<GHPK:@K&:ITM:P8*3L;$C5:]MKX8?:*-C XX20WP2XY!XKD8-
M.KC^$8Z/CN0ZD\;!UZ8$<Q',MYQJS(>L8<-(@9*T%>=-CX.<;-R>RH?!IEY+
M 9K5$H0K 10$JQ4, P!NI*LK &QTL#P(P/PNYJH4MD]& X+(3-4@.NHJ2I.S
M#6K*2+C4I!W!QY(GVCB[CTAXP.#_ !GA(/\ 8O;TB>[QD@_%V"$6L^C1F#@D
M;X[&+%8X+Z/D]H8)D&1_IVYDG%S/DRH?.=7[&'^.,>5_,_-%%[>HQ[G?M$NR
M:Q(B0'N!_'2O2QT>K3($-V*>$R(,42+D/TF5$CYC8[L6.,"V"4]5GV<,&X0L
MW(<$Y-Q"3BO17X-,N<:DS6I9;L+K% PNK%6%P2+JP*L.(8$'<'$G^%W-D.E\
MFI%:RG2\U2ITNH938V-F4JRG@RD$7!!QZ&?M#.TQ H:;C\!>/HP''6L>T%V1
MUCA"F%"_+!-,]MGX"VH;2B?;KR,K'I7<?0>@MD,5]+TIAO# ^#;+2Y09O4%Q
M>Z". N-(0M=;W&D2QD[;"1"=G6^3\+>;A!(<EI1&; 2&6J"'49 H#$:3J,,H
M%CN8I +E&M28GVCB[CTAXP.#_&>%B/4&L!(GN\9(*U>//B5I8:,P<$C+78A4
MI%!_1\GM,<E/9@>G;F2,7)^3*A\YU?L8?XXAY7\S\TT7MZCGQ]>$3[1Q=X"0
M\8'!_C/"Q'^Q^@QB>[QD@_&(T^'6O1HS!P2-\>B%2D4']'R>TQB4]B!Z=J9(
MQ<>3*A\YU?L8?XX>5_,_-%%[>HQ6@'VA/;,Q!^-7X :!E)%9RDBL0 JROI&8
MU=7B!7*0/0<*R^BSKJJ%"I+)V,F.%1KQ$A,7(>-F27'(-\&^6)?7F]0EC&#J
M2G6QE?JX@;L+&23L1C^F_96[;8FGPM9Q);1DE+)<2D:)*IKK#'ULQ%@;B*(=
M9*>"1C6]EWQ7/^7MW\ KU8M?_)P:="U0MA =IED^*W0=7B;=&&FT%NU@Q[$R
M-FX4\0[8T@9BI+F-?&N&TCK$BYSN\!\'>4-(\2YW*98BHDC IC)&6("AT#:D
M+%E"Z@+E@!<D8L;X5,]6*.9NC\*PS!C%*QK!%*%#,YCD*Z'"A&+:2;!6)X&U
MDQ/M&]W@)#Q@\'^,\+$?[&L!(GN\9(*UB+/A5I8:,P<$C?'H14I$!_1\GM,4
ME/CP/3M3)&#EWDRH?.=7[&'^.*/*_F?FFB]O481/M'%W@)#Q@\'^,\+$?['Z
M!(GN\9(/QB+/@UKT:,P<$C?'H14I#!_1\GM,4E/CP/3LS)&#CR94/G.K]C#_
M !P\K^9^:*+V]1SX^O")]HXN\!(>,'@_QGA8C_8_08Q/=XZ0?C$6?!K?HT9@
MX)&^/0BI2&#^CY/:8I*?'@>G9F2,''DRH?.=7[&'^.'E?S/S31>WJ,(GVCB[
MP$AXP>#_ !GA8CU!K QB>[QT@K6(D^!6UAHS!P2,M>@E2<,']'R>TQ"4^/ ]
M.S,D8./)E0^<ZOV,/\</*_F?FFB]O4<^/KPB_:.+O 2)C!X/\9X>(_V/T&,7
MW>.D+XS$GP*WZ1&8."1OCT$J3A _H^3VF(2GQH'IV9DC!QY,J'SG5^QA_CAY
M7\S\T47MZC"+]HWN\!(F,'@_QGAXC_8U@8Q?=XZ0EK,2>/K:Q$9@X)&^/0"I
M.$#^CY/:8A*?&@>G9F2,''DRH?.=7[&'^.'E?S/S11>WJ,(OVCB[P4AXP>#_
M !GAXC_8_08Q?=XZ0?C,.>/K?HT9@X)&^/P"A."#^CY/:89&?&@>G9F2,''D
MRH?.=7[&'^.'E?S/S11>WJ.?'UX1?M&]W@I$QA<'^,\/$?[(L#&+[O'2$M9A
MSQU;6(C,'!(WQ\>4)P0GT?)[3#(SXL#T[$R1@X\F5#YSJ_8P_P </*_F?FFB
M]O481?M'%W@I$QA<'^,\/$?[(L#&+[O'2$M9A3AM;6(C,'!(WQ\<4)P GT?)
M[5"(SHL#T[$N0VX\F5#YSJ_8P_QP\K^9^:*+V]1SX^O&9/#+Q_\ C/?;A$I'
M*GCOKSC_  WY==9IVR:*$CV*D!'0$&8)K<2V"W N)^LQP$4H3@ +&']X@!H1
MF9$?@5X5[@3?X^;_  <U5-#U^55)KB@)DII46*=K<X6#=7(;?FVT,;=@NQ"X
M[N1?"O25<_@^=4PRX.;15<#R34ZD_P!&H0KUL8)X2IUBW(UK&JE\?3!3ZSI.
MS5ZN6JA5[5QZJD(-=*U.PU(/5"0&8-"#YT"ID*^5$1GH#\,.+*DH5>E#W\F1
MT C.BCLV8\N0VY\WDBDAD>*:-XI8V*R1R*R.C#8JZ, RL#Q! (Q]9BGCJ(DF
M@F2:&10\<L4BR1R(W!D=2596'-20<5R+K+6\%(F,+7U(AXC_ &18&,6J 8Z0
MEK4&>,KBQ$:@8)&^/C2A,>$^CY/:H)&?$@?08ER&W(8LN>\^O"+K+6\%(F,+
M7U(AXP%"+ QBU0#'2$M:@SAE<6(C4#!(RU\:4)CPGT?)[5!(SHD#Z$>7(;<8
M7/>?7A%UGK>"D3&%KZD0\1_LBP,8M4 QTA+6H,X77%B(U P2-\?&%"8X)]'R
M>U02,Z) ^A'ER&W&%SWGU]_'UX1=9:W@I$QA:^I$3& H18&,6J 8Z0EK4"<+
MKBQ$:@8)&4 ,*$QP3Z/D]J@$9T.#]"/+D-N,+GO/K.$76>MX6,3&%KZD1,1_
MLBP,8M4 Q\82UJ!.%5Q8B-0,$C>P"R9(:$^CY/:H!&=#@_0CRY#;C"Y[SZ^_
MCZ\(VL];PTAXQ-?4B+B/]D] D:J 6$@_&A\X37/1HU Q2-\?%%"8P)]'R>U#
MR,Z% ^A&ER&W&%SWGUGZ_P"_?"-K+6\-(:0]?4B(@_V18"1JH!82"M:'3A%<
M6&C4#!(WL DH3&!/H^3VH<1G0H/T(TN0TXPN>\^O"-K/6\-(>,37U(BXC_9?
M0)&J@%A(/QH=.#UST:-0,4C>P"2A,6%^CY/:AQ&="@_0C2Y#3C"Y[SZ\(VLM
M;PTAXQ-?4B*@_P!E6 D:J 6$@K6ATX/7%AHU Q2-[ (*$Q87Z/D]J'$9T&#]
M"-+D-.,+GO/K.$;6>MX:0\8FOJ1%Q'^R^@QC50"PD'XV-G!J[Z-&H&*1O8!!
M,D*"_1\GM0TC.@P?H19<AIQA<]Y]>$;66MX:0\8FOJ1%Q'^RK 2-5 +"05K8
MV<&KJPT:@8I&]@#DR0H+]'R>U#2,Z#!^A%ER&G&%SWGUX1M9ZWAI#QB:^I$7
M$?[*L!(U4 L)!6MC9P:NK#1J!BD;V$.3)"0OT?)[6-(3H,'Z$67(:<87/>?7
MA'UGK>&D3&)KZD1<1_LOH,8]4 L)!^-C)P6N^D1J!BD;V .3)"0OT?)[6,(3
MH$'Z$67(:<87/>?6?K_OWPCZSUO#2'C$U]2(N(_V58&,>J 6$@K6QDX)75AH
MU Q2-["&)DA 7Z/D]K&$)T"#]"++D-.,+GO/KPCZSUO$2)C$U]2(N(_V7T&,
M>J 64A?&QDX)7?2(W Q2-["&)DA 7Z/D]K&$)T"#]")+?:<87/>?7A'UGK>(
MD/&)KZD1<1ZA5@8QZH!92"M<%S@E>6&C<#%(R@0I,D("_1\GM8LA.'P?H1);
M[+C"Y[SZ\(^L];Q$B8Q=?4B-B/\ 9O08QZH!92%\<%S@=>](C<#%(WL(4F2#
MAOH^3VL60G#X/T(DM]EQA<]Y]>$?66MXB1,8NOJ1&Q'^S+ QCU0"RD):X+G
MZ\L1&X&*1O80A,D'#?1\GM8LA.'P?H1);[+C"Y[SZ\<QM9ZWB>BQBZ^I$;$>
MH7T&,>J 6<87QP7-!5[TB-P,4C>Q!"9(.&^CY/:Q1"</@_0B2WV7&%SWGUG'
MMV42XN:$K0ZW[9<T=J.I1BE="";%=F*3304<P%KYL=4Q@\D6:@0V)X>K96*
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MNI-D@Z<##5 @S[;8U*;#M%9FDO6SA_LT,+[O$<D38T>(]LTTRP%W(+-HTHO
M7+J22PW%E!M8&][8IFC:0*H("W)8\3;2P  ((-R1]5KXUWU7@GSWD\?^9.@+
M[3=.S"O+SBUJ/6A#;C6YR.;-:VAJ?A75-&O/DJ@FMGYYD+=-E4YIU\S$-1)
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MU/T>?V,G^'#[OK[_ &(M_P#LT9_W+IU\'ST7M$_CAX+4_1Y_8R?X</N^OO\
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M.15UI\CS&K10V)A PFT1]KH,P>Y*%?9EO9J;4"515[(JE @U\R,G)=G+%'(
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M#>)<Y\TYG]PJOPL#TAZ/[VSK*>)M_.E%L+BWYWD+@_7Z, ?*RL16P*6'Q+^
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M.*O+LO:.^Z]JZ#'B#*,3GS(I;7NSK)A&AX[')AZ?#\QBJ"'"$XF1CN,AFB>
M_P"J1=BLN7TZ1NSF3Y*1E^)'!T7?2">#&UAQM?:^)RLRA='%FT[6O\EC_2('
M$"^_#AOMC6MOWQ5.1^NI1?73-*UV%V5I*[ZW:W#-K!:1=<[**JM!)W;=M::I
M90"/DTK#8#H4DWIDG@<+DR==CYD\ECRE7%K8CI8WLVIBKAM%QIL2P5#J!.H+
M?M[ 7Q2\[K<66ZE=1!O>REG%B!8FW9W-\>^Q>(ERTK?AH!=TNCA93EW<.0.W
M=7U^M!->3+!&:STZ4VUL.SUE*8!8G39#,/6.F+-52=FR8<Q!I(RN)3-A(+SF
M!:>)JDI<B%8T8DL!\L(H;4=MW<&W/@,9,L@AU?G"S  +?Y-R187X*IWW[SB5
M>'?B#["WGO:_ATVEIV]ZTGV?8^ L8:) Z#+U*-'\TC.B=05IX\ @G9IFY[;U
M$C=EH--N V&5O]Q M0P]B$!SCTV!&:G5$4Z'5M*W(NP8F 2.;&U@C[,1LJDW
M!/#,<K,S=I2+FUR!I D*J+B]RR[@<R.-CBQ^4//O>^M[_P LQFO]ZZ6:I&I+
M[I'74N>3KE78/:9/WFQUC$VRV,*VI\A9A8ZL%X<6XW^["1]):OES!U*CK(+5
M>WP(,HZ>-DB+(^IU=@ 39PH-KD*0+D-I53JTJ6.Q!QAY6#. RV5E4D@=G41R
M)N2 1<_)N0-R#C'.V>*=REC:/VKMD+N31&# $A1P4MQ:>"@3]6[,PT7R+V_;
M]>/5$K<IQ_*KN6.@:@TPY;MA,BR-FVG.VT'URWC$@U>3%L%+%K1"DES<VU7U
M(9(T5@0+7LSO87L@4MSQ#KWTLVI-K<AV3I=BI%[VV5238EM0'(X^F&KDIIFL
MUTN1BI!(%00@E/@I@ZVD.;.'QY4J*C;W=[!([[KC/D=57<?)Y7/Y:+US2+$@
M< 2/WXW!N >\#%=ZQC.'3##IAC!BU\AMH^EWS<:H1T/6ZGQ_/6H&9J.S"=AB
M6^P+2P$&P3B!VS#RT(9JF#:(\S&3479=0V"DFJR@-T>^HV=2OCO00Y92:LM@
MF7,)9LSCADCFI$B:&/KY6B58XG4O6-"5M.%FIM,RRP"QCZUN:]7/:JDC-,D=
M(\B,DS.'?JT#DM(ITP!P;H3'-="LA^5I$::4Y*[HVI1MI[= 7'0\'6]=LYNR
MUD=M"6:@6?[NC%1 ;/JC=P/!)0H3K(>[4;..S&DYH#8;GQYV'<7GR,6<R$8V
MZ_*J"CJ*.BE@S%JJ6&.*9J-8WB\*2:2DGZB.0.]6PGA<.BRTPZT-  A4R&FF
MK)YXYJA9*80J[.@F+!^I:-9DZQE*K #&ZD$I*=/QAN&"CTZ7Y!<@=DUW;NPL
M3>EJ75:E;I!>!4-SN'!MVKU2,Z[INS1@2^E@LD(.UDQ!$VC%ELF0 [ ?P%+C
M:'LI<5Q@&S&ORS+:26CIC'7SS30A&GH>K>GEF2JGI&DID<2-5%GA)*+)3C7\
M2 K R'-/5U4R5$H:GC2.0LL=1J$BQM#',JRE2H@LK\2DITV<WOI%W5;FH1(4
MN-&L>M9 ;?-W'4\[I#3[\]T=(VR!VL(<L- (Q)\F++?"LTR$T7'<@LEB%)6J
M'*/;+/)@$*J0I,RS4S9"JSEHJH29?3M/'F%:$U"BDHG$52K*"HD,[&-\M[2"
ML%1#"&69:A89IF),8#0E:F01M34Y:QG6=2\1#$'2(P&%5L3!U;N04:,O%\GF
M+N:-L@UIJN4MRQVT.0V 6,VA:J1NHIR!7;LY3(P.F4^NDZ$14;!D0Y) R0-V
MLM/K$4G4X<YZPO6;&:)VQD= :6.NEJ!##(M,B0]<L#AI*?KS)//*E0@=@RK&
ML<*+*4G91&(K/3X?4=<U.D>N13*S/H,BV27J],:*T1T@@EBSLR!HP=6L%<^-
M+6>_W+6P&Q;/I^%$NDZ38VB%=PR1$0:-M!H763N4/UY5T*Y;:O"#6URM2RA(
MA5W#>5=)3YD\7)D.>=KX::"JDBI)_":=1$5E_P#$\,;RQZM*"00S-)")51%F
M$?6HJJX ZE.\LD2M-'U4A+@IZ [!'MJ;3UB!7T%BR%M#$E2<2GUIXNPZ88=,
M,.F&'3#%N%:?4CQNL68Y5JX9LE)DE9E,L!4(,(FZC+.B9 $Y*K!69%>G@))D
M%,EA2KXJ1$=(B94@=,R>AONLY9!(! ) :VH D V-Q<<#8[B_ [XQ8$@D D<#
M;<7V-NZXQ" _AIQ $FFK&*XI\;1EA8K4NF,GA^C-80S3-/GU:31IU4:*1JNW
M.;K4VDS)=/E@L'T%R:M*DU]Z+F)?=B96&:8C2992NK58R,1JO?5:]M5][\;[
M\<1ZN,;B- 0+ Z5V%K6X<+;6X6VX8]@GB-Q2 XZRQ!\9>/P;'2I&>7TZ@K3>
MNQZ:I+%9^!4H4UQZ2NM?"2)(HVV3GS:U[;)F$FVY\AUR7A@\F#+*=5Y9#K #
MW=CK V ;?M #8 WMAU:"UD0:=U[([)XW&VV^^V+XUCI+3.E(A^!IK4FL]2P;
M6;?LUHAZTHE7HL6QV.5CY9)X]'JXH6T7,OX(F#I,AA(FYX(F&3RXHB)AY'>V
MMW?2+#6Q:P[A<FP] VQ(*JWTJ%N;FP N>\VXGTXD[J&,X=,,.F&'3##IABW[
M%4JI;V1\:V5FO6>.(*PSHIBQ!1IID8;'KFL R/:)1I.$(K!5QQ89&-BU+C*Y
MFK+V"Y9=V&*;+USKV?/%E9]$ILTH#)%#(4E+JX23/#F#<O$@:*BYCT'.0/)%
MY^&$TI.B.,RB$O#&3+==>Q3-&&*1CIK4&"88X:IUMCBV1]XP3&C5C%,"R)BB
M%,$06B8D43'%/7)VD]L<?YW\$Z8S<]YX6^SN^K'LD:JU?+;,M2M;T*2U8S\6
MUV%N13Z\\V>M$'/%R%9#.#@[+$H?AYXXYQ3$Y'R,?/'')J3@J(J,8QB_X@_#
MFI<Z^.!?0%UMUBI (G::I9G#U6C#)19J369^<R/&P9+,OPU8DYN+@_EDW]3'
M%$5M47KKY)F\V1UZ5\$4<TB1R1A)2P0B5=))T$-<#AO]>.!TDR*#I%E;Y943
M2T\3S0RF2$(7!A8L  X9;'@=K]V-+@?[/33Z^4F' 7.;E:',D#(BQSB@TC7X
M4^6?K[$B*#,R94=EMYXF(BRI,8;-SSRD0H[[C,?-MO)<>O5/\($\B!'R7*G1
M4>-49)&58W(9T +$!695+*-B0"<>&C^#"FB<R1](,Z1VD25G62)6:2(,L<A(
M6Y=%9@K'=0; VQV)]GNJ.)7$YASEY5-E\'&'<"+4VN-2L<XQ:OGV,L7&X^"I
M],Y5*R7Q1/Y/N0 1-5%D#XSC>/R_GT:/$N5%""-)64BQ22,\6YI+*G_TR..#
M&X?!C3"3K1T@SH27!UAX0UQ)'*-PO*6&&3_ZXHVXHI'01^SRTLNY)=*<X>5,
M_.9G)SDK+FUUY'LI;=U:D^?'-A<?*\SLC8+.>"8I@K-VM+28HV=)8R,K\($Z
M@!<ERI;6 LLHM;J2.#<C34Y^N&(_T%L?X,::0L7Z09TQ8DMJ>(W+>$ W[/,5
M=4#Z*B8<)'OV/?9ZZA(#.UZ1SEY5O WWB4A\4[.KN<)YTQ6B5,*J\QDPN#N)
M"IFC-<EM9IDT\&,%A^>"QB4UM\.G\X<2#)<J#@* P64, DBS+8ZMM,JK(#Q#
MJK<5%GDQIC&8CT@SHQ$NQ0O"5)>)X')&FQU0R21$<#&[I\EB#0,_LW^J'*6U
MKESF'R0SH;!-#+-0R9J&5>;*8K(RPFX"E@K$1UMR9->:[->1J1-FR6\<7Y<A
MQVP?")6"8U RG+1.5T&7X[K"NVQ;7>VP'U #@ !6?@KH33BE.>9L:8/U@@^(
MZH/O9M&C3<:F(VV+,1NQ)ON3X" ^:88L$WGYRZFF8[+,=HA,+ )4A&&$N?TV
MLE?9<Q=;7/8^P7GL7<<TD2;S;Y4A'9-D,.S*!T[D"&,9%E 0DDJ$E N>IN=F
MX_R> >@0Q ;1H!L'X-HRXD/23/&<  ,TD3&RB< ;J;C^55)(/$U$[&YED+<"
M_ 0@A,AS@CQ .7XYT0I7(:_$.!F9$)PV>AVHJ^P_A@CV$F9:!P^R.2?.LC$_
M!AF6G,"45B2V;IV[ZM6190P?3J!CD((1#$H(U6L(V:.W QLR$%202?!M''HT
M=),]7JRY0K-&"IDD69V!TWU-*BREKWZU5D!U@$>1S[/^!=AJ/SYX<L<H"U:3
M25A>X5U(N53F0H(R4 RCI'1K(=(%BQ8EUE<5\XD8-%*JCX$2,SG\O9=6KQ'E
M.KK1-JT2WZU2S+)?5?4&=V!_69F^4Q)P?@TA*Z3TBSO3U+4^GK(=/4,JHT5M
M%M#(B(1S1$0]E5 M][[.9J-VF!*)CRNWU& @9,AZ)A#'5&*^_%S*9GQHJ<K,
M;&-)&5VQS;#8JZSE%Q>&&K;99N$AS(@WC&L'PAUHF>?Q70%Y  ;F8@'2$9Q=
MKAI(UCCD-[,D4:V&DWJ/P6T!@CI_'.9B.(DKI$ )76941K)8I%*TLL0M=))Y
MFN2PM>C7@* \R=5)&><G*.UI2;1'O%7&6R6".A!-U@2BA(/;&A$M%A/&PI@P
M1,#I$II]I)TV<W,8EP"92%-I/3J4+*J9+E<771&&5HED1VA8*KQ:PVH(Z(J,
M 0; $$,JL+Q\&\.N%Y.D.<S>#S"IA2=XI8TJ%9W2<(RE3(DDCNI8$:F8,&5W
M5H,_-?\ C?\ O*[N_P!1T/\ X9UN^4S,O-U#_:J/Q,<_R193YUS'^Q3?AX?F
MO_&_]Y7=W^HZ'_PSIY3,R\W4/]JH_$P\D64^=<Q_L4WX>'YK_P ;_P!Y7=W^
MHZ'_ ,,Z>4S,O-U#_:J/Q,/)%E/G7,?[%-^'A^:_\;_WE=W?ZCH?_#.GE,S+
MS=0_VJC\3#R193YUS'^Q3?AX?FO_ !O_ 'E=W?ZCH?\ PSIY3,R\W4/]JH_$
MP\D64^=<Q_L4WX>'YK_QO_>5W=_J.A_\,Z>4S,O-U#_:J/Q,/)%E/G7,?[%-
M^'A^:_\ &_\ >5W=_J.A_P##.GE,S+S=0_VJC\3#R193YUS'^Q3?AX?FO_&_
M]Y7=W^HZ'_PSIY3,R\W4/]JH_$P\D64^=<Q_L4WX>'YK_P ;_P!Y7=W^HZ'_
M ,,Z>4S,O-U#_:J/Q,/)%E/G7,?[%-^'C,GAYX$/#+BE<EV,98/\@[N/EL2J
MG,VY&!S*W3G8Z89M3Q5.&CXP6>=QDHLA@S8,##@QQJ(^#CBIS#DV1R,WZ<YS
MFL/@Z&.@@8$2K2%UDF!XJ\S,SJEMBD90,"P<NITCNY'\'.0Y-4>%N)<SJ%(,
M#5PC:* BQ#I B+&TH.XDE$A0A3$$8%CNM_1^CKQF/?8=,,.F&'3##IAATPPZ
M88=,,.F&'3##IAATPPZ88=,,.F&'3##IAATPPZ88YQ_2G_6G_?TPQ*F;;;BX
M*XWAFK>:.-KGCCDK;B)EBCF'F1?+FF.66*98]LD3+)$7LJ],;&/*HT<KTB2L
M"$LB6K*RI"Q6/K25C-YLQUD._3\[RL,NN-,JYEE])MS/##RXYY(JY[\8L.X8
M[O2Q?Y*>F8[8YNN8I]%O^2X^F>+[F/\ )_#-[%QS%W-.V3B.9IFJIEEW8SCJ
M9'P(^.6+$&&SCFXV]GBS&9;QR>:R3)IW),,,4R<:R1,F\U[Y89(BXJBIWZS<
M]YQBP[AW\.??CK>$BI"2D?&#WTFXIC-1Z%&=27BF6.:8RDS;R21BF>..2([Y
MT3+'')$[HBHN>\[</1A8=PWX[<<'! IU'\71@]S&4ZT_)Q<A1LTD/,/)(9>?
M3)I4>=9D(C[3CGFS;>1'<%3-$RZ7/><+#N&*AUC&<.F&'3##IABPCFJM7V>Q
M#[?9=;T*PVP3Z7VNT'*?7BUB&^A>63"]O-SQT@E#]'(57XOIY+?IWE5UGR9_
MRNMB.LJXHFABJJB*%[ZXHYY4B;4+-JC5@C:AL;@W&QVQ4T$+N)'AB>1;:7:-
M&=;&XLQ!86.XL=COBG%M):8/$A!@YJ/6!DO7X@Z !*EJ#5")()!#JF0B$(G3
M!+TH;$%Y8HHZ-#=99@JB+&P:5$ZFE?71JZ1UM7&DC.TB)4S*LC2?+9U5P&9_
MZ98$MS)QAJ:G<J7@A8H %+1(Q4+NH4E20%.X M;ECU6;4&I;H<AV>XZNUU;+
M*/PC-0+#9J36CQR"W#>RD0VX98H,E3XV$61GF_&P9D88L/99.M)CGDN2QBK:
MR"-HH*NIAB8DM%%/+'&Q8 ,61'526  )(-P #MC+P02,'DABD=;69XT=A8W%
MF9218[BQV.XWQ>3X81**#CDD4-DFA$8C#$EWX,5XH+AF%A9%HHX@XUE+A1BF
M0T=D18C/--35'PEDX.K%8^G2)'"-&'<1N59T#$([)JT,R@Z6*:WTD@E=36MJ
M-YE5+!BJEE!"L0-0#6U 'B ;"X!WL+\,6K:=5ZPO,5N!==<4*X062,DPU#M-
M/KU@BM%YN&+<PHW'+#I;.!&6WA@W)G8X))?PQQQ==SQQ1$MAK*NG):"JJ(&*
MA"T,\L9*+NJ$HRDJIW"\!R&(2002BTL,4@N6M)&CC4>+68$7/,\3BXJ[6Z[4
M T&N5, %J]>%X.-#0-=%P0@8<V\^[*>;@BQK$:#$P=DOO2',([#>.;[SKV2*
MXYGDM<LLLTC2S222RN07DE=I)&(  +.Y+,0  +D[ #@,31$C4)&BHB[*B*%4
3"][!5  W).PXXK75>)8=,,?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g838337g46l17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g46l17.jpg
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MQ  >  $  00# 0$             !P$%!@@#"0H$ O_$ $\0  $# P0#  (
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MWCSUK0P-#E$JK@9$-4<MGPUHX:NZKMKTZU2W+]JF\5&W@"WM/:0Z)#J;W4W
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M77AFIELQ6=7K/TIH6AM;]2M-.I0?3;68YU)S;.VM2I5:#K14IN>&]>'U!2%
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M>D6QFMNBS5R,9O4*+I+BTNDNK$F\6,)F9N-_DMB7=$^D#G7S;+('=GY-IM#
M+@>&P&V< 714J1$1UC_Y3IP&2_PO'Y?YBW?,Y3J'TPGF))PW<O6!/->:'(]=
M5FV&,F7[8WX-JT328,0H=BP021L08L10UFT31;,6R26;>DVR61=H6AL @$4*
M((DDG$5IQ+G$XXDDG,JM_0W;KY#[58W!Q!(=:;002  ,/<\8!K0,, UH$  "
M/_YI#^33^LO1O_>AEG_ ;S/X5;-^;M?U5/\ &5?P(VO\]8/KJ_[LG\TA_)I_
M67HW_O0RS_@-X^%6S?F[7]53_&3X$;7^>L'UU?\ =E.6(?X;37%IHA.J$MEC
M,.C@"&RIIKDN& )M?+<\'!QDME61,8'!*\B)2#$ 1H/#JH14@TN<-U7SZX@Y
M'MFXU>BZBB%53;]DME2RLL]"VU'T[2VL6-H-<]S&4ZH==:RJXDB\#N$ DD0K
MZ716W6"C;:EJM6SJ5.M9'6<5'VBHRFVI4K4'-+WU*#&M:;A;())<6@-,X:$?
MS=+4_P#VP/QM?^)P_P#X4>=+WX;]';6^Q'\1<?X/N^F-@_UB/PD_FZ6I_P#M
M@?C:_P#$X?\ \*/'OPWZ.VM]B/XB?!]WTQL'^L1^$L_CWX*-=43N871K7YH$
M"4&!KHXP2'ZMY<W;MHZH=)R98!8VLQ=Q[@CD^:,EG8F]*X>[>%RJKENK4B\H
MM@[:E%TAVRMINDWC-@!EP :'?+^4&@ .S   , *QNQ:[(N;<V(V&W!&U"(87
M%Y;A2^27N<XMR)))&)6<)_AS_)8DN@Z3_)EHNM=MEF+I!W36G/JNTWPV].K$
MG1U7&U7%2[5!%(>D7N4J3H'3L"5=U$6T94P]\++C_@?:,&9'O<V(.8B_$',M
MB)QB<58-E6P$$=(=C@B"#[[.D$9&>KF\!@'3(;V9NX+X;/PP_D<3*JG4_P D
MFB),RL,&AKB:>LN<IO;!0=R4=BF+=Q9C.U1J@.6.GJ,K6UR56Z!\\U2K:U-%
M$7<^^-GB/>C:,271[WMB2 "2+\$D-;,YW6Z"(]Z;5-[W_P!C7KH;/OJZ;K2X
M@ ]7( O.B,@YPR<9B@M_#UZM3SNQ^;UI_CH+/DV D4F[(ZII*\<V# (ID"",
M+5E\57J49B0HT>*'-Z7;3,>R:M$+;$$$[+;!M=@$#9NU0))@6&!+B7..%3,N
M)).9)).)5+M@O<9=MG83B ULG:4FZUH:T8TLFM :!D  !@%;?YNEJ?\ [8'X
MVO\ Q.'_ /"CR??AOT=M;[$?Q%'P?=],;!_K$?A+9?2M^#/.^$IWD&32W5M^
M/5X/E6FC5=AX<F!U)$GCI*49PTX9.Q)$';Q-]C@8DF$9R:9"G1]TBLN]9ADG
MSIB.)O$D6#C7M.T^N93:S9VU06VBS53>L;@+M&T4ZKP(>>T6L(:, 3 ) Q6U
M8]C"SU:CW[7V&0ZRVV@+NT6DW[18Z]GIDS3'9#ZC2XS(:"0'$ '6C^;I:G_[
M8'XVO_$X?_PH\V/?AOT=M;[$?Q%J_!]WTQL'^L1^$E/X=/4_2M*TU@_C:I6E
M?W2M-3I^E:5I_P!%:5_DH_T5IX]^&_1VUOL1_$3X/N^F-@_UB/PE)(/\&NO:
M-2)[+@'Y!M!H>4$I"]EI$^PU?3)N5(2@DR-C2$@>O4\847=F'H^2R%DZ(+WJ
M.5VQLHBHI<F^<6J8.VG1<T,=LK:;F!H:&FP M#06D- +X !:T@# %K2,0(M;
ML6T,>:C=N[%:\N+R\;4(<7N#@7%PIR7$/>"XF2'.!.)G(,8?@$_)!6U]",.Z
MW=%SFXB38S%[&,>ZH\B/G3@K'RH8RTD=PT!B==U:Y'F@D;)J$;$K:]B$CSMR
MK>X$"KVU=;;-D8!5M&SK>P06"I6L;&B'!P++SZ@'::7B)Q!<,BZ;;-T?MU1Q
MHV3:^RJCB14-*S[0J/<2QS7!]RG1)[+VL=>C!S6&9:V);;?PXGYE6;IP];:I
M,").G;FKQXM;GK.-;WCFZ4N)PHJ\]L,5M=U6F+MU)E[7%%+'!MRX(K6J.5U5
M+M<](=DD &RUR ( ]ST,!=#,/TV'8 9A^R W(0ML=$]N@DBVV4%V+OUJU8]L
MU,?U?'](2\SF\EV9)7!,/X;K\Q>0!B@:<ZF]/DM%+*O5UQ\ASGFPJU<N"3P,
M_?N':3S"JMKIP[=1N.*+KN-U6^V/ D:W[(<<FV-Z1;*8999J[#ABVA0;$!P$
M16$0'.@#^4[^49/Z);=JB[4MME>)<8?:;4X$N+2XD&SF22QDDYW&_P D1%'\
MU$_))_61I _O,RM_@7Y9\)]G_-6OZNE^.J?@5M;YZP?75_W5;,:/OX:;7Y@+
M4/!,KS2>Z6WT;C+&>-B#6.9"R2],**2?'$NB0^K1L0PX*:*6IDSS-5W55^A5
M-E8X52HNM8FW5U[7TBL->@^DRG:@YQ9!=3I =FHUQDBL3DT[CBMNP]$=IV:T
MLK5*UB+6MJ@AE6L72^C4IM@&SM'RGB<1A.>2UG_FHGY)/ZR-(']YF5O\"_-C
MX3[/^:M?U=+\=:GP*VM\]8/KJ_[JG\U$_))_61I _O,RM_@7X^$^S_FK7]72
M_'3X%;6^>L'UU?\ =5<F/\*[^3H8U,LAV6M)S%G(AJ0<\U:95RX@W,BD"XJ0
M(C2:26#K;'K)(X##%TVSBU1&PD*'O+;*+M$+[(/2;9QB:5J-TRV:5$P8+9'Z
M? W7.$C&"1D2I'0S:X#@+180'"ZX"M: '-#FN@_JV(O-:Z#A+0<P%*P'^'1_
M,_%AM T<U5X("":*QE>T<-SWG%JSM5AC)@-B2EC=+"]J=ET;8"A;0+6VVG7(
MC!UC7;HQ:[-;ND.R'&\ZRUG$7H)L]G)[9)?B:W[1)+M23,R9N;T4V^P766ZS
M-;V.RVU6H#]& *9@6>)8&M#3^R&B(@+&)C_#.?EQR$Q'C)SJ%TURT<)?%"0M
M@?S/F0FS'/33I1Z378MG6$E$6O*=K.'%R:%EB22KEU<@FGR5]S)O2/9;"2RS
MVAA, EM&B"8$"2*V,  8[@!N"P?T0VW5#6U+78WAI):'6BTN#;QDP#9H$DDX
M:G58@9_A7?R=2(N5D![+6DTR<.$GQ@R7)Y5RV])%2Q-TJ](DB#QQ@Y1=V^?/
M%UG3MRNI>LNNJHJK?=??=6N0Z3;.: UM&U!H   I40  (  %>  , !@ L'=#
M-KO<Y[K187.<2YSG5K07.<XR22;-))))).).*MO\U$_))_61I _O,RM_@7Y/
MPGV?\U:_JZ7XZCX%;6^>L'UU?]U6R.C?^&BU_:?M7>EK/$UGVEI]#<*ZBL*Y
M9EC*-Y"R4^D+R-8[R1&Y<<:@61'#8D>[,KC!#I(8U?%1K1=[>BDY?LT;[W">
MO;.D5AKV2U4&4[4'UK/7I,+J=(-#JE-S&EQ%8D-!<)(!(&0.2V[!T1VG9;=8
MK34K6(T[/:[/7>&5:Q>64:S*C@T&SM!<6M(:"YH)B2!BM=G?\*3^2)=TY7LR
M1I!I8LX65MI=DO*M+J6J*77VTNI3!E:4K2E:?NE*UI^_^BM?^GS8^$^S_FK7
M]72_'6I\"MK?/6#ZZO\ NJ^?^:B?DD_K(T@?WF96_P "_'PGV?\ -6OZNE^.
MGP*VM\]8/KJ_[JKD/_A7?R="4R:(O+6DX>D:&J!RZ;/*N7&UA,2JZ:/51K^U
M+!UM'3%1XP9.KVRU+T;EVC=6ME;T;*VP>DVSC$TK48,B:5$P8(D?I\#!(D;B
M1O4CH9M<3%HL(O"#%:T"1(,&+-B) ,'"0#N4FQW^'%_,M$6ES"+ZI<"Q]E<R
MN'4;",]YQ8)),KX\*B-R#>QOAA.C:ET3!B8O6]OM*5CC%$'[]7[M;L'=(=DO
M,NLU=QU=0H']HNQFMCVG%V/[1+OE8JYG1/;U,0RW69@@B&VJU# L%,Q%GP[#
M0S#]@!OR<%Q&OX;[\QLBN'W'-3>GHG43)PTS%4=9PS2I8+E,;'(B(V<&I_R)
MTL8/HX+03'1Y1K:E:#9;C878T166L4#I#LELQ9JXEI88H4,6N,N:?TV(<<7
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M&#K+[V)D&3(B";:ZM47HU\[9N+%$%U4[H/2;9Q$&C:B)!@TJ)$M(<TXU\PX
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M754A6>+@<UEE;5#"70Y_5,=B0X.(+B3 (Y8*+[S2F\036<R\ )#>L(@2(F!
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M[NQV)QI&&9QP<DN,#]$$2U#PMDF4W1OQ[6)!&0DD9Z"2=P.]77\F&<#VH_\
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MDN50H6PLK4-])4Q0QV72Y>+T5^ H,972WJ*E>;21!_A/M;D)!:"*//Z_9O\
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MHSF_-<FKXKAM2@CO2Y,:4J1ZW+1&JOQC-@UD$EZFA2KH0:&(P^DL/)&0@E/
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M&N7G-RE8P(9MYV<ZVTA1Q%"K!G&JR&<)E(:-)YQZ?8B$_EBUS&BF#\H-:.Z
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M8K$8NOD*<&([$8NDP&=4X30DU3[ENPN'TNH46WH94>6VP4;H=BYD5"&M@9F
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MDRLEV.3Q19,8J.[1RJY:-5[@[,#$:_=JD<1OWZ>W=JC'(KY[4=2_&63&'/\
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M8Y,9<^L<I?5Z+CB=!WT!LD&7J0V92O5.D;2'IG)'L4<\4(2&KC^S>JN&#5/
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MRXAH!F&D++KZD7B&@>YS5$29=V!B-P!)P!.&97:YH/SG,\\X4,F,DDG#_),
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MF]B+)K&[X@6QP%*FTU4!B$%79 #$L2$5.C71(DG7*=^N??,^ K8 T[Z(E1A
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M <+I$Y70 (PO @ 1CGCFMP=,P/3_ (&@U\+Q[D*23!6>3MUDZ1S.=NG1>99
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M1:<:\-5!/1YIU-9?C,!3RM/%Y?CN 8\QFH>4C%LTEN0)F'CB3"X\D).JC4!
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M/55K*P-IDZ5J +656SO%RJ,(J706GM[$\HG2#95HO6NTU-KV1Y'6V>VU'.J
M#]JSVDAU2B\#"'"I1()O4BZ'M]I&B3\@NG#7O"'<IPA)75L@C[<?=.\:R=K:
M*G4&<D:*T;6E6%BKED2&.E&Z]C&0 'Y0*ZN2O;U>($$G+%OY!MG86T-AUQ2M
MM(7*A=U%HIF]0KAL26.@%K@"+U.HUKVR#=ND./O?1_I-LKI)9W5MGUCUM(-]
MTV2LVY:;,Y\W0]LEKV.+3=JTG/INB+P>'-;N]YQE] GA$\(GA$\(GA$\(GA$
M\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$\(GA$
M\(GA$\(I1:_ZLW_V"/\ N[?*'9GO/K5[<AW#U+G\A2GA$\(GA$\(GA$\(GA$
M\(GA$\(GA$\(GA$\(GA$\(HP&9NPN;H.J&R[C O0Q\E0149/HH_H5K/NX^$H
M.JT+*T??:_.R#Y+C;OT?1F.GYG6/=@D'1!>;L+FZ#JA<O8O+T,?)=147/XH_
MH4^^J8I!>NJT+*T??:UCQ^D2XV[]'4&8H'YG6/=@I@Z'\L^2UEU!8YT;ZT6^
M%@^5\E8ZR+"(!DZ(96!8X0G.-3T"RE(YK"<F03&#":A7[<XK+ !I$O,)! !8
M9\*K(I3$4W[1P9:QT@.K;2K/HWRPPY[;M[&\T7@XW2"()@ G'">]5OIMJ70\
M$AKKT;B0",01C ,[H6FF#_QU:'<;2G%!N%ZQ,BSB)PT[ICE$5Q49S+I\-0&7
MR?%4>ED4TIFB3J-XO#Y",J#Q[$[_ ">B0L]81V8/X?1TH&D*L==42M?:ZCPX
M%E,%P>"YH>' 5""\"7EO:B"2TF"8(E5MLS6D$.J$-+3=-V":8ALPT'LR#F,8
MF=\N.M*&D"5Z3M/.DN$ZI" :/X(-8ID>#\GQ3)^%#F3TCY%E/ 6.2?N6B)W'
MTHOR$&?9!"!&MT 4929%H86C;?L@=[QGB+0\57U2UCC4#@]A!N$.()&#KP$@
M'Y6Z#(E9&B#3;3!<+D7787@6B)RB8)!PW[E%$"_'EHD%0_*.,HKK%G<AQ'J+
MP?B; !_&E^3],9\62A*>(4L(X#4B4V0P_=E]%XB$@)D_C$0TR2[A1Z>-YU(&
MT2-WD9,S6R-KJ%S'7*8?3>:C7#K/E.>7NEO67.T3!-V]  !$",19V@.%Y\.;
M<([.0 :,;DX9P3$DF)*W:TK@]/& X,_B</U' \M&,FY(?9;E&09;D#%3R59(
MR#J!-&"(DW:SQV-A\-02FJ\<*"X&+B46%CBS**O4 [<D[&E75U-6H:C@2UK0
MUK6-:V8:UH@"7%SB<R22223N@"UE.X"!><27.<3F2<23  '+ 0MAAF;L+FNM
MJ&R[C M0Q\G0149/HH_[6L]5+HP:@WBEE>=]HM'SR,3XN[]$J$+IA^9>->T1
MK6<'0_EGR6J&4<1:,=1^28IE6199C!F5I"L*A8S=%<N1.T<49LLJ$LJ8AHS9
MMG+WLEIC-8R;3!7M5K_K600R.#VKJ#GBJ!,1A&OH!!'F!*@N(:&_QVH-(2SB
MV5F15 =7%/R=6>;XD4N*5="M(D8Q;Q;FOO0I]DW_ !U8B;Q[BTN^I>1[(_3\
MF\B[L$E,G37=WSRD_>L>$_CX_'.5>"7 7-#@LQ)0&#8\!!1N=H2_$D1TO9O(
MW"# RQJT5?$)!/V$-7#1YRB^782'Y!]2.#*OFIY9P0N=OXC(><+/<=:.OQ\@
MLEP[)<;R;&YC>@R8I!X0:RKCV98]EQG+2^;14.E#T"NT<NI :DXK)67X;"&S
M8K2.2,8B]L; #)V-6%6)"3C/JTW>J5CDYT*?CLS4^.EK,L#42^1I&!E08C",
MP8\5ZT[DN7/SD,=P08Z'G07ZEA&-2,)!FZHDPW(M!YQ&,I*%PR9 64 D>G ^
MD'T8*[PO1EH"99-:95C&:.].&IEAB;Q<9_+K$SX-(VC+HO),8VQY.F^7+-\A
MR_#-'++L#!I[,7HN4L@CRY-LJV'%))W@3B)B-T1IA.FBQ0#^/W\<I&.DXR/S
M!]2.G;=V*!WIYRA+UTRC>:\?2O#F/HK#5P[9M1T(L!(RUMB1=Y8;.FCPDJX<
MF9:L*=-T"29!C+AF1B9U.JAXY^.O3A)<DQN68UU;XW=1 GBF:1@K$)65CL](
MYIRAJ4 ZZ(I&\A2X]'L@18(['3>0:Q,Z% \9@4*C'U#X.6 QLE1@V0;Q8IDQ
M$<<)!$7>_<!Z#WM<.G",Y+_$I&M"VFK,>(LDS4'%M+42BIDME"%AJ9"582X1
M1E+G#N\\21O+Y6(0F9& J:+M_?)S[4ZS$.23EB\N3^BZ*[1LNRMMV:VVQSVT
M*;+0UQ8PO=-2A4ILAHQ,N<)T"^1Z;[)MNW.CMMV?8&,?:J]6RO8VH\4F11M5
M*K4ESL!#&F!K 7E$'?A.UCF.NZF1Z8BG<?+T$]=J5QD^[2LX=E6$+H.XQ17G
M?7O@1QE%^-N]^[#%6PGEK#G=B/K/P_Z.?/6G[,_VKPWXK^EHSLUD^V4O8@[\
M)VL<QUW4R/3$4[CY>@GKM2N,GO:5F[PJ/A=!W&**\WZ]^"-L8OQMWOW@8JV$
M\M8>[L1?#_HY\]:?LS_:GQ7]+<?U:R89_KE+#OP0=^$[6.7Z[J9'IB*=O\O0
M3UVI3&3WM*S=X5'0N@[C%%>;]>0!&V,7XV[W[P,5;">6N/=V(OA_T=^>M/V9
M_M3XK^EO\VLF_P#CE+=GNW;UM]HR_ VI.9J-+:M=16%X?CFCF(7BHCB'+4*F
MLXR76:O"C&(-!AYLY<@(X(EY$&9&1XBW3D1F3O0AP6!$HK,E"K7E;5\HEC91
MN;(I/M%H>".MM+#3HT9P!ZL.OUGG$ALL8,"7.Q8NWL3R3[0JVB_MZLRRV6F0
M>HLE05K1:(Q(ZR[U="F/VGQ4J&"T,9(J#UPZ=P6C+3UC^.8OTYE,(0J%J_+7
MB!D1F,7>.I.]FSDD'B!8@8J8>FID=FSZ/EQ@$V5(%BLG= R# <[>WBET&WEE
MMVA:]I5W6FVVE]HK.,7GN!#03(938(938,893:UHQ@9KVS9VRK#LBS,L>SK)
M3LEG9C<IM(+G  &I5>Z:E6H0!>JU7/>8%YQ@*9A^:<.%NNZK+.,R?<5C%!/7
MSR+/>TK-GQ07#*#N,55YM9<3!FQT8XV[W[X.4:"N6X'NTT=.1J.86_!&8/(H
M/S5ALMUU!66L9DZF*QB@GKYY%GO:5FS\H*AE!W&*J<VLN)@S8V,4;;O?OPY1
MF*Y;@>[312-1S"0<<#AG@<.]!^:<.%NNH+RSC,E4O6,4$T'SR+/.TK-GY05#
M*#N,54YM9<4!FAL8HVW>_?ARC,5RW ]VFBD:CFD$9@CS'=F@_-.'"W74%99Q
MF3J7K&*">OGD6>=I6;$"@F&4'<8JIS:RXJ#-#(QQMWOB <HR%<MR/=IHI&HY
MI!&8(\QW9H/S3APMUU!>6<9DJEZQF@F@^>19YVE9J1*"(;0=QRJG-K+2P,T+
MC/&W>^(ARC(5RW(]VDBD:CF$@C,'D489IPX5J.H+RSC,E4O6,T$T83R+/*E*
MS4B4#PV@[CE5.;66EP9H5&>-N]\1$%&(KEN1[M)%(U'-(..!PSP.'>C#-6&R
MM1U!>6L9DJEZQF@FC">19Y4I6:DB@:&T'<<JIS:RTN$-"HS1MN]\2$%&(KEN
MA[M))(U',)!T/(HPS5ALK4=07EK&9*I>L9H)HPGD6>5*5FI(H%AM!W'*J<VL
MM,!#0F,T;;O?$A!1B*Y;I@[222-1S2#H>2,,TX<*U'4%Y9QF2J7K&:":,)Y%
MGE2E9H3*!8=0=1N54YM989"&A,9XV[WQ,048"^4Z8.TDDC4<T@Z'DC#-.'"E
M1U!F6<9D:EZQF@FC">19Y4I6:%"@.'4'4;E5.;66&@AD1&>-N]\4$%!XOE.V
M#M%)(U',)!&8/(HPS5ALI4=09EK&9&I?YJ@FC">19Y4I6:%28.'4'<<JIS?K
M#80R'C7&W>]*B"8\7RG;!TBDD:CFD'0\D89JPV4J.H,RUC,C4O6-4$T83R+.
MZE*S,J3!0^@ZC<JIS:RPV$,AHU1MN]Z5$$QPOE.V#I%)(U',)!T/(HQS5ALI
M4=09EK&9&I>L:H)HQGD6=U*5FA8F!AU!U&Y53FUEAP(9#1JC;=[TL))CA?*>
M,'2*21J.:0=#R1CFG#A2HZ@W+.,R-2]8U031C/(L[J3K,RQ,!#Z#J-RJG-K*
MSH4R%C7&W>]+"28X7RGC!TBDD:CF$@Z'D48YJPV4J.H-RUC,C4O\U031C/(L
M[J4K,RY./P^@ZC<JIS?JSP4R$C7&W>]+B28T7RGC!TBDD:CFD'0\D8YJPV3J
M.H-RUC,A4O\ -T$T8SR+.ZE*S(P3CT/H.HW*J<WZL^%, XWQMWO3 DF,%\IZ
MP=())&HYI!T/)&.:L-DZCK1N6L9D*E_FZ":,9Y%G=2=9D8)QZ(4'40*J5>_5
MGPI@'&^-N]X8$DQ@OE/6#I!)(U',)!T/(HRS3APG4?0;EG&9"I>L;H*HRGD6
M=U)UF1DG'8A0?1 JI5[652 *8!1OC;O>&1),8+Y3U@Z022-1S2#H=<CD,SYD
M99IPX2J/H.RSC,A4O6-T%493R+.JDZS(R3CD0H/H@54J]K*I"%, 8WQMWO#(
MDF+&<I\P=())&HYA(.AY%&6:<.$JCZ#LLXS?U+_-]51E/(LZJ3^R-$HW$.OH
M@54J]^JD08P!C?&W>\-"B0L9RGS%T@DD:CFD'0X9X'O]6*,LTX<)5'VCLLXS
M?W%OG*"J,IY%G52=9B;)1J(T'T0*J5>_4R,,8 1SC;O>&Q)(4,Y3]BZ022-1
MS2#C@<,\#A&<HSS3APA<.L899QF^O,5C=!-K.>19S<4K,31*-Q"@ZU$K?5[6
M52(,8 QOC45[PT*)"QG*?,72"21J.82Z[0X9X'=GR1GFG#A"X=8PRSC-]>7K
M&Z";6<\BSFXI68FB4:B-!UJ)6^KVLJD88P C=&U%>\-"20H9RGS%T@DD:CF$
MNNT.&>!W9\D:9IPX0N'6,,LXS>WEZQR@FUI/(LYN*5F)LE&8C0=:B5OJ]K*9
M(&,1^.4;45[PV*)"AG*?L73=)(U'-(..!PSP.$9RC3-.'']PZQCEG&;V\O6.
M4$VM)Y%G-Q2LQ.$HQ$:#K42M]7M93) Q>/1SC45[PX*)"1G*?L73=)(U'-(.
M.!PSP.$9RC3-.'"%PZQAEG&;V\O\Y03:TGD6<W%*S Z2B\2H.M1*WU>_4R4,
M7CL<XU%>[.BB0@9RB#%TW22-1S2#H<,\#W^K%&F:<./[AUC'+.,WMY>L<H)L
M:3R+.;BE9@=)1>)4'6HE;ZO:RF3!B\=CG&HKW9T42$#.408NFZ21J.82Z[0Z
MY'+.>6*-,TX<?W#K&.6<9O;R]8Y038TGD6<7%*S \2BT2H.M1*WU>UE,G#%X
MY'*-J*]V>%$A SE$&+INDD:CF$@Z'D4:YIPX_N'6,<LXS>7EZQV@FQK/(LXN
M*5F!XE%8E0=:B5OJ]K*)0'+QN.T;45[L\*)!QG*(,73=)(U'-(.APSP/?ZL4
M:YIPX^N'6,<LXS>7EZQV@FUK/(LXN*5EY\C%(E0=:B5OJ]K*)2'+QJ.\:BO=
MGQ1$.,Y)%BY;))&HYI!T.&>![_5BC7-.''UPZQCEG&;R\O\ .T$V-9Y%G%Q2
MLOD!&)Q.@ZU$K?5[]1*@Y>-1WC45[N0"R(8;R2+%RV22-1S2#H<,\#W^K%&N
M:<./KAUC++.,WEY>L=H)L:SR+.+B=9?(",3B=!UJ16^KVLHE0<O&8[1M17NY
M +(AAO)(L7+9)(U',)==H=<CEG/+%&N:<./KA]C++.,WEY>L=H*L:SR+.+B=
M9?(2,2B=!]J16^KVLGE8<M&([1M17NI"+(A1O)),7+9)(U'-(.APSP/?ZL4:
MYIPX]N'V,LLXS=WEZQZ@JQK/(LXN)UETB(Q")T'VI%;ZO:R>6!RT8CU&U%>Z
MD0LB%&\DDR<MDDC4<T@Z'#/ ]_JQ1KFG#CVX?8RRSC-W>7^>ZJQK/(LXN)_7
M2(C$(IU]J16^KWZ>6!RT7CW&HKW4B%D0@WDDF3ELDD:CF$@Z'D5)PS-V%WJ(
M=-GEW&#M0LC%Z"K&T^BB]Y.LOD+^&1*@^U(M?<]K*)@'+Q2.T;45[N2"R((;
MR2C%RU2I.9[SZU< 8&!R'JGU+F:YOPN]N'6,LO8O=WE_G:";&L_BCBXI67R4
MC#(G0=:D6OJ]^HF <O%([QJ*]W)19$$-Y)1BY:I0I@Z>!GR1KF_"[V\?8RR]
MB]W>7^>H*L:S^*.+R=9=)2,,B=!]J1:^KWZ>8!RT3CW&HKW4E%D00WDE&3EJ
MD2#IX&?)5;9NPN]N'V,\NXP=WE_GNJL;3Z*+W$_KI*1A<4Z^U(M?5[]/,1!:
M)Q[C45[J2BR((;R2C)RU2*8.A5&V;\+O;A]C/+V+W=Y;Y[JK&T_BB]Q/ZV3$
M85%.OM2+7U>_33$06B4>XU%.ZDPPB!&\DJR<M4BB#IXS]6*JVS=A=[</L9Y>
MQ>[O+?/]58VG\47N)_6R8C"HKU]J1:^KWZ:9""T2C_&HIW,F%D0(WDE63EHD
M4P="C;-V%WEP^QGE[%[J\M\_U=K:?Q1>XE]9)R$)BW7VI%KZO/I9F(*Q&/\
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M^_E?0OA1-D#V-SMG8Y^W8<A9FXL32-1S2#H>2,\FXW(<+@9!A#[L>BH/X<L
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MQ(U'-(.AY(ADW&[JK.UKD&$.;B/3]?:A*P*U7WT1AY'8_P .B;^ZKGO) .(
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M,A_.QB:BXG&&T\A,OB4MA*"$I.C)FB<C1"I=R\A[4>SO;)N'+I&VE5-$O<T
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M4R=3^>?-:YZH<@:<-%&")#GV7X9%$HYCY]BH0(BV,<>0=S-BY]Q-64#Q2!A
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M%LT8C6JBZZC&/@6(H$TO54<6L5'ZSIZX\AVQMW:&W*PJVVJ+E,NZBSTQ<H4
MZ)#&R7.<8%ZI4<]Y@"]=  ]ZZ/\ 1K971NSNH;.HGK*H;[IM=8W[3:7-FZ:C
MX#6L;)NTJ364FDEP:7N<YV[7G&7T">$3PB>$3PB>$3PB>$3PB>$3PB>$3PB>
M$3PB>$3PB>$3PB>$3PB>$3PB>$3PB>$3PB>$3PB>$3PB>$3PB>$3PBE%K_JS
M?_8(_P"[M\H=F>\^M7MR'</4N?R%*>$3PB>$3PB>$3PB>$3PB>$3PB>$3PB>
M$3PB>$3PBC 9A'"X2@Z@;$6,!% _R51%!D!BC"@JL![CX2HZC02E1C\5]%(/
MDN-M?.=X8Z?A]F]WR2=4%X1PN$H.H%Q#B\10/\EU%!< BC"@OX&IBL%ZZC02
ME1C\560GZQ+C;7SE3ABH?A]F]WRF3J?SSYK7_4;*-)>BG"1K/>1,3PP-!\;N
M\5#VC6!XJBI"2VE6DN3A>(Q</!LF+!18C&9!D)\E$6[)=O6,('9 [%7,4G9&
MY:RE2=6>*;(O$..)@ -:7$D[@ "L'O%-I>XF!I),D@8#>3/M4 ,-6^@P!F>&
M87#883'+/3VF:*QG)('!,9MQ,#E>3H><G>EV.UE0E*KL"0<##I]#'RU B R,
MF)"19,R J\RX5<V>YJEPO[. >2V]#XINNO,$"0TYXS&Y8]<V]=EV):)W2\2T
M$@_M9:3 T4+1#\EGXX;XM'I" T_R^.OWPG!LBP_"D=,\>'S'(T;*%LJC<.2+
M$[$3>N*<B88]B&65 RS@R"6A=J<@4&(-%#-UC[,V.J#$TR 7M<X/[+',#20[
M"0>VV,#,K'W2R)[>(! NF7!TP0-X-TSW+,0'Y OQI-:-GT:QQ:RB@C%@7*\(
MG(;37>UB<A8XHQ-%L\1V(8Z<,8[84?3['&.,Y!9!'8^S$,THX^FAD&"(H2&Z
M0#4<?<E;*&7KX86WVRTESF!SL8#2YKA,[IR()>Z*9WN(+2Z8,&&M<0-7002/
MO"W%TU%-+V=X/]OBS"T:B%D&FZ^-3$5DV(8U"IACB?8"/'@S&*D1"(]5N,(X
MX)FCJT46"OWHX*E(R#J.OD>U?;E-2FZFZZZ#+6N!:9:YKA((.A&L%6-??!(D
M8D$' R#!!'F\ZG(9A'"X7K:!L18P$T#_ "=1%!D!BC#JJP)4NM!JC>*)2X/Q
M:T@/+1/B[7SJILNH'X=Y)[5;!9R=3^>?-1YD0)I=T[XZ-Y7FF/,8P:!8N&14
MT0-BL7"G5T9'0!X1MA#@8+C$;?%Z5A;V4&;XFD'8*KQU4\76#IL^P?WJD$DP
M,S._FK>)4T6"CB47!7Z71LDBB@Y)&.B;L3LSD;6P^G)2PA-(2SJF_#J8M1>S
M F.LL;MKH0F[DKUM09:N45O)CQQ[\9]OI5(FKHJ<T0K!E-+CBV+WPA-M6)WX
MG5I'5(F8DS''%B%0];J"+XT?=S)G"+4^/<&,.9,W T;/5BMEQ,=\[_[_ .]5
M:*:*XVW>N6-^ET UQX*@)X@X:78G%-X,#CSTA?BXT]51J@G&10,C*2MT!(KW
M,F8Q[(B%T=607+N:N"8\=Y]I]&/<LF=0[2[CYE#R3V*X#A XB5@ 2 /W0/'D
M:9/S<?5,O\6B(>Z5:LD'14(N=D#V , JE[L:J8,N8ZDC>0>WK%"L Q'1H&6:
MM@Z6F,4XCDL@D%8H#+,5L5@,YC;H^ZQC#FJ36B5XN6 'I.4N8)'D;4# MT0/
MK1]F@J[(W*%)G?.N/'?YUCE))H@B,CB,4'M-/[ PL;)1P#;&HM#7(Z*GM.D?
MD&0G HT; "EPN/7^(PA22R$4WDC\ I%[RY:\/1J]*.;'!,>/Y^WTJ^C+]%@C
MY/IK]+HOE@HG*8-UEV*&7*C,&<R9]!I'$^+5+>!0]XZF+R)EP_L/C[EQ)G =
MPT56*7W$QQSXY^GDM&/RDY*B&CC0A/=1>G#&.GQ678\E6'X[%G*^.(H:C(I:
M*Y8K%63)!N H*JV?XY)R*9(1Y!H0:JPR1/CM&B3-ZX)I*_0]%MF6;:^VK-8;
M7UG4566ASNJ<&/FE0J5&PXM<!VFB>R9&F:^5Z:;8MFPNCULVE8>J-IHU+*UG
M7L-2G%:TTJ3[S0]A)N/,=H8P3.2\B [\[&JP/UW4X7T8"^G^7J)Z[3PS8]76
M#NRK^%U'<:3I<'Y!\=./8OQMKH'9DJY$\18B[O6]5^+SH_K;OM%/\!>)?&MT
MI.8V;]EJ_O*#OSL:K _7=3A?1@+Z?Y>HGKM/#-EU=80\*D(74=QI.EPOD'YT
MV^B_&VN@>&2KD3Q%B#N]9\7G1_6W?:*?X"?&KTIQPV;CG^JU<>_]90=^=C58
M(Z[J<+Z,!?4?+U$]=IX:,NKK"'A4C"ZCN-)TN%\@0.FWT7XVUT#PR5<B>(N0
M=WK/B\Z/ZV[[13_ 3XUNE.FS=_\ %:N_/^,[]ZV]T9?GPC &:C@.K[3#@VR!
M5<Q!,!/\%8H#1P_C:^%O2;V'N%XB\<$FYX)$"1TR5C]0#X*=ARY<^_C[0R\*
M7,+N5M;R=6?J>LV-7J-KL!)H6M[',K1B RJUC#2J;A?#F.,2ZF)<>YL/RLVH
M6CJ]OV:D^S5# M5A8]E6SS@34H/J5!7IG-UQS*C1)#:IAB]8V#;M(>:X'%\G
M8 "X.FL$5LC%T:D4(B<2XPE>#.R)6)CZ-VXEL^C)F"$9"8>"0C]J,,0XH:*W
MHL1;Y^]W?+K78K38*[[-;+.^S5V$7J=1MT\'-.+7M.;7L+FN&+7$8KV>P[1L
M>T[,RV6"UTK79ZH-VK1?>$P+S'C!U.H)A].H&U&'LO:#@I0'X6PX)Z[JL38S
M&=/6,5$]? XLRZNL)?%"D,J.XPI+A5B),X;(QCC;70/C!1V*XC@@[46UH&@Y
M!;DDYD\R@_"N&Q/75%8EQF,J(K&*B>O@<69=76$ORA6&5'<84GPJQ$F<-$HQ
M5MM= _,%'@KB."#M19 T'()).9/,H/PMAP3UU1>)L9C:B*QBHFH^!Q9GU=82
M_*%894=QA2?"K$2APT2C%6VUT#\P4>"N(X(.U%D#0<DDG,D^<[\T'X6PX)ZZ
MHK$V,QE1%8Q43U\#BS/JZPD@4+0RH[C"D^%6(E3AHG&.-M="0,%'HKB.2#M1
M9 T')))S)/G._-!^%L.">NJ+Q-C,;416,U$U'P.+,^KK"B)0O#:CN.*3X58D
M6.&BD9XVUT)$P4>BN(Y(.U5D#0<@DDYD\RC#"V'!51U1>)L9C:B*QFHFK"!Q
M9G476%$2AB&U'<<4GPJQ(N<-%8SQMKH2)<H^%<1R0=JK(&@Y))QQ..>)Q[T8
M85PV*J.J+Q+C,;416,U$U80.+,ZBZPHD4,PVH[CBD^%6)%S9HK&:MMKH21<H
M^%<1T0=JJH&@Y!).IYE&&%<-BJCJB\2XS&U$5C-1-6$#BS.HNL*)%#4-J.XX
MI/A5B1@V:+1FK;:Z$D7*/A7$=/W:JJ!H.22=3S1AA;#@JHZHO$V,QM1%8S43
M5A XLSJ+K"R90U#JCJMQ2?"K$S)LT6C/&VNA)ERC\7Q73]VJJ@:#DDG4\T88
M6PX+J.J,Q-C,=416,U$U80.+,ZBZPLH4.0ZHZK<4GPJQ,T;,EXSQMKH2A<H0
M%\5V_=K*H&@Y!))S)YE&&%<-BZCJC,2XS'5$?-5$U80.+,ZBZPLJ3.0ZH[CB
MD^%\F;-F3$:XVUT14N3("^*[?NEE4#0<DDZGFC#"N&Q=1U1F)<9CJB*QJHFK
M"!Q9I476&%29V'U'5;BD^%6)FS9DS&JMMKHBI<F1%\5V_=+*H&@Y!).IYE&.
M%<-BZCJC,2XS'5$5C51-6,#BS2HNL++$ST.J.JW%)\*L3.&S)F-5;;71%BQ,
MB+XKQ^Z650-!R23J>:,<+8<%U'5&XFQF.J(K&JB:L8'%FE1E886)GX?4=5N*
M3X58H=-&34:XVUT18L3(B^*\?NEE4#0<@DG4\RC'"N&Q=1U1N)<9CJB/FJB:
ML8'%FE1=887)R"'U'5;BD^%\H>-&3<:XVUT1<L3)"^*\?NEE4#0<DDZGFC'"
MN&QE1U1N)<9CZB/FZB:L8'%FE1=8:8)R&'U'5;BD^%\H?-&#D;XVUT1@L3)B
M^*]?NEU4#0<DDZGFC'"N&QE1UPW$N,Q]1'S=1-6,#BS2HRL-,$Y#$*CJH"DZ
MLOE#YHP<C?&VNC,%B9,7Q7K]TNJ@:#D$DZGF4986PX,J/J-Q-C,?416-U%59
M0.+-*C*PTR3D40J/J@*3JRK%9 :,'8WQMKHS)8F3%\5Z_=+JH&@Y))U.F9R.
M8\Z,L+8<&U'U'8FQF/J(K&ZBJLH'%FM1E8:9)R.(5'U0%)U95BLA-&#T;XVU
MT9DL3*#.*^?NEU4#0<@DG4\RC+"V'!M1]1V)L9L*B/F^JJR@<6:U&?&FB4DB
M'7U0%)U9?*R(R8/1OC;71FBI(H,XKY\Z750-!R23J<<\3W>K!&6%L.#:C[AV
M)L9L+A/SE1564#BS6HRL.-DI+$:CZH"DZLOEI&9,'XYQMKHS98D5&<5^^=+J
MH&@Y))QQ..>)QG.49X6PX/N'7L,38S8WAZQNHFYG XLVN%UAQHE)(A4=<B*L
MJRK%9$9,'HWQJI=&:*DB@SBOGSI=5 T'()>=J<<\3OSYHSPMAP?<.O88FQFQ
MO$5C=1-S.!Q9M<+K#C1*2Q&HZY$595E6*R,R8/QNK:J71FBQ(J,XKY\Z750-
M!R"7G:G'/$[\^:-,+8<'W#KV&)L9LKQ%8Y43<T@<6;7"ZPXV2DT1J.N1%659
M5BTD,F)!'*MJI=&;*DBHSBOWSIPJ@:#DDG'$XYXG&<Y1IA;#C"X=>QQ-C-E>
M(K'*B;FD#BS:X76''"4GB-1UR(JRK*L6DADO(8YQJI=&<*DBPSBOWSIPJ@:#
MDDG'$XYXG&<Y1IA;#@^X=>PQ-C-E>(^<J)N:0.+-KA=8>=)2B)5'7(BK*LOE
MI*9+R*.<:J72'2I(N,XI!\Z<*H&@Y))U..>)[O5@C3"V'&%PZ]CB;&;*\16.
M5$WM('%FUPNL/.DI1$JCKD15E658M)C)>11SC52Z0Z5)%QG%(/G3A5 T'()>
M=J=,SEE'+!&F%L.,+AU['$V,V5XBL<J)O:0.+-[A=8>>)2F)5'7(BK*LJQ:3
MF2\CCE6U4ND/%21<9Q2#YTX50-!R"2=3S*-<+8<87#KV.)L9L[Q%8[43>U@<
M6;W"ZP\\2E42J.N1%6595B\H,%Y)':MJI=(>*DC SBD'SIPJ@:#DDG4XYXGN
M]6"-<+8<8W#KV.)L9L[Q%8[43<U@<6;W"ZQ ^1E<2J.N1%6595B\I,%Y+'>-
M5+I#Y4B8&<8B^<N54#0<DDZG'/$]WJP1KA;#C&X=>QQ-C-G>(^=J)O:P.+-[
MA=8A(",LB=1UR(JRK+Y>5&"\ECO&JETD@*$3(WC$7SERJ@:#DDG4XYXGN]6"
M-<+8<8W#KV6)L9L[Q%8[43>U@<6;W#*Q"0$99$ZCKDA5E658O*C!>31VK:J7
M22 H1,C>,1?.7*J!H.02\[4Z9G+*.6"-<+8<8W#[V6)L9L[Q%8[45>U@<6;W
M#*Q"0D9;$ZC[DA5E658Q*S!:3QVK:J72R$H1-#>,2?.7*J!H.22=3CGB>[U8
M(UPMAQE</O98FQFTO$5CU15[6!Q9O<,K$9$1E\3J/N2%6595C$L,%I/'JMJI
M=+(BA$T-XQ)ZY<JH&@Y))U..>)[O5@C7"V'&5P^]EB;&;2\1\]U5[6!Q9O<,
M^1D1&7Q3K[DA5E67S$L,%I1'N-5+I9$4(FQO&)/7+E5 T'())U/,J3AF$<+L
MD0ZC/$6,&B@E&+U%7MH#%$+QE8A(7\SB51]R0FRYE6+S P7E<=JVJETDD*$3
MHWC%'SETK2<SWGUJX$P,3D/5'J7,UPAA=E<.O98AQ>TO$?.U$WM8!%&]PNL0
MDI&9Q.HZY(395E\O,#!>5QWC52Z22E")T;QBCYRZ5A3)U\'/FC7"&%V5X^]E
MB'%[2\1\]45>U@$4;WC*Q&2D9G$ZC[DA-E67S$P,%I9'N-5+I9*4(G1O&*/7
M+I4DG7P<^:JVPCA=E</O9XBQ@TO$?/=5>V@,40N&?(R4C-(IU]R0FRK+YB8E
MRTLCW&JETLE*$3HWC%'KETJ4R=2J-L(8797#[V>(<7M+Q/SW57MH!%$+AGR4
MF(S6*=?<D)LJR^9F)<M+8]QJI]+)B9$\-XQ5ZY=*E$G7QEZL%5MA'"[*X?>S
MQ#B]I>)^?ZJ]M (HA<,^2DQ&:Q7K[DA-E67S,R+EI;'^-5/II,4(GAO&*O7+
MM4IDZE&V$<+L[A][/$.+VMXGY_J[FT BB%PWY.3D)M%NON2$V59_-3,N5ET?
MX]4^FDY,@>'<8J]<NU22=2C;".%V=S"]IB'%[6\5T'5W-H!%$+AORDG(3>+<
M"Y(3;5G\U,RY67 ./5/II.3('QW&*O7+M4HDZ^#GS5&V$,+L[F%[3$.+VMXK
MH.KO;0"*(7#?E)00F\7X%R0FVK/YN:%RLO <>J?3R@F0/CN,5>N7:I).O@Y\
MU5OA'"[2YA>TQ%C!K<*Z#J[F\!BB-PWY64$)Q%^!5,3;5G\W-"Q67@./5/IY
M03('QW'+/7+M0IDZE&^$<+L[F%[3$.+VMPKH>KN;P"*(7#?E900G$7X%R0FV
MK/YN:EBLP \>J?3R@F0D _CEGCEVH42=?&7JP1OA'"[2YA<TQ#B]K<+Z'K+F
M\ BB-P[Y:4D)Q&.!5,3;5G\Y-2Q28 >/5/J)22(2 ?QRSQP[4*9.I1OA'"[2
MYC<UQ#B]M<+H"H,N;P"*(W#J1>4D)S&:,:IB;:M*1V;%BDQ!<>J?42DD0D _
MCEGCAVH23J51OA#"[2YC>UQ#B]M<+Z+K+F\ BB-P[Y>5/YU&>#<F)MJT^=FY
M4I,07'JGU$J)/Y"/XY=XX>*$DZE50PCA=K<QN;8AQ>VN%T!T&7(0"*(W#J1B
M5/YU&J,:IB;:M*1Z;E2DQ!\>J?4RHD_D+#CEWCAXH23J51#"&%VMS&YMB'%[
M>X90'0;<A (HC</I&)6_G<:HQJF)MJTI'IP5)S('1O5/J962?R%AQR[QP\4)
M)U*JAA'"[6K&YMB+&#:X90'0;<A 8HC4?2,RM_/(W1C5,3;5I2/3@J3F0.C?
M;ZF5D7\B8<<N\</%"2=3X$>K#N6/WZ9=-RE]U]^GS"%]]]UU]]]^*('=???=
M6M;KKKJ@*UNNNK6M;KJUK6M:UK6O[\))U/,J;_"A/"+1[7+I)-:RHUA7&W\H
M+['>/HGG(%E7*#Z/<*DU.A(=#INC%H_$E#0&2QIL\MR(8B,C?.SXAXV1'QU:
MUJA>^50NLOH5A1+W7 ]QIEC))AI<6RXP03V0YL C-5U*9J!K;UUH<'.C,P#
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M_D_SW'W\V+],;+_K"R?C+\W_  ;Z1?0&VOZKMWX"?Y!FN7^QCJO_ /#KE_\
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E]2Y_(4IX1/")X1/")X1/")X1/")X1/")X1/")X1/")X1/"+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g838337g52k24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g52k24.jpg
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M&G"4HMLC&30:,6ICL"M/J^X^:IO=5BGL<\-[I,GYG5_;5Y\*%[R54_#F[$[
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MWB(8XONK%,CF,AF;7=60L2,1H/ <69H"%#:S[@AQ9HP9WY9.S;TWY9RD_*N
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MR;<*(FH#O0^3;A1$U =Z'R;<*(FH#O0^3;A1$U =Z'R;<*(FH#O0^3;A1$U
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M]BUB(U<%0E,O;F%8M0669<-["L'5O:]\CHZ0U5DZ\+>/T[FKE4K;16:^-MD
M5ND18BW"1V\F]"4FV[6V[6=8EDM>Z)P]LE#*:MT[0NA?=-4M9>B*R&7/NF!(
MS$%+9R[I(QEL=GV;'9U(?ST>CAZ^>*_KWC_OZO9X/];^Y//_ !7;^27@\*/!
MQ[N-+_'-'Y9/ST>CAZ^>*_KWC_OZG@_UO[D\_P#%=OY)/"CP<>[C2_QS1^65
MN9!DO0QE<@<Y#)LG87D)K]$$<&D;2^2F)O$>DD=:G\R3,*5^8W,Y6WN0XZ\J
MW98R&'%?\B,?'86J8-04-/<:^E.$:K7'7K:<U)7B"W.[7*#'W@V*]@H&K'D
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MKF&>X] +BRF*(Y;C%B%P#C"]*4YM*<)2W6>+!G&P[L"3$>QFUWI2N4P;%ZR
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M:=:]_DV(YG=W[K&TMM<0'0=RHQZ)68L%N2G'<=DV0C\)M[6FBKBH<HH25BB
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M@M;OR\FD-2]'D:[[R\D%?11?*%*(E$2B)1$HB41*(E$7IJY/#YT+%7\M/?\
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M.GBM+9&=34NMLJ>CD#FITK-#4=W,$Q@B$%A,BY"T:N1# E>57BAN,@*]AQM
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MQ:*VE4NDM@3;-;V7#5&0HZ[3,,=S_FLIXR$Q-\ER@[.[NT 2(8^9AFSA'9)
MXN/%^/7LN(J+1U0L&[DFM#.I<?*?4VEX5W>EA@O;C0.*F]C!8:0<><E;&B$$
MKSG8;+\78KWK39*^%[4>Z(P83L8T1^ROH[69+>S(:@.U">3JGO-5U+J!CY,
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MRDUN;2SFUO\ 4,(^]5LKH_@2^M[B_NO*_I ZY']45M\*N;V[-O<6%YO[*JK
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M:T9['W=\9(NTX;=F]%GA)VY(SB_*O34X7=4!L#);C0N5VDW&@[F8$IPV_1-
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M,]<PK "Q:8C!) HB0ERM,9!O*$XNW*THN[/XG7SDL5;-0Y:UNN>M9!.0S5[
MB!,(D7V2@01(QG"<7Y'C*+.S\[*5<U]E_P"R]551V/T/\#IS7V7_ ++T38_0
M_P #IS7V7_LO1-C]#_ Z<U]E_P"R]$V/T/\  Z<U]E_[+T38_0_P.G-?9?\
MLO1-C]#_  .G-?9?^R]$V/T/\#JL8#CR=93EC-!<<1)_FLPD"LE"T1Z.-JES
M<EAYQ@2[7"0F+'T*<JX[#5+% BD:,BPU*L\A.68:'R7K]+&537<A:!3J @\R
MV+!(C'"+,[_32=MLGV;(PCMG.6R,(RD[,_NQN+R.8N@QV+HV;]ZR2(P5JH9E
M*24G9F^ABS[L6V[9DD\8#BSSG*,6=V_1ST:\=.V(-'?!&*7\Y.H?L:X=QK W
MP]&/I$9KS$X:S,3H8D,YK=(E$N0J+IAWMSC)N 5^W>]?/K460%EL_F\H",H@
MR.7R-X,9MLFP;5PQQM-O%)H3CO-XGVKZE:4Q9\)I?3F&LRA*SB<%B<=8D-]H
MY'I4 5S/!_'!R#D\'\<=BO75G5_5$)U[L+)#NUC4Q&[$3"(ZO(1DJ17G@'92
M_2E.K4N2/I+@!$34:5$4RJ;E!$:\DOY03!V)$$MXOA^UXO\ E_O*'C?[3?;\
M?_+??5;T45J#Y5K%$TE+-C3(T;9ESVQPTJ3-,ILVICEBEF*>#&=6W.JDA.$P
MT+6(3>L3+%MP6(1'71A/,M96"X>C. #4&,H6LWA;MD56UDY4;%#CIQ'"S*LU
MD9J\)S=HN=F,*8A;7F6/&O%GXM]O)?JI-+9G)T]-ZAQU,]VCAXY*KE.YQS*2
MG&W*F6M:) ;2FU5WKG&8SQ88)\2TY?PT=FBW4'WHO)OPKJQ<1IJ#[T7DWX41
M-0?>B\F_"B)J#[T7DWX41-0?>B\F_"B)J#[T7DWX41-0?>B\F_"B)J#[T7DW
MX419IZ!V)IK/](C'<@965>*,P21I)3)I$-*<%G;4[/82PA$8N$"Q W%T5 (1
M(T)0QJA],8JN59&E5'DZQX6=08S$:-S-.U9$U[*TR4*-)B1>R>=EV',L1;=]
M@@&\RE+)F&V[$>]QA!PEN/@.TKF,_P (&G[U*F=\;@\B#*9+(..;5*PZ;\<,
M,CNW%O8M%C (01DY9;\B[C!$4D/1_E2+K)QC#(\+;C2B'"7P.7Q="<?>X2"5
MD@CSBTIC3A6M>]BBSU8!F7M:][ L*]K7KBO 7QXK.X7*&C*8<;EL;?+&#;92
M'3N!L3C%N3;)XC=F;I=E]$-48LV;TSJ+"UY0@?+X++XL$R/LA U_'V*@Y3=F
M=VA&98O)V9]C,_(O(A+(;*H(_N,7F# Z1R0-2@Q,O:W5(:E4DF%C$#7#88;
M/3F:NNG5IQ&I51-P'ICC21@&+Z*X[)4,M4#?QML%VG8A$@CUR1)"49,S['>+
MN\)QV[)CFT2#DSPG&,F=F^3F5Q.3P=^QC,O1LXZ_5)(9ZML4A%A*+NVUFDVR
M8Y;-X91O(18.TQSG"49/3FH/O1>3?A7M5O34'WHO)OPHB:@^]%Y-^%$34'WH
MO)OPHB:@^]%Y-^%$34'WHO)OPHB:@^]%Y-^%$48WM;F[K4S:U-RYS<5IP$Z-
MO;TBA:M5J#+ZI9"9*F+-//.,%>P0%%%C&*]^8(;WJD8X:PB'L&$  HO,IC$@
M(0X-RO(A)O&$(LW/*3LS>-U6KUSVC"K50&LV#38805QS,8Q)/LC 0AQE,DY/
MR-&$7D[\S+U3:&V.9'BC1KQA")<E$@DB!N>'-U;AWM<YM.DLE>I*4W*;!N((
M5B!,[D)5Q=A"L4L*/+L(5@6O?@7A*S5+4&ML[E,<1C4C&K KF;;NGC1HU:,C
M0V['<19UID$[LV\.4'V-M7U X(-/9'2W!SIK"Y83@R(*]RS:KOLWZT\CDKN1
MA7)L=V8P!6QB/%G=HF@2+.[,M47*9X)R,'-!N66F-N[_  R5,+$D.=&9O5.)
M;&\,B$+4>WNX$91QB$*A,E2K42M2$M,KNH.3DFB/2' #T#P':LPKZ9CIZS>K
M4\GC[=LD06C# ]JM:*]B)J[DE&)7A.9!%'!WF/<A.46@2,GY:]4CHC4$=8SU
M75QUN]ALK1HCG:J5RV(4KE($:DZ]MA1FX&(,0C@*5HC-QA!CD\PDC'61UIRK
MP9D'L,X^]JWEWQQ_MZGYR#]M<U][<C[0N^:G^33K3E7@S(/89Q][4[XX_P!O
M4_.0?MIWMR/M"[YJ?Y-.M.5>#,@]AG'WM3OCC_;U/SD'[:=[<C[0N^:G^33K
M3E7@S(/89Q][4[XX_P!O4_.0?MIWMR/M"[YJ?Y-.M.5>#,@]AG'WM3OCC_;U
M/SD'[:=[<C[0N^:G^33K3E7@S(/89Q][4[XX_P!O4_.0?MIWMR/M"[YJ?Y-.
MM.5>#,@]AG'WM3OCC_;U/SD'[:=[<C[0N^:G^33K3E7@S(/89Q][4[XX_P!O
M4_.0?MIWMR/M"[YJ?Y-;8^2ZP9D1LR1(,O2&.NL<B*6'N,::%+T@4MQT@=G=
MQ:% A-:=862<I;F](VJ+JW L%TW59R9*28:8%6%-S[P\:JPQ\)3T[3NU[N1)
MD0WK$*IH'C3KU@V(,QYC>48&,0T.+"[[_%Q(248Q<;SZI]3-HG4%;45_5F0Q
MUK'XD6(L8ZH2X E>=^W;L5".]49HPF6N -<CFL19Q\;,0H2G)BL/>;7*J[:6
M+^E-IFZ->A5$XY.=)K)1>,HM+9%>)Q]U,BDXEEG"0!;%CQ=OLC@L:DZ]+>S<
MWJU/5*Q*G1_Y'HK*.G&46.Y8S#Y',%('&UGLE$/C208H!;H]YH;VTY!1?Z*3
M-LB[OR[=FS:ZM&8SV)P 16,O<C3"8O$BG(1R[Y=R4]QHUQ%DS[L9/M=F;DY]
MO(L&1\O-R2APK",TJT)@N;FM<>%-(,0K6Y[WYN<6)+WM:U[WOS=RU[WOMJ]^
ML?53?]53^]<H?JM+'O"/HE^?."?9TTLCZ'^1+<N_R25^YI3MWV$]('\DE1]8
M^J]FWO7/SVAM^#NO:H>$?1'EL/F61V_!W'M7*W+N<DI?N:4S=]A/2 _)+4?6
M-JSR7/SW'^EJ'A(T/Y<#YED?0URMR[7)+7[FE*W?84S_ /DEIZQ=6^2I^>T/
M2U!^$K0S<CYT/F61]#7*W+K\DQ?FYM*5N[?;M^HKG[M__P"35'UB:N\DDY/Z
M90]+ZE+X3-"\G^'0\K[/Y%DN?S)<[<NGR35^YI1MU^WS?N+9][OV)J>L35WD
MDGGE#TM/"9H3R\#D_H61]"7.W+G\D\*_-;2B;K_\%\]V]O$]J>L35WDDGGE#
MTM1\)>A?+H?,LEZ$NT/+D\E$+FN'2@;K\_<_48SU^'%%/6)J[R23SRAZ6GA*
MT*__ %Z'S+(^A+O+Y<GDJ2[W$5I1(2[WMS7N##F>@7O;M7YKW#BJU[V[E^;N
M4]8>K7Y\01__ !E#TM1;A*T._-G0^99%O_9J(MRY?)9W[FE*F^Q!GS\EE0]8
M6K>?O1/SO'^EJ/A+T1Y='YEDO0EQ%RX')7G7L(S2>0F"YK6L(>'<\"%S=N]K
M<XL5WOS<][WM;QWVU-ZPM7-S8F;?^-Q_I:E?A+T-X\Z+S')OS?\ @E\MRW/)
M77[FDRW_ &&\[?AQ74?6%J_R3/I_EN/?DZ>2XI?";H3R\'H_D.2Y^C^1+LMR
MVO)8W[FDPWW_ .#F=?R64]86K_)!//<?Z6GA-T)Y>#YCDO0ERMRV/)9B[FDN
MW7_X.YSM[>+:AZPM7^29^>X_TQ/";H3R\'S')^A+G;EKN2VOW-)9NV?N/9R_
M#BZH^L+5[_\ 5!.;;_+<?S>=J'A.T'R_X>#R/L_D.3Y_,O?79;EJ>2YOW-)1
MN^P_G'\.+Z>L'5_)_@B?+S?QW'^F(W"=H-W=FSP>3G_B.3]!7,/+2\EX*]K6
MTDF^][]S]1_.'T_6OYJ>L'6'D@GGF/\ 2T\)V@^;O\+S#)_E[AV+MMRS_)@"
M[FD@WW[?-^Y#F[N_UXPIZP=8/_U1/SW'L_P/<4?";H3R\'H_D.3]"7:7RT/)
MCE7O<K231%WO;FO<O$F;P7O;N\U[AQE:_-Z?->H^L#6#\^(F_P#XW'>F*'A/
MT&W-GA-_X#*>@KOMRTG)GWYN;273WY^Y^I1G'\FE0\'^K_(\O/<=Z8GA1T&W
M_: 73_(<IZ$O@N68Y,PZ^N/2/1&"YK6UAXES:,7-V^:W.+&=[\W=YK=RIFX/
MM8OS8>?GV.;_ -XH/PHZ"\>?$_\ X#*/_P"Q2W+(\F6+N:1;?]B3-5O;QG:G
M@_UCY(EY_C?35#PHZ!\OB^+\IZ N=N6,Y,Z_-S:1+??G[GZDN:?R:4\'VL?)
M$O/\;Z:GA1T#Y>%\7Y7T!=EN6'Y-*_<TAV_[$V:/R:U'P>ZR\CS\_P ;Z:I?
M"GH#R^+GV?Y.RK\OWJ"[+<L'R:HNYI"H+\W_ (3YF_)K4?![K/D_P//EYMM_
M&M_[W_\ U/"GH#R^+XNROH"YVY7[DV+]S2$;_L49E_)M46X/-:/S8>?G^-]-
M3PJ<'_N@%\7Y7T!<[<KWR;=^:]M(-OOS]S]2G,GY-Z>#O6GD:?G^-]-4'X5>
M#YN?4 F_\NRWS>N=N5VY-X5N>VD"@O:_:_<IS'^3BG@[UIY&GY_C?35#PK<'
MON@%\79;YO405RNO)S@O?H=(-&7>]N:]P8NS&#GM;TKWMCJW/S;+WIX.M:/R
M=YIOL_I^,?\ ][[_ (E#PL\'C?\ :$;<FW_)V7YG_P#+U$6Y7?D\!=S2'3W[
M?-^YGF/N_8]H_!QK1O\ J2?)_3L9Z:GA:X/?=$/E_P#IV7^;TORMG)VG"YQ:
M0"(P5K<W./&.7Q7YK>ESBQYS]KM]JIFX.=;-R-AB-X^2_C&;JN[-O6I7X6>#
MOGEJ$+^^^-RS_P#Z]<@\K%R=XNYGM!?_ (89<_#CVH^#K6_D<GQAC?3E*_"S
MP<-SZB WV\;EF_+CUSMRKW)Y"[F>4-_^&&7/2_X>T\'6M_(Y/C#&>G*'A;X-
M_=$#XMRWS>NVW*L\GL+N9W0W[7/^YCEKN?UX^IX.=;^1R?&.,].4'X7>#9N?
M48.?9_DS+\_Q<NVW*I\GS>_-;.Z#[&66OR?5,W!QKE^5L,3XQQGIRE\+_!M[
MH@_%N6^;URMRI_)^7[5LZH+^E^YGEKV^Q]S4\&^N>?O,3XQQ?Y.[]J>%_@V;
MD]<(OBS+?-ZY_)3.3^]?1!]C3+'X@5%N#773\V%)\8XMORWE*_##P:-SZB#\
M69?YO79;E1M *]^:V<V^]^;G_<VRMW/K!\=1\&NNW_ZE+S[/\HXSTY/##P:>
MZ,/Q9EOF]=Y?*C:!(+WN5G5$"][6Y[@QSE8%[V]*U^:!V_LO4'X,]=/SX,C[
M'\>0Q?(_W[RBW#'P:QYM2";;R<F-R[>_XL>HBW*C:"0NW;.Z>_TL>98_$2G@
MPUR__4,_/\5Z<H/PS\&C<^IA-_Y;F/F]=EN5!T%K]S.I%_\ A[E?\1:CX+]=
M>09?&.)]/4OAIX,V_P"TX_BS,_-RZ@<IAH'=5F. ,TM]EYR8E&:NMC?*-E9J
M-.:>>G2F*>L.QPTQ!RI2<20(=RBC5!Y@ !&:9<4?!=KQ^; 3^,,3Z>H/PU<&
M3<^IQ\O_ -,S/S<HT/*;Z#PNV'.)%_\ A_E3\,'J;P6:]YN\$]O1WQQ/IZ@_
M#9P8MM_^*!\G/_@S-/[_ (L<NRW*8Z$5^YF\CZP<I?B13P6:]\@3^,<3Z>H>
M&W@PV[/70/D_^EYM_P F-2W*2Z$ ^:]LSH[\_;Y^Q]D[M_VPCVZG;@MX0-FW
MO$39S?Y3Q+?>_P H*1^&S@M;GU,+XHS?S8NRW*/Z$=^;FS*C[?<_4_R9Z?\
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M/^7%+C^?_P!#OUV4GUC9#_$^H^"'A)]SI?C7#?.2AX>."/W5A^)\[\U)^?\
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MC.1>3O1V,[^V:?2_18]]1Q.B9I V$#G@'-S6OS_IJA/>W_C)46SF+]M>-_\
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M9O;2F ='S+_,']*/I"_[?C&VW^NO%48ZFPC,S/=_%K?3]SHVC-2[TO\ !O\
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D%T;N--*E6C9J'C7&7+!,*K'N8LWV "[#:3PA%VAR;-K,O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g838337g53l12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g53l12.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2\ 4&AO=&]S:&]P(#,N,  X0DE-! 0
M     "$< 5H  QLE1QP!6@ #&R5'' (   (  !P"!0 %4')I;G0R.$))300E
M       0^*S$H2T?_KQ""!DS".HC_CA"24T$.@      Y0   !     !
M   +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0
M  !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I
M;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    ,
M %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !
M $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7
M $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B
M;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M  !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M          !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
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M8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M    "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \     !  $#
MP     $  3A"24T$)@      #@             _@   .$))30/R       *
M  #_______\  #A"24T$#0      !    !XX0DE-!!D       0    >.$))
M30/S       )           ! #A"24TG$       "@ !          (X0DE-
M _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $
M,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M '   /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z   .$))300(       0     0   D
M  )      #A"24T$'@      !      X0DE-!!H      S4    &
M      1T   $U          !                          $
M    !-0   1T                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   1T     %)G:'1L;VYG   $U     9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   $=     !2
M9VAT;&]N9P  !-0    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     PX0DE-! P     )*4    !    H    )0   '@  $5@
M)(D &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( )0
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M_C)FL#GNK;4USZXWM%[B6SJW</S=REZ#_P#0?^#.55GU=H8VMK;[ &%I( 8
M=KO4<UK?3VU5N]FUE7\RRO\ 1*!^JN!Z7I,>]C3LW[0T;M@:T;]K6[OHO?\
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MQ,AY.58"6AK<^AK=NCI+*]PMV;=_M/Z-UO\ 4_T:GUQF.W'Q?3:QI&;B#V@
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MWU+^L=<LQ;J*FD%K7-OO ;/TG>F6.^E^?^^N]7GX_P :EI_[R(U(UO=V,?\
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M)'Z+\[>__A%"FSK&ZLVUL+-S18W0. </>]KFV/9^A_PG[_Z3TO\ !I*:.-T
M8N9C758>,TL(<^UKK9:8BSTVO=_6V?\ 4+8ROYIO_&5?^?&*L,CJHT.*UT=P
M]HGC\V?ZW^OZ1%<;3B5&X1;OJW\<[ZY^B7)*?__0](9ZGO\ 2]?9O?QZ,3N=
MOV[_ '_33_K/_=C_ , 7S"DDI^GOUK_NQ_X E^L_]V/_  !?,*22GZ>_6?\
MNQ_X E^L_P#=C_P!?,*22GZ>_6?^['_@"7ZS_P!V/_ %\PI)*?I[]9_[L?\
M@"7ZS_W8_P# %\PI)*?I[]9_[L?^ )?K/_=C_P  7S"DDI^GOUG_ +L?^ )?
MK/\ W8_\ 7S"DDI^GOUG_NQ_X E^L_\ =C_P!?,*22GZ>_6?^['_ ( E^L_]
MV/\ P!?,*22GZ>_6?^['_@"9_J>SUO7V;V<^C$[F[-WI^_Z:^8DDE/\ _]D
M.$))300A      !=     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S
M &@ ;P!P    %P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $,
M0P @ #( ,  Q #4    ! #A"24T$(@     !,DU- "H    (  <!$@ #
M 0 !   !&@ %     0   &(!&P %     0   &H!*  #     0 "   !,0 "
M    (@   '(!,@ "    %    )2':0 $     0   *@   #4 "W&P   )Q
M+<;    G$$%D;V)E(%!H;W1O<VAO<"!#0R R,#$U("A7:6YD;W=S*0 R,#$Y
M.C Q.C(W(# V.C$P.C R   #H $  P    '__P  H ( !     $   34H ,
M!     $   1T          8! P #     0 &   !&@ %     0   2(!&P %
M     0   2H!*  #     0 "   " 0 $     0   3(" @ $     0
M        2     $   !(     3A"24T#_0      "           _^$!-$U-
M "H    (  <!$@ #     0     !&@ %     0   &(!&P %     0   &H!
M*  #     0 "   !,0 "    (@   '(!,@ "    %    )2':0 $     0
M *@   #4   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#0R R,#$U
M("A7:6YD;W=S*0 R,#$Y.C Q.C(W(# V.C$P.C R   #H $  P    '__P
MH ( !     $   34H , !     $   1T          8! P #     0 &   !
M&@ %     0   2(!&P %     0   2H!*  #     0 "   " 0 $     0
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M 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %M 8P# 1$  A$! Q$!_\0 'P
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M8MA)J:5*)>RG'M\EMD[)7?:#;1@[.R,KU$66@&I]*&E]I>T :E2]T4A#]=&
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M]_R932('(> ^4,SMF^0O'O\ -LA^O975U/C-QB"?"';YC'"JGV1N6?Q,H/\
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MDA+9*LS^QP"#>U,4&-\57BXI2! 1[:5K35PIV]P;F/:-*[ X5].[.*E@#@
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MHX 8P@7JX#D  INKS'D X,'D)0-Y"''(:B]A4=8TSPSSKAQX=M$/3MM1<O\
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MSLC=XU6;)MW@(:L< R[A"H8[HN U#=EGZ>NR-[;&@;UE=OICG.4ZF;,6@MT
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M+RF,@+\Z9U3@=02GZ0F%T #$PXB.O#7GW;8=6-W7[)<H1*##.NR#%\6V=OC
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M^V$PB)A^,1Y$?/4#_1^[\Q@&8\?D$4[?52P<YLVI" <B7%&0A^W\7NMB>K@
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ME: %1IJSY\O&(#8JC)?(V3*;3SI*R\I;+[6H])%1$SAV\?S<_&(&.Z./<-3
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M+-TE9<ANCU:/@VQ@._*X;N 9V)PV\"<07Z&[=)@FNETB\D)&/4XY?"B0.S5
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MAD[,;)JE(XTQI",RG2\9+*RL='VV^JI)G19,(_P[\!*Z3X=_?SV4RPBX5
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M)-$T&2":)T7*40Q$<1IQPXXXZPAO=J1C>L]MQ O ].>L.E!3J( J$]\.O%
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M% ( %*<>OI(!BE$ $.!-TB(#YG$QS'$ Y^((QIES\O"O9"/0N^IY^ [,O'
M;K ,BY:^%\75S;W0\\<!Q\?W-2.JFSYCO'SB S'C\@BFSZJ;4Z,Y[3 'CI-B
MC(8&Z@Y 0]U\-R7GX@,;GX(B(>8:@ KJKPB8ZK)G *G @B4$Q. @ B!..DHE
M#^#\$#<?[;@1'@//[B@AM[L!U_6$?23D2%*8%.@0ZRB7H1+\$W'("/0!OB#@
M!YZA*(CSR(CJ1"E<-U0'"N=/H..&<(WDG9T%2.6[A1LN03&*HB)4O(3!S\,
M\@$Q>G@H@;S$0,7R$(J(<Y<Y0A_*?NVW+X\9'CZ/G+)U=8FX$S6*N,ZT:'.!
M0 IQ(@_*F!R@ @4Q2 /PCE'XP$MP,.&(!QKNQ\]<5NEV<\CS0(6EXW\;RLE1
M[6'N^Y++$[&-4$T$F3BW2J#;N"))I@FH@V<)I.A[M,$Q4<E45'D1,H(G/U+P
MU&Z'=M$<!'G/NA=#9WU'SB+$G.2LP\4>R\B^?/CB8RKMZX,X4.)@$1$AU.H
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M\X7B_N]X^L _4RW9P"/(YEW4<_=]]O$W\GS,:BAM@]PPO%_=[Q]8T'ZF5[.
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M/FFEL)UZXU&_R,/#Q5E<.7P0G,U)0:,<6!CY9V"[@S]@SC@BFSE59)@B#4B
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M5B*-J%CV;<] B=KY>I-49=+5'$Z),G"*LW62(BBDB]T*7\Y;-S=11NG%%+1
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MR\NL3+I+9X6Z1[1+.YQ-)D_OF.J$K!\NPD;<@%4%(J;ALW.]4**9504.0#"
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MK^#:1#UC(L/#0%XAH]J];-+/$U^2/+Q#65!-Z"BYF<F<STKGO"NUEAZG"ZH
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M<(%5\*[.S:BZ06\.CT:$LGTXDR;]&5S%TR1FC4S.8)(*42>-CE.44ETQ 2'
M"J* 41+>(!SW#%O&KU)S9BS]H5I6XG<H93)Q)'R<RE*[E$#K2]ZF8ARN&JH4
M42-?22,<I37%!33%0IKA:)9OMAV]-,L+9T;8=H*.7%UE'2M]3K[,)X7ZR'AE
MY4JW1W*<RNV$R"TTF@6561.HFH\,10X&W#6MM,>2ELZ:>3(TD* %"6BZ4%MH
MRFOE1NUJ*!3^\5 3"B4P ($ 0"G/)8.QB=HS6N)9B2EM*<QCFG0,4 ?"J9/1
M&< K=P<G2_5G=  .#$$2&5$HB X6M[/MKM0R$OE:LX)QK"Y!7=/WPV9C6F2;
MM!_*E6))OV+<2F81KY^1PX([>Q[1LY<%<+E55,"J@&SNK;VO?2PLF=VBFSB6
M%(FGU11VH*9DT1**2:AJZ15-,2$$B:ASD*)2T +H4U6/1K8"6SH]HF%D) TG
M9U%EAF*,N0(N59P!@<+)>[HT%EP.<%542)J* <X',('-7>QQM'VRXAN3C(.,
ML(8[I5S<)/$ L,%7VS5\R1D $K]&(\CHPB+Q,QDG24.DQ(NB<Z"I3)',08FM
MM;63QB663>T$TF# HIFZLY='.FH9+%(RV0N#)CB0RXJ"4P 8H@(5B9'T;V#L
MU,U)S(+)2*4S10JI!>LF"**R9%O],1N)2W6I%0P4(V*D4Y?=, EPC*98VQ[?
MLZ2\+/Y>Q)2L@3=>9KQT/*V*)3=/F<<X.JLI'@Y*9-5=B5PLJZ0:.3+-VKQ0
M[QLFDZ,*PX9-:VTMG45VTDG<PEB#I0JJZ+5<R::BI0*4%!)B!5+I2D,<H%,8
M@ 0PB0+L;-HK!V-M:Y:/+2V;E,Z=,4SHM7#]HFLJBB<PG,B!Q #&1OB*A4CB
M8A%1%0A2J")H25GV3[3KHPI49:\"X\GV>.Z^PJ=-))0_B%86KQ9U58^ND=&6
M\6]A6BJZZB$9(KO&9%%US]SU+JB?=:6_MFP4?K,[231LI-'2CU^*+BX#AXJ
M JZ$@!<(X.!2@99(I%! I0O4*%.;,.BSHZFJ4I0F5CI$]2D;)&72HKAD106<
MO0$3(L2&-[YVB9C&,5NJ91(#'.:[4YA%Z+/C'']QQ^^Q58ZE#2..9&%;UQW3
M0:@R@CP+,$"M(E)G'F:E:L&Q&K<C=NU%%-%-%--,"D*!=<%I-IDQF:<Y:O5T
MIHDX,Z(^OWW .3B83K"HI?$ZAQ.83&/>$PF$1J(QZE_(I/,Y.M9]]+FJ\D<-
M2L598*0$9F9D I2-@12N%(B0I"%*F2Z4I2@4H  4C#FPEBD]D<6\U)B#65UC
M+WFG$P/BO%*XO%UX[W&&_?/=^B?%_7_),'/7_P#2./+6<)_. :%8A,%^J$FW
MMTJ%27 F^CT77Z7:Z?1^Y41NT_HQKC9B0"^-,QE347YY'^C1G5TVE-(=**WL
ML37O]ZZ414NTO7L;T(*S[0-L=TI-)QS:\)T2P4S&[8[*B0TG%BZ+562HE,X9
M0[\ZWI-LR="FF+UH#T6[WND?%)+ DGT])G;>ULOF$PFC*?S)L_FIP4F+A%>X
M+Q0*W5%TP#1'4)>-HSW+Z=XUP2WAKQIAT;6"FLJE,DF5E),^E<B3T4G:.6A5
M2RU(;H&2:*&$5DDC@4H*)E4N*@0FD*:X6F[==HVV/(K2EL+K@W'$^QQU%! T
MAFYK;)%M6X(O'1"1J#,K9).'3. +)1:A5&*3CERF@5P(J#5A;:ULK4?JL+0S
M5LI-%A<S!0CM03NW YN%3'$PBN(8"L @H)?=$UW"+37HXL'.TY4C-;(R%ZE(
MVX-)2DK+D 3E[0 "C5LF0I"$:A0!*WH*(&"^! -C&&LNR7:;<8FE0=HP+CR=
MC<=0B%9IB,C$"NK!UQJX7=MX%%Z*WC7,,BY<N7!(Q^Y=,@6<N%.YZEE1-G:6
M_MFQ7?N&=I)HV6FC@SM^9)Q<*X=&*4AG)DP#1D<"0I2BLF0BETI0O4*%-5_T
M6='4U;RII,;'2)ZA(VA&$J(X9D5%FQ3,8Y&2:AA%0S4IS&,#=4YTKQS")*F-
M517_ &H[;,I#3O?!PECJTEQ]&I0M+3D:VQ!&N0B!2E;PD<BW3013A6O04[2)
M.0\<U5*"S=LDL'7K5EMLK52?KWLR?S1F,S5,N_%)VK>=.##4[A4QA,8RYZB!
MUJ@J<!$ICB41"-Z<]'MAK0#*_;5E)%,O8J)6TJ!S+VYBL6I0 "-6Y (!2M27
M2B1M042& #$(!@ 8SU=V^88J3W&LE6\?0<0^P[ 356QDY:^,[RG5^Q$(G-Q4
M5WCM0OAI$B9"K^)*X4X*'0<FM9U:6>O4YLDZF;A=.>.F[R;$/<H^=-1$6ZRU
M"![Z0F,);ET,<0&-QE8ZS$N5D:[&2LVRMFF+J6R%1(IP-+&+TI"NFK81.-$E
MP(0#E->^$*" A&)RGM<V[YOGX:U9;PY0\@6* 03:1DQ9()L^?),47"CI&-<K
M"!1D8M)RJLNG%R7BX\BJRRA6P&64$V>3VOM/9]LNSDL]F4L:N3"HL@T<G33,
MH)0(*I2@/ZI82%*45DKBHE*4+]"A35M#8"Q5K'C686DLO)9T]9$!)NYF#%%P
ML1$#BH"!SF+59N!S&.#=;2(@8YQ E3FKCLF;1MLV9)QI9LG82Q_<I]A C6&D
MO*P:/C48$$5T$(P%FPMS&08IN5_10GZE8@Z@JQ:C14"G#+*;:VLD3<[246@F
M;!LHYZV=!!R8$S.1$IC+737@ R@D+IJ4!8 NK <M0C#/NCBPEJ'B;^T%DY)-
MGJ3,9>FZ=LDCKE9B50I6X* !3"1(%5-!41%N8XF0%,V,+N0Q13+'CF2P[:JG
M7Y'%:D/'U"/IR?C_ $>:EQ4?&M8Z(D.I=-?J:G9=TF#9?I!H@TZE3+=\.N<E
M.7[6:)3QF]<I3@JZCY1\.CTH/UE53JKIT*)??TEX1,6M\Q_= M([*]GY4^DB
MUFG\N9KV?.U2EJ<KHH+<TL01132:JE$0&Z31W"E(:FB(G4PFO0V,/MAQ_AJJ
M9&#:I1,886R3=8SN6MJ3J0/HQ.30$QHY28CV[ANZ>Q+)15=<D.U=-67B%#+=
MSWACF-UE[6S.>O97^F4QF\_E3!:\=F+X4U11-0%005.4Y$UU *4HKG(=2Z %
MK0  //M;!26S$OGG^3R3V?LK/9JW$J<P)*RJ-P<DO=7,[01.BHNV1,8QP:IK
M))WC&,  )C".7VJ[?8G:_@RE8;BY7W0KUY.3?V"S&8)1BMEM%AE7DY/S)V*2
MJY6B:[]\H@Q:BNN9I&-F30RRHH=9L-L;3+VNM"_GJR/52NC))MF@*"L5HS;(
MIMVS<%!*43B5),#*'NE ZIE#@4MZ@;'1]8UM8&R4KLPW<"],R*X6>/S(E;F?
MS!\Y5>/78HE,<$BJ.%SE12OGT*!$D;Y@3 8<L^,,?J9)1S >IPYLG(5$]"1N
M@MQ]-IT]24]-'@"K]?1X$93EYQW?>@<QRE5!(YR&Y(3>9A*C2,'JX2@SX)D9
MA?\ YN+X$>K@Y$E*Z30_J\Z4 !I4 &.\,ADPSPMI1ES49\26C)RS71_SP)6+
MCK8L@4K_ * 7/ZZ[2M^N-!I"$B-L&WJ RH^S=#8=H,;EB26=NGEZ:5]FE.'?
M2"9TI&235 G<MI:1356)(RS5%&2?E67!VZ6!97KZ*]KK3N9.G9]>>S)62I%(
M0DN.Z4,V!-(0,DD)1&\9%(P *2)C&23$I;A"W0IQVU@K%L[0K6L:V8DK>T:Y
ME3JSA)BB1Z95<HD77!0"T*X7*)BKN"%*NL4QP44,!S5VC[6=NRC?*K,^':*=
MCF]XSD<L,#0J)H^\2,>Z>/F<E,,!'P8R2$A(/)(D@U1;/!DW!Y$RQGO"X6"V
M%J -)U GLQ!2SY%$I,IU@VEEZ2I$TU$D%/C!(R22:0I&,9/0E!("@G[L0-@+
M%"2T*0V8DXI6L437M&B+-,49PNDHJJFN\1IHSKE6657!8I2JBN<RXG%7WX3D
M)LNVKUNIWBBU_"%(A:ADJ-KL1>Z_&,W3./L\?5':C^OHRB2#LAE#Q[U99V#D
MADW3ERJHN\6<*',8=EQ;RV#M[+YBZM#,7#Z5*NEI<Y65*HJS4>$*FY,B)B"!
M053*4ET0$A"% I"E* !&DTZ+^CYA+9M*&5DI.TED];LVLX9-VVA0F*$O.=5H
M1T4ABZ045%%% .(Z0YSG.H8YC"(N._P9B63L%GM3^BPSJPW3'(XCM,JH#KQ,
MUC<>^ :B[$'()^BQ\0OY)$3<?7#?7_BXY:5H9TBV:,TIBX(V830)TS1 27$)
MJ%VCXE2UTP7"XB(EP#W8[BUEK/.'K^8KREJH^F<E_1Q^Y,4PJ.I'50WLQ4;U
M!;7EE1N@ #4YO>QA$6[:%MDOU6HE+N>%*'9:UC**;P5!C9:)\4-7A&J*#=*'
MC'IE?2)(L46S<B\>J[5:.@13%TBL8H#KH,;;6MECR8OY?/YDT=S98SB9*H+B
M3KC@YC&%=9, T0K7CG$JH$ Y!,-PQ:QR9IT;V#G3"42N;64DTP8R%NFSDR#I
MH17V<T3(1,K5LH;]<1O<23*9#2"DH!"Z0IKH0L+%@#"ML#&03^,:>^]YB1BY
M7%/$.W9CC]W#"P-&>Y86(-ABFC48J+XCFXECE?1S$%FJ@-$ 3T6MI9^S]K=6
MF[Y/V\DLC.?UYS^TR+Z0%NN:03Z<Y],M54]50TJETX7S5Z3VQ]EYC[!ZY(98
MM^BZR#BSM6J9/8JK4$00]G:,"=6(F#=  13HB(((WB#HB7<W4,3XYH5=L-2I
M]3C(&N6N9L=@L42R\3X65FK<<REED'/?+JJ=_+G.8SKNU$R<F'NR)ZUWTYFD
MR=-GKYZLY=,T&K5JLI=OHMV0 #5(E"@%U   " (#O$8VY;9Z2R=F\E\LES=D
MR?NGSUXW1 P)N'<R.)WRZ@"81ONCF,940$ $1&@!#:V':%MEMF/J;BNS85HL
M[0<>=\%'KLG%B[0JQ72QEW:4,\56-),T7JIA,^03>]R^ J9'9%B))E)UFMMK
M6,IF_G+2?S%M,YG=]H.D5M&=X)0 ""N0H DH8@!^K,)*IC42"41$1X3[HWL)
M,Y-*[/3"RLF>2:2U]DL'#4JJ4O PB)P:&,(JHE4J.E*50"JA0% ,   .C,8N
MQ[/8Y<XBE*A"+8R=5M&H*TE%H#& "KMVJ3)O!(,F M2M8Y!HBDV1;M11*DBF
M0B?24 #7(0F\S;30D[1?."S8CL7Q9@8XJ.>N&.*AG)E%+XG5,H83F.>\(F$1
M&HQZ!S(9,[DJEG'$M:'D2C$LL-*BI%39>SRI%1*S*BE<*FW*B4J94R72E( %
M*  $<"VX<QC>\:#AVWTZ*G<9#%PD*-.>>)]%#%UM5@M!LN$7"3GN8U6,8';_
M +XZ@,U2ZS'\^;LIY-I=-?;C)\LVFVF<+]>3NZ;3.@4*X4J)1+>5!90#>[2A
MQH 1AF-FY%-Y&-FYE+&SR1&;MFII8L4PMA;LS)&:I"4# :Z@9!$2>]4!3+B-
M(W6V(<:-+](900IT02_2U*;XYDK,8BRKY[1VCQ-^WK3@BJQVAXU-VDFOW8M^
M\.8O!U#%$2C!YW-CRU*4&?+C+47YYHDT 2@FG,%""F=V42E X+"01+6]0 R
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MV%S_ (4+Y/M%_$'K&X;M(+(J!1:Q&Q1 3?&68[2O&C42!SY=7HK$TX ^7Q]
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M7S4665(F0/,Q@#2$5X97[0JK1+:20PW"H7<6JQ&2=WFSNV-)4=J&(F!H9DU
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MAVEPK$2H*IC%)*UMTL )F(BJ['I,;L%M?-&:9%)NP>D;& #!,Y0Y/-9:9,0
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MJGI""L=N82-IA<(<""[9KH&,C,&I3&)_/&QEBH"JD1SU5T?0E]02TEI94T2
MSUI:ZS)!*F1&:)'F+1$I\0:*"J9*<R%4P@("FT>,06$AA;KN42Z0>>;$V_3
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M3P[6[O<W$9TL$G9&L,A#N';U1&/9MP B3"(8D*T8H)  %X,=-(7*I^/A+N%
M+\$ Y\9T1=&KJPDN;2P[P[I-% IUE3"(F<NUC"JX4,(B8* 8VC*%0]PA:B(U
MI[&P+!:PLAF2LP74.]F*RZB6GJ!P3]XB12ZPJ4"B;"E3:\XVL#YE?8OI=&D)
M<BR]2&:M3&19$>.4&KDD@OXDII J"B8*HBHQ<("101*)#&,<O %$OZ[L\ %E
M:)2A0 .J !_VQ'Q&HT&/Q9TT*JKV^F*ZX?K5&<M,-,0$!9IW:"(!6A;H9TO
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MS#J;"3$>-U"F 7*Z:9U')KY#)D*W$2H*&OJD.8A2#7]=,39(QW%-W=UA'$?
MD$Q&;)5RBJV5?E ?$N^X34,0_!NI)-82CP0G)>GO#=7E)-:NS=H7:B,D>)K/
MC%*==8J)RJ B8:)HB8Y ,4:!42E&E<ZYQ]5LQ-&S0DPGMIW#5ZV264]DL=,B
MZ21I2^NDB)@(4QC&.4B@@-TGN@%1I$<WMA(Y.<#+E(=$H]"*QN .B3^"4O\
M*'D3DP\<AR'Q:^BHL-& >Z)@-2\8H4H;:(4RPJ8-7GY*;]('MPQE!<D0!L!S
M-V;FEU=N C<(40  OT*!"#78&01>IV7^V2!S#CYU:LTPA9C'S&7=/*W4GASG
M83#@R+991[(@EW)U8TH'.B:*557;.UN\.Y(*1034]W*&_5V1"WBGOF,H!BUQ
M VVM,:URPC\I]($X]N6E<N]$=N*2*+0R)Z"*9FX&*!2C4PF()1*8+U! 1I2@
M!$G,]J+;@-TN+-M#5%.,QLP )NQ1T:D#1E[E:X0JAX1!)N!"-DI _A(@Q4@2
M[M!ZH9,Q3$*.NG'BL![.:X^?=#_[HXJQR]A@*'"1Y8ZJ-6;%J@*)3(1;!HW[
MIH1 2($*";=%+X0$3*/20GP""4HB" @(A3SYY#.L,EM&V\^]IN6N]HDG*,^[
MK]658+NA(KX>%=3!HZ50CVIENDHF7CT6SER=,ABI'%-OWIC)CI ,^<^_G;"-
ME]_%FQA>YV0DJ^A)45&]25=F54^[.^!LG(.$EE6YU52JKH,DT16<@@0X))!\
M,2F$HZ0KC3G/Z#G2'LWJQ*=UHU&S;CY=&0CWZ4:TD#LQ!?O(=8B[^+6ZB@<.
M6DHHFV,B( 42/P$?-,"F0'?X5^48W.F2 I^W2G41])^)G<F-XYL1@Z.=,Y8(
MZ3=>8!0"FZTR>&!PQ#I >%52E*/ IETB8R*3F1IV 9S-1GJZMH.Q&)A6KE--
MT8SA)TBS!E'I'Y*V32<'(P0!D5-14Q (=0XB :1 Y9TYY]!CFR<59<;4>U3L
ME(JQEPCH1CF2ENX]8R$A$3K &S23+&NDQ &[N*DP@G8@D8HG7DG"Y15*182H
M;ZX=GAJ[X[4&$\PU+.>/(6_T]PY,T?)E;2D9))(-9NOS:*""KZ%G&3==RBTD
M$"N$'!01<.&CMBZ924>Y=1SUHZ61,.SI"#2$&D(-(163D[<;>,;;Q&D3-Y.5
MCMO[1[&P-Q9DQ?D*:B:Q.+XR6NK:O/+57\(3E78R;AD1?(%FL\[FF&:5RBBP
M%Y68=K%.)&VM7//.X8C7SX[]F&K.$SNLQQ3D=V.%[&RQ 61D;7-8L6N5UKV.
M*]/3(R57R>WL%.D@M@XIM3G'ZS"2@4&%RNDW>Z6>5K#R!A($'KZ'/8J,B=OY
M<\C%KFD(-(155V,'V!54_+GN\_\ %=F72$6JZ0@TA!I"#2$1WR/MXA;1/*Y$
MQ_8)3#V8"H$2)D.G(,SA.(H\BC&WVKO2'K][AP-T\-YMJ9^TZ2&C)-@<H&UQ
MEY2)'"C^5+A+9@J)3.1!'3L)C< "E+-&&D1*X&Z $!XW5:35%,-$WF**0G3/
MV&TW,"";&9(!,Y>F E2144T3ID!QJ8TN>W5#M1J(FT!R.&)SCI%F:IP*()"&
MW#V3';Y*J[I:PRQV[Y%*/S)7A>N\#VCZX1- [F??"H\QC*NNH>82]K)QY5"=
MRQM,FJX:I*W0FH:7JLR;C*GE4RI@LL"LO>F.(%#V=,]$BBJH*@@0C%XFQFBA
MA'J[)R@F9R-EY454HN).L:8MO>$R%PJ<T:E*6^;K3$AU#&3(4#&ZVT,X:W
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M#E_8G*$2T>R8$,1U+$1-X9:1$QA4(V5;(H) DHD='3?NNIM3K@03B42%#$
MHJ& A3&$1#W0,8+U*CNI40]-9&SWZ43UK*!<E; H1PN<P@85%4VB!W*J*!2E
M$!7432.4E^ZF4:G,(T IJV-MW:"5/!V"+G3%H))[<I_QC]A-B5,APG%N3(OC
M*=(% @.3BX.B4"AR4"E @ 4 _"'2?T"3SI"Z1)9:9:8G&6I*E*\;&J8%6HF
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MFZ"VMR$>/9R@U9F9Y/OF8F;QS%\Y=,VC K3D[8):4/WBB3"*;KD76.=1PF!
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M   3#F(@ !7( CCN%NL+K+@DB@"RJBN@;D%-!&^83:)$@F.)$B5NIE$QA*4
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M+/;5%S+MX8"F>+.!*400B?12E(4I"%*0A"@4I2@!2E*4."E*4. *4H
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MU6$&D(-(0A\F_)OD#\2;5^HWVI#,.(><(Q6%_DCQI^)%:_5374G^,WWC>8Q
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M!PUD@7J4E!V&*CIR&D4 4!"0B99FB_CGJ(*D35!)TS<(KI@HF10"* !R%-R
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M0DF7E0RP])"EY5-SU*CP <J&Y'J/_"'D>1TA&YI"#2$:&*!@$I@ Q3 )3%,
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,J(B.8C7OBX881__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g838337g58a33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g58a33.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ U )4 P$1  (1 0,1 ?_$ !\
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M6?.')2/PF4(19?$/),&>5(M\;'#/%.>4'ELFW[EEFM7:VEGEB#J 64LIA/0
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MI^U%Q-_PU@OWV0_6K"VU_P!)9YL0UMF:A?%3C_, J"7?O6?C;9&$@8VPQ_\
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M\4D$\<<$L<,;6M5"=W[$("$X9O$#,SL$O+50SN=78@0#5F))9CU8]22:D?\
MHOY^0JTG&&/D951%9[&]<JD8"QHI:<D*B@*BCHH    JHW_1\.0&3BSK+EY&
M<G6)?$_BYO'9K=QB>PQQPP-V6N?\)8OCAAAAB2MEVS''''&RUK8VM:/Y^<&!
MM'"EP%,1@*]IL].0228=.SZ<HDDF/R"2>E2?LS<2EMYXVLRXF%R'[+?[NT
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MOA9BS6L[,Q)9FE0LQ/4DDC4DGJ2>IKK"\ SHJJM_;JJ@*JK X55 T"J P
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M%CU-N/Q"-.I2A#.1^+)';C?0[-BOQZV0B;.[=R<2]D1@,=$9B;/#4DCC^#R
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MM=7%Q+&\@;43+;[%4D=&@DAW1L1Y!"Z $ZPRX'FP&-ID65;2"VBEC0KM,+7
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M4MQ;"U8J1*%1I1V\M'-D8Y+6>VY<S&29Y(VDE1N4'E64]5B1W)VE2KL4U.\
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M^/9U1O\ XE?4"_\ O1Y.?_[-,Z[1B?\ 9>._^AM?_P#@E<!S/^U\I_XA>?\
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MY1T[Q>*O11]<Q_Q=/G+X)].+ZAE/@:>?OZ2_K:M/<OR)^4=.\7BKT4?7,?\
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MV>'R]V_;X6FG6K>J2HJ4I2E*4I2E*R9I[<FS] ;'BVW-.30Y -APPDD4C\E
M.LFSMLJG>UEFCI*]LVI,210[]D8"DD'8DR.7<#BC-VR<+(9VUW:6U_;RVMW"
MD]O,I62.0:@CZB/K5E/5'4AD8!E((!J\L,A>8N[AOK"XDM;JW</%+$VA!^M6
M'DO&XU62-PR2(2CJRDBO<1H/ELCS@U=&.1B@QJ#D4O'#QLZ LLL[LA$]BHD=
M')6D/Q44761$$"8U0X"0<+N'2((J-3=KJNL5L[_.&?Q)PF5NL?N9XHV$EO(W
ME/;RC?$6.@!90>7(0 #(C: #2OKSA?.KQ'A++*A5CEE0QW42^3'=0GES*NI)
M",PYL8))$4B:DG6O&3S:&$@G,GE@#,8]X4"<D=W!7Z=EL%\470G9,D'*H8+)
MY9)JIH9-KHIYIY9)Y888WPO?#N7KZ!X?T^0<+IXODK'G_G:1'_\ VOE;BLD\
M3\1:G4C.94=?,M]. /N  ']PJ,-9>L!2E*4I2E*4I7H*Z"L@%Q/'J12<W/)I
MJT/'^"LW,%-DZX0NYV! V \V/=.I;"V^+P=DO)P"*>9((EB_9WS(-T,;.4;W
M\)CH7',;2][L:00W+R9N!%M[@Z03LR,!%,=K:12$[7.T^"3T-=/[FDJ0'BR:
M2YN+..+ANYD>[M!NN;94D1C/;C<NLT0&^,;EU<#PAXZV_P =:B>4&[>AO+XC
MN/<6VM0$V_.*"J<H);)9/JSEG+)DQUGL V0 R(E'&P0D+BX.T1N( E@4ID&1
MH7XY$G'5O"*D91J<A;&67&L4UI9VMVIPL_R9%%'<XJ*$W$"+)&LA=6D?F[Y$
M>*/8VQHQIHL6]Q!,QD>YU/!?WU]8MWQ6WRQ/++99N>=;.YD:.1HEC=(8^08X
MWCFEYB;TD/7?-K4XM\"N$$G ]/K3.X]3;,V)N+J/1+?$R4Y @=M&8NEHA6#J
MR>\891/7C06[C4X420!HJRM28N%LV;M=P03[4R70#LMDRF<S,4N?N[.ZMH+/
MAV:QA%A):)*;X3<OFF:X+B2#4N1'R5&H '@L"YU+#<-<.31<,8^_LKR[R'%<
M&2N#DXKZ2'Y-[-SN2L-HJ-%<=(P9C<$[6W/X2GEKD[C=T]^GA*%.GGQXVEH[
M8,DVSS<TWO\ D$@WQ$]W2:-HP$[I7Z:DVIR-P)PS-1PR[DC&+.F&2)7'$&)L
MD-=6"EE73_O+7(Y[/Q#/Y"VO;>.UPM[811V,ME'(9TNS"A22<%)$"&4-JOAM
MX0#H H-YBN%^%I3PMBKS'74U]Q#89.67)0Y&:(6TN/$[K)%;%9(I&F$++H_T
M<?@GEOJVF"A/"3BGR+!\ ^0'&?B1,FD6W3,N2\/V]QSD?*5Z'!/06AA^3]IL
M<MON51UP\@XQ ;90].4!XA!!WABC'(LB/(72)E+Y\SE,?)G;#)96$RV<.-FM
M,A'C%>0/?.%:V2QBD G8M]' 68D=9)2R^"N-3A["96/AG)XC!W AR$^7@OL5
M+F6CC:/&KN6[DR4\1:W0+K+<!$4,-(H=KZ.\FL.F+P',;:XHS?+7(S'4N[>+
MG-39DYUOI#DY)-TZ]1E/&%]'$0YG6F]%VPHT;S+-SKE$RR?)K!A9T?D(S9..
MP/5WV-/$F=2URD N&[599/#6T%S>XV.SN#'DED+I<V(+(FPH"C+H[QMOU&Y0
M,OWG\,O>X6X[(@L<AAN(+RXM,=F)LA:\[#M"(Y+3)$)))S%E(D5@8TD785.U
MBU4Z96FN+O4(X]<]-,ZCUJ6X@:8G,XX"-)I%RNX'VV2C\E%=AS>2R-K#I?,
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M93;3P,P:XL2Q2*:-R"R(R'10FX>$QZ%+PEPQ!>7-T]DTU@G!5QQ$+*SRLUQ
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MC7B8\:H2'W:/'S:SO-2]9_AR]R5Q<YNSR-U'>/C;V.VBFCMX[<.AB+%FCCU
M9NA92S;6U4'0"M5XOQN(M;/AO(8BQEQZ9G'37DUM+=2W>QUF5%599=&**"0K
M;5WKM9ANUJ2>_=7<$N-45X#:^!\:9^^Y#\G>(_#'D??D".Y#3($S@D\V5(FJ
M!]P-UWF,+#7V)):/21\X\$5%XB\W0-"-)!E6SI_GC["ZS>1ESMP^1MQC\;EL
MQCA8-CX9#/!;(2@>XWHR[1)&H\!]VDADWZ@#+9.SX;Q$/#-K'B+ILKF,)@,M
M\J)E+B-;:YNY5$I6U*.C!S%,QT=-A,8BY>A:I-<O..'$724MY^\O^2&K=K<M
MTHISC@G%:&:\,;]F\2)#FI#2$:V,8V',=E-T3\UDA*[)>T? (%'>8]-PT:M7
M&"Z2V&3/&XK(Y:]AP.)QUU:XHRX6?*37"V$$JL5O9+=+>&V)CAC74<R0J Q!
M)!!!W9C.XG!X^?B;.Y:RO<X(>(K;"V]J^3N(&4/CH;N2ZGNU$EQ*^UN5$&;;
MJ K @@K>^G&7"[:?"/IC:DVWQLG4TUSR,YS<B]4:A"8[T,QTMHP;L7:[(&UD
M)>01V."EMFFXTD4CK1!F_91\6_0;EWKU%1UFU1O#>',6V9XCNK3(P0W&.P>/
MN[MS8I(EZUM:O(T:1R2,+9)2LA)4R,I*!3INJ?'KP_></\(V-]B;FXM,KQ)E
M;*QC^49(GQR75XD0EDEAB0W<D6^)0K+&C .S:G0'3_QKX-:_VOU:$>!LGDL@
M3UF)Y'[LUB4D#19FTDY>)Z66V$_R23=7:YLF)B4CX)B,R>I,<TV3HKDY;M<K
MHIHWVS(YNXM>%3G(HX^TOC[*Y6,@M$DMX+===-062)I]VA;J%T)ZFM%Q/#EK
M>\;CAJ::46<>6R-F\JE1-)!CS=-H&V[5DF6VV%@NBE]P7H!6P;@;/.*$YY#\
ME67%_BU,.-><>Z>W.<-+&9_=TBV^WF2:0<"VC3Y)A)XZQ*1@\U;-W5CK9H:(
M"W#MYBV9L6UF/:7F!S<&4@L,:V3R<.1WY_"/&R6<=IR?I',JDQR,LD9)7861
M6 &K$[M!M/#-SA+C+95</AI\1RN&.(HYQ+D9;Y;@!(Q$P6:)7AE !Y@61HR6
MT51MW->W%GB3I7D7J3HK0S>V>RIMKK9&M>I_)91#[[-F+<.'7U1+52 '+7HK
M O@-@V;EP+:/3J,?18-9,1;H.3Z;W+&][PY/*WF/NN,9K'L\-Q;W/#444W9H
M2[BZB57[0VS=/H'98S(6,2DB/;4^%PF/RUCP!;Y+M=Q:75IQA++!VN=40V5Q
MNB[,@<+;ZE T@B"B5@#(&JY>('&?BAL7>'2>Y.<;]?;7XN#>0>RN6NK)_! &
M_9M)3K!WJ;6,PN$E45VJFE&I@&(2%C=TE*&H[Q<,7;OO%#)@W9HO7!B++9+*
M6]EQ3C,C/:Y-["VQ5U!/)801QLMU<Q<R*6U)DB=8VVF(MN8%2[,6*A)L%B,+
M=9'@G,8FUO<,F4N\W97-M'D[B:1#96=P(YH;W2*>-I5W<Y5VH0VQ5"AB\%9]
MJ7A!Q;X@\;=E;MX[;(Y([<YF@^1DPPGPS?9W5C/42D!FSV'1-A& XV,20/+G
MV3I8>5EKF9-2631?MBB3=ZW=MAS7.0W6:R>6R-O9Y"WQUIAY,?#R&L4NC=\^
M%9I6E=I8WB735(A R:C34J06;7+JRX=PV#Q-WD,3=Y:^S\>6G%TF3ELEL3:W
M+6\"0QI%-'.V[:\[3JQ4EB P9464;3IM\=B/"3<;V>Z"B^C^1^I>#Z7*4:;8
M\T%]I;T/$!@L4<2*;#XWM(X-B^N]>SYF\RR99645,QRSQ@'=+9F%NV(XL\19
M!<U:""^EO<==9KY,9&PXMK%%9W3;;Y$R-+<7$!&C=-DFUG'@#:<RO"6*?AV_
M:YQD./RUCPZ,RDBY]KS)2.B)*'NL2(4@MK6Z4^"1J\098R>8=PA?UUK7MSD&
MWO:]K9\9^,N6-[V^K+'^RD)CWV-_\+V[['+'NV[MN[:]O\;7K,\$_P"Q7_\
M$LE_YMZU_ND?^LB_^$XC_P E'6VR7:$X*\H>4?2;T8:XIK0.([2Z=@+=9TA$
M]KGT"/T%9:BW'(8MKDAXL"QU23RR-R:.M#9#;A4@G(9>GX$0<%8,4K7SU6&^
MS>-QG%5\F4$\MKQ ]G&LMK&5YQO+..6X7<\G+BDBE*+:*O+AT+H^XUN\V,X;
MS.9X*QTF%-M!><*Q9"1H;V4/V=;*^EAM'V1Q&::*:)9&OG<2SC1)$"BM=^DG
M7&[=G'CJ9RKC1IC:_&&/PGB3K6Q#7C+DA.]BB9W+E]LNQN96265&QFYX:\#O
M6B-XH;;%PK<M@N^%-&%UO!Y9^]&0LLAPW%D;RUR<DV6N-MPV.@MV@B[*&V1Z
M-)RV5U)$J%'*$*Y;36M6QS8G(8KB^;$6%[AXK?"6@>U7+7-TES,;UUWS:I%S
M%:-E!AD#QA]S(%UZRBV;TX..,1XL[KESG0\4X\\F>*2?%63E0D<YI*\CMFW(
M;'G,1#20/O\ UJWCH6+:U4*"RZIN*9QM-OV]51!9"Z(\<X:%,9;<19"7*640
MOI;_ !N4.3C1Y,-\G6VVWAE>-["Y,CRW.UD"2\PG;U!\)@5S-UPGB8,/?SG&
MP8O+X7Y%F>.+B Y6\WW5S DR9.T$4<%IO1R\!ATW$@CP4(>_MZZ7X4;@ZMW4
MV9\K"&OG^PP>6BW/'O6.Y=_'>+VI=AD2>O(6VGUY'N:/1Z0$0A\&(Q *0P+9
MO="1D"SAHLV4;XJDPL%C>9FTX4X;;%K.MN_;1D+FSL$R5U;JMQ,8.79R21JZ
M.^\3-KK&J@@Z^"]SDL?P]?\ ''%ZYIK5[N/Y-.+L[_)RX>RNG>TMQ<\V_BBE
M>.6-.4;=-I$KN5*D:O'I'V=Q#2&]3H=PT-P ]QW#3'DIJO5:</(3P;M0O XA
MMB0Q!H(*,IZ@+&,)4@O&Y6TDP)VY'8K8,7K$>64>/FKUTON=MEMW#;9A)TR#
MPXZZNC,L#6J3RVD<I=6@+LT1$D31R -IN5F0!2H'/+S!A.,$P$EK+BHY\M96
M8MWN4O9+:"]E@5'6Y"(LP:*831$KKM94<LP9COJQTEQ3F/'3GGPJX_Z;F7'R
M/@.I#PTXD[ G!W9YK9+W85L>1C?66&SFK63#F[6(F;66/%5H\.R> [M'@%7#
M%*]UTKZ/VW*0Y#!YF_O(;]Y.'<QE;>!+9+86_P#Z/[2;8F-B94.D:"1ML@*R
M _572_D_"SXKB7A_%V%QBXHN+,!A+JXDO)+MKK_TJMIVP+,H$$G65S$A:,J8
MR #J*CAS!X6=(W6<KB<0PV#%=)E]:\S8KIC;<>@W(J3;MG<NX^6(*@IY/IS%
MY)#&+C56R8Z99V5+!H>C)04>%+OU,49 \R8MV60Q.8XKN8I9NSRWB7.'EO+2
M2?'QV4$5_M#P6\$L<S"ZMI$;P7FY<DCA1K$NXG$YWA_@>SFA@%U!CWL\]!87
MT5ME9LC<SXS<8[FYN8);=6LKN*1=7CMQ-%&A8@2$J$S7%^$6A(?S^Z?THXTZ
MS&0#0NQMP;D@3/D5QBYTRG=P6<YA]8R@Q'QN1I,)%YSJ'9N(-N\=R@0*.N@N
M39T2!MG#[%JY7JRES-]+@L]%D;EKB^M[2SG;'Y/!Q63P;[F)';87E@N[?>5$
M3L@<$*Y U J_BX>QMOQ/PQ-B+-+7&W5_?VJY7$<1S9&.YV6<KQ)S.7#<6-X(
MPS31I(T>A>,,^A-8@XZ\)^"MU.!,<Y Z.V+O?8G48W+R?0>;*;;IET*9Z@%:
M?V84B0@6-C\?0LG.ECMT6Y"9/SY1H6&9."3MB_5M=HU1N\AF<WIG9+"]M[&W
MX?L\81;&RBF-VUW;+,[-(Y^@V:E85C5D8*H91U)LL5P]PYKPU%E,==9*ZXKO
M\R&NUR%Q;K8I8W;PQHD40TN3)H'G:1U=-78,1M%5+57"3ITA([P6B^U.-\ZV
M#-.:_*'EWQ[QF@;>\TAK?6XG5>_36NH9*$8Z@F29R0P'%.(PP09N%AHYV@@:
M)'4S1%9GAA3=9GB!Y,W+:Y"""'#8S%9#DO8PS&X>YL4N)HS(=K1H["5B1N8$
MHJ%%#579\.\*11\.P7N)N;JXX@S.=Q8N(\E<0"T2RR<MI;S"(!EFD1#"H4E%
M($CR"1B!56TWTS>F_K#1>OSG+B5QA!7=6Z^7^N%]N3[D4:TW(M6QOCQM&5:A
MCI'5>O T2,Q/:4D?DP Z1RQK-WXM@%;'$,VR1)OX,=5%WQ'Q%<WUQ'BHI3V*
MSQ-P+2WQZ7D=U)?VL5W(MU</*DMK$JNT<1@5F8H=2IU:J[#A'A*SQMK+G)X0
M<AD,Y:F^NLK)CY;.'%WLUC$UE:I \%Y,S1)+.MPR+&) 5WC1:R%TTN/O$CBY
MO3I9J+:OE6Y>0?*ZV_MC N1H_9IH#$=<L8*VG8 $)CFKV#!S'YB(-1ABK](W
M)\BD4#N"5S;!\NADU#LH.([_ "N3L>)]+J*SL,5V"W?'M;))+<M.8'D:2Y9A
M)"R2M]&(T*N%Y;#760W7"6+P>&R/!I-G-?Y3-?*=U'E4O)(X+1;9;F.-(K-%
M,4\<D*GFF1]\9;F*Q&B#65T:V&M#O5Y@<5V=K45LP=+))O$/'F9UYA8)&9,W
MC$R/HRDI'W(TD-F2"0,*=CZ,=*X-6:+V0M)+@ZL_CK)NXV/B]KE.$YY;:X:V
M:*.R>0H/#DC,L,9B60,K0G>Z2&1=25C,>FV0D:?P$MG)QS;07EFEXL\N2CB6
M5OHX9A#<2B=XBCI< 1QRQ")]%#2K,&W1*#G_ %#QZZ?!?7,$Y%;!XGS^4AN7
MG4!PXDZ[U4$Y"S <PXZ11,< 'OI2WDPV/LC&R9L]DA F<8@)*W'!G I1D+;^
M+_%CAX5L;N_SZW,^/@RL$;XG!'*W%T^/B9LC,7D98C&TA2VA$:HC21EG#[F.
M[< F5LL7PL]I;Y6ZP=S.F<XG^0[6QCRMPBXJ$)$C3K*D2R7=PTK/(L4P2,JR
MQC:$+/#;5'"O4Z'6-9<&9GF6G.FQ?**8ZD>9*E7(<\;AP5W(,!6+\O'\QR[0
MU9HS88%7(OL.&1!)UX!%NCG9#'+W>8NCPB<W#L@O&QD-V-%#QI,ZQEMJ2;@4
MU9MH;=X.FI)ZUK]EP_8CCQ>'+CF7-@F8N+%M7,<LD$9EV;GBV$2;57>R;06!
MT !TJ<W'OC/TV.2VZ^4'BCC<4U%KS@]J_9C^3@=D\M)DSAN\).PV/A#H7*Y_
M/&\)?2744;#B!Q(A+,8;@51R)&QN#='L0)>TCPE_DN(L=98S?D5N[C-7-LL3
MVV*A,UE$UN9IHH(#,([N1W95BYVSP48DZN.7LF+P_"67R.9V8E[&UX=L[MIH
MKO.7"V^1F2[[/!/<W(MFFL841'>?D;QOD0!=L9YOQ)NGOP1Y!'N5.D^#1$5/
M=\-./VE^2^@D(?N YLB+QPJWEV45Y(<?DCSQ(0C.+ V7B22PHT5 82YVUE&*
M[FV+1EBWM['G\W8)B[S-*\%BV0O,;?&6TCMY9%,7-QU^8P6,&]M\<Z+(8E,7
M3PFU/DW"_#>4ES6/X<>.YR2XO'Y?&""_DNX8G$_)RV+$K;!<<M>7+;R/'SRL
M^K:*FE2+:=.3IBPR0\JY*?"1N2P#BG/M$\5#.6T^2T[TG!#^V'$;3.[WVH5F
M@03,3C638&":L-A\!9-1,/L9AI1%=+"Q.SQECSQ#Q)-'BXXWDCGRD%]E$[+C
MH+V>.U$ACL;58'>%#'L7G2W!+2E)ETUV:'+#A/@^WES4TL<,MKA;K'863MN6
MN<=;2WQB$N2O'N(TN)1,'?D06RA(.9 X/E[EPQQTZ?'"LQN7<B5M:Z^Y \4#
M/+F':&T;R4V+S>5T2.>LY=&H_)"&N]5Q"+QRQ7<^WHDA)D\$NV$F0>5N1U@S
M5H+?M2SJ]YD,]F4L[,]IN+#*IB9KZ]QUOA>W,#%(\2W%U-))LL[.4Q'7:A>(
M-O+,I05C\5PMP_)?W_\ HEKD\))G(,;C<O=<1''(RSPQ3-:V4$,6_(7\ ET&
MYECG*&-0KJYK%G/?3P'C_P!,N2Z1B3HF0B>I.LQR1UY&WQC-)<JL!C&LGPD)
M<LY;HMVZY.XUDC9XX1;M4G3E-==)JW3RLBG=8.[>_P"(XKV4*LMUP?CIY53H
MHDEN=[[022%W,=H)) (!)\=67$UA'B^$)<= SM!8\>Y6UB:30N8XK-TCWD
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MDE(5U5.=D!V3N#:X'=2"LLWT;"R?:R![6VJI+$91*(VV;M8])L8">A)"$ Y
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M%M?PMT31L?$6(Z5*S:'5=YY;EU;+M.;&W8UD$(V"#BL?V!;^R_40V53EG""
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M[/+%OA!)(1]PU)_WFUGQ_&/$>+[7V3(L.VW37UP9X+:Z+7K:;KM#<PR\NX8
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g838337g59z81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g59z81.jpg
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MK>'H-_-[0_M^4_FS73-:JK+Z41*(LFD-_P T(K\&V/\ 1B6OT!]%7YK^C?\
M<+1__P#7L<O.#5WY5ZG_ 'AS7WE97TE7ZK>2B)1$HB_VWKV]^W]]$62>K?7<
M)1%%L1Z>.7_$'C[K$LJH_DQ^<Z@WCOZNY6E5-32B*+)7T]<3^3Y.^M"6JC>3
M+YS*#^.WJ[U:=4U-*(NMLNF<7CR0;K[KCLV%V_T\-X;["M_[>%7(J^7C_P [
MZ@)U1L>2/_-_B91!7<+K4HB41*(E$7Q.2?\ ,&8?!]S_ .&'6)>GG\R_2A^Y
M.H/Y"97CT>_ESI+]OXS^:C6-VO!E>AZ41*(N]]._^?Q_P><?^*;JW'^ W^>>
MW^Y&<^\<&L'_  @/R&K_ +P4/Y3(JX:]>5I>E$2B)1$HBH;3[_SE)/\ P*#_
M !SZX-[Q8_G/]BY=3PGZF^UU45=:N:HLVAW0\S![T![4(54X_''UJ)^*_L^U
MEY;//H>X?\">=ILTK[+Y0O9_"R!XK>W[75HU34DHBBB=QF3N,SD:E''7U60:
MZ'W)/3M*\XDTL&X 1EFEIQ%C!>P?4B"*X;V]:]=O!)&,4;/(#.P]K.0L[>QW
M76R ;R&[ 3MQ/VL+NWV+YH$#FAGL8L_6\-L5%_XA8:J<^']('O91Y4GH%[G7
M+!C:=&>QC+G;PRRR_P#$,#7SK$/Z04Y,OH%[ERP8JR 9[&-J+>&K;2_\1:'=
M_P#JOG68/TC>XNY?>1+Z#_5WKE P_D,7KL(0>&ZLW]P7 5_QVKYUN#T]_P#-
M/_:*^]7E]#_6'O7*!A:?"]DWHR_#<T=_\,P=1ZW!Z1?1=?>KR^9OI-WK&GJ<
MCSC&,M.K2ZA)"L*:F0T82#;'%V >@+,!N,M:UKWX-^>UK<U^;?>O'#X9,@R=
M.N<(=]OP-IMNUMO!BH5NYT'@X='] 2\/7\G^OPVS=3[6K"RZE$2B+-CC?!*I
MTQ]!'*\D(3A<(;%UP2K-AAPB@JV1"?8NXKKBK"$"QG!O>UK6O>V^UK;Z]]>B
MVZP]&/1R/+=^'0>D&\;;?;3^/;S/M]:\ZM657?56IGXV[=09E_ _RY&S^M?>
M T]!_P#N2V]_] &.UO\ >)WO^;5]]>\T7^O_ .EET'5/^\_U/_4N6#3X@M]T
MDRP7@-I)?YRLROG7B_1M])^Y?>J-Z;_1_P":Y0-/[%;[H_.P_ *1E_G%FU\Z
M\?R /O?_ )+[U4?E,O<W_-<L& HI;[HZR$7@'MH/[VPRH]=E^08_<7^\R^]5
M#Y2/WMW.N47@B& W7NJ?S-V[V:Y';?N_KXMM+]?_ $;O]&ZOG79O,#?YK_[2
M=.JQ^<_>W^ZNZ:XBY*411;$>GCE_Q!X^ZQ+*J/Y,?G.H-X[^KN5I534THBBR
M5]/7$_D^3OK0EJHWDR^<R@_CMZN]6G5-32B+Y2:QL<MCRMB+6!075&I1W4B(
MNHL$*926HX/%6-)N+AW+L&U^,MNW[^?=NJK#)RI&/;BVW[-]O"VWZU3E#F X
M[[;[=OA\#KI8&GK_ *\M_P#(#%_\KO'_ ,:Y?7O^Z_U__0N/U3_O/]7_ -2Y
M0-/B*WW24*A> UE%_G+3*^=>?]&WTG[E]ZHWIO\ 1_YKE T_,MOND@=!> G2
M%_G6,KYUX_0'WNG51]-_<W_O_P!^%<H& 8Q;[H[OPO ,;P?WH#*^=>D] /\
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MJ@L\M=X;9F(.=@A>09.J\H8V;\9+BH^=,VU^ER(ZZ25Q]O:7=,".+>1I%=B
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M2B+6:^R-8FI/8=*DZ**%=&V.^6(FX'<'> *E\1P1X:"KB]8(AE1Y\&$-_96
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M4H6J61X+?90_HGQB6W3+"%;2D*4I.,2%6*M;+1O'B]/4!'\9)$=AVV^,SV2
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M@J3('I<4YN#459P*7N)2QT.26X.D]+YK3VH\D1W\I=PAX>C%+;RV8ER,V:U
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M7>G/E]-_J[D]%7('ND4?DC;_  5.K0?HV]Y=Z<^7TW^KN3T5<@>Z11^2-O\
M!4ZM!^C;WEWISY?3?ZNY:$&1S!G9#GAQHN$8;,Y088*]K6X0QOBX0Q;K6M:V
M\5[WW6M:W]5K6KT_Q#;8G&,W@;'TF;V5HEYDY7^E,E_;[G\Q(J'TT:7UVI2%
M:@/.27(9/F/'$6A4AQMBV+6:S7>;IW6;H&6;.=T2X5E[DWP^/'W6'HF.WFB)
M8YMR@5Q(TRD@^VM5ZMCTK?TWU]ZU3!Y2Y?K97+V^<T&/*''R6*$7,C;EQ27K
M(\ R6/Q7!%*#;&8D-QZ7TI)JBCJ+J#6+6;QE2A9QF)J<IY[XS7XX+\O+/\9+
M'2K%QE'7_&\<L1/N F)>ZS-H]E>G[3O#<B9D9I=C+,,OS!)(DUXPF)#<W*GC
M&C/#V1U#.VYIO>S^D WRE6J8'%2X!L@6\N;+( %F)E1BFA@M;T]2:GO8S!ST
MLM@Z6$JW9<M1*64(,K->L0OCI9O^K&\E0 LQ!%^,CY<KR.[&#!7S>B[FG=-4
MLGFX+F*S5W-6J<.)NC'$<V+AI5YFR$<#_P#20:.V9UI3E;ER<</+9G W.*ZO
MQ6,MZ33/DV=(].&GY(FD!Y2=+A'%*<@JR5O%8LDB",)10+7$D$*]@ "$-KB%
M<5]V^][WYZ\T]85X7U;JEWC;=]1YMW[7\+Y.T[_*O2+1\TC:2TLS&[,VG,(S
M>#P-C*OZEW=Z*N0/=(H_)&W^"JW.K0?HV]Y=ZN/GR^F_U=R>BKD#W2*/R1M_
M@J=6@_1M[R[TY\OIO]7<GHJY ]TBC\D;?X*G5H/T;>\N].?+Z;_5W)Z*N0/=
M(H_)&W^"IU:#]&WO+O3GR^F_U=R>BKD#W2*/R1M_@J=6@_1M[R[TY\OIO]7<
MGHJY ]TBC\D;?X*G5H/T;>\N].?+Z;_5W)Z*N0/=(H_)&W^"IU:#]&WO+O3G
MR^F_U=R^(T\OCK(=8V7G!X6#7+/05A9''C+)+%Q14A-X ."064#<'A"Y^#OO
MOY[WKA6P&/A$&X6\.W:_;V^=W\RY<!.3;D^[]O;[661VN&N0E$462OIZXG\G
MR=]:$M5&\F7SF4'\=O5WJTZIJ:41*(E$2B)1%^9YE-2SK<GY(6QVX[Q]7.YB
MJ8AF6X)EVE3(7 QK$.UM]@C$B,)N(-M]K7WVMS6J_N@[+6)]1=-'2M;?BFP.
MC<_>A+M=HK^4DEM4 C=]G9VAQ,U2)G=OB'LZ\>CG@EU%J[+5G=ZP6<O-4=^Q
MVBGN3'5]3\D&%F_6JVV?NNR>:$\LJI@Q( 2C'TR+:VC*<#,,+3"D+.V'JS6Y
MR:5XP#\SI-'KN3B<RJ3+#1G 7+VY>5=.NN>F[SX/?1%C]==&^J<G;)Z>6LZA
M&IA<GPN;P_@O'Q2F$H=CRT[4V3..<6=C8ZXR ['$S%D+H.UUD.CV]<R<$76L
M=DIH*N6Q[NP/:KU&,XI89'9^7:JE:F> WWC+CEBD;AD<AWBM..J/".JZ!I<@
MX4FK?)FT1:<+TRC&6DE<1<3R[CNSRV/#-$N9G L0#0%B,"8WN("A+&=>XMXR
M5AME:HTCG]'9$\;GJ$E25G+D3LSG3NQ"^W/I669HYXG9Q=]MI(G)@GCBE8@;
MT?TQJW ZOQX9+!7H[46PM/ [L%RE(3._(N5G=Y()&=B9G?>*5A<X))8G$WH.
MK:5R)1$HB413MJ4U4X1TF0%5D'-4R11Y#8M0%B8"!E+)=,7(@NP@L\2CX3BU
M;LN&(90#COM#6V -"L>7!M0!-5EW-I71^?UED@QF!HR69.(>L628@I48B=_Q
M]VSPN$,;,Q.(_&EE<7""*638'MK5&KL#H[''DLY=CK1[%U>L+L=V]*+>1IUN
M)CFD=W%B+XL43$QSRQ1LYMHW:[]<>1M<N6QSB4EF1V#1T*QKQCCLA6)4WQ%B
M4&EC/4*CK!*+<I0^73IE,B>N(*NI,(2($I:=K;&Y*1Z!]'?1_C.C["MCZCM:
MR%K@FRV3(&"2[8%G81 =W>*I7XS"K!Q/PL1R&Y32RF6A'2!KW)Z^S+W[;/6H
M5N9#BL:)N4=*N9,Y$3]C2VK'"!69^%N-Q",&&**,!M_8%P15)=:SQ+N)%YGX
MXP[,'8U5P=Y0'.0N4?BB!'<7_1.5(G9Y4%6ONL(IO4<^^UK7L#X1V1"KH*"E
MQ-S<IG*4+!\KQ5HK-R0_FA)# #_KE%7Y\'C'E:UU-<X7Y>,PEV9SV[&ELRUJ
M<8;_ "$<<TY-YVC);G=:*K>!*(E$2B*+-H=T/,P>] >U"%5./QQ]:B?BO[/M
M91%I1]H& >#)^N4BKN8O)C[?XG76R^4+V?PLJ(JHJ:41*(E$2B)1$HB41:+^
M0_\ /^<?#"3?II;7IQB?Z*QG[/I?RT:\SLK_ $IDO[?<_F)%;FB3'.,<EP74
M*S2C(&&<99*3*,'KL72W+N3&O%@D:%-.W!1DU/%9$N7(U85[A#T]T"T#;8PZ
MY:E*48:E"> ZK$U]E,MBLAIJ>IC<[EL40Y^/+4L+BILOQR%CHPQ)VZT<9ARX
MKI-)&\KL.X&3,;CPJ^="XS$Y3'ZD@N9+!XK*"6!DQ-S,Y2+$\$8Y"0LJ-2S)
M(!-))2%XS:+<MB$7<&+==RZ],68 QYC*6KL=Y.P;DR0R/5U)E^-CL>9J19CF
M\:TWC@ZH$6CDF7G/KW(4:)$_)Q&F <ECB&R]22(QT/4*+VOT/1SE]29/+4H\
MGB=08FM5T55CRHY/ GA*%O5+9 'MVJL8UX*TDDE8F9GB"+\6),T(B"[KI!Q.
MG,;B[LF,RV RMFSK*W)BRQN=#-WZNF'HFU.K:D*Q/9"..P.[M*<OXPF=Y2(N
MW$=6:5AU;M.G#H\8&\3&+NH['7FSJ_\ *S5'[Q9O[RLKT>TA^2>E_P!W<)]V
MUEW/5NJXDHB41*(E$2B)1%Q-,'2ZR]XFH=U@,KKKWA#U?[77.K>+[_M99,ZX
M"Y24119*^GKB?R?)WUH2U4;R9?.90?QV]7>K3JFII1$HB41*(E$6F'MQ-(;-
M@34!'<MX[B;;&L8YP:#CE:%@;B6YC:,FQ\=BY,F*1(BP(FX,A:U3/(R   1Y
MHNALF/))OR10.MP_@Y_W,9+2&I-+28?%-9.Q+^&H>IP,^<Q62CD",K_Q&>X,
M)%<ID)\800' +<+S]NBW3OH''::U &5Q6+JTL/J:$RLPU:X0UARD'Q+@%'&+
M1@UF&2*R(["TDIVR$?BFZPA6M:UMUO\ ^_\ ._/6Q> T[A-+8N#"Z>QE7$XN
ML\A0TZ@.$0G,922R$Y.1R22&3D<DAF9/X2?9ML%05X:T;0P1C%&+N[ +=F[O
MN[]N[N[_ "N[NZ^_QKE3).&Y4BG&*IS)\?2UO]2F?HH\+6=?<D0P#-1J1I#2
MP+FY3<L 5;:M H0+"[<4J3'%7N"_(RN'Q6=IR8_,8^IDJ4O:5>Y $\?$S.S2
M QL[QRCN_!+&XR1OV@8OVKM\7E\IA+<=_$7[>-N1^+8ISR02<.[.X$X.S21E
MLS'%(Q1FW88DW8LT6&-O]JH@Z1(V9;A&.\VHTP  ,>!$J<=3%9P;6"*ZISCI
M*Z*7O<-K7L(B#$&<.XAF#-WV"'!.=^#?I#(&<V%R&3P!F[NT#$.3HAOX."*R
M4=QNWTL@3;;,S-MVYQP?PBM74 "',T,;G@!F9YW8L;>DV\/'+6$Z?@^4<>+[
M]KN2M]C^R+L4*$X!2333D-I57#:YA+'.(W($X1[N<(%*]IC)@PVOZPA)2[WM
M_P!"WK58%CX,.9$G:KJK&3!\A6,?:K$[?K&.:VS>KC?UJ_*_PE\00L]K2V2A
M/Y1KY"K9%O4<D-1W^@WJ7^/OV1=BE.0,49TT9"=E5@WXLE]G4<CQ A[N:PU#
M>T2<P ;W]<04IE[6Y[!OZU*_P8<P1,UO5>,A#Y2KX^U:)O4,D]1G]IMZU\L?
M"7Q B[U-+9&8^W8;&0K5A?S;E'!;=OU[ ZB#,VW^U4SA(K:\2PC'6$T:D P
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MG!9BCGA-X\?<EC<XI1("<) "0-Q?A,!)MB%G;?V  !0 %E@"666$("RP!L
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MV(]/'+_B#Q]UB654?R8_.=0;QW]7<K2JFII1%C*U.=+[$_B4EG66N=2\9_\
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M%ZY="E8R-N"C5$2L6#X(A(F 7)A<NTG[&[!?M=<#)Y*KB*%G)72(*M0&DF(
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MQERXN=PL_"1<6SL\<]5O6]88# 1YW-TJ<N G*U+2O%!9LG6*=FFD(1Y'6)'
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M^B_<F[>=O>R=T?IX[_.&/E1@_P!.4X#]$OHOW)NWG;WLG='Z>._SACY48/\
M3E. _1+Z+]R;MYV][)W1^GCO\X8^5&#_ $Y3@/T2^B_<F[>=O>R=T?IX[_.&
M/E1@_P!.4X#]$OHOW)NWG;WLG='Z>._SACY48/\ 3E. _1+Z+]R;MYV][)W1
M^GCO\X8^5&#_ $Y3@/T2^B_<F[>=O>R=T?IX[_.&/E1@_P!.4X#]$OHOW)NW
MG;WLG='Z>._SACY48/\ 3E. _1+Z+]R;MYV][)W1^GCO\X8^5&#_ $Y3@/T2
M^B_<F[>=O>R=T?IX[_.&/E1@_P!.4X#]$OHOW)NWG;WLG='Z>._SACY48/\
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9HB41*(E$2B)1$HB41*(E$2B)1$HB41?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g838337g69p62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g69p62.jpg
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M 0$! 0$! 0$! ?_  !$( .P"4@,!$0 "$0$#$0'_Q  ?  $  04! 0$! 0
M        " 8'"0H+!0$$ P+_Q !/$  !! (" 0 %! T*! 4"!P % P0&!P "
M 0@)$1(3%!4*%A=X&#$W.#E8EYBUMK>XUQHA-E9Q=79WL=8B(U38&3)7E=4D
M)31!47.'EM3_Q  = 0$  @,! 0$!             0(#! @'!@4)_\0 31$
M @$" P,%"0H,!@(#      $1 B$#!#$205$%$V%QD08R@:&QLL'1\ <4%R(T
M-E5S=)05(S-6<G63L[32T]06-5*5X?$D8B5"PO_:  P# 0 "$0,1 #\ W^,
M8 P#'7Y:[9L:B_'!VXMRI)83@MD02K5C41EH?W;XF"*ZG@C75ZS]\0=-O;<-
MW*Z7_.;JZ>JIM_P^GT<\"U*3JI3T=23ZFS!:\[:=R:*;]T8;)K5[L5XVY\5]
MY]@Z/#]X>.NLEM\C>]<.DMG=@4K-NN4:5A+"$PF-/VG)V)3LXK)WA@T&+, :
MXP:1<-Q=4I[/>OXZI>SM:/C,:WAKMT)[%O+G95>QN>S1'K\,L;KWU#;=5X1V
MSN(O;OS9MAU-+ZA]9&"1NIJB2KTL+F@R#:65'7LBVD4\@[J3O7A!A$6KC0?[
MXX%53,7O4FTK1:5=RHTX,NQQY!.PMNM.R1RL^O\ $0G7*NY?VUZ]B+Q6OL2/
MN<5:776'2[5W8'-(G(0-$OH27G4>< HX.C]C2"?H-&VDN,Q!J&]NV0!TI)7O
M"JB+0^F7=6U273QBIT>\Q<YL_H5(K>)12%'S_7&K^IU8RB7WQ=&M3RJY.QEI
M0N *2Z3F8TVKF0DHY7#TI)7CBOST='3*4W@:'%1=>0C_ /"+*B:J(KC<VXB\
M*>EJ6EK>RU>I=JJ?,);EW(4_65;]7H4Z[-VCV:[-=>MHW,[=L6N*;'CNJ$!B
MEEV#8/SMEG7EI<+)&21^;Q@=$8A(:*#21$L]?KG4&3(.KJZ<.GP$;*6KLDG9
M)N^Y*8\?CL0WZ^>:V]H-UMH*.G:C)=DNP4AK;M=V.LU22RR8CR[BO*_[FW53
M4(JJNMJEI*V4)59[YG#UXW&UI.S@-?M6<7%\&)CJZD+79(2Z%=S"^*KQJZ4V
MVFY7&+[UN,VO:#NP5IJJ^LTBJZIG%@VKW"LVMJEI.O;"D3BI1 F26-##M@;$
MK8D7,<EY2(#(?%(V9<GA8N+R&2.S*#>/C1>[APL[9BJIEN]DFVU>RM;2>TQ/
M65WR[=]H+WZ/45  "?7@AKWK[%=9NVX"#WPJV4,SCK/4N]IF!<(LCFC3;LU5
MKZ"DV,]'<N(Y&34JD*255R4;%D-G$\%B52OC3/>ITVXM*7%5M8B^][DG<GR/
MVWV%T\B]-T#7$N[[:5P5Z8SBVS,!Z .^NS*S7<T"77'(@QELD5[((?-':$L@
MAMR(*IBW>L@Y-/8OLS;[#]2ZFHFE+9;>S*J2^-M1$/\ TWG_ )+R3WR5G>L-
M:]S !"L)G8Y3Q^TUT1+JF[>L8"/M*XB':'5<$1VL]>&03>)1B<1-P+V=2-Y$
MV1D!)3SA\F*9 6&K?UH;A-\"NS,/3:G=91NN[GTKY5;8%7H9BF_62(*T/%?)
M'"?&[(+-UO CK8:\^LT-#"$3G(6L.:G^"JQD.XF8M.6MGUC-B/";YGP"1(\H
MDE6<DJF5,WV74E%H3:<N=;.+/I@H&1^3OMS8W4CL/VGI3K55L;IE*D.Y$SZ\
M6I(NP8YY88XMU<>RJ/KR6T*.*5HTUY3D>\1E$GB<;@\EL/1L^ "XQ8SR*BY-
MQ*1H*E32FW+=,J+7X.;Z]'1):T9Y0K=I'?297=$)/85F*^/#HW80^K(M;L;3
MJ*:W)V:OV75%#'[=1[2,3)0*02IPXCANRYD[+%HK'Q.R\<C,"=.(ZW-2P3L)
MZ.VU4I:O%-,O?&DQI?5QI?22^6&\H$=-T7,>J,#5[913MQU?ZN&X3'.P1-W2
MQ!IVYKJ;S^JK)#6P^IIK*&[!C\R2 J:QHG5NI@(BBJ7&[G?>!PUV(V5K+B&Y
M:X:J)?EWE'R[S)6E&Z9=GOL?J<:WK"[X[:439-9$KYGY88[+]0E6>LO+TVQK
MOKS.[@LT9*^"@M-F36J:,QV![O4'%B'PC!TR=.H]M_AW7Z+7&SQ;B$YCC>\M
M);]]VK2G)>_HQW$G?:KN#/C6Y Z#IV<>/+H;V4@M2$WK(DT@,COOBUSTEX3)
M-A[%4B168,@0E\_YU1;/=0R#ENQ9\*[IY)%5,+I55=+?Z.SZV9C,%1@# & ,
M 8 P!@# & :L/;?LGVVJ#M7>UTS/L9V$B75BL.P]80Z&W/U@VZ\=B>I%(1)I
MM78VQ*=[H=;DG\:O0)/'1B0D&DKF:TY2.1WF91@I$P6S4:Q%D!D2I:224PVT
MY53>YTNZC@K3#XR2JBWD=MH+==J=>*MKU]<]WVCY,>R/76J1M\W@UB-60R$T
M+UOJZ[)N^:2F%486D44B;4066;0VO5(O8TC5D!4P4=SM\RX;AFPJJ4U+LE3-
ME,MU0INNVRMI.M.Q/S.=@+5CD ^BKIW7;F>2ZFNZ-RGP4U[($@T=AH?IK>"M
M3GQFLD 4O)E)22F+5MRL$Y9#!8Y"1$1K)V23C^K^1-A;82UJM-*LI[ZG:XKJ
M\9$_N'Y/>Q<TI+L!;'6%[-ZS)ROHWXV[R'-SEK1_@+3XCMA;1:-2-S6X)O2)
M0@M9R:K\1"C$I,2Q00Z!/MI> !QTW$FHN3GHPJ4FD_\ 56K+792C5Q$OAUS-
MI-UWWVO"AYW:76Q.,RV]>QY/M9UPZEUX#N_L<T*U:!FLAZ=QJY;"DCBT077:
M-R]A!0>PN1.GVZ\&E\QL*3.M"XP9$FI?>. !&RK/1;+J;2<QM.E6;N]-ZZ>)
M<+MGY>KLZI5Q#9%+.LM.<64/JB?V]=-1)=G2<ZD@8%7T_<P99&M^:1I&UW+\
M'(T&+V1-K+MP;4-?13ALZBTM+,I0.*,&0FFA5-J7$I)Q";?&6N&BEGJ65Y>;
M3AMFW&D"ZN14U0'7^^.G5.V78A>[2 .R';/N-$JH-1HS"ZR;549"DB$%*6BW
M0E(TU88-!VQ:#N0[URN4)[1H0J)2O>I5-*/]+=IG>EP)(>,CL5V=[$<=UW78
MP= FC6IN[UXTC6V\+D"I7<8!K4ND!?0QRTV@,-X7$Q;V M<-,WSPH?F[HZ<=
M%Q472%CF+H14DHB;I-RO^68HNJ/ES[;">G-(:\5'&NSMG@O'':??^Y+4M:ZW
MU7NRD-JV][*@TDC YA':BG>IF:.P,:&IQ/17D$'<.%%?C! 8W&:[%1>JA;55
MX6ULI)3JIWM6,BL)\FEPWE:Y,!UXZOQ.8575<:Z=R&_))8'8$-5\^"Z]QX#&
MK0CS>KXR8A;N%S'Z-H++ Y62\RFQH(XEIA5>)0QH[,)([.Q392UJAWBTJW&\
MJ7969'R3>:"Z(Y 9)93WJE 1\1/]TI=T2H@D]NZ:%'$LM&$3>Q1,FG]B H90
MTJD40K,7#:^)&M6T1%6'.2DE;K1T;'%1SEO(4A.PN/\ ]54[*TI0M>+OI:_5
M_&U?-O84'Z]0JW!76.)#Y]Q$.P\WM"I+'LZU8]*$P?70Z@')D:BC47ZWS*RI
M7";#8J\R2,W#9->5)543$[MDK D@1WN\U'B51=J;6AI*+W4MU))]$MSI.I<9
M/S%']>V=.4=(Z% 535MT;]?D('8%R3FQX4=LA"^ZZCLU3/5401HHO0LG2A,@
MDC>MWL,*7K'Y[)I6Q?H@PFBR7P_@5V;3,N&X4/1PYO.EYAJ-^L>[TD\O)?N-
M?<<@3+KH4CM.6JI>*54V>')V-(3 +:D)"]#:<7DP+4Y%*UAOTICA!PW!^(+;
M-D[#'8OF)R;5H;=I;Z"72DM;VE6WK<Y;E;[+>4Q<WD5L/KUVL[B0R,0"4723
M#]@?&;UZ@%>3"X@T3KP>=[=166,M"<,U'4^2-0;3DVS8+2_F0&K$3D#W=$H,
MXBC9BH(?B53-*<I6K>E_BP^-];:$^NBO:R9]IXE>FEF5K':ML_KCV9LSK#8@
M*&SA_8<)*2:NA<0/<R>&R@O$((:=QXR(FHG=LB9BPDFW<(.M7+5+GG5/05J4
M1OE)K=QZ7P)P8*C & , 8 P!@# & :T/DON?N+ >R5^3.*W9V/ =:Z,JFLCK
M&2=(2?6RU77566_"34OGDK[M=6+"6%6A8L3D,?;,):"]QF$6CK:M!Y!VRT=$
M5G3IN,E*I:2A2WOVE.Y;-2E*)O*UXEW'OD]E4,NR^8M6P<KV!E=E7]X\: Z[
M,9O936O*'7D':+JAO=7,Z&M!]3'9U4,"W! CDHDH,F2NF4R&1K,FH+D"F\Y&
M- V92>BV:F[2[5-7NI<PMT+70JJ*^63L)/99!:;B?4BL];ZF_</MMTYVCYSL
MH8;UI'Y/U0J,+9TAG#JP!=%%#A.,%^79MJV8MH U.<,A3'=1FW*%G P.*NE+
M?;956E[Q:)Z=9(<7%Y8+ZM.DYA=M&@9+4]AE/$CVC[ -X:2MF/$ZOKB=4WVL
M!4--)B*%;TB4-S&QXBW8RF15J;?R('$SC)%G$9)#1ZQM29 !=4J4G=.JE3$.
M&I6^R<J=]K,N#3O?RZNL',_KRQV-EWW>6T,\9E=5[%;%[&!I/7!NZ^[DFN)H
M&=JSU+KO")1"@S?1BU>SJ3%!4WY>C@H"/QZ,A51*Y20"NRG=64U[KQ2J7$3=
MP_*W4]TO.Q/DH['=;ZHB+Z>=<Z%%7R3D]Y#3%<)=G9'.0QV,4@%''5I74S&H
MJ%L2Z)CK,VA9@AR,DE/0C>KG#A%:U'D=&OA+XD(A-V;BU]E6;X_&A;]]VH18
MN<>;>T&=?36XJVZBQB35C4W3CJ!W7M-Q*[^>Q66L(%VC8%GSB"PX&/IV2#9+
M-(IH-659ORAR, ## <4<KJCGVXD21%E0IAU0]JJE0INHOK97\'DF;T>[(]EK
MM[8^1V VP.@B-0T'>$/@=,J1X^JY/B0A:KH?-!S H+^8 'E]O(@4D9S,Z8(R
MDJ\!2<N0@@MH0C\>'28J*U*E*EJ9:;:?6UZ-"!/6[R1=L4@E65''J]C?9:Y;
M][ >4QG&I-;=N.ZFCD%A_3VWQ;>-@"3V-5989 F.7BDI3 !=&8=)T@1$AVC]
MSHP*$CP,2Z5Q:2IH=E+FJE/>UOZ2]-6^7:XNR["LG/5[J5$IF17ZIU3VQO$)
M9G8T;5&\4 6E,Y+"6->5>=)5R4CTWE3!Q#)2?5D$W(5=#_@S(:U<D69HO[@Q
M!T*F=JJ+M*%.B3XJ%=<3\]I>8&U*V1[>S/;JO%R52=:.QX_J!%I+O=A?B66;
M?\N)T^C#&3J'@ZAD7$5@C4'9SD],9$P+2\LW^$M!$4CLG)$>$DP5*<7U3;A3
M"4SOUM9=.JW_ )C/F#M%G1PN5H]<X&"N;FY;6JEU#)W8EV@8O.Q54P /8BUC
M]?PP_J\8[%7'&I:,D(8.UT9T #T@YY0DG/R(8:/;$2H;"G5M1,I)ZN+_ !DE
M?I92S_SBG6Q#JQ(2?7$#5U.=B:@Z]VAQ9EV619$3C!$C=A989*H/7%C1OKY,
M*87,TVBFB3.*7)9-,*2]$@-:@F#'=V@Y5!T1-Y:;4)<.,M..I/I+T5'Y;S%N
M=QRE A.NA9Q3C?LC;O55*U0Q*QC<S!3VG69E(K8,ZBJ5--ZPCU0R:6 "4)!$
M6MVE9F.(;""LDB(Q@9T29 Z84MWA.+73B-\S>8C3>>=W4\A4FZ==D>S9(?$)
MO:@^GNEO5FSAM6N+.C\7KHV;N;N)(Z'7="A7-7DSX&;H-'C=X_D[^<&(^:&#
M!$?2B,=<(/9.]"FF4G,7J6C;M3M<?!93??9$R>GO;&RKWLGM?1]UU'$:FMSJ
MA8%>1:3-:\LTI:\$D02V:N VS"RH:3G:[J\UJ0:@CNHN0,'<3;HI$F>R[)TL
M@YX1;"&DH:<RINH:NUQ?#CX$8S^GDN[$=E*LIWR(6'Y()%U_(67VFE\3=];Y
MF*J/?K SKF/WE-JF"]9&D3+L(C--KFEHZ*LD!-A*V4O+M9.6XY91HYLFV3>"
M7"E*F?BJ]YEI.=ZB>"4IZ[RR,=[(=M(%W.B,WO?L1V"'TS9W>\M4-9VM4?V.
M_9+QSV75$GFQZ#UYU\,1R#OHS;O76X422 V%D;+D9B;$(]8@0SO*!!84\7<,
MQ:*6H23:I;:>U34FE+<Z-;X=XA6N5SXK;'[*=A+9TL&UK$\FLC%#+W[1!?CJ
MY+JFET$(@J^L2R(A%HF\8Z#-^QZC@>.&C17J(HM$=YV.24X(:QSC;=416J:;
M+9TI?_VVE*3?_K_PS95P8Q@# & 6NNJEZR[$U7-J3N6+I36K[&#[ )G%5R9H
M,D;$;N6[O9GN4CA(.<9<<N&J"GMAI-FXXY3XUX6XTVVUV$IM--:JZ]F1$AWB
MGZ#P5A9C '0W#KZ7ZID-'3XI+;0N:?R4G4LKXXXDD$%2R>6)))1$09KG5)0@
ME#BX!=PLW:K[+^V:-MTA.U4VG-TYLDKK1PE!44I\:/2":68 MV2T0+(S4 E6
MR?K<2^Q644E"M.M&C"JB%D5V/E[6O;6,5\R'L&D4-V9%Y87$-V+%)L]TT9->
M$1"J:4)^OP/5:WC4_B5\</1E&UYGV),4N&:SF2.)]*I68>SJPF<&;R"P(D\B
M5DV,VKS>9HU;%I]*(BZ?CI/9H2*")F[:N'KMU(>'+ARZ4"6U'H4]4ZM3NF)W
M%N@W1+QE79 ^$H-$J^FT&C58U'1/!^J[RG&Z(&'=<##>54TQ4F5?66B_83FI
MR".CF+V,L8TM *-</!7SLX!DG[%T)VJIF;RW=+6I7M&C6JT9X\:Z.^+:?UL:
M#P=A!93#('<$D[ 2&;0?LU9)*50JWCT19QF>3@M=$<MY6PHP_ET2CR2%AM74
MU8"9<DU?EI:P)OW)%^L(E^*(BT:JVG5XBGV_17Q%3ZNXS HT%I]S7U#Q&R6K
M1G6G8Z81]*,U=8\T?639T6GIVO[9%E9!3QZ9%'Q\Q"+%*&:Z:*N=D$ K-AQH
MUU$[=3;;<S&J3NE">FL;]23U@Q7HUW,A8KK_ "20TU;8 (^!2R)0^ VH/8RJ
M&F(+IZ([+( 6J^6")S!C,5;K;MQTBAY4,0%L73EEH]29/'""PB6K^SZ^)_FH
M>F72^&LZ=>T]7D6Y3ZW6+;,IK<Z#G$JDY&/VQ8 D_7UR'Y;(W,L+DI_/C3 J
M=CTM(6<0E9YJ]];5=1H4&M5&@2[]*2=EHHCJ5EH7@#U?1<VMJ/\ ;*.L ,IL
MUM5A^EXY:8"4$"X]2L"\R&2L_&&3<6;7AKY%69Q@>[<%/AC@TT=C%!Z1-!MR
M[9J!+AK=,QTJ5Z61P[+= >A-TR^17%V3KH(Y-S@+"*^F1DQ;-CUU%9NVC)S=
MU6K"71V.6!%(3*Y)'3S_ &T@IDX'(2D0[<I- !%#GANCH)534)/28LK39]I5
M$FZV](!#N7\RX/ PKQ/LI >\<UT.6<;$*CNPX]S'(W7=P&47<S:\ADW+Z%Q\
M,$"*Z,X&<(B>6G$??O5WVC@1+XZ)JW"\KQN2UZ_03QI5W/+6EI>N:UC<GFU>
MVNO/PLIM65I1B.5Q?JSF-W(?C%:R*?;P>GPMI.%7@*8RRO8Q#/CKA5X-<E=U
M5G*.Z->DF:FM7:/$K=B7BZ#^M==%?&Y.8!)89 89 K>@I&F8GUME*6US36YD
M]JEATUD%F0:&/SQBQ9:28NXK-)"6D<2D&A)K+P*Z8Q(*;9L(Z!;"PVJN,7;X
M7=F_#$=O%ERH-XZ>F]=!(\#C%/\ /&L:O*)=DV1Z0V!:,RG!&[H&)=@89.Y5
M8<QFQV=S9U&0KYT)#!YC(CL;8CE?<T VB&B>F@C:;U>Z/ _)X#P9AXQ.C\Z)
MKF9!2R_!=Y8EU6D3* ;0N.(D#4K[&+"U[Q1/O(G8(1R=AUFJ!!7$HK8NH\KI
MXBST;)Q5%LHNBJ)VJN/!;MVG9N+S4KU%Z\==S")^G*[3AQAO4%7T(B^XD\S/
MJ)U'3"9E&L8;KI*)&;2]UB:,@+(M"7*?)MXBZU1*DWZ;5GJW$-MZO>WX7$OP
MPB2."!@# & , 8 P!@# & 8P>P'0WQ>O;D^G;L3#*PC5AS^2!I<32FMT2NNX
M%:<NK[81R)DDMJ':QH[4UGG8YM\&Y<D9+"9 ZYW68;E]W&ZK7;D6554-*8ON
MT3UO$I:VF-66O[:^/.E.P(*/".O<GZ^PZ<SWL*=[I&&%BMYQ9 ZY)>5A@:!2
MB<QHO7MVUA;D&2Y#LXDB\+T].PT0=LV^@8]'GS<[RX3!5-.\QHXA>AIO75:W
MU1=3IIXMJ)ZN4Q6D$D[ 79ECPFMK[JTC8@QG(J_#.81V6L\A:UI0B-P(9+R0
MF/Q-0TY&B '*SHK)A(4 PT;2%!9P_P#;@ZFWJ]4[W<TJ$VX4N->.\NDMXU.D
M;B'EH"M1C'>(G*CH^B2H?F;69QH[JCK=)T9E2L2V=ZS3@@DE!Y*W1)H%D':1
MXUMIPVDI4RRYV;<M1M.9G>WHM:M7X8/9LSQ[=/[>UL[:>U D3(6]:,+NR:R
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M02M74T3):#52(R+@FNPP+J-!M]6&JK08W67=*+B&VXG<H7476P0, 8 P!@#
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M&'!%N?:\N!A0>UX"(?#5'S^-ZZGY4*&OB1;X[=VF^]4O16T,R'CO\>-B]?\
ML'->UUA-NJM8.9]UU@=(C*2Z8U0>JJKG[8+)UYRK:=CMSI)3>26LIN[TC+8H
MT$LDFL=X6:[K+[[>GF2E52:26UJV]ISV<.DS/8*# & , 8 P!@# & , 8 P!
M@&OKY;*>G]U]_O%)$:]KCKK9I12*^0%58#VQKPU9=!^R3@%%.>5)A' FFSA8
MEJBT<KQ7?91+5,XV;K>GG5%3G5[<2]+254SNT</5D(2]"SOQ7S/K^(TD\LFL
MDISQV^4&S%I+1%9-WP^#2BP+8JZ>,8]3->3!V<",HY W1G;F,!Y<\?CE6@=^
M<,#.6"CL,D+)JJ9A37AV;>B52N];[WQ<V+81KOAW5?43VL;BNXCU&+P&\^DS
MZ"6O,90WF.YFK+CKRR2EJ0M'M="NE8B#5NR-S2("F>MLRBEG=95<?8'*SYL1
M^X)#I"0CV]N"Z7_V=-,JUVFFEK*T^+M3/6TVKQ,S=X%VU[LW_65"HQB^^T-.
ML].DOD6M652C8/1LDEEG3WK?-XRA3A5C83&DVD.ET+?^]Z#P\UA\$@Q"RXDS
M(J\(I/2S@ZM/A(A*95+O2M\)5)M[U%HG6'I&[^6_=ON=3E83626EV)[#S9G<
M'B^Z(]NGDI&UW2@PO1-U]BKHVK^Q!T$=<54QAU?UD B[AKI(2$WCT_*088W>
M3;EJ7D"2:+L2U3,)*U5:U=U2DU.K;=XB)=M(C(QXLKYN^^.I/=IK=M@D;2(5
M9V!N^M:OE90NREI0O3O-,UM,86ZTGHZH:+2L\2Z)R^2<Q^Q=:OC2<H&ZH[L&
MZXQJP<*BM:4II1-*;6D.6M)<:<3&!XS?&GV2D_7GIKVWC"?5JBY54'4N_M*<
M5I*J)#!^Q-R6)<E12BNX5KVGL0R08B#;>%G7S65L>41CWE(VVTW]=NDX4<MA
M>NI;52NTVIO9).;+I6_KXEI>O4ZZ_0\EXD*HI;J;3LD[>5[:]'Q_MG'Y/479
M>&][:HNM^:WB_9.]9C/(*)C :05<Q:D)3*BR-QR^20H\Q>A]W<=+@X_NV$ Y
M>VVWLM-TPTZ7'>KKTTNM\%I:LZ^S %%NK-SW!6]$0WJN]\I]GE9YV2K;KD\U
M[P5-*8AVDG#ZL.+&NDA+-/<Z&G,L9-XX:FP>,(*P.,*@V#AH5]Z:.EGM[>,E
MM35#NJ-&ULM;*3A1JE>)O#W'FV#7G8ZE:S["2J)AI?.>N?=KRP2N*VC%.6;Q
M92D+PI/R,!9O7MO"F>C;95.#VU4T2+P*4+:M]$?G/&X$^<F=T7@L;@6<<:<.
MW2G1&SUIN5UOH-DWR.R^<Q+M)XX5H6S8[>W.=WWK\RK!HQ)RP!V Z4VB:C;T
M%)#<?+F(0[5/M&2"[N,D0:\@;[;Q\LH3$O' U<8Z4FJIW;.^-:E/B]9%SQI7
M-W$)WQTT87CV"M:Z(SVI\8;KL?8T=L2(UV&!P*YH]/:H#!]86K"J^AY(%PO%
M)@68G0Y\F:<GB:3F0.]^7.K9(>)J5,50DMFN%TJ^^;Z+JG5R8U/(! >Q-<]A
M/.GVNI(5*IC%3T/C/4_L/431L[5:2VGKRZ 0&,1&XXJV3;J;/)'0=M$QY8PH
MT0>J*U^>G;;A<4@V(JN!:EJ,-.+73X-5MP^BI6TLTBOH]6_;,[,O)0[HBRX-
M5,9:^++H$C9X>Q*-/V83LP6WZ<VJEQ&X&98V' DH8='((R(:^>K#9CMR_.B%
M=Q;?83NV)B$Z531M)M[56^(NKNS]&\LQ3G2FWNWLMB-50^N^J+M$WX/?&]"3
M\T[:T[*;$+5BI(JJDH%Q)*+V$JCN(S:D<544?^^O'K?9F08 E5.->6NVNSV]
M782VE+O^4K?Q7&^G7P3!N-4#5G-&432U)[2<K-MJ?J:NJNVF9S7U#4MY@$0#
MQ3F3%T_>'?LR9WD3\4?)^].?4<NE=?>%O1[388FY;=E+F%HNKH+MX(& , 8
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MARKQD@^]X8<NN7K-X@@'MVER< 8 P!@# & , 8!ADZ[>4&VKKN#MG7!#JP]
MHT+'I/+(FH_LZI@ T^S@#%&$2X*VG[JQS4=L!LC?D6M6&&K'BX>/0JKF80$#
MG^J4L=/4-7M[7WEG3$7U[>,QU-.)WVM<O5XS^]\V[V0*QY5,J7*U,K")L_&#
M%B[J.BWDAB\M+GYS4CA6 LYQ.).!W==>#U*RM[+"[]",V&>EQXQ7C;2(,ARB
MP5+9>J=EOG=?<M\VW:,R8X*C & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M#)6PQZL!!%#6\<&%RZ:&^PX>2D"0HZL$'NG7"23TJ@#,KL&VRKE 2262T9K
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MW]T;A6\Y,EP45;\N7K=!\4+.P04\6=)B!RCLHW"LF3920/&C<'N;CB)!20#
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M<N56&U<3>:)-=1W*"&CC4LH/46Y>(\LM'.J;GE 07-P!@# & , 8 P!@# &
M, 8 P!@# & :XI:KY--.U4S$5P]MB:]9B5]3D!-S,>Z<D2Y-E,-NV@2[[AC(
M6_R]V1J/O1D0OR'%8GS9G%-FB%?Q(66AD=W,FXF F0H6;B+7CBFNB5U19N'U
M6-CK!48!%WJ!]R:5_6@[O_OI7]@$HL 8 P!@# & , 8 P!@# & , 8 P!@#
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M))64/'UW,G4JL>'KKM)5 (ZC'R&YJ:1U\U$G7 XS&!W#DT/)I!B6PURR3?\
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MHO53!+TIZO2R46"!@# & , 8 P!@# & , B[U ^Y/+?K1=X?WU+_ , E%@#
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M-[!<8 P#:]^2%_?]=AOJ@2/]L]+X,&/I3UOR'0[P:PP!@# & , 8 P!@# &
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M!S04U<.DX*Q,C$(=$(XZBCP*H(BD;9\I!6(/6_!:<(4>+V9(VTH$SM2LK&K
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MW?#9RDR<<ME^$'BZ/#A%HMREOPDY6;[*H<+I(;^JJHCRNCPKIISIRJGQMZ_
MJ8S^I\CL[DG:%A0V8WAV?H%C7,(#163R\I"=#G8>]1)B2<V99U!-984@<7C%
M1EACD .%J[26.U+*";%P_J9@VBPS24SP6:74Y=KV6Y;WT<5%];7PZDGRLHE'
M<,Z;A$GKDH^[0CN74,F;N%OI*%Y;=5.KS1'@DZKV73N'J\OV[=(HT^#RLMQH
MQ>M4WW+(GH]'-!#W=7I9,G! P!@# & , 8 P#'%Y>/P:7<?_ ">*?I05GV/N
M??/3N<_6.'YF(?@]U'S?Y5^RU>=2<R3.USGT8 P!@&S;\ER^^[[!_5P6_:=
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MS9-V3TXJ496]?M<?V<?Z8(/N <BCS!_A1^^GUG;4_6-U@W</O*>HQO8+C &
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MJ46>U%U&YN-=->Q7U=YF7.6/)*C (N]?/NF]UOK1 _W1>JF"7I3U>EDHL$#
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MC & ;7OR0O[_ *[#?5 D?[9Z7P8,?2GK?D.AW@UA@# & , 8 P!@# & , 8
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M^ZE6O^/X;^L0W-3/_(<[]DS/[FLS9?Y1@?787GTG6YS@(Z:& , 8 P!@# &
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M\ER^^[[!_5P6_:= L\4]W'YO<D_KE?P.;/0?<[_S3/?8'_$8!O%YS$>OC &
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MI!QG] \#\A@_58?F4G,-??U?I5>5G@YE*C & 5_4_P!U*M?\?PW]8AN:F?\
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MN<^C & , V;?DN7WW?8/ZN"W[3H%GBGNX_-[DG]<K^!S9Z#[G?\ FF>^P/\
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M8>]=MMM%MP]NW0M/U ^Y-*_K0=W_ -]*_L E%@# & , B[TE^]$ZX?Y/P?\
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M$!!</ & , 8 P!@$8NY4QJBO^M%J3.[R5O"JQCPP,0D;BA3]O1BW5U=)0#3
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MWJ!]R:5_6@[O_OI7]@$HL U=?E;GX-&K?KF5C^Q^_L&7![]=3.<C@VQ@# &
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M3<>2_P#Z/KO^6 M_#[/?OARY&^A.4_VV5_G/,_@YSWTED_V>/_*/Y-QY+_\
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M0?BKA?S@8S_LW A<5X_48B_-'TU[N^3WJE$.OE=4S6U:'8W>L2MAP?FMZ,B
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M0EB7(+FMR2HL*^R<.2 \W6?SB0OT+&>5O9LS8)3KFPQ32,:%=]XA'FIF.-M
MXKA 6JZ5%W'5T64ZVOV$JJW&]SX+*KTD3BB>O1!.WK886.S:H]IITAN$:LZ:
MJ*K=A;I3?JBIJ\74=UHZ+\.4M44]6Y5NUY2Y4;**JA:UW91HN+?'I+L?/;N-
M^+K0/YUTV_[3,$6XOL7K,7'EYZ6=Z?)CU,0ZW1>O^LU4DT;4AMB<RD_V.L63
M,-FT7'25DJ,X&CNKPMQPN[V/)J)N/>O9I<-]]=D]^5->=1>BJFBJ;NS6B]9J
M]_R2+R6_^JG3+\IUP_P P9N?HX5=B]9\Y^21^2WCCGGFU.F7HXXYY^Z;</\
M^7_\ 8'/T<*NQ>LH:KODLGD2MNLZZM:,V9U$:QRS8+$;"C[4U8]LM3#8)-(^
M/D@IN6;,Z+(-&Y)%@2;IOT&K]ZV1=:JIH.W*6NJVX<_1PJ[%ZRNOY)%Y+?\
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M.??L#^@><?!QF/I7!^ZU_P!8?R9/R._UTZ??E;MO_MYQ\.G)_P";V<^_8']
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MW)E?=-2Y!LT;(OR7P]'9%AJ1=I)ZN'GN3=39)IPY44]V14V31]33?GCD#T,
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MI-&L3W6B)(PR6D4?;1Y@;3B$=$.-WM_P7DP0, 8 P!@# & , 8 P!@# & ,
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M.+'@M3CNQ8&4R="F(Y"A)E%R+?.^3 -Q$/=?H;F8M:T:6F8L9>\%1@# & ,
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MFZFZV^C9DS21;(:[JJ**[:I)Z<;*;[[\\<[;;<\@>A@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P#SR@@4<:>X&A@\NP]Z'OO<BC)L0:>^B7[8J
M*>>[.TED?>AA1DS)#W'J>V9OVC9XVW3<()*: >A@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# /S.V3-^FFD^:-GB23EH]22=H).$TGC!RD]
M8NT]%M-]='+)X@@[:+Z\<*MG**2Z.^BJ>F_ 'Z< 8 P!@# & , 8 P!@# &
(, 8 P!@'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g838337g72l82.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g72l82.jpg
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M 0$! 0$! ?_  !$( /("8 ,!$0 "$0$#$0'_Q  ?  $  @(" P$!
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M CF-1>WS' [2@0/9/)\)%I%F0P&+:U3>9W&N<&KGKF;\YFEV%<T5\;8]M?\
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MK$VNJX:JJV4_6)X4%VNC1U+C''F*:<3(WUNNIY2I1+5NE&S96E-G;WYF=)9
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M6Z<CSQ$V1/8XGF+0NFD_NYQN9:HD;8W?I8KVOSRG+5+A)5D.0&Y5$HZ\CM+
MUUY*85'4<35[>C:QG%L&;6Y^ 6IK7AJ-)XLL&P!+=DM.(XDEJ]W$VRBHZ@F[
M;=DHE-IG&4;=FD4QIN2E+W$+E2$OZ<8B4,XV'J?5^W!;0)M374'V.(8.[/V
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MN7D)0A#]DA3*FY[J$--)0[))U:2;025%N)T\,=TIIV(^!EXKJK74;OKJT@M
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MWU9!I7-^E$A_'560/("F^9/@<TUHL^<2.6LAY(6\D<C0(,AZBA/OBQ>NF++
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MV1&A^H7;Y@7KGV>0E?4!,* % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4
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M]G@0@GI5V^)@2^&%'_14M[8;H7J'V^0'ZY=GF)7U 3"@!0 H 4 * % "@!0
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M[RP3QNX?D7;I\\6OFX=N5W"BBN04W3ZT_P!-'^(>W_:\<$?EUNS_ ,E_-?\
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ML\3%B%!0* % "@!0 H 4 * (C2W5/+TK)SQ*(\NH?$8N^*O70",.^,862N@
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MB>K/-+:O\OCU=5[9_F!9_I59]O8'=?W/GY4*?]"N?[LDC[GZ\5CZ&A0 H 4
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MAK 4 9%$/\V1?SB"?Q)M4'/Q;GYBOU3'*Q^/9_G6_P!<AW"U>2A[K"@!0 H
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M"*'%+WKVKZ53_L[*IKZ>[Q,01T=_@0 /AA3;T5-/;(C0_4+M\P+US[/(2OJ
MF% $*><<DA:NJL]8G-Z:+TP<G3\4NW7W.?U&TQ>@@95J^>OP$>W''YG$3;@4
M72"N'&9&&&L&[;!Q@,7#2)4*9'A4BY^@S+Z=!SO" X9DF@!ATW,6,^<%)QM)
MZA*A[G79),J@YV))%\U7![4D2A>M).^Q>J/,'LDAX91B8<6S=$"YL]D7*NP'
MT\_-_P#@28ED2BD]C)Z%3F,QZ:0V4BGH*3Q*6!1LCC,C"$4,VQ .> F&SP47
M%/VRF;=Z/(-7#1TAGFDNCFGE?&X4$$>!>M]=ZBG/2%Z\U1 H7K" 1[FT$L @
MVO(L#A4/!V)\$N$)DE8/&8VQ&A1EB!<@_*OK,F2%G9)\\?+]8Z<K*YA4SUT,
M^<]/$Q8?04"@!0 H 4 * % '7\=*U^,+Y1>?8_ZH1NO=FS'YA8U^@K^U2!\T
M]L?Y3<O^LD?8XHKVK?!UF% "@#L3NCY^ UQ)^;[JSZHBZ\!YY\],J^OK/[6Z
M/J!LS_)[A7^[-/\ 861,*M3&\!0 H 4 * (H<?\ RI\EO/MC[=+:FKH3V>!"
M">E7;XF!+X84?]%2WMANA>H?;Y ?KEV>8E?4!,* % "@"I8;MK:VG=CP&Y*=
M:ODFN3$FY(QH<FW.<BS-W0HCR:!MB4ZG;:.:1DL0@UM3$WR.LVLEF)YA">S(
MG2PZ;L8UW:YR"O3T>S]O:9_MJ+::"@A-S?\ >/C/\]GBY_,-O05+H/L\2$V:
M"@4 * % "@!0 H ZT7>_EPW+Z5MB?6\Q7T4H_P!Y:?ZKK_LC(^4&1_.&]^N;
M3[<^-4UE!A@H MQZ#S\8GJSS2VK_ "^/5U7MG^8%G^E5GV]@=U_<^?E0I_T*
MY_NR2/N?KQ6/H:% "@!0 H BES(\CUO.L)]"1J:.GN\2$%]'?X&'#?R/7\ZS
M?T(ZB^GN\3!'1W^!"5M0$PH 4 5G\E2&Q"NZXZXAKC9R(UU'8J)BI07'>8@@
M1J^7A=ESH5+YH9B>J^/<YU3NME(F20)-K#]T3.+1Y(!&&1\([%QC8R,W<!(N
MOF^'/[SU+V&1"S"@B*].=6GME[(-:*D\+';(D<:@3K;S>6QG4V.DEYUD2G>M
MGD:B$E&,^0.&6O%V8YS<O$S665[EK!YX]:KHKPY[,L*"I?3XZ]9=7.(P:RXP
M<GV\BU=&S<9;ZEG\9W2YW=,^26M6&IW<";A#/ 93CRI H%%##TH9S6CNT20(
M(#A9_7EH0T@NJ!)WO@FHC$V#@*ZE\-"+GYOE:_V=1])B4W1] Y#&Q'*X'*YJ
M2V+(1W,[;*)2:F!$= $I XO$]:*6>.Q$3&!HZQ4LGG@A9$6,:-^U2QSNG=3+
M/+("OH_-(6"4$1U:'2Q?C*.;'SA=@_Q7.O36+_-VF^KX_P"H0\;9I\[,A^M9
M?_4,5[5GAK 4 9%$/\V1?SB"?Q)M4'/Q;GYBOU3'*Q^/9_G6_P!<AW"U>2A[
MK"@!0 H 4 * % "@!0 H 4 10XI>]>U?2J?]G95-?3W>)B".CO\  @ ?#"FW
MHJ:>V1&A^H7;Y@7KGV>0E?4!,* -%\B(-L'8>NK1W6QK .=\*8D4?I*3^>:M
M2.QL2;:OC\<SV!J]%38$8N68(YI)/XRJV<9KX)-"63P$Y*BB !C_ !IA^\(!
M&"L2V\M%R3)F<D!.(%A>V=F;9D"0<])#)=G&#A[:<5&2I\WBHQV.$#C):42<
M@3Q16_P@8UN-$M@"2E $).)WEJZ2+Y[<7_T <%:"I]!=GB8FW04"@!0 H 4
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MI]EE@&0U5;6RPYX-R53:)W.9;-:+8X.5E.\N5VN*;D*ET*Z]/$O;X"RF@H%
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MZ#S\8GJSS2VK_+X]75>V?Y@6?Z56?;V!W7]SY^5"G_0KG^[)(^Y^O%8^AH4
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M.Z/GX#7$GYONK/JB+KP'GGSTRKZ^L_M;H^H&S/\ )[A7^[-/]A9$PJU,;P%
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M[8^W2VIJZ$]G@0@GI5V^)@2^&%'_ $5+>V&Z%ZA]OD!^N79YB5]0$PH 4 *
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M * % $4N9'D>MYUA/H2-31T]WB0@OH[_  ,.&_D>OYUF_H1U%]/=XF".CO\
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M?X$ #X84V]%33VR(T/U"[?,"]<^SR$KZ@)A0 H 4 * (2<3O+5TD7SVXO_H
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MW%+14QO(]K3*5PR]H^3OX+0$SFQRC<-OW0\2[%P6*#K&]D.L;V[H_P )7/\
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MYUA/H2-31T]WB0@OH[_ PX;^1Z_G6;^A'47T]WB8(Z._P(2MJ F% "@!0 H
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M66O0FJ8'&M>QU<@[$QEADS0>E<F-R+]==RN_($7B8I@*#-%B!%V[>Y#P0@.
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MR/(];SK"?0D:FCI[O$A!?1W^!APW\CU_.LW]".HOI[O$P1T=_@0E;4!,* %
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M[5]*I_V=E4U]/=XF((Z._P " !\,*;>BII[9$:'ZA=OF!>N?9Y"5]0$PH 4
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MU-70GL\"$$]*NWQ,"7PPH_Z*EO;#="]0^WR _7+L\Q*^H"84 * % "@!0 H
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M * % %FW"'R?2OSR4_@@FN)?3W>)CE1T=_@0C%RY\MAO_NB/?PM&IH]4N_\
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EZO#^E #J$/R*7ZO#^E #J$/R*7ZO#^E #J$/R*7ZO#^E '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g838337g74r49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g74r49.jpg
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M"!87(W1VM"1257)S=925LM,8)30U5(6&L[;4\3-%4U>2EM)"5F6"U4>#_]H
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MWQ]OB'O)ROR\VI\];_W;&U[*?<&R?[X^WQ#WDY7Y>;4^>M_[MC:]E/N#9/\
M?'V^(>\G*_+S:GSUO_=L;7LI]P;)_OC[?$8Y'F^5PJ\HW$EMBR^8,[Q"7UZ/
M3R)64:66K2JRTQ.P%$%E@WU@=;$$0M;%H0M]3?4R>(TF>HB,C\Q:O1XB"UDH
MBUF>LO'P'[V:SK)==L*AXY5,8XSJX,^.BD,3D"ED..5HG'02!F[+"<09]R/8
M!;&G$9UNM!",.M8+FF>HC/7YRZ!)\XBUF1:O,?2.<[W=L\J=W?I".^S<C:]E
M/N$[/M*]X=[NV>5.[OTA'?9N-KV4^X-GVE>\.]W;/*G=WZ0COLW&U[*?<&S[
M2O>'>[MGE3N[](1WV;C:]E/N#9]I7O#O=VSRIW=^D([[-QM>RGW!L^TKWAWN
M[9Y4[N_2$=]FXVO93[@V?:5[P[W=L\J=W?I".^S<;7LI]P;/M*]X=[NV>5.[
MOTA'?9N-KV4^X-GVE>\.]W;/*G=WZ0COLW&U[*?<&S[2O>'>[MGE3N[](1WV
M;C:]E/N#9]I7O#O=VSRIW=^D([[-QM>RGW!L^TKWAWN[9Y4[N_2$=]FXVO93
M[@V?:5[P[W=L\J=W?I".^S<;7LI]P;/M*]X=[NV>5.[OTA'?9N-KV4^X-GVE
M>\.]W;/*G=WZ0COLW&U[*?<&S[2O>'>[MGE3N[](1WV;C:]E/N#9]I7O#O=V
MSRIW=^D([[-QM>RGW!L^TKWAWN[9Y4[N_2$=]FXVO93[@V?:5[P[W=L\J=W?
MI".^S<;7LI]P;/M*]X=[NV>5.[OTA'?9N-KV4^X-GVE>\.]W;/*G=WZ0COLW
M&U[*?<&S[2O>'>[MGE3N[](1WV;C:]E/N#9]I7O#O=VSRIW=^D([[-QM>RGW
M!L^TKWB N1$(7U/$&=_C5EVPI6KY,F9SBWB<KE2;24YI>%HA%EI2D(]':.0$
MZ",1H@:!LS6R]B$$0;)/6>HR3R>@546HM9&KE](GSBMX"83^7)O:Y^RJ^<?5
MW$+(YI=?>8L+E18, & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & #
M!@!#W(#P,V)YO'_KR,LCG%U]QBJ^:?5WD,^AWQ1BWFXR>K$N0?*?2?>)+D+H
M+N$/4Y\?K^]("/U0#+*Y$]'P(53RJZ?B8L)E!<, & # !@ P 8 , & # !@
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M1\=JYY'5>AJZ4R YD=F&T;&9JJ8HC,U4E;@J&Q^:)9(V@QY<FGMIJ/; +S4
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M:BO530K!\K28J(\KAUFI$!LE,I6LU&HBV+V[RTD$4XY4C;$%K\HZP.14GIJ
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M@IEEY:O69LBLREG6IB.RB5(@UKR%N1H$E55&KCEU\B<]+=ERVXZ52P1R)?\
MC/,.1,$8:PCCC:49WP#HN)HA6C:\BAKW/K3@#JS-8'1TGCP\*&Z+1+;:M_\
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MCCA2$S31+6\M]II:,6B?1X<<(W&+#BKLBGECH;)@[16+LMLZP)#,7EDK>.K
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MX3Y:A44G'F=3Q%$\GRYK4]W:8V-:G]^RC9=WA$E&M.P>O6/7Y >!FQ/-X_\
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M-NH>9:@RYJX=?'6;[KK:8[*G8[Q-*9=0AM2',$@Z!X[./7.+V.6SK&IGX_\
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M=;(@6$M:4KULMIBI<4M!.*&@[3\(?+U:(:ZMC2)<?2:VXT[<V11V">CXLVQ
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M=CK=TXBN::>NSH/B7 K*@C04>R(TP9F19#6VMBIQ<A%KC=M)S6%N":0G2Z6
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MT@(_5 ,LKD3T? A5/*KI^)BPF4%PP 8 , & # !@ P 8 , & # !@ P 8 ,
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M3GQ^O[T@(_5 ,LKD3T? A5/*KI^)BPF4%PP 8 , & # !@ P 8 , & # !@
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MU>8]?+]_7J&U76^KK6_Z.KK6^I\/_P#NM;_\]:W_ ..M8$#S@ P 8 , & #
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M32_.<1CT0F)B:U&JXR(X!<U/*<T1!>ZY>$NQ)CB=KEH3RUH <1F?6?+TGZ/
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M 997(GH^!"J>573\3%A,H+A@ P 8 , & %6.%7BTUY_6Y]]94PP M/@ P 8
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M;8^PM98R6YG9T9#>VH2C#3#QEI4:8!9! !GFFFB"6 .MF&#'O77"WO80.9P
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M/H5W&+L8$!@ P JSRO\ BY3/]Z;C=]:C#@!:; !@ P 8 , & # !@ P 8 ,
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MP^>.Q*.NFAP?;#3.3M&ZV?9W)VJ,:+JVL6J+L[C(+#C,%?')=NOVR'NC3M-
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M->V_DX_[9&&;Z./GK1_RLOZOECLSL^<1]<A@ P 8 , & # !@ P 8 , (>Y
M>!FQ/-X_]>1ED<XNON,57S3ZN\AGT.^*,6\W&3U8ER#Y3Z3[Q)<A=!=PAZG/
MC]?WI 1^J 997(GH^!"J>573\3%A,H+A@ P I/S8:";!K\-6&P:S)&:Y*V>6
M-[M&*G;K>@:=TCSGLY"V3Z'N4JBA,C;]G TX%M 79J5I' AHD+2]-KRTH%1
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M?NXR]Q\9!KU<G%RE[^(_>7$88 ; ^BO\?WCCYQRCZO)?FL=,OT9Y5^BPOK6
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M;X[W)[TN2?\ U ,](]%WT>8A_,D3^R8\<M-WTMZ0/UEG_P!I(IKF>C5@8 ,
M/MRZ(?[WGQ^_Q3^NFQ<\]].'TH9-_J;Z@JQZT?@S?0CA7^T7_%=Z-DV:G&^
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M2UDYBN;?->V_DX_[9&&;Z./GK1_RLOZOECLSL^<1]<A@ P 8 , & # !@ P
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M./G'*/J\E^:QTR_1GE7Z+"^M8 W5^#M],^"_IUC]1V@^Y7/.T>NP8 , & #
M"O3[XS$%]&4E]:!RY<P^GP%#YY='B/+]XRT"]&LH]9 P7,/I\ /GET>(L)E!
M<, & %%^3;MQL,D4X'??'NM+=]YKC^ONA.\S>$P*:O/<(#W(4;C$XTGF;,I[
M1//,C>UVQ@=DR-2>H) >07LKM@026OBU'JUGJ]'H\1;*OX'7-;QTJ+U9#(3
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MCL3BHG7M$J;YLBN9N6%N2<+4@=2'8XI$WC0D]S$RYM>T13^@+*4(G(LET)-
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M4PP M/@ P 8 , & # "!^4WBQ<C?0/;WU?2',CP[YW8M^L=)]9Q1AVD3Z/\
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M$.M!SZ,'R0& # #;5T%?WUSB%YR6-]2UDYBN;?->V_DX_P"V1AF^CCYZT?\
M*R_J^6.S.SYQ'UR& # !@ P 8 , & # !@ P A[D!X&;$\WC_P!>1ED<XNON
M,57S3ZN\AGT.^*,6\W&3U8ER#Y3Z3[Q)<A=!=PAZG/C]?WI 1^J 997(GH^!
M"J>573\3%A,H+A@ P J#R\G,#C$$<$MS<8%U_4NE0)Y/,7-]4<6!5=&E#0Y
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M*_O1Z3;R0Y$,[>A:6B^KH:FIL2)T#:V-MI3A"WMZ%(4$A*C0HDKZ4F2)$Q(
M$ITY!99))0 EE@" .M:@JRM(B(J^"1%Q$11&"(B]!$3?$).ZN5&:E6UF9F9F
M9G/E&9F?&9F9NZS,SXS,^4>[WT7)G\8J]?TN3_\ B#)\FUW^@0OZ*Q_=B/+-
MQ_"ME_3I7]Z.T)Z/YU<WS@APL>GMQ7O#R[\4./+F[.SJL4.#FZ.2^I(BJ7.#
MBO5F'*EJY8I--4*U:DTU0H/,,..,&8,0M_-5^A+=Y<H0E*$(M)Z4(01)2E*9
M3I)2E)$1)21$1$1$1$7$0^P<76MS&L?<<6IQQRDJUK6M1J6M:H+"E+6I1FI2
ME*,S4HS,S,S,SUBW6=2.]'P8](;X[W)[TN2?_4 STCT7?1YB'\R1/[)CQRTW
M?2WI _66?_:2*:YGHU8& # #[<NB'^]Y\?O\4_KIL7//?3A]*&3?ZF^H*L>M
M'X,WT(X5_M%_Q7>C9-FIQO@, & # "G?-;P:1KS\0^SLERZ.7J^)"B^3K^!C
M/^*W@)A/Y<F]KG[(7SCZNXA*.:77WF+"Y46%'^4;K [(;7>M'J-4U(%5>V-0
MZ=R)Y$T?N\:^V]7P^K:QKL4;C2.61U6CDILGD:!K5R9286F8F5R=BS23TBY2
ML0A)=?GY#U>L33QJI8OC[3S#5A2B*'@:G^Q)%V&!PL%=P=J,L.QY;8QT>AL)
M ]2/<<BT;.E9C"PMQCXYG ;&Y,8:HT88(HL!GK,3O@0& %6.5?\ RJBO[T]!
M>V9.!)<O4?<8M/@0-0O3S_>FN7/]EU']?U4YEF#?.FJ_C2_V"4,&TD_,F\_B
M0?K.$.M!SZ,'R0& # #;5T%?WUSB%YR6-]2UDYBN;?->V_DX_P"V1AF^CCYZ
MT?\ *R_J^6.S.SYQ'UR& # !@ P 8 , & # !@ P A[D!X&;$\WC_P!>1ED<
MXNON,57S3ZN\AGT.^*,6\W&3U8ER#Y3Z3[Q)<A=!=PAZG/C]?WI 1^J 997(
MGH^!"J>573\3%A,H+A@ P U4\\&&L9'/Q-]MPGCBTI/>&?R:GMV_N/L=MAK7
MVHYO;JC)BYT\DL0F;/ FJNTX6J8AB*]G5+++63 :IE!MO@<N2.(27%Z?-KU'
M\.+O[Q8G@PWLK/4#\S1*)0IA@3194H0P"4P.H&RB62V(L%"Q'EV0.M6=J96U
MN<#W<]WARJ0MK6@9)Z&&DSZ,HD,6DS(B3@/7Y^T]?WZ/,+FX$"K'"KQ::\_K
M<^^LJ88 6GP 8 , & # !@! _*;Q8N1OH'M[ZOI#F1X=\[L6_6.D^LXHP[2)
M]'^=?J=DWU).'7OYZ>CQ0# !@!L#Z*_Q_>./G'*/J\E^:QTR_1GE7Z+"^M8
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MM5H\1:'N.4*IC/8[+E3^N!$-+U$;M^XX A7GU^\;D,'<%[)7\^C#&M>(D^[
M[Q][5-QKPU.*=&K1KBCD209 21F7_0A-4(A;'7D7:X?&Q/PV5G[=[2%)Y=+)
MV^;[?<%;HH[>E4Y>Y'*77J*UI^DVW1Y6=I)-$-R+M=N2)$I 0,KW_P#3X=X
M:WT?(_DB9.T],K"J0W.I)8=<UXGL)@C,[?:TK"=2&FKXO>QZI?6A1.V1XM:3
MUG!Z?B(=2EHDE5II![]<5=G"%1(3 X,3L%M1:M?W/C(NK7K]?)YQC$SY/PRV
M8-PV1/3FSL=MSRY>-,Q<H$W]UE9*-0H?0+7?N6Y*4!1)[44:E7'-XU9Q*X:
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M?X_O''SCE'U>2_-8Z9?HSRK]%A?6L ;J_!V^F?!?TZQ^H[0?<KGG:/78, &
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M6+D;Z![>^KZ0YD>'?.[%OUCI/K.*,.TB?1_G7ZG9-]23AU[^>GH\4 P 8 ;
M^BO\?WCCYQRCZO)?FL=,OT9Y5^BPOK6 -U?@[?3/@OZ=8_4=H/N5SSM'KL&
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M[^FH_P"6#\BDC_[A9_JU?_.C/O\ A;.D6\J/#']*%V?[<,?E2C_P,]_34?\
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MO+=FS7&;B8PTN0Z>M:D,H5LMI,RXDIXB\PP+_AYJ'_&BY-?-Z*_[.YV7Y?\
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M$R%S ?$?W]W5R"=\" P 8 , *+/')J1V-(&-UXM+HW8S+"8XZS>R:JE47FL
ML2X8,\K&%#"9+QZ?YXVQ&,OL?6)2IJZQVQ4YS]5LY?6R.PCW51U#*5,^B(3J
M]/\ TZ?#E]VH[<5_/8Q9\/8YU#EIZZ/OZ<\U*-8WN#.YHE2)8I;'=E?&-W3(
MGF/R*/O")>Q2..O2%"]1]];G%F=T2-R0JDQ00,QP 8 , & # !@!3OFMX-(U
MY^(?9V2Y='+U?$A1?)U_ QG_ !6\!,)_+DWM<_9"^<?5W$)1S2Z^\Q87*BP8
M , & # !@ P 8 , (4Y#6S&:4JB03F7)1JV7MR.Q0PGN^VQ%'I;/)&U0IL.=
MYB\N3.U1!D3N#\F/=Y&J<B#FQ"6<:U$N3UMM:EP/M[.,:_*SJ^:7K[F&^3-D
MG<H40R-<9D;W9;O''V;!IYU0MTS4\6N7M=^ZY._O-JQUJDT=G% WDRG$V/&4
MLC;I;/MM#\;/F6^PGU^?W<?I+XE[O5M<9FHAC9VIE2J')6F:&U"UIU;RZ.#X
M[JB6]*4D*4.KT[*%CJ\.1Q9(3%SHYJU3@X*1&JUBD]0:88((')8 , &]]36]
M[_Z?#_X__P!:^' "ML[2O_(*O:ZG/&V_2(9INDH+!CTJ8FQOF4,L5*AC4NCQ
M4 GK4<I2G+(,LD+NC43-L;E;/+T"J-"1,[O$Y4D3/30$\FO67J$&U9QV<9(X
MPZ5.)$AI>.0RUUEG.W'98TM<B:H9=+41(6E\?*(M;0D*MEIFRO=*Y2)S:F1D
M((EK<\K$9K96"Z26I G$!GZ]?K])>O[GZN0;!," P 8 , & # "'N0'@9L3S
M>/\ UY&61SBZ^XQ5?-/J[R&?0[XHQ;S<9/5B7(/E/I/O$ER%T%W"'J<^/U_>
MD!'ZH!EE<B>CX$*IY5=/Q,6$R@N& # !@ P 8 , & &NZ_[Z5FW8Q5U5"J5(
M[-KM4\(7?;^^1EOX\RM.\0J+39[KBXFLZ6"G<<0O#,]5XW0KD R5J\-%=6A.
M8;%$KW)RY38-528)^_KZ?LU\?:,\XT4*IC2HVQI.U3V,.2QA50F/0RQG>/.]
MBLM8D. SF2N;EDT'G]B0FZ2(&Y%.2RFIPZ.JZ=Q2#2YQBT@>G)Y<9@Y2$!G]
MRY.KB+5Z_7U"ZN! 8 , ,&L:R(94L273NP7CW.P]I5-*=ZD)R!S6MC"0[NJ)
MG*>) H;4:P+#&6U0N)5R.5N_:4;BK*4MD$E=6IC;E[@G *W7M2\Q='N46M"G
M%QM=OE$);8'8W%F=/2!;4%O5FC _&NC-$FY]V&/0NTU)+^XK6*4*S"([,A==
M";)4$QY5')A6@27W/[^;M[CSZG./3;5DB<9D=/K/GCNMAC!7[ "SG2+O+K"J
M^C[N]O[/#?="PQYKD$T.;%L@4I1RFQY'/Y:I3HDQA\G6N:Z2/,C!K^_WXO=J
M%C," P 8 , & # !@!7I]\9B"^C*2^M Y<N8?3X"A\\NCQ'E^\9:!>C64>L@
M8+F'T^ 'SRZ/$6$R@N& # !@ P 8 , & %6)/)GF[V:1D4//UU=W11=AJ2'*
M(31 J1L[B\-J9R2IX=;<6+">XK:MM*-K@OL2FL;&:J(2JXY8,06.BED5,"X
MH]7G'&\VJ7U+:\'CYL".%9\J136'N</BS3.0P6?W,&57A">2,].F0V2]*_BB
M0-FJ^.\ZA,*7SF2RF75G*W%R;68-IR.PPL9Z_OYRY-1>;U^;EU>8;B-:ZGP:
M^#6O@UK7_3 J& # #P(6@ZV(6]!"'6Q"$+>M:#K6NKO>][^#6M:^'>]_!K6
M$!6ONWII$J_E_&.PZ_*,1OJ.=*"9 G(D4%N>!'0^1=H0<$J9R719&&N6.SI&
MG=OL>*A<5C!MM1O &J8,FG.&R4)Z?^GW] JS3E%/$E=*CE43<W&N*NJ2=/3V
MP538<(=4MWT2YEM;M%I_QXA\\2R8$?<:!?'$UM6-;<8W3B)$1IG;D]8R!Y@P
MZA<JL!K_ .OIY#^_)Z^/7KV28$!@ P 8 , & # "G?-;P:1KS\0^SLERZ.7J
M^)"B^3K^!C/^*W@)A/Y<F]KG[(7SCZNXA*.:77WF+"Y46# !@ P 8 , & #
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M\OWC+0+T:RCUD#!<P^GP ^>71XBPF4%PP 8 , & # "DW)ODXGAJ9=754R5
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MYBPN5%@P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & $/<@/
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M"8,ELRO9^HA-D,C!&??7M&M83%6A#;1[#)8*BM.NC JFEJC4G;61UAK!8CE
M1/B2/CB,JD+A983KU>C[]G?JZ2XK]8$!@ P 8 , & # !@ P 8 , & # !@
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...R>O7KZA52MKBU:A_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g838337g77n88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g77n88.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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MP'S>U_>G90HGX-/[S2GQG',O/[&]R<!\WM?WIV4*)^#3^\TI\9QS+S^QO<G
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MGFC (.]ZRK$6[=OUM]3*CB.S]GU/];K5EDJB6X3BA]Q,/_>)+_5#QD)_G/\
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M,TLP/,D<[<D=8.R" 31 R2-3$STM?O*=2M,=WY7($^D#=&G9(PR%7I0G5A;
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MPB81,(F$3")A$PB81,(F$3")A%&=S_='9?\  \F_E"K*MY6_>WXJC^1_W/\
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MJ#2(.>X5J@CO:TS 6PN84*<4=RD[CU)0BRDLQN?39_--U'URTOG?RN !8J
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MSIFAS8)2:3(%C*Z+249:8E<4K>3M&!84[IYNO+?#J_ V\E0QM2*W=GR%*AD
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M">+;B9[@9\>F/-8S4<:9IU8L4B$F>G=G;)$[)6?UMH(+5KMK7 T"1O(*"I-
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M?@=0X"/$6#KZB/#G9G.I;ZT#X:S/:@:#B+!M*4Y#+U!+Q6'AQ??>R_*3F;R
MY550R53*J.41IO:YQ&["/7L8;;="/;D=@2^OBV^-QN5OK]&X#$SVQ;I<&*0M
MN9FA*Z@/6%DC,6J-[YW3.D]/Z8RDV4JYV.R<E*Q0:.<L3&71L7@OO)9LU88+
M%ZTTH.#VKDDTI1.(.[, KJ=6ZWU+J_#08>YI\ZL<.0JY(I*XYJ4>^*N.DQHQ
M5*MRQ9JXVD44G4:E0B@@"5B,1W,M]?']WT]^")?W:>?_ &6=Y\Y8[T^E]J@^
M(O-_FS)?J^]]DL?#5F:EX+7]:'JSBKB+M!8P?YAGMN4L[FF5*"!?M](UL.B
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M'ROZ%S-9"E%J>I?U'M\_7*_='P$5G,.(%&!9&8-4M);..,SCB.8B.*,RCB(
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M@/V$#[TZ-_N!/"]W/OU\7JK,_P!/3L8\C_E^5WNA/ZBQ]$GY0'["!]Z=&_W
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MK8 [%K$>"81(BAE81/ID3QFPB?\ T$[MLQ__ (7[?]%F-/ 1"(S1$1!U!%I
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MCM.%8W"'%MS8T.B U;%&]4N<$TQXRN4\D ,<,;WAC%R;D?3:I/-M&;BY$,I
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M$G"3ENO0 G.+4D$*"MBV4H)+.+V(LPH6RS0!,!L11P0&E"V$6M[+-  P&_\
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M?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY
M?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9
M:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)
M[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/
M!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UG
MZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY
M ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[
M9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A
M)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>
M/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4U
MGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/F
MY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;
M[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/
MA)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@
M>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4
MUGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/
MFY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.
M;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U
M/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'
M@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA
M4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3
M/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT
M.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7
MU/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7
M'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*G
MA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U
M3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_IC
MT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]
M7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS
M7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*
MGA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9
MU3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_I
MCT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6
M]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?H
MS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^
M*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q
M9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_
MICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?
M6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?
MHS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:
M^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[
MQ9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!
M_ICT.;[9:^*GA4UGZ?6]7U/A)[Q9U3/FY ?HS7'@>/!_ICT.;[9:^*GA4UGZ
M?6]7U/A+)(I_:2.IO'WE*Y/,KJ&=("# #/CTEJ5D0MBTO6];&4<IABJ*/97G
MA\NM#3.Q(@[\F]>7R>3<4O<\TU(#B$-J G\DD5N0B;_5FG:8/^X.I8>ZQJ^*
M1CDGHV1;RQ348Q O]'>N\$C?P-EZ6N"W64J#J.TQ;4"=6$NH.2$9K&4/#S6J
MEVTZLDN9$K4<2OE%</9Q*-2XI$1II)CU&W%*6]L!:HH99[\VDJ7H'F.IM(6]
M/&$X2=]XZ61@"RP<#BD?=QBL SDPN3,_"07X&[.SM&3L#^SZ-U[1U6!UCB[Q
MRT,3R25'/G'/&.S%-4D=A(A%W9Y(3%I(N3;/*#/(L7SEEVZ\7_49M>1VQS!N
M0]]<%2I#7\I=:JBC>>:,Q,QQZ!NK@U#0MQ8M[TG3+Y![>D:@L'^$QT?'!3_S
MG[SZ,TC2CI:>QHQBS/8KA=E)F[3DMBTO(O.XQE'$S_\ 1&+?4OD?7F1FR6J\
MP<I.XU+<F.@!W=QCAHF5?B#/Y&.4)9B;R/)*;_6J/YTBX]6IX1\91<R.4]/\
M9PS75="M=[=6;4T%'=RS3#[,B[[)/6-QW3Y&MN?I_8OJ?HO;C?Z/UGUCTAGH
M?0&ZS,Y+YHQEO(]'OCO4!/H]3I<^4@1[=3A)QVY[[\"WVV[-]VW.GL1\_9FA
MB.^.]>_9#C[XZ77Z7&&27?I=2'GOT^.W4#;???LV?90^=(SCW+V#D@AXI]1N
M'\A[IXOU]8-FV)33QQOLNF%6XQ5BS2";^RIC)Y(]LJ]P;U^RVQ&6A3JVY6YJ
MV\M0Z-[>LTYE\Z&JK\,F.?*:>EQ]/)V(*U>X&2JW6ZMIN4'.&*,#$2'QBY.)
M"+$[ 1#Q772:'Q<\>6#"ZK@RN0P]6U<M4),3;Q[]&D7"QPL3321D0%L \6("
M,@9S$2YMKNMGBN7!ZSXD2^"2&RK)FG*&/2%R%7ZCCO9\#)87YJ>F1F:8Y7$S
M?R#V3D%M\->/(-VK,D](TK2TK8K+&K<T@=[^KD^M9RL4\=>O#C)(QZ[9"K.Y
M@0&9R6(8WYT.##^99V<Q=R;L$MN5NX9JU3"3UI;=NQF(I3[U?%7*S12!)&$<
M52Q*SQY3J/)VG39QC)A MR,5@5K\3.4%$GQ=-<W'FYZN/FZHMOAP)S6\MC?V
MG<S=EA T,0G1J3A='G0CB0F,Z,1KF4(XD)J0&S2]"GJY3&W6E>G?IV6A9RF>
M"S#+TA;?QY.!OQ#L?8WV%]GV?L=8UW"9C&O"U_%Y"F]DF&NUFI/#UC?;\G'S
M!N<G:V\8[FV[;CVLNZ<N$_,AF:%;^\<3^2+2S(9.VPM:XN=(V4@2I9>\K4+:
MT1E0-5&BO1/CFY.C8V(&P>M*U;DY-S>04-8N2DFV#F,09M&&4QQF413"(W:Q
M.\("1'*S-(^\8B!$1MXHB)$[LS.[2'I[/1QE*>$RP1C,-<C/'6Q89S(0"%]X
M6VD,S !!_&(S$6;D3,^(2;C/R,AEFLE+2VAKBC=P28I&?&ZM>JUF+=8,B(<?
M6/43V&'J6<M_>25>T:P*<UM0*2S1HUA8!;&E/"7-'D<?-6.Y%>IR5(W=I+(6
M82KQN.W)CF8WC!VY#NQ$VV[>=ECS8C*U[D>/GQM^&_,PO%3DJ3A:E8]^+QP%
M&TLC%Q+9P%V?B3?\K[=S,>(W*JO9O$:TG'&V]8I8=@&&$P*$/M43ENE4Y.)T
M#9Y$.8E#&!QE!R?T@ J"6-.O,3C%HLX(!_X<LBRN+G@ELPY&C+7KLSSSA:@*
M*!GWV>:1CXQ,^S[=1QWVW926,'FJMB"I9Q.2@M6MVK5Y*5D)K+MMNT$3Q\YG
M;=MVC8G9^Q]G5E*'Z;5P6C#^2DLLU'.>/P:&XLV1R?CC?8%4R%*=;#56SA[(
M<X^QC?'**&MB8UU H;CY,0ED"=O6ICDPVM0: 80ZZ]J*I6EQT59X+_?V4KXR
M0J]J-VJE8'F,A],96)V#8FC=XW(79V-F6WQND[]V#+3VQLXOYMPUO,1#:I2B
M]T*A<#BC>0X7!G-G!YF&5A)G9P=V51NSQ?\ Z2M"O[C;@T;=!?IJ=+W6<TT.
MUR=E)5'IJU#MEUN=%>@7(C_21?VH#T*M*;YWF'E"'M>_Z/\ F?\ .U/\GV6_
M\S#_ )5]W;:SX_Y#M$F_*\>UG;ZG6C^:\GO4;YNO;Y#_ -!_E+'^=[&?_*?D
M_P#,]A"_Y'GV$S_6RR>6<0^5D$GT4JJ8\;+VC=F3P"@R#0!VJB<I)A-0)"1G
MK!1"/&,>G23:1$EF#6^Q$R[U/11OK/HME&:#'%E<7/!+:BR-&2M!MU[ 6X'A
MAW[&ZTC2<(M_^7FX[[MMONRFGP>:K6H:5C$Y**Y99WK53I6&GL,+;D\$73YS
M<6WY=-BX[/RVV=1Q/ZDM.J=QL-H5Q.:Z',&3<EBA4YBKY%#Y%'O7U;7I]9B'
MQ"A.<6@;B@6HRW%* Q(:>E/++-%LL7DG@M5;74[VL06.B?3E>"4)6CDXL7 W
M BXEQ(7XOL^SLL2S1NTNEWY4LU'GCZL+689('EBY$'4C:01<@YB0\F9VW%VW
M[%(C7Q&Y4OE6FW>S<;KT=J<(0JG4VT6VJ9PM@06A#Z72YY^U2=C,9A,J'9!P
M%KN%9MM1C*,+4JBA@$'4!97&!::D>1HC<<F!JI6H&G<RVXATG/GS+=N(<>1;
M]C.LH,'FI*;Y&/$Y(Z#"1O<"E9*MP'?E)UFC>/ICL[%)RX"[.SDSLN3 N'?+
M6TVQA>JUXP\@9XRRIF>9%%WJ(T]8#^SR5ACJ\EI?G>/.K9'U*!Z;FAV4IFEP
M5MBA42E=5*9M-$%:H)('2?+8JL4@6,E0@.(PCE"6W7C.,Y!<HPD$I&(",6<A
M8F9W%G)NQG=5K8+-W BDJ8?*68YHY)89(*%J6.:*(F"62(PB<9 C-V B!W9C
M=@?QG9GQFM>-_(2Y9))H=4E&VY9DLA0%)DQC4$KN6RI]BFD:D]$I#)&IE:5B
MUD-+7)E"#T+D2F.$O),0@ )6'9.26,A0J1QS6KM2M%-MT9)[$44<N[,3=,S,
M1/<78MQ=_%??R=JBJ8G*7Y9H*..O7)Z^[SPUJL\TL'%W%^J$8$4;L0N.QLS\
MF<6;EV*?^<'"9QX5G<:$CM.3IBX\A.,-;<C%C<JAA\+6U^JGXG4I37ZY,ID#
MZ>[K(Z>U&$*7DTIB,5&B$68Q(!DB"+!PN9',-D2"%HAH9.SCF)IFF&=J_!VL
M"[1@PC(QL[ SGLW_ #ENMGJ+3QZ>?$#)9><\IAZF5('KO7*J]GFSU29Y9'D*
M)P=GD=HG=^QXQV7$FG"^0D0#B2]TQ_?->%F<GXC8,F-JEDXPV]'U4>.@9R U
M2BKJ4K$#@V<@4&V8]Q>GZ05HD/;8BF:Q ?-E^M%& 0YB-[&5"YWG2K8R6O'W
MT>3J2-(T[%L]B(2$J!<V  CLNQ3.?B>1U;8P$K5<))C_ )PR-S,0VI7I1X>]
M$43UG%W&I.0F&4'IN<DLM,7"NP;2[<FVP5+P?YFK5D(;TG$_D<H766UJWROD
MI5+6(,^9,R!.F6+W:.%ZCOG.K<B1+4*Y6M2>E3ID*Y"M., E6)CC<A\SB!:8
MGRF.8:Q,%A^_:^T)D[L(2_E/$)W$A82V=R$A9MQ=FQFT]GR*N(X3+.5L"DJB
MV/MN]B,6%R.%NE^4 1(2(AW81(2=V$F=\,A?&7D;8UAR&I(#0UPS&T8B8M+E
MU=QRMY>[32)C;E.D3AJ41M&T&NT>]16B"C5[>$J(*=6,"8W8#QA!N6;(X^O!
M':GO5(:TW'I6)+,(0R\FY#TI2-@DY#XP\'?<>UNSM4%?$96W:EHU<;?GN0<N
MO5BJ3G8@X/Q+K1"#G%Q+Q2Z@CL3L+]KLR^)7&[D,=;&J&+HNWA7<(S9?]T/]
MW$O#96MA2;<!#%"1-&I& D#=K;B-0-N"0!OUM<(S236SM5?(T&J]_/=J=Y>7
MOOOB'O;\[C_Q^?3_ #O%9N6[EXOE[%1L3E'N_-K8V]\X^3O'O2?OO\WGOWOT
M^KMP\=WX;,'C;\>U3'7_  @NQ3<]55G?-97[Q]C%D68&L3IT\<;[9E[BW/I)
M7K+JWQN -+,@D-AR9K2[+5F0Z+G&OAR8T"@LK1(@C%ASYJDU.U9HV:%^2O6[
MZ: ,C4A$H]]A*2<S*.O&3L[--*S SMMONL^MI[(/?IU,E4R>+AMW.\WLR8F]
M8()6;<PBJQQC+:F!MG>O"[R.S[LVW:NB7<,>03_8<_BE(TS?-W16)W3.J38Y
MS'*%LUN#(I/#%+DH$U.<=/95JZ%38Z+(02Q[KE_5!E,1;C3@OB<H*)0HU(.8
MH1UZ\MVY1I2S4X+AP2WJQ=..9A;D,G,1FA:4ND%B-NE*3-P=^3,HRP&4EM68
M,=0R61A@R%G'QV8L9<#JS5W-^!Q/&15[#PCUY*DI=: '?J,W%W4<MW&WD*[V
MRJH5LHRW%]W(33B5]1):[EIUDH!)TA:]0)="P-.Y"C)3MYQ3@>H4MY1!* TM
M<88%*,)N\@LA0"JUX[M0:1,SC;>Q"U8MW<6XSN?3+<F<69B=W)N+=O8L0,3E
M#NOC0QUXLB+NQ41JSO;%V%B?E7X=46878G<A9F%^3NP]JX5E<?KXIE(@<+>I
M6V*M;G5X?(\U.-B5W+H8WNC]&3PII$S-BZ1-#<E<'1B4""2\(49QREN,$$"L
MLH0@ZW=7OT;CD-2Y5M$ !(8U[$4Q"$K.\9DT9DXC(S.X$[,Q,S\7=6V\7DL>
M(E>Q]ZD)G)$!6ZD]<3DA?:6,"EC!B.-^R01=W!^PF9<Z"<:^1%HL2*4UM1%Q
M3V+.+N[L""40^M9C(HTK?(^RG21^9R) TLRIH,=&2.IU#\[H K-J6UF(-<UA
M1*(L9VK9\CCZQO%8O4X)1 )"BFLPQR-'(;1@;QF;&P'([1@6VQ&_%G<NQ75L
M3E;D8S5,;?LPG(<0S05)Y82DBC>62-I0C>/G'$+R&/+<(V<R9A;=3'=O$-?
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M5J^$/']_Y&WF*]B=Z4>'OQ%$]?B[C5F(2#*!TW.22:F+A"P/U-M]U%3WQ6Y
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ML/#&0'A9;2VB"Z5PH7$I3)8UK$BEI+4Z-\F8U;.8NQ4J7'O4X MU^^0":W7
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M,=BO3L30LX_GMU(XR%W#RGL[\&[2V95]+).-. G**,,/,,"2606 0SC#ABT
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M\7I!J_1C+T28'S@YV.N:YVL17A&.25CRM%C&,2(NFY2,;^(SNS,S]I>1O.N
M[FED*>?MSG-% X83)/&<I  ]5AB*,?RCL)$[MV#V\MMMG6Q'IN\D9+R4X-\F
MH4Y2647_ ,WY;R7C,]F$9=N91O%.Z+2IAL@D48HH;&[J=P*%3Q'J]?6E[ ?
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M*.6?.:W>7Z&K(O,8Y5-95?232^-%44U1L%)KRKH."4+$CA)UK2Q>T'EP-<I
ML0(E#DK<GE=L1R<1R<"<Y8X&*XL5A:F)*U)#):LV;I@=JY=G>Q9GZ3.,0F?$
M!88V(F%A =F?9]V86:;-ZCO9T:<,\5*G3QX2!2Q^.K-5I5^L3',01<I"<Y2$
M7,CD+M;=F9R)RIGFX6@3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$7/
M:G1>R.C:]-2@2-T:%Z-T;58 EC&E7MZ@M6C4  : PH8B%!19H0F%C+%L.M#
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6_P!1@'_0#_\ :'_TUGS.OL=?K"+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g838337g77r31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g77r31.jpg
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M@% * 4 H"JJ4.%3&$TY\0LK)KR&<*+O@I1,X29,)IER2E![MAR/[,YINENK
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M:S@X>'CN["PO6B>6WLSKS".PS:*"HJ)-<6LB3""&?,A#GT+!X-X@M#()X?#
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M02"(":3#P*.2"$*Y8%4H(ZBHYP-/ Q#*8&DE,,8@V%(%<P@/9: 4 H!0"@%
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ML3)&L; ^-%QP+7SRPROF%G:V-[6[M <:,\2W1 E<MB<V:C@ID=-!D2=C)A6
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M5H\L@* QJ[X<\'8+[0E'\,4KSFPI[X=;>5XWH0SW)W.^\E@V\FI;[6.1)KX
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M8L:&CVHYJN8KV)C(CFJK;41R+G,.7]: XBW_ (;JU_IJ_P#_ )=K=/L:U?\
M\ZD_K,#[H5V]F&M7_P!>AOJDU]^(?N/C!22[G N.IR:@Z'K#B<JNI+Z\K'(=
MD3(VJ+*P<&4%-1-983-ACD9.G3 QD?+''&V0HF67<MW>Y3V-:O\ ^=2?UF!]
MT,^S%6O_ "*'^J37WXYV3XG#Q*/APO6^JNF)H-?:K/:^+.-QA((K)0LVDK/=
M5S<K?1K2[@,0=#JQ>@:8[E,0^9"54IG,HJ"4)9HPXQ_'L:T!:JY>D[+$1$[H
ME\RHJVK;W)GMM1+.#%TJ2]F.M6*B=ST/C(YRJ[N:;SHJ-1K;.[K$Q51RV\.-
MH0Z_'G&FF:)W@CR!'&JNC3/>;?R.9HKC1XAD,%23<E!/-I1W(J+G,@F(>1A.
M/&R@E^\O?P)@3&U[7OW;9]C6K_\ G4G]9@?="/LQ5K_R*'^J37WXE+_6@.(M
M_P"&ZM?Z:O\ _P"7:>QK5_\ SJ3^LP/NACV8:U?_ %Z&^J37WXW\IX^9H@1,
MB6QL(9)EAQ+86O;&V8P. F5L;7O>]L>^ROW+7O>]K=SNWO\ ]ZT2Y+'*G$JI
M]"EF6+C-:Y;U:BK9I1%/[*P2*8.-7YE8A^U$U^4U>JW;I3P<J[RW%YA&+U;@
M[P\KKY(PO7,D9OJIP>HPH!0"@+'.%+STF#T;D'\GJM;BP#[Y-$_,Z7]73!5[
M=B;Q-8N5:M^NI0UB5?8\<!0"@% * K0W@\N&=T4%][G:Y67:^A#B??JZ5)!:
M;^9Z_2M;^Y3JB^_5TJ29=KZ$)6U F* Y]*1>533&60(35H^1)*SS3?H^IRDW
MW&Z6,7PQ5262Q990VDYF>OG,QD2RB FW).$C8LJB$C1K$V4!')C@49$ML)I;
M[)3M?IVXN/"9BN4$Q#3XZE5;3G. )L*SW("7 2'683?I1LRBMT"42@]CF) Z
MN1^63"+AN">.,\< #-&&$\6W.C'JG!^+%\^LT'4('ZQ10@ A!QQ P00<,A11
MA<\0P@@\,;Y9B""9WMAAAAC:^66>5[8XXVO>][6M0'X$&!!\'X44(+PPF((/
MA!,,/"C9VRO@$'WU[=^)E;'*^.&/=RRMCE>UKVM>@(5\2K]W;O9[(&QWPB=U
M86Y?$OF,I>GC3SDV:R8% 8Q?E9/E/HS]0[#>\(9K<&"WO5-?*2'HS9H+#7W^
MKOR5*>G(&0&ML&C!0"@% :;/DKW/FG/V3W-\7X:K7&$[WDDN587-)TV]@9\(
MJ2Y%B\^D3>96CBR0H#&KOASP=@OM"4?PQ2O.;"GOAUMY7C>A#/<G<[[R6#;R
M:EOM8Y$FO@#<XH!0"@-5G"2YG2'T\?7O$"KVX -[N5Y5I3[5AX^;LW?OI'R>
MJ]S5Y(UY-H^;V^A!UA1Q+:JG(\0S(E&I01)5"1H::)A65X_%+-I\1%=RE!GF
M['-B1%':KF#;2B&W04L]@(/ED*&81=UE4^!<Z7IFLS^.VSI/&<0+F&;M^R+L
ME\&GG7;4![^T+RM1W/()T59_!JL/(=+<PF#Y0-6B*5B@% * 4!]B9&_8Z5]6
MD?PH55)?[MWQG>=2]L/O</XC?10\E4293!QJ_,K$/VHFORFKU6[=*>#E7>6X
MO,(Q>K<'>'E=?)&%ZYDC-]5.#U&% * 4!8YPI>>DP>C<@_D]5K<6 ??)HGYG
M2_JZ8*O;L3>)K%RK5OUU*&L2K['C@* 4 H!0%:&\'EPSNB@OO<[7*R[7T(<3
M[]72I(+3?S/7Z5K?W*=47WZNE23+M?0A*VH$Q0"@,NTKVU\C*/DS5-M;Q<.@
M!X%X!=.F,V*C^F$LS7Q&Y\G(AU::T[LYNMU*>^:_L0A?.RLNNIF.M88&0<O6
M3W 7?R?8@9)'1-+;[%OM2Q+47B3@S<'#F5<W NHFA S:<=[9!-<T.[0:HGG*
M]HU9S&U?=4HO%936?(7<F^2EAOK0T00H@.]!;AQ"36,W5!/!D:95A16DHDIC
M!1]'GC)Y"6),($1.'[IJ\.,B)LM7Z,R9L^?A0[?E'^N7$)VVVV'GI&2I+BN*
M-/M8AM=\'PCJB4#&:-,7*"6)(G%B([I)):JQY*..%B(B,!)11/2'BW"T=II-
M-54\"XV)@+5:B69LZVZ;+,R\::-.?@.6.O:#8A^<#\Z<?6L<]2.?D/A=G%5Z
M[$E7;K@59IHVZ=;#8BP_G"CO"?&W,9SP(1G)Q.BZ7%RBIJ0PAT5K)J_X<B&:
MPMR^)18F/>B>VTK9GT)8:+ZR0% 8Q?E9/E/HS]0[#>\(9K<&"WO5-?*2'HS9
MH+#7W^KOR5*>G(&0&ML&C!0"@% :;/DKW/FG/V3W-\7X:K7&$[WDDN587-)T
MV]@9\(J2Y%B\^D3>96CBR0H#&KOASP=@OM"4?PQ2O.;"GOAUMY7C>A#/<G<[
M[R6#;R:EOM8Y$FO@#<XH!0"@-5G"2YG2'T\?7O$"KVX -[N5Y5I3[5AX^;LW
M?OI'R>J]S5Y(IY,@PH;A0<_L(45G 6;</3.@C3R!- R CQP(OK,>#!,0[!6*
MJ"%(9E__ #=D>+O?)).8L?Z,6*#& 15TE?'=95/@7/Q9K+[^'@LVGC^(%S#-
MV_9%V2^#3SKMJ ]_:%Y6H[GD$Z*L_@U6'D.EN83!\H&K1%*Q0"@% * ^Q,C?
ML=*^K2/X4*JDO]V[XSO.I>V'WN'\1OHH>2J),I@XU?F5B'[437Y35ZK=NE/!
MRKO+<7F$8O5N#O#RNODC"]<R1F^JG!ZC"@% * L<X4O/28/1N0?R>JUN+ /O
MDT3\SI?U=,%7MV)O$UBY5JWZZE#6)5]CQP% * 4 H"M#>#RX9W107WN=KE9=
MKZ$.)]^KI4D%IOYGK]*UO[E.J+[]72I)EVOH0E;4"8H#PZBX4!'/(28K+B.E
MJ3H4#"0V4Y14B1(\XE8JE*"Z:3$(H9&",*Z@61$E563!)/#,&04I,4% 0+$H
M2,C!@4=ZXR]/&M45LJ D&5N$@L-J.<S[:0E 3<=Z(#G/(=ET^.GC.=,+0X?*
MJ3^&*&<,G>N!CE,70Z\E-=$(IPBD(5!$EL5;?;)QHMBY_I0O<H1.?2Q%;!G&
M,WW#LIM\-UQO)C6666^&T*H*R4&NMEP$A4]72\U)"/I:R1Q.$QA0;FDM1)'@
M;9=^7,@B6QSL"9LZ7H<+G[1_6_9A?373*S3=(SA),\Y&ZDKL25Y8B0Z\XO43
MUU11BN1QHJ>S-RDB-#JEF,>%8[X^?F]@8.*>8!$'YW5K'AE%5/QMT+I3.>D<
M1!%2&WPU=UFZWTM/1$%!TMV 141%2B@">EI"0EPNZ2*:EII K@$6))Y D "4
M)E"X08!8N$&"#A@'ACC;"W+XE\P2]/&GG)V5DP* QB_*R?*?1GZAV&]X0S6X
M,%O>J:^4D/1FS06&OO\ 5WY*E/3D#(#6V#1@H!0"@--GR5[GS3G[)[F^+\-5
MKC"=[R27*L+FDZ;>P,^$5)<BQ>?2)O,K1Q9(4!C5WPYX.P7VA*/X8I7G-A3W
MPZV\KQO0AGN3N=]Y+!MY-2WVL<B37P!N<4 H!0&JSA)<SI#Z>/KWB!5[< &]
MW*\JTI]JP\?-V;OWTCY/5>YJ\D ]F454-S8'?><-L)>.-Z&9N12\WJ4GF$B1
M& 765J.,S3.;$38DLR[S0'CF6*CK[K$-89-,5,)%;"%+K.!=9W653X++5O3-
MP7+GMX]1^GB!<PS=OV1=DO@T\Z[:@/?VA>5J.YY!.BK/X-5AY#I;F$P?*!JT
M12L4 H!0"@/L3(W['2OJTC^%"JI+_=N^,[SJ7MA][A_$;Z*'DJB3*8.-7YE8
MA^U$U^4U>JW;I3P<J[RW%YA&+U;@[P\KKY(PO7,D9OJIP>HPH!0"@+'.%+ST
MF#T;D'\GJM;BP#[Y-$_,Z7]73!5[=B;Q-8N5:M^NI0UB5?8\<!0"@% * K0W
M@\N&=T4%][G:Y67:^A#B??JZ5)!:;^9Z_2M;^Y3JB^_5TJ29=KZ$)6U F* \
M6?0T54.(R@II"6HGVZ>&5&^>/IY0V<0E(RFGD8PHHQDP$(,F'ATA34DH8V2S
M ,"IJ@>(YB9%38X0@%)\,,:<=D64WYR:29PJXF:[Y/JBJG1>[])G;*\EL$L4
M7SY 1H2#(*3M+$B89D]"S)")KX*%8U0P6X[P%1%\6/?-MS9H3M1,RXR\'NK$
M^BQ?.7B4("@% 0FXE7[NW>SV0-COA$[JPMR^)?,92]/&GG)LUDP* QB_*R?*
M?1GZAV&]X0S6X,%O>J:^4D/1FS06&OO]7?DJ4].0,@-;8-&"@% * TV?)7N?
M-.?LGN;XOPU6N,)WO))<JPN:3IM[ SX14ER+%Y](F\RM'%DA0&-7?#G@[!?:
M$H_ABE><V%/?#K;RO&]"&>Y.YWWDL&WDU+?:QR)-? &YQ0"@% :K.$ES.D/I
MX^O>(%7MP ;W<KRK2GVK#Q\W9N_?2/D]5[FKSOCV;R>:W1@9QBL;7Y14DR&)
ML)%7\YG:(2V/;I<VLQYX='B]F62A@UZ/U2]\/IZM9J8&:&9R2 ,,BME3,JN[
MK*I\"YUO3-P+I7/T'^>(%S#-V_9%V2^#3SKMJ ]_:%Y6H[GD$Z*L_@U6'D.E
MN83!\H&K1%*Q0"@% * ^Q,C?L=*^K2/X4*JDO]V[XSO.I>V'WN'\1OHH>2J)
M,I@XU?F5B'[437Y35ZK=NE/!RKO+<7F$8O5N#O#RNODC"]<R1F^JG!ZC"@%
M* L<X4O/28/1N0?R>JUN+ /ODT3\SI?U=,%7MV)O$UBY5JWZZE#6)5]CQP%
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M:GXX@7,,W;]D79+X-/.NVH#W]H7E:CN>03HJS^#58>0Z6YA,'R@:M$4K% *
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M<*7GI,'HW(/Y/5:W%@'WR:)^9TOZNF"KV[$WB:Q<JU;]=2AK$J^QXX"@% *
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MQ_59>'QZ7-Q?]18;_P" :?ES6GX5=]4D/NH]C>I'P!"^O4M]_+=@=1I:+@A
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M]J=_J@_.MP^?M]%_A^JO]#.AQ;P=(^A9Y$) C+<+=!KN],+GRA%8"4=553,
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MX@#WE-SH4B:I<2>$V^QE05"=R =<;I<XRULA+C@R;&$*-^[,+#LHTN.2)',
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M 7PS2N;)JK*)* !H)JFDG)>6"R#FA6(6;Z8>%2$3%/2K!DL!$ZG0"@% * Y
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MVO!TKIT95<[V>KC/99J#C=[J63)M77UD[GX0T=,Y8 !%20)4F7$56TZ;0P*
M4!Q)PL>05&?8VD!,/Q:'&S98$B-UTIZQ'XRG+IAPN50:)IO"LJ1\5@ )L-/
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)67D7+C+;<?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g838337g77u24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g77u24.jpg
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MT^$V0E-6='6RL[2UTO$6%Q@C,S4W5%63E=1SDI:BU20E0V)$PN+_V@ , P$
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MJ2WQHADIQNKR,N<>D:6-.#;'&^4KVB4D?!=4=K.93,W8I[:7A6A5M3:X%(C
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MBO4+)9XG'2CDS%%F!&7HD:69 F(TQN=L><:#<YFP($
M
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M >7<WSNL?9TJ^\P \NYOG=8^SI5]Y@!Y=S?.ZQ]G2K[S #R[F^=UC[.E7WF
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M5!6#2#\%GE:&EX.2GEJ4QV-#-=M<&IU))2@@S&/7*/*+-+SJ9IKM@#F
M        <)R=.H\KSR"3_(.T4$^<5H9Y*@OT^6>5Z^NWEG%^MMZANGHWT].?
M5VQZ<@#F   <)"=.FTV+3$$IR]SE"C?0@K0K390K/,5*C]M2]===CE*DXU0H
M-SC.YQYIAIFVQF^VV0.8            !PFITY^2=CR"3MDYVJA/DTK0S)"C
M73<O4\G.^NV2CM2S3--3=/5WQH9OKC;U=]L9 Y@  '"0G3IM-BTQ!*<O8Y0H
MV+(*T*TV4*U!JI4?MH7KKKDY2J..4J#<XSN<H--.,VV,,WVR!S
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MO;7.==M-M<XSIMKG.N=<XSC/H] U<LR3]@     "B7LOY25C_H?]@HN +V@
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M5]21]"QL;2R=3KO=XO*:22MJ;K2J8VT^U[M8-MY/6=2W)/$R02;
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MKU;1V;KJ=E3719M^C3:5TVE:4?;5TV=E34YERK.G#",)?VBI0
M                      (UM;^++1]95.?TN0D;-T_I:_P:^_H=N0\N>GM1
M)0UB0        HE[+^4E8_Z'_8*+@"]H    $,=$LK.^47;B9[:6QX3)JWG#
MBF3NJ!*X$)W!%%7<Y$N(*5E'%E+$AN,&I51>NIZ<S'KE;Z;?E FG-<J[29P(
M        "/H9_&.VOK!;?Z*JR%:<Z_E+\BDT;I\(TI^'6?ZMT<2"+&\
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M]/[OUW_JN?O^.[QU3Y4/>:!^5I7LT8>8O9&Y\#N3A!VZ$/2*.I3S(
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M/[OUW_JN?O\ CN\=4^5#WF@?E:5[-&'F+V1N? [DX0=NA#TBCJ4\R
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M8[J\FG]3W[\95_HMV/6WL>?L=T[^.J/T&[E%([&/00    !Z._V/I_=^N_\
M5<_?\=WCJGRH>\T#\K2O9HP\Q>R-SX'<G"#MT(>D4=2GF0
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M$Y)1>Y3GJLU4Z858/P)*<IDP BN]?S(W']5=A?9%W FG-<J[25 (
M"/H9_&.VOK!;?Z*JR%:<Z_E+\BDT;I\(TI^'6?ZMT<2"+&\
M                  !Y4/'QU-VZ+IKRS<%^BE=?3Z2\;^G_ .>I7Z/X<X]'
MH_+_ *?2.Z_)FTM#WZ5/_N56V/\ \6['K;V//V.Z=_'5'Z#=RB7RE/SK'^XT
M_P#N'8\T_%_[F>@CYE9+CLG-PE6%Z'9+,]3.Z77?T[9TVQKC7.%!.--O7]7T
M;[;9UU_OZ_W\7LZK)5+7H;IE3%;48J6_1J;4;%#>QDJ)4[UX>#DYBREN-?0:
ML+WW].?WQ:3!>OH_O8]78\W/IQ_?SZ_Y?\&!6IV<^C0TMU5>L^E4T]A&&SMG
MU(_?E*?G6/\ <:?_ '")I^+_ -S!Z0/V/AJ9J=UYYAF#,Y*Y^]&<:8T]&/7N
M_P#)Z,9SZ1U1Y46G1H&%'I:5VSLT8>8O9&Y\#N3A!VZ$/22.I#S(
M                    '^?[XQG_ &F?5W_GU6?T 5(/:/DE^P'0?+I+]:7T
MXOI3X9:?)L_R$5HCL<^>=*Z^^!FY)2,I7@O3791E0E,2:YV5%YQ[E(-T/6)=
MS$OK>L:K+USK@[74HCS,EF'ZXQ6GG'"H54)-S2Z<:E[U.:J7JSC4EG@IAU(O
M1JXRUNASEM:BEX[%NSW':D;F&$DF'$Y3F[E%[FD;;Z&9),VUQG<K)A><EF9+
MVSG3.^F<Z;>CUM<^C.!D3;2;4-I-J4X<8J5@XRE8,HXEPY4X/*5O@Y1(/;UX
M 7R!M/KJL?\ ]'%QX\\LWV<WO\ T=^8.4:+^!V?RK3\MEVPZJ/H   !1+V7\
MI*Q_T/\ L%%P!F77$ \/1+T>[QJ7<E]*6Q>#W%(Q;5HD\C1;H8AD4,DY?I?%
M(E);R34A-X+!Y.[3)RKF:HDFTX1R)Z=4$2<<N&N6].F\P64QLAX8QLA[>5-P
M6^06!PFKXA'Z_KB)1V"P:*-Q33&HC$V= P1UB;2=M]]$;6T-A"9$C)\PPPXS
M4DG7)IYIIYN=SC3-]A4RP 0QT2],['1=N*7MV;&=,IK><-R90ZKTK>0H<%L5
M=R42$@U6:26:L5FYP4E2E[;'J#,^H5IOM^0":<URKM)G @        (^AG\8
M[:^L%M_HJK(5ISK^4OR*31NGPC2GX=9_JW1Q((L;P
M            'E5\>WY1=-_4KK]N96.ZO)I_4]^_&5?Z+=CUM['G['=._CJC
M]!NY12.QCT$     >CO]CZ?W?KO_ %7/W_'=XZI\J'O- _*TKV:,/,7LC<^!
MW)P@[="'I%'4IYD                            #_/\ ?&,_[3/J[_SZ
MK/Z *D'M'R2_8#H/ETE^M+Z<7TI\,M/DV?Y"*T1V.?/     /;UX 7R!M/KJ
ML?\ ]'%QX\\LWV<WO\ T=^8.4:+^!V?RK3\MEVPZJ/H   !1+V7\I*Q_T/\
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MJ'O- _*TKV:,/,7LC<^!W)P@[="'I%'4IYD
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M;GQG:OD/L:Z?*UP#;=E"T]8/T;>QJ?\ 16V5--HZGR)-GMH',S]=0
M                        ,%M'\V=B?["R[[/N VKC\-N?X5=_SU!O:+_K
M+1WX==/TBS,Z&J:(
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MP&U<?AMS_"KO^>H-[1?]9:._#KI^D69G0U31
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M9XP^5GSE]<<!^T*$;FC_ (;=_P#B+L9VMY#?[6^ 7X^L/S5L>U<<T/UZ
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MLJZK.UHKL[2EQ51:4U45TN)BJFI*I.&G#2P9]@J4
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MHOMC=KS=[A386U=%-5.I:565G3:*EJMXTM--(N*'UCU$
M
M       %$O9?RDK'_0_[!1< 0MXM%40JP+]N.1NCE!53; ^(:J=KYF$WYJ?;
MJF_']0&WO:R1HZ Y;F[7/8MI7=T.NJVR)A(,D,[NL0QKG)GG)ARG>*M<4DPO
M2\$HS;C'"IPL'O6Y?_9QB>D+7T>KKZ,^MCT8]&WIQGUL>C\F?3C\F?3_  ^G
M'Y,@4/Z (KO7\R-Q_5787V1=P)IS7*NTE0"         CZ&?QCMKZP6W^BJL
MA6G.OY2_(I-&Z?"-*?AUG^K='$@BQO
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MPJ5JBFXIU>G9>6DU-\DM4XJS=-,;'[YSKVM*IKA*%"WOM,E+;2;\8ER8QE@
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MC\HU;;&O#<C+2FJ5*C/M9>\,18                       *)>R_E)6/\
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M#X?J>KBKN45N>F9$#@I3(]-L^E4XJ2BF]$7_ &Y:J3E8SN!-.:Y5VDS@0
M                    %4W:GY[V_P"JJ)?:ZQQDL]O-ZS':;.?U&J R&,
M   W-X+_ #D75_L14O\ SZUQCM-G/ZC)9[>;UEG8QF0
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MLY_49+/;S>LL[&,R
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M<_J,EGMYO66=C&9
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M[>;UEG8QF0
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M3)VR716EV48+PI(R92MIQ#3S]1DH34RHR]99@,9<
M                                           *)>R_E)6/^A_V"BX
MS:W/#CZ9F#;T]S[![YH9DX^[#M&=6C:Y<OHF127I6&G6PX(72RX]7<W1V2TU
MXXFJ5R11O7<SF,&6R"LDZU F0$/>8JPG%BTK!PY248X2LI33PWK;Q3)=%II@
MO30O7.V==-==,9WVVWWSC7&-<9VWWSMOOMG&/WVVVV=ML^G.V<YSG(%3] "*
M[U_,C<?U5V%]D7<":<URKM)4 @
M
M    *)>R_E)6/^A_V"BX O:    !#/1*]2W45;IR5F<WO<VMYRFW3-9C26>G
M)415WT-<#LO#HTI\HT6O]M4ZISSUVQ>/0D1*C?06!*S7*NTF8"
M
M                             HE[+^4E8_Z'_8*+@"]H    $5WK^9&X
M_JKL+[(NX$TYKE7:2H!
M                                                          42
M]E_*2L?]#_L%%P!>T    "*[U_,C<?U5V%]D7<":<URKM)4 @
M
M                           *)>R_E)6/^A_V"BX O:   :K];7?(:)@L
M8D,?=8!&MG^6N[ Y3*T$;DOA$31M546=8B)0\)6N30X_<V42"",E=M&^TC0X
M)>YFW&IDKXX:(H\["4IG-PIA9O%+CWG87+-9 LY\F+AM64RW.D]'2=V=B4BR
M&$Z0]6ZPE>>K:7PN0RJ.NYJIGV.WT69:V9=G;!&^I1>RG_HN IS7*NTV8 @
M
M                                     *)>R_E)6/\ H?\ 8*+@"]H
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M3B;EM#"\+VQAG3#)"917:=*I.8UZ)F:5TV*^$S8X -1X8K&EU<D*8ZT77 4
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MI1BU,F-5$)5)J<A3L:428H3)S]R]==CB"3,[%ZC&=D
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M$KX;,F5"SM"&4)F23N;7J@?W:&OZ,I.D*U;U2\-5PWA@DVML-I+BVK;)9$!
M           %.]9^+,?*7ZMWFQ>7)G5W/5P]+V'R;7O0^]H5[*V+>WH-,K#@
MR!'-8.E,:)G#8_+Y!6,D;&B1&(W9N1N&[62Z[I$CB2X8%W1$XIM)-K')P\-C
MB<<C9ZO?$NX>M18SH(-?3.[*Y%-ZVKV/$JXE8D?R_P CN,F4G50:Q[R2(-!;
MO%K&^!4G3PR?-^ZF"2)>U;MK9)%+@I1)E(ATU+-;]VS/HW'TW=WO2U4\CR?L
M:++2;3K-CE[) FL]M>FJ"-TAE+O>;3SV>05++',C499V-EL%R4DN\N>5Z2*I
MFEG<WO#ONT$X7["$FW&W'9N4Y9FL<^\42Q(71U:]!,_%4HL^NK,4L3"QO%4=
M0<HV&E=)W+[)7UM"8!"5,3LYW+LZ12I>4TKT6M?X?DB,IW.2.1Z15'Y%AM>/
M'CE)U<6IAJ9E58)*9RG?.!;HC./4(TIZI)N@4G)B#E"$PTD\Q&>85KN<DW/3
M[F)SMTYFVQ.QI!FY)FVF=RM]M,Z[9%3Z0
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H897\90[R+*#=P*4FN^SF1NY*!.MGA$I+D2V8[XQ+0 *@      ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g838337g80e75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g80e75.jpg
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M,S8W<W1U@:&Q\!0B-':2L[2U%Q@R55;!U.$5%M-3<I/2U?$C0E=BE)66_]H
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MYTO41[6F<Q%K0B*E73*N%?CWXF2&"!@%BH_ZS-N?$5SK]?\ J+ +ZX P!@#
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M3B#D M'$@":2,P"^6 , 8 P!@# & >8A9_ZR[#^',M_O[AEK[%]#LGFTC[J
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M 8 P!@# & , 8!IG>R 7AW0=N1(A"Z.*(G?/$%,V2D7*4Q6S!3>S@B'LLDT
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MT.R>;2/NH#KE#9V0, ]$GPUO4(Y-^)2'?0<K-I3X1WSY_/ZQSPY+F7N,W\\
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MVN#:I9AF*!R0:V-'1557K:NQX5WYM9TI6A*[P7"PUUQ?S#! JY,M!$J5@;"
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M7F1TA:AA-"-ZQ292//X#TQ%N,( )DY4\Z7$E/VH51Y/Z4:LPU67LDLKRI])
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M/1IGMG10@Z"2#8@+E%%%$%%D$%EDDDE@*))* $LHHHL.@%EEE@UH!998-:"
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-:.M.1_--C7!@, __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g838337g84w86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g84w86.jpg
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MW95_V"^9&I9L3<*B$XP-=-UG09V4+APJM7+%5NK7!<EV1>/K\''R<?5@J<X
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M :&?IEXV[>K!B6CT0*>:O&2VKD:Q6XW:I"K*P[C\,DI*AEV,:?F,$J5[9W;
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MO"5.GB+L,%1@&F_B*_Z?7>O]S?L[_1.;X)6*XUYS<?CX./DX^K!!S@# & ,
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M!@'HV] /T'.H?[N%.?8('G@#7COSUJ_6'3'M\\[39NYY'@H/11MWG5C., 8
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M@*56_,KO3CZ)Z5=:5J2C+ZPY>^([24Z (C.U*P]^T=[&74).1B03IB"DLH]
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M7CYIKR[_ /L#V?"*Z;H@C[-B@NV<MU'&J[=9/013X^.-&8,7]2,>+; #EL0
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g838337g94e00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g94e00.jpg
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M8FIE8W1S('=E<F4@8VAA;F=E9"!T;R!G<F%Y<V-A;&4N)B-X03LF(WA!.^*
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M\SUE2^D?AP(6HZ)>/$Q/.1$@P 8 >.G71T].NC^WI\W]GZ_^/FP&8\X , &
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MAD;RMCU455.%PG"J815+%<A<PLYZ8CI,DBED%/EIR5*Y0YJV>Z-5:M,%9(F
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M1M8)#$90JCR\!;TWM#LS/:AC="S#.S Z)42A28V+P'$F]0*LLA0$PHSJZT(
MNCX+T2Q@I9=D1IL-$ILSCN/,OQTR&3(LS96M*"=;-*DYF@U),C+J,AM4:PI[
M-<B/#FUM@Y!>2F6S&DQ9:X<@E'JID-M+<5'>)2%:I.I0LE)/+:1Y;G$F3#/*
M5#3D#4D!, 0H$46(\D!O1VH"CMAV86$SJA[0(!:T/JZZVM]&L_(2UDE2"4HD
M*,C4@E&25&GHFI.>1F69Y&9;,]@_>;;9K2X:$&X@E$A9I(UI)66L25&6LDE9
M%K$1D1Y%F/!:1*2<>H)3)RE"K8-JCRR2P'*=E!ZI>SS0AT,[98=["#9@A=0.
M^@/1K!K6I*4J6I249ZB349I3GM/5(SR3F>T\LLP2VVE2UI;0E;F7*+2E)*7J
MEDG7419JU2V%K&>1;"'T9$3# !@!2#<OI:LKUXD_M=7EY;B[BX"@]Y]Y\1:+
MQC]!D"^;/?WF>LJ7TC\.!"U'1+QXF)YR(D& # !@!!_)*"/UFT=8L$C$;KJ8
M/DB924J*+6P0]'0%_P"P<T"U2UOAD=6M[VWF*T:504S/;<J H8'[;6]Z+4 ;
MQ)S=API8QJC$-58S)=I!CQ9!K<F4JV$V4;6:<;0]'*2V['=)M:TJ?CNH-,J,
M3T;60;I+3J./*>;?X1O*>O@4=I,G14MM5V)$2ETTTDOLNN1Y9P7F);"G&FUI
MBRV'27"F<WEZJR9-"JOB>&W)=[B,]CS:S*ZQKAQE''=UAE$S+D._WJG8G:N;
M<:YG.Y:QRZ0MVS(JT*HNA):VF*)EKB8ZKDHUK@) +2),5U\\>82CS:V4\^BW
MM6H6*6)^(X&%XN'%R6;6D>@5L*1!BNY37T3'%//S5MM$PVLFVR=+E%J\^HT6
MX]E5MS!CQ7,/T+UA@>158/M<;S<8(B2J+$T>UN+*)9SH^M717*YE$:+7-O/'
M)>;4\_R!\BVG6)YQ@YFQV"6W1E);(:&I\MRRKJJN^(M?\FJ=[9_?ZO<)&H@U
M@Q"/L)KM+'%*XKES0V*]/I,84C/9GUTTDVT&H#?SUN+\!RK*DQ%B$EOO1Z2I
MH+G#DS#42ZCR/HQIJ(BQK)TJ2EB"RMEMM]Y!QU3$:DB,R:^72ZG]-QH^TIPJ
M?$V$,)\G%C3,37V*\.8QKL:6.&Y<4KEY^<NHNJN##5)LGVWWGHL=PIB:YPUQ
M)D@FCBJ97/E<0OE53%Y7V[L5-P2P8#=MJ1*8BESA=FHF]L+8B@L1A[P89%Q5
M_(QNZM.8S+G$DL3VW"6_T:?KD[,[QK6[6?@R^P[AMB3?6599X?IIT H+6'^>
MQY+SEE/GQR*9])Q290HI#32C*.[R?UE?6RU1N=%5:1<*XNQE)B86I[JFQ;B.
MMM3LWL6%6RX<=JGK*N49UQTLXY+K:HKSZ$G+8Y7ZJ,T:VN(+X]\0[3K&:J0R
MSCTT.0G>R;7<5ERM?+BP6[3;$[,D,J'IP(H8EB/@2YT9XQ)-I0H3S [6N)(7
M,:I,Y=125L6)\;TUO 0<+$[S1,5-*TBA>P15NF[-J(L(C:5B54A-DVR_+B:_
M*)29-M*Y$D+9S0>GX)T98BP_;.%98)C/\ZOL1ONXIC:3;QCD*V_FV)\NC!B8
M:Z5Z1%KYW)\BM1&Z\CG)K1(R64Y\:('S)J-@IGCRYQ*HVBK:=4GM4CNA/*E3
M^Y67 &D#IJ-M,8K?30VK(;+',2IIU(G=[?G! W]Q<E#:6XF+""<UW%EE@2[D
MWV*&IMV]<7J4OQ:!4)$9FILWS9.6],M>7=1/A,ZCQQ68\9IUWE&4O&T2%J&X
M8!IM*6&H6%<$2*W#,;#N%W%QIV*D6+LV1?TL8I!0(]?0E%CNU5D^;D;GTF7,
M?99Y%]R.4A3J$#].;]-\C+X*'6\'BT(<H,XEP=\AT\.GT@A[O6-CQV6;7NSS
M8D.T)SC=Q0;Q,6WK(_%5#(K+*?4RO;D@&/36Z),:/KW"V&S*VL)E@U8M'8QY
M]:FMBSF+>JE0N288JY^34NBL.7-UN5-1(0I49:":<(N696TN86QSC%"J&HKJ
MF14/IJ9=7<*NIM7)P_?0;+EI$N\J\Y$#%%245+#L&N7#<2F8VYSADSYO);WW
MRVI.<6-+./MAQF!PJZVNG'Z>K912<_>44?C\WU-8?[VFF1IU;PQR6.^/8.N"
M8N;4[TTF$B2.KIM$L2N!:81GSL$W]=5PL35<RRL,/O7L:M;AX@K([DJ37_1\
M_G;\5:&),25S:Q;R;=5'?)6NRSRB'&C61?9TE83N+RRP3>5]/4XKCX6F7+MA
MA.YE-0H5M]+5?,(T]MV3$GPBF5#I*=81+C*2;4F3R3C;Y-F>$S!X.2Q00]Y9
M9M'JQE:[7"*\*GA*-4I*>&>OK@L:UIQ/X6S1(U]:>]-K- V64(8XUS @A*K0
M@0G!;2$J(PLC70).E2J.='?KY-O";_&%AZ[L'$(.._9T=535]9/?FIC/ZKLB
MRD0W);T!2G&W#<(W5+<(U#DL/07>_14J);0L/V#_ .*7%V&ZEIQQ,J+28GO<
M1VUU51:U4N,;C$6FB3V8,>T0AMUDF5%'0VT9(+,"^.,LPN"@^,52JRFM:= K
M#HMUM,*QSZ"C8M$(TN8IV)N4F$CVZK1A7&]S)'HK:_0A"V,&][Z=&PYBV#1X
MEQ==H-YM-E68B9IS;9^LF9.EMR:XG4$HN1;(VTZZBUN3V%D8ZAC' %GBC!F
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M09 OFSW]YGK*E](_#@0M1T2\>)B><B)!@ P 8 , & # !@ P 8 , & # !@
MP 8 , & # !@ P 8 , & # "D&Y?2U97KQ)_:ZO+RW%W%P%![S[SXBT7C'Z#
M(%\V>_O,]94OI'X<"%J.B7CQ,3SD1(, & # !@ P 8 , & # !@ P 8 , &
M# !@ P 8 , & # !@ P 8 4@W+Z6K*]>)/[75Y>6XNXN H/>?>?$6B\8_09
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M3"%:(XERV9L].2$?GYVC(+ !@ P 8 , & # !@ P 8 , & # !@ P 8 , &
M# "D&Y?2U97KQ)_:ZO+RW%W%P%![S[SXBT7C'Z#(%\V>_O,]94OI'X<"%J.B
M7CQ,;BOB8,]>4C;U@2$B6*F&"5G.)F\IH(M,;9JH;(M&G)\6D11>4N:]HI :
MG0& :5)CD@3DK1$F*EB=,$XT,1(BS,B[=@K I**O_)JP6._)(NDEB,,7GU=U
MC*E5=3>E7)HDKKQZFSS9M22J3R5LB:>.VG#:YEEHR%[=IUQYEU'.:I^$YUA.
MZ.G8(F[!+"6XM_OW=I9']OO+=MS(7*B"$81!$'0@BUL(@BUK81!WKHV$6M].
MMZWK?1O6_-O7FW@1'Q&MC:>8 T]O0G&EA  LPU(G,,  O?26$ QE[$$(-[WL
M 0[UH.]^;6L /8EN;TRM:X)T*-.O<N[^,5I*4@I6O[F7LE)WU26 )RKNI(A%
M)^W&9V!>]@*ZH=[U@!C? _VL^1WT2\9?:_(3 #)S !@ P 8 , & # !@ P 8
M , & # !@ P 8 , & # "D&Y?2U97KQ)_:ZO+RW%W%P%![S[SXBT7C'Z#(%\
MV>_O,]94OI'X<"%J.B7CQ,2O+(X1+HV\1I0ZR%C+=T8TOCF)OB^-R-K-ZP3"
M%[0]-II2I&L2GEEG T+MD:H(1(W)(N;E"I&?$2&'9/'+D<V"(9%?/:P4-;E'
M)D)*=LI+CE&[*.3J5 $R9J'/DL!U"TQ[B>>6AVJ8*C9'40U'2S*6UT&F6DAG
M,O\ 9\SR]?/T&9#>E:X=&42(US5@98LQ)TQCS*7]>\+@-;(@ 4-SD4ID:Y8Z
M.:H*1-M4[/SZY*ERPW2AP<UIQYAQX@P-ONMKU:Q.4'9GNR8"SO%G#[.MFIUF
M,=;W*PC.P3JNS@Z%6XDJI8/NRQ(HZK"4X"[!4G.Z.S/*$( ^EDLFNI+*I1!8
MY/H5()M!^Y>_6',DI8W651#QD7LUN]]$>0+SW>/]_*ULQ%XV2).]%ZV,CM ^
M? "&('^UGR.^B7C+[7Y"8 9.8 , & # !@ P 8 , & # !@ P 8 , & # !@
M P 8 4@W+Z6K*]>)/[75Y>6XNXN H/>?>?$6B\8_09 OFSW]YGK*E](_#@0M
M1T2\>)B6I3)V2%QYVE4C5'(F-C2#7.:I.WN+J<0F ((1#+;FA(O<E8M"&'79
M(T:@[?3TZ+WK6]ZB)#C8,520S7-J(C(<*WGMFJ.3D>7/5CRD'*4^31ISK7DS
M9%C*7])&Y+1;C5TCEEH5M.BZ45H3; :H+5+M65;V7 )0L*9V%MC 2SV9>[L(
ML]A%OW]6?O,S+WG?/RTJELN[C/>E7N<433CWVU;-V]IBRK01%/$CW'7$R,IM
M!&>G)$;M^ WB("H. FV<$OO']%U\".X5@7#05R*&Z2Q$FFI9+9'=_"/A;0]5
M3-I1L2]KHJW*9L.TI#.7::.JIU(-@:*&K)W7UJ-\C0@4"E3A7JIG:1+95'(B
MUN02S(S\5'U[2/+8676>W?L[A(G&JEK79;AJ%E<JSEM>/-&H^=Q%J76M;8\6
MQ62IY!W6T3""+(>[Z6N)L[,L$Q.GN)\+7-IJ>'NT93L,S*02-2E:S@'W]FSN
M+^SS[3R,97T)&I1%>3')1MEMBOUG.9E;<;%9<AD3)#F%<0C-<;Z**:@(H1'X
MVSC3)C23U):@UO&O&8L- <J,)*3EDA$9IX 58^&$YKVSP&X@#ONF&>!O<S#:
M$)A>D-BM#X]QWQ5(T[\:N.VBC\EBCAWXL38G[J=XU[ O0C=&ICMB#L&S82IH
MM[;%!F+?0R<9Y[6CK0AS6;-&J6LXVZG5^L>9:F?89#3<=8@FX9HOI. W&<D<
M\CQ]66AQQK4=)TU'JM/,+UBU"U3U\BVYD8XFTL]TQ\^)K'G.+OM<\8@-+N44
M2M$P1Z]X@[Z+*4$J@=RD<1Y"L<B:Q[-(+T8:V.J,TXC9J4X8TQYY)G3_ ,6E
M!_.+7]HB_P $.,_CCQ1_,Z/]DF_XB,:Y)X;CE;(8Z_L">-P^,J'QE=6<B21R
MY.<Z>0Q\YS0GHBGMA/<N83HW$/34,X*]K.7MCBB+7)R!JD*L@)B<S!Z,Z#(\
MI-J1Y;#YQ%/(^W+F6W+L$BTRXH(R,X5$9$99ES2869=99_2!Y9]QC6O].ARG
M_P#K^MO\7^>G^=#,_BTH/YQ:_M$7^"&/QR8I_F=%^QS/\1&1;1[IX\(&QM+6
MRH*XXK"0L[<B:T0G&&7,\N DC>F*2)]KGAYOI>[NRS9)(-JG)U7+7)<?UU2Y
M6H5&FG#?BTH/YQ:_M$7^"&/QQXH_F='^RSO\2',H\&_R/G?+GA-0G(RS6^+M
M4ZL]@D+I(4$+0.;7&$RAJG$HC:8+2@>'F0.2<D2!E2&'!5/"T0E0SS #+*&
MDODF(JYBIN9U?&4ZMB,MM+:GE)4Z9+8:=/74A#:3^LLR+)"=F6\]I]WPI:R;
MS#];:RTLHDS&G%NICI6ADC1(>:+42XXZLBU6TYZSBCSS//+86;V?%&PA@ P
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M:?Q8G^><,:^U%M^E8^Z1QZ\T>>QE%\._]]DBUW-6&Z!@ P 8 , & # !@ P
M8 , & %(-R^EJRO7B3^UU>7EN+N+@*#WGWGQ%HO&/T&0+YL]_>9ZRI?2/PX$
M+4=$O'B8G0\\A*0<I4G%)TR<HP]0H/, 20002#9AIQQIFPEE%%%A$,PP8@@
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M]^?>][\^][_7FW(Z"?\ RIX$/[=X>/.@HS/:9T]89F?7_P!"8$@9(?8# !@
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6L0A;WL6][_7O>]].][W_ %[W@!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g838337g96a70.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g96a70.jpg
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M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+6_\
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MI;0AM.U*7M*$I1K:UJVI:MZ3K6MJ6K>U*5^U2M[WO>][S VM:T8:T-!)<0T
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M+,^H<::&&$F:3[^33H+#J&-BTM!R0 5415M57-9+45<TLD;!$.;(]X$30-+
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MMQVKFTRS]-AE#+/5/8]Q1-Q!PXZGK9^=<+74&FF<X-#Y('#F4DKFM#6@<K5
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MOW+[;S'F]^\TCKCQN^W#O!:ZTOHRCMNNK@D*!L%$G0&6.A\8NKG7.4&*R)E
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M85\[K74O)YJTT"EE?Q9ATD3>2OFTF,D5+T)VAKH_F83NL".D)KOY?+"/NPQ
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M==5#U*:A;6[N)MU&V-Y+'.)^,*FM8Q^@7>Y7(QNT"004\M372,V<6<T0QN
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M<^:01:C#I92 2<=#OG.=L>]GS>E>?=N]\JZ/8[GR<MP:R=N \O[1Q;E745O
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M/15LW479O0.C\HXO.YMW12+(P\8Z/08_;A;TZ@VVT2@HXB5J=H()(-DXD)N
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M2R[FG[FPY&FB2'";DS #RVHY0RW,KST&(M$Z?H40$#'^RX>^0X#Y0HNB^/\
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M\/<%2.'?A@">6@1UTJ;XPY9O%WH7IG8.@4.J$[=8!YB"^FL6D+6J+9N@1JO
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M-SZWGV3W7W>KOWA*O%!^1J+W,IOFK%1!C^1W6_W3\R_[#5\N$/LSJO=:Z_\
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MOIKGGL*^=YOQ.CR;CWSMKM)J/&ZS1@$HC^B$J!9J4B/)257$;*'2**145T6
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M:I-6D .?J)UNWU.!.3U5P/5>857K]"ME M@Z#+'VJK6>K;F2!\.=+$-6D'-
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MH,V\4:XMT/FD$'7Z#;:S:K&&L;%2NP6^Q#+^A0DO8:M4G-W>E/A51[X!@0S
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MP_%COSLKV,*$PB81,(F$6D7ZD]C>OP_JCU#7:]ZE[I6:W5?1'8*Q6Z\ O4V
M&"  =V+0!(L=#TTXF-$@PVFHT=E"OD;:;0A.M:3G9?!G G"-PX5X?K:RPVZ>
MJJ;302SS/IXR^65]-$Y\CW%I+G/<2YQ/4DE<_P!_XDOM->KI3P72KBAAKJJ.
M.-LK@UC&S/:UK1W-:  !W *#?ZM/VK_C@^C/](TW_9\R;[7'!']7+9^K1_\
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MDQS1DZ6B9W1M1Y#_ .,UKG[.:\NS>YI]9XF$3")A$PBQ<>[.Z=6\T]X\N=?
MVZ<QYW #^BR/7=$>8A2Q,CE)*Y\1Y<(ZW%D28SQ(%*X;:>MP>@6E\._'CD^<
MC[?HM'E.#1;T0O0 (/EVQZ=]O?Q@>?'=E1]8/2_4"?M?MK"K':)/G*D>'.VW
MFB<\IDT37B5GN').H"N?7'IC5CEM-3F#KYN3>J94F)Q!RJ,":K7KV/@2IQJ/
M+:)C8#&^1OGRYQ_'W_>5S_-/5DNX":.%Y;RZY]12#H_ETIU!^;=0*+K4QOH<
M9 DA":OSIH?#Z 3HU8<1T'K<YXI5%?HS(^]I;5UM*YE1@E&._P N?B5'<_\
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MQG*[29@&L<0[?SWCUU,!(EW;KA2U"C0WH8CI'-I+PRMS+E69(J%+&UPS-)1
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M3^/<<(7$G2A39.0(<G1"\:7T2^[FFXKS4R2Q:I4)'T(8BL1P1,GX"2/,3C^
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M^);9:YG-8?*AS9RM1K?U7I?5B4WN9SC_ $BR]DOK%0$A^E2YX[C_ %.@VV)
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0FI;$6%%=G*BPHC+)1U7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g838337g96o97.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g838337g96o97.jpg
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M&1HC07BVN-,D,C8Y459767&6H<G5UM<S-6&8U$)#4V-RAI.4E?_$ !T! 0$
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MZ;($Z\YRI^Y;;$B7NF^R".Y$*+8D.B6'9#$;<-^LLUIFJSQ]A@:-$6'+4#'
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M[?N)\,,'PO(,DRC$:AJEE9@W7+<1:QTX])(<KTD*Q-C4[)#7193R23*1(C,
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MPZGE:RNS D5Q([P[]Q)KD7;^*39#LOS*J$GX%UPO8C5."J-^(8+Y"%WG3?\
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M\<7H_P";'^[SM'+9OXFN>TO]8!J$/X[!]"?U86IJ/(G5WIQIJ*C\7-3*[)]
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M&'@PS+"JQ8NXO#L4&,PWX>$VJ<K?9"<Y4V!30?5$03[1H5447954E0>7+4M
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M(820D5G)TN0)@OM (N.=0DY17=":/;G#E<6SFU_PANK_ -_S]_;?^C^Y&/\
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@IQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIK_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
